

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Medicare & Medicaid Services**

**42 CFR Parts 409, 410, 414, 424, 484, 488, and 489**

[CMS–1780–P]

RIN 0938–AV03

**Medicare Program; Calendar Year (CY) 2024 Home Health (HH) Prospective Payment System Rate Update; HH Quality Reporting Program Requirements; HH Value-Based Purchasing Expanded Model Requirements; Home Intravenous Immune Globulin Items and Services; Hospice Informal Dispute Resolution and Special Focus Program Requirements, Certain Requirements for Durable Medical Equipment Prosthetics and Orthotics Supplies; and Provider and Supplier Enrollment Requirements**

**AGENCY:** Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS).

**ACTION:** Proposed rule.

**SUMMARY:** This proposed rule would set forth routine updates to the Medicare home health payment rates for calendar year (CY) 2024 in accordance with existing statutory and regulatory requirements. This rule would—provide information on home health utilization trends and solicits comments regarding access to home health aide services; implement home health payment-related changes; rebase and revise the home health market basket and revise the labor-related share; codify statutory requirements for disposable negative pressure wound therapy (dNPWT); and implement the new items and services payment for the home intravenous immune globulin (IVIG) benefit. In addition, it proposes—changes to the Home Health Quality Reporting Program (HH QRP) requirements and the expanded Home Health Value-Based Purchasing (HHVBP) Model; to implement the new Part B benefit for lymphedema compression treatment items, codify the Medicare definition of brace, and make other codification changes based on recent legislation; to add an informal dispute resolution (IDR) and special focus program (SFP) for hospice programs; to codify DMEPOS refill policy; and to revise Medicare provider and supplier enrollment requirements.

**DATES:** To be assured consideration, comments must be received at one of

the addresses provided in the **ADDRESSES** section, no later than 5 p.m. EDT on August 29, 2023.

**ADDRESSES:** In commenting, please refer to file code CMS–1780–P. Because of staff and resource limitations, we cannot accept comments by facsimile (FAX) transmission.

Comments, including mass comment submissions, must be submitted in one of the following three ways (please choose only one of the ways listed):

1. *Electronically.* You may (and we encourage you to) submit electronic comments on this regulation to <https://www.regulations.gov>. Follow the instructions under the “submit a comment” tab.

2. *By regular mail.* You may mail written comments to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–1780–P, P.O. Box 8013, Baltimore, MD 21244–8013.

Please allow sufficient time for mailed comments to be received before the close of the comment period.

3. *By express or overnight mail.* You may send written comments via express or overnight mail to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–1780–P, Mail Stop C4–26–05, 7500 Security Boulevard, Baltimore, MD 21244–1850.

For information on viewing public comments, we refer readers to the beginning of the **SUPPLEMENTARY INFORMATION** section.

**FOR FURTHER INFORMATION CONTACT:**

Brian Slater, (410) 786–5229, for home health and home IVIG payment inquiries.

For general information about the Home Health Prospective Payment System (HH PPS), send your inquiry via email to [HomeHealthPolicy@cms.hhs.gov](mailto:HomeHealthPolicy@cms.hhs.gov).

For information about the Home Health Quality Reporting Program (HH QRP), send your inquiry via email to [HHQRPquestions@cms.hhs.gov](mailto:HHQRPquestions@cms.hhs.gov).

Frank Whelan (410) 786–1302, for Medicare provider and supplier enrollment inquiries.

For more information about the expanded Home Health Value-Based Purchasing Model, please visit the Expanded HHVBP Model web page at <https://innovation.cms.gov/innovation-models/expanded-home-health-value-based-purchasing-model>.

For more information about the hospice informal dispute resolution and special focus program, send your inquiry to [QSOG\\_hospice@cms.hhs.gov](mailto:QSOG_hospice@cms.hhs.gov).

**SUPPLEMENTARY INFORMATION:**

*Inspection of Public Comments:* All comments received before the close of the comment period are available for viewing by the public, including any personally identifiable or confidential business information that is included in a comment. We post all comments received before the close of the comment period on the following website as soon as possible after they have been received: <https://www.regulations.gov>. Follow the search instructions on that website to view public comments.

**Table of Contents**

- I. Executive Summary
  - A. Purpose and Legal Authority
  - B. Summary of the Provisions of This Proposed Rule
  - C. Summary of Costs, Transfers, and Benefits
- II. Home Health Prospective Payment System
  - A. Overview of the Home Health Prospective Payment System
  - B. Monitoring the Effects of the Implementation of PDGM
  - C. Proposed Provisions for CY 2024 Payment Under the HH PPS
- III. Home Health Quality Reporting Program (HH QRP)
  - A. Background and Statutory Authority
  - B. General Considerations Used for the Selection of Quality Measures for the HH QRP
  - C. Quality Measures Currently Adopted for the CY 2024 HH QRP
  - D. HH QRP Quality Measure Proposals Beginning With the CY 2025 HH QRP
  - E. Form, Manner, and Timing of Data Submission Under the HH QRP
  - F. Policies Regarding Public Display of Measure Data for the HH QRP
  - G. Health Equity Update
  - H. Proposal To Codify HH QRP Data Completion Thresholds
  - I. Principles for Selecting and Prioritizing HH QRP Quality Measures and Concepts Under Consideration for Future Years: Request for Information (RFI)
- IV. Proposed Changes to the Expanded Home Health Value-Based Purchasing (HHVBP) Model
  - A. Background
  - B. Proposed Changes to the Applicable Measure Set
  - C. Proposed Changes to the Appeals Process
  - D. Public Reporting Reminder
  - E. Health Equity Update
- V. Medicare Home Intravenous Immune Globulin (IVIG) Items and Services
  - A. General Background
  - B. Proposed Scope of Expanded IVIG Benefit
  - C. Proposed IVIG Administration Items and Services Payment
  - D. Proposed Home IVIG Items and Services Payment Rate
  - E. Billing Procedures for Home IVIG Items and Services
- VI. Hospice Informal Dispute Resolution and Special Focus Program

- A. Background and Statutory Authority
  - B. Proposed Regulatory Provisions
  - VII. Proposed Changes Regarding Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS)
    - A. Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program (CBP)
    - B. Scope of the Benefit and Payment for Lymphedema Compression Treatment Items
    - C. Definition of Brace
    - D. Documentation Requirements for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies Products Supplied as Refills to the Original Order
  - VIII. Proposed Changes to the Provider and Supplier Enrollment Requirements
    - A. Background
    - B. Proposed Provisions
  - IX. Collection of Information Requirements
    - A. Statutory Requirement for Solicitation of Comments
    - B. Information Collection Requirements (ICRs)
    - C. Submission of PRA-Related Comments
  - X. Regulatory Impact Analysis
    - A. Statement of Need
    - B. Overall Impact
    - C. Detailed Economic Analysis
    - D. Regulatory Review Cost Estimation
    - E. Alternatives Considered
    - F. Accounting Statements and Tables
    - G. Regulatory Flexibility Act (RFA)
    - H. Unfunded Mandates Reform Act (UMRA)
    - I. Federalism
    - J. Conclusion
- Regulations Text

## I. Executive Summary

### A. Purpose and Legal Authority

#### 1. Home Health Prospective Payment System (HH PPS)

As required under section 1895(b) of the Social Security Act (the Act), this proposed rule would update the payment rates for home health agencies (HHAs) for CY 2024. In this proposed rule we include analysis on home health utilization and solicit comments related to access to home health aide services. This rule also provides analysis determining the difference between assumed versus actual behavior change on estimated aggregate expenditures for home health payments as result of the change in the unit of payment to 30 days and the implementation of the PDGM case-mix adjustment methodology, and proposes a permanent prospective adjustment to the CY 2024 home health payment rate. In addition, this rule proposes to recalibrate the PDGM case-mix weights and update the LUPA thresholds, functional impairment levels, and comorbidity adjustment subgroups under section 1895(b)(4)(A)(i) and (b)(4)(B) of the Act for 30-day periods of care in CY 2024. This rule proposes to rebase and revise

the home health market basket and proposes to revise the labor-related share. Additionally, this rule proposes to codify statutory requirements for dNPWT and updates the CY 2024 fixed-dollar loss ratio (FDL) for outlier payments (so that outlier payments as a percentage of estimated total payments are not to exceed 2.5 percent, as required by section 1895(b)(5)(A) of the Act).

#### 2. Home Health (HH) Quality Reporting Program (QRP)

In accordance with the statutory authority at section 1895(b)(3)(B)(v) of the Act, we are proposing updated policies, the codification of the previously finalized 90 percent Outcome and Assessment Information Set (OASIS) data completion threshold policy in the Code of Federal Regulations (CFR) and the public reporting of four measures. We are also including a request for information on future HH QRP measure concepts and an update on health equity in the HH QRP.

#### 3. Expanded Home Health Value-Based Purchasing (HHVBP) Model

In accordance with the statutory authority at section 1115A of the Act, we are proposing updated policies, including the codification of previously finalized measure removal factors, changes to the applicable measure set, updating the Model baseline year, and an amendment to the appeals process for the expanded HHVBP Model. We are also including updates on health equity and public reporting.

#### 4. Home Intravenous Immune Globulin (IVIG) Items and Services

As required under Division FF, section 4134 of the Consolidated Appropriations Act, 2023 (CAA, 2023), this proposed rule would implement coverage and payment for items and services related to the administration of IVIG in the home of a patient with a diagnosed primary immune deficiency disease (PIDD).

#### 5. Hospice Informal Dispute Resolution and Special Focus Program

As required under Division CC, section 407 of the Consolidated Appropriations Act of 2021 (CAA 2021), this proposed rule would implement a special focus program (SFP) for poor performing hospices that includes the SFP algorithm (including data sources) to identify indicators of hospice poor performance, the criteria for selection and completion of the SFP, hospice termination from Medicare, and public reporting of the SFP. We are also

proposing regulations to implement an informal dispute resolution (IDR) process to provide hospice programs an informal opportunity to resolve disputes related to condition-level survey findings for those hospice programs that are seeking recertification for continued participation in Medicare.

#### 6. Durable Medical Equipment, Prosthetics, Orthotics, and Supplies Products and CAA 2023-Related Changes

Section 3712 of the Coronavirus Aid, Relief, and Economic Security Act (CARES) Act (Pub. L. 116–136, March 27, 2020) <https://www.govinfo.gov/link/plaw/116/public/136> requires that Medicare payment rates for durable medical equipment (DME) in areas other than rural and noncontiguous areas during the coronavirus disease 2019 (COVID–19) public health emergency (PHE) be equal to 75 percent of the adjusted payment amounts (based on the DME competitive bidding program information), and 25 percent of the unadjusted fee schedule amounts. The regulations at § 414.210(g)(9)(v) codified these payment rates for the duration of the PHE. Section 4139 of the Consolidated Appropriations Act (CAA), 2023 (Pub. L. 117–328, December 29, 2022) requires payment based on these rates through the end of the COVID–19 PHE or December 31, 2023, whichever is later. We are proposing to make changes to the regulations to codify these payment rates through the end of the COVID–19 PHE or unless otherwise specified by law.

The scope of the benefit and payment for lymphedema compression treatment items in section 4133 of the CAA, 2023 adds section 1861(s)(2)(JJ) to the Act, adding the Medicare Part B benefit for lymphedema compression treatment items effective January 1, 2024. This rule would address the scope of the new benefit by defining what constitutes a standard or custom fitted gradient compression garment and determining what other compression items may exist that are used for the treatment of lymphedema and would fall under the new benefit.

This rule would also implement section 1834(z) of the Act in establishing payment amounts for items covered under the new benefit and frequency limitations for lymphedema compression treatment items. CMS expects to conduct outreach for individuals with Medicare and issue provider education regarding this benefit.

The definition of brace in section 1861(s)(9) of the Act provides coverage

under Part B for leg, arm, back, and neck braces. This rule would codify the existing definition of a brace found in the Medicare Benefit Policy Manual (CMS 100–02) and clarify that this definition encompasses newer, technology-powered devices.

#### 7. Documentation Requirements for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies Products Supplied as Refills to the Original Order

Section 1893(b)(1) of the Act, authorizes “[r]eview of activities of providers of services or other individuals and entities furnishing items and services for which payment may be made under this title . . . including medical and utilization review . . .”. The requirement for documentation to support DMEPOS refills originally arose in response to concerns related to auto-shipments and delivery of DMEPOS products that may no longer be needed or not needed at the same level of frequency/volume. We are proposing to codify our long-standing refill policy, with some changes. We propose to require documentation indicating that the beneficiary confirmed the need for the refill within the 30-day period prior to the end of the current supply. We propose to codify our requirement that delivery of DMEPOS items (that is, date of service) be no sooner than 10 calendar days before the expected end of the current supply. We seek comments for consideration in future rulemaking on ways to balance beneficiary burden with the potential risks/burdens of not verifying the beneficiary’s actual need for recurring supplies for certain individuals with permanent conditions.

#### 8. Provider and Supplier Enrollment Requirements

The purpose of our provider enrollment provisions is to strengthen and clarify certain aspects of the provider enrollment process. This includes, but is not limited to: (1) subjecting a greater number of providers and suppliers, such as hospices, to the highest level of screening, which includes fingerprinting all 5 percent or greater owners of these providers and suppliers; (2) applying the change in majority ownership (CIMO) provisions in 42 CFR 424.550(b) to hospices; and (3) reducing the period of Medicare non-billing for which a provider or supplier can be deactivated under § 424.540(a)(1) from 12 months to 6 months. These changes are necessary to help ensure that payments are made only to qualified providers and suppliers and/or

that owners of these entities are carefully screened. We believe that fulfilling both of these objectives would assist in protecting the Trust Funds and Medicare beneficiaries.

#### B. Summary of the Provisions of This Proposed Rule

##### 1. Home Health Prospective Payment System (HH PPS)

In section II.B.1. of this proposed rule, we provide monitoring and data analysis on PDGM utilization for CYs 2020, 2021, and 2022. In this section we also solicit comments related to access to home health aide services. In section II.C.1. of this rule, we provide analysis determining the difference between assumed versus actual behavior change on estimated aggregate expenditures for home health payments as result of the change in the unit of payment to 30 days and the implementation of the PDGM case-mix adjustment methodology; and a proposal to apply a permanent prospective adjustment of –5.653 percent to the CY 2024 home health payment rate.

In section II.C.2. of this proposed rule, we explain plans to recalibrate the PDGM case-mix weights, LUPA thresholds, functional levels, and comorbidity adjustment subgroups for CY 2024.

In section II.C.3. of this rule we set out proposals to rebase and revise the home health market basket to reflect a 2021 base year. We propose to use this 2021-based home health market basket to calculate the home health payment update percentage for CY 2024 as well as to revise the labor-related share.

In section II.C.4. of this rule, we detail proposals to update the home health wage index, the CY 2024 national, standardized 30-day period payment rates, and the CY 2024 national per-visit payment amounts by the home health payment update percentage. The proposed home health payment update percentage for CY 2024 is 2.7 percent. Additionally, this rule proposes the CY 2024 FDL ratio to ensure that aggregate outlier payments do not exceed 2.5 percent of the total aggregate payments, as required by section 1895(b)(5)(A) of the Act.

In section II.C.5 of this rule, we discuss our proposal to codify statutory payment changes for negative pressure wound therapy using a disposable device (dNPWT).

##### 2. Home Health Quality Reporting Program (HH QRP)

In section III. of this proposed rule, we are proposing the adoption of the measure “COVID–19 Vaccine: Percent of

Patients/Residents Who Are Up to Date” (Patient/Resident COVID–19 Vaccine) to the HH QRP beginning with the CY 2025 HH QRP. CMS also proposes to adopt the “Functional Discharge Score” (DC Function) measure to the HH QRP beginning with the CY 2025 HH QRP. With the addition of the Discharge Function measure, we propose to remove the measure “Application of Percent of Long-Term Care Hospital (LTCH) Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function” (Application of Functional Assessment/ Care Plan) from the HH QRP beginning with the CY 2025 HH QRP. CMS additionally propose the removal of two OASIS items no longer necessary for collection, the M0110—Episode Timing and M2220—Therapy Needs items. We are also proposing technical changes to § 484.245(b) to codify our requirement that HHAs must meet or exceed a data submission threshold set at 90 percent of all required OASIS and submit the data through the CMS designated data submission systems. Lastly, we seek input on future HH QRP measure concepts and provide updates on HH QRP health equity initiatives.

##### 3. Expanded Home Health Value Based Purchasing (HHVBP) Model

In section IV. of this proposed rule, we discuss our proposal to codify the HHVBP measure removal factors at § 484.380. We are proposing to remove five and add three quality measures to the applicable measure set. Along with the proposed revisions to the current measure set, we propose to revise the weights of the individual measures within the OASIS-based measure category and within the claims-based measure category starting in the CY 2025 performance year. We are proposing to update the Model baseline year from CY 2022 to CY 2023 starting in the CY 2025 performance year to enable CMS to measure competing HHAs performance on benchmarks and achievement thresholds that are more current for all applicable measures. Additionally, we are amending the appeals process such that reconsideration decisions may be reviewed by the Administrator. We are including an update to the RFI, *Future Approaches to Health Equity in the Expanded HHVBP Model*, that was published in the CY 2023 HH PPS rule. We will also include an update that reminds stakeholders that we will begin public reporting of HHVBP performance data on or after December 1, 2024.

#### 4. Home Intravenous Immune Globulin (IVIG) Items and Services

As required under Division FF, section 4134 of the Consolidated Appropriations Act, 2023 (CAA, 2023), section V. of this rule proposes regulations to implement coverage and payment of items and services related to administration of IVIG in a patient's home for a patient with PIDD.

#### 5. Hospice Informal Dispute Resolution and Special Focus Program

In section VI. of this proposed rule, we discuss our proposal for a new hospice informal dispute resolution (IDR) process at § 488.1130 to align with the process that is available for home health agencies (HHAs). We are proposing the hospice IDR to address disputes related to condition-level survey findings following a hospice program's receipt of the official survey statement of deficiencies. The IDR will provide hospice programs an informal opportunity to resolve disputes in the survey findings for those hospice programs that are seeking recertification from the State Survey Agency (SA) or reaccreditation from an accrediting organization (AO) for continued participation in Medicare. Additionally, the IDR may be initiated for those hospice programs that are currently under SA monitoring (either through a complaint investigation or validation survey) and those in the SFP. In section VII we discuss our proposal to add the hospice Special Focus Program (SFP) at § 488.1135. In the proposed rule, we include the SFP algorithm (including data sources) to identify indicators of hospice poor performance, the criteria for selection and completion of the SFP, hospice termination from Medicare, and public reporting of the SFP. In response to previous comments urging CMS to seek technical expert panel (TEP) recommendations to better inform the development of the SFP, a TEP was convened to gain input from key stakeholders on various aspects of the SFP proposed in this rule. We propose the hospice SFP will commence beginning the effective date of the rule with implementation during CY 2024. We propose to periodically review the effectiveness of the methodology and the algorithm.

#### 6. Durable Medical Equipment, Prosthetics, Orthotics, and Supplies Products and CAA 2023 Related Changes

In section VII.A.3. of this rule, we discuss our proposal to make conforming changes to § 414.210(g)(9), consistent with section 4139(a) and

4139(b) of the CAA, 2023. First, section 4139 of the CAA, 2023 does not change the current policy under § 414.210(g)(9)(iii) of paying for DMEPOS items and services furnished in rural and non-contiguous non-competitive bidding areas (CBAs) based on a 50/50 blend of adjusted and unadjusted fee schedule amounts through the duration of the PHE for COVID-19.

As a result, we are proposing to revise § 414.210(g)(9)(iii), to state that for items and services furnished in rural areas and non-contiguous areas (Alaska, Hawaii, and U.S. territories) with dates of service from June 1, 2018 through the duration of the emergency period described in section 1135(g)(1)(B) of the Act (42 U.S.C. 1320b-5(g)(1)(B)) or December 31, 2023, whichever is later, based on the fee schedule amount for the area is equal to 50 percent of the adjusted payment amount established under this section and 50 percent of the unadjusted fee schedule amount.

We are proposing to revise § 414.210(g)(9)(v) to state that for items and services furnished in areas other than rural or noncontiguous areas with dates of service from March 6, 2020 through December 31, 2023 or through the remainder of the duration of the emergency period described in section 1135(g)(1)(B) of the Act (42 U.S.C. 1320b-5(g)(1)(B)), whichever is later, the fee schedule amount for the area is equal to 75 percent of the adjusted payment amount established under this section and 25 percent of the unadjusted fee schedule amount.

We are proposing to remove outdated text from § 414.210(g)(9)(v) that states "for items and services furnished in areas other than rural or noncontiguous areas with dates of service from the expiration date of the emergency period described in section 1135(g)(1)(B) of the Act (42 U.S.C. 1320b-5(g)(1)(B)), through December 31, 2020, the fee schedule amount for the area is equal to 100 percent of the adjusted payment amount established under this section."

We are proposing to revise § 414.210(g)(9)(vi) to state that for items and services furnished in all areas with dates of service on or after January 1, 2024, or the date immediately following the duration of the emergency period described in section 1135(g)(1)(B) of the Act, whichever is later, the fee schedule amount for the area is equal to the adjusted payment amount established under paragraph (g) of this section.

We are proposing to make conforming changes to § 414.210(g)(2) for the rural and non-contiguous areas in order to specify the December 31, 2023 date

specified in section 4139 of the CAA, 2023.

In section VII.B.8. of this rule, we discuss our proposal to amend 42 CFR 410.36(a) to add paragraph (4) and the following new category of medical supplies, appliances, and devices covered under Medicare Part B; Lymphedema compression items including: standard and custom fitted gradient compression garments; gradient compression wraps with adjustable straps; compression bandaging systems; and other items determined to be lymphedema compression treatment items under the process established under § 414.1670. Other covered items would include accessories such as zippers in garments, liners worn under garments or wraps with adjustable straps, and padding or fillers that are necessary for the effective use of a gradient compression garment or wrap with adjustable straps.

We are proposing to modify and add to the existing HCPCS codes for lymphedema compression treatment items.

We are proposing to add § 414.1670 under new subpart Q and use the same process described in § 414.240 to obtain public consultation on preliminary benefit category determinations and payment determinations for new lymphedema compression treatment items.

We are proposing to add a new subpart Q under the regulations at 42 CFR part 414 titled, "Payment for Lymphedema Compression Treatment Items" to implement the provisions of section 1834(z) of the Act.

We are proposing to add § 414.1600 to explain the purpose and definitions found in subpart Q.

We are also proposing to add § 414.1660 to address continuity of pricing when HCPCS codes for lymphedema compression treatment items are divided or combined.

We are proposing to add § 414.1680 and the following frequency limitations for lymphedema compression treatment items

We are proposing to revise the regulations for competitive bidding under at 42 CFR part 414, subpart F to include lymphedema compression treatment items under the competitive bidding program as mandated by section 1847(a)(2)(D) of the Act. We propose to add lymphedema compression treatment items to the definition of item at § 414.402. We are proposing to revise § 414.408 to indicate that payment for these items would be calculated on a lump sum purchase basis and payment under the program would be made in accordance with any frequency

limitations established under subpart Q in accordance with section 1834(z)(2) of the Act. We are also proposing to add lymphedema compression treatment items to § 414.412 to address limiting bids submitted under the program using the payment established under subpart Q.

We are proposing to add § 414.1690 indicating that the payment amounts established under § 414.1650(b) may be adjusted using information on the payment determined for lymphedema compression treatment items as part of implementation of the competitive bidding programs under subpart F using the methodologies set forth at § 414.210(g).

In section VII.C.3. of this rule, we discuss our proposal to amend the regulations at 42 CFR 410.2 to add the definition of brace and to add clarification at § 410.36(a)(3)(i) for the

purpose of determining the Medicare Part B benefit and scope for leg, arm, back, and neck braces and making benefit category determinations regarding specific items in accordance with the review process for benefit category and payment determinations under § 414.240.

#### 7. Documentation Requirements for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies Products Supplied as Refills to the Original Order

We propose updating the refill documentation requirements such that a beneficiary affirmation would need to be documented by the supplier. We propose to require documentation indicating that the beneficiary confirmed the need for the refill within the 30-day period prior to the end of the current supply. We propose to codify our requirement that delivery of

DMEPOS items (that is, date of service) be no sooner than 10 calendar days before the expected end of the current supply. There is no associated paperwork burden as the burden is already accounted for and approved by the Office of Management and Budget under OMB control number 0938–0969 (CMS–10417).

#### 8. Provider and Supplier Enrollment Requirements

We are proposing a number of changes to our Medicare provider and supplier enrollment requirements. These include, but are not limited to: (1) provisions related to hospice enrollment and ownership; and (2) deactivation of providers and suppliers.

#### *C. Summary of Costs, Transfers, and Benefits*

**BILLING CODE 4120–01–P**

**TABLE A1: SUMMARY OF COSTS, TRANSFERS, AND BENEFITS**

| Provision Description              | Costs and Cost Savings | Transfers  | Benefits   |
|------------------------------------|------------------------|--|--|
| CY 2024 HH PPS Payment Rate Update |                        | <p>The overall economic impact related to the changes in payments under the HH PPS for CY 2024 is estimated to be -\$375 million (-2.2 percent). The \$375 million decrease in estimated payments for CY 2024 reflects the effects of the CY 2024 proposed home health payment update percentage of 2.7 percent (\$460 million increase), an estimated 5.1 percent decrease* that reflects the effects of the permanent behavioral assumption adjustment (-\$870 million) and an estimated 0.2 percent increase that reflects the effects of an updated FDL (\$35 million increase).</p> <p>*The estimated 5.1 percent decrease related to the proposed behavioral assumption adjustment includes all payments, while the proposed -5.653 percent BA adjustment only applies to the national, standardized 30-Day period payments and does not impact payments for 30-day periods which are LUPAs.</p> | To ensure that home health payments are consistent with statutory payment authority for CY 2024.   |
| HH QRP                             |                        | The total economic impact of these proposals including the addition of the COVID-19 QM, removal of the Application of Functional Assessment/Care Plan, and the removal of the M0110 – Episode Timing and M2220- Therapy Needs OASIS items proposed for implementation in CY 2025 is an estimated \$5,123,429.  | The reduction of unnecessary data collection burden and the introduction of more impactful quality measures.   |
| Expanded HHVBP Model               |                        | The overall economic impact of the expanded HHVBP Model for CYs 2024 through 2027 is an estimated \$3.376 billion in total savings to FFS Medicare from a reduction in unnecessary hospitalizations and SNF usage as a result of greater quality improvements in the HH industry. As for payments to HHAs, there are no aggregate increases or decreases expected to be applied to the HHAs competing in the expanded Model.   |  |
| Home IVIG Items and Services       |                        | The overall economic impact for CY 2024 is an estimated increase of \$8,779,095 in total costs to Medicare FFS.  | To implement a new payment under the home intravenous immune globulin benefit in accordance with section 4134 of the CAA of 2023, in order to ensure beneficiaries have comprehensive access to home IVIG. |

| Provision Description  | Costs and Cost Savings   | Transfers   | Benefits   |
|--|--|---|--|
| Hospice Informal Dispute Resolution and Special Focus Program  | The IDR is an administrative process conducted by CMS, the SA, or the AOs as part of their survey activities, and is separate from the SFP. The Congress has already allocated \$10 million annually to CMS to implement the CAA 2021 hospice provisions, which includes the SFP. Additionally, CMS obligates monies to the SAs to carry out survey and certification responsibilities under their agreement with CMS. SAs and AOs may already have existing IDR processes in place for the HHA IDR requirements. The hospice IDR requirements will align with the IDR requirements for HHAs. Therefore, no additional burden will be incurred by CMS, SAs, the AOs. |   |  |
| Durable Medical Equipment, Prosthetics, Orthotics, and Supplies Products and CAA 2023 -Related Changes |  | For the conforming change to sections in CAA of 2023 provision, the overall economic impact for CY 2023 and CY 2024 is an estimated \$100 million in total cost to FFS Medicare. For the lymphedema provision, the overall economic impact for CYs 2024 through 2028 is an estimated \$300 million in total cost to FFS Medicare. | The codification of refill requirements is intended to help ensure the appropriateness of recurring DMEPOS payments, to protect both beneficiaries and the Trust Fund. |
| Documentation Requirements for DMEPOS Products Supplied as Refills to the Original Order               | The fiscal impact of these requirements cannot be estimated as claims often deny for multiple reasons, which may include non-compliance with our refill requirements; creating an inability for us to accurately demonstrate a causal relationship. In addition, to demonstrate impacts we would have to be able to predict behaviors and anticipated non-compliance in future claim submissions, which are unknown variables to us.   |   |  |
| Provider Enrollment Provisions   | As explained in the collection of information and regulatory impact sections of this proposed rule, we expect a combined annual cost to affected providers and suppliers of \$1,081,782.   |   | To strengthen CMS' ability to detect and deter fraud, waste, and abuse in the Medicare program.  |

BILLING CODE 4120-01-C

**II. Home Health Prospective Payment System**

*A. Overview of the Home Health Prospective Payment System*

1. Statutory Background

Section 1895(b)(1) of the Act requires the Secretary to establish a Home Health Prospective Payment System (HH PPS) for all costs of home health services paid under Medicare. Section 1895(b)(2) of the Act requires that, in defining a prospective payment amount, the Secretary will consider an appropriate unit of service and the number, type,

and duration of visits provided within that unit, potential changes in the mix of services provided within that unit and their cost, and a general system design that provides for continued access to quality services. In accordance with the statute, as amended by the Balanced Budget Act of 1997 (BBA), (Pub. L. 105-33, enacted August 5, 1997) we published a final rule in the July 3, 2000 **Federal Register** (65 FR 41128) to implement the HH PPS legislation.

Section 5201(c) of the Deficit Reduction Act of 2005 (DRA) (Pub. L. 109-171, enacted February 8, 2006) added new section 1895(b)(3)(B)(v) to

the Act, requiring home health agencies (HHAs) to submit data for purposes of measuring health care quality, and linking the quality data submission to the annual applicable home health payment update percentage increase. This data submission requirement is applicable for CY 2007 and each subsequent year. If an HHA does not submit quality data, the home health market basket percentage increase is reduced by 2 percentage points. In the November 9, 2006 **Federal Register** (71 FR 65935), we published a final rule to implement the pay-for-reporting requirement of the DRA, which was codified at § 484.225(h) and (i) in

accordance with the statute. The pay-for-reporting requirement was implemented on January 1, 2007.

Section 51001(a)(1)(B) of the Bipartisan Budget Act of 2018 (BBA of 2018) (Pub. L. 115–123) amended section 1895(b) of the Act to require a change to the home health unit of payment to 30-day periods beginning January 1, 2020. Section 51001(a)(2)(A) of the BBA of 2018 added a new subclause (iv) under section 1895(b)(3)(A) of the Act, requiring the Secretary to calculate a standard prospective payment amount (or amounts) for 30-day units of service furnished that end during the 12-month period beginning January 1, 2020, in a budget neutral manner, such that estimated aggregate expenditures under the HH PPS during CY 2020 are equal to the estimated aggregate expenditures that otherwise would have been made under the HH PPS during CY 2020 in the absence of the change to a 30-day unit of service. Section 1895(b)(3)(A)(iv) of the Act requires that the calculation of the standard prospective payment amount (or amounts) for CY 2020 be made before the application of the annual update to the standard prospective payment amount as required by section 1895(b)(3)(B) of the Act.

Additionally, section 1895(b)(3)(A)(iv) of the Act requires that in calculating the standard prospective payment amount (or amounts), the Secretary must make assumptions about behavior changes that could occur as a result of the implementation of the 30-day unit of service under section 1895(b)(2)(B) of the Act and case-mix adjustment factors established under section 1895(b)(4)(B) of the Act. Section 1895(b)(3)(A)(iv) of the Act further requires the Secretary to provide a description of the behavior assumptions made in notice and comment rulemaking. CMS finalized these behavior assumptions in the CY 2019 HH PPS final rule with comment period (83 FR 56461).

Section 51001(a)(2)(B) of the BBA of 2018 also added a new subparagraph (D) to section 1895(b)(3) of the Act. Section 1895(b)(3)(D)(i) of the Act requires the Secretary annually to determine the impact of differences between assumed behavior changes, as described in section 1895(b)(3)(A)(iv) of the Act, and actual behavior changes on estimated aggregate expenditures under the HH PPS with respect to years beginning with 2020 and ending with 2026. Section 1895(b)(3)(D)(ii) of the Act requires the Secretary, at a time and in a manner determined appropriate, through notice and comment rulemaking, to provide for one or more

permanent increases or decreases to the standard prospective payment amount (or amounts) for applicable years, on a prospective basis, to offset for such increases or decreases in estimated aggregate expenditures, as determined under section 1895(b)(3)(D)(i) of the Act. Additionally, section 1895(b)(3)(D)(iii) of the Act requires the Secretary, at a time and in a manner determined appropriate, through notice and comment rulemaking, to provide for one or more temporary increases or decreases to the payment amount for a unit of home health services for applicable years, on a prospective basis, to offset for such increases or decreases in estimated aggregate expenditures, as determined under section 1895(b)(3)(D)(i) of the Act. Such a temporary increase or decrease shall apply only with respect to the year for which such temporary increase or decrease is made, and the Secretary shall not take into account such a temporary increase or decrease in computing the payment amount for a unit of home health services for a subsequent year. Finally, section 51001(a)(3) of the BBA of 2018 amends section 1895(b)(4)(B) of the Act by adding a new clause (ii) to require the Secretary to eliminate the use of therapy thresholds in the case-mix system for CY 2020 and subsequent years.

Division FF, section 4136 of the Consolidated Appropriations Act, 2023 (CAA, 2023) amended section 1834(s)(3)(A) of the Act to require that, beginning with 2024, the separate payment for furnishing negative pressure wound therapy (NPWT) be for just the device and not for nursing and therapy services. Payment for nursing and therapy services are to be included as part of payments under the HH PPS. The separate payment for 2024 is to be equal to the supply price used to determine the relative value for the service under the Medicare Physician Fee Schedule (as of January 1, 2022) for the applicable disposable device updated by the percentage increase in the Consumer Price Index for All Urban Consumers (CPI-U). The separate payment for 2025 and each subsequent year is to be the payment amount for the previous year updated by the percentage increase in the CPI-U (United States city average) for the 12-month period ending in June of the previous year minus the productivity adjustment as described in section 1886(b)(3)(B)(xi)(II) for such year. The CAA, 2023 also added section 1834(s)(4) of the Act to require that beginning with 2024, as part of submitting claims for the separate payment, the Secretary shall accept and

process claims submitted using the type of bill that is most commonly used by home health agencies to bill services under a home health plan of care.

## 2. Current System for Payment of Home Health Services

For home health periods of care beginning on or after January 1, 2020, Medicare makes payment under the HH PPS on the basis of a national, standardized 30-day period payment rate that is adjusted for case-mix and area wage differences in accordance with section 51001(a)(1)(B) of the BBA of 2018. The national, standardized 30-day period payment rate includes payment for the six home health disciplines (skilled nursing, home health aide, physical therapy, speech-language pathology, occupational therapy, and medical social services). Payment for non-routine supplies (NRS) is also part of the national, standardized 30-day period rate. Durable medical equipment (DME) provided as a home health service, as defined in section 1861(m) of the Act, is paid the fee schedule amount or is paid through the competitive bidding program and such payment is not included in the national, standardized 30-day period payment amount. Additionally, the 30-day period payment rate does not include payment for certain injectable osteoporosis drugs and negative pressure wound therapy (NPWT) using a disposable device (though this rule is proposing changes to this provision pursuant to section 4136 of the CAA, 2023), but such drug and services must be billed by the HHA while a patient is under a home health plan of care, as the law requires consolidated billing of osteoporosis drugs and NPWT using a disposable device.

To better align payment with patient care needs and to better ensure that clinically complex and ill beneficiaries have adequate access to home health care, in the CY 2019 HH PPS final rule with comment period (83 FR 56406), we finalized case-mix methodology refinements through the Patient-Driven Groupings Model (PDGM) for home health periods of care beginning on or after January 1, 2020. The PDGM did not change eligibility or coverage criteria for Medicare home health services, and as long as the individual meets the criteria for home health services as described at 42 CFR 409.42, the individual can receive Medicare home health services, including therapy services. For more information about the role of therapy services under the PDGM, we refer readers to the Medicare Learning Network (MLN) Matters article SE20005 available at <https://www.cms.gov/>




*regulations-and-guidanceguidance transmittals2020-transmittals/se20005.* To adjust for case-mix for 30-day periods of care beginning on and after January 1, 2020, the HH PPS uses a 432-category case-mix classification system to assign patients to a home health resource group (HHRG) using patient characteristics and other clinical information from Medicare claims and the Outcome and Assessment Information Set (OASIS) assessment instrument. These 432 HHRGs represent the different payment groups based on five main case-mix categories under the PDGM, as shown in Figure B1. Each

HHRG has an associated case-mix weight that is used in calculating the payment for a 30-day period of care. For periods of care with visits less than the low-utilization payment adjustment (LUPA) threshold for the HHRG, Medicare pays national per-visit rates based on the discipline(s) providing the services. Medicare also adjusts the national standardized 30-day period payment rate for certain intervening events that are subject to a partial payment adjustment. For certain cases that exceed a specific cost threshold, an outlier adjustment may also be available.

Under this case-mix methodology, case-mix weights are generated for each of the different PDGM payment groups by regressing resource use for each of the five categories (admission source, timing, clinical grouping, functional impairment level, and comorbidity adjustment) using a fixed effects model. A detailed description of each of the case-mix variables under the PDGM have been described previously, and we refer readers to the CY 2021 HH PPS final rule (85 FR 70303 through 70305).

BILLING CODE 4120-01-P

**FIGURE B1: CASE-MIX VARIABLES IN THE PDGM**



*B. Monitoring the Effects of the Implementation of PDGM*

## 1. Routine PDGM Monitoring

CMS routinely analyzes Medicare home health benefit utilization, including but not limited to, overall total 30-day periods of care and average periods of care per HHA user; distribution of the type of visits in a 30-day period of care; the percentage of periods that receive the LUPA; estimated costs; the percentage of 30-day periods of care by clinical group, comorbidity adjustment, admission source, timing, and functional

impairment level; and the proportion of 30-day periods of care with and without any therapy visits, nursing visits, and/or aide/social worker visits. For the monitoring included in this rule, we examine simulated data for CYs 2018 and 2019 and actual data for CYs 2020, 2021, and 2022 for 30-day periods of care. We refer readers to the CY 2022 HH PPS final rule (86 FR 35881) for discussion about simulated data for CYs 2018 and 2019.

## (a) Utilization

Table B1 shows the overall utilization of home health services and Table B2

shows the average utilization of visits per 30-day period of care by home health discipline. This data indicates the average number of 30-day periods of care per unique HHA user is similar between CY 2021 and CY 2022. The data also indicates that the number of 30-day periods of care decreased between CY 2018 and CY 2022. Table B3 shows the proportion of 30-day periods of care that are LUPAs and the average number of visits per discipline of those LUPA 30-day periods of care over time.

**TABLE B1: OVERALL UTILIZATION OF HOME HEALTH SERVICES, CYs 2018-2022**

| Volume of Periods and Number of Beneficiaries           | CY 2018 (Simulated) | CY 2019 (Simulated) | CY 2020   | CY 2021   | CY 2022   |
|---|---------------------|---------------------|-----------|-----------|-----------|
| 30-Day Periods of Care                                  | 9,336,898           | 8,744,171           | 8,423,688 | 9,269,971 | 8,386,706 |
| Unique Beneficiaries                                    | 2,980,385           | 2,802,560           | 2,850,916 | 3,017,464 | 2,781,575 |
| Average Number of 30-Day Periods per Unique Beneficiary | 3.13                | 3.12                | 2.95      | 3.07      | 3.02      |

**Source:** CY 2018 and CY 2019 simulated PDGM data with behavioral assumptions came from the Home Health Limited Data Set (LDS). CY 2020 PDGM data was accessed from the Chronic Conditions Data Warehouse (CCW) Virtual Research Data Center (VRDC) on July 12, 2021. CY 2021 PDGM data was accessed from the CCW VRDC on July 14, 2022. CY 2022 PDGM data was accessed from the CCW VRDC on March 17, 2023.

**Note:** All 30-day periods of care claims were included (for example LUPAs, partial payment adjustments, and outliers). There are approximately 540,000 60-day episodes that started in 2019 and ended in 2020 that are not included in the analysis.

**TABLE B2: UTILIZATION OF VISITS PER 30-DAY PERIODS OF CARE BY HOME HEALTH DISCIPLINE, CYs 2018-2022**

| Discipline                     | CY 2018 (Simulated) | CY 2019 (Simulated) | CY 2020     | CY 2021     | CY 2022     |
|--------------------------------|---------------------|---------------------|-------------|-------------|-------------|
| Skilled Nursing                | 4.53                | 4.49                | 4.35        | 4.05        | 3.89        |
| Physical Therapy               | 3.30                | 3.33                | 2.70        | 2.74        | 2.77        |
| Occupational Therapy           | 1.02                | 1.07                | 0.79        | 0.78        | 0.77        |
| Speech Therapy                 | 0.21                | 0.21                | 0.16        | 0.15        | 0.14        |
| Home Health Aide               | 0.72                | 0.67                | 0.54        | 0.48        | 0.43        |
| Social Worker                  | 0.08                | 0.08                | 0.06        | 0.05        | 0.05        |
| <b>Total (all disciplines)</b> | <b>9.86</b>         | <b>9.85</b>         | <b>8.59</b> | <b>8.25</b> | <b>8.05</b> |

**Source:** CY 2018 and CY 2019 simulated PDGM data with behavior assumptions came from the Home Health LDS. CY 2020 PDGM data was accessed from the CCW VRDC on July 12, 2021. CY 2021 PDGM data was accessed from the CCW VRDC on July 14, 2022. CY 2022 PDGM data was accessed from the CCW VRDC on March 17, 2023.

**Note:** All 30-day periods of care claims were included (for example LUPAs, partial payment adjustments, and outliers). There are approximately 540,000 60-day episodes that started in 2019 and ended in 2020 that are not included in the analysis.

**TABLE B3: THE PROPORTION OF 30-DAY PERIODS OF CARE THAT ARE LUPAs AND THE AVERAGE NUMBER OF VISITS BY HOME HEALTH DISCIPLINE FOR LUPA HOME HEALTH PERIODS, CYs 2018-2022**

|  | CY 2018<br>(Simulated) | CY 2019<br>(Simulated) | CY 2020     | CY 2021     | CY 2022     |
|--|------------------------|------------------------|-------------|-------------|-------------|
| Total LUPA % of Overall 30-day Periods                     | 6.7%                   | 6.8%                   | 8.7%        | 7.9%        | 7.8%        |
| Discipline (Average # visits for LUPA home health periods) |                        |                        |             |             |             |
| Skilled Nursing  | 1.15                   | 1.14                   | 1.19        | 1.12        | 1.08        |
| Physical Therapy   | 0.43                   | 0.46                   | 0.53        | 0.55        | 0.60        |
| Occupational Therapy                                       | 0.07                   | 0.07                   | 0.08        | 0.08        | 0.09        |
| Speech Therapy   | 0.02                   | 0.02                   | 0.02        | 0.02        | 0.02        |
| Home Health Aide   | 0.01                   | 0.01                   | 0.01        | 0.01        | 0.01        |
| Social Worker  | 0.01                   | 0.01                   | 0.01        | 0.01        | 0.01        |
| <b>Total</b>   | <b>1.69</b>            | <b>1.71</b>            | <b>1.84</b> | <b>1.79</b> | <b>1.81</b> |

**Source:** CY 2018 and CY 2019 simulated PDGM data with behavioral assumptions came from the Home Health LDS. CY 2020 PDGM data was accessed from the CCW VRDC on July 12, 2021. CY 2021 PDGM data was accessed from the CCW VRDC on July 14, 2022. CY 2022 PDGM data was accessed from the CCW VRDC on March 17, 2023.

**Note:** All 30-day periods of care claims were included (for example LUPAs, partial payment adjustments, and outliers). There are approximately 540,000 60-day episodes that started in 2019 and ended in 2020 that are not included in the analysis.

(b) Analysis of 2021 Cost Report Data for 30-Day Periods of Care

In the CY 2023 HH PPS proposed rule (87 FR 37607), we provided a summary of analysis on FY 2020 HHA Medicare cost report data, as this was the most recent and complete cost report data at the time of rulemaking, and CY 2021 home health claims to estimate 30-day period of care costs. Our analysis showed that the CY 2021 national, standardized 30-day period payment rate of \$1,901.12 was approximately 34 percent more than the estimated CY 2021 estimated 30-day period cost of \$1,420.35. In MedPAC’s March 2023

Report to Congress,<sup>1</sup> their review of home health payment adequacy found that “access is more than adequate in most areas and that Medicare payments are substantially in excess of costs”.

Using this same process in this proposed rule to compare home health payment to costs, we examined 2021 HHA Medicare cost reports (CMS Form 1728–20, OMB No. 0938–0222), as this is the most recent and complete cost report data at the time of rulemaking, and CY 2022 home health claims, to estimate 30-day period of care costs. We excluded LUPAs and partial payment adjustments in the average number of

visits. The 2021 average NRS costs per visit is \$6.71. To update the estimated 30-day period of care costs, we begin with the 2021 average costs per visit with NRS for each discipline and multiply that amount by the CY 2022 home health payment update percentage of 2.6 percent. That amount for each discipline is then multiplied by the 2022 average number of visits by discipline to determine the 2022 estimated 30-day period costs. Table B4 shows the estimated average costs for 30-day periods of care by discipline with NRS and the total 30-day period of care costs with NRS for CY 2022.

**TABLE B4: ESTIMATED COSTS FOR 30-DAY PERIODS OF CARE IN CY 2022**

| Discipline              | 2021<br>Average Costs per<br>visit with NRS | 2022<br>Home Health<br>Payment Update | 2022<br>Average Number<br>of Visits | 2022<br>Estimated 30-Day<br>Period Costs |
|-------------------------|---|---------------------------------------|-------------------------------------|--|
| Skilled Nursing         | \$159.31                                    | 1.026                                 | 4.14                                | \$676.69                                 |
| Physical Therapy        | \$165.31                                    | 1.026                                 | 2.96                                | \$502.04                                 |
| Occupational Therapy    | \$163.55                                    | 1.026                                 | 0.83                                | \$139.28                                 |
| Speech Pathology        | \$188.41                                    | 1.026                                 | 0.15                                | \$29.00                                  |
| Medical Social Services | \$265.69                                    | 1.026                                 | 0.05                                | \$13.63                                  |
| Home Health Aides       | \$86.33                                     | 1.026                                 | 0.47                                | \$41.63                                  |
| <b>Total</b>            |   |                                       |                                     | <b>\$1,402.27</b>                        |

**Source:** 2021 Medicare cost report data obtained on February 1, 2023. Home health visit information came from 30-day periods of care with a through date in CY 2022 (obtained from the CCW VRDC on March 17, 2023).

<sup>1</sup> Report to Congress, Medicare Payment Policy. Home Health Care Services, Chapter 8. MedPAC.

March 2023 [https://www.medpac.gov/wp-content/](https://www.medpac.gov/wp-content/uploads/2023/03/Ch8_Mar23_MedPAC_Report_To_Congress_SEC.pdf)

[uploads/2023/03/Ch8\\_Mar23\\_MedPAC\\_Report\\_To\\_Congress\\_SEC.pdf](https://www.medpac.gov/wp-content/uploads/2023/03/Ch8_Mar23_MedPAC_Report_To_Congress_SEC.pdf).

The CY 2022 national, standardized 30-day period payment rate was \$2,031.64, which is approximately 45 percent more than the estimated CY 2022 estimated 30-day period cost of \$1,402.27. Note that in the CY 2023 HH PPS proposed rule (87 FR 37608), the average number of visits for non-LUPA, non-partial payment adjustments 30-day periods of care in 2021 was 8.81 visits. Using actual CY 2022 claims data, the average number of visits for a non-LUPA, non-partial payment adjustments 30-day periods of care was 8.6 visits—a decrease of approximately 2.4 percent. Note that in the CY 2020 HH PPS final rule with comment period (84 FR 60484), the average number of visits for non-LUPA, non-partial payment

adjustments 30-day periods of care in 2017 was estimated to be 10.5 visits. Therefore, the average number of visits for non-LUPA, non-partial payment adjustments, 30-day periods of care in CY 2022 represents a decrease of 18 percent from the average number of visits for non-LUPA, non-partial payment adjustments 30-day periods of care in CY 2017. In its March 2023 Report to Congress, MedPAC assumed a cost growth of 4.1 percent for CY 2023.<sup>2</sup> Furthermore, MedPAC noted that for more than a decade, payments under the HH PPS have significantly exceeded HHAs' costs primarily due to two factors. First, agencies have reduced the average number of visits per period to reduce period costs. Second, cost

growth in recent years has been lower than the annual home health payment update percentages. As shown in Table B4 in this proposed rule, HHAs have reduced visits under the PDGM in CY 2022.

(c) Clinical Groupings and Comorbidities

Each 30-day period of care is grouped into one of 12 clinical groups, which describe the primary reason for which a patient is receiving home health services under the Medicare home health benefit. The clinical grouping is based on the principal diagnosis reported on the home health claim. Table B5 shows the distribution of the 12 clinical groups over time.

**TABLE B5: DISTRIBUTION OF 30-DAY PERIODS OF CARE BY THE 12 PDGM CLINICAL GROUPS, CYs 2018-2022**

| Clinical Grouping         | CY 2018 (Simulated) | CY 2019 (Simulated) | CY 2020 | CY 2021 | CY 2022 |
|---------------------------|---------------------|---------------------|---------|---------|---------|
| Behavioral Health         | 1.7%                | 1.5%                | 2.3%    | 2.4%    | 2.3%    |
| Complex Nursing           | 2.6%                | 2.5%                | 3.5%    | 3.3%    | 3.2%    |
| MMTA – Cardiac            | 16.5%               | 16.1%               | 18.9%   | 18.5%   | 17.9%   |
| MMTA – Endocrine          | 17.3%               | 17.4%               | 7.2%    | 6.9%    | 6.8%    |
| MMTA – GI/GU              | 2.2%                | 2.3%                | 4.7%    | 4.7%    | 4.9%    |
| MMTA – Infectious         | 2.9%                | 2.7%                | 4.8%    | 4.6%    | 4.6%    |
| MMTA – Other              | 4.7%                | 4.7%                | 3.1%    | 3.6%    | 3.5%    |
| MMTA – Respiratory        | 4.3%                | 4.1%                | 7.8%    | 8.0%    | 7.8%    |
| MMTA – Surgical Aftercare | 1.8%                | 1.8%                | 3.6%    | 3.4%    | 3.4%    |
| MS Rehab                  | 17.1%               | 17.3%               | 19.4%   | 19.8%   | 20.8%   |
| Neuro Rehab               | 14.4%               | 14.5%               | 10.5%   | 10.9%   | 11.0%   |
| Wounds                    | 14.5%               | 15.1%               | 14.2%   | 13.9%   | 13.7%   |

**Source:** CY 2018 and CY 2019 simulated PDGM data with behavioral assumptions came from the Home Health LDS. CY 2020 PDGM data was accessed from the CCW VRDC on July 12, 2021. CY 2021 PDGM data was accessed from the CCW VRDC on July 14, 2022. CY 2022 PDGM data was accessed from the CCW VRDC on March 17, 2023.

**Note:** All 30-day periods of care claims were included (for example LUPAs, partial payment adjustments, and outliers). There are approximately 540,000 60-day episodes that started in 2019 and ended in 2020 that are not included in the analysis.

Thirty-day periods of care will receive a comorbidity adjustment category based on the presence of certain secondary diagnoses reported on home health claims. These diagnoses are based on a home health specific list of clinically and statistically significant

secondary diagnosis subgroups with similar resource use. We refer readers to section II.B.4.c. of this proposed rule and the CY 2020 HH PPS final rule with comment period (84 FR 60493) for further information on the comorbidity adjustment categories. Home health 30-

day periods of care can receive a low or a high comorbidity adjustment, or no comorbidity adjustment. Table B6 shows the distribution of 30-day periods of care by comorbidity adjustment category for all 30-day periods.

<sup>2</sup> Report to Congress, Medicare Payment Policy. Home Health Care Services, Chapter 8. MedPAC.

March 2023 <https://www.medpac.gov/wp-content/>

[uploads/2023/03/Ch8\\_Mar23\\_MedPAC\\_Report\\_To\\_Congress\\_SEC.pdf](https://www.medpac.gov/wp-content/uploads/2023/03/Ch8_Mar23_MedPAC_Report_To_Congress_SEC.pdf)

**TABLE B6: DISTRIBUTION OF 30-DAY PERIODS OF CARE BY COMORBIDITY ADJUSTMENT CATEGORY FOR 30-DAY PERIODS, CYs 2018-2022**

| Comorbidity Adjustment | CY 2018 (Simulated) | CY 2019 (Simulated) | CY 2020 | CY 2021 | CY 2022 |
|------------------------|---------------------|---------------------|---------|---------|---------|
| None                   | 55.6%               | 52.0%               | 49.1%   | 49.6%   | 37.3%   |
| Low                    | 35.3%               | 38.0%               | 36.9%   | 36.9%   | 47.9%   |
| High                   | 9.2%                | 10.0%               | 14.0%   | 13.5%   | 14.9%   |

**Source:** CY 2018 and CY 2019 simulated PDGM data with behavioral assumptions came from the Home Health LDS. CY 2020 PDGM data was accessed from the CCW VRDC on July 12, 2021. CY 2021 PDGM data was accessed from the CCW VRDC on July 14, 2022. CY 2022 PDGM data was accessed from the CCW VRDC on March 17, 2023.

**Note:** All 30-day periods of care claims were included (for example LUPAs, partial payment adjustments, and outliers). There are approximately 540,000 60-day episodes that started in 2019 and ended in 2020 that are not included in the analysis.

(d) Admission Source and Timing

Each 30-day period of care is classified into one of two admission source categories—community or institutional—depending on what healthcare setting was utilized in the 14 days prior to receiving home health care. Thirty-day periods of care for beneficiaries with any inpatient acute care hospitalizations, inpatient psychiatric facility (IPF) stays, skilled nursing facility (SNF) stays, inpatient rehabilitation facility (IRF) stays, or long-term care hospital (LTCH) stays within 14-days prior to a home health

admission will be designated as institutional admissions. The institutional admission source category will also include patients that had an acute care hospital stay during a previous 30-day period of care and within 14 days prior to the subsequent, contiguous 30-day period of care and for which the patient was not discharged from home health and readmitted.

Thirty-day periods of care are classified as “early” or “late” depending on when they occur within a sequence of 30-day periods of care. The first 30-day period of care is classified as early

and all subsequent 30-day periods of care in the sequence (second or later) are classified as late. A subsequent 30-day period of care would not be considered early unless there is a gap of more than 60 days between the end of one previous period of care and the start of another. Information regarding the timing of a 30-day period of care comes from Medicare home health claims data and not the OASIS assessment to determine if a 30-day period of care is “early” or “late”. Table B7 shows the distribution of 30-day periods of care by admission source and period timing.

**TABLE B7: DISTRIBUTION OF 30-DAY PERIODS OF CARE BY ADMISSION SOURCE AND PERIOD TIMING, CYs 2018-2022**

| Admission Source | Period Timing | CY 2018 (Simulated) | CY 2019 (Simulated) | CY 2020 | CY 2021 | CY 2022 |
|------------------|---------------|---------------------|---------------------|---------|---------|---------|
| Community        | Early         | 13.5%               | 13.8%               | 12.4%   | 11.6%   | 11.7%   |
| Community        | Late          | 61.1%               | 60.9%               | 61.8%   | 63.9%   | 63.2%   |
| Institutional    | Early         | 18.6%               | 18.4%               | 20.0%   | 18.6%   | 19.1%   |
| Institutional    | Late          | 6.8%                | 6.9%                | 5.8%    | 5.9%    | 6.0%    |

**Source:** CY 2018 and CY 2019 simulated PDGM data with behavioral assumptions came from the Home Health LDS. CY 2020 PDGM data was accessed from the CCW VRDC on July 12, 2021. CY 2021 PDGM data was accessed from the CCW VRDC on July 14, 2022. CY 2022 PDGM data was accessed from the CCW VRDC on March 17, 2023.

**Note:** All 30-day periods of care claims were included (for example LUPAs, partial payment adjustments, and outliers). There are approximately 540,000 60-day episodes that started in 2019 and ended in 2020 that are not included in the analysis.

(e) Functional Impairment Level

Each 30-day period of care is placed into one of three functional impairment levels (low, medium, or high) based on responses to certain OASIS functional items associated with grooming, bathing, dressing, ambulating, transferring, and risk for hospitalization.

The specific OASIS items that are used for the functional impairment level are found in Table B7 in the CY 2020 HH PPS final rule with comment period (84 FR 60490).<sup>3</sup> Responses to these OASIS

<sup>3</sup> CMS continues to use the M1800–1860 items to determine functional impairment level for case-mix purposes while we continue to analyze the

items are grouped together into response categories with similar resource use and each response category has associated points. A more detailed description as to how these response categories were

relationship between the analogous GG items (required as standardized patient assessment data) and the M1800 items used for payment.

established can be found in the technical report, “Overview of the Home Health Groupings Model” posted on the HHA webpage.<sup>4</sup> The sum of these points results in a functional impairment score used to group 30-day periods of care into a functional impairment level with similar resource use. The scores associated with the

functional impairment levels vary by clinical group to account for differences in resource utilization. A patient’s functional impairment level will remain the same for the first and second 30-day periods of care unless there is a significant change in condition that warrants an “other follow-up” assessment prior to the second 30-day

period of care. For each 30-day period of care, the Medicare claims processing system will look for occurrence code 50 on the claim to correspond to the M0090 date of the applicable assessment. Table B8 shows the distribution of 30-day periods by functional impairment level.

**TABLE B8: DISTRIBUTION OF 30-DAY PERIODS OF CARE BY FUNCTIONAL IMPAIRMENT LEVEL, CYs 2018-2022**

| Functional Impairment Level | CY 2018<br>(Simulated) | CY 2019<br>(Simulated) | CY 2020 | CY 2021 | CY 2022 |
|-----------------------------|------------------------|------------------------|---------|---------|---------|
| Low                         | 33.9%                  | 31.9%                  | 25.7%   | 23.2%   | 28.1%   |
| Medium                      | 34.9%                  | 35.5%                  | 32.7%   | 32.6%   | 33.1%   |
| High                        | 31.2%                  | 32.6%                  | 41.7%   | 44.2%   | 38.9%   |

**Source:** CY 2018 and CY 2019 simulated PDGM data with behavioral assumptions came from the Home Health LDS. CY 2020 PDGM data was accessed from the CCW VRDC on July 12, 2021. CY 2021 PDGM data was accessed from the CCW VRDC on July 14, 2022. CY 2022 PDGM data was accessed from the CCW VRDC on March 17, 2023.

**Note:** All 30-day periods of care claims were included (for example LUPAs, partial payment adjustments, and outliers). There are approximately 540,000 60-day episodes that started in 2019 and ended in 2020 that are not included in the analysis.

(f) Therapy Visits

Beginning in CY 2020, section 1895(b)(4)(B)(ii) of the Act eliminated the use of therapy thresholds in calculating payments for CY 2020 and subsequent years. Prior to implementation of the PDGM, HHAs could receive an adjustment to payment based on the number of therapy visits provided during a 60-day episode of care. We examined the proportion of actual 30-day periods of care with and without therapy visits. To be covered as skilled therapy, the services must require the skills of a qualified therapist

(that is, PT, OT, or SLP) or qualified therapist assistant and must be reasonable and necessary for the treatment of the patient’s illness or injury.<sup>5</sup> As shown in Table B2, we monitor the number of visits per 30-day period of care by each home health discipline. Any 30-day period of care can include both therapy and non-therapy visits. If any 30-day period of care consisted of only visits for PT, OT, or SLP, then this 30-day period of care is considered “therapy only”. If any 30-day period of care consisted of only visits for skilled nursing, home health aide, or social worker, then this 30-day

period of care is considered “no therapy”. If any 30-day period of care consisted of at least one therapy visit and one non-therapy, then this 30-day period of care is considered “therapy + non-therapy”. Table B9 shows the proportion of 30-day periods of care with only therapy visits, at least one therapy visit and one non-therapy visit, and no therapy visits. Figure B2 shows the proportion of 30-day periods of care by the number of therapy visits (excluding zero) provided during 30-day periods of care.

**BILLING CODE 4120-01-P**

<sup>4</sup> <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HomeHealthPPS/HH-PDGM>.

<sup>5</sup> Medicare Benefit Policy Manual, Chapter 7 Home Health Services, Section 40.2 Skilled Therapy Services <https://www.cms.gov/Regulations>

[-and-Guidance/Guidance/Manuals/Downloads/bp102c07.pdf](#).


**TABLE B9: PROPORTION OF 30-DAY PERIODS OF CARE WITH ONLY THERAPY, AT LEAST ONE THERAPY VISIT, AND NO THERAPY VISITS FOR CYs 2018-2022**

| 30-day Period Visit Type    | CY 2018 (Simulated) | CY 2019 (Simulated) | CY 2020          | CY 2021          | CY 2022          |
|-----------------------------|---------------------|---------------------|------------------|------------------|------------------|
| Therapy Only                | 13.5%               | 14.4%               | 15.2%            | 17.8%            | 19.4%            |
| Therapy + Non-therapy       | 48.2%               | 48.4%               | 42.2%            | 42.3%            | 42.7%            |
| No Therapy                  | 38.3%               | 37.2%               | 42.6%            | 39.9%            | 38.0%            |
| <b>Total 30-day periods</b> | <b>9,336,898</b>    | <b>8,744,171</b>    | <b>8,423,688</b> | <b>8,962,690</b> | <b>8,386,706</b> |

**Source:** CY 2018 and CY 2019 simulated PDGM data with behavioral assumptions came from the Home Health LDS. CY 2020 PDGM data was accessed from the CCW VRDC on July 12, 2021. CY 2021 PDGM data was accessed from the CCW VRDC on July 14, 2022. CY 2022 PDGM data was accessed from the CCW VRDC on March 17, 2023.

**Note:** All 30-day periods of care claims were included (for example LUPAs, partial payment adjustments, and outliers). There are approximately 540,000 60-day episodes that started in 2019 and ended in 2020 that are not included in the analysis.

**FIGURE B2: PROPORTION OF 30-DAY PERIODS OF CARE BY THE NUMBER OF THERAPY VISITS DURING 30-DAY PERIODS, CYs 2018-2022**



**Source:** CY 2018 and CY 2019 simulated PDGM data with behavioral assumptions came from the Home Health LDS. CY 2020 PDGM data was accessed from the CCW VRDC on July 12, 2021. CY 2021 PDGM data was accessed from the CCW VRDC on July 14, 2022. CY 2022 PDGM data was accessed from the CCW VRDC on March 17, 2023.


**Note:** There are approximately 540,000 60-day episodes that started in 2019 and ended in 2020 that are not included in the analysis. Thirty-day periods with ≥13 therapy visits were combined into one category for illustrative purposes only.

Both Table B9 and Figure B2, as previously discussed, indicate there have been changes in the distribution of both therapy and non-therapy visits in CY 2022 compared to CY 2021. For

example, the percent of 30-day periods with one through seven therapy visits during a 30-day period increased in CY 2022 compared to CY 2021. Comparing therapy utilization from before the

PDGM (CYs 2018 and 2019) to after the implementation of the PDGM (CYs 2020–2022), we have also seen a decline in therapy visits across all clinical groups, as shown in Figure B3.

**FIGURE B3: AVERAGE THERAPY VISITS PER 30-DAY PERIOD BY CLINICAL GROUP, CYs 2018-2022**



**Source:** CY 2018 and CY 2019 simulated PDGM data with behavioral assumptions came from the Home Health LDS. CY 2020 PDGM data was accessed from the CCW VRDC on July 12, 2021. CY 2021 PDGM data was accessed from the CCW VRDC on July 14, 2022. CY 2022 PDGM data was accessed from the CCW VRDC on March 17, 2023.

**Note:** All 30-day periods of care claims were included (for example LUPAs, partial payment adjustments, and outliers).

We also examined the proportion of 30-day periods of care with and without skilled nursing, social work, or home health aide visits. Table B10 shows the

number of 30-day periods of care with only skilled nursing visits, at least one skilled nursing visit and one other visit type (therapy or non-therapy), and no

skilled nursing visits. Table B11 shows the number of 30-day periods of care with and without home health aide or social worker visits.



**TABLE B10: PROPORTION OF 30-DAY PERIODS OF CARE WITH ONLY SKILLED NURSING, SKILLED NURSING + OTHER VISIT TYPE, AND NO SKILLED NURSING VISITS FOR CYs 2018-2022**

| 30-day Period Visit Type    | CY 2018 (Simulated) | CY 2019 (Simulated) | CY 2020          | CY 2021          | CY 2022          |
|-----------------------------|---------------------|---------------------|------------------|------------------|------------------|
| Skilled Nursing Only        | 33.8%               | 33.1%               | 38.5%            | 36.2%            | 34.7%            |
| Skilled Nursing + Other     | 51.6%               | 51.5%               | 45.3%            | 44.9%            | 44.9%            |
| No Skilled Nursing          | 14.7%               | 15.5%               | 16.2%            | 18.9%            | 20.4%            |
| <b>Total 30-day periods</b> | <b>9,336,898</b>    | <b>8,744,171</b>    | <b>8,423,688</b> | <b>8,962,690</b> | <b>8,386,706</b> |

**Source:** CY 2018 and CY 2019 simulated PDGM data with behavioral assumptions came from the Home Health LDS. CY 2020 PDGM data was accessed from the CCW VRDC on July 12, 2021. CY 2021 PDGM data was accessed from the CCW VRDC on July 14, 2022. CY 2022 PDGM data was accessed from the CCW VRDC on March 17, 2023.

**Note:** All 30-day periods of care claims were included (for example LUPAs, partial payment adjustments, and outliers). There are approximately 540,000 60-day episodes that started in 2019 and ended in 2020 that are not included in the analysis.

**TABLE B11: PROPORTION OF 30-DAY PERIODS OF CARE WITH AND WITHOUT HOME HEALTH AIDE OR SOCIAL WORKER VISITS FOR CYs 2018-2022**


| 30-day Period Visit Type              | CY 2018 (Simulated) | CY 2019 (Simulated) | CY 2020          | CY 2021          | CY 2022          |
|---------------------------------------|---------------------|---------------------|------------------|------------------|------------------|
| Any home health aide or social worker | 16.6%               | 15.9%               | 13.2%            | 12.2%            | 11.3%            |
| No home health aide or social worker  | 83.4%               | 84.1%               | 86.8%            | 87.8%            | 88.7%            |
| <b>Total 30-day periods</b>           | <b>9,336,898</b>    | <b>8,744,171</b>    | <b>8,423,688</b> | <b>8,962,690</b> | <b>8,386,706</b> |

**Source:** CY 2018 and CY 2019 simulated PDGM data with behavioral assumptions came from the Home Health LDS. CY 2020 PDGM data was accessed from the CCW VRDC on July 12, 2021. CY 2021 PDGM data was accessed from the CCW VRDC on July 14, 2022. CY 2022 PDGM data was accessed from the CCW VRDC on March 17, 2023.

**Note:** All 30-day periods of care claims were included (for example LUPAs, partial payment adjustments, and outliers). There are approximately 540,000 60-day episodes that started in 2019 and ended in 2020 that are not included in the analysis.

Finally, we looked at home health aide utilization during CYs 2018–2022. Figure B4 shows the total and average

of home health aide visits by 30-day periods of care.

**FIGURE B4: TOTAL OF HOME HEALTH AIDE VISITS AND AVERAGE NUMBER OF HOME HEALTH AIDE VISITS BY 30-DAY PERIOD FOR CYs 2018-2022**

**Source:** CY 2018 and CY 2019 simulated PDGM data with behavior assumptions came from the Home Health LDS. CY 2020 PDGM data was accessed from the CCW VRDC on July 12, 2021. CY 2021 PDGM data was accessed from the CCW VRDC on July 14, 2022. CY 2022 PDGM data was accessed from the CCW VRDC on March 17, 2023.

**Note:** All 30-day periods of care claims were included (for example LUPAs, partial payment adjustments, and outliers). There are approximately 540,000 60-day episodes that started in 2019 and ended in 2020 that are not included in the analysis.

#### BILLING CODE 4120-01-C

We will continue to monitor the provision of home health services, including any changes in the number and duration of home health visits, composition of the disciplines providing such services, and overall home health payments to determine if refinements to the case-mix adjustment methodology may be needed in the future.

#### 2. Request for Information (RFI) for Access to Home Health Aide Services

Medicare covers intermittent/part-time personal care services and assistance with activities of daily living (ADL) provided by home health aides if a Medicare beneficiary is certified as needing a skilled service<sup>6</sup> (§ 409.45). All home health services, including aide services, are to be furnished in accordance with a physician-established plan of care. For home health services to be covered, the individualized plan of care must specify the services necessary to meet the patient-specific needs

<sup>6</sup>Intermittent skilled nursing care, physical therapy, speech language pathology, or a continuing need for occupational therapy.

identified in the comprehensive assessment. In addition, the plan of care must include the identification of the responsible discipline(s) and the frequency and duration of all visits as well as those items listed in § 484.60(a) that establish the need for such services. As the population ages, the prevalence of chronic disease increases and the need for home-based dependent services is on the rise.<sup>7</sup> For eligible beneficiaries, home health aides can provide a necessary adjunct to medical care in managing medical conditions; assisting with ADLs (help with tasks such as bathing, grooming, dressing and toileting allows beneficiaries, particularly those with physical disabilities or chronic health conditions, to maintain their independence); assisting with medication management and adherence (help with reminders for beneficiaries to take their medications as prescribed and monitoring for adverse reactions or side effects); taking

<sup>7</sup>Maresova, P., Javanmardi, E., Barakovic, S. et al. Consequences of chronic diseases and other limitations associated with old age—a scoping review. *BMC Public Health* 19, 1431 (2019). <https://doi.org/10.1186/s12889-019-7762-5>

vital signs (home health aides can take vital signs such as blood pressure and heart rate, and report changes to the beneficiary's health care provider); and supplementing socialization (instances of social interaction during prescribed visits can help to improve the mental health and well-being of beneficiaries).<sup>8</sup>

Anecdotally, CMS has heard that beneficiaries have had difficulty receiving home health aide visits under the Medicare home health benefit. Additionally, our monitoring has shown that home health aide visits have decreased, as exhibited in Table B2 and Figure B4. CMS wants to ensure that all Medicare beneficiaries receiving care under the home health benefit are afforded all covered services for which they qualify. Therefore, in an effort to better understand any challenges facing Medicare beneficiaries in accessing home health aide services, CMS solicits public comment on the following:

<sup>8</sup>Russell D, Rosati RJ, Peng TR, Barrón Y, Andreopoulos E. Continuity in the Provider of Home Health Aide Services and the Likelihood of Patient Improvement in Activities of Daily Living. *Home Health Care Management & Practice*. 2013;25(1):6–12. doi:10.1177/1084822312453046

- Why is utilization of home health aides continuing to decline as shown in Table B2 and Figure B4 if the need for these services remains strong?

- To what extent are higher acuity individuals eligible for Medicare (for example, individuals with multiple comorbidities or impairments of multiple activities of daily living) having more difficulty accessing home health care services, specifically home health aide services?

- What are notable barriers or obstacles that home health agencies experience relating to recruiting and retaining home health aides? What steps could home health agencies take to improve the recruitment and retention of home health aides?

- Are HHAs paying home health aides less than equivalent positions in other care settings (for example, are aides in the inpatient hospital setting or nursing home setting paid more than in home health)? What are the reasons for the disparity in hourly wages or total pay for equivalent services?

- In what ways could HHAs ensure that home health aides are consistently paid wages that are commensurate with the impact they have on patient care that they provide to Medicare beneficiaries?

- How effective is the coordination between Medicare and Medicaid to ensure adequate access to home health aide services? Please share insights on the level of utilization of Medicaid benefits by dually eligible beneficiaries for additional home health aide services that are not being provided by Medicare.

- Are physicians' plans of care less reliant on home health aide services in the past, or are HHAs less willing/able to provide these services? If so, what are the primary reasons for why such services are not provided?

- What are the consequences of beneficiary difficulty in accessing home health aide services?

### *C. Proposed Provisions for CY 2024 Payment Under the HH PPS*

#### 1. Proposed Behavior Assumption Adjustments Under the HH PPS

##### (a) Background

As discussed in section II.A.1. of this rule, starting in CY 2020, the Secretary was statutorily required by Section 1895 (b)(2)(B) of the Act, to change the unit of payment under the HH PPS from a 60-day episode of care to a 30-day period of care. CMS was also required to make assumptions about behavior changes that could occur as a result of the implementation of the 30-day unit of payment and the case-mix adjustment factors that eliminated the use of

therapy thresholds. In the CY 2019 HH PPS final rule with comment period (83 FR 56455), we finalized three behavior change assumptions which were also described in the CY 2022 and 2023 HH PPS rules (86 FR 35890, 87 FR 37614, and 87 FR 66795 through 66796). In the CY 2020 HH PPS final rule with comment period (84 FR 60519), we included these behavior change assumptions in the calculation of the 30-day budget neutral payment amount for CY 2020, finalizing a negative 4.36 percent behavior change assumption adjustment ("assumed behaviors"). We did not propose any changes for CYs 2021 and 2022 relating to the behavior assumptions finalized in the CY 2019 HH PPS final rule with comment period, or to the negative 4.36 percent behavior change assumption adjustment, finalized in the CY 2020 HH PPS final rule with comment period.

In the CY 2023 HH PPS final rule (87 FR 66796), we stated, based on our annual monitoring at that time, the three assumed behavior changes did occur as a result of the implementation of the PDGM and that other behaviors, such as changes in the provision of therapy and changes in functional impairment levels also occurred. We also reminded readers that in the CY 2020 HH PPS final rule with comment period (84 FR 60513) we stated we interpret actual behavior changes to encompass both behavior changes that were previously outlined as assumed by CMS, and other behavior changes not identified at the time the budget-neutral 30-day payment rate for CY 2020 was established. In the CY 2023 HH PPS final rule (87 FR 66796) we provided supporting evidence that indicated the number of therapy visits declined in CYs 2020 and 2021, as well as a slight decline in therapy visits beginning in CY 2019 after the finalization of the removal of therapy thresholds, but prior to implementation of the PDGM. In section II.B.1. of this rule, our analysis continues to show overall the actual 30-day periods are similar to the simulated 30-day periods and there continues to be a decline in therapy visits, indicating that HHAs changed their behavior to reduce therapy visits. Although the analysis demonstrates evidence of individual behavior changes (for example, in the volume of visits for LUPAs, therapy sessions, etc.), we use the entirety of the behaviors in order to calculate estimated aggregate expenditures. The law instructs us to ensure that estimated aggregate expenditures under the PDGM are equal to the estimated aggregate expenditures that otherwise would have been made under the prior system.

Section 4142(a) of the CAA, 2023, required CMS to present, to the extent practicable, a description of the actual behavior changes occurring under the HH PPS from CYs 2020–2026. This subsection of the CAA, 2023, also required CMS to provide datasets underlying the simulated 60-day episodes, and discuss and provide time for stakeholders to provide input and ask questions on the payment rate development for CY 2023. CMS complied with these requirements by posting online both the supplemental LDS and descriptive files and the description of actual behavior changes that affected CY 2023 payment rate development. Additionally, on March 29, 2023, CMS conducted a webinar entitled *Medicare Home Health Prospective Payment System (HH PPS) Calendar Year (CY) 2023 Behavior Change Recap, 60-Day Episode Construction Overview, and Payment Rate Development*. The webinar was open to the public and discussed the actual behavior changes that occurred upon implementation of the PDGM, our approach used to construct simulated 60-day episodes using 30-day periods, payment rate development for CY 2023, and information on the supplemental data files containing information on the simulated 60-day episodes and actual 30-day periods used in calculating the permanent adjustment to the payment rate. Materials from the webinar, including the presentation and the CY 2023 descriptive statistics from the supplemental LDS files, containing information on the number of simulated 60-day episodes and actual 30-day periods in CY 2021 that were used to construct the permanent adjustment to the payment rate, as well as information such as the number of episodes and periods by case-mix group, case-mix weights, and simulated payments, can be found on the Home Health Patient-Driven Groupings Model web page at <https://www.cms.gov/medicare/medicare-fee-for-service-payment/homehealthpps/hh-pdgm>.

(b) Method To Annually Determine the Impact of Differences Between Assumed Behavior Changes and Actual Behavior Changes on Estimated Aggregate Expenditures

In the CY 2023 HH PPS final rule (87 FR 66804), we finalized the methodology to evaluate the impact of the differences between assumed and actual behavior changes on estimated aggregate expenditures. For CYs 2020 through 2026, we will evaluate if the 30-day budget neutral payment rate and resulting aggregate expenditures are equal under the PDGM to what they

would have been under the 153-group case-mix system and 60-day unit of payment. An overview of the methodology is listed in this section, followed by detailed instructions on each step.

- Create simulated 60-day episodes from 30-day periods
- Price out the simulated 60-day episodes and determine aggregate expenditures
- Price out only the 30-day periods which were used to create the simulated 60-day episodes and determine aggregate expenditures
- Compare aggregate expenditures between the simulated 60-day episodes and actual 30-day periods
- Determine what the 30-day payment rate should have been to equal aggregate expenditures

#### (1) Create Simulated 60-Day Episodes From 30-Day Periods

The first step in our methodology is to determine which PDGM 30-day periods of care could be grouped together to form simulated 60-day episodes of care. To facilitate grouping, we made some exclusions and assumptions as described later in this section prior to pricing out the simulated 60-day episodes of care. We note in the early months of CY 2020, there were 60-day episodes which started in 2019 and ended in 2020 and therefore, some of these exclusions and assumptions may be specific to the first year of the PDGM. We identify, through footnotes, if an exclusion or assumption is specific to CY 2020 only.

##### (a) Exclusions

- Claims where the claim occurrence code 50 date (OASIS assessment date) occurred on or after October 31 of that year. This exclusion was applied to ensure the simulated 60-day episodes contained both 30-day periods from the same year and would not overlap into the following year (for example, 2021, 2022, 2023). This is done because any 30-day periods with an OASIS assessment date in November or December might be part of a simulated 60-day episode that would continue into the following year and where payment would have been made based on the “through” date. For CYs 2021 through 2026, we also excluded claims with an OASIS assessment date before January 1 of that year.<sup>9</sup> Again, this is to ensure a simulated 60-day episode (simulated

from two 30-day periods) does not overlap years.

- Beneficiaries and all of their claims if they have overlapping claims from the same provider (as identified by CCN).<sup>10</sup>
- Beneficiaries and all of their claims if three or more claims from the same provider are linked to the same occurrence code 50 date.<sup>11</sup>

##### (b) Assumptions

- If two 30-day periods of care from the same provider reference the same OASIS assessment date (using occurrence code 50), then we assume those two 30-day periods of care would have been billed as a 60-day episode of care under the 153-group system.
  - If two 30 day-periods of care reference different OASIS assessment dates and each of those assessment dates is referenced by a single 30-day period of care, and those two 30-day periods of care occur together close in time (that is, the “from” date of the later 30-day period of care is between 0 to 14 days after the “through” date of the earlier 30-day period of care), then we assume those two 30-day periods of care also would have been billed as a 60-day episode of care under the 153-group system.
    - For all other 30-day periods of care, we assume that they would not be combined with another 30-day period of care and would have been billed as a single 30-day period.

##### (2) Price Out the Simulated 60-Day Episodes and Determine Aggregate Expenditures

After application of the exclusions and assumptions described previously, we have the simulated 60-day episodes dataset for each year. We assign each simulated 60-day episode of care as a normal episode, PEP, LUPA, or outlier based on the payment parameters established in the CY 2020 HH PPS final rule with comment period (84 FR 60478) for 60-day episodes of care. Next, using the October 2019 3M Home Health Grouper (v8219)<sup>12</sup> we assign a HIPPS code to each simulated 60-day episode of care using the 153-group methodology. Finally, we price the simulated 60-day episodes of care using

<sup>10</sup> Claims are dropped from the same provider that extend into the following calendar year to ensure episode timing is accurate for simulated 60-day episodes. All of a beneficiary's claims are dropped, rather than only a subset, so as not to create a conflict in assigning episode timing.

<sup>11</sup> This is done because if three or more claims link to the same OASIS it would not be clear which claims should be joined to simulate a 60-day episode.

<sup>12</sup> <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HomeHealthPPS/CaseMixGrouperSoftware>.

the payment parameters described in the CY 2020 final rule with comment period (84 FR 60537) for 60-day episodes of care.

For CYs 2021 through 2026, we adjust the simulated 60-day base payment rate to align with current payments for the analysis year (that is, wage index budget neutrality factor and home health payment update). For example, to calculate the CY 2021 simulated 60-day episode base payment rate, we started with the final CY 2020 60-day base payment rate (\$3,220.79) and multiplied by the final CY 2021 wage index budget neutrality factor (0.9999) and the CY 2021 home health payment update (1.020) to get an adjusted 60-day base payment rate (\$3,284.88) for CY 2021. We used that adjusted 60-day base payment rate (\$3,284.88) to price out the CY 2021 simulated 60-day claims. Once each claim is priced under the pre-PDGM HH PPS, that is each claim is adjusted from the base payment rate by case-mix, wage index, etc., we calculate the estimated aggregate expenditures for all simulated 60-day episodes in CY 2021. This method is then replicated to price out the simulated 60-day episodes for each year of claims data through CY 2026.

##### (3) Price Out the 30-Day Periods and Determine Aggregate Expenditures

Next, we calculated the PDGM aggregate expenditures for CY 2020 using those specific 30-day periods that were used to create the simulated 60-day episodes. Therefore, both the actual PDGM expenditures and the simulated pre-PDGM aggregate expenditures are based on the exact same claims for the permanent adjustment calculation.

##### (4) Compare Aggregate Expenditures Between the Simulated 60-Day Episodes and Actual 30-Day Periods

We determine if the total aggregate expenditures under the PDGM were higher or lower than under the 153-case mix group system in each year beginning with CY 2020 through CY 2026. If expenditures were higher under the PDGM (that is, we paid more than we would have if the 153-group payment system was in place), then the actual base payment rate we implemented was too high. If the expenditures were lower under the PDGM (that is, we paid less than we would have if the 153-group payment system was in place), then the actual base payment rate we implemented was too low.

<sup>9</sup> There are no 30-day PDGM claims which started in CY 2019 and ended in CY 2020, and therefore this exclusion would not apply to the CY 2020 dataset.

(5) Determine What the 30-Day Payment Rate Should Have Been

Using an iterative process, we determine what the 30-day base payment rate should have been, in order to achieve the same estimated aggregate expenditures as obtained from the simulated 60-day episodes. This is our recalculated (“repriced”) base payment rate.

(c) Calculating Permanent and Temporary Payment Adjustments

To offset prospectively for such increases or decreases in estimated aggregate expenditures as a result of the impact of differences between assumed behavior changes and actual behavior changes, in any given year, we calculate a permanent prospective adjustment by calculating the percent change between the actual 30-day base payment rate and the recalculated 30-day base payment rate. This percent change is converted into a behavior adjustment factor and applied in the annual rate update process.

To offset retrospectively for such increases or decreases in estimated aggregate expenditures as a result of the impact of differences between assumed behavior changes and actual behavior changes in any given year, we calculate a temporary prospective adjustment by calculating the dollar amount difference between the estimated aggregate expenditures from all 30-day periods using the recalculated 30-day base payment rate, and the aggregate expenditures for all 30-day periods using the actual 30-day base payment rate for the same year. In other words, when determining the temporary retrospective dollar amount, we use the full dataset of actual 30-day periods using both the actual and recalculated 30-day base payment rates to ensure that the utilization and distribution of claims are the same. In accordance with section 1895(b)(3)(D)(iii) of the Act, the temporary adjustment is to be applied on a prospective basis and shall apply

only with respect to the year for which such temporary increase or decrease is made. Therefore, after we determine the dollar amount to be reconciled in any given year, we calculate a temporary adjustment factor to be applied to the base payment rate for that year. The temporary adjustment factor is based on an estimated number of 30-day periods in the next year using historical data trends, and as applicable, we control for a permanent adjustment factor, case-mix weight recalibration neutrality factor, wage index budget neutrality factor, and the home health payment update. The temporary adjustment factor is applied last.

(d) CY 2020 Results

This section discusses the final results CMS determined from CY 2020 claims data that was previously published in the CY 2023 final rule (87 FR 66804 through 66805). CMS did not do any recalculations for CY 2020 data and this section simply reiterates what was done previously for informative purposes only. Using the methodology described previously, we simulated 60-day episodes using actual CY 2020 30-day periods to determine what the CY 2020 permanent and temporary payment adjustments should be to offset for such increases or decreases in estimated aggregate expenditures. For CY 2020, we began with 8,423,688 30-day periods and dropped 603,157 30-day periods that had a claim occurrence code 50 date after October 31, 2020. We also eliminated 79,328 30-day periods that didn’t appear to group with another 30-day period to form a 60-day episode if the 30-day period had a “from date” before January 15, 2020 or a “through date” after November 30, 2020. This was done to ensure a 30-day period would not have been part of a 60-day episode that would have overlapped into CY 2021. Applying the additional exclusions and assumptions as described previously, an additional 14,062 30-day periods were excluded

from this analysis. Additionally, we excluded 66,469 simulated 60-day episodes of care where no OASIS information was available in the CCW VRDC or could not be grouped to a HIPPS due to a missing primary diagnosis or other reason. Our simulated 60-day episodes of care produced a distribution of two 30-day periods of care (70.6 percent) and single 30-day periods of care (29.4 percent). This distribution is similar to what we found when we simulated 30-day periods of care for implementation of the PDGM. After all exclusions and assumptions were applied, the final dataset included 7,618,061 actual 30-day periods of care and 4,463,549 simulated 60-day episodes of care for CY 2020.

Using the final dataset for CY 2020 (7,618,061 actual 30-day periods which made up the 4,463,549 simulated 60-day episodes) we determined the estimated aggregate expenditures under the pre-PDGM HH PPS were lower than the actual estimated aggregate expenditures under the PDGM HH PPS. This indicates that aggregate expenditures under the PDGM were higher than if the 153-group payment system was still in place in CY 2020. As described previously in the methodology, we needed to calculate what the actual CY 2020 30-day base payment rate (\$1,864.03) should have been to equal the aggregate expenditures that we calculated using the simulated CY 2020 60-day episodes. We determined the CY 2020 30-day base payment rate should have been \$1,742.52 based on actual behavior rather than the \$1,864.03 based on assumed behaviors. The percent change between the two payment rates (actual and recalculated) would be the permanent adjustment. Next, we calculated the difference in aggregate expenditures for all CY 2020 PDGM 30-day claims using the actual and recalculated payment rates. This difference is the retrospective dollar amount needed to offset payment. Our results are shown in Table B12.

**TABLE B12: CY 2020 FINAL PERMANENT AND TEMPORARY ADJUSTMENTS**

|                               | <b>Budget-neutral 30-day Payment Rate with Assumed Behavior Changes*</b> | <b>Budget-neutral 30-day Payment Rate with Actual Behavior Changes**</b> | <b>Adjustment</b>                   |
|-------------------------------|--|--|-------------------------------------|
| <b>Base Payment Rate</b>      | \$1,864.03   | \$1,742.52   | <b>Permanent</b><br>- 6.52%         |
| <b>Aggregate Expenditures</b> | \$15,170,223,126   | \$14,297,150,005   | <b>Temporary</b><br>- \$873,073,121 |

Source: CY 2020 Home Health Claims Data, Periods that begin and end in CY 2020 accessed on the CCW July 12, 2021.

\*This was the finalized CY 2020 base payment rate.

\*\*This is what we determined the CY 2020 30-day base payment rate should have been.

As shown in Table B12 and in the CY 2023 HH PPS final rule (87 FR 66805), a permanent prospective adjustment of -6.52 percent to the CY 2023 30-day payment rate would be required to offset for such increases in estimated aggregate expenditures in future years.

Additionally, we determined that our initial estimate of base payment rates required to achieve budget neutrality resulted in excess expenditures of HHAs of approximately \$873 million in CY 2020. This would require a temporary adjustment to offset for such increase in estimated aggregate expenditures for CY 2020.

#### (e) CY 2021 Results

This section discusses the final results CMS determined from CY 2021 claims data that was previously published in the CY 2023 final rule (87 FR 66805 through 66806). CMS did not do any recalculations for CY 2021 data and this section simply reiterates what was done previously for informative purposes only. Using the methodology described previously, we simulated 60-day episodes using actual CY 2021 30-day periods to determine what the permanent and temporary payment adjustments should be to offset for such increases or decreases in estimated aggregate expenditures as a result of the impact of differences between assumed behavior changes and actual behavior changes. For CY 2021, we began with 9,269,971 30-day periods of care and dropped 570,882 30-day periods of care that had claim occurrence code 50 date

after October 31, 2021. We also excluded 968,434 30-day periods of care that had claim occurrence code 50 date before January 1, 2021 to ensure the 30-day period would not be part of a simulated 60-day episode that began in CY 2020. Applying the additional exclusions and assumptions as described previously, an additional 5,868 30-day periods were excluded.

Additionally, we excluded 14,302 simulated 60-day episodes of care where no OASIS information was available in the CCW VRDC or could not be grouped to a HIPPS due to a missing primary diagnosis or other reason. Our simulated 60-day episodes of care produced a distribution of two 30-day periods of care (70.0 percent) and single 30-day periods of care (30.0 percent) that was similar to what we found when we simulated two 30-day periods of care for implementation of the PDGM. After all exclusions and assumptions were applied, the final dataset included 7,703,261 actual 30-day periods of care and 4,529,498 simulated 60-day episodes of care for CY 2021.

Using the final dataset for CY 2021 (7,703,261 actual 30-day periods which made up the 4,529,498 simulated 60-day episodes) we determined the estimated aggregate expenditures under the pre-PDGM HH PPS were lower than the actual estimated aggregate expenditures under the PDGM HH PPS. This indicates that aggregate expenditures under the PDGM were higher than if the 153-group payment system was still in place in CY 2021. As described

previously in the methodology, we needed to calculate what the actual CY 2021 30-day base payment rate (\$1,901.12) should have been to equal aggregate expenditures that we calculated using the simulated CY 2021 60-day episodes. We determined the CY 2021 30-day base payment rate should have been \$1,751.90 based on actual behavior rather than the \$1,901.12 based on assumed behaviors. The actual CY 2021 base payment rate of \$1,901.12 does not account for any behavior adjustments needed for CY 2020, and therefore to evaluate changes for only CY 2021 we would need to control for the -6.52 percent prospective adjustment that we determined for CY 2020. Therefore, using the recalculated CY 2020 base payment rate of \$1,742.52, multiplied by the CY 2021 wage index budget neutrality factor (0.9999) and the CY 2021 home health payment update (1.020), the CY 2021 base payment rate for assumed behaviors would have been \$1,777.19. The percent change between the two payment rates would be the annual permanent adjustment for CY 2021 (assuming the -6.52 percent adjustment was already taken). Next, we calculated the difference in aggregate expenditures for all CY 2021 PDGM 30-day claims using the actual (\$1,901.12, as this was what CMS actually paid in CY 2021) and recalculated (\$1,751.90) payment rates. This difference is the retrospective dollar amount needed to offset payment. Our results are shown in Table B13.

**TABLE B13: CY 2021 FINAL PERMANENT AND TEMPORARY ADJUSTMENTS**

|                               | <b>Budget-neutral 30-day Payment Rate with Assumed Behavior Changes</b> | <b>Budget-neutral 30-day Payment Rate with Actual Behavior Changes</b> | <b>Adjustment</b>                    |
|-------------------------------|---|--|--------------------------------------|
| <b>Base Payment Rate</b>      | \$1,777.19*   | \$1,751.90   | <b>Permanent</b><br>-1.42%           |
| <b>Aggregate Expenditures</b> | \$17,068,503,155**  | \$15,857,500,202   | <b>Temporary</b><br>-\$1,211,002,953 |

**Source:** CY 2021 Home Health Claims Data, Periods that end in CY 2021 accessed on the CCW March 21, 2022

**Notes:** \*The \$1,777.19 is equal to the recalculated budget neutral 30-day base payment rate of \$1,742.52 for CY 2020 (shown in Table B13) multiplied by the CY 2021 wage index budget neutrality factor (0.9999) and the CY 2021 home health payment update (1.020).

\*\*The estimated aggregate expenditures for assumed behavior (\$17.1 billion), uses the actual CY 2021 payment rate of \$1,901.12 as this is what CMS actually paid in CY 2021.

As shown in Table B13 and in the CY 2023 HH PPS final rule (87 FR 66806), a permanent prospective adjustment of -1.42 percent (assuming the -6.52 percent adjustment was already taken) would be required to offset for such increases in estimated aggregate expenditures in future years. Additionally, we determined that our initial estimate of base payment rates required to achieve budget neutrality resulted in excess expenditures of approximately \$1.2 billion in CY 2021. This would require a one-time temporary adjustment factor to offset for such increases in estimated aggregate expenditures for CY 2021.

#### (f) CY 2022 Preliminary Results

We will continue the practice of using the most recent complete home health claims data at the time of rulemaking. The HH PPS limited data set (LDS) file released with this proposed rule includes two files: the actual CY 2022 30-day periods and the CY 2022 simulated 60-day episodes. We remind readers a data use agreement (DUA) is required to purchase the CY 2024 proposed HH PPS LDS file. Access will be granted for both the 30-day periods and the simulated 60-day episodes under one DUA. Visit the HH PPS LDS web page for more information.<sup>13</sup> In addition, the proposed CY 2024 Home Health Descriptive Statistics from the LDS Files spreadsheet is available on the Home Health Prospective Payment System Regulations and Notices web

page,<sup>14</sup> does not require a DUA, and is available at no cost to interested parties. The spreadsheet contains information on the number of simulated 60-day episodes and actual 30-day periods in CY 2022 that were used to determine the behavior adjustments. The spreadsheet also provides information such as the number of episodes and periods by case-mix group, case-mix weights, and simulated payments. The CY 2022 analysis presented in this proposed rule is considered preliminary and, as more data become available from the latter half of CY 2022, we will update our results in the final rule. The CY 2024 final rule will utilize the CY 2022 finalized data for determining any behavior adjustment needed to the CY 2024 payment rate. However, while the claims data and the permanent and temporary behavior adjustment results will be considered complete, any adjustments to future payment rates may be subject to additional considerations such as permanent adjustments taken in previous years.

Using the methodology described previously, we simulated 60-day episodes using actual CY 2022 30-day periods to determine what the permanent and temporary payment adjustments should be to offset for such increases or decreases in estimated aggregate expenditures as a result of the impact of differences between assumed behavior changes and actual behavior changes. For CY 2022, we began with 8,386,706 30-day periods of care and dropped 476,889 30-day periods of care

that had claim occurrence code 50 date after October 31, 2022. We also excluded 894,319 30-day periods of care that had claim occurrence code 50 date before January 1, 2022 to ensure the 30-day period would not be part of a simulated 60-day episode that began in CY 2021. Applying the additional exclusions and assumptions as described previously, an additional 5,452 30-day periods were excluded.

Additionally, we excluded 17,054 simulated 60-day episodes of care where no OASIS information was available in the CCW VRDC or could not be grouped to a HIPPS due to a missing primary diagnosis or other reason. Our simulated 60-day episodes of care produced a distribution of two 30-day periods of care (69.1 percent) and single 30-day periods of care (30.9 percent) that was similar to what we found when we simulated two 30-day periods of care for implementation of the PDGM. After all exclusions and assumptions were applied, the final dataset for this proposed rule included 6,982,837 actual 30-day periods of care and 4,127,754 simulated 60-day episodes of care for CY 2022.

Using the final dataset for CY 2022 (6,982,837 actual 30-day periods which made up the 4,127,754 simulated 60-day episodes) we determined the estimated aggregate expenditures under the pre-PDGM HH PPS were lower than the actual estimated aggregate expenditures under the PDGM HH PPS as shown in Table B14. This indicates that aggregate expenditures under the PDGM were higher than if the 153-group payment system was still in place in CY 2022. As described previously in the methodology, we needed to calculate

<sup>13</sup> [https://www.cms.gov/research-statistics-data-and-systems/files-for-order/limiteddatasets/home\\_health\\_pps\\_lds](https://www.cms.gov/research-statistics-data-and-systems/files-for-order/limiteddatasets/home_health_pps_lds).

<sup>14</sup> <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HomeHealthPPS/Home-Health-Prospective-Payment-System-Regulations-and-Notices>.

what the actual CY 2022 30-day base payment rate (\$2,031.64) should have been to equal aggregate expenditures that we calculated using the simulated CY 2022 60-day episodes. We determined the CY 2022 30-day base payment rate should have been \$1,841.55 based on actual behavior rather than the \$2,031.64 based on assumed behaviors. We note, the actual CY 2022 base payment rate of \$2,031.64 does not account for any behavior adjustments needed for CYs 2020 and

2021, and therefore to evaluate changes for only CY 2022 we need to account for the -7.85 percent prospective adjustment that we determined for CYs 2020 and 2021. Therefore, using the recalculated CY 2021 base payment rate of \$1,751.90 (shown in Table B13), multiplied by the CY 2022 case-mix weights recalibration neutrality factor (1.0396), the CY 2022 wage index budget neutrality factor (1.0019) and the CY 2022 home health payment update (1.026), the CY 2022 base payment rate

for assumed behavior would have been \$1,872.18. The percent change between the two payment rates would be the additional permanent adjustment (assuming the -7.85 percent adjustment was already taken). Next, we calculated the difference in aggregate expenditures for all CY 2022 PDGM 30-day claims using the actual (\$2,031.64) and recalculated (\$1,841.55) payment rates. This difference is the retrospective dollar amount needed to offset payment. Our results are shown in Table B14.

**TABLE B14: CY 2022 PROPOSED PERMANENT AND TEMPORARY ADJUSTMENTS**

|                               | <b>Budget-neutral 30-day Payment Rate with Assumed Behavior Changes</b> | <b>Budget-neutral 30-day Payment Rate with Actual Behavior Changes</b> | <b>Adjustment</b>                    |
|-------------------------------|---|--|--------------------------------------|
| <b>Base Payment Rate</b>      | \$1,872.18*   | \$1,841.55   | <b>Permanent</b><br>-1.636%          |
| <b>Aggregate Expenditures</b> | \$16,152,035,891**  | \$14,796,827,236   | <b>Temporary</b><br>-\$1,355,208,655 |

**Source:** CY 2022 Home Health Claims Data, Periods that end in CY 2022 accessed on the CCW March 17, 2023

**Notes:** \*The \$1,872.18 is equal to the recalculated budget neutral 30-day base payment rate of \$1,751.90 for CY 2021 (shown in Table B14) multiplied by the CY 2022 wage index budget neutrality factor (1.0019) and the CY 2022 home health payment update (1.026).

\*\*The estimated aggregate expenditures for assumed behavior (\$16.2 billion), uses the actual CY 2022 payment rate of \$2,031.64 as this is what CMS actually paid in CY 2022.

As shown in Table B14, a permanent prospective adjustment of -1.636 percent to the CY 2024 30-day payment rate (assuming the -7.85 percent adjustment was already taken) would be required to offset for such increases in estimated aggregate expenditures in future years. Additionally, we determined that our initial estimate of base payment rates required to achieve budget neutrality resulted in excess expenditures of approximately \$1.4 billion in CY 2022. This would require a one-time temporary adjustment factor to offset for such increases in estimated aggregate expenditures for CY 2022.

(g) Proposed CY 2024 Permanent Adjustment and Temporary Adjustment Calculations

To offset the increase in estimated aggregate expenditures for CYs 2020 and 2021 based on the impact of the differences between assumed and actual behavior changes, CMS needed to apply a -7.85 percent permanent adjustment to the CY 2023 base payment rate, as well as implement a temporary adjustment of approximately \$2.1 billion to reconcile retrospective overpayments in CYs 2020 and 2021.

We recognized that applying the full permanent and temporary adjustment immediately would result in a significant negative adjustment in a single year. However, if the PDGM 30-day base payment rate remains higher than it should be, then there would likely be a compounding effect, potentially creating the need for an even larger reduction to adjust for behavioral changes in future years. Therefore, we proposed to apply only the permanent adjustment to the CY 2023 base payment rate. We believed this could mitigate the need for a larger permanent adjustment and could reduce the amount of any additional temporary adjustments in future years.

We also recognized the potential hardship to some providers of implementing the full -7.85 percent permanent adjustment in a single year. As we have the discretion to implement any adjustment in a time and manner determined appropriate, in accordance with section 1895(b)(3)(D) of the Act, we finalized only a -3.925 percent (half of the -7.85 percent) permanent adjustment for CY 2023. However, we emphasized that the permanent adjustment needed in CY 2023 to

account fully for actual behavior changes in CYs 2020 and 2021 was -7.85 percent, and applying a -3.925 percent permanent adjustment to the CY 2023 30-day payment rate would not fully account for differences in behavior changes on estimated aggregate expenditures during those years, as well as CYs 2022 and 2023. We stated we would need to account for that difference in future rulemaking, and any additional adjustments needed to the base payment rate, to account for behavior change based on more recent data analysis.

The percent change between the actual CY 2022 base payment rate of \$2,031.64 (based on assumed behaviors) and the CY 2022 recalculated base payment rate of \$1,841.55 (based on actual behaviors) (shown in Table B14) is the total (cumulative) permanent adjustment for CY 2022. The summation of the dollar amount for CYs 2020, 2021, and 2022 is the amount that represents the temporary payment adjustment to offset for increased aggregate expenditures in CYs 2020, 2021, and 2022. Our results are shown in Table B15 and B16.



**TABLE B15: TOTAL PERMANENT ADJUSTMENT FOR CYs 2020, 2021, and 2022**

| Actual CY 2022 Base Payment Rate (Assumed Behavior) | Recalculated CY 2022 Base Payment Rate (Actual Behavior) | Total Permanent Prospective Adjustment |
|---|--|--|
| \$2,031.64  | \$1,841.55   | -9.36%*                                |

Source: CY 2022 Home Health Claims Data, Periods that end in CY 2022 accessed on the CCW March 17, 2023.

\*This is the total permanent adjustment based on CY 2022 data which did not have any previous behavior adjustments applied. However, as described below, we recognize for CY 2024 we must account for adjustments made in CY 2023.

**TABLE B16: TOTAL TEMPORARY ADJUSTMENT FOR CYs 2020, 2021, and 2022**

| CY 2020 Temporary Final Adjustment | CY 2021 Temporary Final Adjustment | CY 2022 Temporary Proposed Adjustment | Total Temporary Adjustment Dollar Amount for CYs 2020, 2021, and 2022 |
|------------------------------------|------------------------------------|---------------------------------------|---|
| -\$873,073,121                     | -\$1,211,002,953                   | -\$1,355,208,655                      | -\$3,439,284,729  |

Source: CY 2020 Home Health Claims Data, Periods that begin and end in CY 2020 accessed on the CCW July 12, 2021. CY 2021 Home Health Claims Data, Periods that end in CY 2021 accessed on the CCW March 21, 2022. CY 2022 Home Health Claims Data, Periods that end in CY 2022 accessed on CCW March 17, 2023.

We remind readers adjustment factors are multiplied in this payment system and therefore individual numbers (that is, percentages) do not sum precisely to the permanent adjustment needed to account for the total permanent adjustment in that year. Additionally, as we stated in the CY 2023 HH PPS final rule (87 FR 66808), applying a -3.925 percent permanent adjustment to the CY 2023 30-day payment rate would not adjust the rate fully to account for differences in behavior changes on estimated aggregate expenditures in CYs 2020 and 2021. Therefore, we cannot determine the CY 2024 proposed permanent adjustment by simply subtracting -3.925 percent from the total permanent adjustment of -9.356 percent.

Instead, we look at the total permanent adjustment needed for the current year of data and account for any prior permanent adjustments through multiplication and division of factors. In other words, we determined the total permanent adjustment based on CY 2022 data (which had no prior adjustments) is -9.356 percent, which is converted to a 0.90644 factor. We recognize that in CY 2023 we implemented a -3.925 percent permanent behavior adjustment, converted to a 0.96075 factor, and we must account for it in the proposed CY 2024 permanent adjustment. Next, we calculated the CY 2024 permanent

adjustment factor by solving  $(1 - x) = 0.90644$  (9.356 percent) divided by 0.96075 (3.925 percent). The resulting factor  $(1 - x)$  is 0.94347, which is converted to a 5.653 percent reduction to the CY 2024 national, standardized base payment rate. In other words, 1 minus the factor 0.94347 equals 0.05653 which is equal to 5.653 percent reduction. Therefore, to offset the increase in estimated aggregate expenditures for CY 2022 based on the impact of the differences between assumed and actual behavior changes, and to account for the permanent adjustment of -3.925 percent taken in CY 2023 rulemaking, CMS would need to apply a -5.653 percent permanent adjustment to the CY 2024 base payment rate. We are proposing to apply a -5.653 percent permanent adjustment to the CY 2024 national, standardized 30-day payment rate.

We acknowledge that, as previously discussed, we finalized, in the CY 2023 HH PPS final rule, half of the -7.85 percent permanent adjustment, noting that the full permanent adjustment may be burdensome for some providers. However, we believe applying the full permanent adjustment of -5.635 in CY 2024 would potentially reduce any future permanent adjustments, stem the accrual of the temporary payment adjustment dollar amount, and would help fulfill the statutory requirements at section 1895(b)(3)(D) of the Act to offset

any increases or decreases on the impact of differences between assumed behavior and actual behavior changes on estimated aggregate expenditures. We previously explained when reducing the permanent adjustment in CY 2023 that we would need to implement a greater rate reduction in future years, therefore home health agencies have had some time to consider this proposed rate reduction.

In order to calculate the temporary adjustment, we would add the CY 2022 temporary adjustment dollar amount of \$1,355,208,655 to the previously finalized CYs 2020 and 2021 dollar amounts for a total of \$3,439,284,729. We stated in the CY 2023 HH PPS final rule (87 FR 66804) and in this proposed rule, after we determine the dollar amount to be reconciled we will calculate a temporary adjustment factor to be applied to the base payment rate for that year. That is, the dollar amount will be converted to a factor. However, as we noted in the CY 2023 HH PPS proposed rule (87 FR 37682), we recognize that implementing both the permanent and temporary adjustments may adversely affect HHAs. Given that the magnitude of both the temporary and permanent adjustments for CY 2024 rate setting may result in a significant reduction of the payment rate, we are not proposing to take the temporary adjustment in CY 2024. We will propose a temporary adjustment factor to the

national, standardized base payment rate when we propose this temporary payment adjustment in future rulemaking. As noted previously, we will update these permanent and temporary adjustments in the final rule to reflect more complete claims data for CY 2022. We solicit comments on the proposal to apply a –5.653 percent permanent adjustment to the CY 2024 base payment rate.

## 2. Proposed CY 2024 PDGM LUPA Thresholds and PDGM Case-Mix Weights

### (a) Proposed CY 2024 PDGM LUPA Thresholds

Under the HH PPS, LUPAs are paid when a certain visit threshold for a payment group during a 30-day period of care is not met. In the CY 2019 HH PPS final rule with comment period (83 FR 56492), we finalized that the LUPA thresholds would be set at the 10th percentile of visits or 2 visits, whichever is higher, for each payment group. This means the LUPA threshold for each 30-day period of care varies depending on the PDGM payment group to which it is assigned. If the LUPA threshold for the payment group is met under the PDGM, the 30-day period of care will be paid the full 30-day period case-mix adjusted payment amount (subject to any partial payment adjustment or outlier adjustments). If a 30-day period of care does not meet the PDGM LUPA visit threshold, then payment will be made using the CY 2024 per-visit payment amounts as described in section I.C.4.f.2 of this proposed rule. For example, if the LUPA visit threshold is four, and a 30-day period of care has four or more visits, it is paid the full 30-day period payment amount; if the period of care has three or less visits, payment is made using the per-visit payment amounts.

In the CY 2019 HH PPS final rule with comment period (83 FR 56492), we finalized our policy that the LUPA thresholds for each PDGM payment group would be reevaluated every year based on the most current utilization data available at the time of rulemaking. However, as CY 2020 was the first year of the new case-mix adjustment methodology, we stated in the CY 2021 HH PPS final rule (85 FR 70305, 70306) that we would maintain the LUPA thresholds that were finalized and shown in Table 17 of the CY 2020 HH PPS final rule with comment period (84 FR 60522) for CY 2021 payment purposes. We stated that at that time, we did not have sufficient CY 2020 data to reevaluate the LUPA thresholds for CY 2021.

In the CY 2022 HH PPS final rule with comment period (86 FR 62249), we finalized the proposal to recalibrate the PDGM case-mix weights, functional impairment levels, and comorbidity subgroups while maintaining the LUPA thresholds for CY 2022. We stated that because there are several factors that contribute to how the case-mix weight is set for a particular case-mix group (such as the number of visits, length of visits, types of disciplines providing visits, and non-routine supplies) and the case-mix weight is derived by comparing the average resource use for the case-mix group relative to the average resource use across all groups, we believe the COVID–19 PHE would have impacted utilization within all case-mix groups similarly. Therefore, the impact of any reduction in resource use caused by the PHE on the calculation of the case-mix weight would be minimized since the impact would be accounted for both in the numerator and denominator of the formula used to calculate the case-mix weight. However, in contrast, the LUPA thresholds are based on the number of overall visits in a particular case-mix group (the threshold is the 10th percentile of visits or 2 visits, whichever is greater) instead of a relative value (like what is used to generate the case-mix weight) that would control for the impacts of the COVID–19 PHE. We noted that visit patterns and some of the decrease in overall visits in CY 2020 may not be representative of visit patterns in CY 2022. Therefore, to mitigate any potential future and significant short-term variability in the LUPA thresholds due to the COVID–19 PHE, we finalized the proposal to maintain the LUPA thresholds finalized and displayed in Table 17 in the CY 2020 HH PPS final rule with comment period (84 FR 60522) for CY 2022 payment purposes.

For CY 2023, we proposed to update the LUPA thresholds using CY 2021 Medicare home health claims (as of March 21, 2022) linked to OASIS assessment data. After reviewing the CY 2022 home health claims utilization data we determined that visit patterns have stabilized. Our data analysis indicated that visits in 2022 were similar to visits in 2020. We believed that CY 2021 data will be more indicative of visit patterns in CY 2023 rather than continuing to use the LUPA thresholds derived from the CY 2018 data pre-PDGM. Therefore, we finalized a policy to update the LUPA thresholds for CY 2023 using data from CY 2021.

For CY 2024, we are proposing to update the LUPA thresholds using CY 2022 home health claims utilization

data (as of March 17, 2023), in accordance with our policy to annually recalibrate the case-mix weights and update the LUPA thresholds, functional impairment levels and comorbidity subgroups. The proposed LUPA thresholds for the CY 2024 PDGM payment groups with the corresponding Health Insurance Prospective Payment System (HIPPS) codes and the case-mix weights are listed in Table B22. We solicit public comments on the proposed updates to the LUPA thresholds for CY 2024.

### (b) CY 2024 Functional Impairment Levels

Under the PDGM, the functional impairment level is determined by responses to certain OASIS items associated with activities of daily living and risk of hospitalization; that is, responses to OASIS items M1800–M1860 and M1033. A home health period of care receives points based on each of the responses associated with these functional OASIS items, which are then converted into a table of points corresponding to increased resource use. The sum of all of these points results in a functional score which is used to group home health periods into a functional level with similar resource use. That is, the higher the points, the higher the response is associated with increased resource use. The sum of all of these points results in a functional impairment score which is used to group home health periods into one of three functional impairment levels with similar resource use. The three functional impairment levels of low, medium, and high were designed so that approximately one-third of home health periods from each of the clinical groups fall within each level. This means home health periods in the low impairment level have responses for the functional OASIS items that are associated with the lowest resource use, on average. Home health periods in the high impairment level have responses for the functional OASIS items that are associated with the highest resource use on average.

For CY 2024, we propose to use CY 2022 claims data to update the functional points and functional impairment levels by clinical group. The CY 2018 HH PPS proposed rule (82 FR 35320) and the technical report from December 2016, posted on the Home Health PPS Archive web page located at: <https://www.cms.gov/medicare/home-health-pps/home-health-pps-archive>, provides a more detailed explanation as to the construction of these functional impairment levels using the OASIS items. We are proposing to use this

same methodology previously finalized to update the functional impairment levels for CY 2024. The updated OASIS functional points table and the table of

functional impairment levels by clinical group for CY 2024 are listed in Tables B17 and B18, respectively. We solicit public comments on the updates to

functional points and the functional impairment levels by clinical group.  
BILLING CODE 4120-01-P

**TABLE B17: PROPOSED OASIS POINTS TABLE FOR CY 2024**

|   | Responses  | Points (2024) | Percent of Periods in 2022 with this Response Category |
|---|--|---------------|--|
| <b>M1800: Grooming</b>                            | 0 or 1   | 0             | 28.0%  |
|   | 2 or 3   | 3             | 72.0%  |
| <b>M1810: Current Ability to Dress Upper Body</b> | 0 or 1   | 0             | 22.9%  |
|   | 2 or 3   | 5             | 77.1%  |
| <b>M1820: Current Ability to Dress Lower Body</b> | 0 or 1   | 0             | 10.5%  |
|   | 2  | 3             | 66.0%  |
|   | 3  | 11            | 23.5%  |
| <b>M1830: Bathing</b>                             | 0 or 1   | 0             | 2.6%   |
|   | 2  | 0             | 10.8%  |
|   | 3 or 4   | 7             | 50.4%  |
|   | 5 or 6   | 14            | 36.2%  |
| <b>M1840: Toilet Transferring</b>                 | 0 or 1   | 0             | 62.4%  |
|   | 2, 3 or 4  | 6             | 37.6%  |
| <b>M1850: Transferring</b>                        | 0  | 0             | 1.4%   |
|   | 1  | 3             | 20.1%  |
|   | 2, 3, 4 or 5   | 6             | 78.5%  |
| <b>M1860: Ambulation/Locomotion</b>               | 0 or 1   | 0             | 3.2%   |
|   | 2  | 6             | 13.4%  |
|   | 3  | 4             | 65.6%  |
|   | 4, 5 or 6  | 20            | 17.8%  |
| <b>M1033: Risk of Hospitalization</b>             | Three or fewer items marked (Excluding responses 8, 9 or 10) | 0             | 61.5%  |
|   | Four or more items marked (Excluding responses 8, 9 or 10)   | 11            | 38.5%  |

Source: CY 2022 Home Health Claims Data, Periods that end in CY 2022 accessed from the CCW on March 17, 2023.

Note: For item M1860, the point values for response 2 is worth more than the point values for response 3. There may be times in which the resource use for certain OASIS items associated with functional impairment will result in a seemingly inverse relationship to the response reported. However, this is the result of the direct association between the responses reported on the OASIS items and actual resource use.

**TABLE B18: PROPOSED THRESHOLDS FOR FUNCTIONAL LEVELS BY CLINICAL GROUP, FOR CY 2024**

| Clinical Group   | Level of Impairment | Points (2024) |
|--|---------------------|---------------|
| MMTA - Other   | Low                 | 0-28          |
|  | Medium              | 29-41         |
|  | High                | 42+           |
| Behavioral Health  | Low                 | 0-28          |
|  | Medium              | 29-41         |
|  | High                | 42+           |
| Complex Nursing Interventions                                    | Low                 | 0-28          |
|  | Medium              | 29-52         |
|  | High                | 53+           |
| Musculoskeletal Rehabilitation                                   | Low                 | 0-28          |
|  | Medium              | 29-41         |
|  | High                | 42+           |
| Neuro Rehabilitation   | Low                 | 0-34          |
|  | Medium              | 35-49         |
|  | High                | 50+           |
| Wound  | Low                 | 0-28          |
|  | Medium              | 29-49         |
|  | High                | 50+           |
| MMTA - Surgical Aftercare  | Low                 | 0-28          |
|  | Medium              | 29-39         |
|  | High                | 40+           |
| MMTA - Cardiac and Circulatory                                   | Low                 | 0-28          |
|  | Medium              | 29-41         |
|  | High                | 42+           |
| MMTA - Endocrine   | Low                 | 0-27          |
|  | Medium              | 28-39         |
|  | High                | 40+           |
| MMTA - Gastrointestinal tract and Genitourinary system           | Low                 | 0-31          |
|  | Medium              | 32-46         |
|  | High                | 47+           |
| MMTA - Infectious Disease, Neoplasms, and Blood-Forming Diseases | Low                 | 0-28          |
|  | Medium              | 29-43         |
|  | High                | 44+           |
| MMTA - Respiratory   | Low                 | 0-29          |
|  | Medium              | 30-44         |
|  | High                | 45+           |

Source: CY 2022 Home Health Claims Data, Periods that end in CY 2022 accessed from the CCW on March 17, 2023.

#### (c) CY 2024 Comorbidity Subgroups

Thirty-day periods of care receive a comorbidity adjustment category based on the presence of certain secondary diagnoses reported on home health claims. These diagnoses are based on a home-health specific list of clinically and statistically significant secondary diagnosis subgroups with similar resource use, meaning the diagnoses have at least as high as the median resource use and are reported in more than 0.1 percent of 30-day periods of

care. Home health 30-day periods of care can receive a comorbidity adjustment under the following circumstances:

- *Low comorbidity adjustment:* There is a reported secondary diagnosis on the home health-specific comorbidity subgroup list that is associated with higher resource use.
- *High comorbidity adjustment:* There are two or more secondary diagnoses on the home health-specific comorbidity subgroup interaction list that are associated with higher resource

use when both are reported together compared to when they are reported separately. That is, the two diagnoses may interact with one another, resulting in higher resource use.

- *No comorbidity adjustment:* A 30-day period of care receives no comorbidity adjustment if no secondary diagnoses exist or do not meet the criteria for a low or high comorbidity adjustment.

In the CY 2019 HH PPS final rule with comment period (83 FR 56406), we stated that we would continue to

examine the relationship of reported comorbidities on resource utilization and make the appropriate payment refinements to help ensure that payment is in alignment with the actual costs of providing care. For CY 2024, we propose to use the same methodology used to establish the comorbidity subgroups to update the comorbidity subgroups using CY 2022 home health data.

For CY 2024, we propose to update the comorbidity subgroups to include 21 low comorbidity adjustment subgroups as identified in Table B19 and 101 high comorbidity adjustment interaction subgroups as identified in Table B20. The proposed CY 2024 low comorbidity adjustment subgroups and the high comorbidity adjustment interaction subgroups including those diagnoses within each of these comorbidity

adjustments will also be posted on the HHA Center web page at <https://www.cms.gov/Center/Provider-Type/Home-Health-Agency-HHA-Center>.

We invite comments on the proposed updates to the low comorbidity adjustment subgroups and the high comorbidity adjustment interactions for CY 2024.

BILLING CODE 4120-01-P

**TABLE B19: LOW COMORBIDITY ADJUSTMENT SUBGROUPS FOR CY 2024**

| Low Comorbidity Subgroup | Description  |
|--------------------------|--|
| Cerebral 4               | Sequelae of Cerebrovascular Diseases, includes Cerebral Atherosclerosis and Stroke Sequelae      |
| Circulatory 10           | Varicose Veins and Lymphedema  |
| Circulatory 2            | Hemolytic, Aplastic, and Other Anemias   |
| Circulatory 7            | Atherosclerosis, includes Peripheral Vascular Disease, Aortic Aneurysms and Hypotension          |
| Circulatory 9            | Other Venous Embolism and Thrombosis   |
| Endocrine 4              | Other Combined Immunodeficiencies and Malnutrition, includes graft-versus-host-disease           |
| Gastrointestinal 2       | Intestinal Obstruction and Ileus   |
| Heart 10                 | Dysrhythmias, includes Atrial Fibrillation and Atrial Flutter                                    |
| Heart 11                 | Heart Failure  |
| Neoplasms 1              | Malignant Neoplasms of Lip, Oral Cavity and Pharynx, includes Head and Neck Cancers              |
| Neoplasms 17             | Secondary neoplasms of respiratory and GI systems.   |
| Neoplasms 18             | Secondary Neoplasms of Urinary and Reproductive Systems, Skin, Brain, and Bone                   |
| Neoplasms 2              | Malignant Neoplasms of Digestive Organs, includes Gastrointestinal Cancers                       |
| Neurological 10          | Diabetes with neuropathy   |
| Neurological 11          | Disease of the Macula and Blindness/Low Vision   |
| Neurological 12          | Nondiabetic neuropathy   |
| Neurological 4           | Alzheimer’s disease and related dementias  |
| Neurological 5           | Spinal Muscular Atrophy, Systemic atrophy and Motor Neuron Disease                               |
| Neurological 7           | Paraplegia, Hemiplegia and Quadriplegia  |
| Skin 1                   | Cutaneous Abscess, Cellulitis, and Lymphangitis  |
| Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| Skin 4                   | Stages Two-Four and unstageable pressure ulcers by site  |

Source: CY 2022 Home Health Claims Data, Periods that end in CY 2021 accessed on the CCW March 17, 2023.

TABLE B20: HIGH COMORBIDITY ADJUSTMENT INTERACTIONS FOR CY 2024

| Comorbidity Subgroup Interaction | Comorbidity Group | Description   | Comorbidity Group | Description  |
|----------------------------------|-------------------|---|-------------------|--|
| 1                                | Behavioral 2      | Mood Disorders, includes Depression and Bipolar Disorder  | Circulatory 10    | Varicose Veins and Lymphedema  |
| 2                                | Behavioral 2      | Mood Disorders, includes Depression and Bipolar Disorder  | Neurological 5    | Spinal Muscular Atrophy, Systemic atrophy and Motor Neuron Disease                               |
| 3                                | Behavioral 2      | Mood Disorders, includes Depression and Bipolar Disorder  | Neurological 7    | Paraplegia, Hemiplegia and Quadriplegia  |
| 4                                | Behavioral 4      | Psychotic, major depressive, and dissociative disorders, includes unspecified dementia, eating disorder and intellectual disabilities | Skin 3            | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 5                                | Behavioral 4      | Psychotic, major depressive, and dissociative disorders, includes unspecified dementia, eating disorder and intellectual disabilities | Skin 4            | Stages Two-Four and unstageable pressure ulcers by site  |
| 6                                | Behavioral 5      | Phobias, Other Anxiety and Obsessive Compulsive Disorders   | Circulatory 10    | Varicose Veins and Lymphedema  |
| 7                                | Behavioral 5      | Phobias, Other Anxiety and Obsessive Compulsive Disorders   | Neurological 5    | Spinal Muscular Atrophy, Systemic atrophy and Motor Neuron Disease                               |
| 8                                | Behavioral 5      | Phobias, Other Anxiety and Obsessive Compulsive Disorders   | Neurological 7    | Paraplegia, Hemiplegia and Quadriplegia  |
| 9                                | Cerebral 4        | Sequelae of Cerebrovascular Diseases, includes Cerebral Atherosclerosis and Stroke Sequelae   | Circulatory 2     | Hemolytic, Aplastic, and Other Anemias   |
| 10                               | Cerebral 4        | Sequelae of Cerebrovascular Diseases, includes Cerebral Atherosclerosis and Stroke Sequelae   | Circulatory 7     | Atherosclerosis, includes Peripheral Vascular Disease, Aortic Aneurysms and Hypotension          |
| 11                               | Cerebral 4        | Sequelae of Cerebrovascular Diseases, includes Cerebral Atherosclerosis and Stroke Sequelae   | Neurological 10   | Diabetes with neuropathy   |
| 12                               | Cerebral 4        | Sequelae of Cerebrovascular Diseases, includes Cerebral Atherosclerosis and Stroke Sequelae   | Neurological 11   | Disease of the Macula and Blindness/Low Vision   |
| 13                               | Cerebral 4        | Sequelae of Cerebrovascular Diseases, includes Cerebral Atherosclerosis and Stroke Sequelae   | Respiratory 2     | Whooping cough   |
| 14                               | Cerebral 4        | Sequelae of Cerebrovascular Diseases, includes Cerebral Atherosclerosis and Stroke Sequelae   | Respiratory 9     | Respiratory Failure and Atelectasis  |

| <b>Comorbidity Subgroup Interaction</b> | <b>Comorbidity Group</b> | <b>Description</b>  | <b>Comorbidity Group</b> | <b>Description</b>   |
|---|--------------------------|---|--------------------------|--|
| 15                                      | Cerebral 4               | Sequelae of Cerebrovascular Diseases, includes Cerebral Atherosclerosis and Stroke Sequelae | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 16                                      | Cerebral 4               | Sequelae of Cerebrovascular Diseases, includes Cerebral Atherosclerosis and Stroke Sequelae | Skin 4                   | Stages Two-Four and unstageable pressure ulcers by site  |
| 17                                      | Circulatory 1            | Nutritional, Enzymatic, and Other Heredity Anemias  | Neurological 7           | Paraplegia, Hemiplegia and Quadriplegia  |
| 18                                      | Circulatory 1            | Nutritional, Enzymatic, and Other Heredity Anemias  | Skin 1                   | Cutaneous Abscess, Cellulitis, and Lymphangitis  |
| 19                                      | Circulatory 1            | Nutritional, Enzymatic, and Other Heredity Anemias  | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 20                                      | Circulatory 10           | Varicose Veins and Lymphedema   | Circulatory 2            | Hemolytic, Aplastic, and Other Anemias   |
| 21                                      | Circulatory 10           | Varicose Veins and Lymphedema   | Endocrine 3              | Type 1, Type 2, and Other Specified Diabetes   |
| 22                                      | Circulatory 10           | Varicose Veins and Lymphedema   | Endocrine 5              | Obesity, and Disorders of Metabolism and Fluid Balance   |
| 23                                      | Circulatory 10           | Varicose Veins and Lymphedema   | Heart 8                  | Other Pulmonary Heart Diseases   |
| 24                                      | Circulatory 10           | Varicose Veins and Lymphedema   | Musculoskeletal 3        | Joint Pain   |
| 25                                      | Circulatory 10           | Varicose Veins and Lymphedema   | Neurological 10          | Diabetes with neuropathy   |
| 26                                      | Circulatory 10           | Varicose Veins and Lymphedema   | Renal 1                  | Chronic kidney disease and ESRD  |
| 27                                      | Circulatory 10           | Varicose Veins and Lymphedema   | Renal 3                  | Other disorders of the kidney and ureter, excluding chronic kidney disease and ESRD              |
| 28                                      | Circulatory 10           | Varicose Veins and Lymphedema   | Respiratory 9            | Respiratory Failure and Atelectasis  |
| 29                                      | Circulatory 10           | Varicose Veins and Lymphedema   | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 30                                      | Circulatory 2            | Hemolytic, Aplastic, and Other Anemias  | Neurological 5           | Spinal Muscular Atrophy, Systemic atrophy and Motor Neuron Disease                               |
| 31                                      | Circulatory 2            | Hemolytic, Aplastic, and Other Anemias  | Neurological 7           | Paraplegia, Hemiplegia and Quadriplegia  |
| 32                                      | Circulatory 2            | Hemolytic, Aplastic, and Other Anemias  | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 33                                      | Circulatory 2            | Hemolytic, Aplastic, and Other Anemias  | Skin 4                   | Stages Two-Four and unstageable pressure ulcers by site  |
| 34                                      | Circulatory 4            | Hypertensive Chronic Kidney Disease   | Neurological 7           | Paraplegia, Hemiplegia and Quadriplegia  |
| 35                                      | Circulatory 4            | Hypertensive Chronic Kidney Disease   | Skin 1                   | Cutaneous Abscess, Cellulitis, and Lymphangitis  |
| 36                                      | Circulatory 4            | Hypertensive Chronic Kidney Disease   | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 37                                      | Circulatory 4            | Hypertensive Chronic Kidney Disease   | Skin 4                   | Stages Two-Four and unstageable pressure ulcers by site  |
| 38                                      | Circulatory 7            | Atherosclerosis, includes Peripheral Vascular Disease, Aortic Aneurysms and Hypotension     | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |

| <b>Comorbidity Subgroup Interaction</b> | <b>Comorbidity Group</b> | <b>Description</b>   | <b>Comorbidity Group</b> | <b>Description</b>   |
|---|--------------------------|--|--------------------------|--|
| 39                                      | Circulatory 9            | Other Venous Embolism and Thrombosis   | Endocrine 4              | Other Combined Immunodeficiencies and Malnutrition, includes graft-versus-host-disease           |
| 40                                      | Circulatory 9            | Other Venous Embolism and Thrombosis   | Neurological 10          | Diabetes with neuropathy   |
| 41                                      | Circulatory 9            | Other Venous Embolism and Thrombosis   | Renal 3                  | Other disorders of the kidney and ureter, excluding chronic kidney disease and ESRD              |
| 42                                      | Endocrine 1              | Hypothyroidism   | Neurological 5           | Spinal Muscular Atrophy, Systemic atrophy and Motor Neuron Disease                               |
| 43                                      | Endocrine 1              | Hypothyroidism   | Neurological 7           | Paraplegia, Hemiplegia and Quadriplegia  |
| 44                                      | Endocrine 1              | Hypothyroidism   | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 45                                      | Endocrine 1              | Hypothyroidism   | Skin 4                   | Stages Two-Four and unstageable pressure ulcers by site  |
| 46                                      | Endocrine 3              | Type 1, Type 2, and Other Specified Diabetes   | Neurological 5           | Spinal Muscular Atrophy, Systemic atrophy and Motor Neuron Disease                               |
| 47                                      | Endocrine 3              | Type 1, Type 2, and Other Specified Diabetes   | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 48                                      | Endocrine 3              | Type 1, Type 2, and Other Specified Diabetes   | Skin 4                   | Stages Two-Four and unstageable pressure ulcers by site  |
| 49                                      | Endocrine 4              | Other Combined Immunodeficiencies and Malnutrition, includes graft-versus-host-disease | Neurological 7           | Paraplegia, Hemiplegia and Quadriplegia  |
| 50                                      | Endocrine 4              | Other Combined Immunodeficiencies and Malnutrition, includes graft-versus-host-disease | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 51                                      | Endocrine 4              | Other Combined Immunodeficiencies and Malnutrition, includes graft-versus-host-disease | Skin 4                   | Stages Two-Four and unstageable pressure ulcers by site  |
| 52                                      | Endocrine 5              | Obesity, and Disorders of Metabolism and Fluid Balance                                 | Neurological 7           | Paraplegia, Hemiplegia and Quadriplegia  |
| 53                                      | Endocrine 5              | Obesity, and Disorders of Metabolism and Fluid Balance                                 | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 54                                      | Endocrine 5              | Obesity, and Disorders of Metabolism and Fluid Balance                                 | Skin 4                   | Stages Two-Four and unstageable pressure ulcers by site  |
| 55                                      | Heart 10                 | Dysrhythmias, includes Atrial Fibrillation and Atrial Flutter                          | Neoplasms 18             | Secondary Neoplasms of Urinary and Reproductive Systems, Skin, Brain, and Bone                   |
| 56                                      | Heart 10                 | Dysrhythmias, includes Atrial Fibrillation and Atrial Flutter                          | Neurological 5           | Spinal Muscular Atrophy, Systemic atrophy and Motor Neuron Disease                               |
| 57                                      | Heart 10                 | Dysrhythmias, includes Atrial Fibrillation and Atrial Flutter                          | Neurological 7           | Paraplegia, Hemiplegia and Quadriplegia  |
| 58                                      | Heart 10                 | Dysrhythmias, includes Atrial Fibrillation and Atrial Flutter                          | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |



| <b>Comorbidity Subgroup Interaction</b> | <b>Comorbidity Group</b> | <b>Description</b>  | <b>Comorbidity Group</b> | <b>Description</b>   |
|---|--------------------------|---|--------------------------|--|
| 59                                      | Heart 10                 | Dysrhythmias, includes Atrial Fibrillation and Atrial Flutter | Skin 4                   | Stages Two-Four and unstageable pressure ulcers by site  |
| 60                                      | Heart 11                 | Heart Failure   | Neurological 7           | Paraplegia, Hemiplegia and Quadriplegia  |
| 61                                      | Heart 11                 | Heart Failure   | Skin 1                   | Cutaneous Abscess, Cellulitis, and Lymphangitis  |
| 62                                      | Heart 11                 | Heart Failure   | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 63                                      | Heart 11                 | Heart Failure   | Skin 4                   | Stages Two-Four and unstageable pressure ulcers by site  |
| 64                                      | Heart 12                 | Other Heart Diseases  | Neurological 5           | Spinal Muscular Atrophy, Systemic atrophy and Motor Neuron Disease                               |
| 65                                      | Heart 12                 | Other Heart Diseases  | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 66                                      | Heart 8                  | Other Pulmonary Heart Diseases                                | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 67                                      | Heart 8                  | Other Pulmonary Heart Diseases                                | Skin 4                   | Stages Two-Four and unstageable pressure ulcers by site  |
| 68                                      | Heart 9                  | Valve Disorders   | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 69                                      | Heart 9                  | Valve Disorders   | Skin 4                   | Stages Two-Four and unstageable pressure ulcers by site  |
| 70                                      | Infectious 1             | C-diff, MRSA, E-coli  | Neurological 7           | Paraplegia, Hemiplegia and Quadriplegia  |
| 71                                      | Infectious 1             | C-diff, MRSA, E-coli  | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 72                                      | Infectious 1             | C-diff, MRSA, E-coli  | Skin 4                   | Stages Two-Four and unstageable pressure ulcers by site  |
| 73                                      | Musculoskeletal 2        | Rheumatoid Arthritis  | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 74                                      | Musculoskeletal 3        | Joint Pain  | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 75                                      | Musculoskeletal 4        | Lumbar Spinal Stenosis  | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 76                                      | Neurological 10          | Diabetes with neuropathy                                      | Neurological 5           | Spinal Muscular Atrophy, Systemic atrophy and Motor Neuron Disease                               |
| 77                                      | Neurological 10          | Diabetes with neuropathy                                      | Neurological 7           | Paraplegia, Hemiplegia and Quadriplegia  |
| 78                                      | Neurological 10          | Diabetes with neuropathy                                      | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 79                                      | Neurological 10          | Diabetes with neuropathy                                      | Skin 4                   | Stages Two-Four and unstageable pressure ulcers by site  |
| 80                                      | Neurological 11          | Disease of the Macula and Blindness/Low Vision                | Skin 3                   | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |

| Comorbidity Subgroup Interaction | Comorbidity Group | Description  | Comorbidity Group | Description  |
|----------------------------------|-------------------|--|-------------------|--|
| 81                               | Neurological 12   | Nondiabetic neuropathy   | Neurological 7    | Paraplegia, Hemiplegia and Quadriplegia  |
| 82                               | Neurological 12   | Nondiabetic neuropathy   | Skin 3            | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 83                               | Neurological 4    | Alzheimer's disease and related dementias  | Neurological 5    | Spinal Muscular Atrophy, Systemic atrophy and Motor Neuron Disease                               |
| 84                               | Neurological 4    | Alzheimer's disease and related dementias  | Skin 3            | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 85                               | Neurological 4    | Alzheimer's disease and related dementias  | Skin 4            | Stages Two-Four and unstageable pressure ulcers by site  |
| 86                               | Neurological 5    | Spinal Muscular Atrophy, Systemic atrophy and Motor Neuron Disease                               | Neurological 7    | Paraplegia, Hemiplegia and Quadriplegia  |
| 87                               | Neurological 5    | Spinal Muscular Atrophy, Systemic atrophy and Motor Neuron Disease                               | Renal 1           | Chronic kidney disease and ESRD  |
| 88                               | Neurological 5    | Spinal Muscular Atrophy, Systemic atrophy and Motor Neuron Disease                               | Respiratory 5     | Chronic Obstructive Pulmonary Disease, and Asthma, and Bronchiectasis                            |
| 89                               | Neurological 5    | Spinal Muscular Atrophy, Systemic atrophy and Motor Neuron Disease                               | Skin 3            | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 90                               | Neurological 5    | Spinal Muscular Atrophy, Systemic atrophy and Motor Neuron Disease                               | Skin 4            | Stages Two-Four and unstageable pressure ulcers by site  |
| 91                               | Neurological 7    | Paraplegia, Hemiplegia and Quadriplegia  | Neurological 8    | Epilepsy   |
| 92                               | Neurological 7    | Paraplegia, Hemiplegia and Quadriplegia  | Renal 3           | Other disorders of the kidney and ureter, excluding chronic kidney disease and ESRD              |
| 93                               | Neurological 7    | Paraplegia, Hemiplegia and Quadriplegia  | Respiratory 5     | Chronic Obstructive Pulmonary Disease, and Asthma, and Bronchiectasis                            |
| 94                               | Neurological 7    | Paraplegia, Hemiplegia and Quadriplegia  | Skin 4            | Stages Two-Four and unstageable pressure ulcers by site  |
| 95                               | Neurological 8    | Epilepsy   | Skin 4            | Stages Two-Four and unstageable pressure ulcers by site  |
| 96                               | Renal 1           | Chronic kidney disease and ESRD  | Skin 3            | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 97                               | Renal 3           | Other disorders of the kidney and ureter, excluding chronic kidney disease and ESRD              | Skin 4            | Stages Two-Four and unstageable pressure ulcers by site  |
| 98                               | Respiratory 2     | Whooping cough   | Skin 4            | Stages Two-Four and unstageable pressure ulcers by site  |
| 99                               | Respiratory 5     | Chronic Obstructive Pulmonary Disease, and Asthma, and Bronchiectasis                            | Skin 4            | Stages Two-Four and unstageable pressure ulcers by site  |
| 100                              | Skin 1            | Cutaneous Abscess, Cellulitis, and Lymphangitis  | Skin 3            | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers |
| 101                              | Skin 3            | Diseases of arteries, arterioles and capillaries with ulceration and non-pressure chronic ulcers | Skin 4            | Stages Two-Four and unstageable pressure ulcers by site  |

Source: CY 2022 Home Health Claims Data, Periods that end in CY 2022 accessed from the CCW March 17, 2023.

## (d) CY 2024 PDGM Case-Mix Weights

As finalized in the CY 2019 HH PPS final rule with comment period (83 FR 56502), the PDGM places patients into meaningful payment categories based on patient and other characteristics, such as timing, admission source, clinical grouping using the reported principal diagnosis, functional impairment level, and comorbid conditions. The PDGM case-mix methodology results in 432 unique case-mix groups called home health resource groups (HHRGs). We also finalized a policy in the CY 2019 HH PPS final rule with comment period (83 FR 56515) to recalibrate annually the PDGM case-mix weights using a fixed effects model with the most recent and complete utilization data available at the time of annual rulemaking. Annual recalibration of the PDGM case-mix weights ensures that the case-mix weights reflect, as accurately as possible, current home health resource use and changes in utilization patterns. To generate the proposed recalibrated CY 2024 case-mix weights, we used CY 2022 home health claims data with linked OASIS data (as of March 17, 2023). These data are the most current and complete data available at this time. We believe that recalibrating the case-mix weights using data from CY 2022 would be reflective of PDGM utilization and patient resource use for CY 2024. The proposed recalibrated case-mix weights will be updated based on more complete CY 2022 claims data for the final rule.

The claims data provide visit-level data and data on whether non-routine supplies (NRS) were provided during the period and the total charges of NRS. We determine the case-mix weight for each of the 432 different PDGM payment groups by regressing resource use on a series of indicator variables for each of the categories using a fixed effects model as described in the following steps:

*Step 1:* Estimate a regression model to assign a functional impairment level to each 30-day period. The regression model estimates the relationship between a 30-day period's resource use and the functional status and risk of hospitalization items included in the PDGM, which are obtained from certain OASIS items. We refer readers to Table

B17 for further information on the OASIS items used for the functional impairment level under the PDGM. We measure resource use with the cost-per-minute + NRS approach that uses information from 2021 home health cost reports. We use 2021 home health cost report data because it is the most complete cost report data available at the time of rulemaking. Other variables in the regression model include the 30-day period's admission source, clinical group, and 30-day period timing. We also include home health agency level fixed effects in the regression model. After estimating the regression model using 30-day periods, we divide the coefficients that correspond to the functional status and risk of hospitalization items by 10 and round to the nearest whole number. Those rounded numbers are used to compute a functional score for each 30-day period by summing together the rounded numbers for the functional status and risk of hospitalization items that are applicable to each 30-day period. Next, each 30-day period is assigned to a functional impairment level (low, medium, or high) depending on the 30-day period's total functional score. Each clinical group has a separate set of functional thresholds used to assign 30-day periods into a low, medium or high functional impairment level. We set those thresholds so that we assign roughly a third of 30-day periods within each clinical group to each functional impairment level (low, medium, or high).

*Step 2:* A second regression model estimates the relationship between a 30-day period's resource use and indicator variables for the presence of any of the comorbidities and comorbidity interactions that were originally examined for inclusion in the PDGM. Like the first regression model, this model also includes home health agency level fixed effects and includes control variables for each 30-day period's admission source, clinical group, timing, and functional impairment level. After we estimate the model, we assign comorbidities to the low comorbidity adjustment if any comorbidities have a coefficient that is statistically significant (p-value of 0.05 or less) and which have a coefficient

that is larger than the 50th percentile of positive and statistically significant comorbidity coefficients. If two comorbidities in the model and their interaction term have coefficients that sum together to exceed \$150 and the interaction term is statistically significant (p-value of 0.05 or less), we assign the two comorbidities together to the high comorbidity adjustment.

*Step 3:* After Step 2, each 30-day period is assigned to a clinical group, admission source category, episode timing category, functional impairment level, and comorbidity adjustment category. For each combination of those variables (which represent the 432 different payment groups that comprise the PDGM), we then calculate the 10th percentile of visits across all 30-day periods within a particular payment group. If a 30-day period's number of visits is less than the 10th percentile for their payment group, the 30-day period is classified as a Low Utilization Payment Adjustment (LUPA). If a payment group has a 10th percentile of visits that is less than two, we set the LUPA threshold for that payment group to be equal to two. That means if a 30-day period has one visit, it is classified as a LUPA and if it has two or more visits, it is not classified as a LUPA.

*Step 4:* Take all non-LUPA 30-day periods and regress resource use on the 30-day period's clinical group, admission source category, episode timing category, functional impairment level, and comorbidity adjustment category. The regression includes fixed effects at the level of the home health agency. After we estimate the model, the model coefficients are used to predict each 30-day period's resource use. To create the case-mix weight for each 30-day period, the predicted resource use is divided by the overall resource use of the 30-day periods used to estimate the regression.

The case-mix weight is then used to adjust the base payment rate to determine each 30-day period's payment. Table B21 shows the coefficients of the payment regression used to generate the weights, and the coefficients divided by average resource use.

**BILLING CODE 4120-01-P**

**TABLE B21: COEFFICIENT OF PAYMENT REGRESSION AND COEFFICIENT DIVIDED BY AVERAGE RESOURCE USE**

| Variable  | Coefficient | Percentage of 30-Day Periods for this Model | Coefficient Divided by Average Resource Use |
|---|-------------|---|---|
| <b>Clinical Group and Functional Impairment Level (MMTA - Other - Low is excluded)</b>                            |             |   |   |
| MMTA - Other - Medium Functional  | \$140.29    | 1.0%  | 0.0921                                      |
| MMTA - Other - High Functional  | \$292.96    | 1.2%  | 0.1924                                      |
| MMTA - Surgical Aftercare - Low Functional  | -\$69.63    | 1.3%  | -0.0457                                     |
| MMTA - Surgical Aftercare - Medium Functional   | \$122.02    | 0.9%  | 0.0801                                      |
| MMTA - Surgical Aftercare - High Functional   | \$315.34    | 1.1%  | 0.2071                                      |
| MMTA - Cardiac and Circulatory - Low Functional   | -\$22.34    | 7.2%  | -0.0147                                     |
| MMTA - Cardiac and Circulatory - Medium Functional  | \$131.14    | 5.3%  | 0.0861                                      |
| MMTA - Cardiac and Circulatory - High Functional  | \$292.79    | 5.7%  | 0.1923                                      |
| MMTA - Endocrine - Low Functional   | \$413.78    | 2.3%  | 0.2718                                      |
| MMTA - Endocrine - Medium Functional  | \$426.44    | 2.3%  | 0.2801                                      |
| MMTA - Endocrine - High Functional  | \$589.86    | 2.2%  | 0.3874                                      |
| MMTA - Gastrointestinal tract and Genitourinary system - Low Functional   | -\$78.70    | 1.7%  | -0.0517                                     |
| MMTA - Gastrointestinal tract and Genitourinary system - Medium Functional  | \$123.46    | 1.7%  | 0.0811                                      |
| MMTA - Gastrointestinal tract and Genitourinary system - High Functional  | \$267.72    | 1.5%  | 0.1759                                      |
| MMTA - Infectious Disease, Neoplasms, and Blood-Forming Diseases - Low Functional                                 | -\$34.83    | 1.6%  | -0.0229                                     |
| MMTA - Infectious Disease, Neoplasms, and Blood-Forming Diseases - Medium Functional                              | \$110.40    | 1.4%  | 0.0725                                      |
| MMTA - Infectious Disease, Neoplasms, and Blood-Forming Diseases - High Functional                                | \$301.82    | 1.5%  | 0.1982                                      |
| MMTA - Respiratory - Low Functional   | -\$36.81    | 2.6%  | -0.0242                                     |
| MMTA - Respiratory - Medium Functional  | \$128.61    | 2.6%  | 0.0845                                      |
| MMTA - Respiratory - High Functional  | \$297.03    | 2.7%  | 0.1951                                      |
| Behavioral Health - Low Functional  | -\$60.52    | 0.8%  | -0.0397                                     |
| Behavioral Health - Medium Functional   | \$97.05     | 0.5%  | 0.0637                                      |
| Behavioral Health - High Functional   | \$232.55    | 0.7%  | 0.1527                                      |
| Complex - Low Functional  | -\$91.77    | 1.0%  | -0.0603                                     |
| Complex - Medium Functional   | \$109.85    | 0.9%  | 0.0722                                      |
| Complex - High Functional   | \$74.99     | 0.9%  | 0.0493                                      |
| MS Rehab - Low Functional   | \$70.70     | 7.4%  | 0.0464                                      |
| MS Rehab - Medium Functional  | \$185.45    | 6.2%  | 0.1218                                      |
| MS Rehab - High Functional  | \$396.19    | 7.0%  | 0.2602                                      |
| Neuro - Low Functional  | \$212.04    | 4.0%  | 0.1393                                      |
| Neuro - Medium Functional   | \$383.39    | 3.5%  | 0.2518                                      |
| Neuro - High Functional   | \$585.31    | 3.6%  | 0.3845                                      |
| Wound - Low Functional  | \$495.43    | 4.7%  | 0.3254                                      |
| Wound - Medium Functional   | \$656.59    | 4.9%  | 0.4313                                      |
| Wound - High Functional   | \$852.73    | 4.6%  | 0.5601                                      |
| <b>Admission Source with Timing (Community Early is excluded)</b>   |             |   |   |
| Community - Late  | -\$552.27   | 63.5%                                       | -0.3627                                     |
| Institutional - Early   | \$329.44    | 19.0%                                       | 0.2164                                      |
| Institutional - Late  | \$191.83    | 6.0%  | 0.1260                                      |
| <b>Comorbidity Adjustment (No Comorbidity Adjustment - is excluded)</b>   |             |   |   |
| Comorbidity Adjustment - Has at least one comorbidity from comorbidity list, no interaction from interaction list | \$85.15     | 53.7%                                       | 0.0559                                      |
| Comorbidity Adjustment - Has at least one interaction from interaction list                                       | \$328.04    | 14.7%                                       | 0.2155                                      |
| Constant  | \$1,437.43  |   |   |
| Average Resource Use  | \$1,522.45  |   |   |
| Number of 30-day Periods  | 7,722,374   |   |   |
| Adjusted R-Squared  | 0.3288      |   |   |

Source: CY 2022 Home Health Claims Data, Periods that end in CY 2022 accessed on the CCW March 17, 2023.

The case-mix weights proposed for CY 2024 are listed in Table B22 and will also be posted on the HHA Center web page<sup>15</sup> upon display of this proposed rule.

<sup>15</sup> HHA Center web page: <https://www.cms.gov/Center/Provider-Type/Home-Health-Agency-HHA-Center>.

**TABLE B22: CASE-MIX WEIGHTS AND LUPA THRESHOLDS FOR EACH HHRG PAYMENT GROUP**

| HIPPS | Clinical Group and Functional Level | Admission Source and Timing | Comorbidity Adjustment<br>(0 = none, 1 = single comorbidity, 2 = interaction) | Recalibrated Weight for 2024 | LUPA Visit Threshold (LUPAs have fewer visits than the threshold) |
|-------|-------------------------------------|-----------------------------|---|------------------------------|---|
| 1FC11 | Behavioral Health - High            | Early - Community           | 0   | 1.0969                       | 4   |
| 1FC21 | Behavioral Health - High            | Early - Community           | 1   | 1.1528                       | 4   |
| 1FC31 | Behavioral Health - High            | Early - Community           | 2   | 1.3124                       | 4   |
| 2FC11 | Behavioral Health - High            | Early - Institutional       | 0   | 1.3133                       | 4   |
| 2FC21 | Behavioral Health - High            | Early - Institutional       | 1   | 1.3692                       | 4   |
| 2FC31 | Behavioral Health - High            | Early - Institutional       | 2   | 1.5288                       | 4   |
| 3FC11 | Behavioral Health - High            | Late - Community            | 0   | 0.7342                       | 2   |
| 3FC21 | Behavioral Health - High            | Late - Community            | 1   | 0.7901                       | 2   |
| 3FC31 | Behavioral Health - High            | Late - Community            | 2   | 0.9496                       | 2   |
| 4FC11 | Behavioral Health - High            | Late - Institutional        | 0   | 1.2229                       | 3   |
| 4FC21 | Behavioral Health - High            | Late - Institutional        | 1   | 1.2788                       | 3   |
| 4FC31 | Behavioral Health - High            | Late - Institutional        | 2   | 1.4384                       | 3   |
| 1FA11 | Behavioral Health - Low             | Early - Community           | 0   | 0.9044                       | 3   |
| 1FA21 | Behavioral Health - Low             | Early - Community           | 1   | 0.9603                       | 3   |
| 1FA31 | Behavioral Health - Low             | Early - Community           | 2   | 1.1199                       | 3   |
| 2FA11 | Behavioral Health - Low             | Early - Institutional       | 0   | 1.1208                       | 3   |
| 2FA21 | Behavioral Health - Low             | Early - Institutional       | 1   | 1.1767                       | 3   |
| 2FA31 | Behavioral Health - Low             | Early - Institutional       | 2   | 1.3363                       | 2   |
| 3FA11 | Behavioral Health - Low             | Late - Community            | 0   | 0.5417                       | 2   |
| 3FA21 | Behavioral Health - Low             | Late - Community            | 1   | 0.5976                       | 2   |
| 3FA31 | Behavioral Health - Low             | Late - Community            | 2   | 0.7571                       | 2   |
| 4FA11 | Behavioral Health - Low             | Late - Institutional        | 0   | 1.0304                       | 3   |
| 4FA21 | Behavioral Health - Low             | Late - Institutional        | 1   | 1.0863                       | 3   |
| 4FA31 | Behavioral Health - Low             | Late - Institutional        | 2   | 1.2459                       | 2   |

| HIPPS | Clinical Group and Functional Level | Admission Source and Timing | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | Recalibrated Weight for 2024 | LUPA Visit Threshold (LUPAs have fewer visits than the threshold) |
|-------|-------------------------------------|-----------------------------|--|------------------------------|---|
| 1FB11 | Behavioral Health - Medium          | Early - Community           | 0  | 1.0079                       | 4   |
| 1FB21 | Behavioral Health - Medium          | Early - Community           | 1  | 1.0638                       | 4   |
| 1FB31 | Behavioral Health - Medium          | Early - Community           | 2  | 1.2234                       | 4   |
| 2FB11 | Behavioral Health - Medium          | Early - Institutional       | 0  | 1.2243                       | 4   |
| 2FB21 | Behavioral Health - Medium          | Early - Institutional       | 1  | 1.2802                       | 4   |
| 2FB31 | Behavioral Health - Medium          | Early - Institutional       | 2  | 1.4398                       | 4   |
| 3FB11 | Behavioral Health - Medium          | Late - Community            | 0  | 0.6452                       | 2   |
| 3FB21 | Behavioral Health - Medium          | Late - Community            | 1  | 0.7011                       | 2   |
| 3FB31 | Behavioral Health - Medium          | Late - Community            | 2  | 0.8606                       | 2   |
| 4FB11 | Behavioral Health - Medium          | Late - Institutional        | 0  | 1.1339                       | 3   |
| 4FB21 | Behavioral Health - Medium          | Late - Institutional        | 1  | 1.1898                       | 3   |
| 4FB31 | Behavioral Health - Medium          | Late - Institutional        | 2  | 1.3494                       | 3   |
| 1DC11 | Complex - High                      | Early - Community           | 0  | 0.9934                       | 2   |
| 1DC21 | Complex - High                      | Early - Community           | 1  | 1.0493                       | 2   |
| 1DC31 | Complex - High                      | Early - Community           | 2  | 1.2089                       | 2   |
| 2DC11 | Complex - High                      | Early - Institutional       | 0  | 1.2098                       | 4   |
| 2DC21 | Complex - High                      | Early - Institutional       | 1  | 1.2657                       | 3   |
| 2DC31 | Complex - High                      | Early - Institutional       | 2  | 1.4253                       | 4   |
| 3DC11 | Complex - High                      | Late - Community            | 0  | 0.6307                       | 2   |
| 3DC21 | Complex - High                      | Late - Community            | 1  | 0.6866                       | 2   |
| 3DC31 | Complex - High                      | Late - Community            | 2  | 0.8461                       | 2   |
| 4DC11 | Complex - High                      | Late - Institutional        | 0  | 1.1194                       | 3   |
| 4DC21 | Complex - High                      | Late - Institutional        | 1  | 1.1753                       | 3   |
| 4DC31 | Complex - High                      | Late - Institutional        | 2  | 1.3349                       | 3   |
| 1DA11 | Complex - Low                       | Early - Community           | 0  | 0.8839                       | 2   |
| 1DA21 | Complex - Low                       | Early - Community           | 1  | 0.9398                       | 2   |
| 1DA31 | Complex - Low                       | Early - Community           | 2  | 1.0994                       | 2   |
| 2DA11 | Complex - Low                       | Early - Institutional       | 0  | 1.1003                       | 3   |
| 2DA21 | Complex - Low                       | Early - Institutional       | 1  | 1.1562                       | 3   |
| 2DA31 | Complex - Low                       | Early - Institutional       | 2  | 1.3157                       | 3   |
| 3DA11 | Complex - Low                       | Late - Community            | 0  | 0.5211                       | 2   |
| 3DA21 | Complex - Low                       | Late - Community            | 1  | 0.5771                       | 2   |
| 3DA31 | Complex - Low                       | Late - Community            | 2  | 0.7366                       | 2   |
| 4DA11 | Complex - Low                       | Late - Institutional        | 0  | 1.0099                       | 2   |
| 4DA21 | Complex - Low                       | Late - Institutional        | 1  | 1.0658                       | 2   |

| HIPPS | Clinical Group and Functional Level | Admission Source and Timing | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | Recalibrated Weight for 2024 | LUPA Visit Threshold (LUPAs have fewer visits than the threshold) |
|-------|-------------------------------------|-----------------------------|--|------------------------------|---|
| 4DA31 | Complex - Low                       | Late - Institutional        | 2  | 1.2254                       | 3   |
| 1DB11 | Complex - Medium                    | Early - Community           | 0  | 1.0163                       | 2   |
| 1DB21 | Complex - Medium                    | Early - Community           | 1  | 1.0722                       | 2   |
| 1DB31 | Complex - Medium                    | Early - Community           | 2  | 1.2318                       | 2   |
| 2DB11 | Complex - Medium                    | Early - Institutional       | 0  | 1.2327                       | 4   |
| 2DB21 | Complex - Medium                    | Early - Institutional       | 1  | 1.2886                       | 4   |
| 2DB31 | Complex - Medium                    | Early - Institutional       | 2  | 1.4482                       | 4   |
| 3DB11 | Complex - Medium                    | Late - Community            | 0  | 0.6536                       | 2   |
| 3DB21 | Complex - Medium                    | Late - Community            | 1  | 0.7095                       | 2   |
| 3DB31 | Complex - Medium                    | Late - Community            | 2  | 0.869                        | 2   |
| 4DB11 | Complex - Medium                    | Late - Institutional        | 0  | 1.1423                       | 3   |
| 4DB21 | Complex - Medium                    | Late - Institutional        | 1  | 1.1982                       | 3   |
| 4DB31 | Complex - Medium                    | Late - Institutional        | 2  | 1.3578                       | 3   |
| 1HC11 | MMTA - Cardiac - High               | Early - Community           | 0  | 1.1365                       | 4   |
| 1HC21 | MMTA - Cardiac - High               | Early - Community           | 1  | 1.1924                       | 4   |
| 1HC31 | MMTA - Cardiac - High               | Early - Community           | 2  | 1.3519                       | 4   |
| 2HC11 | MMTA - Cardiac - High               | Early - Institutional       | 0  | 1.3529                       | 4   |
| 2HC21 | MMTA - Cardiac - High               | Early - Institutional       | 1  | 1.4088                       | 4   |
| 2HC31 | MMTA - Cardiac - High               | Early - Institutional       | 2  | 1.5683                       | 4   |
| 3HC11 | MMTA - Cardiac - High               | Late - Community            | 0  | 0.7737                       | 2   |
| 3HC21 | MMTA - Cardiac - High               | Late - Community            | 1  | 0.8297                       | 2   |
| 3HC31 | MMTA - Cardiac - High               | Late - Community            | 2  | 0.9892                       | 3   |
| 4HC11 | MMTA - Cardiac - High               | Late - Institutional        | 0  | 1.2625                       | 4   |
| 4HC21 | MMTA - Cardiac - High               | Late - Institutional        | 1  | 1.3184                       | 3   |
| 4HC31 | MMTA - Cardiac - High               | Late - Institutional        | 2  | 1.4779                       | 4   |
| 1HA11 | MMTA - Cardiac - Low                | Early - Community           | 0  | 0.9295                       | 4   |
| 1HA21 | MMTA - Cardiac - Low                | Early - Community           | 1  | 0.9854                       | 4   |
| 1HA31 | MMTA - Cardiac - Low                | Early - Community           | 2  | 1.145                        | 3   |
| 2HA11 | MMTA - Cardiac - Low                | Early - Institutional       | 0  | 1.1459                       | 4   |
| 2HA21 | MMTA - Cardiac - Low                | Early - Institutional       | 1  | 1.2018                       | 4   |
| 2HA31 | MMTA - Cardiac - Low                | Early - Institutional       | 2  | 1.3613                       | 4   |
| 3HA11 | MMTA - Cardiac - Low                | Late - Community            | 0  | 0.5667                       | 2   |
| 3HA21 | MMTA - Cardiac - Low                | Late - Community            | 1  | 0.6227                       | 2   |
| 3HA31 | MMTA - Cardiac - Low                | Late - Community            | 2  | 0.7822                       | 2   |
| 4HA11 | MMTA - Cardiac - Low                | Late - Institutional        | 0  | 1.0555                       | 3   |

| HIPPS | Clinical Group and Functional Level | Admission Source and Timing | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | Recalibrated Weight for 2024 | LUPA Visit Threshold (LUPAs have fewer visits than the threshold) |
|-------|-------------------------------------|-----------------------------|--|------------------------------|---|
| 4HA21 | MMTA - Cardiac - Low                | Late - Institutional        | 1  | 1.1114                       | 3   |
| 4HA31 | MMTA - Cardiac - Low                | Late - Institutional        | 2  | 1.271                        | 3   |
| 1HB11 | MMTA - Cardiac - Medium             | Early - Community           | 0  | 1.0303                       | 4   |
| 1HB21 | MMTA - Cardiac - Medium             | Early - Community           | 1  | 1.0862                       | 4   |
| 1HB31 | MMTA - Cardiac - Medium             | Early - Community           | 2  | 1.2458                       | 4   |
| 2HB11 | MMTA - Cardiac - Medium             | Early - Institutional       | 0  | 1.2467                       | 4   |
| 2HB21 | MMTA - Cardiac - Medium             | Early - Institutional       | 1  | 1.3026                       | 4   |
| 2HB31 | MMTA - Cardiac - Medium             | Early - Institutional       | 2  | 1.4622                       | 5   |
| 3HB11 | MMTA - Cardiac - Medium             | Late - Community            | 0  | 0.6675                       | 2   |
| 3HB21 | MMTA - Cardiac - Medium             | Late - Community            | 1  | 0.7235                       | 2   |
| 3HB31 | MMTA - Cardiac - Medium             | Late - Community            | 2  | 0.883                        | 3   |
| 4HB11 | MMTA - Cardiac - Medium             | Late - Institutional        | 0  | 1.1563                       | 3   |
| 4HB21 | MMTA - Cardiac - Medium             | Late - Institutional        | 1  | 1.2122                       | 3   |
| 4HB31 | MMTA - Cardiac - Medium             | Late - Institutional        | 2  | 1.3718                       | 4   |
| 1IC11 | MMTA - Endocrine - High             | Early - Community           | 0  | 1.3316                       | 4   |
| 1IC21 | MMTA - Endocrine - High             | Early - Community           | 1  | 1.3875                       | 4   |
| 1IC31 | MMTA - Endocrine - High             | Early - Community           | 2  | 1.5471                       | 4   |
| 2IC11 | MMTA - Endocrine - High             | Early - Institutional       | 0  | 1.548                        | 4   |
| 2IC21 | MMTA - Endocrine - High             | Early - Institutional       | 1  | 1.6039                       | 4   |
| 2IC31 | MMTA - Endocrine - High             | Early - Institutional       | 2  | 1.7635                       | 4   |
| 3IC11 | MMTA - Endocrine - High             | Late - Community            | 0  | 0.9689                       | 3   |
| 3IC21 | MMTA - Endocrine - High             | Late - Community            | 1  | 1.0248                       | 3   |
| 3IC31 | MMTA - Endocrine - High             | Late - Community            | 2  | 1.1843                       | 3   |
| 4IC11 | MMTA - Endocrine - High             | Late - Institutional        | 0  | 1.4576                       | 4   |
| 4IC21 | MMTA - Endocrine - High             | Late - Institutional        | 1  | 1.5135                       | 4   |
| 4IC31 | MMTA - Endocrine - High             | Late - Institutional        | 2  | 1.6731                       | 4   |
| 1IA11 | MMTA - Endocrine - Low              | Early - Community           | 0  | 1.2159                       | 4   |
| 1IA21 | MMTA - Endocrine - Low              | Early - Community           | 1  | 1.2719                       | 4   |
| 1IA31 | MMTA - Endocrine - Low              | Early - Community           | 2  | 1.4314                       | 4   |
| 2IA11 | MMTA - Endocrine - Low              | Early - Institutional       | 0  | 1.4323                       | 4   |
| 2IA21 | MMTA - Endocrine - Low              | Early - Institutional       | 1  | 1.4883                       | 4   |
| 2IA31 | MMTA - Endocrine - Low              | Early - Institutional       | 2  | 1.6478                       | 4   |
| 3IA11 | MMTA - Endocrine - Low              | Late - Community            | 0  | 0.8532                       | 3   |
| 3IA21 | MMTA - Endocrine - Low              | Late - Community            | 1  | 0.9091                       | 3   |
| 3IA31 | MMTA - Endocrine - Low              | Late - Community            | 2  | 1.0687                       | 3   |



| HIPPS | Clinical Group and Functional Level | Admission Source and Timing | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | Recalibrated Weight for 2024 | LUPA Visit Threshold (LUPAs have fewer visits than the threshold) |
|-------|-------------------------------------|-----------------------------|--|------------------------------|---|
| 4IA11 | MMTA - Endocrine - Low              | Late - Institutional        | 0  | 1.3419                       | 3   |
| 4IA21 | MMTA - Endocrine - Low              | Late - Institutional        | 1  | 1.3979                       | 3   |
| 4IA31 | MMTA - Endocrine - Low              | Late - Institutional        | 2  | 1.5574                       | 4   |
| 1IB11 | MMTA - Endocrine - Medium           | Early - Community           | 0  | 1.2243                       | 4   |
| 1IB21 | MMTA - Endocrine - Medium           | Early - Community           | 1  | 1.2802                       | 4   |
| 1IB31 | MMTA - Endocrine - Medium           | Early - Community           | 2  | 1.4397                       | 4   |
| 2IB11 | MMTA - Endocrine - Medium           | Early - Institutional       | 0  | 1.4406                       | 4   |
| 2IB21 | MMTA - Endocrine - Medium           | Early - Institutional       | 1  | 1.4966                       | 4   |
| 2IB31 | MMTA - Endocrine - Medium           | Early - Institutional       | 2  | 1.6561                       | 4   |
| 3IB11 | MMTA - Endocrine - Medium           | Late - Community            | 0  | 0.8615                       | 3   |
| 3IB21 | MMTA - Endocrine - Medium           | Late - Community            | 1  | 0.9174                       | 3   |
| 3IB31 | MMTA - Endocrine - Medium           | Late - Community            | 2  | 1.077                        | 3   |
| 4IB11 | MMTA - Endocrine - Medium           | Late - Institutional        | 0  | 1.3503                       | 4   |
| 4IB21 | MMTA - Endocrine - Medium           | Late - Institutional        | 1  | 1.4062                       | 4   |
| 4IB31 | MMTA - Endocrine - Medium           | Late - Institutional        | 2  | 1.5657                       | 4   |
| 1JC11 | MMTA - GI/GU - High                 | Early - Community           | 0  | 1.12                         | 3   |
| 1JC21 | MMTA - GI/GU - High                 | Early - Community           | 1  | 1.1759                       | 3   |
| 1JC31 | MMTA - GI/GU - High                 | Early - Community           | 2  | 1.3355                       | 2   |
| 2JC11 | MMTA - GI/GU - High                 | Early - Institutional       | 0  | 1.3364                       | 4   |
| 2JC21 | MMTA - GI/GU - High                 | Early - Institutional       | 1  | 1.3923                       | 4   |
| 2JC31 | MMTA - GI/GU - High                 | Early - Institutional       | 2  | 1.5519                       | 3   |
| 3JC11 | MMTA - GI/GU - High                 | Late - Community            | 0  | 0.7573                       | 2   |
| 3JC21 | MMTA - GI/GU - High                 | Late - Community            | 1  | 0.8132                       | 2   |
| 3JC31 | MMTA - GI/GU - High                 | Late - Community            | 2  | 0.9727                       | 2   |
| 4JC11 | MMTA - GI/GU - High                 | Late - Institutional        | 0  | 1.246                        | 3   |
| 4JC21 | MMTA - GI/GU - High                 | Late - Institutional        | 1  | 1.3019                       | 3   |
| 4JC31 | MMTA - GI/GU - High                 | Late - Institutional        | 2  | 1.4615                       | 3   |
| 1JA11 | MMTA - GI/GU - Low                  | Early - Community           | 0  | 0.8925                       | 2   |
| 1JA21 | MMTA - GI/GU - Low                  | Early - Community           | 1  | 0.9484                       | 2   |
| 1JA31 | MMTA - GI/GU - Low                  | Early - Community           | 2  | 1.1079                       | 2   |
| 2JA11 | MMTA - GI/GU - Low                  | Early - Institutional       | 0  | 1.1088                       | 3   |
| 2JA21 | MMTA - GI/GU - Low                  | Early - Institutional       | 1  | 1.1648                       | 3   |
| 2JA31 | MMTA - GI/GU - Low                  | Early - Institutional       | 2  | 1.3243                       | 3   |
| 3JA11 | MMTA - GI/GU - Low                  | Late - Community            | 0  | 0.5297                       | 2   |
| 3JA21 | MMTA - GI/GU - Low                  | Late - Community            | 1  | 0.5856                       | 2   |

| HIPPS | Clinical Group and Functional Level | Admission Source and Timing | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | Recalibrated Weight for 2024 | LUPA Visit Threshold (LUPAs have fewer visits than the threshold) |
|-------|-------------------------------------|-----------------------------|--|------------------------------|---|
| 3JA31 | MMTA - GI/GU - Low                  | Late - Community            | 2  | 0.7452                       | 2   |
| 4JA11 | MMTA - GI/GU - Low                  | Late - Institutional        | 0  | 1.0185                       | 3   |
| 4JA21 | MMTA - GI/GU - Low                  | Late - Institutional        | 1  | 1.0744                       | 3   |
| 4JA31 | MMTA - GI/GU - Low                  | Late - Institutional        | 2  | 1.2339                       | 3   |
| 1JB11 | MMTA - GI/GU - Medium               | Early - Community           | 0  | 1.0253                       | 3   |
| 1JB21 | MMTA - GI/GU - Medium               | Early - Community           | 1  | 1.0812                       | 3   |
| 1JB31 | MMTA - GI/GU - Medium               | Early - Community           | 2  | 1.2407                       | 2   |
| 2JB11 | MMTA - GI/GU - Medium               | Early - Institutional       | 0  | 1.2416                       | 4   |
| 2JB21 | MMTA - GI/GU - Medium               | Early - Institutional       | 1  | 1.2976                       | 4   |
| 2JB31 | MMTA - GI/GU - Medium               | Early - Institutional       | 2  | 1.4571                       | 4   |
| 3JB11 | MMTA - GI/GU - Medium               | Late - Community            | 0  | 0.6625                       | 2   |
| 3JB21 | MMTA - GI/GU - Medium               | Late - Community            | 1  | 0.7184                       | 2   |
| 3JB31 | MMTA - GI/GU - Medium               | Late - Community            | 2  | 0.878                        | 2   |
| 4JB11 | MMTA - GI/GU - Medium               | Late - Institutional        | 0  | 1.1513                       | 3   |
| 4JB21 | MMTA - GI/GU - Medium               | Late - Institutional        | 1  | 1.2072                       | 3   |
| 4JB31 | MMTA - GI/GU - Medium               | Late - Institutional        | 2  | 1.3667                       | 3   |
| 1KC11 | MMTA - Infectious - High            | Early - Community           | 0  | 1.1424                       | 2   |
| 1KC21 | MMTA - Infectious - High            | Early - Community           | 1  | 1.1983                       | 2   |
| 1KC31 | MMTA - Infectious - High            | Early - Community           | 2  | 1.3579                       | 2   |
| 2KC11 | MMTA - Infectious - High            | Early - Institutional       | 0  | 1.3588                       | 3   |
| 2KC21 | MMTA - Infectious - High            | Early - Institutional       | 1  | 1.4147                       | 3   |
| 2KC31 | MMTA - Infectious - High            | Early - Institutional       | 2  | 1.5743                       | 3   |
| 3KC11 | MMTA - Infectious - High            | Late - Community            | 0  | 0.7797                       | 2   |
| 3KC21 | MMTA - Infectious - High            | Late - Community            | 1  | 0.8356                       | 2   |
| 3KC31 | MMTA - Infectious - High            | Late - Community            | 2  | 0.9951                       | 2   |
| 4KC11 | MMTA - Infectious - High            | Late - Institutional        | 0  | 1.2684                       | 3   |
| 4KC21 | MMTA - Infectious - High            | Late - Institutional        | 1  | 1.3243                       | 3   |
| 4KC31 | MMTA - Infectious - High            | Late - Institutional        | 2  | 1.4839                       | 3   |
| 1KA11 | MMTA - Infectious - Low             | Early - Community           | 0  | 0.9213                       | 2   |
| 1KA21 | MMTA - Infectious - Low             | Early - Community           | 1  | 0.9772                       | 2   |
| 1KA31 | MMTA - Infectious - Low             | Early - Community           | 2  | 1.1368                       | 2   |
| 2KA11 | MMTA - Infectious - Low             | Early - Institutional       | 0  | 1.1377                       | 3   |
| 2KA21 | MMTA - Infectious - Low             | Early - Institutional       | 1  | 1.1936                       | 3   |
| 2KA31 | MMTA - Infectious - Low             | Early - Institutional       | 2  | 1.3531                       | 3   |
| 3KA11 | MMTA - Infectious - Low             | Late - Community            | 0  | 0.5585                       | 2   |

|              |                            | Clinical Group and Functional Level        | Admission Source and Timing | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | Recalibrated Weight for 2024 | LUPA Visit Threshold (LUPAs have fewer visits than the threshold) |
|--------------|----------------------------|--|-----------------------------|--|------------------------------|---|
| <b>HIPPS</b> |                            | <b>Clinical Group and Functional Level</b> |                             |  |                              |   |
| 3KA21        | MMTA - Infectious - Low    | MMTA - Infectious - Low                    | Late - Community            | 1  | 0.6145                       | 2   |
| 3KA31        | MMTA - Infectious - Low    | MMTA - Infectious - Low                    | Late - Community            | 2  | 0.774                        | 2   |
| 4KA11        | MMTA - Infectious - Low    | MMTA - Infectious - Low                    | Late - Institutional        | 0  | 1.0473                       | 3   |
| 4KA21        | MMTA - Infectious - Low    | MMTA - Infectious - Low                    | Late - Institutional        | 1  | 1.1032                       | 3   |
| 4KA31        | MMTA - Infectious - Low    | MMTA - Infectious - Low                    | Late - Institutional        | 2  | 1.2628                       | 3   |
| 1KB11        | MMTA - Infectious - Medium | MMTA - Infectious - Medium                 | Early - Community           | 0  | 1.0167                       | 3   |
| 1KB21        | MMTA - Infectious - Medium | MMTA - Infectious - Medium                 | Early - Community           | 1  | 1.0726                       | 2   |
| 1KB31        | MMTA - Infectious - Medium | MMTA - Infectious - Medium                 | Early - Community           | 2  | 1.2321                       | 2   |
| 2KB11        | MMTA - Infectious - Medium | MMTA - Infectious - Medium                 | Early - Institutional       | 0  | 1.2331                       | 3   |
| 2KB21        | MMTA - Infectious - Medium | MMTA - Infectious - Medium                 | Early - Institutional       | 1  | 1.289                        | 3   |
| 2KB31        | MMTA - Infectious - Medium | MMTA - Infectious - Medium                 | Early - Institutional       | 2  | 1.4485                       | 4   |
| 3KB11        | MMTA - Infectious - Medium | MMTA - Infectious - Medium                 | Late - Community            | 0  | 0.6539                       | 2   |
| 3KB21        | MMTA - Infectious - Medium | MMTA - Infectious - Medium                 | Late - Community            | 1  | 0.7099                       | 2   |
| 3KB31        | MMTA - Infectious - Medium | MMTA - Infectious - Medium                 | Late - Community            | 2  | 0.8694                       | 2   |
| 4KB11        | MMTA - Infectious - Medium | MMTA - Infectious - Medium                 | Late - Institutional        | 0  | 1.1427                       | 3   |
| 4KB21        | MMTA - Infectious - Medium | MMTA - Infectious - Medium                 | Late - Institutional        | 1  | 1.1986                       | 3   |
| 4KB31        | MMTA - Infectious - Medium | MMTA - Infectious - Medium                 | Late - Institutional        | 2  | 1.3581                       | 3   |
| IAC11        | MMTA - Other - High        | MMTA - Other - High                        | Early - Community           | 0  | 1.1366                       | 4   |
| IAC21        | MMTA - Other - High        | MMTA - Other - High                        | Early - Community           | 1  | 1.1925                       | 4   |
| IAC31        | MMTA - Other - High        | MMTA - Other - High                        | Early - Community           | 2  | 1.3521                       | 3   |
| 2AC11        | MMTA - Other - High        | MMTA - Other - High                        | Early - Institutional       | 0  | 1.353                        | 4   |
| 2AC21        | MMTA - Other - High        | MMTA - Other - High                        | Early - Institutional       | 1  | 1.4089                       | 4   |
| 2AC31        | MMTA - Other - High        | MMTA - Other - High                        | Early - Institutional       | 2  | 1.5684                       | 4   |
| 3AC11        | MMTA - Other - High        | MMTA - Other - High                        | Late - Community            | 0  | 0.7738                       | 2   |
| 3AC21        | MMTA - Other - High        | MMTA - Other - High                        | Late - Community            | 1  | 0.8298                       | 2   |
| 3AC31        | MMTA - Other - High        | MMTA - Other - High                        | Late - Community            | 2  | 0.9893                       | 2   |
| 4AC11        | MMTA - Other - High        | MMTA - Other - High                        | Late - Institutional        | 0  | 1.2626                       | 3   |
| 4AC21        | MMTA - Other - High        | MMTA - Other - High                        | Late - Institutional        | 1  | 1.3185                       | 3   |
| 4AC31        | MMTA - Other - High        | MMTA - Other - High                        | Late - Institutional        | 2  | 1.4781                       | 4   |
| 1AA11        | MMTA - Other - Low         | MMTA - Other - Low                         | Early - Community           | 0  | 0.9442                       | 3   |
| 1AA21        | MMTA - Other - Low         | MMTA - Other - Low                         | Early - Community           | 1  | 1.0001                       | 3   |
| 1AA31        | MMTA - Other - Low         | MMTA - Other - Low                         | Early - Community           | 2  | 1.1596                       | 4   |
| 2AA11        | MMTA - Other - Low         | MMTA - Other - Low                         | Early - Institutional       | 0  | 1.1605                       | 3   |
| 2AA21        | MMTA - Other - Low         | MMTA - Other - Low                         | Early - Institutional       | 1  | 1.2165                       | 3   |
| 2AA31        | MMTA - Other - Low         | MMTA - Other - Low                         | Early - Institutional       | 2  | 1.376                        | 4   |

| HIPPS | Clinical Group and Functional Level | Admission Source and Timing | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | Recalibrated Weight for 2024 | LUPA Visit Threshold (LUPAs have fewer visits than the threshold) |
|-------|-------------------------------------|-----------------------------|--|------------------------------|---|
| 3AA11 | MMTA - Other - Low                  | Late - Community            | 0  | 0.5814                       | 2   |
| 3AA21 | MMTA - Other - Low                  | Late - Community            | 1  | 0.6373                       | 2   |
| 3AA31 | MMTA - Other - Low                  | Late - Community            | 2  | 0.7969                       | 2   |
| 4AA11 | MMTA - Other - Low                  | Late - Institutional        | 0  | 1.0702                       | 3   |
| 4AA21 | MMTA - Other - Low                  | Late - Institutional        | 1  | 1.1261                       | 3   |
| 4AA31 | MMTA - Other - Low                  | Late - Institutional        | 2  | 1.2856                       | 3   |
| 1AB11 | MMTA - Other - Medium               | Early - Community           | 0  | 1.0363                       | 4   |
| 1AB21 | MMTA - Other - Medium               | Early - Community           | 1  | 1.0922                       | 4   |
| 1AB31 | MMTA - Other - Medium               | Early - Community           | 2  | 1.2518                       | 4   |
| 2AB11 | MMTA - Other - Medium               | Early - Institutional       | 0  | 1.2527                       | 4   |
| 2AB21 | MMTA - Other - Medium               | Early - Institutional       | 1  | 1.3086                       | 4   |
| 2AB31 | MMTA - Other - Medium               | Early - Institutional       | 2  | 1.4682                       | 4   |
| 3AB11 | MMTA - Other - Medium               | Late - Community            | 0  | 0.6736                       | 2   |
| 3AB21 | MMTA - Other - Medium               | Late - Community            | 1  | 0.7295                       | 2   |
| 3AB31 | MMTA - Other - Medium               | Late - Community            | 2  | 0.889                        | 2   |
| 4AB11 | MMTA - Other - Medium               | Late - Institutional        | 0  | 1.1623                       | 3   |
| 4AB21 | MMTA - Other - Medium               | Late - Institutional        | 1  | 1.2182                       | 3   |
| 4AB31 | MMTA - Other - Medium               | Late - Institutional        | 2  | 1.3778                       | 3   |
| 1LC11 | MMTA - Respiratory - High           | Early - Community           | 0  | 1.1393                       | 3   |
| 1LC21 | MMTA - Respiratory - High           | Early - Community           | 1  | 1.1952                       | 3   |
| 1LC31 | MMTA - Respiratory - High           | Early - Community           | 2  | 1.3547                       | 2   |
| 2LC11 | MMTA - Respiratory - High           | Early - Institutional       | 0  | 1.3556                       | 4   |
| 2LC21 | MMTA - Respiratory - High           | Early - Institutional       | 1  | 1.4116                       | 4   |
| 2LC31 | MMTA - Respiratory - High           | Early - Institutional       | 2  | 1.5711                       | 4   |
| 3LC11 | MMTA - Respiratory - High           | Late - Community            | 0  | 0.7765                       | 2   |
| 3LC21 | MMTA - Respiratory - High           | Late - Community            | 1  | 0.8324                       | 2   |
| 3LC31 | MMTA - Respiratory - High           | Late - Community            | 2  | 0.992                        | 2   |
| 4LC11 | MMTA - Respiratory - High           | Late - Institutional        | 0  | 1.2653                       | 3   |
| 4LC21 | MMTA - Respiratory - High           | Late - Institutional        | 1  | 1.3212                       | 3   |
| 4LC31 | MMTA - Respiratory - High           | Late - Institutional        | 2  | 1.4807                       | 3   |
| 1LA11 | MMTA - Respiratory - Low            | Early - Community           | 0  | 0.92                         | 3   |
| 1LA21 | MMTA - Respiratory - Low            | Early - Community           | 1  | 0.9759                       | 3   |
| 1LA31 | MMTA - Respiratory - Low            | Early - Community           | 2  | 1.1355                       | 3   |
| 2LA11 | MMTA - Respiratory - Low            | Early - Institutional       | 0  | 1.1364                       | 3   |
| 2LA21 | MMTA - Respiratory - Low            | Early - Institutional       | 1  | 1.1923                       | 3   |

| HIPPS | Clinical Group and Functional Level | Admission Source and Timing | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | Recalibrated Weight for 2024 | LUPA Visit Threshold (LUPAs have fewer visits than the threshold) |
|-------|-------------------------------------|-----------------------------|--|------------------------------|---|
| 2LA31 | MMTA - Respiratory - Low            | Early - Institutional       | 2  | 1.3518                       | 4   |
| 3LA11 | MMTA - Respiratory - Low            | Late - Community            | 0  | 0.5572                       | 2   |
| 3LA21 | MMTA - Respiratory - Low            | Late - Community            | 1  | 0.6132                       | 2   |
| 3LA31 | MMTA - Respiratory - Low            | Late - Community            | 2  | 0.7727                       | 2   |
| 4LA11 | MMTA - Respiratory - Low            | Late - Institutional        | 0  | 1.046                        | 3   |
| 4LA21 | MMTA - Respiratory - Low            | Late - Institutional        | 1  | 1.1019                       | 3   |
| 4LA31 | MMTA - Respiratory - Low            | Late - Institutional        | 2  | 1.2615                       | 3   |
| 1LB11 | MMTA - Respiratory - Medium         | Early - Community           | 0  | 1.0286                       | 4   |
| 1LB21 | MMTA - Respiratory - Medium         | Early - Community           | 1  | 1.0846                       | 3   |
| 1LB31 | MMTA - Respiratory - Medium         | Early - Community           | 2  | 1.2441                       | 3   |
| 2LB11 | MMTA - Respiratory - Medium         | Early - Institutional       | 0  | 1.245                        | 4   |
| 2LB21 | MMTA - Respiratory - Medium         | Early - Institutional       | 1  | 1.3009                       | 4   |
| 2LB31 | MMTA - Respiratory - Medium         | Early - Institutional       | 2  | 1.4605                       | 4   |
| 3LB11 | MMTA - Respiratory - Medium         | Late - Community            | 0  | 0.6659                       | 2   |
| 3LB21 | MMTA - Respiratory - Medium         | Late - Community            | 1  | 0.7218                       | 2   |
| 3LB31 | MMTA - Respiratory - Medium         | Late - Community            | 2  | 0.8814                       | 2   |
| 4LB11 | MMTA - Respiratory - Medium         | Late - Institutional        | 0  | 1.1546                       | 3   |
| 4LB21 | MMTA - Respiratory - Medium         | Late - Institutional        | 1  | 1.2106                       | 3   |
| 4LB31 | MMTA - Respiratory - Medium         | Late - Institutional        | 2  | 1.3701                       | 4   |
| IGC11 | MMTA - Surgical Aftercare - High    | Early - Community           | 0  | 1.1513                       | 3   |
| IGC21 | MMTA - Surgical Aftercare - High    | Early - Community           | 1  | 1.2072                       | 2   |
| IGC31 | MMTA - Surgical Aftercare - High    | Early - Community           | 2  | 1.3668                       | 3   |
| 2GC11 | MMTA - Surgical Aftercare - High    | Early - Institutional       | 0  | 1.3677                       | 4   |
| 2GC21 | MMTA - Surgical Aftercare - High    | Early - Institutional       | 1  | 1.4236                       | 4   |
| 2GC31 | MMTA - Surgical Aftercare - High    | Early - Institutional       | 2  | 1.5831                       | 4   |
| 3GC11 | MMTA - Surgical Aftercare - High    | Late - Community            | 0  | 0.7885                       | 2   |
| 3GC21 | MMTA - Surgical Aftercare - High    | Late - Community            | 1  | 0.8445                       | 2   |
| 3GC31 | MMTA - Surgical Aftercare - High    | Late - Community            | 2  | 1.004                        | 2   |
| 4GC11 | MMTA - Surgical Aftercare - High    | Late - Institutional        | 0  | 1.2773                       | 3   |
| 4GC21 | MMTA - Surgical Aftercare - High    | Late - Institutional        | 1  | 1.3332                       | 3   |
| 4GC31 | MMTA - Surgical Aftercare - High    | Late - Institutional        | 2  | 1.4928                       | 4   |
| 1GA11 | MMTA - Surgical Aftercare - Low     | Early - Community           | 0  | 0.8984                       | 2   |
| 1GA21 | MMTA - Surgical Aftercare - Low     | Early - Community           | 1  | 0.9543                       | 2   |
| 1GA31 | MMTA - Surgical Aftercare - Low     | Early - Community           | 2  | 1.1139                       | 2   |
| 2GA11 | MMTA - Surgical Aftercare - Low     | Early - Institutional       | 0  | 1.1148                       | 3   |

| HIPPS | Clinical Group and Functional Level | Admission Source and Timing | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | Recalibrated Weight for 2024 | LUPA Visit Threshold (LUPAs have fewer visits than the threshold) |
|-------|-------------------------------------|-----------------------------|--|------------------------------|---|
| 2GA21 | MMTA - Surgical Aftercare - Low     | Early - Institutional       | 1  | 1.1707                       | 3   |
| 2GA31 | MMTA - Surgical Aftercare - Low     | Early - Institutional       | 2  | 1.3303                       | 4   |
| 3GA11 | MMTA - Surgical Aftercare - Low     | Late - Community            | 0  | 0.5357                       | 2   |
| 3GA21 | MMTA - Surgical Aftercare - Low     | Late - Community            | 1  | 0.5916                       | 2   |
| 3GA31 | MMTA - Surgical Aftercare - Low     | Late - Community            | 2  | 0.7511                       | 2   |
| 4GA11 | MMTA - Surgical Aftercare - Low     | Late - Institutional        | 0  | 1.0244                       | 3   |
| 4GA21 | MMTA - Surgical Aftercare - Low     | Late - Institutional        | 1  | 1.0804                       | 3   |
| 4GA31 | MMTA - Surgical Aftercare - Low     | Late - Institutional        | 2  | 1.2399                       | 3   |
| 1GB11 | MMTA - Surgical Aftercare - Medium  | Early - Community           | 0  | 1.0243                       | 2   |
| 1GB21 | MMTA - Surgical Aftercare - Medium  | Early - Community           | 1  | 1.0802                       | 2   |
| 1GB31 | MMTA - Surgical Aftercare - Medium  | Early - Community           | 2  | 1.2398                       | 2   |
| 2GB11 | MMTA - Surgical Aftercare - Medium  | Early - Institutional       | 0  | 1.2407                       | 4   |
| 2GB21 | MMTA - Surgical Aftercare - Medium  | Early - Institutional       | 1  | 1.2966                       | 4   |
| 2GB31 | MMTA - Surgical Aftercare - Medium  | Early - Institutional       | 2  | 1.4562                       | 5   |
| 3GB11 | MMTA - Surgical Aftercare - Medium  | Late - Community            | 0  | 0.6616                       | 2   |
| 3GB21 | MMTA - Surgical Aftercare - Medium  | Late - Community            | 1  | 0.7175                       | 2   |
| 3GB31 | MMTA - Surgical Aftercare - Medium  | Late - Community            | 2  | 0.877                        | 2   |
| 4GB11 | MMTA - Surgical Aftercare - Medium  | Late - Institutional        | 0  | 1.1503                       | 3   |
| 4GB21 | MMTA - Surgical Aftercare - Medium  | Late - Institutional        | 1  | 1.2062                       | 3   |
| 4GB31 | MMTA - Surgical Aftercare - Medium  | Late - Institutional        | 2  | 1.3658                       | 4   |
| 1EC11 | MS Rehab - High                     | Early - Community           | 0  | 1.2044                       | 5   |
| 1EC21 | MS Rehab - High                     | Early - Community           | 1  | 1.2603                       | 4   |
| 1EC31 | MS Rehab - High                     | Early - Community           | 2  | 1.4199                       | 4   |
| 2EC11 | MS Rehab - High                     | Early - Institutional       | 0  | 1.4208                       | 5   |
| 2EC21 | MS Rehab - High                     | Early - Institutional       | 1  | 1.4767                       | 5   |
| 2EC31 | MS Rehab - High                     | Early - Institutional       | 2  | 1.6362                       | 5   |
| 3EC11 | MS Rehab - High                     | Late - Community            | 0  | 0.8416                       | 2   |
| 3EC21 | MS Rehab - High                     | Late - Community            | 1  | 0.8976                       | 2   |
| 3EC31 | MS Rehab - High                     | Late - Community            | 2  | 1.0571                       | 3   |
| 4EC11 | MS Rehab - High                     | Late - Institutional        | 0  | 1.3304                       | 4   |
| 4EC21 | MS Rehab - High                     | Late - Institutional        | 1  | 1.3863                       | 4   |
| 4EC31 | MS Rehab - High                     | Late - Institutional        | 2  | 1.5459                       | 4   |
| 1EA11 | MS Rehab - Low                      | Early - Community           | 0  | 0.9906                       | 4   |
| 1EA21 | MS Rehab - Low                      | Early - Community           | 1  | 1.0465                       | 4   |
| 1EA31 | MS Rehab - Low                      | Early - Community           | 2  | 1.2061                       | 4   |

| HIPPS | Clinical Group and Functional Level | Admission Source and Timing | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | Recalibrated Weight for 2024 | LUPA Visit Threshold (LUPAs have fewer visits than the threshold) |
|-------|-------------------------------------|-----------------------------|--|------------------------------|---|
| 2EA11 | MS Rehab - Low                      | Early - Institutional       | 0  | 1.207                        | 5   |
| 2EA21 | MS Rehab - Low                      | Early - Institutional       | 1  | 1.2629                       | 5   |
| 2EA31 | MS Rehab - Low                      | Early - Institutional       | 2  | 1.4225                       | 5   |
| 3EA11 | MS Rehab - Low                      | Late - Community            | 0  | 0.6279                       | 2   |
| 3EA21 | MS Rehab - Low                      | Late - Community            | 1  | 0.6838                       | 2   |
| 3EA31 | MS Rehab - Low                      | Late - Community            | 2  | 0.8433                       | 2   |
| 4EA11 | MS Rehab - Low                      | Late - Institutional        | 0  | 1.1166                       | 4   |
| 4EA21 | MS Rehab - Low                      | Late - Institutional        | 1  | 1.1725                       | 4   |
| 4EA31 | MS Rehab - Low                      | Late - Institutional        | 2  | 1.3321                       | 4   |
| 1EB11 | MS Rehab - Medium                   | Early - Community           | 0  | 1.066                        | 5   |
| 1EB21 | MS Rehab - Medium                   | Early - Community           | 1  | 1.1219                       | 4   |
| 1EB31 | MS Rehab - Medium                   | Early - Community           | 2  | 1.2814                       | 4   |
| 2EB11 | MS Rehab - Medium                   | Early - Institutional       | 0  | 1.2824                       | 5   |
| 2EB21 | MS Rehab - Medium                   | Early - Institutional       | 1  | 1.3383                       | 5   |
| 2EB31 | MS Rehab - Medium                   | Early - Institutional       | 2  | 1.4978                       | 5   |
| 3EB11 | MS Rehab - Medium                   | Late - Community            | 0  | 0.7032                       | 2   |
| 3EB21 | MS Rehab - Medium                   | Late - Community            | 1  | 0.7591                       | 2   |
| 3EB31 | MS Rehab - Medium                   | Late - Community            | 2  | 0.9187                       | 2   |
| 4EB11 | MS Rehab - Medium                   | Late - Institutional        | 0  | 1.192                        | 4   |
| 4EB21 | MS Rehab - Medium                   | Late - Institutional        | 1  | 1.2479                       | 4   |
| 4EB31 | MS Rehab - Medium                   | Late - Institutional        | 2  | 1.4074                       | 5   |
| 1BC11 | Neuro - High                        | Early - Community           | 0  | 1.3286                       | 4   |
| 1BC21 | Neuro - High                        | Early - Community           | 1  | 1.3845                       | 4   |
| 1BC31 | Neuro - High                        | Early - Community           | 2  | 1.5441                       | 4   |
| 2BC11 | Neuro - High                        | Early - Institutional       | 0  | 1.545                        | 5   |
| 2BC21 | Neuro - High                        | Early - Institutional       | 1  | 1.6009                       | 5   |
| 2BC31 | Neuro - High                        | Early - Institutional       | 2  | 1.7605                       | 5   |
| 3BC11 | Neuro - High                        | Late - Community            | 0  | 0.9659                       | 2   |
| 3BC21 | Neuro - High                        | Late - Community            | 1  | 1.0218                       | 3   |
| 3BC31 | Neuro - High                        | Late - Community            | 2  | 1.1813                       | 3   |
| 4BC11 | Neuro - High                        | Late - Institutional        | 0  | 1.4546                       | 4   |
| 4BC21 | Neuro - High                        | Late - Institutional        | 1  | 1.5105                       | 4   |
| 4BC31 | Neuro - High                        | Late - Institutional        | 2  | 1.6701                       | 4   |
| 1BA11 | Neuro - Low                         | Early - Community           | 0  | 1.0834                       | 4   |
| 1BA21 | Neuro - Low                         | Early - Community           | 1  | 1.1394                       | 4   |

| HIPPS | Clinical Group and Functional Level | Admission Source and Timing | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | Recalibrated Weight for 2024 | LUPA Visit Threshold (LUPAs have fewer visits than the threshold) |
|-------|-------------------------------------|-----------------------------|--|------------------------------|---|
| IBA31 | Neuro - Low                         | Early - Community           | 2  | 1.2989                       | 4   |
| 2BA11 | Neuro - Low                         | Early - Institutional       | 0  | 1.2998                       | 4   |
| 2BA21 | Neuro - Low                         | Early - Institutional       | 1  | 1.3558                       | 4   |
| 2BA31 | Neuro - Low                         | Early - Institutional       | 2  | 1.5153                       | 5   |
| 3BA11 | Neuro - Low                         | Late - Community            | 0  | 0.7207                       | 2   |
| 3BA21 | Neuro - Low                         | Late - Community            | 1  | 0.7766                       | 2   |
| 3BA31 | Neuro - Low                         | Late - Community            | 2  | 0.9362                       | 2   |
| 4BA11 | Neuro - Low                         | Late - Institutional        | 0  | 1.2094                       | 4   |
| 4BA21 | Neuro - Low                         | Late - Institutional        | 1  | 1.2654                       | 4   |
| 4BA31 | Neuro - Low                         | Late - Institutional        | 2  | 1.4249                       | 4   |
| 1BB11 | Neuro - Medium                      | Early - Community           | 0  | 1.196                        | 4   |
| 1BB21 | Neuro - Medium                      | Early - Community           | 1  | 1.2519                       | 4   |
| 1BB31 | Neuro - Medium                      | Early - Community           | 2  | 1.4115                       | 4   |
| 2BB11 | Neuro - Medium                      | Early - Institutional       | 0  | 1.4124                       | 5   |
| 2BB21 | Neuro - Medium                      | Early - Institutional       | 1  | 1.4683                       | 5   |
| 2BB31 | Neuro - Medium                      | Early - Institutional       | 2  | 1.6278                       | 5   |
| 3BB11 | Neuro - Medium                      | Late - Community            | 0  | 0.8332                       | 2   |
| 3BB21 | Neuro - Medium                      | Late - Community            | 1  | 0.8892                       | 2   |
| 3BB31 | Neuro - Medium                      | Late - Community            | 2  | 1.0487                       | 2   |
| 4BB11 | Neuro - Medium                      | Late - Institutional        | 0  | 1.322                        | 4   |
| 4BB21 | Neuro - Medium                      | Late - Institutional        | 1  | 1.3779                       | 4   |
| 4BB31 | Neuro - Medium                      | Late - Institutional        | 2  | 1.5375                       | 4   |
| 1CC11 | Wound - High                        | Early - Community           | 0  | 1.5043                       | 4   |
| 1CC21 | Wound - High                        | Early - Community           | 1  | 1.5602                       | 4   |
| 1CC31 | Wound - High                        | Early - Community           | 2  | 1.7197                       | 4   |
| 2CC11 | Wound - High                        | Early - Institutional       | 0  | 1.7206                       | 5   |
| 2CC21 | Wound - High                        | Early - Institutional       | 1  | 1.7766                       | 4   |
| 2CC31 | Wound - High                        | Early - Institutional       | 2  | 1.9361                       | 4   |
| 3CC11 | Wound - High                        | Late - Community            | 0  | 1.1415                       | 3   |
| 3CC21 | Wound - High                        | Late - Community            | 1  | 1.1974                       | 3   |
| 3CC31 | Wound - High                        | Late - Community            | 2  | 1.357                        | 3   |
| 4CC11 | Wound - High                        | Late - Institutional        | 0  | 1.6303                       | 4   |
| 4CC21 | Wound - High                        | Late - Institutional        | 1  | 1.6862                       | 4   |
| 4CC31 | Wound - High                        | Late - Institutional        | 2  | 1.8457                       | 4   |
| 1CA11 | Wound - Low                         | Early - Community           | 0  | 1.2696                       | 4   |



| HIPPS | Clinical Group and Functional Level | Admission Source and Timing | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | Recalibrated Weight for 2024 | LUPA Visit Threshold (LUPAs have fewer visits than the threshold) |
|-------|-------------------------------------|-----------------------------|--|------------------------------|---|
| 1CA21 | Wound - Low                         | Early - Community           | 1  | 1.3255                       | 4   |
| 1CA31 | Wound - Low                         | Early - Community           | 2  | 1.485                        | 4   |
| 2CA11 | Wound - Low                         | Early - Institutional       | 0  | 1.486                        | 4   |
| 2CA21 | Wound - Low                         | Early - Institutional       | 1  | 1.5419                       | 4   |
| 2CA31 | Wound - Low                         | Early - Institutional       | 2  | 1.7014                       | 4   |
| 3CA11 | Wound - Low                         | Late - Community            | 0  | 0.9068                       | 2   |
| 3CA21 | Wound - Low                         | Late - Community            | 1  | 0.9628                       | 3   |
| 3CA31 | Wound - Low                         | Late - Community            | 2  | 1.1223                       | 3   |
| 4CA11 | Wound - Low                         | Late - Institutional        | 0  | 1.3956                       | 3   |
| 4CA21 | Wound - Low                         | Late - Institutional        | 1  | 1.4515                       | 4   |
| 4CA31 | Wound - Low                         | Late - Institutional        | 2  | 1.611                        | 4   |
| 1CB11 | Wound - Medium                      | Early - Community           | 0  | 1.3754                       | 4   |
| 1CB21 | Wound - Medium                      | Early - Community           | 1  | 1.4314                       | 4   |
| 1CB31 | Wound - Medium                      | Early - Community           | 2  | 1.5909                       | 4   |
| 2CB11 | Wound - Medium                      | Early - Institutional       | 0  | 1.5918                       | 5   |
| 2CB21 | Wound - Medium                      | Early - Institutional       | 1  | 1.6477                       | 5   |
| 2CB31 | Wound - Medium                      | Early - Institutional       | 2  | 1.8073                       | 5   |
| 3CB11 | Wound - Medium                      | Late - Community            | 0  | 1.0127                       | 3   |
| 3CB21 | Wound - Medium                      | Late - Community            | 1  | 1.0686                       | 3   |
| 3CB31 | Wound - Medium                      | Late - Community            | 2  | 1.2282                       | 3   |
| 4CB11 | Wound - Medium                      | Late - Institutional        | 0  | 1.5014                       | 4   |
| 4CB21 | Wound - Medium                      | Late - Institutional        | 1  | 1.5574                       | 4   |
| 4CB31 | Wound - Medium                      | Late - Institutional        | 2  | 1.7169                       | 4   |

Source: CY 2022 Home Health Claims Data, Periods that end in CY 2022 accessed on the CCW March 17, 2023.

period payment rate by a case-mix budget neutrality factor. Typically, the case-mix weight budget neutrality factor is also calculated using the most recent, complete home health claims data available. For CY 2024, we will continue the practice of using the most recent complete home health claims data at the time of rulemaking, which is CY 2022 data. The case-mix budget neutrality factor is calculated as the ratio of 30-day base payment rates such that total payments when the CY 2024 PDGM case-mix weights (developed using CY 2022 home health claims data) are applied to CY 2022 utilization (claims) data are equal to total payments when CY 2023 PDGM case-mix weights (developed using CY 2021 home health claims data) are applied to CY 2022 utilization data. This produces a case-mix budget neutrality factor for CY 2024 of 1.0121.

We invite public comments on the CY 2024 proposed case-mix weights and proposed case-mix weight budget neutrality factor.

### 3. Proposal To Rebase and Revise the Home Health Market Basket and Revise the Labor-Related Share

#### (a) Background

Section 1895(b)(3)(B) of the Act requires that the standard prospective payment amounts for CY 2024 be increased by a factor equal to the applicable home health market basket update for those HHAs that submit quality data as required by the Secretary. Effective for cost reporting periods beginning on or after July 1, 1980, we developed and adopted an HHA input price index (that is, the home health “market basket”). Although “market basket” technically describes the mix of goods and services used to produce home health care, this term is also commonly used to denote the input price index derived from that market basket. Accordingly, the term “home health market basket” used in this document refers to the HHA input price index.

The percentage change in the home health market basket reflects the average change in the price of goods and services purchased by HHAs in providing an efficient level of home health care services. We first used the home health market basket to adjust HHA cost limits by an amount that reflected the average increase in the prices of the goods and services used to furnish reasonable cost home health care. This approach linked the increase in the cost limits to the efficient utilization of resources. For a greater discussion on the home health market

basket, see the notice with comment period published in the February 15, 1980 **Federal Register** (45 FR 10450, 10451), the notice with comment period published in the February 14, 1995 **Federal Register** (60 FR 8389, 8392), and the notice with comment period published in the July 1, 1996 **Federal Register** (61 FR 34344, 34347). Beginning with the FY 2002 HH PPS payments, we have used the growth in a home health market basket to update payments under the HH PPS.

We have rebased and revised the home health market basket periodically through the years since FY 2002. We rebased the home health market basket effective with the FY 2005 update (69 FR 31251–31255), with the CY 2008 update (72 FR 25435–25442), and with the CY 2013 update (77 FR 67081). We last rebased and revised the home health market basket effective with the CY 2019 update (83 FR 56425 through 56435) reflecting a 2016 base year. Beginning with CY 2024, we are proposing to rebase and revise the home health market basket to reflect a 2021 base year. In the following discussion, we provide an overview of the proposed home health market basket and describe the methodologies used to determine the proposed 2021-based home health market basket.

The home health market basket is a fixed-weight, Laspeyres-type price index. A Laspeyres-type price index measures the change in price, over time, of the same mix of goods and services purchased in the base period. Any changes in the quantity or mix of goods and services (that is, intensity) purchased over time relative to the base period are not measured.

The index itself is constructed in three steps. First, a base period is selected (for the proposed home health market basket, we are proposing to use 2021 as the base period) and total base period costs are estimated for a set of mutually exclusive and exhaustive cost categories. Each category is calculated as a proportion of total costs. These proportions are called cost weights. Second, each expenditure category is matched to an appropriate price or wage variable, referred to as a price proxy. In almost every instance, these price proxies are derived from publicly available statistical series that are published on a consistent schedule (preferably at least on a quarterly basis). Finally, the cost weight for each cost category is multiplied by the level of its respective price proxy. The sum of these products (that is, the cost weights multiplied by their price index levels) for all cost categories yields the composite index level of the market

basket in a given period. Repeating this step for other periods produces a series of market basket levels over time. Dividing an index level for a given period by an index level for an earlier period produces a rate of growth in the input price index over that timeframe.

As noted previously, the market basket is described as a fixed-weight index because it represents the change in price over time of a constant mix (quantity and intensity) of goods and services needed to provide HHA services. The effects on total costs resulting from changes in the mix of goods and services purchased subsequent to the base period are not measured. For example, an HHA hiring more nurses after the base period to accommodate the needs of patients would increase the volume of goods and services purchased by the HHA, but would not be factored into the price change measured by a fixed-weight home health market basket. Only when the index is rebased would changes in the quantity and intensity be captured, with those changes being reflected in the cost weights. Therefore, we rebase the home health market basket periodically so that the cost weights reflect recent changes in the mix of goods and services that HHAs purchase to furnish inpatient care between base periods.

#### (b) Proposed Rebasing and Revising of the Home Health Market Basket

We believe that it is technically appropriate to rebase the home health market basket periodically so that the cost category weights reflect changes in the mix of goods and services that HHAs purchase in furnishing home health care. For the CY 2024 HH PPS proposed rule, we propose to rebase and revise the home health market basket to reflect a 2021 base year using 2021 Medicare cost report data for Medicare-participating freestanding HHAs, the latest available and most complete data on the actual structure of HHA costs at the time of this rulemaking. In prior rulemaking, commenters have expressed concern that recent cost pressures and the impact of the COVID–19 PHE have impacted input price inflation in providing home health services. We are proposing to use 2021 as the base year because we believe that the Medicare cost reports for this year represent the most recent, complete set of Medicare cost report data available for developing the proposed home health market basket that captures recent cost trends. Given the potential impact of the COVID–19 PHE on the Medicare cost report data, we will continue to monitor these data going forward and any changes to the

home health market basket will be proposed in future rulemaking.

The terms “rebasings” and “revising,” while often used interchangeably, denote different activities. The term “rebasings” means moving the base year for the structure of costs of an input price index (that is, in this exercise, we are proposing to move the base year cost structure from 2016 to 2021) without making any other major changes to the methodology. The term “revising” means changing data sources, cost categories, and price proxies used in the input price index. For the CY 2024 HH PPS proposed rule, we propose to rebase and revise the home health market basket to reflect a 2021 base year.

(c) Derivation of the Proposed 2021-Based Home Health Market Basket Major Cost Weights

The major cost weights for the proposed revised and rebased home health market basket are derived from the Medicare cost reports (CMS Form 1728–20, OMB No. 0938–0022) for freestanding HHAs whose cost reporting period began on or after October 1, 2020 and before October 1, 2021. Of the 2021 Medicare cost reports for freestanding HHAs, approximately 84 percent of the reports had a begin date on January 1, 2021, approximately 5 percent had a begin date on July 1, 2021, and approximately 3 percent had a begin date on October 1, 2020. The remaining 8 percent had a begin date within the specified range. Using this methodology allowed our sample to include HHAs with varying cost report years including, but not limited to, the Federal fiscal or calendar year.

We propose to maintain our policy of using data from freestanding HHAs, which account for about 93 percent of HHAs (87 FR 66882), as our analysis has determined that they better reflect HHAs’ actual cost structure. Cost data for hospital-based HHAs can be affected by the allocation of overhead costs over the entire institution.

We are proposing to derive seven major cost categories (Wages and Salaries, Benefits, Transportation, Professional Liability Insurance (PLI), Fixed Capital, Movable Capital, and Medical Supplies) from the 2021 HHA Medicare cost reports. The residual cost category, “All Other”, reflects all remaining costs not captured in the seven major cost categories. These costs are based on those cost centers that are reimbursable under the HH PPS, specifically cost centers 16 through 25 (Skilled Nursing Care—RN, Skilled Nursing Care—LPN, Physical Therapy, Physical Therapy Assistant, Occupational Therapy, Certified

Occupational Therapy Assistant, Speech-Language Pathology, Medical Social Services, Home Health Aide, and Medical Supplies Charged to Patients). While the cost centers have changed in CMS Form 1728–20, these generally coincide with those cost centers from CMS Form 1728–94 that were used to derive the 2016-based home health market basket (83 FR 56425). The cost centers used from CMS Form 1728–94 were cost centers 6 through 12 (Skilled Nursing Care, Physical Therapy, Occupational Therapy, Speech Pathology, Medical Social Services, Home Health Aide, and Supplies). Total costs for the HH PPS reimbursable services reflect overhead allocation. We note that Medical Supplies was not considered to be a major cost category in the 2016-based home health market basket because it was not derived directly from Medicare cost report data, and was instead derived from the residual “All Other” category using Benchmark Input-Output (I–O) data published by the Bureau of Economic Analysis (BEA). Next, we provide details on the proposed calculations for the total Medicare allowable costs and each of the proposed seven major cost categories derived from the Medicare cost report data. Unless otherwise specified, proposed calculations are consistent with 2016 methodology.

(1) Total Medicare Allowable Costs

We propose that total Medicare allowable costs for HHAs would be equal to the sum of total costs for the Medicare allowable cost centers as reported on Worksheet B, column 10, lines 16 through 25. We propose that these total Medicare allowable costs for the HHA will be the denominator for the cost weight calculations for the Wages and Salaries, Benefits, Transportation, Professional Liability Insurance, Fixed Capital, Movable Capital, and Medical Supplies cost weights. With this work complete, we then set about deriving cost levels for the seven major cost categories.

(2) Costs for the Seven Major Cost Categories Derived From the Medicare Cost Report Data

(a) Wages and Salaries

We propose that wages and salaries costs reflect direct patient care wage and salary costs, overhead wage and salary costs (associated with the following overhead cost centers: Plant Operations and Maintenance, Transportation, Telecommunications Technology, Administrative and General, Nursing Administration, Medical Records, and Other General Service cost centers), and

a portion of direct patient care contract labor costs. The estimation of the wage and salary costs is derived using a similar methodology to that which was implemented for the 2016-based home health market basket, with the primary difference being the specific cost report line items now available on the HHA cost report form.

(i) Direct Patient Care

We are proposing to calculate direct patient care wages and salaries by summing costs from Worksheet A, column 1, lines 16 through 25.

(ii) Overhead

We are proposing to calculate overhead wages and salaries by summing costs from Worksheet B, columns 3 through 9, lines 16 through 25 multiplied by the percentage of costs in the overhead cost centers that were reported as salaries. This ratio is calculated as the sum of costs on Worksheet A, column 1, lines 3 through 9, divided by the sum of costs on Worksheet A, columns 1 through 5, lines 3 through 9.

(iii) Wages and Salaries Portion of Direct Patient Care Contract Labor

Contract labor costs allocated to wages and salaries costs reflect a portion of the direct patient care contract labor costs. Specifically, we are proposing to calculate direct patient care contract labor costs by first summing costs from Worksheet A, column 4, lines 16 through 25. These contract labor costs are then multiplied by each provider’s ratio of direct patient care wages and salaries costs to total direct patient care wages and salaries and benefits costs. This ratio is calculated as the sum of costs on Worksheet A, column 1, lines 16 through 25, divided by the sum of costs on Worksheet A, columns 1 and 2, lines 16 through 25. Similarly, the 2016 method for deriving the wages and salaries costs multiplied the combined salaries and benefits (both Direct Patient Care (DPC) and non-DPC) and DPC contract labor, by the ratio of combined DPC and non-DPC salaries to total DPC and non-DPC salaries and benefits.

(b) Benefits

Benefits costs reflect direct patient care benefit costs, overhead benefit costs (associated with the following overhead cost centers: Plant Operations and Maintenance, Transportation, Telecommunications Technology, Administrative and General, Nursing Administration, Medical Records, and Other General Service) and a portion of direct patient care contract labor costs. Similarly, the 2016 method for deriving

the benefits costs multiplied the combined salaries and benefits (both DPC and non-DPC) and DPC contract labor, by the ratio of combined DPC and non-DPC benefits to total DPC and non-DPC salaries and benefits.

(i) Direct Patient Care

We are proposing to calculate the cost of the direct patient care benefit costs by summing costs from Worksheet A, column 2, lines 16 through 25.

(ii) Overhead

We are proposing to calculate overhead benefit costs by summing costs from Worksheet B, columns 3 through 9, lines 16 through 25 multiplied by the percentage of costs in the overhead cost centers that were reported as benefits. This percentage is calculated as the sum of costs on Worksheet A, column 2, lines 3 through 9, divided by the sum of costs on Worksheet A, columns 1 through 5, lines 3 through 9.

(iii) Benefits Portion of Direct Patient Care Contract Labor

Contract labor costs allocated to Benefits costs reflect a portion of the direct patient care contract labor costs. Specifically, we are proposing to first calculate direct patient care contract labor costs by summing costs from Worksheet A, column 4, lines 16 through 25. These contract labor costs are then multiplied by each provider's ratio of direct patient care benefits costs to total direct patient care wages and salaries and benefits costs. This ratio is calculated as the sum of costs on Worksheet A, column 2, lines 16 through 25, divided by the sum of costs on Worksheet A, columns 1 and 2, lines 16 through 25.

(c) Transportation

Transportation costs reflect direct patient care costs as well as transportation costs associated with Capital Expenses, Plant Operations and Maintenance, and Administrative and General cost centers. Specifically, we are proposing to calculate transportation costs by summing costs from Worksheet A, column 3, lines 16 through 25; Worksheet A, column 3, lines 1 through 3; and costs on Worksheet B, column 4, lines 16 through 25 multiplied by a ratio that reflects the non-salary and benefits portion of these costs. Specifically, this ratio was calculated as 1 minus the sum of costs on Worksheet A, columns 1 and 2, line 4, divided by the sum of costs on Worksheet A, columns 1 through 5, line 4.

(d) Professional Liability Insurance

Professional Liability Insurance reflects premiums, paid losses, and self-insurance costs. Specifically, we are proposing to calculate Professional Liability Insurance by summing costs from Worksheet S-2 Part I, line 14, columns 1 through 3.

(e) Fixed Capital

Fixed Capital-related costs reflect the portion of Medicare-allowable costs reported in Capital Related Buildings and Fixtures (Worksheet A, column 5, line 1). We are proposing to calculate this Medicare allowable portion by first calculating a ratio for each provider that reflects fixed capital costs as a percentage of HHA reimbursable services. Specifically, this ratio was calculated as the sum of costs from Worksheet B, column 1, lines 16 through 25 divided by the sum of costs from Worksheet B, column 1, line 1 minus lines 3 through 9. This percentage is then applied to the costs from Worksheet A, column 5, line 1.

(f) Movable Capital

Movable Capital-related costs reflect the portion of Medicare-allowable costs reported in Capital Related Movable Equipment (Worksheet A, column 5, line 2). We are proposing to calculate this Medicare allowable portion by first calculating a ratio for each provider that reflects movable capital costs as a percentage of HHA reimbursable services. Specifically, this ratio was calculated as the sum of costs from Worksheet B, column 2, lines 16 through 25 divided by the sum of costs from Worksheet B, column 2, line 2 minus lines 3 through 9. This percentage is then applied to the costs from Worksheet A, column 5, line 2.

(g) Medical Supplies

Medical Supplies costs reflect the cost of supplies furnished to individual patients and for which a separate charge is made, as well as minor medical and surgical supplies not expected to be specifically identified in the plan of treatment or for which a separate charge is not made. Specifically, we propose to calculate Medical Supplies as the sum of Worksheet A, column 5, line 25; and Worksheet B, column 6, line 25 multiplied by a ratio that reflects the non-salary and benefits portion of these costs. Specifically, this ratio was calculated as 1 minus the sum of costs on Worksheet A, columns 1 and 2, line 6, divided by the sum of costs on Worksheet A, columns 1 through 5, line

6. We note that in the 2016-based home health market basket, the Medical Supplies cost weight was derived from the "All Other" residual cost weight.

(3) Derivation of the Major Cost Weights

After we derive costs for each of the seven major cost categories and total Medicare allowable costs for each provider using the Medicare cost report data, we propose to address data outliers using the following steps. First, for each of the seven major cost categories, we divide the costs in that category by total Medicare allowable costs calculated for the provider to obtain cost weights for the universe of HHA providers. We propose to trim the data to remove outliers (a standard statistical process) by: (1) requiring that major costs (such as wages and salaries costs) and total Medicare allowable costs be greater than zero and requiring that category costs are less than the total Medicare allowable costs; and (2) excluding the top and bottom five percent of the major cost weight (for example, wages and salaries costs as a percent of total Medicare allowable costs). We note that missing values are assumed to be zero consistent with the methodology for how missing values were treated in the 2016-based home health market basket. After these outliers have been excluded, we sum the costs for each category across all remaining providers. We then divide this by the sum of total Medicare allowable costs across all remaining providers to obtain a cost weight for the proposed 2021-based home health market basket for the given category.

Finally, we propose to calculate the residual "All Other" cost weight that reflects all remaining costs that are not captured in the other categories listed by subtracting the major cost weight percentages (Wages and Salaries, Benefits, Transportation, Professional Liability Insurance, Fixed Capital, Movable Capital, and Medical Supplies) from 1. We note that non-direct patient care contract labor costs (such as contract labor costs reported in the Administrative and General cost center of the Medicare cost report) are captured in the "All Other" residual cost weight and later disaggregated into more detail as described later in this section.

Table B23 shows the major cost categories and their respective cost weights as derived from the Medicare cost reports for this proposed rule.

**TABLE B23 – MAJOR COST WEIGHTS AS DERIVED FROM THE MEDICARE COST REPORTS**

| Major Cost Categories            | Proposed 2021-based | 2016-based       |
|----------------------------------|---------------------|------------------|
| Wages and Salaries               | 64.2                | 65.1             |
| Benefits                         | 10.7                | 10.9             |
| Transportation                   | 2.3                 | 2.6              |
| Professional Liability Insurance | 0.4                 | 0.3              |
| Fixed Capital                    | 1.3                 | 1.4              |
| Movable Capital                  | 0.5                 | 0.6              |
| Medical Supplies                 | 2.0                 | n/a <sup>1</sup> |
| “All Other” residual             | 18.6                | 19.0             |

\* Figures may not sum to 100.0 due to rounding

1. In the 2016-based home health market basket, the Medical Supplies cost category is part of the “All Other” residual cost weight.

The decrease in the proposed wages and salaries cost weight of 0.9 percentage point and the decrease in the proposed benefits cost weight of 0.2 percentage point is primarily attributable to direct patient care

contract labor costs as reported on the Medicare cost report data, as shown in Table B24. Our analysis of the Medicare cost report data shows that a decrease in the compensation cost weight from 2016 to 2021 occurred, in aggregate, among

for-profit, nonprofit, and government providers and among providers serving only rural beneficiaries, only urban beneficiaries, or both rural and urban beneficiaries.

**TABLE B24 – COST WEIGHTS FOR DIRECT PATIENT CARE CONTRACT LABOR AND WAGES AND SALARIES AND EMPLOYEE BENEFITS THAT EXCLUDE DIRECT PATIENT CARE CONTRACT LABOR**

| Major Cost Categories  | Proposed 2021-Based Home Health Market Basket | 2016-Based Home Health Market Basket |
|--|---|--------------------------------------|
| Wages and Salaries, excluding Direct Patient Care Contract Labor   | 58.3  | 58.1                                 |
| Employee Benefits, excluding Directing Patient Care Contract Labor | 9.8   | 9.8                                  |
| Direct Patient Care Contract Labor                                 | 6.8   | 8.1                                  |

Our analysis of the Medicare cost report data shows that decreased contract labor utilization has occurred over most occupational categories, including higher-paid specialties in particular, and that utilization of direct patient care contract labor has been trending downward since 2010. We also note that over the 2016 to 2021 time period, the average number of full-time equivalents per provider decreased considerably.

**(4) Derivation of the Detailed Cost Weights**

We propose to divide the “All Other” residual cost weight estimated from the 2021 Medicare cost report data into more detailed cost categories. To divide

this cost weight, we are proposing to use the 2012 Benchmark I–O “Use Tables/ Before Redefinitions/Purchaser Value” for North American Industrial Classification System (NAICS) 621600, Home Health Agencies, published by the BEA. These data are publicly available at [http://www.bea.gov/industry/io\\_annual.htm](http://www.bea.gov/industry/io_annual.htm). For the 2016-based home health market basket, we used the 2007 Benchmark I–O data, the most recent data available at the time (83 FR 56427).

The BEA Benchmark I–O data are generally scheduled for publication every five years with the most recent data available for 2012. The 2012 Benchmark I–O data are derived from the 2012 Economic Census and are the

building blocks for BEA’s economic accounts. Therefore, they represent the most comprehensive and complete set of data on the economic processes or mechanisms by which output is produced and distributed.<sup>16</sup> Besides Benchmark I–O estimates, BEA also produces Annual I–O estimates. While based on a similar methodology, the Annual I–O estimates reflect less comprehensive and less detailed data sources and are subject to revision when benchmark data become available. Instead of using the less detailed Annual I–O data, we are proposing to inflate the detailed 2012 Benchmark

<sup>16</sup> [http://www.bea.gov/papers/pdf/IOmanual\\_092906.pdf](http://www.bea.gov/papers/pdf/IOmanual_092906.pdf).

I–O data forward to 2021 by applying the annual price changes from the respective price proxies to the appropriate market basket cost categories that are obtained from the 2012 Benchmark I–O data. We repeated this practice for each year. Then, we calculated the cost shares that each cost category represents of the 2012 I–O data inflated to 2021. These resulting 2021 cost shares were applied to the “All Other” residual cost weight to obtain the detailed cost weights for the proposed 2021-based home health market basket. For example, the cost for Utilities represents 11.0 percent of the sum of the “All Other” 2012 Benchmark I–O HHA costs inflated to 2021. Therefore, the Utilities cost weight represents 11.0 percent of the proposed

2021-based home health market basket’s “All Other” cost category (18.6 percent), yielding a Utilities proposed cost weight of 2.0 percent in the proposed 2021-based home health market basket ( $0.110 \times 18.6 \text{ percent} = 2.0 \text{ percent}$ ). For the 2016-based home health market basket, we used the same methodology utilizing the 2007 Benchmark I–O data (aged to 2016).

Using this methodology, we propose to derive eight detailed cost categories from the proposed 2021-based home health market basket “All Other” residual cost weight (18.6 percent). These categories are: (1) Utilities; (2) Administrative Support; (3) Financial Services; (4) Rubber and Plastics; (5) Telephone; (6) Professional Fees; (7) Other Products; and (8) Other Services.

We note that the proposed Utilities cost category is currently referred to as Operations & Maintenance in the 2016-based home health market basket; however, the methodology and data sources underlying this cost category remain the same.

Table B25 compares the cost categories and weights for the proposed 2021-based home health market basket compared to the 2016-based home health market basket. In cases where a cost category has been recategorized in the proposed 2021-based home health market basket, we have entered “n/a” to maintain correct totals as they appear in the CY 2019 HH PPS final rule with comment period (83 FR 56428).

**BILLING CODE 4120–01–P**

**TABLE B25: PROPOSED 2021-BASED HOME HEALTH MARKET BASKET COST WEIGHTS COMPARED TO 2016-BASED HOME HEALTH MARKET BASKET COST WEIGHTS**

| Cost Categories                  | Proposed 2021-based | 2016-based |
|----------------------------------|---------------------|------------|
| Compensation                     | 74.9                | 76.1       |
| Wages and Salaries               | 64.2                | 65.1       |
| Benefits                         | 10.7                | 10.9       |
| Medical Supplies                 | 2.0                 | n/a        |
| Operations & Maintenance         | n/a                 | 1.5        |
| Professional Liability Insurance | 0.4                 | 0.3        |
| Transportation                   | 2.3                 | 2.6        |
| All Other <sup>1</sup>           | 18.6                | 17.4       |
| Administrative Support           | 1.2                 | 1.0        |
| Financial Services               | 1.1                 | 1.9        |
| Medical Supplies <sup>2</sup>    | n/a                 | 0.9        |
| Rubber & Plastics                | 2.0                 | 1.6        |
| Telephone                        | 0.6                 | 0.7        |
| Professional Fees                | 5.9                 | 5.3        |
| Utilities <sup>3</sup>           | 2.0                 | n/a        |
| Other Products                   | 2.9                 | 2.8        |
| Other Services                   | 2.9                 | 3.2        |
| Capital-Related                  | 1.9                 | 2.1        |
| Fixed Capital                    | 1.3                 | 1.4        |
| Movable Capital                  | 0.5                 | 0.6        |
| Total                            | 100.0               | 100.0      |

**Note:** Figures may not sum due to rounding.

1. The 2016-based home health market basket refers to this cost category as Administrative & General.
2. The 2016-based home health market basket estimated these costs as a component of Administrative & General.
3. The 2016-based home health market basket refers to this cost category as Operations & Maintenance.

## BILLING CODE 4120-01-C

## (d) Selection of Price Proxies

After developing the cost weights for the proposed 2021-based home health market basket, we select the most appropriate wage and price proxies currently available to represent the rate of price change for each cost category. With the exception of the price index for Professional Liability Insurance costs, the proposed price proxies are based on Bureau of Labor Statistics (BLS) data and are grouped into one of the following BLS categories:

- *Employment Cost Indexes.* Employment Cost Indexes (ECIs) measure the rate of change in employment wage rates and employer costs for employee benefits per hour worked. These indexes are fixed-weight indexes and strictly measure the change in wage rates and employee benefits per hour. ECIs are superior to Average Hourly Earnings (AHE) as price proxies for input price indexes because they are not affected by shifts in occupation or industry mix, and because they measure pure price change and are available by both occupational group and by industry. The industry ECIs are based on the NAICS and the occupational ECIs are based on the Standard Occupational Classification System (SOC).

- *Producer Price Indexes.* Producer Price Indexes (PPIs) measure the average change over time in the selling prices received by domestic producers for their output. The prices included in the PPI are from the first commercial transaction for many products and some services (<https://www.bls.gov/ppi/>).

- *Consumer Price Indexes.* Consumer Price Indexes (CPIs) measure the average change over time in the prices paid by urban consumers for a market basket of consumer goods and services (<https://www.bls.gov/cpi/>). CPIs are only used when the purchases are similar to those of retail consumers rather than purchases at the producer level, or if no appropriate PPIs are available.

We evaluate the price proxies using the criteria of reliability, timeliness, availability, and relevance:

- *Reliability.* Reliability indicates that the index is based on valid statistical methods and has low sampling variability. Widely accepted statistical methods ensure that the data were collected and aggregated in a way that can be replicated. Low sampling variability is desirable because it

indicates that the sample reflects the typical members of the population. (Sampling variability is variation that occurs by chance because only a sample was surveyed rather than the entire population.)

- *Timeliness.* Timeliness implies that the proxy is published regularly, preferably at least once a quarter. The market baskets are updated quarterly, and therefore, it is important for the underlying price proxies to be up-to-date, reflecting the most recent data available. We believe that using proxies that are published regularly (at least quarterly, whenever possible) helps to ensure that we are using the most recent data available to update the market basket. We strive to use publications that are disseminated frequently, because we believe that this is an optimal way to stay abreast of the most current data available.

- *Availability.* Availability means that the proxy is publicly available. We prefer that our proxies are publicly available because this will help ensure that our market basket updates are as transparent to the public as possible. In addition, this enables the public to be able to obtain the price proxy data on a regular basis.

- *Relevance.* Relevance means that the proxy is applicable and representative of the cost category weight to which it is applied. The CPIs, PPIs, and ECIs that we have selected to propose in this regulation meet these criteria. Therefore, we believe that they continue to be the best measure of price changes for the cost categories to which they would be applied.

The following is a detailed explanation of the price proxies we are proposing for each cost category weight.

## (e) Proposed 2021-Based Home Health Market Basket Price Proxies

As part of the revising and rebasing of the home health market basket, we are proposing to rebase and revise the home health blended Wages and Salaries index and the home health blended Benefits index. We propose to use these blended indexes as price proxies for the Wages and Salaries and the Benefits categories of the proposed 2021-based home health market basket, as we did in the 2016-based home health market basket. The following is a more detailed discussion.

## (1) Wages and Salaries

For measuring price growth in the 2021-based home health market basket, we are proposing to apply six price proxies to six occupational subcategories within the Wages and Salaries cost weight, which would reflect the 2021 occupational mix in HHAs. This is a similar approach that was used for the 2016-based market basket. We propose to use a blended wage proxy because there is not a published wage proxy specific to the home health industry.

We are proposing to continue to use the National Industry-Specific Occupational Employment and Wage estimates for NAICS 621600, Home Health Care Services, published by the BLS Office of Occupational Employment and Wage Statistics (OEWS) as the data source for the cost shares of the home health blended wage and benefits proxy. We note that in the spring of 2021, the Occupational Employment Statistics (OES) program began using the name Occupational Employment and Wage Statistics (OEWS) to better reflect the range of data available from the program. Data released on or after March 31, 2021 reflect the new program name. This is the same data source that was used for the 2016-based HHA blended wage and benefit proxies; however, we are proposing to use the May 2021 estimates in place of the May 2016 estimates. Detailed information on the methodology for the national industry-specific occupational employment and wage estimates survey can be found at [http://www.bls.gov/oes/current/oes\\_tec.htm](http://www.bls.gov/oes/current/oes_tec.htm).

The six occupational subcategories (Health-Related Professional and Technical, Non-Health-Related Professional and Technical, Management, Administrative, Health and Social Assistance Service, and Other Service Occupations) for the Wages and Salaries cost weight were tabulated from the May 2021 OEWS data for NAICS 621600, Home Health Care Services. Table B26 compares the proposed 2021 occupational assignments to the 2016 occupational assignments of the six CMS designated subcategories. Data that are unavailable in the OEWS occupational classification for 2016 or 2021 are shown in Table B26 as “n/a.”

BILLING CODE 4120-01-P

**TABLE B26: PROPOSED 2021 OCCUPATIONAL ASSIGNMENTS COMPARED TO 2016 OCCUPATIONAL ASSIGNMENTS FOR CMS HOME HEALTH WAGES AND SALARIES PROXY BLEND**

| 2021 Proposed Occupational Groupings |  | 2016 Occupational Groupings |  |
|--------------------------------------|--|-----------------------------|--|
| Group 1                              | Health-Related Professional and Technical                  | Group 1                     | Health-Related Professional and Technical                  |
| 29-1021                              | Dentists, General  | n/a                         | n/a  |
| 29-1031                              | Dietitians and Nutritionists                               | 29-1031                     | Dietitians and Nutritionists                               |
| 29-1051                              | Pharmacists  | 29-1051                     | Pharmacists  |
| n/a                                  | n/a  | 29-1062                     | Family and General Practitioners                           |
| n/a                                  | n/a  | 29-1063                     | Internists, General  |
| n/a                                  | n/a  | 29-1065                     | Pediatricians, General                                     |
| n/a                                  | n/a  | 29-1066                     | Psychiatrists  |
| n/a                                  | n/a  | 29-1069                     | Physicians and Surgeons, All Other                         |
| 29-1071                              | Physician Assistants                                       | 29-1071                     | Physician Assistants                                       |
| 29-1122                              | Occupational Therapists                                    | 29-1122                     | Occupational Therapists                                    |
| 29-1123                              | Physical Therapists  | 29-1123                     | Physical Therapists  |
| 29-1125                              | Recreational Therapists                                    | 29-1125                     | Recreational Therapists                                    |
| 29-1126                              | Respiratory Therapists                                     | 29-1126                     | Respiratory Therapists                                     |
| 29-1127                              | Speech-Language Pathologists                               | 29-1127                     | Speech-Language Pathologists                               |
| 29-1129                              | Therapists, All Other                                      | 29-1129                     | Therapists, All Other                                      |
| 29-1141                              | Registered Nurses  | 29-1141                     | Registered Nurses  |
| 29-1171                              | Nurse Practitioners  | 29-1171                     | Nurse Practitioners  |
| n/a                                  | n/a  | 29-1199                     | Health Diagnosing and Treating Practitioners, All Other    |
| 29-1215                              | Family Medicine Physicians                                 | n/a                         | n/a  |
| 29-1216                              | General Internal Medicine Physicians                       | n/a                         | n/a  |
| 29-1229                              | Physicians, All Other                                      | n/a                         | n/a  |
| 29-1292                              | Dental Hygienists  | n/a                         | n/a  |
| 29-1299                              | Healthcare Diagnosing or Treating Practitioners, All Other | n/a                         | n/a  |
| <b>Group 2</b>                       | <b>Non Health Related Professional and Technical</b>       | <b>Group 2</b>              | <b>Non Health Related Professional and Technical</b>       |
| 13-0000                              | Business and Financial Operations Occupations              | 13-0000                     | Business and Financial Operations Occupations              |
| 15-0000                              | Computer and Mathematical Occupations                      | 15-0000                     | Computer and Mathematical Occupations                      |
| 19-0000                              | Life, Physical, and Social Science Occupations             | 19-0000                     | Life, Physical, and Social Science Occupations             |
| 23-0000                              | Legal Occupations  | n/a                         | n/a  |
| 25-0000                              | Educational Instruction and Library Occupations            | 25-0000                     | Education, Training, and Library Occupations               |
| 27-0000                              | Arts, Design, Entertainment, Sports, and Media Occupations | 27-0000                     | Arts, Design, Entertainment, Sports, and Media Occupations |
| <b>Group 3</b>                       | <b>Management</b>  | <b>Group 3</b>              | <b>Management</b>  |
| 11-0000                              | Management Occupations                                     | 11-0000                     | Management Occupations                                     |
| <b>Group 4</b>                       | <b>Administrative</b>                                      | <b>Group 4</b>              | <b>Administrative</b>                                      |
| 43-0000                              | Office and Administrative Support Occupations              | 43-0000                     | Office and Administrative Support Occupations              |
| <b>Group 5</b>                       | <b>Health and Social Assistance Services</b>               | <b>Group 5</b>              | <b>Health and Social Assistance Services</b>               |
| 21-0000                              | Community and Social Service Occupations                   | 21-0000                     | Community and Social Service Occupations                   |
| 29-2010                              | Clinical Laboratory Technologists and Technicians          | n/a                         | n/a  |
| n/a                                  | n/a  | 29-2011                     | Medical and Clinical Laboratory Technologists              |
| n/a                                  | n/a  | 29-2012                     | Medical and Clinical Laboratory Technicians                |
| n/a                                  | n/a  | 29-2021                     | Dental Hygienists  |
| 29-2031                              | Cardiovascular Technologists and Technicians               | n/a                         | n/a  |
| 29-2032                              | Diagnostic Medical Sonographers                            | 29-2032                     | Diagnostic Medical Sonographers                            |
| 29-2034                              | Radiologic Technologists and Technicians                   | 29-2034                     | Radiologic Technologists                                   |
| n/a                                  | n/a  | 29-2041                     | Emergency Medical Technicians and Paramedics               |
| 29-2051                              | Dietetic Technicians                                       | 29-2051                     | Dietetic Technicians                                       |
| 29-2052                              | Pharmacy Technicians                                       | 29-2052                     | Pharmacy Technicians                                       |
| 29-2053                              | Psychiatric Technicians                                    | 29-2053                     | Psychiatric Technicians                                    |
| n/a                                  | n/a  | 29-2054                     | Respiratory Therapy Technicians                            |
| n/a                                  | n/a  | 29-2055                     | Surgical Technologists                                     |
| 29-2061                              | Licensed Practical and Licensed Vocational Nurses          | 29-2061                     | Licensed Practical and Licensed Vocational Nurses          |
| n/a                                  | n/a  | 29-2071                     | Medical Records and Health Information Technicians         |
| 29-2072                              | Medical Records Specialists                                | n/a                         | n/a  |
| 29-2099                              | Health Technologists and Technicians, All Other            | 29-2099                     | Health Technologists and Technicians, All Other            |
| 29-9021                              | Health Information Technologists and Medical Registrars    | n/a                         | n/a  |
| 29-9099                              | Healthcare Practitioners and Technical Workers, All Other  | 29-9099                     | Healthcare Practitioners and Technical Workers, All Other  |
| 31-0000                              | Healthcare Support Occupations                             | 31-0000                     | Healthcare Support Occupations                             |
| <b>Group 6</b>                       | <b>Other Service Occupations</b>                           | <b>Group 6</b>              | <b>Other Service Occupations</b>                           |
| 33-0000                              | Protective Service Occupations                             | 33-0000                     | Protective Service Occupations                             |



|         |   |         |   |
|---------|---|---------|---|
| 35-0000 | Food Preparation and Serving Related Occupations          | 35-0000 | Food Preparation and Serving Related Occupations          |
| 37-0000 | Building and Grounds Cleaning and Maintenance Occupations | 37-0000 | Building and Grounds Cleaning and Maintenance Occupations |
| 39-0000 | Personal Care and Service Occupations                     | 39-0000 | Personal Care and Service Occupations                     |
| 41-0000 | Sales and Related Occupations                             | 41-0000 | Sales and Related Occupations                             |
| n/a     | n/a   | 47-0000 | Construction and Extraction Occupations                   |
| 49-0000 | Installation, Maintenance, and Repair Occupations         | 49-0000 | Installation, Maintenance, and Repair Occupations         |
| 51-0000 | Production Occupations                                    | 51-0000 | Production Occupations                                    |
| 53-0000 | Transportation and Material Moving Occupations            | 53-0000 | Transportation and Material Moving Occupations            |

Total costs by occupation were calculated by taking the OEWS number of employees multiplied by the OEWS annual average salary for each subcategory, and then calculating the proportion of total wage costs that each subcategory represents of the total industry wage costs. The proportions listed in Table B27 represent the

proposed 2021 wages and salaries blend weights, and the proposed ECIs for each occupational category within the Wages and Salaries price proxy blend. We note that the ECIs reflect the 2021 occupational mix of workers. We also note that 2018 updates to the Standard Occupational Classification (SOC) system included a reclassification of

Personal Care Aides from SOC code 39-9021 to 31-1122, which is reflected in the updated weights and represents the major reason for the higher weight for health care and social assistance services and lower weight for other service occupations.<sup>17</sup>

**TABLE B27: COMPARISON OF THE PROPOSED 2021-BASED HOME HEALTH WAGES AND SALARIES PROXY BLEND AND THE 2016-BASED HOME HEALTH WAGES AND SALARIES PROXY BLEND**

| Cost Subcategory                              | Proposed 2021 Weight | 2016 Weight | Price Proxy   | BLS Series ID      |
|---|----------------------|-------------|---|--------------------|
| Non Health-Related Professional and Technical | 2.9                  | 2.3         | ECI for Wages and salaries for Private industry workers in Professional, scientific, and technical services | CIU2025400000000 I |
| Health-Related Professional and Technical     | 29.7                 | 33.7        | ECI for Wages and salaries for All Civilian workers in Hospitals  | CIU1026220000000 I |
| Management                                    | 6.7                  | 7.6         | ECI for Wages and salaries for Private industry workers in Management, business, and financial              | CIU2020000110000 I |
| Administrative                                | 5.9                  | 6.7         | ECI for Wages and salaries for Private industry workers in Office and administrative support                | CIU2020000220000 I |
| Health and Social Assistance Services         | 53.5                 | 35.3        | ECI for Wages and salaries for All Civilian workers in Health care and social assistance                    | CIU1026200000000 I |
| Other Service Occupations                     | 1.4                  | 14.4        | ECI for Wages and salaries for Private industry workers in Service occupations                              | CIU2020000300000 I |
| <b>Total *</b>                                | 100.0                | 100.0       |   |                    |

\*Totals may not sum due to rounding.

A comparison of the yearly changes from CY 2021 to CY 2024 for the 2016-based home health Wages and Salaries proxy blend and the proposed 2021-based home health Wages and Salaries proxy blend is shown in Table B28. The annual increases in the wages and

salaries proposed price proxy is 0.3 percentage point lower in 2021 and 2022 relative to the 2016-based price proxy, and 0.1 to 0.2 percentage point higher in 2023 and 2024. These differences are primarily driven by the aforementioned reclassification of

Personal Care Aides, which caused a shift in the relative share from the Other Service Occupations to Health and Social Assistance Services as illustrated previously in Table B27.

<sup>17</sup> [https://www.bls.gov/soc/2018/soc\\_2018\\_whats\\_new.pdf](https://www.bls.gov/soc/2018/soc_2018_whats_new.pdf).

**TABLE B28: ANNUAL CY GROWTH IN PROPOSED 2021-BASED AND 2016-BASED HOME HEALTH WAGES AND SALARIES PROXY BLENDS**

|                       | 2021 | 2022 | 2023 | 2024 |
|-----------------------|------|------|------|------|
| Wage Proxy Blend 2021 | 3.6  | 5.6  | 5.2  | 3.6  |
| Wage Proxy Blend 2016 | 3.9  | 5.9  | 5.0  | 3.5  |

Source: IHS Global Inc. 1<sup>st</sup> Quarter 2023 forecast with historical data through 4<sup>th</sup> Quarter 2022

## (2) Benefits

For measuring Benefits price growth in the proposed 2021-based home health market basket, we are proposing to

apply applicable price proxies to the six occupational subcategories that are used for the proposed Wages and Salaries price proxy blend. The proposed six

categories in Table B29 are the same as those in the 2016-based home health market basket and include the same occupational mix as listed in Table B27.

**TABLE B29: COMPARISON OF THE PROPOSED 2021-BASED HOME HEALTH BENEFITS PROXY BLEND AND 2016-BASED HOME HEALTH BENEFITS PROXY BLEND**

| Cost Category                                 | Proposed 2021 Weight | 2016 Weight  | Price Proxy   |
|---|----------------------|--------------|---|
| Non-Health-Related Professional and Technical | 2.8                  | 2.3          | ECI for Benefits for Private industry workers in Professional, scientific, and technical services |
| Health-Related Professional and Technical     | 30.1                 | 33.9         | ECI for Benefits for All Civilian workers in Hospitals  |
| Management                                    | 6.5                  | 7.3          | ECI for Benefits for Private industry workers in Management, business, and financial              |
| Administrative                                | 5.8                  | 6.7          | ECI for Benefits for Private industry workers in Office and administrative support                |
| Health and Social Assistance Services         | 53.5                 | 35.5         | ECI for Benefits for All Civilian workers in Health care and social assistance                    |
| Other Service Occupations                     | 1.3                  | 14.2         | ECI for Benefits for Private industry workers in Service occupations                              |
| <b>Total *</b>                                | <b>100.0</b>         | <b>100.0</b> |   |

\*Totals may not sum due to rounding.

There is no available data source that exists for benefit costs by occupation for the home health industry. Thus, to construct weights for the home health benefits blend we calculated the ratio of benefits to wages and salaries for 2021 for the six ECI series we are proposing to use in the blended 'wages and salaries' and 'benefits' indexes. To derive the relevant benefits weight, we applied the benefit-to-wage ratios to the 2021 OEWS wage and salary weights for each of the six occupational

subcategories, and normalized. For example, the 2021 ECI data shows a ratio of benefits to wages for the health-related professional & technical category of 1.010. We applied this ratio to the 2021 OEWS weight for wages and salaries for health-related professional & technical (9.7 percent) to get an unnormalized weight of 30.0 (29.7 times 1.010), and then normalized those weights relative to the other five benefit occupational categories to obtain a final

benefit weight for health-related professional & technical (30.1 percent).

A comparison of the yearly changes from CY 2021 to CY 2024 for the 2016-based home health Benefits proxy blend and the proposed 2021-based home health Benefits proxy blend is shown in Table B30. With the exception of a 0.2 percentage point difference in 2022, the annual increases in the two price proxies are the same when rounded to one decimal place.

**TABLE B30: ANNUAL GROWTH IN THE PROPOSED 2021-BASED HOME HEALTH BENEFITS PROXY BLEND AND THE 2016-BASED HOME HEALTH BENEFITS PROXY BLEND**

|                           | 2021 | 2022 | 2023 | 2024 |
|---------------------------|------|------|------|------|
| Benefits Proxy Blend 2021 | 2.6  | 4.8  | 4.2  | 3.4  |
| Benefits Proxy Blend 2016 | 2.6  | 5.0  | 4.2  | 3.4  |

Source: IHS Global Inc. 1<sup>st</sup> Quarter 2023 forecast with historical data through 4<sup>th</sup> Quarter 2022

(3) Medical Supplies

We are proposing to use a 75/25 blend of the PPI Commodity data for Surgical and Medical Instruments (BLS series code #WPU1562) and the PPI Commodity data for Personal Safety Equipment and Clothing (BLS series code #WPU1571), which would replace the current price proxy of the PPI for Medical, Surgical, and Personal Aid Devices (BLS series code #WPU156). The PPI Commodity data for Personal Safety Equipment and Clothing would reflect personal protective equipment (PPE) including but not limited to face shields and protective clothing. The 2012 Benchmark I–O data does not provide specific costs for the two categories we are proposing to blend. In absence of such data, we have based the weights of this blend on the change in the medical supplies weight as reported in the Medicare cost reports in the years prior to and after the COVID–19 PHE. Specifically, analysis of Medicare cost report data found that the average weight for medical supplies for the 2016–2019 period (stable around 1.5 percent) was about 75 percent of the weight observed for the 2020–2021 period (roughly 2.0 percent). Thus, we believe that it was likely that the increase in the cost weight was mainly attributable to costs such as those associated with personal safety equipment and clothing, and are basing the proposed 75/25 blend on that analysis. We believe this change will more closely proxy the rate of change of the underlying costs, including increased utilization of personal protective equipment.

(4) Professional Liability Insurance

We are proposing to use the CMS Physician Professional Liability Insurance price index to measure price growth of this cost category. To generate this index, we collect commercial insurance premiums for a fixed level of coverage while holding non-price factors constant (such as a change in the level of coverage). The same proxy was

used for the 2016-based home health market basket.

(5) Transportation

We are proposing to use the CPI U.S. city average for Transportation (BLS series code #CUUR0000SAT) to measure price growth of this category. The same proxy was used for the 2016-based home health market basket.

(6) Administrative and Support

We are proposing to use the ECI for Total compensation for Private industry workers in Office and administrative support (BLS series code #CIU20100002200001) to measure price growth of this cost category. The same proxy was used for the 2016-based home health market basket.

(7) Financial Services

We are proposing to use the ECI for Total compensation for Private industry workers in Financial activities (BLS series code #CIU201520A0000001) to measure price growth of this cost category. The same proxy was used for the 2016-based home health market basket.

(8) Rubber and Plastics

We are proposing to use the PPI Commodity data for Rubber and plastic products (BLS series code #WPU07) to measure price growth of this cost category. The same proxy was used for the 2016-based home health market basket.

(9) Telephone

We are proposing to use CPI U.S. city average for Telephone services (BLS series code #CUUR0000SEED) to measure price growth of this cost category. The same proxy was used for the 2016-based home health market basket.

(10) Professional Fees

We are proposing to use the ECI for Total compensation for Private industry workers in Professional and related (BLS series code #CIS20100001200001) to measure price growth of this category.

The same proxy was used for the 2016-based home health market basket.

(11) Utilities

We are proposing to use CPI–U U.S. city average for Fuel and utilities (BLS series code #CUUR0000SAH2) to measure price growth of this cost category. The same proxy was used for the 2016-based home health market basket.

(12) Other Products

We are proposing to use the PPI Commodity data for Final demand–Finished goods less foods and energy (BLS series code #WPUFD4131) to measure price growth of this category. The same proxy was used for the 2016-based home health market basket.

(13) Other Services

We are proposing to use the ECI for Total compensation for Private industry workers in Service occupations (BLS series code #CIU20100003000001) to measure price growth of this category. The same proxy was used for the 2016-based home health market basket.

(14) Fixed Capital

We are proposing to use the CPI U.S. city average for Owners’ equivalent rent of residences (BLS series code #CUUS0000SEHC) to measure price growth of this cost category. The same proxy was used for the 2016-based home health market basket.

(15) Movable Capital

We are proposing to use the PPI Commodity data for Machinery and equipment (BLS series code #WPU11) to measure price growth of this cost category. The same proxy was used for the 2016-based home health market basket.

(f) Summary of Price Proxies of the Proposed 2021-Based Home Health Market Basket

Table B31 shows the price proxies for the proposed 2021-based home health market basket.

**TABLE B31: PRICE PROXIES FOR THE PROPOSED 2021-BASED HOME HEALTH MARKET BASKET**

| <b>Cost Description</b>                                      | <b>Price Proxy</b>  | <b>Weight</b> |
|--|---|---------------|
| <b>Total</b>   |   | <b>100.0</b>  |
| <b>Compensation</b>  |   | <b>74.9</b>   |
| <b>Wages and Salaries (W&amp;S)</b>                          |   | <b>64.2</b>   |
| Non-Health-Related Professional and Technical (P&T) W&S      | ECI for Wages and salaries for Private industry workers in Professional, scientific, and technical services                             | <b>1.8</b>    |
| Health-Related Professional and Technical (P&T) W&S          | ECI for Wages and salaries for All Civilian workers in Hospitals  | <b>19.1</b>   |
| Managerial / Supervisory W&S                                 | ECI for Wages and salaries for Private industry workers in Management, business, and financial  | <b>4.3</b>    |
| Administrative / Clerical W&S                                | ECI for Wages and salaries for Private industry workers in Office and administrative support  | <b>3.8</b>    |
| Other Service Occupations W&S                                | ECI for Wages and salaries for Private Industry workers in Service occupations  | <b>0.9</b>    |
| Health and Social Assistance Services W&S                    | ECI for Wages and salaries for All Civilian workers in Health care and social assistance  | <b>34.3</b>   |
| <b>Benefits</b>  |   | <b>10.7</b>   |
| Non-Health-Related Professional and Technical (P&T) Benefits | ECI for Total benefits for Private industry workers in Professional, scientific, and technical services                                 | <b>0.3</b>    |
| Health-Related Professional and Technical (P&T) Benefits     | ECI for Total benefits for All Civilian workers in Hospitals  | <b>3.2</b>    |
| Managerial / Supervisory Benefits                            | ECI for Total benefits for Private industry workers in Management, business, and financial  | <b>0.7</b>    |
| Administrative / Clerical Benefits                           | ECI for Total benefits for Private industry workers in Office and administrative support  | <b>0.6</b>    |
| Other Service Occupations Benefits                           | ECI for Total benefits for Private industry workers in Service occupations  | <b>0.1</b>    |
| Health and Social Assistance Services Benefits               | ECI for Total Benefits for All Civilian workers in Health care and social assistance  | <b>5.7</b>    |
| <b>Medical Supplies</b>                                      | 75/25 blend: PPI Commodity data for Surgical and Medical Instruments, and PPI Commodity data for Personal Safety Equipment and Clothing | <b>2.0</b>    |
| <b>Professional Liability Insurance</b>                      | CMS Professional Liability Insurance Index, physicians  | <b>0.4</b>    |
| <b>Transportation</b>  | CPI for Transportation  | <b>2.3</b>    |
| <b>All Other</b>   |   | <b>18.6</b>   |
| Administrative Support                                       | ECI for Total compensation for Private industry workers in Office and administrative support  | <b>1.2</b>    |
| Financial Services   | ECI for Total compensation for Private industry workers in Financial activities   | <b>1.1</b>    |
| Rubber & Plastics  | PPI for Rubber and plastic products   | <b>2.0</b>    |
| Telephone  | CPI for Telephone Services  | <b>0.6</b>    |
| Professional Fees  | ECI for Total compensation for Private industry workers in Professional and related   | <b>5.9</b>    |
| Utilities  | CPI for Fuels and Utilities   | <b>2.0</b>    |

|                      |  |            |
|----------------------|--|------------|
| Other Products       | PPI for Finished goods less foods and energy                                   | 2.9        |
| Other Services       | ECI for Total compensation for Private industry workers in Service occupations | 2.9        |
| <b>Capital Costs</b> |  | <b>1.9</b> |
| Fixed Capital        | CPI for Owners' equivalent rent of residences                                  | 1.3        |
| Movable Capital      | PPI for Machinery and equipment  | 0.5        |

Note: Totals may not sum to 100.0 percent due to rounding.

We invite public comment on our proposal to rebase and revise the home health market basket to reflect a 2021 base year.

4. Proposed CY 2024 Home Health Payment Rate Updates

(a) Proposed CY 2024 Home Health Market Basket Percentage Increase

A comparison of the yearly percent changes from CY 2019 to CY 2026 for

the 2016-based home health market basket and the proposed 2021-based home health market basket based on IHS Global Inc.'s (IGI's) first quarter 2023 forecast, with historical data through the fourth quarter of 2022, is shown in Table B32. IGI is a nationally recognized economic and financial forecasting firm with which CMS contracts to forecast the components of the market baskets. Based on IGI's first quarter 2023

forecast, the proposed CY 2024 home health market basket percentage increase is 3.0 percent based on the proposed 2021-based home health market basket. We propose that if more recent data subsequently become available (for example, a more recent estimate of the market basket), we would use such data, if appropriate, to determine the market basket percentage increase in the final rule.

**TABLE B32: COMPARISON OF THE 2016-BASED HOME HEALTH MARKET BASKET AND THE PROPOSED 2021-BASED HOME HEALTH MARKET BASKET, PERCENT CHANGE, 2019-2026**

|                       | 2016-based Home Health Market Basket | Proposed 2021-based Home Health Market Basket | Difference (Proposed 2021-based less 2016-based) |
|-----------------------|--------------------------------------|---|--|
| Historical data:      |                                      |   |  |
| CY 2019               | 2.6                                  | 2.4   | -0.2   |
| CY 2020               | 2.2                                  | 2.1   | -0.1   |
| CY 2021               | 4.1                                  | 3.9   | -0.2   |
| CY 2022               | 6.3                                  | 6.2   | -0.1   |
| Average CYs 2019-2022 | 3.8                                  | 3.7   | -0.1   |
| Forecast:             |                                      |   |  |
| CY 2023               | 4.5                                  | 4.6   | 0.1  |
| CY 2024               | 3.1                                  | 3.0   | -0.1   |
| CY 2025               | 2.9                                  | 2.8   | -0.1   |
| CY 2026               | 2.8                                  | 2.8   | 0.0  |
| Average CYs 2023-2026 | 3.3                                  | 3.3   | 0.0  |

Source: IHS Global Inc. 1<sup>st</sup> Quarter 2023 forecast with historical data through 4<sup>th</sup> Quarter 2022

**BILLING CODE 4120-01-C**

Table B32 shows that the forecasted percentage increase for CY 2024 of the proposed 2021-based home health market basket is 3.0 percent; 0.1 percentage point lower growth as estimated using the 2016-based home health market basket. The average historical estimates of the growth in the proposed 2021-based and 2016-based home health market baskets over CY 2019 through CY 2022 differ by an average of 0.1 percentage point. As discussed previously, this is primarily driven by a reclassification of Personal

Care Aides, which caused a shift in the relative weight of the Wages and Salaries and Benefits blended price proxies from Other Service Occupations to Health and Social Assistance Services, which over this period grew relatively slower. Forecasted updates from CY 2023 through CY 2026 are the same on average; however, there is year to year variation of ±0.1 percentage point for any given year.

(b) Proposed CY 2024 Productivity Adjustment

In the CY 2015 HH PPS final rule (79 FR 38384), we finalized our methodology for calculating and applying the multifactor productivity adjustment. As we explained in that rule, section 1895(b)(3)(B)(vi) of the Act, requires that, in CY 2015 (and in subsequent calendar years, except CY 2018 (under section 411(c) of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (Pub. L. 114-10, enacted April 16,

2015)), the market basket percentage under the HH PPS as described in section 1895(b)(3)(B) of the Act be annually adjusted by changes in economy-wide productivity. Section 1886(b)(3)(B)(xi)(II) of the Act defines the productivity adjustment to be equal to the 10-year moving average of change in annual economy-wide private nonfarm business multifactor productivity (as projected by the Secretary for the 10-year period ending with the applicable fiscal year, calendar year, cost reporting period, or other annual period). The BLS publishes the official measures of productivity for the United States economy. We note that previously the productivity measure referenced in section 1886(b)(3)(B)(xi)(II) of the Act was published by BLS as private nonfarm business multifactor productivity. Beginning with the November 18, 2021 release of productivity data, BLS replaced the term “multifactor productivity” with “total factor productivity” (TFP). BLS noted that this is a change in terminology only and will not affect the data or methodology. As a result of the BLS name change, the productivity measure referenced in section 1886(b)(3)(B)(xi)(II) of the Act is now published by BLS as “private nonfarm business total factor productivity”. We refer readers to <https://www.bls.gov> for the BLS historical published TFP data. A complete description of IGI’s TFP projection methodology is available on the CMS website at <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareProgramRatesStats/MarketBasketResearch>. Based on IGI’s first quarter 2023 forecast, the proposed productivity adjustment (the 10-year

moving average of TFP for the period ending December 31, 2024) for CY 2024 is 0.3 percent. We also propose that if more recent data subsequently become available (for example, a more recent estimate of the productivity adjustment), we would use such data, if appropriate, to determine the productivity adjustment in the CY 2024 HH PPS final rule.

(c) Proposed CY 2024 Annual Update for HHAs

In accordance with section 1895(b)(3)(B)(iii) of the Act, we propose to base the CY 2024 market basket percentage increase, which is used to determine the applicable percentage increase for HHA payments, on the most recent estimate of the proposed 2021-based home health market basket percentage increase. Based on IGI’s first quarter 2023 forecast with history through the fourth quarter of 2022, the projected increase of the proposed 2021-based home health market basket for CY 2024 is 3.0 percent. We propose to then reduce this percentage increase by the current estimate of the productivity adjustment for CY 2024 of 0.3 percentage point in accordance with section 1895(b)(3)(B)(vi) of the Act. Therefore, the proposed CY 2024 home health payment update percentage is 2.7 percent (3.0 percent market basket percentage increase, reduced by 0.3 percentage point productivity adjustment). Furthermore, we propose that if more recent data subsequently become available (for example, a more recent estimate of the market basket and productivity adjustment), we would use such data, if appropriate, to determine the CY 2024 market basket percentage increase and productivity adjustment in the final rule.

Section 1895(b)(3)(B)(v) of the Act requires that the home health percentage update be decreased by 2 percentage points for those HHAs that do not submit quality data as required by the Secretary. For HHAs that do not submit the required quality data for CY 2024, the proposed home health payment update percentage is 0.7 percent (2.7 percent minus 2 percentage points).

We invite public comment on our proposals for the CY 2024 home health market basket percentage increase and productivity adjustment.

(d) Labor-Related Share

Effective for CY 2024, we are proposing to update the labor-related share to reflect the proposed 2021-based home health market basket Compensation (Wages and Salaries plus Benefits, which include direct patient care contract labor costs) cost weight. The current labor-related share is based on the Compensation cost weight of the 2016-based home health market basket. Based on the proposed 2021-based home health market basket, the proposed labor-related share is 74.9 percent and the proposed non-labor-related share is 25.1 percent. The labor-related share for the 2016-based home health market basket was 76.1 percent and the non-labor-related share was 23.9 percent. As explained earlier, the decrease in the compensation cost weight of 1.2 percentage points is primarily attributable to a lower cost weight of direct patient care contract labor costs as reported in the Medicare cost report data. Table B33 details the components of the labor-related share for the 2016-based and proposed 2021-based home health market baskets.

**TABLE B33: LABOR-RELATED SHARE OF CURRENT AND PROPOSED HOME HEALTH MARKET BASKETS**

| Cost Category           | 2016-Based Market Basket Weight | Proposed 2021-Based Market Basket Weight |
|-------------------------|---------------------------------|--|
| Wages and Salaries      | 65.1                            | 64.2                                     |
| Employee Benefits       | 10.9                            | 10.7                                     |
| Total Labor-Related     | 76.1                            | 74.9                                     |
| Total Non-Labor-Related | 23.9                            | 25.1                                     |

The revised labor-related share will be implemented in a budget neutral manner through the use of labor-related share budget neutrality factor (as described in section II.C.4.f.(2) below) so that the aggregate payments do not increase or decrease due to changes in

the labor-related share values. We invite public comments on the proposed labor-related share and the use of a labor-related share budget neutrality factor.

(e) Proposed CY 2024 Home Health Wage Index

Sections 1895(b)(4)(A)(ii) and (b)(4)(C) of the Act require the Secretary to provide appropriate adjustments to the proportion of the payment amount under the HH PPS that account for area

wage differences, using adjustment factors that reflect the relative level of wages and wage-related costs applicable to the furnishing of home health services. Since the inception of the HH PPS, we have used inpatient hospital wage data in developing a wage index to be applied to home health payments. We propose to continue this practice for CY 2024, as it is our belief that, in the absence of home health-specific wage data that accounts for area differences, using inpatient hospital wage data is appropriate and reasonable for the HH PPS.

In the CY 2021 HH PPS final rule (85 FR 70298), we finalized our proposal to adopt the revised OMB delineations with a 5-percent cap on wage index decreases, where the estimated reduction in a geographic area's wage index would be capped at 5-percent in CY 2021 only, meaning no cap would be applied to wage index decreases for the second year (CY 2022). Therefore, we proposed and finalized the use of the FY 2022 pre-floor, pre-reclassified hospital wage index with no 5-percent cap on decreases as the CY 2022 wage adjustment to the labor portion of the HH PPS rates (86 FR 62285). However, as described in the CY 2023 HH PPS final rule (87 FR 66851 through 66853), for CY 2023 and each subsequent year, we finalized that the CY HH PPS wage index would include a 5-percent cap on wage index decreases. Specifically, we finalized for CY 2023 and subsequent years, the application of a permanent 5-percent cap on any decrease to a geographic area's wage index from its wage index in the prior year, regardless of the circumstances causing the decline. That is, we finalized that a geographic area's wage index for CY 2023 would not be less than 95 percent of its final wage index for CY 2022, regardless of whether the geographic area is part of an updated CBSA, and that for subsequent years, a geographic area's wage index would not be less than 95 percent of its wage index calculated in the prior CY. For CY 2024, we propose to base the HH PPS wage index on the FY 2024 hospital pre-floor, pre-reclassified wage index for hospital cost reporting periods beginning on or after October 1, 2019 and before October 1, 2020 (FY 2020 cost report data). The proposed CY 2024 HH PPS wage index would not take into account any geographic reclassification of hospitals, including those in accordance with section 1886(d)(8)(B) or 1886(d)(10) of the Act but would include the 5-percent cap on wage index decreases. We will apply the appropriate wage index value to the revised labor portion of the HH

PPS rates based on the site of service for the beneficiary (defined by section 1861(m) of the Act as the beneficiary's place of residence).

To address those geographic areas in which there are no inpatient hospitals, and thus, no hospital wage data on which to base the calculation of the CY 2024 HH PPS wage index, we propose to continue to use the same methodology discussed in the CY 2007 HH PPS final rule (71 FR 65884) to address those geographic areas in which there are no inpatient hospitals. For rural areas that do not have inpatient hospitals, we propose to use the average wage index from all contiguous Core Based Statistical Areas (CBSAs) as a reasonable proxy. Currently, the only rural area without a hospital from which hospital wage data could be derived is Puerto Rico. However, for rural Puerto Rico, we do not apply this methodology due to the distinct economic circumstances that exist there (for example, due to the close proximity to one another of almost all of Puerto Rico's various urban and non-urban areas, this methodology would produce a wage index for rural Puerto Rico that is higher than that in half of its urban areas). Instead, we propose to continue to use the most recent wage index previously available for that area. The most recent wage index previously available for rural Puerto Rico is 0.4047, which is what we propose to use. For urban areas without inpatient hospitals, we use the average wage index of all urban areas within the State as a reasonable proxy for the wage index for that CBSA. For CY 2024, the only urban area without inpatient hospital wage data is Hinesville, GA (CBSA 25980). Using the average wage index of all urban areas in Georgia as proxy, we propose the CY 2024 wage index value for Hinesville, GA to be 0.8601.

On February 28, 2013, OMB issued Bulletin No. 13-01, announcing revisions to the delineations of MSAs, Micropolitan Statistical Areas, and CBSAs, and guidance on uses of the delineation of these areas. In the CY 2015 HH PPS final rule (79 FR 66085 through 66087), we adopted OMB's area delineations using a 1-year transition.

On August 15, 2017, OMB issued Bulletin No. 17-01 in which it announced that one Micropolitan Statistical Area, Twin Falls, Idaho, now qualifies as a Metropolitan Statistical Area. The new CBSA (46300) comprises the principal city of Twin Falls, Idaho in Jerome County, Idaho and Twin Falls County, Idaho. The CY 2022 HH PPS wage index value for CBSA 46300, Twin Falls, Idaho, will be 0.8707. Bulletin No. 17-01 is available at [https://](https://www.whitehouse.gov/wp-content/uploads/legacy_drupal_files/omb/bulletins/2017/b-17-01.pdf)

[www.whitehouse.gov/wp-content/uploads/legacy\\_drupal\\_files/omb/bulletins/2017/b-17-01.pdf](https://www.whitehouse.gov/wp-content/uploads/legacy_drupal_files/omb/bulletins/2017/b-17-01.pdf).

On April 10, 2018 OMB issued OMB Bulletin No. 18-03, which superseded the August 15, 2017 OMB Bulletin No. 17-01. On September 14, 2018, OMB issued OMB Bulletin No. 18-04 which superseded the April 10, 2018 OMB Bulletin No. 18-03. These bulletins established revised delineations for Metropolitan Statistical Areas, Micropolitan Statistical Areas, and Combined Statistical Areas, and provided guidance on the use of the delineations of these statistical areas. A copy of OMB Bulletin No. 18-04 may be obtained at: <https://www.bls.gov/bls/omb-bulletin-18-04-revised-delineations-of-metropolitan-statistical-areas.pdf>.

On March 6, 2020, OMB issued Bulletin No. 20-01, which provided updates to and superseded OMB Bulletin No. 18-04 that was issued on September 14, 2018. The attachments to OMB Bulletin No. 20-01 provided detailed information on the update to statistical areas since September 14, 2018, and were based on the application of the 2010 Standards for Delineating Metropolitan and Micropolitan Statistical Areas to Census Bureau population estimates for July 1, 2017 and July 1, 2018. (For a copy of this bulletin, we refer readers to <https://www.whitehouse.gov/wp-content/uploads/2020/03/Bulletin-20-01.pdf>). In OMB Bulletin No. 20-01, OMB announced one new Micropolitan Statistical Area, one new component of an existing Combined Statistical Area and changes to New England City and Town Area (NECTA) delineations. In the CY 2021 HH PPS final rule (85 FR 70298), we stated that if appropriate, we would propose any updates from OMB Bulletin No. 20-01 in future rulemaking. After reviewing OMB Bulletin No. 20-01, we have determined that the changes in Bulletin 20-01 encompassed delineation changes that would not affect the Medicare home health wage index for CY 2022. Specifically, the updates consisted of changes to NECTA delineations and the re-designation of a single rural county into a newly created Micropolitan Statistical Area. The Medicare home health wage index does not utilize NECTA definitions, and, as most recently discussed in the CY 2021 HH PPS final rule (85 FR 70298) we include hospitals located in Micropolitan Statistical areas in each State's rural wage index. In other words, these OMB updates did not affect any geographic areas for purposes of the HH PPS wage index calculation.

The proposed CY 2024 wage index is available on the CMS website at: <https://www.cms.gov/Center/Provider-Type/Home-Health-Agency-HHA-Center>.

(f) Proposed CY 2024 Home Health Payment Update

(1) Background

The HH PPS has been in effect since October 1, 2000. As set forth in the July 3, 2000 final rule (65 FR 41128), the base unit of payment under the HH PPS was a national, standardized 60-day episode payment rate. As finalized in the CY 2019 HH PPS final rule with comment period (83 FR 56406), and as described in the CY 2020 HH PPS final rule with comment period (84 FR 60478), the unit of home health payment changed from a 60-day episode to a 30-day period effective for those 30-day periods beginning on or after January 1, 2020.

As set forth in § 484.220, we adjust the national, standardized prospective payment rates by a case-mix relative weight and a wage index value based on the site of service for the beneficiary. To provide appropriate adjustments to the proportion of the payment amount under the HH PPS to account for area wage differences, we apply the appropriate wage index value to the labor portion of the HH PPS rates. In the CY 2019 HH PPS final rule with comment period (83 FR 56435), we finalized rebasing the home health market basket to reflect 2016 Medicare cost report data. We also finalized a revision to the labor-related share to reflect the 2016-based home health market basket Compensation (Wages and Salaries plus Benefits) cost weight. We finalized that for CY 2019 and subsequent years, the labor-related share would be 76.1 percent and the non-labor related share would be 23.9 percent. As discussed earlier in section II.C.3, for CY 2024 we are proposing to rebase the home health market basket using 2021 Medicare cost report data. We are also proposing that the labor-related share based on the proposed 2021-based home health market basket would be 74.9 percent and the non-labor-related share would be 25.1 percent. The following are the steps we take to compute the case-mix and wage-adjusted 30-day period payment amount for CY 2024:

- Multiply the national, standardized 30-day period rate by the patient's applicable case-mix weight.
- Divide the case-mix adjusted amount into a labor (74.9 percent) and a non-labor portion (25.1 percent).
- Multiply the labor portion by the applicable wage index based on the site of service of the beneficiary.

- Add the wage-adjusted portion to the non-labor portion, yielding the case-mix and wage adjusted 30-day period payment amount, subject to any additional applicable adjustments.

We provide annual updates of the HH PPS rate in accordance with section 1895(b)(3)(B) of the Act. Section 484.225 sets forth the specific annual percentage update methodology. In accordance with section 1895(b)(3)(B)(v) of the Act and § 484.225(i), for an HHA that does not submit home health quality data, as specified by the Secretary, the unadjusted national prospective 30-day period rate is equal to the rate for the previous calendar year increased by the applicable home health payment update percentage, minus 2 percentage points. Any reduction of the percentage change would apply only to the calendar year involved and would not be considered in computing the prospective payment amount for a subsequent calendar year.

The final claim that the HHA submits for payment determines the total payment amount for the period and whether we make an applicable adjustment to the 30-day case-mix and wage-adjusted payment amount. The end date of the 30-day period, as reported on the claim, determines which calendar year rates Medicare will use to pay the claim.

We may adjust a 30-day case-mix and wage-adjusted payment based on the information submitted on the claim to reflect the following:

- A LUPA is provided on a per-visit basis as set forth in §§ 484.205(d)(1) and 484.230.
- A partial payment adjustment as set forth in §§ 484.205(d)(2) and 484.235.
- An outlier payment as set forth in §§ 484.205(d)(3) and 484.240.

(2) CY 2024 National, Standardized 30-Day Period Payment Amount

Section 1895(b)(3)(A)(i) of the Act requires that the standard prospective payment rate and other applicable amounts be standardized in a manner that eliminates the effects of variations in relative case-mix and area wage adjustments among different home health agencies in a budget-neutral manner. To determine the CY 2024 national, standardized 30-day period payment rate, we will continue our practice of using the most recent, complete utilization data at the time of rulemaking; that is, we are using CY 2022 claims data for CY 2024 payment rate updates. We apply a permanent behavioral adjustment factor, a case-mix weights recalibration budget neutrality factor, a wage index budget neutrality factor, a labor-related share budget neutrality factor and the home health

payment update percentage to update the CY 2024 payment rate. As discussed in section II.C.1 of this proposed rule, we are proposing to implement a permanent behavior adjustment of -5.653 percent to ensure that payments under the PDGM do not exceed what payments would have been under the 153-group payment system as required by law. The proposed permanent behavior adjustment factor is 0.94347. As discussed previously, to ensure the changes to the PDGM case-mix weights are implemented in a budget neutral manner, we apply a case-mix weight budget neutrality factor to the CY 2024 national, standardized 30-day period payment rate. The proposed case-mix weight budget neutrality factor for CY 2024 is 1.0121.

Additionally, we apply a wage index budget neutrality factor to ensure that wage index updates and revisions are implemented in a budget neutral manner. To calculate the wage index budget neutrality factor, we first determine the payment rate needed for non-LUPA 30-day periods using the CY 2024 wage index so those total payments are equivalent to the total payments for non-LUPA 30-day periods using the CY 2023 wage index and the CY 2023 national standardized 30-day period payment rate adjusted by the case-mix weights recalibration neutrality factor. Then, by dividing the payment rate for non-LUPA 30-day periods using the CY 2024 wage index with a 5-percent cap on wage index decreases by the payment rate for non-LUPA 30-day periods using the CY 2023 wage index with a 5-percent cap on wage index decreases, we obtain a wage index budget neutrality factor of 1.0015. We then apply the wage index budget neutrality factor of 1.0015 to the 30-day period payment rate. After we apply the wage index budget neutrality factor, we will also apply a labor-related share budget neutrality factor so that aggregate payments do not increase or decrease due to changes in the labor-related share values. In order to calculate the labor-related share budget neutrality factor, we simulate total payments using CY 2022 home health utilization claims data with the CY 2024 HH PPS wage index and the proposed labor-related share (labor-related share of 74.9 percent and non-labor-related share of 25.1 percent) and compare it to our simulation of total payments using the CY 2024 HH PPS wage index with the current labor-related share (labor-related share of 76.1 percent and non-labor-related share of 23.9 percent). By dividing the base payment amount using the proposed labor-related share



and CY 2024 wage index and payment rate by the base payment amount using the current labor-related share and CY 2024 wage index and payment rate, we

obtain a labor-related share budget neutrality factor of 0.9998.

Next, we propose to update the 30-day period payment rate by the proposed CY 2024 home health

payment update percentage of 2.7 percent. The CY 2024 national, standardized 30-day period payment rate is calculated in Table B34.

**TABLE B34: CY 2024 NATIONAL, STANDARDIZED 30-DAY PERIOD PAYMENT AMOUNT**

| CY 2023 National Standardized 30-Day Period Payment | Permanent BA Adjustment Factor | Case-Mix Weights Recalibration Budget Neutrality Factor | Wage Index Budget Neutrality Factor | Labor-Related Share Budget Neutrality Factor | CY 2024 HH Payment Update Factor | CY 2024 National, Standardized 30-Day Period Payment |
|---|--------------------------------|---|-------------------------------------|--|----------------------------------|--|
| \$2,010.69  | 0.94347                        | 1.0121  | 1.0015                              | 0.9998                                       | 1.027                            | \$1,974.38   |

The CY 2024 national, standardized 30-day period payment rate for an HHA that does not submit the required

quality data is updated by the proposed CY 2024 home health payment update percentage of 0.7 percent (2.7 percent

minus 2 percentage points) and is shown in Table B35.

**TABLE B35: CY 2024 NATIONAL, STANDARDIZED 30-DAY PERIOD PAYMENT AMOUNT FOR HHAs THAT DO NOT SUBMIT THE QUALITY DATA**

| CY 2023 National Standardized 30-Day Period Payment | Permanent BA Adjustment Factor | Case-Mix Weights Recalibration Budget Neutrality Factor | Wage Index Budget Neutrality Factor | Labor-Related Share Budget Neutrality Factor | CY 2024 HH Payment Update Factor Minus 2 Percentage Points | CY 2024 National, Standardized 30-Day Period Payment |
|---|--------------------------------|---|-------------------------------------|--|--|--|
| \$2,010.69  | 0.94347                        | 1.0121  | 1.0015                              | 0.9998                                       | 1.007  | \$1,935.93   |

(3) CY 2024 National Per-Visit Rates for 30-Day Periods of Care

The national per-visit rates are used to pay LUPAs and are also used to compute imputed costs in outlier calculations. The per-visit rates are paid by type of visit or home health discipline. The six home health disciplines are as follows:

- Home health aide (HH aide).
- Medical Social Services (MSS).
- Occupational therapy (OT).
- Physical therapy (PT).
- Skilled nursing (SN).
- Speech-language pathology (SLP).

To calculate the proposed CY 2024 national per-visit rates, we started with the CY 2023 national per-visit rates. Then we applied a wage index budget neutrality factor to ensure budget neutrality for LUPA per-visit payments. We calculated the wage index budget neutrality factor by simulating total

payments for LUPA 30-day periods of care using the CY 2024 wage index with a 5-percent cap on wage index decreases and comparing it to simulated total payments for LUPA 30-day periods of care using the CY 2023 wage index with 5-percent cap. By dividing the total payments for LUPA 30-day periods of care using the CY 2024 wage index by the total payments for LUPA 30-day periods of care using the CY 2023 wage index, we obtained a wage index budget neutrality factor of 1.0015. We apply the wage index budget neutrality factor in order to calculate the CY 2024 national per-visit rates. In order to calculate the labor-related share budget neutrality factor for the national per visit amounts, we simulate total payments for LUPA 30-day periods using CY 2022 home health utilization claims data with the CY 2024 HH PPS wage index and the proposed labor-related share (labor-

related share of 74.9 percent and non-labor-related share of 25.1 percent) and compare it to our simulation of total payments for LUPA 30-day periods using the CY 2024 HH PPS wage index with the current labor-related share (labor-related share of 76.1 percent and non-labor-related share of 23.9 percent). By dividing the payment amounts for LUPA 30-day periods using the proposed labor-related share and CY 2024 wage index and payment rate by the payment amounts for LUPA 30-day periods using the current labor-related share and CY 2024 wage index and payment rate, we obtain a labor-related share budget neutrality factor of 0.9999.

The LUPA per-visit rates are not calculated using case-mix weights. Therefore, no case-mix weight budget neutrality factor is needed to ensure budget neutrality for LUPA payments. Additionally, we are not applying the

permanent adjustment to the per visit payment rates but only to the case-mix adjusted 30-day payment rate. Lastly, the per-visit rates for each discipline are updated by the proposed CY 2024 home health payment update percentage of 2.7 percent. The national per-visit rates are

adjusted by the wage index based on the site of service of the beneficiary. The per-visit payments for LUPAs are separate from the LUPA add-on payment amount, which is paid for episodes that occur as the only episode or initial episode in a sequence of

adjacent episodes. The CY 2024 national per-visit rates for HHAs that submit the required quality data are updated by the proposed CY 2024 home health payment update percentage of 2.7 percent and are shown in Table B36.

**TABLE B36: CY 2024 NATIONAL PER-VISIT PAYMENT AMOUNTS**

| HH Discipline             | CY 2023 Per-Visit Payment Amount | Wage Index Budget Neutrality Factor | Labor-Related Share Budget Neutrality Factor | CY 2024 HH Payment Update Factor | CY 2024 Per-Visit Payment Amount |
|---------------------------|----------------------------------|-------------------------------------|--|----------------------------------|----------------------------------|
| Home Health Aide          | \$73.93                          | 1.0015                              | 0.9999                                       | 1.0270                           | \$76.03                          |
| Medical Social Services   | \$261.72                         | 1.0015                              | 0.9999                                       | 1.0270                           | \$269.16                         |
| Occupational Therapy      | \$179.70                         | 1.0015                              | 0.9999                                       | 1.0270                           | \$184.81                         |
| Physical Therapy          | \$178.47                         | 1.0015                              | 0.9999                                       | 1.0270                           | \$183.55                         |
| Skilled Nursing           | \$163.29                         | 1.0015                              | 0.9999                                       | 1.0270                           | \$167.93                         |
| Speech-Language Pathology | \$194.00                         | 1.0015                              | 0.9999                                       | 1.0270                           | \$199.52                         |

The CY 2024 per-visit payment rates for HHAs that do not submit the required quality data are updated by the

proposed CY 2024 home health payment update percentage of 2.7

percent minus 2 percentage points and are shown in Table B37.

**TABLE B37: CY 2024 NATIONAL PER-VISIT PAYMENT AMOUNTS FOR HHAs THAT DO NOT SUBMIT THE REQUIRED QUALITY DATA**

| HH Discipline             | CY 2023 Per-Visit Payment Amount | Wage Index Budget Neutrality Factor | Labor-Related Share Budget Neutrality Factor | CY 2024 HH Payment Update Factor Minus 2 Percentage Points | CY 2024 Per-Visit Payment Amount |
|---------------------------|----------------------------------|-------------------------------------|--|--|----------------------------------|
| Home Health Aide          | \$73.93                          | 1.0015                              | 0.9999                                       | 1.0070   | \$74.55                          |
| Medical Social Services   | \$261.72                         | 1.0015                              | 0.9999                                       | 1.0070   | \$263.92                         |
| Occupational Therapy      | \$179.70                         | 1.0015                              | 0.9999                                       | 1.0070   | \$181.21                         |
| Physical Therapy          | \$178.47                         | 1.0015                              | 0.9999                                       | 1.0070   | \$179.97                         |
| Skilled Nursing           | \$163.29                         | 1.0015                              | 0.9999                                       | 1.0070   | \$164.66                         |
| Speech-Language Pathology | \$194.00                         | 1.0015                              | 0.9999                                       | 1.0070   | \$195.63                         |

#### (4) LUPA Add-On Factors

Prior to the implementation of the 30-day unit of payment, LUPA episodes were eligible for a LUPA add-on payment if the episode of care was the first or only episode in a sequence of adjacent episodes. As stated in the CY 2008 HH PPS final rule, the average visit lengths in these initial LUPAs are 16 to 18 percent higher than the average visit lengths in initial non-LUPA episodes

(72 FR 49848). LUPA episodes that occur as the only episode or as an initial episode in a sequence of adjacent episodes are adjusted by applying an additional amount to the LUPA payment before adjusting for area wage differences. In the CY 2014 HH PPS final rule (78 FR 72305), we changed the methodology for calculating the LUPA add-on amount by finalizing the use of three LUPA add-on factors: 1.8451 for SN; 1.6700 for PT; and 1.6266 for SLP.

We multiply the per-visit payment amount for the first SN, PT, or SLP visit in LUPA episodes that occur as the only episode or an initial episode in a sequence of adjacent episodes by the appropriate factor to determine the LUPA add-on payment amount.

In the CY 2019 HH PPS final rule with comment period (83 FR 56440), in addition to finalizing a 30-day unit of payment, we finalized our policy of continuing to multiply the per-visit

payment amount for the first skilled nursing, physical therapy, or speech-language pathology visit in LUPA periods that occur as the only period of care or the initial 30-day period of care in a sequence of adjacent 30-day periods of care by the appropriate add-on factor (1.8451 for SN, 1.6700 for PT, and 1.6266 for SLP) to determine the LUPA add-on payment amount for 30-day periods of care under the PDGM. For example, using the proposed CY 2024 per-visit payment rates for HHAs that submit the required quality data, for LUPA periods that occur as the only period or an initial period in a sequence of adjacent periods, if the first skilled visit is SN, the payment for that visit would be \$309.85 (1.8451 multiplied by \$167.93), subject to area wage adjustment.

#### (5) Occupational Therapy LUPA Add-On Factor

In order to implement Division CC, section 115, of CAA, 2021, CMS finalized changes to regulations at § 484.55(a)(2) and (b)(3) that allowed occupational therapists to conduct initial and comprehensive assessments for all Medicare beneficiaries under the home health benefit when the plan of care does not initially include skilled nursing care, but either PT or SLP (86 FR 62351). This change, led to us establishing a LUPA add-on factor for calculating the LUPA add-on payment amount for the first skilled occupational therapy (OT) visit in LUPA periods that occurs as the only period of care or the initial 30-day period of care in a sequence of adjacent 30-day periods of care.

As stated in the CY 2022 HH PPS final rule with comment period (86 FR 62289) since there was not sufficient data regarding the average excess of minutes for the first visit in LUPA periods when the initial and comprehensive assessments are conducted by occupational therapists we finalized the use of the PT LUPA add-on factor of 1.6700 as a proxy. We also stated that we would use the PT LUPA add-on factor as a proxy until we have CY 2022 data to establish a more accurate OT add-on factor for the LUPA add-on payment amounts (86 FR 62289). At this time, we are analyzing the CY 2022 data and will continue to use the PT LUPA add-on factor for OT LUPAs and plan to propose a LUPA add-on factor specific to OT in future rulemaking.

#### (6) Payments for High-Cost Outliers Under the HH PPS

##### (a) Background

Section 1895(b)(5) of the Act allows for the provision of an addition or adjustment to the home health payment amount otherwise made in the case of outliers because of unusual variations in the type or amount of medically necessary care. Under the HH PPS and the previous unit of payment (that is, 60-day episodes), outlier payments were made for 60-day episodes whose estimated costs exceed a threshold amount for each HHRG. The episode's estimated cost was established as the sum of the national wage-adjusted per visit payment amounts delivered during the episode. The outlier threshold for each case-mix group or PEP adjustment defined as the 60-day episode payment or PEP adjustment for that group plus a fixed-dollar loss (FDL) amount. For the purposes of the HH PPS, the FDL amount is calculated by multiplying the home health FDL ratio by a case's wage-adjusted national, standardized 60-day episode payment rate, which yields an FDL dollar amount for the case. The outlier threshold amount is the sum of the wage and case-mix adjusted PPS episode amount and wage-adjusted FDL amount. The outlier payment is defined to be a proportion of the wage-adjusted estimated cost that surpasses the wage-adjusted threshold. The proportion of additional costs over the outlier threshold amount paid as outlier payments is referred to as the loss-sharing ratio.

As we noted in the CY 2011 HH PPS final rule (75 FR 70397 through 70399), section 3131(b)(1) of the Affordable Care Act amended section 1895(b)(3)(C) of the Act to require that the Secretary reduce the HH PPS payment rates such that aggregate HH PPS payments were reduced by 5 percent. In addition, section 3131(b)(2) of the Affordable Care Act amended section 1895(b)(5) of the Act by redesignating the existing language as section 1895(b)(5)(A) of the Act and revised the language to state that the total amount of the additional payments or payment adjustments for outlier episodes could not exceed 2.5 percent of the estimated total HH PPS payments for that year. Section 3131(b)(2)(C) of the Affordable Care Act also added section 1895(b)(5)(B) of the Act, which capped outlier payments as a percent of total payments for each HHA for each year at 10 percent.

As such, beginning in CY 2011, we reduced payment rates by 5 percent and targeted up to 2.5 percent of total estimated HH PPS payments to be paid as outliers. To do so, we first returned

the 2.5 percent held for the target CY 2010 outlier pool to the national, standardized 60-day episode rates, the national per visit rates, the LUPA add-on payment amount, and the NRS conversion factor for CY 2010. We then reduced the rates by 5 percent as required by section 1895(b)(3)(C) of the Act, as amended by section 3131(b)(1) of the Affordable Care Act. For CY 2011 and subsequent calendar years we targeted up to 2.5 percent of estimated total payments to be paid as outlier payments, and apply a 10-percent agency-level outlier cap.

In the CY 2017 HH PPS proposed and final rules (81 FR 43737 through 43742 and 81 FR 76702), we described our concerns regarding patterns observed in home health outlier episodes. Specifically, we noted the methodology for calculating home health outlier payments may have created a financial incentive for providers to increase the number of visits during an episode of care in order to surpass the outlier threshold; and simultaneously created a disincentive for providers to treat medically complex beneficiaries who require fewer but longer visits. Given these concerns, in the CY 2017 HH PPS final rule (81 FR 76702), we finalized changes to the methodology used to calculate outlier payments, using a cost-per-unit approach rather than a cost-per-visit approach. This change in methodology allows for more accurate payment for outlier episodes, accounting for both the number of visits during an episode of care and the length of the visits provided. Using this approach, we now convert the national per-visit rates into per 15-minute unit rates. These per 15-minute unit rates are used to calculate the estimated cost of an episode to determine whether the claim will receive an outlier payment and the amount of payment for an episode of care. In conjunction with our finalized policy to change to a cost-per-unit approach to estimate episode costs and determine whether an outlier episode should receive outlier payments, in the CY 2017 HH PPS final rule we also finalized the implementation of a cap on the amount of time per day that would be counted toward the estimation of an episode's costs for outlier calculation purposes (81 FR 76725). Specifically, we limit the amount of time per day (summed across the six disciplines of care) to 8 hours (32 units) per day when estimating the cost of an episode for outlier calculation purposes.

In the CY 2017 HH PPS final rule (81 FR 76724), we stated that we did not plan to re-estimate the average minutes per visit by discipline every year.

Additionally, the per unit rates used to estimate an episode's cost were updated by the home health update percentage each year, meaning we would start with the national per visit amounts for the same calendar year when calculating the cost-per-unit used to determine the cost of an episode of care (81 FR 76727). We will continue to monitor the visit length by discipline as more recent data becomes available, and may propose to update the rates as needed in the future.

In the CY 2019 HH PPS final rule with comment period (83 FR 56521), we finalized a policy to maintain the current methodology for payment of high-cost outliers upon implementation of PDGM beginning in CY 2020 and calculated payment for high-cost outliers based upon 30-day period of care. Upon implementation of the PDGM and 30-day unit of payment, we finalized the FDL ratio of 0.56 for 30-day periods of care in CY 2020. Given that CY 2020 was the first year of the PDGM and the change to a 30-day unit of payment, we finalized maintaining the same FDL ratio of 0.56 in CY 2021 as we did not have sufficient CY 2020 data at the time of CY 2021 rulemaking to propose a change to the FDL ratio for CY 2021. In the CY 2022 HH PPS final rule with comment period (86 FR 62292), we estimated that outlier payments would be approximately 1.8 percent of total HH PPS final rule payments if we maintained an FDL of 0.56 in CY 2022. Therefore, in order to pay up to, but no more than, 2.5 percent of total payments as outlier payments we finalized an FDL of 0.40 for CY 2022. In the CY 2023 HH PPS final rule (87 FR 66875), using CY 2021 claims utilization data, we finalized an FDL of 0.35 in order to pay up to, but no more than, 2.5 percent of the total payment as outlier payments in CY 2023.

#### (b) Proposed FDL Ratio for CY 2024

For a given level of outlier payments, there is a trade-off between the values selected for the FDL ratio and the loss-sharing ratio. A high FDL ratio reduces the number of periods that can receive outlier payments, but makes it possible to select a higher loss-sharing ratio, and therefore, increase outlier payments for qualifying outlier periods. Alternatively, a lower FDL ratio means that more periods can qualify for outlier payments, but outlier payments per period must be lower.

The FDL ratio and the loss-sharing ratio are selected so that the estimated total outlier payments do not exceed the 2.5 percent aggregate level (as required by section 1895(b)(5)(A) of the Act). Historically, we have used a value of 0.80 for the loss-sharing ratio, which,

we believe, preserves incentives for agencies to attempt to provide care efficiently for outlier cases. With a loss-sharing ratio of 0.80, Medicare pays 80 percent of the additional estimated costs that exceed the outlier threshold amount. Using CY 2022 claims data (as of March 17, 2023) and given the statutory requirement that total outlier payments do not exceed 2.5 percent of the total payments estimated to be made under the HH PPS, we are proposing an FDL ratio of 0.31 for CY 2024. CMS will update the FDL, if needed, once we have more complete CY 2022 claims data.

### 5. Proposal for Disposable Negative Pressure Wound Therapy

#### (1) Background

Negative pressure wound therapy (NPWT) is a medical procedure in which a vacuum dressing is used to enhance and promote healing in acute, chronic, and burn wounds. The therapy involves using a sealed wound dressing attached to a pump to create a negative pressure environment in the wound. Applying continued or intermittent vacuum pressure helps to increase blood flow to the area and draw out excess fluid from the wound. Moreover, the therapy promotes wound healing by preparing the wound bed for closure, reducing edema, promoting granulation tissue formation and perfusion, and removing exudate and infectious material. The wound type and the location of the wound determine whether the vacuum can either be applied continuously or intermittently. NPWT can be utilized for varying lengths of time, as indicated by the severity of the wound, from a few days of use up to a span of several months.

The therapy can be administered using the conventional NPWT system, classified as durable medical equipment (DME), or can be administered using a disposable device. A disposable NPWT (dNPWT) device is a single-use integrated system that consists of a non-manual vacuum pump, a receptacle for collecting exudate, and wound dressings. Unlike conventional NPWT systems classified as DME, dNPWT devices have preset continuous negative pressure, no intermittent setting, are pocket-sized and easily transportable, and are generally battery-operated with disposable batteries.

In order for a beneficiary to receive dNPWT under the home health benefit, the beneficiary must qualify for the home health benefit in accordance with existing eligibility requirements. To be eligible for Medicare home health services, as set out in sections 1814(a)

and 1835(a) of the Act, a physician must certify that the Medicare beneficiary (patient) meets the following criteria:

- Is confined to the home.
- Needs skilled nursing care on an intermittent basis or physical therapy or speech-language pathology; or have a continuing need for occupational therapy.
- Is under the care of a physician.
- Receive services under a plan of care established and reviewed by a physician.
- Has had a face-to-face encounter related to the primary reason for home health care with a physician or allowed Non-Physician Practitioner (NPP) within a required timeframe.

Coverage for dNPWT is determined based upon a doctor's order as well as patient preference. Treatment decisions as to whether to use a dNPWT system versus a conventional NPWT DME system are determined by the characteristics of the wound, as well as patient goals and preferences discussed with the ordering physician to best achieve wound healing.

#### (2) Current Payment for Negative Pressure Wound Therapy Using a Disposable Device

Prior to CY 2017, a dNPWT system was considered a non-routine supply and thus payment for the disposable device was included in the episode payment amount under the previous home health payment system. However, section 504 of the CAA, 2016 (Pub. L. 114–113) amended both section 1834 of the Act (42 U.S.C. 1395m) and section 1861(m)(5) of the Act (42 U.S.C. 1395x(m)(5)), and required a separate payment for an applicable disposable device when furnished on or after January 1, 2017, to an individual who receives home health services for which payment is made under the Medicare home health benefit. Therefore, in the CY 2017 HH PPS final rule (81 FR 76736), we finalized the implementation of several changes in payment for furnishing dNPWT for a patient under a home health plan of care beginning in CY 2017, and each subsequent year. These payment changes included the implementation of a separate payment amount for dNPWT that was set equal to the amount of the payment that would be made under the Medicare Hospital Outpatient Prospective Payment System (OPPS) using the CPT codes 97607 and 97608. This separate payment amount included furnishing the service as well as the dNPWT device. As a reminder, codes 97607 and 97608 are defined as follows:

- HCPCS 97607—Negative pressure wound therapy, (for example, vacuum

assisted drainage collection), utilizing disposable, non-durable medical equipment including provision of exudate management collection system, topical application(s), wound assessment, and instructions for ongoing care, per session; total wound(s) surface area less than or equal to 50 square centimeters.

- HCPCS 97608—Negative pressure wound therapy, (for example, vacuum assisted drainage collection), utilizing disposable, non-durable medical equipment including provision of exudate management collection system, topical application(s), wound assessment, and instructions for ongoing care, per session; total wound(s) surface area greater than 50 square centimeters.

We also finalized that for instances where the sole purpose of a home health visit is to furnish dNPWT, Medicare does not pay for the visit under the HH PPS. Visits performed solely for the purposes of furnishing a new dNPWT device are not reported on the HH PPS claim (TOB 32x). Where a home health visit is exclusively for the purpose of furnishing dNPWT, the HHA submits only a TOB 34x. However, if the home health visit includes the provision of other home health services in addition to, and separate from, furnishing dNPWT, the HHA submits both a TOB 32x and TOB 34x—the TOB 32x for other home health services and the TOB 34x for furnishing NPWT using a disposable device. Payment for home health visits related to wound care, but not requiring the furnishing of an entirely new dNPWT device, are covered by the HH PPS 30-day period payment and must be billed using the home health claim.

### (3) CAA, 2023

Division FF, section 4136 of the CAA, 2023 (Pub. L. 117–328) amends section 1834 of the Act (42 U.S.C. 1395m(s)), and mandates several amendments to the Medicare separate payment for dNPWT devices beginning in CY 2024. Section 4136(a) of the CAA, 2023 amends 1834(s)(3) of the Act by adding subparagraph (A) which outlines the calculation of the payment amounts for (i) years prior to CY 2024, (ii) CY 2024, (iii) CY 2025; and each subsequent year. As discussed previously, for a year prior to CY 2024, the amount of the separate payment was set equal to the amount of the payment that would be made under the Medicare Hospital OPPS using the CPT codes 97607 and 97608 and included the professional service as well as the furnishing of the device. For CY 2024, the CAA, 2023 requires that the separate payment amount for an applicable dNPWT device would be set

equal to the supply price used to determine the relative value for the service under the Physician Fee Schedule (PFS) under section 1848 as of January 1, 2022 (CY 2022) updated by the specified adjustment described in subparagraph (B) for such year. For 2025 and each subsequent year, the CAA, 2023 requires that the separate payment amount will be set equal to the payment amount established for the device in the previous year, updated by the specified adjustment described in subparagraph (B) for such year.

Division FF section 4136 of the CAA, 2023 also adds a new subparagraph 1834(s)(3)(B), which requires that the separate payment amount to be adjusted by the percent increase in the CPI-U for the 12-month period ending with June of the preceding year minus the productivity adjustment described in section 1886(b)(3)(B)(xi)(II) for such year. Accordingly, this may result in a percentage being less than 0.0 for a year, and may result in payment being less than such payment rates for the preceding year.

Section 1834(s)(3)(C) of the Act, as added by Division FF, section 4136 of the CAA, 2023, specifies that the separate payment amount for applicable devices furnished on or after January 1, 2024, would no longer include payment for nursing or therapy services described in section 1861(m) of the Act. Payment for such nursing or therapy services would now be made under the prospective payment system established under section 1895 of the Act, the HH PPS, and is no longer separately billable.

Division FF, section 4136 of the CAA, 2023 also added a new paragraph 1834(s)(4) of the Act that mandates a change in claims processing for the separate payment amount for an applicable disposable device. Beginning in CY 2024 and each subsequent year, claims for the separate payment amount of an applicable dNPWT device would now be accepted and processed on claims submitted using the type of bill that is most commonly used by home health agencies to bill services under a home health plan of care (TOB 32X). That is, claims with a date of service on or after January 1, 2024 for an applicable dNPWT device will no longer be submitted on TOB 34X.

### (4) Proposed Payment Policies for dNPWT Devices

For the purposes of paying for a dNPWT device for a patient under a Medicare home health plan of care, CMS is proposing that the payment amount for CY 2024 would be equal to the supply price of the applicable

disposable device under the Medicare PFS (as of January 1, 2022) updated by the specified adjustment as mandated by the CAA, 2023. The supply price of an applicable disposable device under the Medicare PFS for January 1, 2022 is \$263.25. Therefore, the payment amount for CY 2024 would be set equal to the amount of \$263.25 updated by the percent increase in the CPI-U for the 12-month period ending in June of 2023 minus the productivity adjustment. We note that the CPI-U for the 12-month period ending with June of 2023 is not available at the time of this proposed rulemaking. The CPI-U for the 12-month period ending in June of 2023 and the corresponding productivity adjustment will be updated in the final rule. We are also proposing that the separate payment for CY 2025 and each subsequent year would be based on the established payment amount for the previous calendar year updated by the percentage increase in the CPI-U minus the productivity adjustment for the 12-month period ending in June of the previous year. The application of productivity adjustment may result in a net update that may be less than 0.0 for a year, and may result in the separate payment amount under this subsection for an applicable device for a year being less than such separate payment amount for such device for the preceding year.

In accordance with the changes made by the CAA, 2023, we are also proposing that claims reported for a dNPWT device would no longer be reported on TOB 34x. Instead, for dates of service beginning on or after January 1, 2024, the HHA would report the Healthcare Common Procedure Coding System (HCPCS) code A9272 (for the device only) on the home health type of bill TOB 32. The code HCPCS A9272 is defined as a wound suction, disposable, includes dressing, all accessories and components, any type, each. We will provide education and develop materials outlining the new billing procedures for dNPWT under the home health benefit including MLN Matters® articles and manual guidance after publication of the CY 2024 HH PPS final rule.

We are also proposing that the services related to the application of the device would be included in the HH PPS and would be excluded from the separate payment amount for the device. In addition, only the home health services for the administration of the device would be geographically adjusted and the payment amount for HCPCS A9272 would not be subject to geographic adjustment.

We are soliciting public comment on all aspects of the proposed payment

policies for furnishing a dNPWT device as articulated in this section as well as the corresponding proposed regulations text changes at § 409.50 and § 484.202.

### III. Home Health Quality Reporting Program (HH QRP)

#### A. Background and Statutory Authority

The HH QRP is authorized by section 1895(b)(3)(B)(v) of the Act. Section 1895(b)(3)(B)(v)(II) of the Act requires that, for 2007 and subsequent years, each home health agency (HHA) submit to the Secretary in a form and manner, and at a time, specified by the Secretary, such data that the Secretary determines are appropriate for the measurement of health care quality. To the extent that an HHA does not submit data in accordance with this clause, the Secretary shall reduce the home health market basket percentage increase applicable to the HHA for such year by 2 percentage points. As provided at section 1895(b)(3)(B)(vi) of the Act, depending on the market basket percentage increase applicable for a particular year, as further reduced by the productivity adjustment (except in

2018 and 2020) described in section 1886(b)(3)(B)(xi)(II) of the Act, the reduction of that increase by 2 percentage points for failure to comply with the requirements of the HH QRP may result in the home health market basket percentage increase being less than 0.0 percent for a year, and may result in payment rates under the Home Health PPS for a year being less than payment rates for the preceding year. Section 1890A of the Act requires that the Secretary establish and follow a pre-rulemaking process, in coordination with the consensus-based entity (CBE) with a contract under section 1890 of the Act, to solicit input from certain groups regarding the selection of quality and efficiency measures for the HH QRP. The HH QRP regulations can be found at 42 CFR 484.245 and 484.250.

In this proposed rule, we are proposing to adopt two new measures and remove one existing measure. Second, we propose the removal of two OASIS items. Third, we are proposing to begin public reporting of four measures in the HH QRP. Fourth, we are providing an update on our efforts to close the health equity gap. Fifth, we

propose codifying of our 90 percent data submission threshold policy in the Code of Federal Regulations. Lastly, we are seeking information on principles we could use to select and prioritize HH QRP quality measures in future years. These proposals are further specified in the following sections.

#### B. General Considerations Used for the Selection of Quality Measures for the HH QRP

For a detailed discussion of the considerations we historically use for measure selection for the HH QRP quality, resource use, and other measures, we refer readers to the CY 2016 HH PPS final rule (80 FR 68695 through 68696). In the CY 2019 HH PPS final rule with comment period (83 FR 56548 through 56550) we finalized the factors we consider for removing previously adopted HH QRP measures.

#### C. Quality Measures Currently Adopted for the CY 2024 HH QRP

The HH QRP currently includes 20 measures for the CY 2023 program year, as described in Table C1.

**BILLING CODE 4120-01-P**

**TABLE CI: MEASURES CURRENTLY ADOPTED FOR THE CY 2023 HH QRP**

| Short Name                           | Measure Name & Data Source  |
|--------------------------------------|---|
| <b>QM Name</b>                       | <b>OASIS-based</b>  |
| Ambulation                           | Improvement in Ambulation/Locomotion (CBE #0167).   |
| Application of Falls                 | Application of Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (CBE #0674).   |
| Application of Functional Assessment | Application of Percent of Long-Term Care Hospital (LTCH) Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (CBE #2631).  |
| Bathing                              | Improvement in Bathing (CBE #0174).   |
| Bed Transferring                     | Improvement in Bed Transferring (CBE # 0175).   |
| DRR                                  | Drug Regimen Review Conducted With Follow-Up for Identified Issues- Post Acute Care (PAC) HH QRP.   |
| Dyspnea                              | Improvement in Dyspnea.   |
| Influenza                            | Influenza Immunization Received for Current Flu Season  |
| Oral Medications                     | Improvement in Management of Oral Medications (CBE #0176).  |
| Pressure Ulcer/Injury                | Changes in Skin Integrity Post-Acute Care   |
| Timely Care                          | Timely Initiation Of Care (CBE #0526).  |
| TOH -Provider                        | Transfer of Health Information to Provider-Post-Acute Care <sup>1</sup>   |
| TOH -Patient                         | Transfer of Health Information to Patient-Post-Acute Care <sup>1</sup>  |
| <b>QM Name</b>                       | <b>Claims-based</b>   |
| ACH                                  | Acute Care Hospitalization During the First 60 Days of HH (CBE #0171).  |
| DTC                                  | Discharge to Community-Post Acute Care (PAC) Home Health (HH) Quality Reporting Program (QRP) (CBE #3477)   |
| ED Use                               | Emergency Department Use without Hospitalization During the First 60 Days of HH (CBE #0173).  |
| MSPB                                 | Total Estimated Medicare Spending Per Beneficiary (MSPB)—Post Acute Care (PAC) HH QRP.  |
| PPR                                  | Potentially Preventable 30-Day Post-Discharge Readmission Measure for HH Quality Reporting Program.   |
| PPH                                  | Home Health Within Stay Potentially Preventable Hospitalization   |
| <b>QM Name</b>                       | <b>HHC AHPS-based</b>   |
| CAHPS Home Health Survey             | CAHPS® Home Health Care Survey (experience with care) (CBE #0517) <sup>2</sup><br>- How often the HH team gave care in a professional way.<br>- How well did the HH team communicate with patients.<br>- Did the HH team discuss medicines, pain, and home safety with patients.<br>- How do patients rate the overall care from the HHA.<br>- Will patients recommend the HHA to friends and family. |

**Notes:**

- 1 Data collection delayed due to the COVID-19 public health emergency for the TOH-Patient and TOH-Provider.
- 2 The HHC-AHPS has five components that together are used to represent one CBE-endorsed measure.

## BILLING CODE 4120-01-C

*D. HH QRP Quality Measure Proposals Beginning With the CY 2025 HH QRP*

## 1. Discharge Function Score Measure Beginning With the CY 2025 HH QRP

## a. Background

Eligibility for Medicare's home health benefit stipulates that beneficiaries must need part-time (fewer than eight hours per day) or intermittent skilled care for their medical conditions and be unable to leave their homes without considerable effort. Unlike skilled nursing facilities, a proceeding hospital stay is not required for beneficiaries to access the Medicare home health benefit.<sup>18</sup> HH patients frequently have complex medical issues, including cardiac, circulatory and respiratory conditions, and between 30–40 percent of HH patients begin their episode of care with a high level of functional debility.<sup>19</sup> Measuring functional status of HH patients can provide valuable information about an HHA's quality of care. A patient's functional status is associated with institutionalization,<sup>20</sup> higher risk of falls and falls-related hip fracture and death,<sup>21 22</sup> greater risk of undernutrition,<sup>23</sup> higher emergency department admissions,<sup>24</sup> higher risk of readmissions following home care<sup>25 26</sup>

<sup>18</sup> Medicare Payment Advisory Commission. (2022). March 2022 report to the congress: Medicare payment policy. *Washington, DC: Medicare Payment Advisory Commission.*

<sup>19</sup> Medicare Payment Advisory Commission. (2022). March 2022 report to the congress: Medicare payment policy. *Washington, DC: Medicare Payment Advisory Commission.*

<sup>20</sup> Hajek, A., Bretschneider, C., Lange, C., Posselt, T., Wiese, B., Steinmann, S., Weyerer, S., Werle, J., Pentzek, M., Fuchs, A., Stein, J., Luck, T., Bickel, H., Mösche, E., Wagner, M., Jessen, F., Maier, W., Scherer, M., Riedel-Heller, S.G., König, H.H., & AgeCoDe Study Group. (2015). Longitudinal Predictors of Institutionalization in Old Age. *PLoS One*, 10(12):e0144203.

<sup>21</sup> Akahane, M., Maeyashiki, A., Yoshihara, S., Tanaka, Y., & Imamura, T. (2016). Relationship between difficulties in daily activities and falling: loco-check as a self-assessment of fall risk. *Interactive Journal of Medical Research*, 5(2), e20.

<sup>22</sup> Zaslavsky, O., Zeller-Sagi, S., Gray, S.L., LaCroix, A.Z., Brunner, R.L., Wallace, R.B., . . . Woods, N.F. (2016). Comparison of Frailty Phenotypes for Prediction of Mortality, Incident Falls, and Hip Fracture in Older Women. *Journal of the American Geriatrics Society*, 64(9), 1858–1862.

<sup>23</sup> van der Pols-Vijlbrief, R., Wijnhoven, H.A.H., Bosmans, J.E., Twisk, J.W.R., & Visser, M. (2016). Targeting the underlying causes of undernutrition. Cost-effectiveness of a multifactorial personalized intervention in community-dwelling older adults: A randomized controlled trial. *Clinical Nutrition (Edinburgh, Scotland)*.

<sup>24</sup> Hominick, K., McLeod, V., & Rockwood, K. (2016). Characteristics of older adults admitted to hospital versus those discharged home, in emergency department patients referred to internal medicine. *Canadian Geriatrics Journal: CGJ*, 19(1), 9–14.

<sup>25</sup> Knox, S., Downer, B., Haas, A., Middleton, A., & Ottenbacher, K.J. (2020). Function and caregiver

and higher prevalence of hypertension and diabetes.<sup>27</sup> Predictors of poorer recovery in function include greater age, complications after hospital discharge, and residence in a nursing home.<sup>28</sup> Understanding factors associated with poorer functional recovery facilitates the ability to estimate expected functional outcome recovery for patients, based on their personal characteristics.

Home health care can positively impact functional outcomes. There is evidence the provision of home care services can lead to statistically significant improvements in function and successful discharge into the community.<sup>29</sup> In stroke patients, home-based rehabilitation programs administered by home health clinicians significantly improved function.<sup>30</sup> Home health services, delivered by a registered nurse positively impacted patient Quality of Life (QOL) and clinical outcomes, including significant improvement in dressing lower body and bathing activities of daily living, meal preparation, shopping, and housekeeping instrumental activities of daily living.<sup>31</sup> In addition, a retrospective study, using data abstracted from the Minimum Data Set and OASIS, reported that nursing home admissions were delayed in the study population receiving home health services by an average of eight months<sup>32</sup>

support associated with readmissions during home health for individuals with dementia. *Archives of physical medicine and rehabilitation*, 101(6), 1009–1016.

<sup>26</sup> Middleton, A., Downer, B., Haas, A., Knox, S., & Ottenbacher, K.J. (2019) Functional status ss associated with 30-day potentially preventable readmissions following home health care. *Medical Care*, 57(2):145–151.

<sup>27</sup> Halawah, H., Willen, C., Grimby-Ekman, A., & Svantesson, U. (2015). Physical activity and health-related quality of life among community dwelling elderly. *J Clin Med Res*, 7(11), 845–52.

<sup>28</sup> Córcoles-Jiménez, M.P., Villada-Munera, A., Del Egado-Fernandez, M.A., Candel-Parra, E., Moreno-Moreno, M., Jimenez-Sanchez, M.D., & Pina-Martinez, A. (2015). Recovery of activities of daily living among older people one year after hip fracture. *Clinical Nursing Research*, 24(6), 604–623.

<sup>29</sup> Bowles, K.H., McDonald, M., Barron, Y., Kennedy, E., O'Connor, M., & Mikkelsen, M. (2021). Surviving COVID-19 after hospital discharge: symptom, functional, and adverse outcomes of home health recipients. *Annals of internal medicine*, 174(3), 316–325.

<sup>30</sup> Asiri, F.Y., Marchetti, G.F., Ellis, J.L., Otis, L., Sparto, P.J., Watzlaf, V., & Whitney, S.L. (2014). Predictors of functional and gait outcomes for persons poststroke undergoing home-based rehabilitation. *Journal of Stroke and Cerebrovascular Diseases: The Official Journal of National Stroke Association*, 23(7), 1856–1864.

<sup>31</sup> Córcoles-Jiménez, M.P., Villada-Munera, A., Del Egado-Fernandez, M.A., Candel-Parra, E., Moreno-Moreno, M., Jimenez-Sanchez, M.D., & Pina-Martinez, A. (2015). Recovery of activities of daily living among older people one year after hip fracture. *Clinical Nursing Research*, 24(6), 604–623.

<sup>32</sup> Asiri, F.Y., Marchetti, G.F., Ellis, J.L., Otis, L., Sparto, P.J., Watzlaf, V., & Whitney, S.L. (2014).

and for a similar population, community dwelling adults receiving community-based services supporting aging in place, health and functional outcomes were enhanced, and improved cognition and lower rates of depression, function assistance, and incontinence were noted.<sup>33</sup>

To satisfy the requirement of the Improving Medicare Post-Acute Care Transformation (IMPACT) Act of 2014 (Pub. L. 113–185) to develop and implement standardized quality measures from five quality measure domains, including the domain of functional status, cognitive function, and changes in function and cognitive function, across the post-acute care (PAC) settings, CMS adopted the “Application of Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function” (Application of Functional Assessment/Care Plan) measure in the CY 2018 HH PPS final rule (82 FR 51722 through 51725). This cross-setting process measure allowed for the standardization of functional assessments across assessment instruments and facilitated cross-setting data collection, quality measurement, and interoperable data exchange.

However, performance on this measure across the PAC settings, including the range of HHAs, is so high and unvarying across most HH providers that the measure no longer offers meaningful distinctions in performance. Several measures addressing functional status are currently part of the PAC QRPs. None of the existing functional outcome measures are cross-setting in nature, in that they are either (a) not implemented in all four settings (for instance, the “Discharge Mobility and Self-Care Score” measures are reported for SNFs and IRFs but not for LTCHs and HHAs); or (b) rely on functional status items not collected in all settings (for instance, the “Discharge Mobility and Self-Care Score” measures rely on items not collected in LTCHs). In contrast, a cross-setting functional outcome measure would include the HH setting. Moreover, the measure specifications would be aligned across settings, including the use of a common set of standardized functional assessment data

Predictors of functional and gait outcomes for persons poststroke undergoing home-based rehabilitation. *Journal of Stroke and Cerebrovascular Diseases: The Official Journal of National Stroke Association*, 23(7), 1856–1864.

<sup>33</sup> Han, S.J., Kim, H.K., Storfjell, J., & Kim, M.J. (2013). Clinical outcomes and quality of life of home health care patients. *Asian Nursing Research*, 7(2), 53–60.



elements, thereby satisfying the requirements of the IMPACT Act.

### (1) Measure Importance

Maintenance or improvement of physical function among older adults is increasingly an important focus of healthcare. Worldwide, close to 20 percent of older adults living at home report needing some form of assistance with their ADLs, and in the US 29 percent of older adults report difficulties completing their activities of daily living (ADLs).<sup>34</sup> Adults aged 65 years and older constitute the most rapidly growing population in the United States, and functional capacity in physical (non-psychological) domains has been shown to decline with age.<sup>35</sup> Moreover, impaired functional capacity is associated with poorer quality of life and an increased risk of all-cause mortality, postoperative complications, and cognition, the latter of which can complicate the return of a patient to the community from post-acute care if the patient exhibits cognitive deficits.<sup>36 37 38</sup> Nonetheless, evidence suggests that physical functional abilities, including mobility and self-care, are modifiable predictors of patient outcomes across PAC settings, including functional recovery or decline after post-acute care.<sup>39 40 41 42 43</sup>

<sup>34</sup> Chen, S., Jones, L.A., Jiang, S., Jin, H., Dong, D., Chen, X., . . . Zhu, A. (2022). Difficulty and help with activities of daily living among older adults living alone during the COVID-19 pandemic: a multi-country population-based study. *BMC geriatrics*, 22(1), 1–14.

<sup>35</sup> High KP, Ziemann S, Gurwitz J, Hill C, Lai J, Robinson T, Schonberg M, Whitson H. Use of Functional Assessment to Define Therapeutic Goals and Treatment. *J Am Geriatr Soc*. 2019 Sep;67(9):1782–1790. doi: 10.1111/jgs.15975. Epub 2019 May 13. PMID: 31081938; PMCID: PMC6955596.

<sup>36</sup> Clouston SA, Brewster P, Kuh D, Richards M, Cooper R, Hardy R, Rubin MS, Hofer SM. The dynamic relationship between physical function and cognition in longitudinal aging cohorts. *Epidemiol Rev*. 2013;35(1):33–50. doi: 10.1093/epirev/mxs004. Epub 2013 Jan 24. PMID: 23349427; PMCID: PMC3578448.

<sup>37</sup> Michael YL, Colditz GA, Coakley E, Kawachi I. Health Behaviors, Social Networks, and Healthy Aging: Cross-Sectional Evidence from the Nurses' Health Study. *Qual Life Res*. 1999 Dec;8(8):711–22. doi: 10.1023/a:1008949428041. PMID: 10855345.

<sup>38</sup> High KP, Ziemann S, Gurwitz J, Hill C, Lai J, Robinson T, Schonberg M, Whitson H. Use of Functional Assessment to Define Therapeutic Goals and Treatment. *J Am Geriatr Soc*. 2019 Sep;67(9):1782–1790. doi: 10.1111/jgs.15975. Epub 2019 May 13. PMID: 31081938; PMCID: PMC6955596.

<sup>39</sup> Deutsch A, Palmer L, Vaughan M, Schwartz C, McMullen T. Inpatient Rehabilitation Facility Patients' Functional Abilities and Validity Evaluation of the Standardized Self-Care and Mobility Data Elements. *Arch Phys Med Rehabil*. 2022 Feb 11;S0003–9993(22)00205–2. doi: 10.1016/j.apmr.2022.01.147. Epub ahead of print. PMID: 35157893.

<sup>40</sup> Hong I, Goodwin JS, Reistetter TA, Kuo YF, Mallinson T, Karmarkar A, Lin YL, Ottenbacher KJ,

rehospitalization rates,<sup>44 45 46</sup> discharge to community,<sup>47 48</sup> and falls.<sup>49</sup>

The implementation of interventions that improve patients' functional outcomes and reduce the risks of associated undesirable outcomes as a part of a patient-centered care plan is essential to maximizing functional improvement. For many people, the overall goals of HH care may include optimizing functional improvement, returning to a previous level of

Comparison of Functional Status Improvements Among Patients With Stroke Receiving Postacute Care in Inpatient Rehabilitation vs Skilled Nursing Facilities. *JAMA Netw Open*. 2019 Dec 2;2(12):e1916646. doi: 10.1001/jamanetworkopen.2019.16646. PMID: 31800069; PMCID: PMC6902754.

<sup>41</sup> Alcusky M, Ulbricht CM, Lapane KL. Postacute Care Setting, Facility Characteristics, and Poststroke Outcomes: A Systematic Review. *Arch Phys Med Rehabil*. 2018;99(6):1124–1140.e9. doi: 10.1016/j.apmr.2017.09.005. PMID: 28965738; PMCID: PMC5874162.

<sup>42</sup> Chu CH, Quan AML, McGilton KS. Depression and Functional Mobility Decline in Long Term Care Home Residents with Dementia: A Prospective Cohort Study. *Can Geriatr J*. 2021;24(4):325–331. doi:10.5770/cgj.24.511. PMID: 34912487; PMCID: PMC8629506.

<sup>43</sup> Lane NE, Stukel TA, Boyd CM, Wodchis WP. Long-Term Care Residents' Geriatric Syndromes at Admission and Disablement Over Time: An Observational Cohort Study. *J Gerontol A Biol Sci Med Sci*. 2019;74(6):917–923. doi: 10.1093/geronol/gly151. PMID: 29955879; PMCID: PMC6521919.

<sup>44</sup> Li CY, Haas A, Pritchard KT, Karmarkar A, Kuo YF, Hreha K, Ottenbacher KJ. Functional Status Across Post-Acute Settings is Associated With 30-Day and 90-Day Hospital Readmissions. *J Am Med Dir Assoc*. 2021 Dec;22(12):2447–2453.e5. doi: 10.1016/j.jamda.2021.07.039. Epub 2021 Aug 30. PMID: 34473961; PMCID: PMC8627458.

<sup>45</sup> Middleton A, Graham JE, Lin YL, Goodwin JS, Bettger JP, Deutsch A, Ottenbacher KJ. Motor and Cognitive Functional Status Are Associated with 30-day Unplanned Rehospitalization Following Post-Acute Care in Medicare Fee-for-Service Beneficiaries. *J Gen Intern Med*. 2016 Dec;31(12):1427–1434. doi: 10.1007/s11606–016–3704–4. Epub 2016 Jul 20. PMID: 27439979; PMCID: PMC5130938.

<sup>46</sup> Gustavson AM, Malone DJ, Boxer RS, Forster JE, Stevens-Lapsley JE. Application of High-Intensity Functional Resistance Training in a Skilled Nursing Facility: An Implementation Study. *Phys Ther*. 2020;100(10):1746–1758. doi: 10.1093/ptj/pzaa126. PMID: 32750132; PMCID: PMC7530575.

<sup>47</sup> Minor M, Jaywant A, Toglia J, Campo M, O'Dell MW. Discharge Rehabilitation Measures Predict Activity Limitations in Patients with Stroke Six Months after Inpatient Rehabilitation. *Am J Phys Med Rehabil*. 2021 Oct 20. doi: 10.1097/PHM.0000000000001908. Epub ahead of print. PMID: 34686630.

<sup>48</sup> Dubin R, Veith JM, Grippi MA, McPeake J, Harhay MO, Mikkelsen ME. Functional Outcomes, Goals, and Goal Attainment among Chronically Critically Ill Long-Term Acute Care Hospital Patients. *Ann Am Thorac Soc*. 2021;18(12):2041–2048. doi: 10.1513/AnnalsATS.202011–1412OC. PMID: 33984248; PMCID: PMC8641806.

<sup>49</sup> Hoffman GJ, Liu H, Alexander NB, Tinetti M, Braun TM, Min LC. Posthospital Fall Injuries and 30-Day Readmissions in Adults 65 Years and Older. *JAMA Netw Open*. 2019 May 3;2(5):e194276. doi: 10.1001/jamanetworkopen.2019.4276. PMID: 31125100; PMCID: PMC6632136.

independence, maintaining functional abilities, or avoiding institutionalization. Studies have suggested that HH care has the potential to improve patients' functional abilities including the performance of ADLs at discharge through the provision of physical and occupational therapy services for community dwelling older adult patients with various diagnoses, including dementia.<sup>50 51 52 53 54 55</sup> Assessing functional status as a health outcome in HH can thus provide valuable information in determining treatment decisions throughout the care continuum, the need for therapy service, and discharge planning,<sup>56 57 58</sup> as well as provide information to consumers about the effectiveness of the care delivered. Because evidence shows that older adults experience aging heterogeneously and require individualized and comprehensive health care, functional status can serve as a vital component in informing the provision of health care

<sup>50</sup> Knox, S., Downer, B., Haas, A., & Ottenbacher, K.J. (2022). Home health utilization association with discharge to community for people with dementia. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, 8(1), e12341.

<sup>51</sup> Prvu Bettger, J., McCoy, L., Smith, E.E., Fonarow, G.C., Schwamm, L.H., & Peterson, E.D. (2015). Contemporary trends and predictors of postacute service use and routine discharge home after stroke. *Journal of the American Heart Association*, 4(2), e001038.

<sup>52</sup> Golding-Day M, Whitehead P, Radford K, Walker M. Interventions to reduce dependency in bathing in community dwelling older adults: a systematic review. *Syst Rev*. 2017 Oct 11;6(1):198. doi: 10.1186/s13643–017–0586–4. PMID: 29020974; PMCID: PMC5637353.

<sup>53</sup> Foster, E.R., Carson, L. G., Archer, J., & Hunter, E.G. (2021). Occupational therapy interventions for instrumental activities of daily living for adults with Parkinson's disease: A systematic review. *The American Journal of Occupational Therapy*, 75(3).

<sup>54</sup> Anderson, W.L., & Wiener, J.M. (2015). The impact of assistive technologies on formal and informal home care. *The Gerontologist*, 55(3), 422–433.

<sup>55</sup> Knox, S., Downer, B., Haas, A., Middleton, A., & Ottenbacher, K.J. (2020). Function and caregiver support associated with readmissions during home health for individuals with dementia. *Archives of physical medicine and rehabilitation*, 101(6), 1009–1016.

<sup>56</sup> Dubin R, Veith JM, Grippi MA, McPeake J, Harhay MO, Mikkelsen ME. Functional Outcomes, Goals, and Goal Attainment among Chronically Critically Ill Long-Term Acute Care Hospital Patients. *Ann Am Thorac Soc*. 2021;18(12):2041–2048. doi:10.1513/AnnalsATS.202011–1412OC. PMID: 33984248; PMCID: PMC8641806.

<sup>57</sup> Warren M, Knecht J, Verheijde J, Tompkins J. Association of AM–PAC “6-Clicks” Basic Mobility and Daily Activity Scores With Discharge Destination. *Phys Ther*. 2021 Apr 4;101(4):pzab043. doi: 10.1093/ptj/pzab043. PMID: 33517463.

<sup>58</sup> Cogan AM, Weaver JA, McHarg M, Leland NE, Davidson L, Mallinson T. Association of Length of Stay, Recovery Rate, and Therapy Time per Day With Functional Outcomes After Hip Fracture Surgery. *JAMA Netw Open*. 2020 Jan 3;3(1):e1919672. doi: 10.1001/jamanetworkopen.2019.19672. PMID: 31977059; PMCID: PMC6991278.

and thus indicate HH quality of care.<sup>59 60 61 62</sup>

We are proposing to adopt the Discharge Function Score (DC Function) measure<sup>63</sup> in the HH QRP beginning with the CY 2025 HHQRP. This assessment-based outcome measure evaluates functional status by calculating the percentage of HH patients who meet or exceed an expected discharge function score. We are proposing that this measure would replace the topped-out, cross-setting Application of Functional Assessment/ Care Plan process measure. Like the cross-setting process measure it is replacing, the proposed measure is calculated using standardized patient assessment data from the current HH assessment tool.

In addition to meeting the requirements of the Act, the DC Function measure supports current CMS priorities. Specifically, the measure aligns with the Streamline Quality Measurement domain in CMS's Meaningful Measures 2.0 framework<sup>64</sup> in two ways. First, the proposed

outcome measure would further CMS's objective to increase the proportion of outcome measures in the HH QRP by replacing the Application of Functional Assessment/Care Plan cross-setting process measure with an outcome measure (see Section III.2 of this proposed rule). Second, this measure adds no additional provider burden since it would be calculated using data from the OASIS that are already reported to the Medicare program for payment and quality reporting purposes.

The proposed DC Function measure would also follow a calculation approach similar to the existing functional outcome measures. Specifically, the measure (1) considers two dimensions of function (that is, self-care and mobility activities) and (2) accounts for missing data by using statistical imputation to improve the validity of measure performance. The statistical imputation recodes missing functional status data to a *likely value* had the status been assessed, whereas the current imputation approach

implemented in existing function outcome measures recodes missing data to the *lowest* functional status.

#### (b) Measure Testing

Measure testing was conducted on the DC Function measure to assess validity, reliability, and reportability, all of which informed stakeholder feedback and Technical Expert Panel (TEP) input (See the *Stakeholder and Technical Expert Panel (TEP) Input* section of this proposed rule). Validity was assessed for the measure performance, the risk adjustment model, face validity, and statistical imputation models. Validity testing of measure performance entailed determining Spearman's rank correlations between the proposed measure's performance and the performance of other publicly reported HH quality measures. Results indicated that the measure captures the most probable determination of actual outcomes based on the directionalities and strengths of correlation coefficients and are further detailed in Table C2.

**TABLE C2. SPEARMAN'S RANK CORRELATION RESULTS OF DC FUNCTION MEASURE WITH PUBLICLY REPORTED HH QUALITY MEASURES**

| Measure – Long Name  | Measure – Short Name                          | $\rho$ |
|--|---|--------|
| Discharge to Community – PAC HH QRP (CBE ID #3477)           | Discharge to Community                        | 0.25   |
| Improvement in Ambulation – Locomotion (CBE ID #0167)        | Improvement in Ambulation                     | 0.25   |
| Improvement in Bed Transferring (CBE ID #0175)               | Improvement in Bed Transferring               | 0.31   |
| Improvement in Bathing (CBE ID #0174)                        | Improvement in Bathing                        | 0.26   |
| Improvement in Dyspnea (CBE ID #0179)                        | Improvement in Dyspnea                        | 0.26   |
| Improvement in Management of Oral Medications (CBE ID #0176) | Improvement in Management of Oral Medications | 0.23   |

Validity testing of the risk adjustment model showed good model discrimination, as the measure model has the predictive ability to distinguish patients with low expected functional capabilities from those with high expected functional capabilities.<sup>65</sup> The ratios of observed-to-predicted discharge function score across eligible episodes, by deciles of expected functional capabilities, ranged from 0.98 to 1.01. Both the Cross-Setting Discharge Function TEPs and patient-family feedback showed strong support for the

face validity and importance of the proposed measure as an indicator of quality of care. Lastly, validity testing of the measure's statistical imputation models indicated that the models demonstrate good discrimination and produce more precise and accurate estimates of function scores for items with missing scores when compared to adopting the current imputation approach implemented in the SNF QRP functional outcome measures, specifically Change in Self-Care Score measure, Change in Mobility Score

measure, Application of IRF Functional Outcome Measure: Discharge Self-Care Score for Medical Rehabilitation Patients (CBE ID #2635) (Discharge Self-Care Score) measure, and Application of IRF Functional Outcome Measure: Discharge Mobility Score for Medical Rehabilitation Patients (CBE ID #2636) (Discharge Mobility Score) measure. The current imputation approach involves recoding "Activity Not Attempted" (ANA) codes to "1" or "most dependent."

<sup>59</sup>Chase, J.-A. D., Huang, L., Russell, D., Hanlon, A., O'Connor, M., Robinson, K.M., & Bowles, K.H. (2018). Racial/ethnic disparities in disability outcomes among post-acute home care patients. *Journal of aging and health, 30*(9), 1406–1426.

<sup>60</sup>Fashaw-Walters, S.A., Rahman, M., Gee, G., Mor, V., White, M., & Thomas, K.S. (2022). Out Of Reach: Inequities In The Use Of High-Quality Home Health Agencies: Study examines inequities in the use of high-quality home health agencies. *Health Affairs, 41*(2), 247–255.

<sup>61</sup>Criss MG, Wingood M, Staples WH, Southard V, Miller KL, Norris TL, Avers D, Ciolek CH, Lewis

CB, Strunk ER. APTA Geriatrics' Guiding Principles for Best Practices in Geriatric Physical Therapy: An Executive Summary. *J Geriatr Phys Ther. 2022 Apr-June;45*(2):70–75. doi: 10.1519/JPT.000000000000342. PMID: 35384940.

<sup>62</sup>Cogan AM, Weaver JA, McHarg M, Leland NE, Davidson L, Mallinson T. Association of Length of Stay, Recovery Rate, and Therapy Time per Day With Functional Outcomes After Hip Fracture Surgery. *JAMA Netw Open. 2020 Jan 3;3*(1):e1919672. doi: 10.1001/jamanetworkopen.2019.19672. PMID: 31977059; PMCID: PMC6991278.

<sup>63</sup>Discharge Function Score for Home Health Agencies (HHAs) Technical Report, which is available at <https://www.cms.gov/files/document/hh-discharge-function-score-measure-technical-report.pdf>.

<sup>64</sup><https://www.cms.gov/medicare/meaningful-measures-framework/meaningful-measures-20-moving-measure-reduction-modernization>, accessed February 1, 2023.

<sup>65</sup>"Expected functional capabilities" is defined as the predicted discharge function score.

Reliability and reportability testing also yielded results that support the measure's scientific acceptability. Split-half testing revealed the proposed measure's excellent reliability, indicating an intraclass correlation coefficient value of 0.94. Reportability testing indicated good reportability (79 percent) of providers meeting the public reporting threshold of 20 eligible episodes. For additional measure testing details, we refer readers to the document titled *Discharge Function Score for Home Health Agencies (HHAs) Technical Report*, which is available at <https://www.cms.gov/files/document/hh-discharge-function-score-measure-technical-report.pdf>.

#### b. Competing and Related Measures

Section 1899B(e)(2)(A) of the Act requires that, absent an exception under section 1899B(e)(2)(B) of the Act, measures specified under section 1899B of the Act be endorsed by the entity with a contract under section 1890(a). In the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed, section 1899B(e)(2)(B) permits the Secretary to specify a measure that is not so endorsed, as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary.

The proposed DC Function measure is not CBE-endorsed, so we considered whether there are other available measures that (1) assess both functional domains of self-care and mobility in HHs and (2) satisfy the requirement of the Act to develop and implement standardized quality measures from the quality measure domain of functional status, cognitive function, and changes in function and cognitive function across the PAC settings. While the Application of Functional Assessment/Care Plan measure assesses both functional domains and satisfies the Act's requirement, this cross-setting process measure is not CBE-endorsed and the performance on this measure among HHs is so high and unvarying across most providers that the measure does not offer meaningful distinctions in performance. Additionally, after review of the CBE's consensus-endorsed measures, we were unable to identify any CBE-endorsed measures for HHs that meet the aforementioned requirements.

Therefore, after consideration of other available measures, we find that the exception under section 1899B(e)(2)(B) of the Act applies and are proposing to adopt the DC Function measure

beginning with the CY 2025 HH QRP. We intend to submit the proposed measure to the CBE for consideration of endorsement when feasible.

#### c. Interested Parties and Technical Expert Panel (TEP) Input

In our development and specification of this measure, we employed a transparent process in which we sought input from stakeholders and national experts and engaged in a process that allowed for pre-rulemaking input, in accordance with section 1890A of the Act. To meet this requirement, we provided the following opportunities for stakeholder input: a Patient and Family Engagement Listening Session, two TEPs, and public comments through a request for information (RFI).

First, the measure development contractor convened a Patient and Family Engagement Listening Session, during which patients and caregivers provided views on the proposed measure concept. Participants expressed support and emphasized the importance of measuring functional outcomes and found self-care and mobility to be critical aspects of care. Additionally, they expressed a strong interest in metrics assessing the number of patients discharged from particular agencies or facilities with improvements in self-care and mobility, and their views of self-care and mobility aligned with the functional domains captured by the proposed measure. All feedback was used to inform measure development efforts.

The measure development contractor subsequently convened TEPs on July 14–15, 2021 and January 26–27, 2022 to obtain expert input on the development of DC Function measure for use in the HH QRP. The TEPs consisted of stakeholders with a diverse range of expertise, including HH and PAC subject matter knowledge, clinical expertise, patient and family perspectives, and measure development experience. The TEPs supported the proposed measure concept and provided substantive feedback regarding the measure's specifications and measure testing data. First, the TEP was asked whether they prefer a cross-setting measure that is modeled after the Inpatient Rehabilitation Facility (IRF) Functional Outcome Measure: Discharge Mobility Score for Medical Rehabilitation Patients (CBE ID #2636) (Discharge Mobility Score) and IRF Functional Outcome Measure: Discharge Self-Care Score for Medical Rehabilitation Patients (CBE ID #2635) (Discharge Self-Care Score) measures, or one that is modeled after the IRF Functional Outcome Measure: Change

in Mobility for Medical Rehabilitation Patients (CBE ID #2634) (Change in Mobility Score) and IRF Functional Outcome Measure: Change in Self-Care Score for Medical Rehabilitation Patients (CBE ID #2633) (Change in Self-Care Score). With the Discharge Mobility Score and Change in Mobility Score measures and the Discharge Self-Care Score and Change in Self-Care Score measures being both highly correlated and not appearing to measure unique concepts, the TEP favored the Discharge Mobility Score and Discharge Self-Care Score measures over the Change in Mobility Score and Change in Self-Care Score measures and recommended moving forward with the Discharge Mobility Score and Discharge Self-Care Score measures for the cross-setting measure. Second, in deciding on the standardized functional assessment data elements to include in the cross-setting measure, the TEP recommended removing redundant data elements. Strong correlations between scores of functional items within the same functional domain suggested that certain items may be redundant in eliciting information about patient function and inclusion of these items could lead to overrepresentation of a particular functional area. Subsequently, our measure development contractor focused on the Discharge Mobility Score measure as a starting point for cross-setting development due to the greater number of cross-setting standardized functional assessment data elements for mobility while also identifying redundant functional items that could be removed from a cross-setting functional measure.

Additionally, the TEP supported including the cross-setting self-care items such that the cross-setting function measure captures both self-care and mobility. Panelists agreed that self-care items added value to the measure and are clinically important to function. Lastly, the TEP provided refinements to imputation strategies to more accurately represent function performance across all PAC settings, including the support of using statistical imputation over the current imputation approach implemented in existing functional outcome measures in the PAC QRPs. We considered all the TEP's recommendations for developing a cross-setting function measure and applied those recommendations where technically feasible and appropriate. Summaries of the TEP proceedings titled *Technical Expert Panel (TEP) for the Refinement of Long-Term Care Hospital (LTCH), Inpatient Rehabilitation Facility (IRF), Skilled*

*Nursing Facility (SNF)/Nursing Facility (NF), and Home Health (HH) Function Measures Summary Report* (July 2021 TEP) available at <https://mms-test.battelle.org/sites/default/files/TEP-Summary-Report-PAC-Function.pdf> and *Technical Expert Panel (TEP) for Cross-Setting Function Measure Development Summary Report* (January 2022 TEP) available at <https://mms-test.battelle.org/sites/default/files/PAC-Function-TEP-Summary-Report-Jan2022-508.pdf>.

#### d. Measure Application Partnership (MAP) Review

Our pre-rulemaking process includes making publicly available a list of quality and efficiency measures, called the MUC List, that the Secretary is considering adopting through the Federal rulemaking process for use in Medicare programs. This allows multi-stakeholder groups to provide recommendations to the Secretary on the measures included on the list.

We included the DC Function measure under the HH QRP in the publicly available MUC List for December 1, 2022,<sup>66</sup> and the CBE received five comments by industry interested parties on the 2022 MUC List. Three commenters were supportive of the measure and two were not. Among the commenters in support of the measure, one commenter stated that function scores are the most meaningful outcome measure in the HH setting, as they not only assess patient outcomes but also can be used for clinical improvement processes. Additionally, the commenter noted the measure's good reliability and validity and that the measure is feasible to implement. The second commenter supported the measure; however, the comments did not appear to be directly related to any aspect of the measure itself. The third commenter supported the measure without providing additional detailed comments.

Among the two commenters who did not support the DC Function measure, one commenter raised the following concerns: the "gameability" of the expected discharge score, the measure's complexity, and the difficulty of implementing a composite functional score. CMS was able to address these concerns during the MAP PAC/LTC Workgroup Meeting held on December 12, 2022. Specifically, CMS clarified that the expected discharge scores are not calculated using self-reported

functional goals and are simply calculated by risk-adjusting the observed discharge scores (see the Quality Measure Calculation section III.C.1.e of this proposed rule). Therefore, CMS believes that these scores cannot be "gamed" by reporting less-ambitious functional goals. CMS also pointed out that the measure is highly usable as it is similar in design and complexity to existing function measures (for example, Discharge Mobility Score and Discharge Self-Care Score for IRF) and that the data elements used in this measure are already in use.

The other commenter who did not support the DC Function measure raised the following concerns: its performance for stabilization patients and its ability to account for patients that change payer during a HH episode. CMS was able to address the first concern during the MAP PAC/LTC Workgroup Meeting held on December 12, 2022.

Specifically, CMS clarified that an episode will contribute to the numerator of DC Function if the observed discharge score meets or exceeds the expected discharge score, a value determined using clinical comorbidity and setting-specific parameters at the start or resumption of care. These parameters can and do predict no improvement among stabilization patients, that is, the expected discharge score can and does occasionally equal the observed admission score if clinical comorbidity and setting-specific parameters indicate no expected improvement in the risk adjustment model.

The second concern was not raised during the MAP PAC/LTC Workgroup Meeting; however, we do not find any convincing evidence that it influences HHA-level performance for the majority of HHAs. Payer changes will only affect episodes ending between December 31 and March 31. By comparing HHA-level performance calculated using the full calendar year versus using a dataset that excludes the dates with possibly affected episodes (January 1 through March 31 and December 31), we assessed the degree to which this requirement influences performance. The Spearman correlation coefficient between the two scenarios is 0.97, and the changes in reliability and validity are smaller than one percentage point. The results imply that including or excluding affected episodes does not appear to influence HHA-level performance for the majority of HHAs. We will continue to monitor this concern in the future, and we will address it accordingly in the future if necessary.

Shortly after, several CBE-convened MAP workgroups met virtually to provide input on the proposed DC Function measure. First, the MAP Health Equity workgroup convened on December 6–7, 2022. The workgroup did not share any health equity concerns related to the implementation of the DC Function measure, and only asked for clarification regarding measure specifications from measure developers. The MAP Rural Health workgroup met on December 8–9, 2022, during which two members provided support for the DC Function measure and other workgroup members did not express rural health concerns regarding the measure. The MAP Post-Acute Care/Long-Term Care (PAC–LTC) workgroup met virtually on December 12, 2022 and provided input on the proposed DC Function measure. The workgroup voted to support the staff recommendation of conditional support for rulemaking.

In response to the MAP PAC/LTC Workgroup's preliminary recommendation, the CBE received one comment in support and one comment not in support of the DC Function measure. The commenter in support of the DC Function measure supported the measure under the condition that it be reviewed and refined such that its implementation supports patient autonomy and results in care that aligns with patients' personal functional goals. The commenter who did not support the DC Function measure raised concern with the applicability of the DC Function measure considering the different patient populations served by the various PAC settings. CMS clarified that the DC Function measure is not designed to compare function across PAC settings, and that this feature is not a requirement of the IMPACT Act.

Finally, the MAP Coordinating Committee convened on January 24–25, 2023, during which the CBE received no comment on the PAC/LTC workgroup's preliminary recommendation for conditional support of the DC Function measure. The MAP Coordinating Committee upheld the PAC/LTC workgroup's recommendation of conditional support for rulemaking with 20 votes in support and one against. We refer readers to the final MAP recommendations, titled *2022–2023 MAP Final Recommendations* available at <https://mmsub.cms.gov/measure-lifecycle/measure-implementation/pre-rulemaking/lists-and-reports>.

#### e. Quality Measure Calculation

The proposed outcome measure estimates the percentage of HH patients who meet or exceed an expected

<sup>66</sup> Centers for Medicare & Medicaid Services. Overview of the List of Measures Under Consideration for December 1, 2022. <https://mmsub.cms.gov/sites/default/files/2022-MUC-List-Overview.pdf>.

discharge score during the reporting period. The proposed measure's numerator is the number of HH episodes with an observed discharge function score that is equal to or higher than the calculated expected discharge function score. The observed discharge function score is the sum of individual function items at discharge. The expected discharge function score is computed by risk adjusting the observed discharge function score for each HH episode. Risk adjustment controls for patient characteristics such as admission function score, age, and clinical conditions. The denominator is the total number of HH episodes in the measure target period (four rolling quarters) that do not meet the measure exclusion criteria. For additional details regarding the numerator, denominator, risk adjustment, and exclusion criteria, refer to the *Discharge Function Score for Home Health Agencies (HHAs) Technical Report* available at <https://www.cms.gov/files/document/hh-discharge-function-score-measure-technical-report.pdf>.

The proposed measure implements a statistical imputation approach for handling "missing" standardized functional assessment data elements. The coding guidance for standardized functional assessment data elements allows for using ANA codes, resulting in "missing" information about a patient's functional ability on at least some items, at admission and/or discharge, for a substantive portion of HH patients. Statistical imputation replaces these missing values with a variable based on the values of other, non-missing variables in the data and which are otherwise similar to the assessment with a missing value. Specifically, in this proposed DC Function measure statistical imputation allows missing values (for example, the ANA codes) to be replaced with any value from 1 to 6, based on a patient's clinical characteristics and codes assigned on other standardized functional assessment data element. The measure implements separate imputation models for each standardized functional assessment data element used in measure construction at admission and discharge. Relative to the current simple imputation method, this statistical imputation approach increases precision and accuracy and reduces the bias in estimates of missing item scores. We refer readers to the *Discharge Function Score for Home Health Agencies (HHAs) Technical Report* available at <https://www.cms.gov/files/document/hh-discharge-function-score-measure-technical-report.pdf> for

measure specifications and additional details on measure testing, including the method for comparing the statistical imputation approach to the current simple imputation method.

We invite public comment on our proposal to adopt the DC Function measure, beginning with the CY 2025 HH QRP.

## 2. Proposed Removal of the "Application of Percent of Long-Term Care Hospital Patients With an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function" Beginning With the CY 2025 HH QRP

We are proposing to remove the "Application of Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function" (Application of Functional Assessment/Care Plan) measure from the HH QRP beginning with the CY 2025 HH QRP. Section 42 CFR 484.245(b)(3) of our regulations specifies eight factors we consider for measure removal from the HH QRP, and we believe this measure should be removed because it satisfies two of these factors.

First, the Application of Functional Assessment/Care Plan measure meets the conditions for measure removal factor one: measure performance among HHAs is so high and unvarying that meaningful distinctions in improvements in performance can no longer be made.<sup>67</sup> Second, this measure meets the conditions for measure removal factor six: there is an available measure that is more strongly associated with desired patient functional outcomes. We believe the proposed DC function measure discussed in section XX of this proposed rule better measures functional outcomes than the current Application of Functional Assessment/Care Plan measure. We discuss each of these reasons in more detail later in this proposed rule.

In regards to removal factor one, the Application of Functional Assessment/Care Plan measure has become topped out, with average performance rates reaching nearly 100 percent over the past 3 years (ranging from 96–98 percent during calendar years (CYs) 2019–2021).<sup>68</sup> For the 12-month period of

<sup>67</sup> For more information on the factors the Centers for Medicare & Medicaid Services (CMS) uses to base decisions for measure removal, we refer readers to the Code of Federal Regulations, § 484.245(b)(3) <https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-484/subpart-E/section-484.245>.

<sup>68</sup> CMS, Home Health Agency Data Archive, 2019–2021, Annual Files National Data. PDC,

third quarter of CY 2021, HHAs had an average score for this measure of 98 percent, with nearly 75 percent of HHAs scoring 100 percent. The proximity of these mean rates to the maximum score of 100 percent suggests a ceiling effect and a lack of variation that restricts distinction among HHAs.

In regards to measure removal factor six, the DC Function measure is more strongly associated with desired patient functional outcomes than this current process measure, the Application of Functional Assessment/Care Plan measure. As described in section III.C.1 of this proposed rule, the DC Function measure has the predictive ability to distinguish patients with low expected functional capabilities from those with high expected functional capabilities.<sup>69</sup> We have been collecting standardized functional assessment elements across PAC settings since 2016 which has allowed for the development of the proposed DC Function measure and meets the statutory requirements to submit standardized patient assessment data and other necessary data with respect to the domain of functional status, cognitive function, and changes in function and cognitive function. In light of this development, this process measure, the Application of Functional Assessment/Care Plan measure which measures only whether a functional assessment is completed and a functional goal is included in the care plan, is no longer necessary, and can be replaced with a measure that evaluates the HHA's outcome of care on a patient's function.

Because the Application of Functional Assessment/Care Plan measure meets measure removal factors one and six, we are proposing to remove it from the HH QRP beginning with the CY 2025 HH QRP. We are also proposing that public reporting of the Application of Functional Assessment/Care Plan measure would end by January 2025 or as soon as technically feasible when public reporting of the proposed DC Function measure would begin (see section III.F.2. of this proposed rule).

Under our proposal, HHAs would no longer be required to report a Self-Care Discharge Goal (that is, GG0130, Column 2) or a Mobility Discharge Goals (that is, GG0170, Column 2) on the OASIS beginning with patients admitted on April 1, 2024. We would remove the items for Self-Care Discharge Goals (that is, GG0130, Column 2) and Mobility Discharge Goals (that is, GG0170,

<https://data.cms.gov/provider-data/archived-data/home-health-services>.

<sup>69</sup> "Expected functional capabilities" is defined as the predicted discharge function score.

Column 2) with the next release of the OASIS. Under our proposal, these items would not be required to meet HH QRP requirements beginning with the CY 2025 HH QRP.

We invite public comment on our proposal to remove the Application of Functional Assessment/Care Plan measure from the HH QRP beginning with the CY 2025 HH QRP.

### 3. COVID-19 Vaccine: Percent of Patients/Residents Who Are Up to Date Beginning With the CY 2025 HH QRP

#### a. Background

COVID-19 has been and continues to be a major challenge for PAC facilities, including HHAs. The Secretary first declared COVID-19 a PHE on January 31, 2020. As of March 15, 2023, the U.S. has reported 103,801,821 cumulative cases of COVID-19, and 1,121,512 total deaths due to COVID-19.<sup>70</sup> Although all age groups are at risk of contracting COVID-19, older persons are at a significantly higher risk of mortality and severe disease following infection, with those over age 80 dying at five times the average rate.<sup>71</sup> Older adults, in general, are prone to both acute and chronic infections owing to reduced immunity, and are a high-risk population.<sup>72</sup> Adults age 65 and older comprise over 75% of total COVID-19 deaths despite representing 13.4% of reported cases.<sup>73</sup> Restrictions on freedom of movement and physical distancing can lead to a disruption of essential care and support for older persons. Physical distancing measures that restrict visitors and group activities can negatively affect the physical and mental health and well-being of older persons, particularly those with cognitive decline or dementia, and who are highly care-dependent.<sup>74</sup>

<sup>70</sup> Centers for Disease Control and Prevention. COVID Data Tracker. 2023, January 20. Last accessed March 23, 2023. [https://covid.cdc.gov/covid-data-tracker/#cases\\_totalcases](https://covid.cdc.gov/covid-data-tracker/#cases_totalcases).

<sup>71</sup> United Nations. Policy Brief: The impact of COVID-19 on older persons. May 2020. <https://unsdg.un.org/sites/default/files/2020-05/Policy-Brief-The-Impact-of-COVID-19-on-Older-Persons.pdf>.

<sup>72</sup> Lekamwasam R, Lekamwasam S. Effects of COVID-19 pandemic on health and wellbeing of older people: a comprehensive review. *Ann Geriatr Med Res.* 2020;24(3):166–172. <http://dx.doi.org/10.4235/agmr.20.0027>. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533189/>.

<sup>73</sup> Centers for Disease Control and Prevention. Demographic trends of COVID-19 cases and deaths in the US reported to CDC. COVID Data Tracker. 2023, March 15. Last accessed March 23, 2023. <https://covid.cdc.gov/covid-data-tracker/#demographics>.

<sup>74</sup> United Nations. Policy Brief: The impact of COVID-19 on older persons. May 2020. <https://unsdg.un.org/sites/default/files/2020-05/Policy-Brief-The-Impact-of-COVID-19-on-Older-Persons.pdf>.

Since the development of the vaccines to combat COVID-19, studies have shown that being up to date on these vaccines continues to provide strong protection against severe disease, hospitalization, and death in adults, including during the predominance of Omicron BA.4 and BA.5 variants.<sup>75</sup> Initial studies showed the efficacy of FDA-approved COVID-19 vaccines in reducing the risk of severe outcomes caused by COVID-19. Further, residents at skilled nursing facilities (SNF) with high rates of staff testing for COVID-19 were less likely to be hospitalized or die due to COVID-19 than their counterparts in SNFs with low rates of staff testing. Prior to the emergence of the Delta variant of the virus, vaccine effectiveness against COVID-19-associated hospitalization among adults age 65 and older was 91% for those receiving a full mRNA vaccination (Pfizer-BioNTech or Moderna), and 84% for those receiving a viral vector vaccination (Janssen). Adults age 65 and older who were fully vaccinated with an mRNA COVID-19 vaccine had a 94% reduction in risk of COVID-19 hospitalization; those who were partially vaccinated had a 64% reduction in risk.<sup>76</sup> Further, after the emergence of the Delta variant, vaccine effectiveness against COVID-19-associated hospitalization for adults who received the primary series of the vaccine was 76% among adults age 75 and older.<sup>77</sup>

More recently, since the emergence of the Omicron variants and availability of booster doses, multiple studies have shown that while vaccine effectiveness against infection has waned, protection is higher among those receiving booster doses than among those only receiving the primary series.<sup>78 79 80</sup> CDC data show

<sup>75</sup> Chalkias S, Harper C, Vrbicky K, et al. A bivalent omicron-containing booster vaccine against COVID-19. *N Engl J Med.* 2022;387(14):1279–1291. doi: 10.0156/NEJMoa2208343. <https://www.nejm.org/doi/full/10.1056/NEJMoa2208343>.

<sup>76</sup> Centers for Disease Control and Prevention. Press Release, April 28, 2021. Fully Vaccinated Adults 65 and Older are 94% Less Likely to Be Hospitalized with COVID-19. <https://www.cdc.gov/media/releases/2021/p0428-vaccinated-adults-less-hospitalized.html>.

<sup>77</sup> Vaccine effectiveness after the emergence of the Delta variant is based on data from CDC's VISION Network, which examined 32,867 medical encounters from 187 hospitals and 221 emergency departments and urgent care clinics across nine states during June–August 2021, beginning on the date the Delta variant accounted for over 50% of sequenced isolates in each medical facility's state (Grannis SJ, et al. *MMWR Morb Mortal Wkly Rep.* 2021;70(37):1291–1293. doi: <http://dx.doi.org/10.15585/mmwr.mm7037e2>).

<sup>78</sup> Surie D, Bonnell L, Adams K, et al. Effectiveness of monovalent mRNA vaccines against COVID-19-associated hospitalization among immunocompetent adults during BA.1/BA.2 and

that, among people age 50 and older, those who have received both a primary vaccination series and booster shots have a lower risk of hospitalization and dying from COVID-19 than their non-vaccinated counterparts.<sup>81</sup> Additionally, a second vaccine booster has been shown to be effective against severe outcomes related to COVID-19, such as hospitalization or death.<sup>82</sup> Furthermore, more recent vaccination and booster doses can decrease the rate of COVID-19 transmission between individuals in close contact.<sup>83</sup> Early evidence also demonstrates that the bivalent booster, specifically aimed to combat the prevalent BA.4/BA.5 Omicron subvariants, provokes a superior antibody response against Omicron than the initial COVID-19 vaccines, underscoring the role of up-to-date vaccination protocols in effectively countering the spread of COVID-19.<sup>84</sup>

#### (1) Measure Importance

Despite the availability and demonstrated effectiveness of COVID-19 vaccinations, significant gaps continue to exist in vaccination rates.<sup>85</sup> As of March 15, 2023, vaccination rates among people age 65 and older are generally high for the primary vaccination series (94.3%) but lower for

BA.4/BA.5 predominant periods of SARS-CoV-2 Omicron variant in the United States — IVY Network, 18 states, December 26, 2021–August 31, 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71(42):1327–1334. <http://dx.doi.org/10.15585/mmwr.mm7142a3>.

<sup>79</sup> Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. *N Engl J Med.* 2022;386(16):1532–1546. <https://www.nejm.org/doi/full/10.1056/NEJMoa2119451>.

<sup>80</sup> Buchan SA, Chung H, Brown KA, et al. Estimated effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. *JAMA Netw Open.* 2022;5(9):e2232760. <http://dx.doi.org/10.1001/jamanetworkopen.2022.32760>. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796615>.

<sup>81</sup> Centers for Disease Control and Prevention. Daily update for the United States. COVID Data Tracker. 2023, January 20. Last accessed January 17, 2023. <https://covid.cdc.gov/covid-data-tracker>.

<sup>82</sup> Centers for Disease Control and Prevention. COVID-19 vaccine effectiveness monthly update. COVID Data Tracker. March 23, 2023. <https://covid.cdc.gov/covid-data-tracker/#vaccine-effectiveness>.

<sup>83</sup> Tan ST., Kwan AT, Rodriguez-Barraquer I, et al. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Preprint at medRxiv:

<sup>84</sup> Chalkias S, Harper C, Vrbicky K, et al. A bivalent Omicron-containing booster vaccine against COVID-19. *N Engl J Med* 2022;387(14):1279–1291. doi: 10.0156/NEJMoa2208343. <https://www.nejm.org/doi/full/10.1056/NEJMoa2208343>.

<sup>85</sup> Centers for Disease Control and Prevention. COVID-19 vaccinations in the United States. COVID Data Tracker. March 23, 2023. [https://covid.cdc.gov/covid-data-tracker/#vaccinations\\_vacc-people-booster-percent-pop5](https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-booster-percent-pop5).

the first booster (73.6%) among those who received a primary series) and even lower for the second booster (59.9%) among those who received a first booster).<sup>86</sup> Additionally, though the uptake in boosters among people age 65 and older has been much higher than among people of other ages, booster uptake still remains relatively low compared to primary vaccination among older adults.<sup>87</sup> Variations are also present when examining vaccination rates by race, gender, and geographic location.<sup>88</sup> For example, 66.2% of the Asian, non-Hispanic population have completed the primary series and 21.2% have received the bivalent booster dose, whereas 44.9% of the Black, non-Hispanic population have completed the primary series and only 8.9% have received the bivalent booster dose. Among Hispanic populations, 57.1% of the population have completed the primary series, with 8.5% receiving the bivalent booster dose, while in White, non-Hispanic populations, 51.9% have completed the primary series and 16.2% have received the bivalent booster dose.<sup>89</sup> Disparities have been found in vaccination rates between rural and urban areas, with lower vaccination rates found in rural areas.<sup>90 91</sup> Data show that 55.1% of the population in rural areas have completed the primary vaccination series, as compared to 66.2% of the population in urban areas.<sup>92</sup> Receipt of first booster doses

<sup>86</sup> Centers for Disease Control and Prevention. COVID-19 vaccination age and sex trends in the United States, national and jurisdictional. Last accessed March 24, 2023. [Vaccination Trends](#).

<sup>87</sup> Freed M, Neuman T, Kates J, Cubanski J. Deaths among older adults due to COVID-19 jumped during the summer of 2022 before falling somewhat in September. Kaiser Family Foundation. October 6, 2022. <https://www.kff.org/coronavirus-covid-19/issue-brief/deaths-among-older-adults-due-to-covid-19-jumped-during-the-summer-of-2022-before-falling-somewhat-in-september/>.

<sup>88</sup> Saelee R, Zell E, Murthy BP, et al. Disparities in COVID-19 vaccination coverage between urban and rural counties—United States, December 14, 2020–January 31, 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71:335–340. <http://dx.doi.org/10.15585/mmwr.mm7109a2>.

<sup>89</sup> Centers for Disease Control and Prevention. Trends in Demographic Characteristics of People Receiving COVID-19 Vaccinations in the United States. COVID Data Tracker. 2023, January 20. Last accessed March 23, 2023. <https://covid.cdc.gov/covid-data-tracker/#vaccination-demographics-trends>.

<sup>90</sup> Saelee R, Zell E, Murthy BP, et al. Disparities in COVID-19 vaccination coverage between urban and rural counties—United States, December 14, 2020–January 31, 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71:335–340. DOI: <http://dx.doi.org/10.15585/mmwr.mm7109a2>.

<sup>91</sup> Sun Y, Monnat SM. Rural-urban and within-rural differences in COVID-19 vaccination rates. *J Rural Health.* 2022;38(4):916–922. <http://dx.doi.org/10.1111/jrh.12625>. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661570/>.

<sup>92</sup> Centers for Disease Control and Prevention. Vaccination Equity. COVID Data Tracker; 2023.

was similar between urban (50.4%) and rural (49.7%) counties.<sup>93</sup> Receipt of bivalent booster doses has been lower, with 16.9% of urban population having received the booster dose, and 10.9% of the rural population having received the booster dose.<sup>94</sup>

We are proposing to adopt the COVID-19 Vaccine: Percent of Patients/Residents who are Up to Date (Patient/Resident COVID-19 Vaccine) measure for the HH QRP beginning with the CY 2025 HH QRP. This proposed measure has the potential to increase COVID-19 vaccination coverage of patients in HHAs. This proposed measure also has the potential to prevent the spread of the virus within the HHA patient population. Although this population receives services within their own homes, they can transfer the virus to their caretakers and home healthcare workers, who could then potentially infect other home health patients. The proposed Patient/Resident COVID-19 Vaccine measure would also support the goal of the CMS Meaningful Measure Initiative 2.0 to “Empower consumers to make good health care choices through patient-directed quality measures and public transparency objectives.” The Patient/Resident COVID-19 Vaccine measure would be reported on Care Compare and would provide patients, including those who are at high risk for developing serious complications from COVID-19, and their caregivers, with valuable information they can consider when choosing a HHA. The proposed Patient/Resident COVID-19 vaccine measure would also facilitate patient care and care coordination during the hospital discharge planning process. For example, a discharging hospital, in collaboration with the patient and family, could use this measure to coordinate care and ensure patient preferences are considered in the discharge plan. Additionally, the proposed Patient/Resident COVID-19 Vaccine measure would be an indirect measure of HHA action. Since the patient’s COVID-19 vaccination status would be reported at discharge from the HHA, if a patient is not up to date with their COVID-19 vaccination per

January 20. Last accessed January 17, 2023. <https://covid.cdc.gov/covid-data-tracker/#vaccination-equity>.

<sup>93</sup> Saelee R, Zell E, Murthy BP, et al. Disparities in COVID-19 vaccination coverage between urban and rural counties—United States, December 14, 2020–January 31, 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71:335–340. <http://dx.doi.org/10.15585/mmwr.mm7109a2>.

<sup>94</sup> Centers for Disease Control and Prevention. Vaccination Equity. COVID Data Tracker; 2023, January 20. Last accessed January 17, 2023. <https://covid.cdc.gov/covid-data-tracker/#vaccination-equity>.

applicable CDC guidance at the time they are admitted, the HHA has the opportunity to educate the patient and provide information on why they should become up to date with their COVID-19 vaccination. HHAs may also choose to administer the vaccine to the patient prior to their discharge from the HHA or coordinate a follow up visit for the patient to obtain the vaccine at their physician’s office or local pharmacy.

## (2) Item Testing

Item testing was conducted for the proposed Patient/Resident COVID-19 Vaccine measure using patient scenarios and cognitive interviews to assess HHA providers’ comprehension of the item and the associated guidance. The patient scenarios were developed in collaboration with a team of clinical experts and represented the most common scenarios HHA providers encounter. The results of the item testing supported its reliability, and provided information to improve the item itself, as well as the accompanying guidance.

## b. Competing and Related Measures

Section 1899B(e)(2)(A) of the Act requires that, absent an exception under section 1899B(e)(2)(B) of the Act, each measure specified under section 1899B of the Act be endorsed by the entity with a contract under section 1890(a) of the Act. In the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed, section 1899B(e)(2)(B) of the Act permits the Secretary to specify a measure that is not so endorsed, as long as due consideration is given to the measures that have been endorsed or adopted by a consensus organization identified by the Secretary.

The proposed Patient/Resident COVID-19 Vaccine measure is not consensus-based entity (CBE) endorsed. After review of other CBE endorsed measures, we were unable to identify any CBE endorsed measures for HHAs focused on capturing COVID-19 vaccination coverage of HHA patients, and found no related measures in the HH QRP addressing COVID-19 vaccination. There have been COVID-19 Vaccination Coverage among Healthcare Personnel (HCP) measures adopted by the Skilled Nursing Facility (SNF) QRP, the Intermediate Rehabilitation Facility (IRF) and the Long-term Care Hospital (LTCH) QRP that captures the percentage of HCPs who receive a complete COVID-19 vaccination course. We also identified Nursing Home (NH) COVID-19 vaccine rates posted on Care Compare. However, these data are

obtained from CDC's NHSN and report rates of vaccination for the NH resident population. HHAs do not report patient/resident or HCP COVID-19 vaccination to the NHSN.

Therefore, after consideration of other available measures that assess COVID-19 vaccination rates, we believe the exception under section 1899B(e)(2)(B) of the Act applies. We intend to submit the measure for CBE endorsement when feasible.

#### c. Interested Parties and Technical Expert Panel (TEP) Input

In the development and specification of this measure, a transparent process was employed to seek input from interested parties and national experts and engage in a process that allows for pre-rulemaking input in accordance with section 1890A of the Act. First, the measure development contractor convened a focus group of patient and family/caregiver advocates (PFAs) to solicit input. The PFAs felt a measure capturing raw vaccination rate, irrespective of HHA action, would be most helpful in patient and family/caregiver decision-making. Next, TEP meetings were held on November 19, 2021 and December 15, 2021 to solicit feedback on the development of Patient/Resident COVID-19 vaccination measures and assessment items for the PAC settings. The TEP panelists voiced their support for PAC Patient/Resident COVID-19 vaccination measures and agreed that developing a measure to report the rate of vaccination in an HHA setting without denominator exclusions was an important goal. All recommendations from the TEP were taken into consideration and applied appropriately where technically feasible and appropriate. A summary of the TEP proceedings titled *Technical Expert Panel (TEP) for the Development of Long-Term Care Hospital (LTCH), Inpatient Rehabilitation Facility (IRF), Skilled Nursing Facility (SNF)/Nursing Facility (NF), and Home Health (HH) COVID-19 Vaccination-Related Items and Measures Summary Report* is available on the CMS Measures Management System (MMS) Hub, at <https://mmshub.cms.gov/sites/default/files/COVID19-Patient-Level-Vaccination-TEP-Summary-Report-NovDec2021.pdf>.

#### d. Measures Applications Partnership Review

The pre-rulemaking process includes making publicly available a list of quality and efficiency measures, called the Measures Under Consideration (MUC) List that the Secretary is considering adopting, through Federal

rulemaking process, for use in Medicare programs. This allows interested parties to provide recommendations to the Secretary on the measures included on the list. The Patient/Resident COVID-19 Vaccine measure was included on the publicly available 2022 MUC List for the HH QRP.<sup>95</sup> Shortly after, several CBE-convened MAP workgroups met virtually to provide input on the proposed measure. First, the MAP Health Equity advisory group convened on December 6, 2022. One MAP member noted that the percentage of true contraindications for the COVID-19 vaccine is low, and the lack of exclusions on the measure makes sense to avoid varying interpretations of valid contraindications.<sup>96</sup> Similarly, the MAP Rural Health advisory group met on December 8, 2022 and publicly stated that the measure is important for rural communities.<sup>97</sup>

Prior to convening the MAP PAC/LTC workgroup, the CBE received seven comments by industry interested parties during the proposed measure's MAP pre-rulemaking process. Interested parties were mostly supportive of the measure and recognized that it is important that patients be vaccinated against COVID-19, and that measurement and reporting is one important method to help healthcare organizations assess their performance in achieving high rates of "up-to-date" vaccination. One interested party noted that patient engagement is critical at this stage of the pandemic because best available information indicates COVID-19 variants will continue to require additional boosters to avert case surges. Another interested party noted the benefit of less-specific criteria for inclusion in the numerator and denominator of the proposed Patient/Resident COVID-19 Vaccine measure, which would provide flexibility for the measure to remain relevant to current circumstances. Other interested parties raised concerns about the proposed measure not including measuring the HHA's action in the numerator and excluding patient refusals from the denominator, and noted that there could

<sup>95</sup> CMS Measures Management System (MMS). Measure Implementation: Pre-rulemaking MUC Lists and MAP reports. Last accessed March 23, 2023 <https://mmshub.cms.gov/measure-lifecycle/measure-implementation/pre-rulemaking/lists-and-reports>.

<sup>96</sup> National Quality Forum MAP Health Equity Advisory Group Materials. Meeting Summary—MUC Review Meeting. Last accessed March 23, 2023. <https://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=97943>.

<sup>97</sup> National Quality Forum MAP Rural Health Advisory Group Materials. Meeting Summary—MUC Review Meeting. Last accessed March 23, 2023. <https://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=97964>.

be unintended consequences to patient access to care should the measure be adopted.

Subsequently, the MAP Post-Acute Care/Long-Term Care (PAC/LTC) workgroup met on December 12, 2022. The voting workgroup members noted the importance of reporting patients' vaccination status but raised concerns that (1) the proposed Patient/Resident COVID-19 Vaccine measure does not account for patient refusals or those who are unable to respond, and (2) the difficulty of implementing "up to date." CMS clarified during the MAP PAC/LTC workgroup that the proposed Patient/Resident COVID-19 Vaccine measure does not have exclusions for patient refusals because the proposed measure was intended to report raw rates of vaccination and this information is important for consumer choice. Additionally, CMS believes that PAC providers, including HHAs, are in a unique position to leverage their care processes to increase vaccination coverage in their settings to protect patients and prevent negative outcomes. CMS also clarified that the measure defines "up to date" in a manner that provides flexibility to reflect future changes in CDC guidance. However, the MAP PAC/LTC workgroup reached a 60 percent consensus on the vote of "Do not support for rulemaking" for this measure.<sup>98</sup>

The MAP received 10 comments by interested parties in response to the MAP PAC/LTC workgroup recommendations. Interested parties generally understood the importance of COVID-19 vaccinations in preventing the spread of COVID-19 infections, however, a majority of commenters did not recommend the inclusion of this measure for HH QRP and raised several concerns. Specifically, several commenters were concerned about vaccine hesitancy, HHAs' inability to influence measure results based on factors outside of their control. Commenters also noted that the proposed Patient/Resident COVID-19 Vaccine measure has not been fully tested, and encouraged CMS to monitor the measure for unintended consequences and ensure that the measure has meaningful results. One commenter was in support of the proposed Patient/Resident COVID-19 Vaccine measure and provided recommendations for CMS to consider, including an exclusion for medical

<sup>98</sup> National Quality Forum MAP Post-Acute Care/Long Term Care Workgroup Materials. Meeting Summary—MUC Review Meeting. Last accessed March 23, 2023. <https://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=97960>.



contraindications and submitting the measure for CBE endorsement.

Finally, the MAP Coordinating Committee convened on January 24, 2023, and raised concerns which were previously discussed in the PAC/LTC workgroup, such as potential for selection bias based on the patient's vaccination status. CMS noted that this measure does not have exclusions for patient refusals since this is a process measure intended to report raw rates of vaccination, and is not intended to be an HHA action measure. CMS acknowledged that a measure accounting for variables (such as HHA actions to vaccinate patients) could be important, but CMS is focused on a measure which would provide and publicly report vaccination rates for consumers given the importance of this information to patients and their caregivers.

The MAP Coordinating Committee recommended three changes to make the Patient/Resident COVID-19 Vaccine measure acceptable to the Committee: (i) reconsider exclusions for medical contraindications, (ii) complete reliability and validity measure testing, and (iii) seek CBE endorsement. The MAP Coordinating Committee ultimately reached consensus on its voted recommendation of 'Do not support with potential for mitigation.' We refer readers to the final MAP recommendations, titled *2022-2023 MAP Final Recommendations*<sup>99</sup> and the *MAP Final Report*.<sup>100</sup> Despite the Coordinating Committee's vote, we believe it is still important to propose the Patient/Resident COVID-19 Vaccine measure for the HH QRP. As we stated in section III.C.3.e of this proposed rule, we did not include exclusions for medical contraindications because the PFAs we met with told us that a measure capturing raw vaccination rate, irrespective of any medical contraindications, would be most helpful in patient and family/caregiver decision-making. We do plan to conduct reliability and validity measure testing once we have collected enough data, and we intend to submit the proposed measure to the CBE for consideration of endorsement when feasible.

#### e. Quality Measure Calculation

The proposed Patient/Resident COVID-19 Vaccine measure is an assessment-based process measure that reports the percent of home health patients that are up to date on their

COVID-19 vaccinations per CDC's latest guidance.<sup>101</sup> This measure has no exclusions, and is not risk adjusted.

The numerator for this proposed measure would be the total number of home health patients that are up to date with the COVID-19 vaccine during the reporting period. The denominator for the measure would be the total number of home health stays with an End of Care OASIS (Discharge, Transfer or Death at Home) during the reporting period.

The data source for the proposed Patient/Resident COVID-19 Vaccine measure is the OASIS assessment instrument for home health patients. For more information about the proposed data submission requirements, we refer readers to section III.E.2 of this proposed rule. For additional technical information about this proposed measure, we refer readers to the draft measure specifications document titled *Patient-Resident-COVID-Vaccine-Draft-Specs.pdf* available at: <https://www.cms.gov/files/document/patient-covid-vaccine-measure-hh-qrp-specifications.pdf>.

We invite public comments on our proposal to adopt the COVID-19 Vaccine: Percent of Patients/Residents Who Are Up to Date measure beginning with the CY 2025 HH QRP.

#### E. Form, Manner, and Timing of Data Submission Under the HH QRP

##### 1. Proposed Schedule for Data Submission of the Discharge Function Score Measure Beginning With the FY 2025 LTCH QRP

As discussed in section III.C.1. of the proposed rule, we are proposing to adopt the Discharge Function Score quality measure beginning with the CY 2025 HH QRP. If finalized as proposed, HHAs would be required to report these OASIS assessment data beginning with patients discharged between January 1, 2024 and March 31, 2024 for the CY 2025 HH QRP. Starting in CY 2024, HHAs would be required to submit data for the entire calendar year beginning with the CY 2026 HH QRP. Because the Discharge Function Score quality measure is calculated based on data that are currently submitted to the Medicare program, there would be no additional information collection required from HHAs.

We invite public comments on this proposal to require HHAs to report

OASIS assessment data for the Discharge Function Score quality measure beginning with patients discharged between January 1, 2024 and March 31, 2024 for the CY 2025 HH QRP.

##### 2. Proposed Schedule for Data Submission of the COVID-19 Vaccine: Percent of Patients/Residents Who Are Up to Date Beginning With the CY 2026 HH QRP

As discussed in section III.C.3 of the proposed rule, we are proposing to adopt the COVID-19 Vaccine: Percent of Patients/Residents Who Are Up to Date quality measure beginning with the CY 2025HH QRP. If finalized as proposed, HHAs would be required to report these OASIS assessment data beginning with patients discharged between January 1, 2025 and March 31, 2025 for the CY 2025 HH QRP. Starting in CY 2025, HHAs would be required to submit data for the entire calendar year beginning with the CY 2026 HH QRP.

If finalized as proposed, we would revise the OASIS in order for HHAs to submit data pursuant to this finalized policy. A new item would be added to the current item set to collect information on whether a patient is up to date with their COVID-19 vaccine at the time of discharge from the HHA. A draft of the new item is available in the *COVID-19 Vaccine: Percent of Patients/Residents Who Are Up to Date Draft Measure Specifications* at <https://www.cms.gov/files/document/patient-covid-vaccine-measure-hh-qrp-specifications.pdf>.

We invite public comments on this proposal to require HHAs to report OASIS assessment data for the COVID-19 Vaccine: Percent of Patients/Residents Who Are Up to Date quality measure. HHAs would be required to submit data beginning with patients discharged between January 1, 2025 and March 31, 2025 for public reporting of this QM in the CY 2025 HH QRP.

##### 3. Data Elements Proposed for Removal From OASIS-E

CMS plans to remove two OASIS items, the M0110—Episode Timing and M2220—Therapy Needs effective January 1, 2025. These items are no longer used in the calculation of quality measures already adopted in the HH QRP, nor are they being used currently for previously established purposes unrelated to the HH QRP, including payment, survey, the HH VBP Model or care planning.

CMS proposes the removal of items from OASIS-E from the specific time points during a home health episode as outlined in Table C3.

<sup>99</sup> 2022-2023 MAP Final Recommendations, can be found at <https://www.qualityforum.org/map/>.

<sup>100</sup> The Final MAP Report is available at <https://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdIdentifier=id&ItemID=98102>.

<sup>101</sup> The definition of "up to date" may change based on CDC's latest guidelines and can be found on the CDC web page, "Stay Up to Date with COVID-19 Vaccines Including Boosters," at <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html> (updated March 2, 2023).

**TABLE C3— PROPOSED DATA ELEMENTS TO BE REMOVED FROM OASIS-E ON JANUARY 1, 2025**

| OASIS-E item         | Data Elements at Each Time Point |                    |           |                                   |               |  |
|----------------------|----------------------------------|--------------------|-----------|-----------------------------------|---------------|--|
|                      | Start of care                    | Resumption of care | Follow-up | Transfer to an inpatient facility | Death at home | Discharge – not to an inpatient facility |
| M0110 Episode Timing | 1                                | 1                  | 1         |                                   |               |  |
| M2200 Therapy Need   | 1                                | 1                  |           |                                   |               |  |
| Total                | 2                                | 2                  | 1         |                                   |               |  |

A list of the proposed two OASIS items and their data elements are outlined in the Downloads Section of the CMS OASIS Data Sets page located at <https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HomeHealthQualityInits/OASIS-Data-Sets.html>

For a discussion in the reduction in burden associated with the removal of these items, see section IX of this proposed rule.

We invite public comment on our proposal to remove the M0110—Episode Timing and M2200—Therapy Needs items from OASIS–E, effective January 1, 2025.

#### *F. Policies Regarding Public Display of Measure Data for the HH QRP*

##### 1. Background

Section 1899B(g)(1) of the Act requires, in part, that the Secretary provide for public reporting of PAC provider performance, including HHAs, on quality measures under section 1899B(c)(1) of the Act, including by establishing procedures for making available to the public information regarding the performance of individual PAC providers with respect to such measures. Section 1899B(g)(2) requires, in part, that CMS give HHAs opportunity to review and submit corrections to the data and information to be made public under section 1899B(g)(1) prior to such data being made public. Section 1899B(g)(3) of the Act requires that such procedures provide that the data and information with respect to a measure and PAC provider is made publicly available beginning not later than 2 years after the applicable specified application date applicable to such measure and provider. Measure data are currently publicly displayed on the Care Compare website, an interactive web tool that assists individuals by providing information on quality of care. For more information on Care Compare, we refer readers to our website at: <https://www.medicare.gov/care-compare/>.

##### 2. Public Reporting of the Cross-Setting Functional Discharge Measure Beginning With the CY 2025 HH QRP

We are proposing to begin publicly displaying data for the DC Function measure beginning with the January 2025 refresh of Care Compare, or as soon as technically feasible, using data collected from April 1, 2023 through March 31, 2024 (Quarter 2 2023 through Quarter 1 2024). If finalized as proposed, an HHAs DC Function score would be displayed based on four quarters of data. Provider preview reports would be distributed in October 2024, or as soon as technically feasible. Thereafter, an HHA's DC Function score would be publicly displayed based on four quarters of data and updated quarterly. To ensure the statistical reliability of the data, we are proposing that we would not publicly report an HHAs performance on the measure if the HHA had fewer than 20 eligible cases in any quarter. HHAs that have fewer than 20 eligible cases would be distinguished with a footnote that notes that the number of cases/patient stays is too small to report.

We invite public comment on the proposal for the public display of the Discharge Function Score measure beginning with the January 2025 refresh of Care Compare, or as soon as technically feasible.

##### 3. Public Reporting of the Transfer of Health Information to the Patient Post-Acute Care and Transfer of Health Information to the Provider Post-Acute Care Measures Beginning With the CY 2025 HH QRP

We are proposing to begin publicly displaying data for the measures: (1) Transfer of Health (TOH) Information to the Provider—Post-Acute Care (PAC) Measure (TOH-Provider); and (2) Transfer of Health (TOH) Information to the Patient—Post-Acute Care (PAC) Measure (TOH-Patient). We would begin

displaying data with the January 2025 Care Compare refresh or as soon as technically feasible. We adopted these measures in the fiscal year (FY) 2020 IPPS/LTCH Prospective Payment System (PPS) final rule (84 FR 42525 through 42535). In response to the COVID–19 public health emergency (PHE), we released an interim final rule (85 FR 27595 through 27597) which delayed the compliance date for the collection and reporting of the TOH-Provider and TOH-Patient measures. The compliance date for the collection and reporting of the TOH-Provider and TOH-Patient measures was revised to October 1, 2022 in the calendar year (CY) 2022 Home Health PPS Rate Update final rule (86 FR 62386 through 62390). Data collection for these two assessment-based measures began with patients admitted and discharged on or after October 1, 2022.

We are proposing to publicly display data for these two assessment-based measures based on four rolling quarters, initially using discharges from April 1, 2023 through March 31, 2024 (Quarter 2 2023 through Quarter 1 2024), and to begin publicly reporting these measures with the January 2025 refresh of Care Compare, or as soon as technically feasible. To ensure the statistical reliability of the data, we are proposing that we would not publicly report an HHAs performance on the measure if the HHA had fewer than 20 eligible cases in any quarter. HHAs that have fewer than 20 eligible cases would be distinguished with a footnote that notes that the number of cases/patient stays is too small to report.

We invite public comment on our proposal for the public display of the (1) Transfer of Health (TOH) Information to the Provider—Post-Acute Care (PAC) Measure (TOH-Provider) and (2) Transfer of Health (TOH) Information to the Patient—Post-Acute Care (PAC)

Measure (TOH-Patient) assessment-based measures.

#### 4. Public Reporting of the COVID-19 Vaccine: Percent of Patients/Residents Who Are Up to Date Beginning With the CY 2026 HH QRP

We are proposing to begin publicly displaying data for the COVID-19 Vaccine: Percent of Patients/Residents Who Are Up to Date measure beginning with the January 2026 refresh of Care Compare or as soon as technically feasible using data collected for Q2 2024 (April 1, 2024 through June 30, 2024). If finalized as proposed, an HHA's Patient/Resident level COVID-19 Vaccine percent of patients who are up to date would be displayed based on one quarter of data. Provider preview reports would be distributed in October 2025, or as soon as technically feasible. Thereafter, the percent of HHA patients who are up to date with their COVID-19 vaccinations would be publicly displayed based on one quarter of data and updated quarterly. To ensure the statistical reliability of the data, we are proposing that we would not publicly report an HHA's performance on the measure if the HHA had fewer than 20 eligible cases in any quarter. HHAs that have fewer than 20 eligible cases would be distinguished with a footnote that notes that the number of cases/patient stays is too small to report.

We invite public comment on the proposal for the public display of the COVID-19 Vaccine: Percent of Patients/Residents Who Are Up to Date measure beginning with the January 2026 refresh of Care Compare, or as soon as technically feasible.

#### G. Health Equity Update

##### 1. Background

In the CY 2023 Home Health Payment Rate Update proposed rule (87 FR 66866), we included a Request for Information (RFI) on several questions related to a proposed health equity measure concept. CMS defines health equity as “the attainment of the highest level of health for all people, where everyone has a fair and just opportunity to attain their optimal health regardless of race, ethnicity, disability, sexual orientation, gender identity, socioeconomic status, geography, preferred language, or other factors that affect access to care and health outcomes.”<sup>102</sup> CMS is working to advance health equity by designing, implementing, and operationalizing policies and programs that support

<sup>102</sup> Centers for Medicare and Medicaid Services. Available at <https://www.cms.gov/pillar/health-equity>. Accessed February 1, 2023.

health for all the people served by our programs and models, eliminating avoidable differences in health outcomes experienced by people who are disadvantaged or underserved, and providing the care and support that our beneficiaries need to thrive. CMS's goals outlined in the *CMS Framework for Health Equity 2022-2023*<sup>103</sup> are in line with Executive Order 13985, on Advancing Racial Equity and Support for Underserved Communities Through the Federal Government (January 25, 2021).<sup>104</sup> The goals included in the CMS Framework for Health Equity include: strengthening CMS's infrastructure for assessment, creating synergies across the health care system to drive structural change, and identifying and working to eliminate barriers to CMS-supported benefits, services, and coverage.

In addition to the CMS Framework for Health Equity, CMS seeks to “advance health equity and whole-person care” as one of eight goals comprising the CMS National Quality Strategy (NQS).<sup>105</sup> The NQS identifies a wide range of potential quality levers that can support our advancement of equity, including: (1) establishing a standardized approach for resident-reported data and stratification; (2) employing quality and value-based programs to publicly report and incentivize closing equity gaps; and, (3) developing equity-focused performance metrics, regulations, oversight strategies, and quality improvement initiatives. The NQS also acknowledges the contribution of structural racism and other systemic injustices to the persistent disparities that underlie our healthcare system.

Racial disparities in health, in particular, are estimated to cost the U.S. an estimated \$93 billion in excess medical costs and \$42 billion in lost productivity per year, in addition to economic losses due to premature deaths.<sup>106</sup> Racial and ethnic diversity has increased. An increase in the percentage of people who identify as two or more races accounts for most of

<sup>103</sup> <https://www.cms.gov/files/document/cms-framework-health-equity-2022.pdf>.

<sup>104</sup> Executive Order 13985, on “Advancing Racial Equity and Support for Underserved Communities Through the Federal Government,” can be found at: <https://www.whitehouse.gov/briefing-room/presidential-actions/2021/01/20/executive-order-advancing-racial-equity-and-support-for-underserved-communities-through-the-federal-government/>.

<sup>105</sup> Centers for Medicare & Medicaid Services. What is the CMS Quality Strategy? Available at <https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Value-Based-Programs/CMS-Quality-Strategy>.

<sup>106</sup> Ani Turner, The Business Case for Racial Equity, A Strategy for Growth, W.K. Kellogg Foundation and Altarum, April 2018.

the increase in diversity, rising from 2.9 percent to 10.2 percent between 2010 and 2020.<sup>107</sup> Social determinants of health, including social, economic, environmental, and community conditions, may have a stronger influence on the population's health and well-being than services delivered by practitioners and healthcare delivery organizations.<sup>108</sup>

Measure stratification helps identify disparities by calculating quality measure outcomes separately for different beneficiary subpopulations. By looking at measure results for different populations separately, CMS and providers can see how care outcomes may differ between certain patient populations in a way that would not be apparent from an overall score (that is, a score averaged over all beneficiaries). This helps CMS to better fulfill their health equity goals. For example, certain quality measures related to oral healthcare outcomes for children, when stratified by race, ethnicity, and income, show how important health disparities have been narrowed, because outcomes for children in the lowest income households and for Black and Hispanic children improved faster than outcomes for children in the highest income households or for White children.<sup>109</sup> These differences in outcomes would not be apparent without stratification.

Additionally, the RFI solicited public comments on a potential health equity structural composite measure. We refer readers to the CY 2023 Home Health Payment Rate Update final rule (87 FR 66866) for a summary of the public comments and suggestions received in response to the health equity RFI.

We took these comments into account, and we continue to work to develop policies, quality measures, and measurement strategies on this important topic. After considering public comments, CMS decided to convene a health equity technical expert panel to provide additional input to inform the development of health equity quality measures. The work of this technical expert panel is described in detail in the following section.

<sup>107</sup> 2022 National Healthcare Quality and Disparities Report, page 15. Content last reviewed November 2022. Agency for Healthcare Research and Quality, Rockville, MD. <https://www.ahrq.gov/research/findings/nhqrdr/nhqrdr22/index.html>.

<sup>108</sup> 2022 National Healthcare Quality and Disparities Report. Content last reviewed November 2022, page 2. Agency for Healthcare Research and Quality, Rockville, MD. <https://www.ahrq.gov/research/findings/nhqrdr/nhqrdr22/index.html>.

<sup>109</sup> 2022 National Healthcare Quality and Disparities Report, page 6. Content last reviewed November 2022. Agency for Healthcare Research and Quality, Rockville, MD. <https://www.ahrq.gov/research/findings/nhqrdr/nhqrdr22/index.html>.

## 2. Home Health and Hospice Health Equity Technical Expert Panel

To support new health equity measure development, the Home Health and Hospice Health Equity Technical Expert Panel (Home Health & Hospice HE TEP) was convened by a CMS contractor in Fall 2022. The Home Health & Hospice HE TEP comprised health equity experts from hospice and home health settings, specializing in quality assurance, patient advocacy, clinical work, and measure development. The TEP was charged with providing input on a potential cross-setting health equity structural composite measure concept as set forth in the CY 2023 Home Health Payment Rate Update proposed rule (87 FR 66866) as part of an RFI related to the HH QRP Health Equity Initiative. In specific, the TEP assessed the face validity and feasibility of the potential structural measure. The TEP also provided input on possible confidential feedback report options to be used for monitoring health equity. TEP members also had the opportunity to provide ideas for additional health equity measure concepts or approaches to addressing health equity in hospice and home health settings. A summary of the Home Health and Hospice HE TEP meetings and final TEP recommendations are available at <https://mmshub.cms.gov/sites/default/files/HomeHealth-Hospice-Health-Equity-TEP-Report-508c.pdf>.

## 3. Anticipated Future Health Equity Activities

CMS is committed to developing approaches to meaningfully incorporate the advancement of health equity into the HH QRP. We are considering health equity measures used in other settings like those in acute care that further health equity in post-acute care. We realize that the social determinants of health data items in post-acute care under the IMPACT Act of 2014 differ from the SDOH data items in the acute care health equity quality measures. We could consider a future health equity measure like screening for social needs and intervention. With 30 to 55 percent of health outcomes attributed to SDOH,<sup>110</sup> a measure capturing and addressing SDOH could encourage providers to identify specific needs and connect residents with the community resources necessary to overcome social barriers to their wellness. We could specify it using the SDOH data items

that we currently collect as SPADEs on the OASIS. These SDOH data items assess health literacy, social isolation, transportation problems, preferred language (including need or want of an interpreter), race, and ethnicity. These SDOH data items differ from data elements considered as screening items in the acute care settings, which are housing instability, food instability, transportation needs, utility difficulties, and interpersonal safety. This means that we might consider in the future adding the SDOH data items used by acute care providers into the HH QRP as we develop future health equity quality measures under our HH QRP statutory authority. This supports our desire to align quality measures across CMS consistent with the CMS path forward for advancing health equity solutions.<sup>111</sup> Consistent with “The Path Forward: Improving Data to Advance Health Equity Solutions” (CMS OMH, November 2022) we also see value in aligning SDOH data items across all care settings and to the United States Core Data for Interoperability (USCDI) where applicable and appropriate. The USCDI is a standardized set of health data classes and constituent data elements for nationwide, interoperable health information exchange, including data elements and associated vocabulary standards to support computerized, interoperable use of SDOH data.<sup>112</sup>

As we move this important work forward, we will continue to take input from interested parties. As of this publication, the Initial Proposals for Updating OMB’s Race and Ethnicity Statistical Standards, (88 FR 5375), has collected public comment. Additionally, the Office of the National Coordinator for Health IT (ONC) welcomes submissions proposing additional data classes and data elements via the USCDI ONC New Data Element and Class (ONDEC) submission system for future versions of the USCDI.<sup>113</sup> In addition, while some of the anticipated health equity efforts will proceed through the rulemaking process, other activities may be pursued through subregulatory channels, such as Open-Door Forums (ODF), Medicare Learning Network (MLN), and public summary reports such as TEP reports or information gathering reports (IGR).

## H. Proposal To Codify HH QRP Data Completion Thresholds

### 1. Compliance

Section 1895(b)(3)(B)(v)(I) of the Act requires that, for the CY 2007 payment determination and subsequent years, each HHA submit to the Secretary quality data specified by the Secretary in a form and manner, and at a time, specified by the Secretary. As required in accordance with subclause (II) for such a year, for any HHA that does not submit data in accordance with section 1895(b)(3)(B)(v)(I) of the Act with respect to a given calendar year will result in the reduction of the annual home health market basket percentage increase otherwise applicable to an HHA for that calendar year by 2 percentage points. In the CY 2016 HH PPS final rule (80 FR 68703 through 68705), we finalized a proposal to define the quantity of OASIS assessments each HHA must submit to meet the pay-for reporting requirement. We finalized a proposal that would increase the reporting threshold for HHAs over three years, starting with the CY 2017 reporting period. HHAs were required to score at least 70 percent on the Quality Assessment Only (QAO) metric of pay-for-reporting performance requirement for CY 2017 (reporting period July 1, 2015 to June 30, 2016), 80 percent for CY 2018 (reporting period July 1, 2016 to June 30, 2017) and 90 percent for CY 2019 (reporting period July 1, 2017 to June 30, 2018) or be subject to a 2 percentage point reduction to their market basket update for that reporting period. In the 2018 HH PPS final rule (82 FR 51737 through 51738), we proposed to apply the 90 percent threshold requirements established in the CY 2016 HH PPS rule to the submission of standardized patient assessment data beginning with the CY 2019 HH QRP.

### 2. Proposal To Codify HH QRP Data Completion Thresholds

We propose to codify these data completeness thresholds at § 484.245(b)(2)(ii)(A) for measures data collected using the OASIS. Under this section, we propose to codify our requirement that HHAs must meet or exceed a data submission threshold set at 90 percent of all required OASIS and submit the data through the CMS designated data submission systems. This threshold would apply to required quality measures data and standardized patient assessment data collected adopted into the HH QRP. We also propose to codify our policy at § 484.245(b)(2)(ii)(B) that a HHA must meet or exceed this threshold to avoid

<sup>110</sup> World Health Organization (WHO). (n.d.).

Social Determinants of Health. [https://www.who.int/health-topics/social-determinants-of-health#tab=tab\\_1](https://www.who.int/health-topics/social-determinants-of-health#tab=tab_1), accessed February 1, 2023.

<sup>111</sup> <https://www.nejm.org/doi/full/10.1056/NEJMp2215539>, February 1, 2023.

<sup>112</sup> <https://www.healthit.gov/isa/united-states-core-data-interoperability-uscdi>.

<sup>113</sup> <https://www.healthit.gov/isa/ONDEC>.

receiving a 2-percentage point reduction to its annual payment update for a given CY as codified at § 484.225(b).

We invite public comment on our proposal to codify in regulations text the HH QRP data completion thresholds at § 484.245(b)(2)(ii)(A) for measures and standardized patient assessment elements collected using the OASIS and compliance threshold to avoid receiving 2 percentage point reduction as described under § 484.245(b)(2)(ii)(B).

### *I. Principles for Selecting and Prioritizing HH QRP Quality Measures and Concepts Under Consideration for Future Years: Request for Information (RFI)*

#### 1. Background

CMS has established a National Quality Strategy<sup>114</sup> for its quality programs which support a resilient, high-value health care system promoting quality outcomes, safety, equity and accessibility for all individuals. The CMS National Quality Strategy is foundational for contributing to improvements in health care, enhancing patient outcomes, and informing consumer choice. To advance these goals, CMS leaders from across the Agency have come together to move towards a building-block approach to streamline quality measures across CMS quality programs for the adult and pediatric populations. This “Universal Foundation”<sup>115</sup> of quality measures will focus provider attention, reduce burden, identify disparities in care, prioritize development of interoperable, digital quality measures, allow for cross-comparisons across programs, and help identify measurement gaps. The development and implementation of the Preliminary Adult and Pediatric Universal Foundation Measures will promote the best, safest, and most equitable care for individuals as we all come together on these critical quality areas.

In alignment with the CMS National Quality Strategy, the HH QRP endeavors to move towards a more parsimonious set of measures while continually improving the quality of health care for beneficiaries. The purpose of this RFI is to gather input on existing gaps in HH

QRP measures and to solicit public comment on either fully developed HH measures, fully developed measures in other programs that may be appropriate for the HH QRP, and measurement concepts that could be developed into HH QRP measures, to fill these measurement gaps. While we will not be responding to specific comments submitted in response to this RFI in the CY2024 HH PPS final rule, we intend to use this input to inform future policies.

This RFI consists of four sections. The first section is the background. The second section discusses a general framework or set of principles that CMS utilizes to identify future HH QRP measures. The third section draws from an environmental scan conducted to identify HH QRP measurement gaps, and measures or measure concepts that could be used to fill these gaps. The final section solicits public comment on (a) the set of principles for selecting measures for the HH QRP, (b) identified measurement gaps, and (c) measures that are available for immediate use, or that may be adapted or developed for use in the HH QRP.

#### 2. Guiding Principles for Selecting and Prioritizing Measures

CMS has identified a set of principles to guide future HH QRP measure set development and maintenance. These principles are intended to ensure that measures resonate with beneficiaries and caregivers, do not impose undue burden on providers, align with CMS’ post-acute care (PAC) program goals, and can be readily operationalized. Specifically, measures incorporated into the HH QRP should meet the following four objectives:

- **Actionability**—Optimally, HH QRP measures should focus on structural elements, healthcare processes, and outcomes of care that have been demonstrated, such as through clinical evidence or best practices, to be amenable to improvement. In other words, activities or approaches that contribute to improvement on a measure have been established and are feasible for providers to implement.

- **Comprehensiveness and Conciseness**—QRP measures should assess performance of all HH core services using the smallest number of measures that comprehensively assess the value of care provided in HH settings. Parsimony in the QRP measure set minimizes provider burden resulting from data collection and submission.

- **Focus on Provider Responses to Payment**—The HH PPS shapes incentives for care delivery. HH performance measures should neither exacerbate nor induce unwanted

responses to the payment systems. As feasible, measures should identify and mitigate adverse incentives of the payment system.

- **Alignment with CMS Statutory Requirements and Key Program Goals**—Measures must align with CMS statutory requirements, such as the IMPACT Act of 2014 and the Meaningful Measures Framework as well as align across PAC programs where possible.

#### 3. Gaps in HH QRP Measure Set Identified by Environmental Scan and Potential New Measures

CMS conducted an environmental scan that utilized the previous-listed principles to guide the identification of gaps in the HH QRP. Measurement gaps were identified in the domains of cognitive function, behavioral and mental health, and chronic conditions and pain management. We discuss each of these in more detail in the next section.

##### a. Cognitive Function

Conditions associated with limitations in cognitive function, which may include stroke, traumatic brain injuries, dementia, and Alzheimer’s disease, as well as intellectual and developmental disabilities (I/DD) affect an individual’s ability to think, reason, remember, problem-solve, and make decisions. The IMPACT Act identifies cognitive function as a key quality measure domain, and an area for inclusion as a standardized assessment data element.

Two sources of information on cognitive function currently collected in HHAs are the Brief Interview for Mental Status (BIMS) and Confusion Assessment Method (CAM©).<sup>116</sup> Both the BIMS and CAM have been incorporated into the OASIS. Scored by providers via direct observation, the BIMS is used to determine orientation and the ability to register and recall new information. The CAM assesses the presence of inattention, disorganized thinking, and level of consciousness.

The BIMS and CAM include items representing different aspects of cognitive function, from which quality measures may be constructed. Although these instruments have been subjected to feasibility, reliability, and validity testing, additional development and testing would be required prior to transforming the concepts reflected in the BIMS and CAM (for example,

<sup>114</sup> Schreiber M, Richards A, Moody-Williams J, Fleisher L. The CMS National Quality Strategy: a person-centered approach to improving quality. Centers for Medicare and Medicaid Services. June 6, 2022. Available at: <https://www.cms.gov/blog/cms-national-quality-strategy-person-centered-approach-improving-quality>. opens in new tab.

<sup>115</sup> Jacobs D, Schreiber M, Seshamani M, Tsai D, Fowler E, Fleisher L. Aligning Quality Measures across CMS—The Universal Foundation. *N Engl J Med* 2023; 338:776–779. DOI: 10.1056/NEJMp2215539.

<sup>116</sup> Centers for Medicare & Medicaid Services. Outcome and Assessment Information Set (OASIS–E) Data Set. Effective January 1, 2023. <https://www.cms.gov/medicare/quality-initiatives-patient-assessment-instruments/homehealthqualityinits/oasis-data-sets>.

temporal orientation, recall) into fully specified measures for implementation in the HH QRP.

This RFI is requesting comment on cognitive functioning measures that may be available for immediate use, or that may be adapted or developed for use in the HH QRP, using the BIMS or the CAM. In addition to comment on specific measures and instruments, CMS seeks input on the feasibility of measuring improvement in cognitive functioning during a HH stay, which typically averages 56 days;<sup>117</sup> the cognitive skills (for example, executive functions) that are more likely to improve during an HHA stay; conditions for which measures of maintenance—rather than improvement in cognitive functioning—are more practical; and the types of intervention that have been demonstrated to assist in improving or maintaining cognitive functioning.

#### b. Behavioral and Mental Health

Estimates suggest that one in five Medicare beneficiaries have a “common mental health disorder” and nearly 8% have a serious mental illness.<sup>118</sup> Behavioral and mental health includes substance use disorders (SUD), which are understudied in PAC.<sup>119</sup> Research using National Survey on Drug Use and Health 2015–2019 data estimated that 1.7 million Medicare beneficiaries, or 8 percent of those aged less than 65 years and 2 percent of those aged 65 years and older, had a past-year substance use disorder, 77 percent attributed to alcohol and 16 percent attributed to prescription drugs.<sup>120</sup> In some instances, such as following an ischemic stroke or a new diagnosis of a chronic condition such as diabetes, patients may develop depression, anxiety, or SUD. In other instances, patients may have been dealing with mental or behavioral health issues long before their post-acute admission. Left unmanaged, however, these conditions make it difficult for affected patients to actively participate in their rehabilitation and

treatment regimen, thereby contributing to poor health outcomes.

Information on the availability and appropriateness of behavioral and mental health measures in PAC is limited, and the 2021 National Impact Assessment of the CMS Quality Measures Report<sup>121</sup> identified PAC program measurement gaps in the areas of behavioral and mental health. Among the mental health quality measures in current use, the HH QRP uses a quality measure, “Depression Assessment Conducted” which is described as “How often the home health team check patients for depression” (CMS ID 0198–10). The measure was removed from Care Compare—Home Health in July 2021. Although it may be possible to adapt this measure for use in other PAC settings, this process measure does not directly assess performance in the management of depression and related mental health concerns.

Information on behavioral and mental health currently collected in HHAs is the Patient Mood Interview (PHQ–2 to 9), a validated interview that screens for symptoms of depression, and provides a standardized severity score and a rating for evidence of a depressive disorder. The PHQ–2 to 9 identifies signs and symptoms of mood distress, a serious condition that is underdiagnosed and undertreated in home health and is associated with significant morbidity. There is currently no information on substance use disorder collected in HHAs.

The PHQ–2 to 9 represents one mental health condition, from which quality measures may be constructed. Although this instrument has been subjected to feasibility, reliability, and validity testing, additional development and testing would be required prior to transforming the concepts reflected in the PHQ–2 to 9 into fully specified measures for implementation in the HH QRP.

This RFI is requesting comment on behavioral and mental health measures that may be available for immediate use, or that may be adapted or developed for use in the HH QRP, using the PHQ–2 to 9. In addition to comment on specific measures and instruments, CMS seeks input on the feasibility of measuring improvement in depressive symptoms during a HH stay, which typically

averages 56 days;<sup>122</sup> the symptoms that are more likely to improve during an HHA stay; and the types of intervention that have been demonstrated to assist in improving depressive symptoms.

CMS seeks feedback on behavioral and mental health, including substance use disorder, measures or instruments that may be directly applied, adapted, or developed for use in the HH QRP. Further, CMS seeks comment on the degree to which measures have been or will require validation and testing prior to application in the HH QRP. Input on the availability of data, the manner in which data could be collected and reported to CMS, and the burden imposed on providers is also sought.

#### c. Chronic Conditions and Pain Management

Despite the availability of measures focused on core HHA clinical care services and, specifically, Improvement in Management of Oral Medications CBE #0176 (CMS ID 0189–11) and Improvement on Dyspnea CBE #0179 (CMS ID 0187–11). HH QRP measures do not directly address aspects of care rendered to populations with chronic conditions, such as chronic kidney disease or cardiovascular disease. Another example of a service area for which existing measures could more adequately capture HHA actions concisely is pain management. Even though pain has been demonstrated to contribute to falls with major injury and restrictions in mobility and daily activity, a host of other factors also contribute to these measure domains, making it difficult to directly link provider actions to performance. Instead, a measure of provider actions in reducing pain interference in daily activities, including the ability to sleep, would be a more concise measure of pain management. Beginning January 1, 2023, HHAs began collecting new standardized patient assessment data elements, including items that assess pain interference with (1) daily activities, (2) sleep, and (3) participation in therapy, providing an opportunity to develop more concise measures of provider performance.

Through this RFI CMS is seeking input on measures of chronic condition and pain management that may be used to assess HHA performance. Additionally, CMS seeks general comment on the feasibility and challenges of measuring and reporting HHA performance on existing QRP measures, such as Discharge to the

<sup>117</sup> Based on home health episodes ending in CY2021 (the most recent year for which complete data are available).

<sup>118</sup> Figueroa J, Phelan J, Orav E, Patel V, Jha A. Association of mental health disorders with health care spending in the Medicare population. *JAMA Network Open* 2020;3(3):e201210.

<sup>119</sup> Desai A, Grossberg G. Substance Use Disorders in Postacute and Long-Term Care Settings. *Psychiatr Clin North Am.* 2022 Sep;45(3):467–482.

<sup>120</sup> Parish W, Mark T, Weber E, Steinberg D. Substance Use Disorders Among Medicare Beneficiaries: Prevalence, Mental and Physical Comorbidities, and Treatment Barriers. *Am J Prev Med* 2022 Aug;63(2):225–232. Doi: 10.1016/j.amepre.2022.01.021.

<sup>121</sup> Centers for Medicare & Medicaid Services. 2021 National Impact Assessment of the Centers for Medicare & Medicaid Services (CMS) Quality Measures Report. June 2021. <https://www.cms.gov/files/document/2021-national-impact-assessment-report.pdf>.

<sup>122</sup> Based on home health episodes ending in CY2021 (the most recent year for which complete data are available).

Community (CBE #3479) and Potentially Preventable 30-day post-discharge readmissions, for subgroups of patients defined by type of chronic condition. For example, measures could assess rates of discharge to community or 30-day post-discharge readmissions among patients admitted to an HHA with chronic obstructive pulmonary disease (COPD) or chronic renal failure.

#### e. Solicitation of Public Comment

We invite general comment on the principles for identifying HH QRP measures, as well as additional beliefs about measurement gaps, and suitable measures for filling these gaps. Specifically, we solicit comment on the following questions:

- Principles for Selecting and Prioritizing HH QRP Measures
  - ++ To what extent do you agree with the principles for selecting and prioritizing measures?
  - ++ Are there principles that you believe CMS should eliminate from the measure selection criteria?
  - ++ Are there principles that you believe CMS should add to the measure selection criteria?
  - ++ How can CMS best consider equity in measures?

- HH QRP Measurement Gaps
  - ++ CMS requests input on the identified measurement gaps, including in the areas of cognitive function, behavioral and mental health, and chronic conditions and pain management.

- ++ Are there gaps in the HH QRP measures that have not been identified in this RFI?

- Measures and Measure Concepts Recommended for Use in the HH QRP
  - ++ Are there measures that you believe are either currently available for use, or that could be adapted or developed for use in the HH QRP program to assess performance in the areas of: (1) cognitive functioning; (2) behavioral and mental health; (3) chronic conditions; (4) pain management; or (5) other areas not mentioned in this RFI?

CMS also seeks input on data available to develop measures, approaches for data collection, perceived challenges, or barriers, and approaches for addressing challenges.

## IV. Proposed Changes to the Expanded Home Health Value-Based Purchasing (HHVBP) Model

### A. Background

As authorized by section 1115A of the Act and finalized in the CY 2016 HH PPS final rule (80 FR 68624), the Center for Medicare and Medicaid Innovation

(Innovation Center) implemented the Home Health Value-Based Purchasing (HHVBP) Model (“original Model”) in nine states on January 1, 2016. The design of the original HHVBP Model leveraged the successes and lessons learned from other CMS value-based purchasing programs and demonstrations to shift from volume-based payments to a model designed to promote the delivery of higher quality care to Medicare beneficiaries. The specific goals of the original HHVBP Model were to—

- Provide higher incentives for better quality care with greater efficiency;
- Study new potential quality and efficiency measures for appropriateness in the home health setting; and,
- Enhance the current public reporting process.

The original HHVBP Model resulted in an average 4.6 percent improvement in HHAs’ total performance scores (TPS) and an average annual savings of \$141 million to Medicare without evidence of adverse risks.<sup>123</sup> The evaluation of the original Model also found reductions in unplanned acute care hospitalizations and skilled nursing facility (SNF) stays, resulting in reductions in inpatient and SNF spending. The U.S. Secretary of Health and Human Services determined that expansion of the original HHVBP Model would further reduce Medicare spending and improve the quality of care. In October 2020, the CMS Chief Actuary certified that expansion of the HHVBP Model would produce Medicare savings if expanded to all states.<sup>124</sup>

On January 8, 2021, CMS announced the certification of the HHVBP Model for expansion nationwide, as well as the intent to expand the Model through notice and comment rulemaking.<sup>125</sup>

In the CY 2022 HH PPS final rule (86 FR 62292 through 62336) and codified at 42 CFR part 484 subpart F, we finalized the decision to expand the HHVBP Model to all Medicare certified HHAs in the 50 States, territories, and District of Columbia beginning January 1, 2022. CY 2022 was a pre-implementation year. During CY 2022, CMS provided HHAs with resources and training, to allow HHAs time to prepare and learn about the expectations and requirements of the expanded HHVBP Model without risk to payments. We finalized that the

expanded Model will generally use benchmarks, achievement thresholds, and improvement thresholds based on CY 2019 data to assess achievement or improvement of HHA performance on applicable quality measures and that HHAs will compete nationally in their applicable size cohort, smaller-volume HHAs or larger-volume HHAs, as defined by the number of complete unique beneficiary episodes for each HHA in the year prior to the performance year. All HHAs certified to participate in the Medicare program prior to January 1, 2022, will be required to participate and will be eligible to receive an annual Total Performance Score based on their CY 2023 performance.

We finalized the quality measure set for the expanded Model, as well as policies related to the removal, modification, and suspension of applicable measures, and the addition of new measures and the form, manner and timing of the OASIS-based, Home Health Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey-based, and claims-based measures submission in the applicable measure set beginning in CY 2022 and subsequent years. We also finalized an appeals process, an extraordinary circumstances exception policy, and public reporting of annual performance data under the expanded Model.

Additionally, in the CY 2022 HH PPS final rule (86 FR 62312), we summarized and responded to comments received on the challenges unique to value-based purchasing frameworks in terms of health equity and ways in which we could incorporate health equity goals into the expanded HHVBP Model. Comments received were related to the use of stabilization measures to promote access to care for individuals with chronic illness or limited ability to improve; collection of patient level demographic information for existing measures; and stratification of outcome measures by various patient populations to determine how they are affected by social determinants of health (SDOH).

In the CY 2023 HH PPS final rule (87 FR 66869 through 66876), we finalized our policy to replace the term *baseline year* with the terms *HHA baseline year* and *Model baseline year*, and to change the calendar years associated with each of those baseline years. Specifically, we changed the HHA baseline year for the CY 2023 performance year from 2021 to 2022 for “new” HHAs with CMS certification numbers (CCNs) with effective dates prior 2022, and the Model baseline year from CY 2019 to CY

<sup>123</sup> <https://innovation.cms.gov/data-and-reports/2020/hhvp-thirdann-rpt>.

<sup>124</sup> <https://www.cms.gov/files/document/certification-home-health-value-based-purchasing-hhvpmodel.pdf>.

<sup>125</sup> <https://www.cms.gov/newsroom/press-releases/cms-takes-action-improve-home-health-care-seniors-announces-intent-expand-home-health-value-based>.

2022 starting in CY 2023. Additionally, we summarized the comments received on future approaches to health equity (HE) in the expanded HHVBP Model. Comments received were related to the support of addressing health equity, potential unintended consequences, thorough consideration and testing of potential HE measures, data collection and, applying HE data to the expanded Model’s cohorts and risk adjustment models.

*B. Proposed Changes to the Applicable Measure Set*

We are proposing to make changes to the applicable measure set. First, we are proposing to codify the HHVBP measure removal factors effective in CY 2024. Second, we are proposing to remove five measures from the current applicable measure set and add three measures starting in CY 2025. Third, due to the net change in the number of measures proposed, we are proposing to adjust the weights for the measures in the OASIS-based and claims-based measure categories starting in CY 2025. Lastly, we are proposing to update the Model baseline year for all measures starting in CY 2025.

1. Codification of the HHVBP Measure Removal Factors

In the CY 2022 HH PPS final rule (86 FR 62312), we stated that removal of an expanded HHVBP Model measure would take place through notice and comment rulemaking. In that same final rule (86 FR 62311 through 62312), we adopted eight measure removal factors that we consider when determining whether to remove measures from the expanded HHVBP Model’s applicable measure set:

- Factor 1. Measure performance among HHAs is so high and unvarying that meaningful distinctions in improvements in performance can no longer be made (that is, topped out).
- Factor 2. Performance or improvement on a measure does not result in better patient outcomes.
- Factor 3. A measure does not align with current clinical guidelines or practice.
- Factor 4. A more broadly applicable measure (across settings, populations, or conditions) for the particular topic is available.
- Factor 5. A measure that is more proximal in time to desired patient outcomes for the particular topic is available.
- Factor 6. A measure that is more strongly associated with desired patient

outcomes for the particular topic is available.

- Factor 7. Collection or public reporting of a measure leads to negative unintended consequences other than patient harm.

- Factor 8. The costs associated with a measure outweigh the benefit of its continued use in the program.

To be consistent with the HH QRP and other quality reporting programs (that is SNF QRP, IRF QRP, and LTCH QRP) we propose to codify the eight HHVBP measure removal factors for the expanded Model at § 484.380.

We invite public comments on this proposal.

2. Changes to the Applicable Measure Set

a. Background

In the CY 2022 HH PPS final rule (86 FR 66308 through 66310), we finalized the applicable measure set effective in the CY 2022 pre-implementation year and subsequent years, which includes five OASIS-based measures, two claims-based measures, and five HHCAPHS Survey-based measures (see Table D1). Details of these measures were included in Tables 26 and 27 of the CY 2022 HH PPS proposed rule (86 FR 35923 through 35926).

**TABLE D1: CURRENT MEASURE SET FOR THE EXPANDED HHVBP MODEL**

| Measure Category     | Measure Full Title/Short Form Name (if applicable)  |
|----------------------|---|
| OASIS-based          | Improvement in Dyspnea/Dyspnea  |
| OASIS-based          | Discharged to Community   |
| OASIS-based          | Improvement in Management of Oral Medications/Oral Medication                                   |
| OASIS-based          | Total Normalized Composite Change in Mobility/TNC Mobility                                      |
| OASIS-based          | Total Normalized Composite Change in Self- Care/TNC Self-Care                                   |
| Claims-based         | Acute Care Hospitalization During the First 60 Days of Home Health Use/ACH                      |
| Claims-based         | Emergency Department Use without Hospitalization During the First 60 Days of Home Health/ED Use |
| HHCAPHS Survey-based | Care of Patients/Professional Care  |
| HHCAPHS Survey-based | Communications Between Providers and Patients/Communication                                     |
| HHCAPHS Survey-based | Specific Care Issues/Team Discussion  |
| HHCAPHS Survey-based | Overall Rating of Home Health Care/Overall Rating   |
| HHCAPHS Survey-based | Willingness to Recommend the Agency/Willing to Recommend  |

In that same final rule (86 FR 62310 through 62313), we finalized that, during the expanded Model, we would address any needed adjustments or modifications to the applicable measure set; this process involves notice and comment rulemaking for removing or adding measures and for adopting changes to measures that we consider to substantially change the nature of the measure. We also post the names of any measures added to the expanded Model finalized through the rulemaking process on the CMS website by the first

December 1 upon publication of the applicable final rule. Examples of changes that we might consider to be substantive would be those in which the changes are so significant that the measure is no longer the same measure, or when a standard of performance assessed by a measure becomes more stringent, such as changes in acceptable timing of medication, procedure/ process, test administration, or expansion of the measure to a new setting. If an update to a measure is necessary in a manner that we consider

to not substantially change the nature of the measure, we will use a subregulatory process to incorporate those updates to the measure specifications that apply to the program. Specifically, we would revise the information that is posted on the CMS website so that it clearly identifies the updates and provides links to where additional information on where the updates can be found.

We have determined that five of the measures finalized in the CY 2022 HH PPS final rule require further



consideration. Specifically, we are proposing to remove the following measures from the applicable measure set: (1) OASIS-based Discharged to Community (DTC); (2) OASIS-based Total Normalized Composite Change in Self-Care (TNC Self-Care); (3) OASIS-based Total Normalized Composite Change in Mobility (TNC Mobility); (4) claims-based Acute Care Hospitalization During the First 60 Days of Home Health Use (ACH); and (5) claims-based Emergency Department Use without Hospitalization During the First 60 Days of Home Health (ED Use).

We propose to replace these five measures with three measures (see Table D2). Specifically, we are

proposing to add the following measures: (1) the claims-based Discharge to Community-Post Acute Care (DTC-PAC) Measure for Home Health Agencies; (2) the OASIS-based Discharge Function Score (DC Function) measure; and (3) the claims-based Home Health Within-Stay Potentially Preventable Hospitalization (PPH) measure. The claims-based DTC-PAC measure would replace the OASIS-based DTC measure. The OASIS-based DC Function measure would replace the two OASIS-based TNC measures (Self-Care and Mobility). The claims-based PPH measure would replace the claims-based ACH and ED Use measures.

We are proposing to make these changes to the applicable measure set beginning with the CY 2025 performance year and subsequent performance years. The proposed changes will align the measures used in the expanded HHVBP Model with the measures in the HH QRP and publicly reported on Home Health Care Compare. This alignment will support comparisons of provider quality and streamline home health providers' data capture and reporting processes. Table D2 summarizes the proposed applicable measure set that would be effective for the CY 2025 performance year (CY 2027 payment year).

**BILLING CODE 4120-01-P**

**TABLE D2: PROPOSED MEASURE SET FOR THE EXPANDED HHVBP MODEL**

| Measure Full Title/Short Form Name (if applicable)                               | Measure Type | Data Source   | Numerator  | Denominator  | Current | Proposed |
|--|--------------|---|--|--|---------|----------|
| Improvement in Dyspnea/Dyspnea <sup>1</sup>                                      | Outcome      | OASIS (M1400)<br>(M2420)<br>(M0100)   | Number of home health quality episodes where the discharge assessment indicates less dyspnea at discharge than at start (or resumption) of care.   | Number of home health quality episodes ending with a discharge during the reporting period, other than those covered by generic or measure-specific exclusions (see note 1). | X       |          |
| Improvement in Management of Oral Medications/Oral Medication <sup>1</sup>       | Outcome      | OASIS (M2020)<br>(M1700)<br>(M1710)<br>(M1720)<br>(M2420)<br>(M0100)  | Number of home health quality episodes where the value recorded on the discharge assessment indicates less impairment in taking oral medications correctly at discharge than at start (or resumption) of care.   | Number of home health quality episodes ending with a discharge during the reporting period, other than those covered by generic or measure-specific exclusions (see note 1). | X       |          |
| Discharge Function Score/DC Function <sup>2</sup>                                | Outcome      | OASIS<br>(GG Item Set)  | Number of home health episodes with an observed discharge function score that is equal to or higher than the calculated expected discharge function score.   | Number of home health episodes of care ending with a discharge during the reporting period, other than those covered by generic or measure-specific exclusions.              |         | X        |
| Home Health Within-Stay Potentially Preventable Hospitalization/PHH <sup>3</sup> | Outcome      | CCW (Claims)  | Number of patients with at least one potentially preventable hospitalization (that is, in an ACIL/TCH) or observation stay during the IHI stay. For the Potentially Preventable Hospitalization measure, a stay is a sequence of HH payment episodes by at least two days, episodes separated from other HH payment episodes by at least 2 days. | All Medicare Fee-for-Service patients in the IHI setting that do not meet the exclusion criteria.  |         | X        |
| Discharge to Community/DTC-PAC <sup>4</sup>                                      | Outcome      | CCW (Claims)  | Number of home health stays for patients who have a Medicare PFS claim with Patient Discharge Status codes 01 and 81, do not have an unplanned admission to an acute care hospital or LTCH in the 31-day post-discharge observation window, and who remain alive during the post-discharge observation window.                                   | Number of home health stays that begin during the 2-year observation period.   |         | X        |
| Care of Patients/Professional Care <sup>5</sup>                                  | Outcome      | Home Health Consumer Assessment<br>Healthcare Providers and Systems<br>(HHCAHPS) Survey; the component questions for this measure are Q9, Q16, Q19, and Q24 | Numerator details are included in the link provided in note 5.   | Denominator details are included in the link provided in note 5.   | X       |          |
| Communications Between Providers and Patients/Communication <sup>5</sup>         | Outcome      | HHCAHPS Survey; the component questions for this measure are Q2, Q15, Q17, Q18, Q22, and Q23.   | Numerator details are included in the link provided in note 5.   | Denominator details are included in the link provided in note 5.   | X       |          |
| Specific Care Issues/Team Discussion <sup>5</sup>                                | Outcome      | HHCAHPS Survey; the component questions for this measure are Q3, Q4, Q5, Q10, Q12, Q13, and Q14   | Numerator details are included in the link provided in note 5.   | Denominator details are included in the link provided in note 5.   | X       |          |
| Overall Rating of Home Health Care/Overall Rating <sup>5</sup>                   | Outcome      | HHCAHPS Survey; the component question for this measure is Q20  | Numerator details are included in the link provided in note 5.   | Denominator details are included in the link provided in note 5.   | X       |          |
| Willingness to Recommend the Agency/Willingness to Recommend <sup>6</sup>        | Outcome      | IHCAIPS Survey; the component question for this measure is Q25  | Numerator details are included in the link provided in note 5.   | Denominator details are included in the link provided in note 5.   | X       |          |

**Notes:**

- <sup>1</sup> <https://www.cms.gov/files/document/home-health-outcome-measures-table-osis-e2023.pdf>
- <sup>2</sup> <https://www.cms.gov/files/document/hh-discharge-function-score-measure-technical-report.pdf>
- <sup>3</sup> <https://www.cms.gov/files/document/hh-qrp-specificationspotentialpreventablehospitalizations.pdf>
- <sup>4</sup> <https://www.cms.gov/files/document/home-health-outcome-measures-table-osis-e2023.pdf>
- <sup>5</sup> [https://homehealthhhs.org/Portals/0/HHCAHPS\\_steps\\_calculate\\_composites.pdf?ver=7PCs8ovwE7U9VewwEhXVg%3d%3d](https://homehealthhhs.org/Portals/0/HHCAHPS_steps_calculate_composites.pdf?ver=7PCs8ovwE7U9VewwEhXVg%3d%3d)

b. Changes to the Applicable Measure Set

We propose to make all changes to the applicable measure set discussed in this rule beginning with the CY 2025 performance year, thus all changes will affect the same payment year beginning with the CY 2027 payment year.

(1) Proposal To Replace the OASIS-Based DTC Measure With the Claims-Based DTC-PAC Measure Beginning CY 2025

We propose to replace the current OASIS-based DTC measure with the claims-based DTC-PAC measure. The claims-based DTC-PAC measure assesses successful discharge to the community from an HHA, with successful discharge to the community including no unplanned re-hospitalizations and no death in the 31 days following discharge. This measure was adopted as part of the Home Health Quality Reporting Program (HH QRP) in the CY 2017 HH PPS final rule (81 FR 76765 through 76770). Details about the measure can be found in the CY 2017 HH PPS final rule (81 FR 76765 through 76770) and the CY 2018 HH PPS final rule (84 FR 60564 through 60566). One difference between the current OASIS-based DTC measure and the proposed claims-based DTC-PAC measure is the time period of the measure. The proposed claims-based DTC-PAC measure uses two years of claims data, whereas the current OASIS-based DTC measure uses one year of OASIS data. Furthermore, the claims-based DTC-PAC measure is aligned across PAC settings in terms of risk-adjustment, exclusions, numerator, and measure intent, whereas the OASIS-based DTC measure is not aligned. Therefore, making the replacement is in accordance with Measure Removal Factor 4: A more broadly applicable measure (across settings, populations, or conditions) for the particular topic is available. Additionally, the replacement would further align the expanded HHVBP Model applicable measure set with the HH QRP measures. The HH QRP added the claims-based DTC measure in 2017 and stopped publicly reporting the OASIS-based DTC measure in 2017. The proposed use of the claims-based DTC-PAC measure has additional benefits as compared to the current OASIS-based DTC measure in that it assesses broader outcomes by assessing post-discharge hospitalization and mortality. Specifically, it first examines whether a patient was discharged to the community from the PAC setting. For patients discharged to the community, this measure examines

whether they remained alive in the community without an unplanned admission to an acute care hospital or LTCH in the 31-day post-discharge observation window following discharge to the community.

(2) Proposal to Jointly Replace the OASIS-Based TNC Self-Care and TNC Mobility Measures With the OASIS-Based Discharge Function Score Measure Beginning CY 2025

We propose to jointly replace the TNC Self-Care and TNC Mobility measures with the DC Function measure. We adopted the TNC Self-Care and TNC Mobility measures in the CY 2019 HH PPS final rule (83 FR 56529 through 56535) for use in the original Model beginning with performance year 4 (CY 2019). The TNC measures, which are composite measures, replaced three individual measures (Improvement in Bathing, Improvement in Bed Transferring, and Improvement in Ambulation-Locomotion). For these composite measures, HHA performance on the three mobility OASIS-items are included in the TNC measures. The TNC measures also include six additional activities of daily living (ADL) measures to create a more comprehensive assessment of HHA performance across a broader range of patient ADL outcomes. The TNC measures report the magnitude of patient change (either improvement, no change, or decline) across six self-care and three mobility patient functional activities. This methodology accounts for changes to the scores on individual OASIS items while also considering that not all patients are able to improve on all aspects of each composite measure. The DC Function measure determines how successful each HHA is at achieving an expected level of functional ability for its patients at discharge. An expectation for discharge function score is built for each HHA episode by accounting for patient characteristics that impact their functional status. The final DC Function measure for a given HHA is the proportion of that HHA's episodes where a patient's observed discharge score meets or exceeds their expected discharge score. Functional status is measured through Section GG of OASIS assessments, which are cross-setting items. Section GG evaluates a patient's capacity to perform daily activities related to three self-care (GG0130) activities and eight mobility (GG0170) activities.

The DC Function measure has been proposed for adoption in all PAC settings. We included the proposed DC Function measure on the 2022 Measure

Under Consideration (MUC) list for the Inpatient Rehabilitation Facility QRP, Home Health QRP, Long Term Care Hospital QRP, SNF QRP, and SNF VBP.<sup>126</sup> It is proposed for the Skilled Nursing Facility (SNF) Value-Based Purchasing program in the FY 2024 SNF PPS proposed rule and in this CY 2024 HH PPS proposed rule for adoption in the HH QRP beginning CY 2025; details about the measure can be found in section III.D. of this proposed rule. We propose adopting the measure for the expanded HHVBP Model on the same timeline as the HH QRP (CY 2025) given that the GG items used in the measure have gone through extensive testing, and the measure has received conditional support for rulemaking as part of the most recent Measure Applications Partnership (MAP) process. While the DC Function measure is not yet implemented in the HH QRP or other PAC programs, the OASIS data elements used to calculate this measure have been collected since 2019. As such, we believe HHAs have had sufficient time to ensure successful reporting of the data elements needed for this measure.

Replacement of the TNC measures with the DC Function measure would further align the expanded HHVBP Model measure set with the HH QRP measures, as well as with other PAC settings. For these reasons, this replacement is in accordance with Measure Removal Factor 4. Additionally, the DC Function measure addresses self-care and mobility through a single measure rather than two measures, thereby streamlining the calculation and reporting of measure results.

(3) Proposal to Jointly Replace the Acute Care Hospitalization During the First 60 Days of Home Health Measure and Emergency Department Use Without Hospitalization During the First 60 Days of Home Health Measure With the Home Health Within Stay Potentially Preventable Hospitalization (PPH) Measure Beginning CY 2025

We propose to jointly replace the Acute Care Hospitalization During the First 60 Days of Home Health Measure ("ACH" measure) and Emergency Department Use Without Hospitalization During the First 60 Days of Home Health Measure ("ED Use" measure) with the Home Health Within Stay Potentially Preventable Hospitalization (PPH) Measure. The

<sup>126</sup> See CMS, Measures Under Consideration List for 2022 (Dec. 1, 2022), available at <https://mmshub.cms.gov/sites/default/files/2022-MUC-List.xlsx>.

current specifications for the PPH measure are available on the CMS website at <https://www.cms.gov/files/document/hh-qrp-specificationspotentiallypreventablehospitalizations.pdf>.

The CY 2022 HH PPS final rule (86 FR 62340 through 62345) finalized the joint replacement of the ACH measure and ED Use measure with the PPH measure in the HH QRP beginning CY 2023. This replacement under the HH QRP was made under Measure Removal Factor 6: A measure that is more strongly associated with desired patient outcomes for the particular topic is available. Additional details of the reason for replacement are found in the CY 2022 HH PPS final rule (86 FR 62340 through 62345). Because these measures have been finalized to be jointly replaced with the PPH measure in the HH QRP beginning CY 2023, we are proposing to remove them from the expanded HHVBP Model.

In the CY 2022 HH PPS proposed rule (86 FR 35929), we requested comments on whether we should align the expanded HHVBP Model with the proposed changes for the HH QRP by proposing to remove the same two measures (“ACH” and “ED Use” measures) from the expanded Model in a future year. As summarized in the CY 2022 HH PPS final rule (86 FR 62312), the feedback was generally supportive,

recommending that the expanded HHVBP Model’s applicable measure set align with the HH QRP measures. Replacing ACH and ED Use with PPH would further align the expanded Model’s applicable measure set with the HH QRP measures.

We propose no changes to the five HHCAHPS Survey-based measures used for the expanded HHVBP Model.

We invite public comments on these proposals.

### 3. Measure Categories

As shown in Table D3, the expanded Model utilizes established measure categories that represent the data sources including OASIS-based, claims-based, and HHCAHPS Survey-based. Although measures in the original Model have been added, removed or substituted in the past, the measure category weights have remained constant, maintaining the weighting proportions of 35 percent, 35 percent and 30 percent for OASIS-based, claims-based and HHCAHPS Survey-based measures for the larger-volume cohort, respectively. For HHAs in the smaller-volume cohort, the weighting proportions of the OASIS-based and claims-based measures are 50 percent and 50 percent, respectively. Weights for individual measures within these categories have changed in the past due to changes to the applicable measure set (for example, replacing three individual

OASIS-based measures with the two TNC measures) and to encourage improvement in the claims-based measures. With the proposed changes to the applicable measures in this proposed rule, the number of measures within the OASIS-based measure category would change. Table D3 illustrates the change in the measure set including the removal of the OASIS-based DTC measure, the replacement of the two OASIS-based TNC change measures to the OASIS-based DC Function measure, and the replacement of the claims-based Acute Hospitalization Measure and claims-based ED Use Measure for the claims-based PPH measure. Despite the changes to the applicable measure set, we intend to maintain the existing measure categories and their relative weights. For example, for the larger-volume cohort, the claims-based measures would continue to have a total weight of 35 percent. The relatively higher weight given to the claims-based measures reflects our belief in the importance of those measures relative to OASIS-based measures, which use self-reported data and that the incentive to reduce hospital utilization is maintained. We continually monitor the effects of weighting and will propose changes if we determine there is a need through future rulemaking.

**BILLING CODE 4120-01-P**

**TABLE D3. CURRENT AND PROPOSED MEASURE CATEGORY WEIGHTS BY QUALITY MEASURE IN THE EXPANDED HHVBP MODEL**

| Measure  | Measure Weights      |                |                       |                |
|--|----------------------|----------------|-----------------------|----------------|
|  | Larger-Volume Cohort |                | Smaller-Volume Cohort |                |
|  | Current              | Proposed       | Current               | Proposed       |
| <b>OASIS-based Measures</b>                          |                      |                |                       |                |
| Discharged to Community (OASIS-based)                | X                    | -              | X                     | -              |
| Improvement in Dyspnea                               | X                    | X              | X                     | X              |
| Improvement in Management of Oral Medications        | X                    | X              | X                     | X              |
| Total Normalized Composite (TNC) Change in Mobility  | X                    | -              | X                     | -              |
| Total Normalized Composite (TNC) Change in Self-Care | X                    | -              | X                     | -              |
| DC Function  | -                    | X              | -                     | X              |
| <b>Sum of OASIS-based Measures</b>                   | <b>35.000</b>        | <b>35.000</b>  | <b>50.000</b>         | <b>50.000</b>  |
| <b>Claims-based Measures</b>                         |                      |                |                       |                |
| Acute Care Hospitalizations                          | X                    | -              | X                     | -              |
| Emergency Department Use Without Hospitalization     | X                    | -              | X                     | -              |
| Potentially Preventable Hospitalization              | -                    | X              | -                     | X              |
| Discharged to Community (Claims-based)               | -                    | X              | -                     | X              |
| <b>Sum of Claims-based Measures</b>                  | <b>35.000</b>        | <b>35.000</b>  | <b>50.000</b>         | <b>50.000</b>  |
| <b>HHCAHPS Survey-based Measures</b>                 |                      |                |                       |                |
| Care of Patients                                     | X                    | X              | -                     | -              |
| Communications Between Providers and Patients        | X                    | X              | -                     | -              |
| Specific Care Issues                                 | X                    | X              | -                     | -              |
| Overall Rating of Home Health Care                   | X                    | X              | -                     | -              |
| Willingness to Recommend the Agency                  | X                    | X              | -                     | -              |
| <b>Sum of HHCAHPS Survey-based Measures</b>          | <b>30.00</b>         | <b>30.000</b>  | <b>-</b>              | <b>-</b>       |
| <b>Sum of All Measures</b>                           | <b>100.000</b>       | <b>100.000</b> | <b>100.000</b>        | <b>100.000</b> |

4. Weighting and Redistribution of Weights Within the Measure Categories

a. Background

As finalized in the CY 2022 HH PPS final rule (86 FR 62240), the expanded HHVBP Model uses the same policies regarding the weighting of measures and the redistribution of weights when measures or measure categories are missing as under the original Model (83 FR 56536).

As previously discussed in section IV.B.2.b of this proposed rule, to align with quality measures used in the HH QRP, CMS proposes to replace the OASIS-based DTC measure with the claims-based DTC measure, jointly replace the claims-based ACH and ED Use measures with the claims-based PPH measure, and jointly replace the OASIS-based TNC Change in Mobility and TNC Change in Self-Care measures with the OASIS-based DC Function measure in CY 2025 and subsequent performance years. Due to these changes to the applicable measure set and the data sources, CMS proposes changes in weights and redistribution of weights within the measure categories accordingly.

b. Quality Measure Weights Within Measure Categories

Along with the proposed revisions to the current measure set, we propose to revise the weights of the individual measures within the OASIS-based measure category and within the claims-based measure category. Currently, the OASIS-based, claims-based, and HHCAHPS Survey-based measures contribute 35 percent, 35 percent, and 30 percent, respectively, to the Total Performance Score (TPS) for HHAs in the larger-volume cohort. For HHAs in the smaller-volume cohort, the OASIS-based and claims-based measures contribute 50 percent and 50 percent, respectively, to the TPS. The weights of the measure categories, when one category is missing, are based on the relative weight of each category when all measures are used. For example, if an HHA is missing the HHCAHPS Survey-based measure category, the remaining two measure categories (OASIS-based and claims-based) each represent 50 percent. Table 28 in the CY 2022 HH PPS final rule (86 FR 62323 through 62324) presents the current weights for measures and measure

categories under various reporting scenarios.

Table D4 shows the measure weights by quality measure in the expanded HHVBP Model currently in place and proposed for CY 2025 and subsequent performance years for HHAs in the larger-volume and smaller-volume cohort, respectively.

As discussed in section IV.B.3 of this proposed rule, for HHAs in the larger-volume cohort, we are keeping the measure category weights unchanged at 35 percent, 35 percent, and 30 percent for OASIS-based, claims-based, and HHCAHPS Survey-based measure categories, respectively. Similarly, for HHAs in the smaller-volume cohort, we are keeping the measure category weights unchanged at 50 percent and 50 percent for OASIS-based and claims-based measure categories, respectively. By keeping these measure category weights unchanged, the number of individual measures in each measure category will affect the magnitude of the individual measure weights. As proposed, changes to the applicable measure set would decrease the OASIS-based measures from five measures to three, while the number of individual

measures for the claims-based measures and HHCAHPS Survey-based measures will remain unchanged. Given these proposals, the individual measure weights within the proposed OASIS-based measure category would be higher than those under the current applicable OASIS-based measure category. The subsequent sections discuss in more detail the proposed measure weight redistributions for each measure category.

#### (1) Proposal To Redistribute Weights Within the OASIS-Based Measure Category

Because we propose to replace the two TNC measures jointly with the DC Function measure, we propose that the sum of the TNC measure weights be given to the DC Function measure. This will maintain the same relative weight

for functional measures. Due to the proposed removal of the OASIS-based DTC measure, we also propose to distribute the weight for that measure across the remaining three OASIS-based measures. In addition, we propose to maintain a relatively small weight for Improvement in Dyspnea compared to the other measures in the applicable measure set. Under the current measure set, Improvement in Dyspnea is weighted at 5.833 for larger-volume HHAs and 8.333 for smaller-volume HHAs. Similarly, under the proposed applicable measure set, Improvement in Dyspnea would be weighted at 6.000 for the larger-volume cohort and 8.571 for the smaller-volume cohort. This approach aims to encourage improvement in quality of care, while reducing its importance relative to other quality measures that encourage both

improvement and maintenance of quality care for all home health patients. These proposed changes would be effective in CY 2025. Table D4 describes the proposed measure weight redistributions for all measure categories by larger-volume and smaller-volume cohort, respectively. In addition to increasing the individual measure weight for Improvement in Dyspnea to 6.000, CMS proposes to increase the individual measure weight for Improvement in Management of Oral Medications to 9.000 and to assign the individual measure weight for DC Function to 20.000 for HHAs in the larger-volume cohort. These changes maintain the overall weight of the OASIS-based measures at 35 percent for the larger-volume cohort and 50 percent for the smaller-volume cohort.

**TABLE D4. PROPOSED MEASURE WEIGHT REDISTRIBUTIONS FOR HHAS IN THE LARGER-VOLUME AND SMALLER-VOLUME COHORT**

| Measure   | Proposed Redistributions |                       |                          |                       |
|---|--------------------------|-----------------------|--------------------------|-----------------------|
|   | Current Measure Weights  |                       | Proposed Measure Weights |                       |
|   | Larger-Volume Cohort     | Smaller-Volume Cohort | Larger-Volume Cohort     | Smaller-Volume Cohort |
| <b>OASIS-Based Measures</b>                           |                          |                       |                          |                       |
| Discharged to Community                               | 5.833                    | 8.333                 | -                        | -                     |
| Improvement in Dyspnea                                | 5.833                    | 8.333                 | 6.000                    | 8.571                 |
| Improvement in Management of Oral Medications         | 5.833                    | 8.333                 | 9.000                    | 12.857                |
| Total Normalized Composite (TNC) Change in Mobility   | 8.750                    | 12.500                | -                        | -                     |
| Total Normalized Composite (TNC) Change in Self-Care  | 8.750                    | 12.500                | -                        | -                     |
| DC Function   | -                        | -                     | 20.000                   | 28.571                |
| <b>Sum of OASIS-based Measures</b>                    | <b>35.000</b>            | <b>50.000</b>         | <b>35.000</b>            | <b>50.000</b>         |
| <b>Claims-based Measures</b>                          |                          |                       |                          |                       |
| Acute-Care Hospitalizations (ACH)                     | 26.250                   | 37.500                | -                        | -                     |
| Emergency Department Use Without Hospitalization (ED) | 8.750                    | 12.500                | -                        | -                     |
| Potentially Preventable Hospitalization               | -                        | -                     | 26.000                   | 37.143                |
| Discharge to Community (DTC-PAC)                      | -                        | -                     | 9.000                    | 12.857                |
| <b>Sum of Claims-based Measures</b>                   | <b>35.000</b>            | <b>50.000</b>         | <b>35.000</b>            | <b>50.000</b>         |
| <b>HHCAHPS Survey-based Measures</b>                  |                          |                       |                          |                       |
| Care of Patients                                      | 6.000                    | 0.000                 | 6.000                    | 0.000                 |
| Communications Between Providers and Patients         | 6.000                    | 0.000                 | 6.000                    | 0.000                 |
| Specific Care Issues                                  | 6.000                    | 0.000                 | 6.000                    | 0.000                 |
| Overall Rating of Home Health Care                    | 6.000                    | 0.000                 | 6.000                    | 0.000                 |
| Willingness to Recommend the Agency                   | 6.000                    | 0.000                 | 6.000                    | 0.000                 |
| <b>Sum of HHCAHPS Survey-based Measures</b>           | <b>30.000</b>            | <b>0.000</b>          | <b>30.000</b>            | <b>0.000</b>          |
| <b>Sum of All Measures</b>                            | <b>100.000</b>           | <b>100.000</b>        | <b>100.000</b>           | <b>100.000</b>        |

Note: The weights of the measure categories, when one category is missing, are based on the relative weight of each category when all measures are used. For example, if an HHA is missing the HHCAHPS category, the remaining two measure categories (OASIS-based and claims-based) represent 50 percent.

#### (2) Proposal To Redistribute Weights Within the Claims-Based Measure Category

Because we propose to remove the ACH and ED Use measures, we propose to allot an individual measure weight of 26.000 to the proposed PPH measure. The redistribution to the PPH measure

is intended to give this measure approximately the same combined weight as the ACH and ED Use measures had previously. In addition, CMS proposes to allot an individual measure weight of 9.000 to the claims-based DTC-PAC measure for the larger-volume cohort. The slight increase in

weight for the claims-based DTC-PAC measure maintains the same overall weight of 35.000 for claims-based measures for the larger-volume cohort. Table D4 lists the corresponding individual claims-based measure weight redistributions applicable to HHAs in the smaller-volume cohort.

(3) Weights Within the HHCAHPS-Based Measure Category

Given there are no changes proposed to the measures within the HHCAHPS Survey-based measure category, we propose to keep the individual measure weights for measures in this measure category unchanged. Specifically, each HHCAHPS Survey-based measure will continue to have an individual measure weight of 6.000 for HHAs in the larger-volume cohort. Given that HHAs in the smaller-volume cohort are not assessed based on their HHCAHPS Survey-based measure performance, the individual

measure weight is set to zero (0.000) for the smaller-volume cohort (see Table D4).

We invite public comments on these proposals.

(4) Alternatives Considered

Several measure weighting alternatives were considered prior to choosing the previously discussed proposals. Tables D5 describes these alternative options for HHAs in the larger-volume cohort, including weights proportional to the weights for the initial measure set (Option 1), maintaining measure category weights

consistent with current measure set weights and equal within-category weights (Option 2), using equal measure category weights and maintaining within-category weight proportions (Option 3), using equal measure category weights and equal within-category weights (Option 4), and having equal weights for all measures (Option 5). We also considered these options for the smaller-volume cohort and came to the same conclusions. Therefore, we only provide a table with measure weighting alternatives for the larger-volume cohort.

**TABLE D5. MEASURE WEIGHTING ALTERNATIVES CONSIDERED FOR HHAs IN THE LARGER-VOLUME COHORT**

| Measure                                       | Option 1<br>Proportional | Option 2<br>Maintain Category Weights;<br>Equal Within Proportion | Option 3<br>Equal Category Weights;<br>Maintain Within Proportion | Option 4<br>Equal Category Weights;<br>Equal Within Proportion | Option 5<br>Equal Weights |
|---|--------------------------|---|---|--|---------------------------|
| <b>OASIS-based Measures</b>                   |                          |   |   |  |                           |
| Improvement in Dyspnea                        | 8.750                    | 11.667  | 8.333   | 11.111   | 10.000                    |
| Improvement in Management of Oral Medications | 8.750                    | 11.667  | 8.333   | 11.111   | 10.000                    |
| DC Function                                   | 17.500                   | 11.667  | 16.667  | 11.111   | 10.000                    |
| <b>Sum of OASIS-based Measures</b>            | <b>35.000</b>            | <b>35.000</b>   | <b>33.333</b>   | <b>33.333</b>  | <b>30.000</b>             |
| <b>Claims-based Measures</b>                  |                          |   |   |  |                           |
| Potentially Preventable Hospitalization       | 26.250                   | 17.500  | 25.000  | 16.667   | 10.000                    |
| Discharged to Community-PAC                   | 8.750                    | 17.500  | 8.333   | 16.667   | 10.000                    |
| <b>Sum of Claims-based Measures</b>           | <b>35.000</b>            | <b>35.000</b>   | <b>33.333</b>   | <b>33.333</b>  | <b>20.000</b>             |
| <b>HHCAHPS Survey-based Measures</b>          |                          |   |   |  |                           |
| Care of Patients                              | 6.000                    | 6.000   | 6.667   | 6.667  | 10.000                    |
| Communications Between Providers and Patients | 6.000                    | 6.000   | 6.667   | 6.667  | 10.000                    |
| Specific Care Issues                          | 6.000                    | 6.000   | 6.667   | 6.667  | 10.000                    |
| Overall Rating of Home Health Care            | 6.000                    | 6.000   | 6.667   | 6.667  | 10.000                    |
| Willingness to Recommend the Agency           | 6.000                    | 6.000   | 6.667   | 6.667  | 10.000                    |
| <b>Sum of HHCAHPS Survey-based Measures</b>   | <b>30.000</b>            | <b>30.000</b>   | <b>33.333</b>   | <b>33.333</b>  | <b>50.000</b>             |
| <b>Sum of All Measures</b>                    | <b>100.000</b>           | <b>100.000</b>  | <b>100.000</b>  | <b>100.000</b>   | <b>100.000</b>            |

Note: The weights of the measure categories, when one category is missing, are based on the relative weight of each category. For example, for HHAs that do not have data for the HHCAHPS measures, the remaining two measure categories (OASIS-based and claims-based) are both 50.000.

Of these alternatives, Option 1 is most consistent with the proposed weights and most consistent with the weights used for the current measure set; however, it fails to apply the minimal weight possible for Improvement in Dyspnea. Similarly, Options 2–4 do not reduce the weight for Improvement in Dyspnea and deviate more substantially than Option 1 from the current weighting scheme. By attributing equal weight to all measures in the proposed measure set, Option 5 satisfies the minimal weight criterion for Improvement in Dyspnea; however, it does so at the expense of applying the same weight, which is inconsistent with

previous decisions about apply differential weighting to measures to incentivize HHAs to act on improving measures with higher weights in the applicable measure set as outlined in the CY 2022 HH PPS final rule (86 FR 62322).

5. Updates to the Model Baseline Year  
a. Background

In the CY 2022 HH PPS final rule, we finalized that the first Model baseline year for the expanded HHVBP Model would be CY 2019 (January 1, 2019 through December 31, 2019), the first performance year would be CY 2023, and the first payment year would be CY

2025 (86 FR 62294 through 62300). We decided on CY 2019 as the Model baseline year, as opposed to CY 2020 or CY 2021, due to the potentially destabilizing effects of the public health emergency (PHE) on the CY 2020 data and because it was the most recent full year of data available prior to CY 2020. The performance year and payment year were finalized after originally proposing CY 2022 to be the first performance year and CY 2024 to be the first payment year. We decided to delay implementation by 1 year to allow additional time for HHAs to prepare and learn about the expanded Model, thus CY 2022 was defined as the pre-

implementation year. In the CY 2023 HH PPS final rule, we changed the Model baseline year to CY 2022 (87 FR 66869 through 66874). We decided to use more recent data from the CY 2022 time period because it is more likely to be aligned with performance years' data under the expanded Model, and provide a more appropriate baseline for assessing HHA improvement for all measures under the Model as compared to both the pre-PHE CY 2019 data, as previously finalized for existing HHAs, and the CY 2021 data, as previously finalized for new HHAs certified between January 1, 2019 and December 31, 2020.

Additionally, in the CY 2022 HH PPS final rule (86 FR 62308 through 62309), we finalized the current measure set, as indicated in Table 25 of that final rule. The removal and replacement of measures from the current measure set necessitates an updated implementation and data reporting timeline, which will be applied to all applicable measures so that the Model baseline year is consistent across measures.

**b. Proposal To Update the Model Baseline Year**

Beginning with performance year CY 2025, we propose to update the Model baseline year to CY 2023 for all

applicable measures in the proposed measure set, including those measures included in the current measure set. The one exception is the new claims-based DTC-PAC measure, which uses two years of data. As such, the Model baseline year for the claims-based DTC-PAC measure will be CY 2022 and CY 2023 for the 2-year performance year spanning CY 2024 and CY 2025. For performance years CY 2023 and CY 2024, the Model baseline year will continue to be CY 2022. Table D6 lists the data periods for each measure and respective Model baseline, performance year, and payment years.

**TABLE D6: DATA PERIODS USED UNDER THE PROPOSED MEASURE SET FOR PERFORMANCE YEAR CY 2025 AND PAYMENT YEAR CY 2027**

| Measure                                       | Data Period | Data Period Used for Model Baseline Year* | Data Period Used for Performance Year | Payment Year |
|---|-------------|---|---------------------------------------|--------------|
| <b>OASIS-based Measures</b>                   |             |   |                                       |              |
| Improvement in Dyspnea                        | 1-year      | CY 2023                                   | CY 2025                               | CY 2027      |
| Improvement in Management of Oral Medications | 1-year      | CY 2023                                   | CY 2025                               | CY 2027      |
| DC Function                                   | 1-year      | CY 2023                                   | CY 2025                               | CY 2027      |
| <b>Claims-based Measures</b>                  |             |   |                                       |              |
| Potentially Preventable Hospitalizations      | 1-year      | CY 2023                                   | CY 2025                               | CY 2027      |
| Discharge to Community-Post Acute Care        | 2-year      | CY 2022/2023                              | CY 2024/2025                          | CY 2027      |
| <b>HHCAPHS Survey-based Measures</b>          |             |   |                                       |              |
| Care of Patients                              | 1-year      | CY 2023                                   | CY 2025                               | CY 2027      |
| Communications Between Providers and Patients | 1-year      | CY 2023                                   | CY 2025                               | CY 2027      |
| Specific Care Issues                          | 1-year      | CY 2023                                   | CY 2025                               | CY 2027      |
| Overall Rating of Home Health Care            | 1-year      | CY 2023                                   | CY 2025                               | CY 2027      |
| Willingness to Recommend the Agency           | 1-year      | CY 2023                                   | CY 2025                               | CY 2027      |

\*Beginning with performance year CY 2025, the baseline year and AT/BMs would be updated to CY 2023 for all remaining measures from the initial measure set.

If we finalize our proposal to use CY 2023 for the Model baseline year, we would provide HHAs with the final achievement thresholds and benchmarks in the July 2024 Interim Performance Report (IPR). For all measures but the claims-based DTC-PAC measure, this timeline allows for one year of performance between the first performance year and the proposed updated Model baseline year. Because the claims-based DTC-PAC measure is a two-year measure, there will be no gap between the proposed updated Model baseline year and the first performance year, which would be consistent with the rollout of the original HHVBP Model, in which benchmarks and achievement thresholds using CY 2015 data were made available to HHAs during the summer of the first performance year (CY 2016).

Furthermore, because the claims-based DTC-PAC measure is a 2-year

measure, there will be an overlap in how discharge to community is measured for the expanded Model. Specifically, CY 2024 performance will be based on the current measure set, which includes the OASIS-based DTC measure. For the OASIS-based DTC measure, CY 2024 performance will be compared to baseline year CY 2022. CY 2025 performance would be based on the proposed measure set, which includes the claims-based DTC-PAC measure and thus replaces the OASIS-based DTC measure. Because the DTC-PAC measure is a two-year measure, CY 2025 performance for the claims-based DTC-PAC measure will be calculated based on two years of performance data (CY 2024/2025) and compared to two years of baseline year data (CY 2022/2023). Thus, for both the OASIS-based DTC measure and the claims-based DTC-PAC measure, CY 2022 data will be used to calculate performance in a

Model baseline year, and CY 2024 data will be used to calculate performance in a performance year. Beyond CY 2025, data for calculating DTC-PAC performance will continue to overlap. For example, CY 2026 DTC-PAC (claims-based) performance will be based on data from CY 2025/2026, which overlaps by one year with the CY 2025 DTC-PAC (claims-based) performance year data. See Table D7. The DTC-PAC measure was designed as a 2-year measure to optimize reliability. In addition, each performance year will consist of 1 year of performance data that does not overlap with the prior performance year data, which provides sufficient opportunity to capture quality improvement over time. Finally, the DTC-PAC (claims-based) will provide a smoother performance trend over time compared to 1-year measures by reflecting performance across a longer reporting period.



**TABLE D7. MODEL BASELINE YEARS AND PERFORMANCE YEAR DATA PERIODS FOR THE DTC MEASURES IN PERFORMANCE YEARS CY 2024-2026**

| Performance Year | OASIS-based DTC | Claims-based DTC-PAC | Data Periods |          |              |               |             |
|------------------|-----------------|----------------------|--------------|----------|--------------|---------------|-------------|
|                  |                 |                      | CY 2022      | CY 2023  | CY 2024      | CY 2025       | CY 2026     |
| PY 2024          | X               |                      | Baseline     |          | Performance* |               |             |
| PY 2025          |                 | X                    | Baseline     | Baseline | Performance* | Performance** |             |
| PY 2026          |                 | X                    | Baseline     | Baseline |              | Performance** | Performance |

\* Indicates the overlap in CY 2024 performance year data used for the OASIS-based DTC measure and claims-based DTC-PAC measure.

\*\* Indicates the overlap in performance year data used for the claims-based DTC-PAC measure starting in performance year CY 2025.

**BILLING CODE 4120-01-C**

**c. Alternatives Considered**

We considered several alternative timelines for updating the Model baseline year. First, we considered leaving the baseline year at CY 2022 for those measures on the previously finalized measure set. We opted against this alternative because it uses less recent data and makes it more difficult for HHAs to track which achievement thresholds and benchmarks are based on which years of baseline data.

Second, because of the time between the Model baseline year and the performance year, we considered delaying the implementation of the claims-based DTC-PAC measure by one year. Under this scenario, the measure’s baseline year would remain CY 2022/2023, but the measure’s first performance year would be CY 2025/2026. The first payment year that uses the claims-based DTC-PAC measure would then be CY 2028. As such, CY 2025 would be a transition year in between the current applicable measure set and the proposed applicable measure set. During this transition year, the OASIS-based DTC measure could be retained through CY 2025 or removed. Retaining the OASIS-based DTC measure during the transition year would ensure that the concept of being discharged to the community will be reflected in all performance and payment years, while removing it before the transition year would better align with the removal of the other measures as proposed. Because we view the concept of being discharged to the community as an important aspect of home health quality, we favor retaining the OASIS-based DTC measure during the transition year over removing it, assuming we delay implementation of the claims-based DTC measure. We rejected delayed implementation, however, because it temporarily increases the complexity of the expanded Model and requires that the Model uses the legacy OASIS-based DTC measure for another year, despite its removal from the HH QRP.

Third, we considered delaying implementation of the OASIS-based DC Function measure, which is proposed for CY 2025 implementation in the HH QRP as indicated in section III. D.1. of this proposed rule. Although a delay would allow more time to evaluate the measure’s performance prior to HHVBP implementation, data utilized in this measure have been a part of the HH QRP’s OASIS assessment tool since CY 2019. We prefer the proposed timeline for the OASIS-based DC Function measure because it expedites alignment with the HH QRP, SNF VBP, and the other PAC programs and the timing corresponds with the proposed removal and replacement of other measures in the Model.

Lastly, we considered delaying implementation for all replacement measures, such that their Model baseline years would end on December 31, 2023 and their first performance years would end on December 31, 2026 (CY 2026 for the OASIS-based DC Function and claims-based PPH measures and CY 2025/2026 for the claims-based DTC-PAC measure). Under this alternative, the first payment year to use the proposed applicable measure set would be CY 2028. We favor the proposed timeline because we prefer aligning more closely with the HH QRP measure set as early as possible.

**6. Future Topics for Measure Considerations**

We will take into consideration opportunities for further alignment with measures in the HH QRP and publicly reported on Home Health Care Compare because alignment will facilitate comparative assessments of provider quality and streamline home health providers’ data capture and reporting processes. If we consider adding new measures that require data that is not already collected through existing quality measure data reporting systems, we will propose that option in future rulemaking while being mindful of provider burden.

To further the goals of the CMS National Quality Strategy, CMS leaders from across the Agency have come together to move towards a building-block approach to streamline quality measure across CMS quality programs for the adult and pediatric populations. This “Universal Foundation”<sup>127</sup> of quality measures will focus provider attention, reduce burden, identify disparities in care, prioritize development of interoperable, digital quality measures, allow for cross-comparisons across programs, and help identify measurement gaps. The development and implementation of the Preliminary Adult and Pediatric Universal Foundation Measures will promote the best, safest, and most equitable care for individuals as we all come together on these critical quality areas. As CMS moves forward with the Universal Foundation, we will be working to identify foundational measures in other specific settings and populations to support further measure alignment across CMS programs as applicable.

In recognition of persistent health disparities and the importance of closing the health equity gap, we will consider future modifications that promote health equity and ways in which we could incorporate health equity goals into the Model. Any changes would be proposed in future notice and comment rulemaking.

While we are not making any specific proposals here, we invite stakeholders to suggest future measures and the value they may provide to the expanded HHVBP Model.

**C. Proposed Changes to the Appeals Process**

**1. Background**

As codified at § 484.375, the appeals process under the expanded HHVBP

<sup>127</sup> Jacobs, D.B., Schreiber, M., Seshamani, M., Tsai, D., Fowler, E., & Fleisher, L.A. (2023). Aligning quality measures across CMS—the universal foundation. *New England Journal of Medicine*, 388(9), 776–779. <https://www.nejm.org/doi/full/10.1056/NEJMp2215539>.

Model allows HHAs to submit recalculation requests for the interim performance reports and the Annual Total Performance Score (TPS) and Payment Adjustment Report (Annual Performance Report or APR). Under this process, an HHA may also make a reconsideration request if it disagrees with the results of a recalculation request for the APR. We refer the reader to the CY 2022 HH PPS final rule (86 FR 62331 through 62332) for details of the appeals process. We also finalized (86 FR 62329) that we would make available the Final APR after all reconsideration requests are processed and no later than 30 calendar days before the payment adjustment takes effect annually, both for those HHAs that requested a reconsideration and all other competing HHAs.

## 2. Proposed Revisions

We are proposing revisions to the policy at § 484.375(b)(5) to acknowledge the ability of the CMS Administrator to review reconsideration decisions, and to change the time for filing a request for reconsideration. In particular, we are proposing to amend § 484.375(b)(5) to specify that an HHA may request Administrator review of a reconsideration decision within 7 days from CMS' notification to the HHA contact of the outcome of the reconsideration request. We propose to amend § 484.375(b)(5) to state that the CMS reconsideration official issues a written decision that is final and binding 7 calendar days after the decision unless the CMS Administrator renders a final determination reversing or modifying the reconsideration decision. And, that an HHA may request within 7 calendar days of the decision that the CMS Administrator review the reconsideration decision. The CMS Administrator may decline to review the reconsideration decision, render a final determination, or choose to take no action on the request for administrative review. Reconsideration decisions are considered final if the CMS Administrator declines an HHA's request for review or if the CMS Administrator does not take any action on the HHA's request for review within 14 days.

This proposed change would ensure that accountability for the decisions of CMS is vested in a principal officer and brings the reconsideration review process to a more similar posture as other CMS appeals entities that provide Administrator review. This revision also ensures that HHAs are aware that administrative review is available to those HHAs who wish to seek

additional review of a reconsideration decision.

We seek comment on these proposals.

### D. Public Reporting Reminder

In the CY 2022 HH PPS final rule (86 FR 62332 through 62333), we finalized that we would publicly report the following information for the expanded HHVBP Model:

- Applicable measure benchmarks and achievement thresholds for each small- and large-volume cohort.
- For each HHA that qualified for a payment adjustment based on the data for the applicable performance year—
  - Applicable measure results and improvement thresholds;
  - The HHA's Total Performance Score (TPS);
  - The HHA's TPS Percentile Ranking; and
  - The HHA's payment adjustment for a given year.

In that same rule, we stated that we anticipate this information would be made available to the public on a CMS website on or after December 1, 2024, the date by which we would intend to complete the CY 2023 Annual Report appeals process and issuance of the Final Annual Report to each competing HHA. For each year thereafter, we anticipate following the same approximate timeline for publicly reporting the payment adjustment for the upcoming calendar year. This policy is codified at § 484.355(c). We are not proposing any changes to this policy. This simply serves as a reminder of our existing policy.

### E. Health Equity Update

#### 1. Background

In the Calendar Year 2023 Home Health Prospective Payment System Proposed Rule (CMS-1766-P), we included a Request for Information (RFI) on a future approach to health equity in the expanded HHVBP Model. We define health equity as “the attainment of the highest level of health for all people, where everyone has a fair and just opportunity to attain their optimal health regardless of race, ethnicity, disability, sexual orientation, gender identity, socioeconomic status, geography, preferred language, or other factors that affect access to care and health outcomes.”<sup>128</sup> We are working to advance health equity by designing, implementing, and operationalizing policies and programs that support health for all the people served by our programs and models, eliminating

<sup>128</sup> Centers for Medicare and Medicaid Services. Available at <https://www.cms.gov/pillar/health-equity>. Accessed February 1, 2023.

avoidable differences in health outcomes experienced by people who are disadvantaged or underserved, and providing the care and support that our enrollees need to thrive. Our goals outlined in the *CMS Framework for Health Equity 2022–2032*<sup>129</sup> are in line with Executive Order 13985, “Advancing Racial Equity and Support for Underserved Communities Through the Federal Government.”<sup>130</sup> The goals included in the CMS Framework for Health Equity serve to further advance health equity, expand coverage, and improve health outcomes for the more than 170 million individuals supported by our programs, and sets a foundation and priorities for our work including: strengthening our infrastructure for assessment, creating synergies across the health care system to drive structural change, and identifying and working to eliminate barriers to CMS-supported benefits, services, and coverage.

In addition to the CMS Framework for Health Equity, CMS seeks to “advance health equity and whole-person care” as one of eight goals comprising the CMS National Quality Strategy (NQS).<sup>131</sup> The NQS identifies a wide range of potential quality levers that can support our advancement of equity, including: (1) establishing a standardized approach for patient-reported data and stratification; (2) employing quality and value-based programs to address closing equity gaps; and, (3) developing equity-focused data collection, analysis, regulations, and quality improvement initiatives.

A goal of this NQS is to address persistent disparities that underly our healthcare system. Racial disparities, in particular, are estimated to cost the U.S. \$93 billion in excess medical costs and \$42 billion in lost productivity per year, in addition to economic losses due to premature deaths.<sup>132</sup> At the same time, racial and ethnic diversity has increased in recent years, with an increase in the percentage of people who identify as two or more races accounting for most of the change, rising from 2.9 percent to

<sup>129</sup> <https://www.cms.gov/files/document/cms-framework-health-equity-2022.pdf>.

<sup>130</sup> <https://www.whitehouse.gov/briefing-room/presidential-actions/2021/01/20/executive-order-advancing-racial-equity-and-support-for-underserved-communities-through-the-federal-government/>.

<sup>131</sup> Centers for Medicare & Medicaid Services. What is the CMS Quality Strategy? Available at <https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Value-Based-Programs/CMS-Quality-Strategy>.

<sup>132</sup> Ani Turner, *The Business Case for Racial Equity*, A Strategy for Growth, W.K. Kellogg Foundation and Altarum, April 2018.

10.2 percent between 2010 and 2020.<sup>133</sup> Therefore, we need to consider ways to reduce disparities, achieve equity, and support our diverse beneficiary population through the way we measure quality and display the data.

We solicited public comments via the previously discussed RFI on policy changes that we should consider on the topic of health equity. We specifically requested input on whether we should explore incorporating adjustments into the expanded HHVBP Model to reflect the varied patient populations that HHAs serve around the country and tie equity-focused outcomes to the payment adjustments we make based on HHA performance under the Model. We refer readers to the CY 2023 HH PPS final rule (87 FR 66876), for a summary of the public comments and suggestions we received in response to the health equity RFI. We will take these comments into account as we continue to work to develop policies and quality measures on this important topic.

## 2. Anticipated Future State

We are committed to developing approaches to meaningfully incorporate the advancement of health equity into the expanded HHVBP Model. As we move this important work forward, we will continue to take input from interested parties. We also note that there are proposals being made to implement a health equity adjustment in the Hospital Inpatient Quality Reporting Program and the SNF Value-Based Purchasing Program. At this time, however, we would like to give HHAs time to learn the requirements of the expanded Model, gather at least 2 years of performance data, and study effects of the expanded Model on health equity outcomes before incorporating any potential changes to the expanded Model regarding health equity.

## V. Medicare Home Intravenous Immune Globulin (IVIG) Items and Services

### A. General Background

#### 1. Statutory Background

Division FF, section 4134 of the CAA, 2023 added coverage and payment of items and services related to administration of IVIG in a patient's home of a patient with a diagnosed primary immune deficiency disease furnished on or after January 1, 2024. Division FF, section 4134(a) of the CAA, 2023 amended the existing IVIG benefit

category at section 1861(s)(2)(Z) of the Act by adding coverage for IVIG administration items and services in a patient's home of a patient with a diagnosed primary immune deficiency disease. This benefit covers items and services related to administration of IVIG in a patient's home of a patient with a diagnosed primary immune deficiency disease. In addition, section 4134(b) of Division FF of the CAA, 2023 amended section 1842(o) of the Act by adding a new paragraph (8) that established the payment for IVIG administration items and services. Under the CAA, 2023 provision, payment for these IVIG administration items and services is required to be a bundled payment separate from the payment for the IVIG product, made to a supplier for all items and services related to administration of IVIG furnished in the home during a calendar day.

#### 2. Overview

Primary immune deficiency diseases (PIDD) are conditions triggered by genetic defects that cause a lack of and/or impairment in antibody function, resulting in the body's immune system not being able to function in a normal way. Immune globulin (Ig) therapy is used to temporarily replace some of the antibodies (that is, immunoglobulins) that are missing or not functioning properly in people with PIDD.<sup>134</sup> The goal of Ig therapy is to use Ig obtained from normal donor plasma to maintain a sufficient level of antibodies in the blood of individuals with PIDD to fight off bacteria and viruses. Ig is formulated for both intravenous and subcutaneous administration (SCIg). Clinicians can prescribe either product to the beneficiary with PIDD according to clinical need and preference, and beneficiaries can switch between intravenous and subcutaneous administration of Ig.

#### 3. Legislative Summary

Section 642 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Pub. L. 108–173), amended section 1861 of the Act to provide Medicare Part B coverage of the IVIG product for the treatment of PIDD in the home, but not the items and services involved with administration.

Section 101 of the Medicare IVIG Access and Strengthening Medicare and Repaying Taxpayers Act of 2012 (Medicare IVIG Access Act) (Pub. L. 112–242), mandated the establishment,

implementation, and evaluation of a 3-year Medicare Intravenous Immune Globulin (IVIG) Demonstration Project (the Demonstration) under Part B of title XVIII of the Act. The Demonstration was implemented to evaluate the benefits of providing coverage and payment for items and services needed for the home administration of IVIG for the treatment of PIDD, and to determine if it would improve access to home IVIG therapy for patients with PIDD. The Medicare IVIG Access Act mandated that Medicare would establish a per visit payment amount for the items and services necessary for the home administration of IVIG therapy for beneficiaries with specific PIDD diagnoses. The Demonstration did not include Medicare payment for the IVIG product which continues to be paid under Part B in accordance with section 1842(o) and 1847(A) of the Act. The Demonstration covered and paid a per visit payment amount for the items and services needed for the administration of IVIG in the home. Items may include infusion set and tubing, and services include nursing services to complete an infusion of IVIG lasting on average three to five hours.<sup>135</sup>

On September 28, 2017, Congress passed the Disaster Tax Relief and Airport and Airway Extension Act of 2017 (Pub. L. 115–63). Section 302 of Public Law 115–63 extended the Demonstration through December 31, 2020.

Division CC, section 104, of the Consolidated Appropriations Act, 2021 (CAA, 2021) (Pub. L. 116–260), further extended the Demonstration for another 3 years through December 31, 2023.

Division FF, section 4134 of the CAA, 2023 (CAA, 2023) (Pub. L. 117–328) mandated that CMS establish permanent coverage and payment for items and services related to administration of IVIG in a patient's home of a patient with PIDD. The permanent home IVIG items and services payment is effective for home IVIG administration furnished on or after January 1, 2024. Payment for these items and services is required to be a separate bundled payment made to a supplier for all administration items and services furnished in the home during a calendar day. The statute provides that payment amount may be based on the amount established under the Demonstration. The standard Part B coinsurance and the Part B deductible is required to apply. In addition, that statute states that the separate bundled

<sup>133</sup> 2022 National Healthcare Quality and Disparities Report. Content last reviewed November 2022. Agency for Healthcare Research and Quality, Rockville, MD <https://www.ahrq.gov/research/findings/nhqrdr/nhqrdr22/index.html>.

<sup>134</sup> Perez EE, Orange JS, Bonilla F, et al. (2017) Update on the use of immunoglobulin in human disease: A review of evidence; Journal Allergy Clin Immunol. 139(3S): S1–S46.

<sup>135</sup> Updated Interim Report to Congress: Evaluation of the Medicare Patient Intravenous Immunoglobulin Demonstration Project, 2022: <https://innovation.cms.gov/data-and-reports/2022/ivig-updatedinttrc>.

payment for these IVIG administration items and services does not apply for individuals receiving services under the Medicare home health benefit. The CAA, 2023 provision clarifies that a supplier who furnishes these services meet the requirements of a supplier of medical equipment and supplies.

#### 4. Demonstration Overview

Under the Demonstration, Medicare provides a bundled payment under Part B, that is separate from the IVIG product, for items and services that are necessary to administer IVIG in the home to enrolled beneficiaries who are not otherwise homebound and receiving services under the home health benefit. The Demonstration only applies to situations where the beneficiary requires IVIG for the treatment of certain PIDD diagnoses, or was receiving SCIg to treat PIDD and wishes to switch to IVIG.

Services covered under the Demonstration are required to be provided and billed by specialty pharmacies enrolled as durable medical equipment (DME) suppliers, that provide the Medicare Part B-covered Ig. The covered items and services under the Demonstration are paid as a single bundle and are subject to coinsurance and deductible in the same manner as other Part B services. HHAs are not eligible to bill for services covered under the Demonstration, but can bill for services related to the administration of IVIG if the patient is receiving services under a home health episode of care, in which case the home health payment covers the items and services.

In order to participate in the Demonstration, beneficiaries must meet the following requirements:

- Be eligible to have the IVIG paid for at home under Part B FFS
- Have a diagnosis of PIDD
- Not be enrolled in a Medicare Advantage plan
- Cannot be in a home health episode of care on the date of service (in such circumstances, the home health payment covers the services)
- Must receive the service in their home or a setting that is “home like”.

To participate in the Demonstration, the beneficiary must submit an application, signed by their physician.

DME suppliers billing for the items and services covered under the Demonstration must meet the following requirements:

- Meet all Medicare, as well as other national, state, and local standards and regulations applicable to the provision of services related to home infusion of IVIG.

- Be enrolled and current with the National Supplier Clearinghouse.

- Be able to bill the DME Medicare Administrative Contractors (MACs).

CMS implemented a bundled per visit payment amount under the Demonstration, statutorily required to be based on the national per visit low-utilization payment adjustment (LUPA) for skilled nursing services used under the Medicare HH PPS established under section 1895 of the Act. The payment amount is subject to coinsurance and deductible.

For billing under the Demonstration, CMS established a “Q” code for services, supplies, and accessories used in the home under the IVIG Demonstration:

- Q2052—(Long Description)—Services, supplies, and accessories used in the home under Medicare Intravenous immune globulin (IVIG) Demonstration.

- Q2052—(Short Description)—IVIG demo, services/supplies.

The code is used for the IVIG Demonstration only. Suppliers must bill Q2052 as a separate claim line on the same claim for the IVIG drug.

#### B. Proposed Scope of Expanded IVIG Benefit

As discussed previously, Division FF, section 4134 of the CAA, 2023, added coverage of items and services related to the administration of IVIG in a patient’s home, to the existing IVIG benefit category at section 1861(s)(2)(Z) of the Act, effective January 1, 2024. Currently, IVIG is covered in the home under Part B if all of the following criteria are met:

- It is an approved pooled plasma derivative for the treatment of primary immune deficiency disease.
- The patient has a diagnosis of primary immune deficiency disease.
- The IVIG is administered in the home.
- The treating practitioner has determined that administration of the IVIG in the patient’s home is medically appropriate.

Therefore, as section 4134(a)(1) of the CAA, 2023, adds the items and services (furnished on or after January 1, 2024) related to the administration of IVIG to the benefit category defined under section 1861(s)(2)(Z) of the Act (the Social Security Act provision requiring coverage of the IVIG product in the home), the same beneficiary eligibility requirements for the IVIG product would apply for the IVIG administration items and services described in section V.A.4. of this proposed rule. Subpart B of Part 410 of the regulations set out the medical and other health services requirements under Part B. The

regulations at § 410.10 identify the services that are subject to the conditions and limitations specified in this subpart. Section 410.10(y) includes intravenous immune globulin administered in the home for the treatment of primary immune deficiency diseases. Section 410.12 outlines general basic conditions and limitations for coverage of medical and other health services under Part B, as identified in section 410.10. Section 410.12(a) includes the conditions that must be met in order for these services to be covered, and include the following:

- *When the services must be furnished.* The services must be furnished while the individual is in a period of entitlement.
- *By whom the services must be furnished.* The services must be furnished by a facility or other entity as specified in §§ 410.14 through 410.69.
- *Physician certification and recertification requirements.* If the services are subject to physician certification requirements, they must be certified as being medically necessary, and as meeting other applicable requirements, in accordance with subpart B of part 424.

As the definition of IVIG at section 1861(zz) of the Act now includes the items and services necessary to administer IVIG in the home, we propose to add the term “items and services” to the regulation at § 410.10(y). Furthermore, sub-regulatory guidance documents (that is, IVIG LCD (33610)<sup>136</sup> and IVIG Policy Article (A52509)<sup>137</sup>) provide direction on coding and coverage for the IVIG product at home. Through the Local Coverage Determination (LCD) for Intravenous Immune Globulin (L33610),<sup>138</sup> the Durable Medical Equipment Medicare administrative contractors (DME MACs) specify the Healthcare Common Procedure Coding System (HCPCS) codes for which IVIG derivatives are covered under this benefit. Therefore, a beneficiary must be receiving one of the IVIG derivatives specified under the LCD for IVIG in order to qualify to receive the items and services covered under section 1861(s)(2)(Z) of the Act. Furthermore, for any item (including IVIG) to be covered by Medicare, it must (1) be eligible for a defined Medicare benefit category, (2) be reasonable and

<sup>136</sup> <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=33610>.

<sup>137</sup> <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52509>.

<sup>138</sup> Local Coverage Determination (LCD): IVIG (L33610) <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=33610&ContrId=389>.

necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member, and (3) meet all other

applicable Medicare statutory and regulatory requirements. Policy guidance for the LCD for IVIG<sup>139</sup> identifies the ICD-10-CM codes that

support medical necessity for the provision of IVIG in the home. These diagnosis codes are listed in Table E1.

**TABLE E1: ICD-10-CM CODES THAT SUPPORT MEDICAL NECESSITY FOR HOME IVIG**

| Code   | Description  |
|--------|--|
| D80.0  | Hereditary hypogammaglobulinemia   |
| D80.2  | Selective deficiency of immunoglobulin A [IgA]   |
| D80.3  | Selective deficiency of immunoglobulin G [IgG] subclasses                                      |
| D80.4  | Selective deficiency of immunoglobulin M [IgM]   |
| D80.5  | Immunodeficiency with increased immunoglobulin M [IgM]   |
| D80.6  | Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia           |
| D80.7  | Transient hypogammaglobulinemia of infancy   |
| D81.0  | Severe combined immunodeficiency [SCID] with reticular dysgenesis                              |
| D81.1  | Severe combined immunodeficiency [SCID] with low T- and B-cell numbers                         |
| D81.2  | Severe combined immunodeficiency [SCID] with low or normal B-cell numbers                      |
| D81.5  | Purine nucleoside phosphorylase [PNP] deficiency   |
| D81.6  | Major histocompatibility complex class I deficiency  |
| D81.7  | Major histocompatibility complex class II deficiency   |
| D81.82 | Activated Phosphoinositide 3-kinase Delta Syndrome [APDS]                                      |
| D81.89 | Other combined immunodeficiencies  |
| D81.9  | Combined immunodeficiency, unspecified   |
| D82.0  | Wiskott-Aldrich syndrome   |
| D82.1  | Di George's syndrome   |
| D82.4  | Hyperimmunoglobulin E [IgE] syndrome   |
| D83.0  | Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function |
| D83.1  | Common variable immunodeficiency with predominant immunoregulatory T-cell disorders            |
| D83.2  | Common variable immunodeficiency with autoantibodies to B- or T-cells                          |
| D83.8  | Other common variable immunodeficiencies   |
| D83.9  | Common variable immunodeficiency, unspecified  |
| G11.3  | Cerebellar ataxia with defective DNA repair  |

In accordance with this guidance, a beneficiary must be diagnosed with one of the primary immune deficiencies identified by the ICD-10-CM codes, set out in Table E1 and as updated in subregulatory guidance, in order to qualify to receive the items and services covered under section 1861(s)(2)(Z) of the Act. This policy guidance is revised as needed by the DME MACs. And finally, in order to qualify to receive IVIG in the home, section 1861(zz) of the Act requires that a treating practitioner must have determined that administration of the IVIG in the patient's home is medically appropriate. Accordingly, we intend to update the sub-regulatory guidance pursuant to the CAA, 2023 to reflect the expansion of the benefit to the items and services related to the administration of IVIG at home. Leveraging the existing

regulations and sub-regulatory guidance would maintain one set of standards across the entire IVIG benefit (that is, for the product and for the related items and services). This would result in seamless implementation from the existing IVIG Demonstration, thereby ensuring immediate access for beneficiaries requiring such items and services. We solicit comments on our proposal to add "items and services" to the regulation at § 410.10(y).

1. Items and Services Related to the Home Administration of IVIG

Section 101(c) of the Medicare IVIG Access Act established coverage for items and services needed for the in-home administration of IVIG for the treatment of primary immunodeficiencies under a Medicare demonstration program. We interpret

section 4134 of the CAA, 2023 to make permanent coverage of the same items and services under the existing IVIG Demonstration in order to ensure continuous and comprehensive coverage for beneficiaries who choose to receive home IVIG therapy. Under the Demonstration, the bundled payment for the items and services necessary to administer the drug intravenously in the home includes the infusion set and tubing, and nursing services to complete an infusion of IVIG lasting on average three to five hours.<sup>140</sup> Although "items and services" are not explicitly defined under section 4134 of the CAA, 2023, we believe the items and services covered under the Demonstration are inherently the same items and services that would be covered under the payment added to the benefit category at section 1861(s)(2)(Z) of the Act. While

<sup>139</sup> <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52509>.

<sup>140</sup> Updated Interim Report to Congress: Evaluation of the Medicare Patient Intravenous Immunoglobulin Demonstration Project, August

2022 found at: <https://innovation.cms.gov/data-and-reports/2022/ivig-updatedintrtc>.

we are not enumerating a list of services that must be included in the separate bundled payment, we anticipate that the nursing services would include such professional services as IVIG administration, assessment and site care, and education. Moreover, it is up to the provider to determine the services and supplies that are appropriate and necessary to administer the IVIG for each individual. This may or may not include the use of a pump. Because IVIG does not have to be administered through a pump (although it can be), external infusion pumps are not covered under the DME benefit for the administration of IVIG. An external infusion pump is only covered under the DME benefit if the infusion pump is necessary to safely administer the drug. The Local Coverage Determination (LCD) for External Infusion Pumps identify the drugs and biologicals that the DME Medicare Administrative Contractors (MACs) have determined require the use of such pumps and cannot be administered via a disposable elastomeric pump or the gravity drip method.<sup>141</sup> As such, under the IVIG Demonstration, coverage does not extend to the DME pump, and thereby, would not be covered separately under the home IVIG items and services payment.

We invite comments on any additional interpretations of items and services that may be considered under the scope of the home IVIG benefit.

## 2. Home IVIG Items and Services and the Relationship to/Interaction With Home Health and Home Infusion Therapy Services

Prior to enactment of the CAA, 2023, IVIG administration items and services were explicitly excluded from coverage under the Part B IVIG benefit. However, if a beneficiary was considered homebound and qualified for the home health benefit, the items and services needed to administer IVIG in the home could be covered as home health services. Section 4134(b) of the CAA, 2023 excludes the IVIG items and services bundled payment in the case of an individual receiving home health services under section 1895 of the Act. Therefore, a beneficiary does not have to be considered confined to the home (that is, homebound) in order to be eligible for the home IVIG benefit; however, homebound beneficiaries requiring items and services related to the administration of home IVIG, and who are receiving services under a home health plan of care, may continue

to receive services related to the administration of home IVIG as covered home health services. As such, in the case that a beneficiary is receiving home health services under the home health benefit, the home health agency could continue to bill for these items and services under the home health benefit and the drug would be continued to be paid under Part B. A separate payment for the IVIG items and services under the IVIG benefit would be prohibited.

With regard to the home infusion therapy (HIT) services benefit, Medicare payment for home infusion therapy services is for services furnished in coordination with the furnishing of intravenous and subcutaneous infusion drugs and biologicals specified on the DME LCD for External Infusion Pumps (L33794),<sup>142</sup> with the exception of insulin pump systems and certain drugs and biologicals on a self-administered drug exclusion list. In order for the drugs and biologicals to be covered under the Part B DME benefit they must require infusion through an external infusion pump. If the drug or biological can be infused through a disposable pump or by a gravity drip, it does not meet this criterion. IVIG does not require an external infusion pump for administration purposes and therefore, is explicitly excluded from the DME LCD for External Infusion Pumps. However, subcutaneous immunoglobulin (SCIg) is covered under the DME LCD for External Infusion Pumps, and items and services for administration in the home are covered under the HIT services benefit. While a DME supplier and a HIT supplier (or a DME supplier also enrolled as a HIT supplier) could not furnish services related to the administration of immunoglobulin (either IVIG or SCIg) to the same beneficiary on the same day, a beneficiary could potentially receive services under both benefits for services related to the infusion of different drugs. For example, a DME supplier also accredited and enrolled as a HIT supplier, could furnish HIT services to a beneficiary receiving intravenous acyclovir as well as IVIG, and bill both the IVIG and the HIT services benefits on the same date of service. We also recognize that a beneficiary may, on occasion, switch from receiving immunoglobulin subcutaneously to intravenously and vice versa, and as such, utilize both the HIT services and the IVIG benefits within the same

month. We invite comments on how typical it is for a patient to alternate between receiving IVIG and SCIg and the frequency with which it may occur.

## C. Proposed IVIG Administration Items and Services Payment

As discussed previously, section 101 of the Medicare IVIG Access Act established the authority for a Demonstration providing payment for items and services needed for the in-home administration of IVIG. We believe the provisions established under that law serve as the basis for the conditions for payment with respect to the requirements that must be met for Medicare payment to be made to suppliers for the items and services covered under section 1861(s)(2)(Z) of the Act.

### 1. Home IVIG Administration Items and Services Supplier Type

Section 4134(b) of the CAA, 2023 amends section 1842(o) of the Act by adding a new paragraph (8) that establishes a separate bundled payment to the supplier for all items and services related to the administration of such intravenous immune globulin, described in section 1861(s)(2)(Z) of the Act to such individual in the patient's home during a calendar day. Section 4134(c) of the CAA, 2023 amends section 1834(j)(5) of the Act, which are a requirement for supplier of medical equipment and supplies, by adding a new subparagraph (E), clarifying with respect to payment, that items and services related to the administration of intravenous immune globulin furnished on or after January 1, 2024, as described in section 1861(zz) of the Act, are included in the definition of medical equipment and supplies. This means that suppliers that furnish IVIG administration items and services must meet the existing DMEPOS supplier requirement for payment purposes under this benefit. Suppliers of IVIG administration items and services must enroll as a DMEPOS supplier and comply with the Medicare program's DMEPOS supplier standards (found at 42 CFR 424.57(c)) and DMEPOS quality standards to become accredited for furnishing medical equipment and supplies. Further, in order to receive payment for home IVIG items and services, the supplier must also meet the requirements under subpart A of Part 424—Conditions for Medicare Payment. The DMEPOS supplier may subcontract with a provider in order to meet the professional services identified in section V.B.1. of this proposed rule. All professionals who furnish services directly, under an individual contract,

<sup>141</sup> <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=33794>.

<sup>142</sup> Local Coverage Determination (LCD): External Infusion Pumps (L33794) <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=33794>.

or under arrangements with a DMEPOS supplier to furnish services related to the administration of IVIG in the home, must be legally authorized (licensed, certified, or registered) in accordance with applicable Federal, State, and local laws, and must act only within the scope of their State license or State certification, or registration. A supplier may not contract with any entity that is currently excluded from the Medicare program, any State health care programs or from any other federal procurement or non-procurement programs.

## 2. Home IVIG Administration

Section 1861(s)(2)(Z) of the Act defines benefit coverage of intravenous immune globulin for the treatment of primary immune deficiency diseases *in the home*. Under the IVIG Demonstration, beneficiaries are eligible to participate if they receive IVIG services in “their home or a setting that is ‘home like’<sup>143</sup>”. Section 410.12(b) identifies the supplier types who can furnish the services identified at § 410.10. Section 410.38 provides the conditions for payment for DME suppliers and identifies the institutions that may not qualify as the patient’s home. As such, the home administration of IVIG items and services must be furnished in the patient’s home, defined as a place of residence used as the home of an individual, including an institution that is used as a home. An institution that is used as a home may not be a hospital, CAH, or SNF as defined in § 410.38(b).

### D. Proposed Home IVIG Items and Services Payment Rate

#### 1. Proposed Payment Amount for Home IVIG Items and Services for CY 2024

Section 1842(o) of the Act provides the authority for the development of a separate bundled payment for Medicare-covered items and services related to the administration of intravenous immune globulin to an individual in the patient’s home during a calendar day, in an amount that the Secretary determines to be appropriate. This payment may be based on the payment established pursuant to section 101(d) of the Medicare IVIG Access Act. Section 4134(d) of the CAA, 2023, amends section 1833(a)(1) of the Act to provide that, with respect to items and services related to the administration of IVIG furnished on or after January 1, 2024, as described in section 1861(zz) of the Act, the amounts paid shall be the lesser of

the 80 percent of the actual charge or the payment amount established under section 1842(o)(8).

In accordance with section 101(d) of the Medicare IVIG Access Act, the Secretary established a per visit payment amount for the items and services needed for the in-home administration of IVIG based on the national per visit low-utilization payment amount (LUPA) under the prospective payment system for home health services established under section 1895 of the Social Security Act. Per the Demonstration, the bundled payment amount for services needed for the home administration of IVIG includes infusion services provided by a skilled nurse. Therefore, the bundled payment is based on the LUPA amount for skilled nursing, based on an average 4-hour infusion. The initial payment rate for the first year of the Demonstration, was based on the full skilled nursing LUPA for the first 90 minutes of the infusion and 50 percent of the LUPA for each hour thereafter for an additional 3 hours. Thereafter, the payment rate is annually updated based on the nursing LUPA rate for such year. The service is subject to coinsurance and deductibles similar to other Part B services.

As we noted in section V.B.1. of this proposed rule, we believe that payment under section 1861(s)(2)(Z) of the Act covers the same items and services covered under the IVIG Demonstration. Likewise, we also agree that the professional services needed to safely administer IVIG in the home would be services furnished by a registered nurse. Therefore, we believe setting the CY 2024 payment rate for the home IVIG items and services under section 1861(s)(2)(Z) of the Act, based on the CY 2023 payment amount established under the Demonstration (\$408.23) is appropriate. However, although the Demonstration used the LUPA rate, which is annually adjusted by the wage index budget neutrality factor, as well as the home health payment rate update percentage, we believe it is appropriate to propose to update the CY 2023 IVIG services Demonstration rate by only the CY 2024 home health payment rate update percentage and not include the wage index budget neutrality factor, as the IVIG items and services payment rate is not statutorily required to be geographically wage adjusted. Therefore, the proposed home IVIG items and services payment rate for CY 2024 would be  $\$408.23 \times 1.027 = \$419.25$ .

Further, although section 1842(o) of the Act states that payment is for the items and services furnished to an

individual in the patient’s home during a *calendar day*, we believe that, as the statute aligns the payment amount with such amount determined under the Demonstration, the best reading of “calendar day” is “per visit.” Additionally, we would expect a supplier to furnish only one visit per calendar day.

We propose to establish a new Subpart R under the regulations at 42 CFR part 414 to incorporate payment provisions for the implementation of the IVIG items and services payment in accordance with section 1842(o) of the Act for home IVIG items and services furnished on or after January 1, 2024. We propose at § 414.1700(a), that a single payment amount is made for items and services furnished by a DMEPOS supplier per visit. We propose at § 414.1700(b), to set the initial payment amount equivalent to the CY 2023 “Services, Supplies, and Accessories Used in the home under the Medicare IVIG Demonstration” payment amount, updated by the proposed CY 2024 home health update percentage of 2.7 percent. We are soliciting comments on these payment proposals, including the proposed CY 2024 payment rate.

#### (a) Proposed Annual Payment Update

As discussed previously, the IVIG Demonstration used the nursing LUPA rate, which is annually adjusted by the wage index budget neutrality factor, as well as the home health update percentage, as the payment rate for such year of services. Because the IVIG services payment is not geographically wage adjusted, we believe it is more appropriate to annually adjust the IVIG items and services payment rate only by the home health payment update percentage. As such we propose at § 414.1700(c), beginning in 2025, the per-visit payment amount from the prior year will be annually increased by the home health update percentage for the current calendar year. We solicit comments on the use of the home health update percentage to annually update the IVIG items and services payment beyond CY 2024.

### E. Billing Procedures for Home IVIG Items and Services

In order to ensure a smooth transition for DME suppliers to bill for the items and services related to the home administration of IVIG, we will use the existing Q-code (Q2052) under the Demonstration, with a new descriptor (“Services, Supplies, and Accessories used in the Home for the Administration of Intravenous Immune Globulin”) in order to bill for items and services under Medicare FFS. The Q-

<sup>143</sup> Intravenous Immune Globulin Demonstration MLN Fact Sheet: <https://www.cms.gov/files/document/mln3191598-intravenous-immune-globulin-demonstration.pdf>.

code would continue to be billed separately from, or on the same claim as, the J-code for the IVIG product and would be processed through the DME MACs. The Q-code should be billed as a separate claim line on the same claim for the same place of service as the J-code for the IVIG. In cases where the IVIG product is mailed or delivered to the patient prior to administration, the date of service for the administration of the IVIG (the Q-code) may be no more than 30 calendar days after the date of service on the IVIG product claim line. No more than one Q-code should be billed per claim line per date of service.

If a provider is billing for multiple administrations of IVIG on a single claim, then the supplier would bill the Q-code for each date of service on a separate claim line, which would be payable per visit (that is, each time the IVIG is administered). There may be situations in which multiple units of IVIG are shipped to the patient and billed on a single “J” code claim line followed by more than one Q-code administration claim line, each with the date of service on which the IVIG was administered. However, only one Q-code shall be paid per infusion date of service. In order to implement the requirements for this separate bundled payment under section 1861(s)(2)(Z) of the Act, we would issue a Change Request (CR) prior to implementation of this payment, including the Q-code needed for billing, outlining the requirements for the claims processing changes needed to implement this payment.

## VI. Hospice Informal Dispute Resolution and Special Focus Program

### A. Background and Statutory Authority

Division CC, section 407 of the Consolidated Appropriations Act of 2021 (CAA), 2021, amended Part A of Title XVIII of the Act to add a new section 1822, and amended sections 1864(a) and 1865(b) of the Act, establishing new hospice program survey and enforcement requirements, required public reporting of survey information, and a new hospice hotline.

The provisions in the CAA, 2021 direct the Secretary to create a Special Focus Program (SFP) for poor-performing hospice programs, give authority for imposing enforcement remedies for noncompliant hospice programs, and require the development and implementation of a range of remedies as well as procedures for appealing determinations regarding these remedies. These enforcement remedies can be imposed instead of, or in addition to, termination of the

hospice programs’ participation in the Medicare program. The remedies include civil money penalties (CMP), directed in-service training, directed plan of correction, suspension of all or part of payments, and appointment of temporary management to oversee operations.

In the CY 2022 HH PPS final rule (86 FR 62240), we addressed provisions related to hospice survey enforcement and other activities described in the rule. A summary of the finalized CAA, 2021 provisions regarding hospice survey and enforcement can be found in the CY 2022 HH PPS final rule (86 FR 62243), available at <https://www.govinfo.gov/content/pkg/FR-2021-11-09/pdf/2021-23993.pdf>. We finalized all the CAA, 2021 provisions related to hospice survey and enforcement in CY 2022 rulemaking except for the SFP. As outlined in the CY 2022 HH PPS final rule, we stated that we would consider public comments we received and seek additional collaboration with stakeholders to further develop a revised proposal and methodology for the SFP.

In the FY 2023 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Requirements final rule (87 FR 4566) (Hospice rule), we affirmed our intention to initiate a hospice Technical Expert Panel (TEP) to provide input on the structure and methodology of the SFP. Public comments received in response to the FY 2023 Hospice rule generally supported CMS’s efforts to establish an SFP and to convene a TEP as part of the SFP development. A 30-day call for nominations was held July 14 through August 14, 2022, and nine TEP members were selected, representing a diverse range of experience and expertise related to hospice care and quality. A CMS contractor convened a TEP in October and November 2022, which provided feedback and considerations on the preliminary SFP concepts, including developing a methodology to identify hospice poor-performers, criteria for completing the SFP and for termination from Medicare when a hospice cannot complete the SFP, and public reporting. Details from the TEP meetings, including their recommendations, are available in the TEP summary report<sup>144</sup> on the CMS website at <https://www.cms.gov/medicare/quality-safety-oversight-certification-compliance/hospice-special-focus-program>.

<sup>144</sup> 2022 Technical Expert Panel and Stakeholder Listening Sessions: Hospice Special Focus Program Summary Report (April 28, 2023).

## B. Proposed Regulatory Provisions

### 1. Overview

In this proposed rule, we are proposing in Subpart M—Survey and Certification of Hospice Programs, to add new definitions of “Hospice Special Focus Program,” “IDR,” “SFP status,” and “SFP survey” at § 488.1105. We are also proposing a hospice informal dispute resolution process at § 488.1130 to provide hospice programs an informal opportunity to resolve disputes related to condition-level survey findings for those hospice programs that are seeking recertification from the State survey agency (SA), CMS, or reaccreditation from the accrediting organization (AO) for continued participation in Medicare. Informal dispute resolution would also be offered to hospice programs following a complaint or validation survey and those in the SFP. We are proposing the specific details on the hospice SFP at § 488.1135, which includes the criteria for selection and completion of the SFP, hospice termination from Medicare, and public reporting of the SFP. We are proposing that the hospice SFP will commence as of the effective date of the rule, and we anticipate selecting SFP hospices in CY 2024. We also propose to periodically review the effectiveness of the methodology and the algorithm.

### 2. Proposed Definitions (§ 488.1105)

We propose to add four new definitions to § 488.1105, that would define the hospice SFP, IDR, SFP status, and SFP survey. The definitions proposed for hospice programs are as follows:

- *Hospice Special Focus Program (SFP)* means a program conducted by CMS to identify hospices as poor performers, based on defined quality indicators, in which CMS selects hospices for increased oversight to ensure that they meet Medicare requirements. Selected hospices either successfully complete the SFP program or are terminated from the Medicare program.
- *IDR* stands for informal dispute resolution.
- *SFP status* means the status of a hospice provider in the SFP with respect to the provider’s standing in the SFP, which is indicated by one of the following status levels: Level 1—in progress; Level 2—completed successfully; or Level 3—terminated from the Medicare program.
- *SFP survey* refers to a standard survey as defined in § 488.1105 and is performed after a hospice is selected for the SFP and is conducted every 6 months, up to three occurrences.



### 3. Informal Dispute Resolution (§ 488.1130)

We propose at new § 488.1130 to make an Informal Dispute Resolution (IDR) process available to hospice programs to address disputes related to condition-level survey findings following a hospice program's receipt of the official survey Statement of Deficiencies and Plan of Correction, Form CMS-2567. The proposed IDR for hospices would be similar to the process already in existence for home health agencies. The proposed IDR process for hospice programs, like that of HHAs, is for condition-level survey findings which may be the impetus for an enforcement action. Standard-level findings alone do not trigger an enforcement action and are not accompanied by appeal and hearing rights. The proposed IDR process would provide hospice programs an informal opportunity to resolve disputes regarding survey findings for those hospice programs seeking recertification from the SA, CMS, or reaccreditation from the AO for continued participation in Medicare. Additionally, proposed IDR may be initiated for programs under SA monitoring (either through a complaint investigation or validation survey) and those in the proposed SFP. For hospice programs deemed through a CMS-approved AO, the AO would receive the IDR request from their deemed facility program, following the same process and coordinating with CMS regarding any enforcement actions. In accordance with 42 CFR 488.5(a)(4), AOs must have a comparable survey process to the SAs. For deemed hospice programs, the AO communicates any condition-level findings to the applicable CMS Location. If a deemed hospice fails to meet the Medicare requirements or shows continued condition-level noncompliance, deemed status is generally removed and oversight is placed under the SA. The purpose of the proposed IDR process would be to provide an opportunity to settle disagreements at the earliest stage, prior to a formal hearing, and to conserve time and money resources potentially spent by the hospice, the SA, and CMS. The proposed IDR process may not be used to refute an enforcement action or selection into the SFP. Additionally, we propose that failure of CMS, or the State or the AO, as appropriate, to complete IDR must not delay the effective date of any enforcement action.

When survey findings indicate a condition-level deficiency (or deficiencies), the hospice program would be notified in writing of its

opportunity to request an IDR for those deficiencies. This notice would be provided to the hospice program when the CMS-2567 Statement of Deficiencies and Plan of Correction is issued to the hospice. We propose that the hospice's request for IDR must be submitted in writing (electronically or hard copy), include the specific survey findings that are disputed, and be submitted within the same 10 calendar days allowable for submitting an acceptable plan of correction.

The proposed IDR provision balances the need for hospice programs to avoid unnecessary disputes and protracted litigation using the most rapid mechanism for correcting deficiencies and aligning with the interests of hospice patients/caregivers. IDR is meant to be an informal process whereby the provider has an opportunity to address the surveyor's findings, either by disputing them or providing additional information.

We propose that if any survey findings are revised or removed by the State or CMS based on IDR, and if CMS accepts the IDR results, the CMS-2567 would be revised accordingly. If CMS accepts the IDR results and the revised Form CMS-2567, then CMS would adjust any enforcement actions imposed solely due to those cited and revised deficiencies. If the survey findings are upheld by CMS or the state following IDR, the Form CMS-2567 would not be revised based on the IDR and there would not be adjustments to the enforcement actions.

### 4. Special Focus Program (§ 488.1135)

Section 1822(b) of the Act requires the Secretary to conduct a Special Focus Program for hospice programs that the Secretary has identified as having substantially failed to meet applicable requirements of the Act. We propose at § 488.1135 a hospice SFP to address issues that place hospice beneficiaries at risk for poor quality of care through increased oversight. We propose that specific criteria would be used to determine whether a hospice program participates in the SFP as outlined in the proposed rule. We also propose the proposed hospice SFP would commence as per the effective date of the final rule when published, and we anticipate selecting SFP hospices starting in CY 2024. We propose to periodically review the effectiveness of the methodology and the algorithm and make adjustments through rulemaking as necessary.

#### a. Proposed Hospice Special Focus Program Algorithm

In establishing the proposed Hospice SFP, we examined the Special Focus Facility program for nursing homes and its methodology for facility selection. Although the proposed methodology for the hospice program SFP is similar in certain facets, the proposed SFP methodology is tailored specifically to this setting and to the data that is available to evaluate hospice performance.

We propose to identify a subset of 10 percent of hospice programs based on the highest aggregate scores determined by the algorithm. The hospices selected for the SFP from the 10 percent would be determined by CMS.

To identify "poor performance," we have identified several indicators, namely, survey reports with Condition-Level Deficiencies (CLDs) and complaints with substantiated allegations, and CMS Medicare data sources from the Hospice Quality Reporting Program (HQR) (Medicare claims and Consumer Assessment of Healthcare Providers and Systems (CAHPS®) Hospice Survey). These indicators, which can be used to identify potential poor performance, have been integrated into the proposed SFP algorithm to assist in identifying potential hospice providers for the SFP.

As discussed previously, we propose to use multiple data sources to provide a comprehensive view of the quality of care provided at the identified hospices. The compilation of these data sources illustrates areas of concern—validated/identified issues based on in-person/on-site review of a hospice to meet Medicare requirements; caregiver and public complaints about hospices not providing quality of care or not meeting Medicare requirements; and quality measures that inform the public of whether a hospice is providing expected care processes or outcomes. We believe these are indicators of poor quality hospice care. The proposed SFP algorithm is designed as an initial step in identifying poor quality indicators.

#### b. Proposed Use of Medicare Data Sources To Identify Poor Performing Hospices

To identify hospices with poor quality indicators, we propose using the most recent complete Medicare hospice data from two data sources: (1) hospice surveys; and (2) Medicare HQR. Each source represents distinct dimensions of hospice care that we have identified as related to a hospice's performance or practices. From these data sources, we propose using multiple indicators of

hospice care delivery to identify poor performing hospices (see Table 1). Hospices would be identified for potential SFP enrollment if they—(1) have data from any of the aforementioned data sources; (2) are

listed as an active provider (that is, have billed at least one claim to Medicare FFS in the last 12 months); and (3) operate in the United States, including the District of Columbia and U.S. territories. Each data source and the

proposed quality indicators are discussed further later in this preamble. Based on these proposed criteria, in CY 2019 through CY 2021 analytic file, 5,943 hospices would be eligible for participation in the SFP.

**TABLE F1. PROPOSED PRIMARY MEDICARE DATA SOURCES AND INDICATORS IN THE SPECIAL FOCUS PROGRAM**

| Data Source | Hospice Surveys                              | Hospice Quality Reporting Program (HQRP) |                                       |
|-------------|--|--|---------------------------------------|
|             |  | Claims Data                              | CAHPS® Hospice Survey Measures        |
| Indicators  | Quality-of-Care Condition-Level Deficiencies | Hospice Care Index (HCI)                 | Help for Pain and Symptoms            |
|             | Substantiated Complaints                     |  | Getting Timely Help                   |
|             |  |  | Willingness to Recommend this Hospice |
|             |  |  | Overall Rating of this Hospice        |

(1) Hospice Survey Data

(a) Quality-of-Care Condition-Level Deficiencies (CLDs)

Hospices are surveyed for compliance with hospice program requirements prior to becoming certified as a hospice provider in Medicare (initial certification survey) and then at least once every 36 months (standard survey for recertification (§ 418.1110)), with roughly one-third of all hospices being surveyed each year. A post-survey revisit or follow-up survey may also occur to determine if the hospice corrected cited deficiencies. Hospice survey data (initial certification, standard recertification, and follow-up) is collected on the Certification And Survey Provider Enhanced Reports (CASPER) system. CMS will be posting publicly available hospice survey finding information to the Quality, Certification and Oversight Report (QCOR) website in CY 2023. For

information related to the hospice survey process, we encourage the public to review the CMS State Operations Manual (SOM), Appendix M (internet Only Publication 100–07).

A CLD is cited on a survey when a hospice is found to be noncompliant with all or part of a condition of participation (CoP), which is one of the health and safety requirements all hospices are required to meet to participate in Medicare. As discussed in the QSOG memo (QSO–23–08–hospice) issued on January 27, 2023, a significant change in the hospice survey protocol was made to provide an enhanced approach to investigating the quality-of-care provided to hospice patients. While each of the 23 CoPs continues to have equal weight in the final certification decision, special attention is directed to those CoPs directly impacting patient care for purposes of the proposed SFP. Consistent with this enhanced survey process, we have identified 11 quality-

of-care CoPs that directly contribute to the quality-of-care delivered to patients, their caregivers, and families, and believe that a cited CLD on any one of them may indicate a hospice is providing poor quality-of-care. Therefore, we propose to include the 11 quality-of-care CLDs noted in Table F2) as data indicators in the SFP algorithm. The SFP algorithm would focus on quality-of-care CLDs because they are based on observable quality concerns seen and reported by hospice surveyors to identify hospices that provide poorer quality-of-care to hospice patients. Additionally, we did not include all 23 hospice CoPs because we did not want to dilute the methodology’s ability to identify quality concerns. However, we may explore incorporating other CoPs into the methodology, and we solicit comments on an alternative approach that would incorporate other CoPs in the calculation for the SFP algorithm.

**TABLE F2. QUALITY OF CARE**

| Tag      | Condition of Participation  |
|----------|---|
| §418.52  | Condition of participation: Patient's rights.   |
| §418.54  | Condition of participation: Initial and comprehensive assessment of the patient.                    |
| §418.56  | Condition of participation: Interdisciplinary group, care planning, and coordination of services.   |
| §418.58  | Condition of participation: Quality assessment and performance improvement.                         |
| §418.60  | Condition of participation: Infection control.  |
| §418.64  | Condition of participation: Core services.  |
| §418.76  | Condition of participation: Hospice aide and homemaker services.                                    |
| §418.102 | Condition of participation: Medical director.   |
| §418.108 | Condition of participation: Short-term inpatient care.  |
| §418.110 | Condition of participation: Hospices that provide inpatient care directly.                          |
| §418.112 | Condition of participation: Hospices that provide hospice care to residents of a SNF/NF or ICF/IID. |

We propose to count the total number of quality-of-care CLDs from the previous 3 consecutive years of data. Our analysis of data from CY 2019 through 2021 found that very few hospices are not present in the survey data, and that the overwhelming majority of hospices (88.3 percent of all proposed SFP-eligible hospices or 5,248 out of 5,943) had no quality-of-care CLDs cited over these 3 years. Of the 5,943 hospices identified that would be SFP-eligible under the CY 2019–2021 data, 5.7 percent (that is, 341 hospices) are not present in the survey data. This means that each of those 341 hospices has not yet received its standard survey or their survey results had not been recorded as of the time the data was accessed for analysis from the CASPER system and/or had no recorded substantiated complaint in the internet Quality Improvement and Evaluation System (iQIES). Considering public comments received on the CY 2022 HH PPS final rule (86 FR 62240) and the SFP TEP feedback, stakeholders expressed concern about inter-surveyor reliability and state-to-state variability in survey policy as potential drawbacks of including survey data as part of the SFP program methodology. However, the TEP also acknowledged the importance and value of survey data that identifies whether a hospice complies with Medicare requirements to support basic care quality. Furthermore, the TEP supported using the total count of quality-of-care CLDs to indicate significant noncompliance with multiple CoPs. To address the inter-surveyor reliability and variability concerns, we have implemented improvements to surveyor training guidelines to increase surveyor standardization between SAs and AOs. Based on our efforts to improve surveyor training, and considering the TEP and stakeholder concerns, we propose counting the total number of quality-of-care CLDs from the last 3 consecutive years of data.

#### (b) Substantiated Complaints

In addition to quality-of-care CLDs, we propose to include the total number of substantiated complaints received against a hospice in the last 3 consecutive years of data before the release of the SFP selection list. Complaints against a hospice may be filed with the SA or Beneficiary and Family Centered Care Quality Improvement Organization at any time by a patient and/or caregiver(s) and hospice staff members (Medicare SOM Chapter 5). Once a complaint is filed with the SA, the SA can conduct an unannounced complaint investigation

survey to substantiate or refute the complaint. If the allegation is found to be substantiated or confirmed, the SA informs the hospice and submits the findings to iQIES. A post-survey revisit or follow-up survey may also occur to determine if the hospice has made corrections and is in compliance with all requirements. A hospice may have many complaints filed against them, but not all complaints may be substantiated upon SA review. The results of the review of complaints are submitted to the iQIES system, which is not publicly available. Like quality-of-care CLDs, most hospices in our analysis currently have no substantiated complaints in the identified 3-year period. Our CY 2019–2021 survey data analysis found that currently 81.8 percent of hospice programs (that is, 4,860 of the 5,943 SFP-eligible hospices) have had no substantiated complaints over the past 3 years. As noted previously, there are 5.7 percent of eligible hospices that have no survey data, or in other words, there is missingness in the survey data for those hospices. Unlike quality-of-care CLDs, where missingness is likely due to the absence of a recent survey, the absence of substantiated complaints from this data is likely because the hospice program has no substantiated complaints.

#### (2) Hospice Quality Reporting Program (HQRP) Data

In addition to survey data, we propose to use quality measures from the Hospice Quality Reporting Program (HQRP) to capture hospice care processes and beneficiary/caregiver care experiences. The HQRP includes data submitted by hospices via the Hospice Item Set (HIS), Medicare hospice claims, and the CAHPS Hospice Surveys. All Medicare-certified hospices must comply with these reporting requirements or face penalties for a failure to report, although some hospices may be exempt from reporting certain measures.<sup>145</sup> This ensures that most hospices have these data available for use in the SFP algorithm. These quality measure data are publicly available in the Provider Data Catalog (PDC) at <https://data.cms.gov/provider-data/topics/hospice-care> and Care Compare at <https://www.medicare.gov/care-compare/?providerType=Hospice>. A description of current HQRP measures and public reporting dates is available online. We propose to include five publicly reported HQRP measures

<sup>145</sup> Information on the reporting requirements and Annual Payment Update payment penalties for the failure to report can be found on the HQRP Overview website or section 1814(i) of the Act.

to identify poor performing hospices. The proposed measures are as follows:

- Medicare claims-based measure:— Hospice Care Index (HCI) Overall Score
- CAHPS Hospice Survey Data measures:
  - ++ Help for Pain and Symptoms
  - ++ Getting Timely Help
  - ++ Willingness to Recommend this Hospice
  - ++ Overall Rating of this Hospice

#### (a) Hospice Care Index (HCI)

We propose including the HCI overall score based on eight quarters of Medicare claims data. The HCI captures multiple aspects of care delivery across ten indicators that comprise a composite HCI overall score, with hospices earning a point for each indicator met (range: 0–10 such that a lower score indicates lower quality of care). The proposed HCI overall score indicates hospice care quality between admission and discharge (HCI Technical Report). Moreover, the HCI score is based on Medicare claims data, which provide direct evidence of care delivery decisions at a hospice that is readily available for all hospices. For public reporting, hospices with less than 20 claims over the eight quarters are excluded from reporting the measure. The HCI measure would also be suppressed if any 1 of the 10 indicators is not reported for any reason. Additional details of the HCI, such as the quality measure specifications, data period, and exclusion criteria, are available in the HQRP Quality Measure (QM) User's Manual posted on the HQRP Current Measures web page. The TEP and previous public comments generally supported the inclusion of HCI data in the preliminary methodology because the HCI captures a robust majority of hospices participating in Medicare and covers key aspects of the hospice care continuum. Our analysis of FYs 2019 to 2021 (excluding January through June 2020) HCI data found that 78.3 percent of hospice programs (that is, 4,656 of the 5,943 SFP-eligible hospices) had a publicly reported HCI score. The overwhelming majority of those hospices receive an HCI score of 8 or more out of 10—4,007 (86.1 percent) of the 4,656 SFP eligible hospices with an HCI score reported.

#### (b) CAHPS Hospice Survey

To represent decedent/caregiver experience of hospice care, and in consideration of TEP and stakeholder perspectives, we propose using four measures from the CAHPS Hospice Survey: (1) help for pain and symptoms;

(2) getting timely help; (3) willingness to recommend the hospice; and (4) overall rating of the hospice. CAHPS Hospice Survey measure scores are calculated across eight rolling quarters for all hospices with at least 30 completed surveys. Some hospices do not participate in CAHPS as new hospices are exempt from reporting CAHPS measures for the calendar year in which they receive their CMS Certification Number (CCN), and hospices can apply for a CAHPS exemption if they serve fewer than 50 survey-eligible decedents/caregivers in a given calendar year. The CAHPS Hospice measures are publicly available from the Provider CAHPS Hospice Survey Data file on the Hospice PDC. Additional details are in the QM User's Manual on the HQR Current Measures web page. These CAHPS Hospice Survey measure scores are also publicly reported on the Care Compare website at <https://www.medicare.gov/care-compare/?providerType=Hospice>. As discussed in the SFP TEP report, TEP and other stakeholders agreed that the algorithm is strengthened by including the four CAHPS Hospice Survey measures as they reflect caregiver-reported experiences in key areas of hospice quality not reflected in claims or inspection surveys.

From the CAHPS Hospice Survey data, we propose to use adjusted bottom-box scores of the four measures described previously above to create a CAHPS Hospice Survey Index. As described in the CMS document, "Calculating CAHPS® Hospice Survey Top-, Middle-, and Bottom-Box Scores," that summarizes the steps we use to calculate CAHPS Hospice Survey measure scores, "bottom-box" scores are calculated for each respondent as "100" if the respondent selected the least positive response categories for that question and "0" if the respondent selected a different response category; survey respondents who do not answer a question are not included in the scoring of that question. In the CAHPS Hospice Survey, different questions have different response scales, so the bottom-box responses vary across the survey. For example, for questions with response options of "Yes, definitely," "Yes, somewhat," and "No," the bottom-box response is "No"; for questions with response options of "Never," "Sometimes," "Usually," and "Always," the bottom-box responses are both "Never" and "Sometimes"; Person-level bottom-box scores for each question are then adjusted for mode of survey administration and case-mix to produce hospice-level bottom-box

scores. Bottom-box scores for a particular question can be interpreted as the percentage of respondents who selected the least positive response category(ies) after adjusting for mode of survey administration and differences in the mix of decedent/caregiver characteristics across hospices. Composite measure scores, such as those for Help for Pain and Symptoms and Getting Timely Help, are formed by taking the average of fully-adjusted hospice-level question scores within the composite. We propose using bottom-box scores for the SFP, because they quantify reported problematic care experiences. To create the CAHPS Hospice Survey Index, we propose to calculate a single score for each hospice by taking a weighted sum of the bottom-box scores for the four CAHPS measures, as described later in this section. Specifically, we propose that the two measures that represent overall assessments of hospice care (that is, Willingness to Recommend this Hospice and Overall Rating of this Hospice) each be given a weight of 0.5 as these measures assess similar concepts. We propose to weight the other two measures, Help for Pain and Symptoms and Getting Timely Help, at 1.0 each to reflect that these measures assess distinct aspects of care.

To illustrate, not including usually applied adjustments to the data for case mix and mode of survey administration, if Hospice A received a bottom-box score of 100 on the Overall Rating of this Hospice, that means that all the survey respondents responded to the question and gave the hospice an overall rating of zero to six, the least positive possible responses (middle-box options: 7–8; top-box option: 9–10). The hospice could then receive, a bottom-box score of 0 on the Help for Pain and Symptoms measure, meaning none of the survey respondents selected the least positive responses on any of the questions that make up this measure. If Hospice A also received a bottom-box score of 12 on the Willingness to Recommend this Hospice and a bottom-box score of 4.5 on the Getting Timely Help measure, meaning that approximately 12 percent and 4.5 percent of respondents, respectively, selected the bottom-box scores, then Hospice A's total CAHPS Hospice Survey Index would be 60.5, calculated as follows:  $((100 + 12) * 0.5) + (0 + 4.5) = 60.5$ . The maximum value for the CAHPS Hospice Survey Index would be 300 points. For this index, a lower number of points would indicate a higher quality score.

Our analysis of CYs 2019 to 2021 (excluding January through June 2020) CAHPS Hospice Survey data found that

49.3 percent of eligible hospice programs (2,929 of the 5,943 SFP-eligible hospices) report the four CAHPS Hospice Survey measures. Compared to the other three indicators (quality-of-care CLDs, substantiated complaints, and HCI), the scores from the four CAHPS measures are more dispersed around their average value. The average CAHPS Hospice Survey Index value for these four measures combined is 24, with an overall range of 2 to 83 from the SFP-eligible hospices (lower scores indicate better performance; total possible range: 0–300). The distribution of these values is roughly symmetric and centered on an average such that the likelihood of observing a value different from the average value becomes smaller the further away the value is from the average.

### c. Proposed Data Source Preparation

We propose to compile the data for the algorithm indicators (quality-of-care CLDs, substantiated complaints, HCI, the four CAHPS Hospice measures) and remove hospices not eligible for SFP to create a single score for every hospice. A Medicare-certified hospice program would be included in the algorithm if it—(1) is an active provider that has billed at least one claim to Medicare FFS in the last 12 months as captured in iQIES; and (2) has data for at least one algorithm indicator.

For the HCI and CAHPS data, we propose pulling the latest HCI and CAHPS data from the Hospice PDC. For example, we would use data from November 2023 to identify the pool of hospices eligible to be in the SFP on or after January 1, 2024.

#### (1) Survey Data and HCI

For the survey data, we propose the following steps to prepare data for the algorithm:

- *Step One:* We propose to pull 3 consecutive years of survey data preceding the release of the SFP selection list, including data for all relevant hospice survey types (initial certification, standard, complaint, and follow-up surveys). For identifying the pool of hospices eligible to be in the SFP on or after January 1, 2024, we propose to use 2020–2023 survey data.
- *Step Two:* From the survey data in Step One, we propose to count the total number of quality-of-care CLDs for each hospice in the data file. Quality-of-care CLDs can be found in any hospice survey (initial certification, standard, complaint, follow-up). They are denoted within a survey under specific citation codes (Table F2).
- *Step Three:* From the data file in Step One, we propose to count the total

number of substantiated complaints for each hospice in the data file. Substantiated complaints can be found in complaint and follow-up hospice surveys.

Our initial analysis found that the proposed SFP-eligible hospices may have missing indicators from the survey data (quality-of-care CLDs, substantiated complaints,) and/or HCI. To address the algorithm’s missing data for these indicators, we propose standardizing each indicator for quality-of-care CLDs, substantiated complaints, and HCI. Specifically, we propose that hospices missing any of these three indicators would be assigned a value of zero for that indicator after standardization (see section VI.B.4.d. of this proposed rule).

(2) CAHPS® Hospice Survey Data

As discussed previously, CAHPS Hospice Survey data are not available for hospices that are exempt from participating due to size or newness, or for hospices for which there are fewer than 30 completed surveys over an eight-quarter reporting period. Since these hospices may differ systematically from hospices that do have publicly reported CAHPS Hospice Survey data, we do not believe it is appropriate to assign hospices the average value of the CAHPS Hospice Survey Index if they are missing these data. After standardizing the CAHPS Hospice Survey measures (using the same process for survey data and HCI as proposed in sections VI.B.4. and VI.B.4.d. of this proposed rule), we propose addressing missing CAHPS Hospice Survey data by averaging the total number of data indicators used to derive the score. The score for hospices with missing CAHPS Hospice Survey data would be based solely on all other indicators (CLDs, complaints, and HCI), and the score for hospices with available CAHPS Hospice Survey data includes the CAHPS Hospice Survey Index in addition to the other indicators

(see section VI.B.4.d.(2) of this proposed ruled.

d. Proposed Data Source Standardization

We propose standardizing each indicator (that is, quality-of-care CLDs, substantiated complaints, HCI, and the CAHPS Hospice Survey Index) to compare indicators equally despite each data source’s different units of measurement. For example, both quality-of-care CLDs and substantiated complaints are continuous variables that have no ceiling to how many quality-of-care CLDs or substantiated complaints a single hospice can receive. In contrast, a hospice can only receive a maximum value of 10 from the HCI quality measure. Therefore, if we do not rescale HCI, we would be deemphasizing the importance of HCI for the SFP as a relevant dimension of care quality because the range of possible values for HCI is much smaller than the range of possible values for quality-of-care CLDs and substantiated complaints. By standardizing the data as proposed, we can understand how different the indicator is for a single hospice compared to the indicator from the average hospice and shift the unit to a magnitude of difference from the average across all indicators to compare the data source indicators under a shared measurement unit.

As a simplified example to illustrate the importance of standardization, Hospice A has one quality-of-care CLD and HCI score of 3. These two numbers’ absolute differences are two (3 HCI – 1 quality-of-care CLD = 2). However, examining the absolute difference in these numbers does not indicate that Hospice A delivers poor care quality. To better explain how these two indicators relate to one another and quality, we look at the likelihood that Hospice A would receive one quality-of-care CLD and the likelihood that it would receive an HCI score of 3. To determine this likelihood, we propose comparing these

numbers to the respective averages of all other hospices for the indicators. The average number of quality-of-care CLDs for hospices is a little less than 0.5. Most hospices have zero quality-of-care CLDs. While a quality-of-care CLD of one is larger than the average (0.5), the magnitude of difference between the one quality-of-care CLD in Hospice A and the 0.5 quality-of-care CLDs for the average hospice is not very large. When considering HCI, the average HCI score for all hospices is 8.9 (a higher HCI score indicates better performance on the measure). An HCI score of three is a large difference from the average of 8.9, and as a result, it is unlikely that a hospice would receive this kind of score if it was an average HCI performer. The likelihood of observing a value different from the average is the type of information we propose to include to determine poor performers. By standardizing the indicators, we shift our interpretation from what value they received to an estimation of how likely they are to receive the value if they were an average hospice. We believe this approach would improve the proposed algorithm’s ability to identify those hospice programs with the most unlikely values across our four indicators and those that are the poorest performers across indicators compared to all other active hospices in the SFP analytic file.

The previous fictitious example illustrates how indicators are standardized. We propose to adopt the most common standardization method, which would be applied to each of the indicators for a specific hospice (hospice indicators). For each indicator, this would be done by taking the indicator’s observed value for the hospice and subtracting that indicator’s average value for all hospices. We propose to then divide this number (the difference) by the standard deviation, a common measure of data variance, to tell us how clustered data are around the average (see the following equation).

$$\text{Standardized Value} = \frac{\text{Hospice Value} - \text{Overall Average}}{\text{Standard Deviation}}$$

As a function of this proposed approach, all indicators are centered with a mean of zero and a standard deviation of one. The transformed indicator tells us how likely a value for a given hospice would be observed and allows us to compare indicators (by adding them together) to determine which hospices have the most unlikely values compared to other hospices.

(1) Proposed Weighting of the Standardized Values

The proposed standardization discussed earlier allows an indicator’s data to be compared to another standardized indicator. Therefore, we would be comparing how different the observed value is from the average value to make all indicators mathematically

equal. We propose to weight each indicator by multiplying an indicator by a constant value to account for their relative importance in the methodology.

As part of our consideration for determining the weights for each indicator, the TEP and stakeholder listening sessions offered considerations related to weighting the data sources. In discussing the weighting of

substantiated complaints, quality-of-care CLDs, and HCI, the TEP and stakeholders agreed that they represent relevant dimensions of care quality but did not raise concerns or discuss whether one of these indicators was more or less indicative of care quality relative to another. However, the TEP and stakeholders emphasized the importance of patient and caregiver perspectives represented by the CAHPS measures, noting they are the most integral dimension of hospice care quality. As discussed in the SFP TEP report on page 15, “some TEP members argued that the valuable perspectives of families and caregivers on the CAHPS Hospice Survey justified weighting it more than other data sources.” Based on the consistent feedback from the TEP and stakeholder listening sessions, we propose to weight the CAHPS Hospice Survey Index by twice that of the other measures (that is, multiply CAHPS Hospice Survey Index by two).

#### (2) Proposed Approach for Missing CAHPS Data

In three of the four indicators used in the algorithm, data exhibit an exceptional amount of concentration around the average value for the indicator. We propose replacing missing values in quality-of-care CLDs, substantiated complaints, and HCI with the average value for each of those indicators for an individual hospice to assign a score to that hospice (see section VI.B.4.d. of this proposed rule).

The CAHPS Hospice Survey, Index is distinct from these other three

indicators for several reasons warranting separate treatment for its missingness. First, the CAHPS Hospice Survey Index does not exhibit the same high concentration around the average value as the other measures. This means that there is more variability in the CAHPS Hospice Survey Index than in the other indicators. As a result of this increased variability, it is increasingly unlikely that those values that are missing are close to the average value. Second, more hospices are missing CAHPS Hospice Survey data than are missing data for other indicators in the algorithm. In our review of the CY 2019–2021 analytic file (excluding January 1–June 30, 2020), there is CAHPS Hospice Survey data for only about 49 percent of all SFP-eligible hospices. Due to reporting exemptions for small and/or newer hospices, those missing values are disproportionately from that cohort of providers. Because of this trend, it is difficult to draw any conclusions about the missing values given that there are no data from small hospices by which we can compare if the smaller/newer hospice CAHPS average is similar to those for which we have observed data. Third, hospices with fewer than 50 distinct beneficiaries can file for an exemption from reporting CAHPS. If we replace missing CAHPS Hospice Survey measure values with the average value, poor performing small hospices could benefit from being small by opting into being treated as an average hospice by becoming exempt from reporting their poor CAHPS Hospice Survey measure values. For

these reasons, we propose a different treatment for CAHPS Hospice Survey missingness. Instead of replacing missing CAHPS Hospice Survey measure scores with the average values for those measures, we propose to run hospices with data for CAHPS Hospice Survey measures through a version of the algorithm that considers the CAHPS Hospice Survey Index, and for those hospices that do not have CAHPS Hospice Survey data, through a version of the algorithm that does not consider the CAHPS Hospice Survey Index. To make the two resulting scores comparable, we then average the scores based on the total number of indicators used to calculate the score.

For the hospices without CAHPS Hospice Survey data, we would divide their scores by three because their score was calculated from three indicators: quality-of-care CLDs, substantiated complaints, and HCI. For the hospices with CAHPS Hospice Survey data, we would divide their scores by five because the weight on the CAHPS Hospice Survey Index means it is mathematically counted twice, so the indicators would be quality-of-care CLDs, substantiated complaints, HCI, and the CAHPS Hospice Survey Index, which is counted twice due to the weight of two on the indicator. This approach to handling missing CAHPS data is beneficial because it does not make assumptions about the values for missing CAHPS data.

- *With CAHPS Hospice Survey Index:*

$$CLDs \text{ over } 3 \text{ years} + \text{Complaints over } 3 \text{ years} - HCI + 2(\text{CAHPS Index}) = \frac{\text{Score}}{5}$$

- *Without CAHPS Hospice Survey Index:*

$$CLDs \text{ over } 3 \text{ years} + \text{Complaints over } 3 \text{ years} - HCI = \frac{\text{Score}}{3}$$

#### (3) Example Results

To illustrate how the proposed algorithm would behave, we discuss later in this section how two example hospices' (Hospice A's and Hospice B's) algorithm scores would be produced based on their indicator values. As discussed previously, the methodology would be one step in determining whether a hospice is selected for the SFP.

Hospice A is a large hospice, serving 500 beneficiaries on average over the

last 3 years. Over the past 3 years, they received zero quality-of-care CLDs, two substantiated complaints, and an HCI score of nine. At the same time, their CAHPS Hospice Survey Index measure is 44.5, which is larger than the average value of 28, which may indicate a quality concern. When we standardize these values to examine how different they are from the average hospice, we find that their quality-of-care CLD standardized value is zero, their substantiated complaint standardized

value is 0.6, their HCI is 0.1, and their CAHPS Hospice Survey Index is 2.4. As we suspected, three of their indicators are closely in line with the average hospice. Only their CAHPS Hospice Survey Index of 2.4 tells us that their bottom-box scores for the four quality measures is 2.4 standard deviations away from the average hospice. We would then include these four indicators in the algorithm:  $0 + 0.6 - 0.1 + (2 * 2.4) = 5.3$ . As explained above, for hospices with CAHPS data, we would

divide their scores by five, and since Hospice A has a CAHPS Hospice Survey Index, the final value would be divided by five. Hospital A's final algorithm score is:  $5.3/5 = 1.06$ . We then take this score and compare it to all other scores generated from all hospices and put them in order from highest to lowest, and we find that Hospice A ranks at 331. Because of the algorithm's emphasis on CAHPS, Hospice A's poor CAHPS Hospice Survey Index would make it more likely to be identified as a candidate, but because Hospice A performed well on the other three indicators, it would be less likely to be selected as a SFP participant compared to other hospices.

Hospice B is a mid-sized hospice serving an average of 120 distinct beneficiaries over the past 3 years. It has not reported CAHPS Hospice Survey data across the four measures. They received 42 substantiated complaints, 15 quality-of-care CLDs, and an HCI of 10. The number of substantiated complaints and quality-of-care CLDs are quite high even though they have achieved all 10 indicators of HCI. After we standardize, Hospice B's quality-of-care CLD value is 9.2, its complaint rate is 16.4, and its HCI is 0.9. We would calculate Hospice B's score in the following way:  $9.2 + 16.4 - 0.9 = 24.7$ . As explained previously, for hospices without CAHPS® data, we would divide their scores by three, and since Hospice B does not have a CAHPS Hospice Survey Index, this final value would be divided by three:  $24.7/3 = 8.2$ . When comparing this score of 8.2 to all other hospices, we would find that Hospice B has the highest algorithm score among all hospices, indicating it has the poorest quality indicator outcomes. Even though its HCI score is high and we do not know its CAHPS value, Hospice B's high substantiated complaint rate and high number of quality-of-care CLDs would make it a very likely candidate for the SFP.

#### e. Proposed Selection Criteria

Based on public comment in the CY 2022 HH PPS final rule and recommendations from the SFP TEP and other stakeholders, we propose a SFP selection process that utilizes a non-stratification approach. In addition, we considered the input of the SFP TEP and stakeholders, who expressed that the selection approach should identify the poorest performing hospices, regardless of characteristics, such as size or location, and therefore favored an approach with no stratification by state or otherwise.

We propose at § 488.1135(b) that hospices with AO deemed status that

are placed in the SFP would not retain deemed status and would be placed under CMS or, as needed, SA oversight jurisdiction until completion of the SFP or termination.

The number of hospices selected to participate in the SFP would be determined in the first quarter of each calendar year. The claims-based quality measure data used in the proposed algorithm is not available until November of each calendar year. This data is needed to run the algorithm, which is used to establish the aggregate score from which SFP participants are selected. As an SFP selectee, a hospice would not be removed from the SFP until they either meet the criteria for graduation or are terminated from the Medicare program.

#### f. Proposed Survey and Enforcement Criteria

As indicated in the CAA, 2021 adding section 1822(b)(2) of the Act, once in the SFP, a hospice must be surveyed "not less than once every 6 months." Based on the TEP discussion, TEP members agreed with the 6-month recertification survey frequency for hospices in the SFP, and we are proposing this frequency at proposed § 488.1135(c). Additionally, SFP hospices would be subject to one or more remedies specified in § 488.1220, and progressive enforcement remedies, as appropriate, at the discretion of CMS and consistent with 42 CFR part 488, subpart N. When CMS chooses to apply one or more remedies specified in § 488.1220, the remedies would be applied on the basis of noncompliance with one or more conditions of participation and may be based on failure to correct previous deficiency findings as evidenced by repeat condition-level deficiencies. The enforcement remedies could be imposed for an SFP hospice with condition-level deficiencies on a SFP survey or complaint survey while in the program. Furthermore, if subsequent surveys also result in the citation of a condition-level deficiency or deficiencies for an SFP hospice, the enforcement remedies imposed could be of increasing severity. Increasing severity could mean a higher CMP than was imposed for the earlier noncompliance or increasing from one remedy to more than one remedy being imposed. CMS would use its discretion to determine what remedies are most appropriate given the survey results, and the hospice may be subject to remedies of increasing severity.

#### g. Proposed SFP Completion Criteria

The TEP generally agreed that to complete and graduate from the SFP, SFP hospices should have no CLDs

cited for two consecutive 6-month recertification surveys in an 18-month timeframe. TEP members also suggested that SFP hospices should have no substantiated complaints and less than a defined number of standard-level deficiencies (SLDs) on two consecutive 6-month recertification surveys within the 18-month timeframe to complete the SFP. TEP members recommended a stepwise completion process, with SFP hospices preliminarily graduating after completing two consecutive 6-month recertification surveys within the 18-month timeframe in accordance with all completion requirements as proposed at § 488.1135(d). We considered the TEP's recommendations. However, we are proposing that SFP hospices have no CLDs for any two SFP surveys in an 18-month period. Therefore, we propose in new § 488.1135(d) that a hospice will have completed the SFP if it has in an 18-month timeframe, no CLDs cited or IJ's for any two 6-month SFP surveys, and has no pending complaint survey triaged at an immediate jeopardy or condition level, or has returned to substantial compliance with all requirements. If there are complaint investigations or a 36-month recertification survey for a hospice while in the SFP, the SFP timeline may extend beyond the 18-month timeframe. The official completion date would be the date of the CMS notice letter informing the hospice of its removal from the SFP. After completing the SFP, hospice programs would receive a one-year post SFP survey and then would start a new standard 36-month survey cycle.

#### h. Proposed Termination Criteria

A hospice in the SFP that fails any two SFP surveys, by having any CLDs on the surveys, in an 18-month period, or pending complaint investigations triaged at IJ or condition-level, would be considered for termination from the Medicare program as proposed at new § 488.1135(e). This criterion would apply to all hospices, regardless of geographical location, and reflects some TEP recommendations. CMS would issue the termination letter to the hospice program in accordance with 42 CFR 489.53. Depending on the deficiencies that brought a hospice into the SFP, CMS recognizes that a provider may need a reasonable period to achieve substantial compliance. But, if the hospice is not able to achieve substantial compliance at any time during the 18 months, they would be considered for termination from the Medicare program. Those providers that are unable to resolve the deficiencies that brought them into the SFP and

cannot meet the proposed completion criteria of having no CLDs cited for any two SFP surveys during an 18-month period, would be placed on a termination track. If a hospice in the SFP has an IJ-level deficiency cited during a survey, CMS would follow the requirements at § 488.1225.

i. Public Reporting of SFP Information

Public reporting of the proposed SFP includes making accessible both general information about the SFP program and hospices selected for SFP. A guideline for communicating SFP information appears in the section 407 of CAA, 2021 (Pub. L. 116–260), which requires hospice survey findings to be “prominent, easily accessible, readily understandable, and searchable for the general public and allows for timely updates.”

We propose in new § 488.1135(f) to publicly report, at least on an annual basis, the hospice programs selected for the SFP under proposed § 488.1135(b). Initially, this information would be posted on a CMS public-facing website at <https://www.cms.gov/medicare/quality-safety-oversight-certification-compliance/hospice-special-focus-program>, or a successor website. Specifically, we propose the website will include, at a minimum, general information, program guidance, a subset consisting of 10 percent of hospice programs based on the highest aggregate scores determined by the algorithm, and SFP selections from the 10 percent subset as determined by CMS, and SFP status as proposed in the definitions at § 488.1105.

**VII. Proposed Changes Regarding Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS)**

*A. Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program (CBP)*

1. Background

a. Durable Medical Equipment, Prosthetics, Orthotics, and Supplies Competitive Bidding Program

Section 1847(a) of the Act, as amended by section 302(b)(1) of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Pub. L. 108–173, December 8, 2003), mandates the Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program (CBP) for contract award purposes to furnish

certain competitively priced DMEPOS items and services subject to the CBP—

- Off-the-shelf (OTS) orthotics, for which payment would otherwise be made under section 1834(h) of the Act;
- Enteral nutrients, equipment, and supplies described in section 1842(s)(2)(D) of the Act; and
- Certain DME and medical supplies, which are covered items (as defined in section 1834(a)(13) of the Act) for which payment would otherwise be made under section 1834(a) of the Act.

For a list of product categories included in the DMEPOS CBP, please refer to <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/DMEPOSCompetitiveBid/Round-2021/PCs>. Areas in which the CBP are not implemented are known as non-competitive bidding areas (non-CBAs). We use the term “former CBAs” to refer to the areas that were formerly CBAs prior to a gap in the CBP, to distinguish those areas from “non-CBAs.” More information on why there was a gap in the CBP from January 1, 2019, through December 31, 2020, can be found in the November 14, 2018 final rule titled “Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program (CBP) and Fee Schedule Amounts, and Technical Amendments To Correct Existing Regulations Related to the CBP for Certain DMEPOS,” (83 FR 56922).

b. Fee Schedule Adjustment Methodology for Non-CBAs

Section 1834(a)(1)(F)(ii) of the Act requires the Secretary to use information on the payment determined under the Medicare DMEPOS CBP to adjust the fee schedule amounts for DME items and services furnished in all non-CBAs on or after January 1, 2016. Section 1834(a)(1)(F)(iii) of the Act requires the Secretary to continue to make these adjustments as additional covered items are phased in under the CBP or information is updated as new CBP contracts are awarded. Similarly, sections 1842(s)(3)(B) and 1834(h)(1)(H)(ii) of the Act authorize the Secretary to use payment information from the DMEPOS CBP to adjust the fee schedule amounts for enteral nutrition and OTS orthotics, respectively, furnished in all non-CBAs. Section 1834(a)(1)(G) of the Act requires the

Secretary to specify the methodology to be used in making these fee schedule adjustments by regulation, and to consider, among other factors, the costs of items and services in non-CBAs (where the adjustments would be applied) compared to the single payment amounts for such items and services in the CBAs.

The methodologies set forth in § 414.210(g) account for regional variations in prices, including for rural and non-contiguous areas of the United States. In accordance with § 414.210(g)(1), regional adjustments to fee schedule amounts for each state in the contiguous United States and the District of Columbia, are determined based on the definition of region in § 414.202, which refers to geographic areas defined by the Bureau of Economic Analysis (BEA) in the Department of Commerce for economic analysis purposes (79 FR 66226). Under § 414.210(g)(1)(i) through (iv), adjusted fee schedule amounts for areas within the contiguous United States are determined based on regional prices limited by a national ceiling of 110 percent of the regional average price and a floor of 90 percent of the regional average price (79 FR 66225). Under § 414.210(g)(1)(v), adjusted fee schedule amounts for rural areas are based on 110 percent of the national average of regional prices. Under § 414.210(g)(2), fee schedule amounts for non-contiguous areas are adjusted based on the higher of the average of the single payment amounts for CBAs in non-contiguous areas in the United States, or the national ceiling amount.

Under existing rules, ZIP codes for rural, non-rural, and non-contiguous areas are used to establish geographic areas that are then used to define non-CBAs for the purposes of the DMEPOS fee schedule adjustments. A rural area is defined in § 414.202 as a geographic area represented by a postal ZIP code, if at least 50 percent of the total geographic area of the area included in the ZIP code is estimated to be outside any Metropolitan Statistical Area (79 FR 66228). A rural area also includes a geographic area represented by a postal ZIP code that is a low population density area excluded from a CBA in accordance with section 1847(a)(3)(A) of the Act at the time the rules in § 414.210(g) are applied. Non-contiguous areas refer to areas outside the contiguous United States—that is, areas such as Alaska, Guam, and Hawaii (81 FR 77936).



Section 3712 of the CARES Act (Pub. L. 116–136, as enacted on March 27, 2020) revised the fee schedule amounts for certain DME and enteral nutrients, supplies, and equipment furnished in non-CBAs through the duration of the emergency period described in section 1135(g)(1)(B) of the Act. Specifically, this emergency period is the Public Health Emergency (PHE) for COVID–19, including renewals of the PHE.

Section 3712(a) of the CARES Act directed the Secretary to implement § 414.210(g)(9)(iii) (or any successor regulation), to apply the transition rule described in such section to all applicable items and services as planned through December 31, 2020, and through the duration of the emergency period described in section 1135(g)(1)(B) of the Act, if longer. Therefore, section 3712(a) of the CARES Act continued our policy at § 414.210(g)(9)(iii) of paying for DMEPOS items and services furnished in rural and non-contiguous non-CBAs based on a 50/50 blend of adjusted and unadjusted fee schedule amounts through December 31, 2020, or through the duration of the emergency period, whichever is longer. This fee schedule adjustment in rural and non-contiguous areas results in fee schedule amounts that are approximately 66 percent higher than the fully adjusted fee schedule amounts previously paid for DMEPOS items and services furnished in non-rural areas in the contiguous United States.

Section 3712(b) of the CARES Act directed the Secretary to increase the fee schedule amounts for DMEPOS items and services furnished in non-CBAs other than rural and non-contiguous non-CBAs through the duration of the COVID–19 PHE (the emergency period described in section 1135(g)(1)(B) of the Act). Beginning March 6, 2020, the payment rates for DME and enteral nutrients, supplies, and equipment furnished in these areas was based on 75 percent of the adjusted fee schedule amount and 25 percent of the historic, unadjusted fee schedule amount until the end of the emergency period, which results in higher payment rates as compared to the fully adjusted fee schedule amounts under § 414.210(g)(9)(iv). This increased payments so that they are approximately 33 percent higher than the payments at the fully adjusted fee schedule amounts.

In the May 8, 2020, interim final rule with comment period (IFC) (85 FR 27550) titled “Medicare and Medicaid Programs, Basic Health Program, and Exchanges; Additional Policy and Regulatory Revisions in Response to the

COVID–19 Public Health Emergency and Delay of Certain Reporting Requirements for the Skilled Nursing Facility Quality Reporting Program” (hereinafter referred to as the “May 2020 COVID–19 IFC”), conforming changes were made to § 414.210(g)(9), consistent with section 3712(a) and (b) of the CARES Act.

The final rule entitled, “Medicare Program; Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Policy Issues, and Level II of the Healthcare Common Procedure Coding System (HCPCS); DME Interim Pricing in the CARES Act; Durable Medical Equipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates To Provide Relief in Rural Areas and Non-Contiguous Areas” published in the December 28, 2021 **Federal Register** (86 FR 73860) (hereinafter CY 2022 DMEPOS final rule), established fee schedule adjustment methodologies for items and services furnished in non-CBAs on or after February 28, 2022, or the date immediately following the duration of the emergency period described in section 1135(g)(1)(B) of the Act (42 U.S.C. 1320b–5(g)(1)(B)), whichever is later.

The CY 2022 DMEPOS final rule explained that the 50/50 blended rates in non-contiguous non-CBAs will continue to be paid, but the 50/50 blend would no longer be a transition rule under § 414.210(g)(9) and would instead be the fee schedule adjustment methodology for items and services furnished in these areas under § 414.210(g)(2) unless revised in future rulemaking. For items and services furnished in non-contiguous non-CBAs, the fee schedule amounts for such items and services furnished on or after the effective date of the CY 2022 DMEPOS final rule (February 28, 2022), or the date immediately following the duration of the emergency period described in section 1135(g)(1)(B) of the Act, whichever is later, would be adjusted so that they are equal to a blend of 50 percent of the greater of the average of the SPAs for the item or service for CBAs located in non-contiguous areas or 110 percent of the national average price for the item or service determined under § 414.210(g)(1)(ii) and 50 percent of the unadjusted fee schedule amount for the area, which is the fee schedule amount in effect on December 31, 2015, increased for each subsequent year beginning in 2016 by the annual update factors specified in sections 1834(a)(14), 1834(h)(4), and 1842(s)(1)(B) of the Act, respectively, for durable medical equipment and supplies, off-the-shelf

orthotics, and enteral nutrients, supplies, and equipment (86 FR 73873).

As explained in the CY 2022 DMEPOS final rule, the 50/50 blended rates in rural contiguous areas will continue to be paid, but the 50/50 blend would no longer be a transition rule under § 414.210(g)(9) and would instead be the fee schedule adjustment methodology for items and services furnished in these areas under § 414.210(g)(2) unless revised in future rulemaking. For items and services furnished in rural contiguous areas on or after February 28, 2022, or the date immediately following the duration of the emergency period described in section 1135(g)(1)(B) of the Act, whichever is later, the fee schedule amounts would be adjusted so that they are equal to a blend of 50 percent of 110 percent of the national average price for the item or service determined under § 414.210(g)(1)(ii) and 50 percent of the fee schedule amount for the area in effect on December 31, 2015, increased for each subsequent year beginning in 2016 by the annual update factors specified in sections 1834(a)(14), 1834(h)(4), and 1842(s)(1)(B) of the Act, respectively, for DME and medical supplies, off-the-shelf orthotics, and enteral nutrients, supplies, and equipment (86 FR 73873).

Finally, for items and services furnished on or after February 28, 2022, or the date immediately following the termination of the emergency period described in section 1135(g)(1)(B) of the Act (42 U.S.C. 1320b–5(g)(1)(B)) (that is, the COVID–19 PHE), whichever is later, in all other non-rural, non-CBAs within the contiguous United States, the fee schedule amounts would be equal to 100 percent of the adjusted payment amount established under § 414.210(g)(1)(iv).

## 2. Current Issues

Section 4139 of Division FF, Title IV, Subtitle D of the CAA, 2023 sets the fee schedule adjustment methodologies for non-competitive bidding areas through the remainder of the duration of the emergency period described in section 1135(g)(1)(B) of the Act or December 31, 2023, whichever is later. The federal PHE for COVID–19, declared by the Secretary under Section 319 of the Public Health Service Act, expired at the end of the day on May 11, 2023. We are proposing to make conforming changes to the regulation at 42 CFR 414.210(g)(9) to account for these changes.

Specifically, section 4139(a) of the CAA, 2023 directs the Secretary to implement 42 CFR 414.210(g)(9)(v) (or any successor regulation), to apply the

transition rule described in the first sentence of such section to all applicable items and services furnished in areas other than rural or noncontiguous areas through the remainder of the duration of the emergency period described in section 1135(g)(1)(B) of the Act (42 U.S.C. 1320b-5(g)(1)(B)) or December 31, 2023, whichever is later. This continues the policy set forth by section 3712(b) of the CARES Act, which requires CMS to pay for these DMEPOS items and services furnished in areas other than rural or noncontiguous areas based on 75 percent of the adjusted fee schedule amount and 25 percent of the historic, unadjusted fee schedule amount until the end of the emergency period. This increases payments so that they are approximately 33 percent higher than the payments at the fully adjusted fee schedule amounts.

Section 4139(b) of the CAA, 2023 directs the Secretary to not implement 42 CFR 414.210(g)(9)(vi) of title 42, Code of Federal Regulations (or any successor regulation) until the date immediately following the last day of the emergency period described in section 1135(g)(1)(B) of the Act (42 U.S.C. 1320b-5(g)(1)(B)), or January 1, 2024, whichever is later. This change has the effect of continuing the policy at § 414.210(g)(9)(vi), but changes the February 28, 2022 date in the regulation to January 1, 2024. That is, the fee schedule amount for all non-CBAs is equal to the adjusted payment amount established under paragraph (g) of this section only until the date immediately following the last day of the emergency period described in section 1135(g)(1)(B) of the Act (42 U.S.C. 1320b-5(g)(1)(B)), or January 1, 2024, whichever is later.

Additionally, section 4139 of the CAA, 2023 does not affect the current adjusted fee schedule amounts in former CBAs. In accordance with § 414.210(g)(10), the fee schedule amounts in the former CBAs will continue to be based on the single payment amounts from 2018 increased by update factors for subsequent calendar years until new competitive bidding contracts are in place.

### 3. Proposed Changes

We are proposing to make conforming changes to § 414.210(g)(9), consistent with requirements in section 4139(a) and 4139(b) of the CAA, 2023. First, section 4139 of the CAA, 2023 does not change the current policy under § 414.210(g)(9)(iii) of paying for DMEPOS items and services furnished in rural and non-contiguous non-CBAs based on a 50/50 blend of adjusted and

unadjusted fee schedule amounts through the duration of the PHE for COVID-19. While section 4139 of the CAA, 2023 does not specifically mention § 414.210(g)(9)(iii), we believe that section 4139(b) of the CAA, 2023 prohibits implementation of the regulation language in § 414.210(g)(vi) until the date immediately following the last day of the PHE, or January 1, 2024. This regulation applies the transition rules for the adjusted payment amount in the non-CBAs established under paragraph (g) of § 414.210 to items and services furnished in “all areas,” and it also provides for extension of the transition 50/50 blended rates in rural, non-contiguous areas and non-rural areas through December 31, 2023, if the PHE ends prior to that date. We are proposing to revise § 414.210(g)(9)(vi), as described in this rule. Further, we are proposing to revise § 414.210(g)(9)(iii), to state that for items and services furnished in rural areas and non-contiguous areas (Alaska, Hawaii, and U.S. territories) with dates of service from June 1, 2018 through the duration of the emergency period described in section 1135(g)(1)(B) of the Act (42 U.S.C. 1320b-5(g)(1)(B)) or December 31, 2023, whichever is later, based on the fee schedule amount for the area is equal to 50 percent of the adjusted payment amount established under this section and 50 percent of the unadjusted fee schedule amount. We are proposing to make conforming changes to § 414.210(g)(2) for the rural and non-contiguous areas in order to reference the December 31, 2023 date specified in section 4139 of the CAA, 2023.

We are proposing to revise § 414.210(g)(9)(v) to state that for items and services furnished in areas other than rural or noncontiguous areas with dates of service from March 6, 2020 through the remainder of the duration of the emergency period described in section 1135(g)(1)(B) of the Act (42 U.S.C. 1320b-5(g)(1)(B)) or December 31, 2023, whichever is later, the fee schedule amount for the area is equal to 75 percent of the adjusted payment amount established under this section and 25 percent of the unadjusted fee schedule amount. We are proposing to remove outdated text from § 414.210(g)(9)(v) that states “for items and services furnished in areas other than rural or noncontiguous areas with dates of service from the expiration date of the emergency period described in section 1135(g)(1)(B) of the Act (42 U.S.C. 1320b-5(g)(1)(B)), through December 31, 2020, the fee schedule amount for the area is equal to 100 percent of the adjusted payment amount

established under this section.” This is text was added in the May 2020 COVID-19 IFC (85 FR 27571), as section 3712(b) of the CARES Act required CMS to pay the higher fee schedule amounts for the duration of the emergency period described in section 1135(g)(1)(B) of the Act (42 U.S.C. 1320b-5(g)(1)(B)), but it did not specify the fee schedule amounts that should be in effect if the emergency period ends before December 31, 2020. If not for section 3712(b) of the CARES Act, CMS would have paid the fully adjusted fee schedule amounts for DME items and services furnished in non-rural and contiguous non-CBAs until December 31, 2020. As such, § 414.210(g)(9)(v) specified that the fee schedule amounts in non-rural and contiguous non-CBAs would again be based on 100 percent of the fee schedule amounts adjusted in accordance with § 414.210(g)(1)(iv) if the emergency period described in section 1135(g)(1)(B) of the Act (42 U.S.C. 1320b-5(g)(1)(B)) ended before December 31, 2020. As this situation no longer applies and is in the past, we are proposing to remove this obsolete text from § 414.210(g)(9)(v).

We are proposing to revise § 414.210(g)(9)(vi) to state that for items and services furnished in all areas with dates of service on or after the date immediately following the duration of the emergency period described in section 1135(g)(1)(B) of the Act, or January 1, 2024, whichever is later, the fee schedule amount for the area is equal to the adjusted payment amount established under paragraph (g) of this section. Finally, we are proposing to make conforming changes to § 414.210(g)(2) for the rural and non-contiguous areas in order to specify the December 31, 2023 date specified in section 4139 of the CAA, 2023.

Finally, section 4139(c) of the CAA, 2023 authorizes the Secretary to implement the provisions of this section by program instruction or otherwise. Given that the PHE for COVID-19 ended on May 11, 2023, which is prior to when the proposed changes to the regulations would be finalized, we intend to issue program instructions or other subregulatory guidance to effectuate the changes, as previously described. We believe this approach will serve to ensure a smooth transition after the end of the PHE for COVID-19.

### *B. Scope of the Benefit and Payment for Lymphedema Compression Treatment Items*

#### 1. Statutory Authority

Effective for items furnished on or after January 1, 2024, section 4133(a)(1)

of Division FF, Title V, Subtitle D of the CAA, 2023 amends section 1861 of the Act, adding subparagraph (JJ) to subsection (s)(2) and coverage under a new benefit category under Medicare Part B for lymphedema compression treatment items as defined in new subsection (mmm) of section 1861 of the Act. Section 4133(a)(2) of the CAA, 2023 amends section 1833(a)(1) of the Act, adding subparagraph (GG) to indicate that the amount paid for lymphedema compression treatment items defined in section 1861(mmm) of the Act shall be equal to 80 percent of the lesser of the actual charge or the amount determined using the payment basis established by the Secretary under paragraph (1) of new subsection (z) of section 1834 of the Act. Paragraph (2) of new subsection (z) of section 1834 of the Act prohibits payments under Part B for lymphedema compression treatment items furnished other than at such frequency as the Secretary may establish. Paragraph (3) of new subsection (z) of section 1834 of the Act specifies that in the case of lymphedema compression treatment items that are included in a competitive bidding program under section 1847(a) of the Act, the payment basis under section 1847(a) of the Act shall be the payment basis determined under the competitive bidding program, and the Secretary may use information on the payment determined under the competitive bidding program to adjust the payment amount otherwise determined under section 1834(z) of the Act for an area that is not a competitive bidding area under section 1847 of the Act. Section 4133(a)(3) of the CAA, 2023 amends section 1847(a)(2) of the Act, adding lymphedema compression treatment items to the competitive bidding program under subparagraph (D) of section 1847(a)(2) of the Act. Finally, section 4133(b)(3) of the CAA, 2023 amends section 1834 of the Act under subsections (a)(20)(D) and (j)(5) to mandate application of the DMEPOS quality standards and accreditation and DMEPOS supplier enrollment and supplier standards requirements, respectively, to suppliers of lymphedema compression treatment items.

## 2. Background

Currently, Medicare Part B does not include coverage for lymphedema compression treatment items other than compression pumps and accessories that meet the definition of DME covered under the DME benefit category under section 1861(n) of the Act. Section 4133 of the CAA, 2023 amends the Act to establish a new Part B benefit category

for lymphedema compression treatment items.

The lymphatic system is an integral component of the human circulatory system and consists of lymphatic vessels, lymph nodes and associated lymphoid organs.<sup>146 147</sup> The International Society of Lymphology defines lymphedema as “an external (and/or internal) manifestation of lymphatic system insufficiency and deranged lymph transport” and is “a symptom or sign resulting from underlying lymphatic disease.<sup>148</sup>” The Centers for Disease Control and Prevention (CDC) defines lymphedema as swelling due to a buildup of lymph fluid in the body.<sup>149</sup> According to the National Institutes of Health (NIH) National Library of Medicine, lymphedema is a chronic disorder characterized by swelling under the skin caused by the inability of protein rich lymph fluid to drain, usually due to a blockage or damage to the lymph system.<sup>150</sup> Additionally, according to the National Lymphedema Network, this swelling commonly occurs in the arm or leg, but it may also occur in other body areas including the breast, chest, head and neck, and genitals.<sup>151</sup> Lymphedema develops when a body region, where lymphatic vessels and lymph nodes are missing or impaired, becomes overloaded with lymphatic fluid. Lymphedema is a chronic condition with no definitive curative treatment that can become progressive, so early detection and institution of decompressive measures are essential in avoiding its potentially disabling sequela.<sup>152 153 154 155</sup> The gradual

<sup>146</sup> Aspelund A, Robciuc MR, Karaman S, Makinen T, Alitalo K. Lymphatic System in Cardiovascular Medicine. *Circulation Research*. 2016. Volume 118(3). 515–530.

<sup>147</sup> Suamia H, Scaglioni MF. Anatomy of the Lymphatic System and the Lymphosome Concept with Reference to Lymphedema. *Seminars in Plastic Surgery*. 2018 Feb; 32(1): 5–11.

<sup>148</sup> International Society of Lymphology Executive Committee. The Diagnosis and Treatment of Peripheral Lymphedema. *Lymphology* 28 (1995).

<sup>149</sup> *Lymphedema* CDC.gov. <https://www.cdc.gov/cancer/survivors/patients/lymphedema.htm>.

<sup>150</sup> Lymphedema. Bryan C. Sleigh; Biagio Manna, September 2018. Found at <https://www.ncbi.nlm.nih.gov/books/NBK537239/>.

<sup>151</sup> <https://lymphnet.org/what-is-lymphedema>.

<sup>152</sup> Korpan MI, Crevenna R, Fialka-Moser V. Lymphedema a Therapeutic Approach in the Treatment and Rehabilitation of Cancer Patients. *American Journal of Physical Medicine and Rehabilitation*. 2011. May. 90(suppl). S69–S75.

<sup>153</sup> Preston NJ, Seers K, Mortimer PS. Physical therapies for reducing and controlling lymphoedema of the limbs. *Cochrane Database of Systematic Reviews* 2004, Issue 4. Art. No.: CD003141.

<sup>154</sup> The International Society of Lymphology. The Diagnosis and Treatment of Peripheral Lymphedema: 2020 Consensus Document of the

accumulation of plasma and cellular components into the interstitial tissue space leads to a chronic inflammatory process that can result in long-term tissue changes and permanent structural damage to the affected anatomical site and its overlying skin layer.<sup>156 157 158</sup> These changes also make the patient more susceptible to skin and potentially disabling or life-threatening soft tissue infections.<sup>159 160</sup> The physical manifestations of lymphedema are tissue swelling, pain, heaviness and difficulty using the affected body part.<sup>161</sup>

Lymphedema occurs in four stages. Stage one may have no outward signs or symptoms but is evidenced by abnormal flow through the lymphatic system. When stage two is reached, there is some swelling that may be alleviated by elevation or compression. Stage three is diagnosed by swelling of an area that does not resolve with elevation and there may be skin thickening and scarring. The fourth stage is characterized by severe swelling and skin abnormalities.<sup>162</sup> Infections such as cellulitis and sepsis may result from lymphedema due to the dense protein rich nature of the lymphatic fluid and requires treatment with antibiotics.<sup>163</sup> Studies have shown that gradient compression garments are effective in reducing and/or preventing progression

International Society of Lymphology. *Lymphology*. 2020. 53: 3–19.

<sup>155</sup> King M, Deveaux A, White H, Rayson. Compression garments versus compression bandaging in decongestive lymphatic therapy for breast cancer-related lymphedema: a randomized controlled trial. *Support Care Cancer*. 2012; 20: 1031–1036.

<sup>156</sup> Korpan MI, Crevenna R, Fialka-Moser V. Lymphedema a Therapeutic Approach in the Treatment and Rehabilitation of Cancer Patients. *American Journal of Physical Medicine and Rehabilitation*. 2011. May. 90(suppl). S69–S75.

<sup>157</sup> Warren AG, Brorson H, Borud LJ, Slavin SA. Lymphedema A Comprehensive Review. *Annals of Plastic Surgery*. 2007. Vol 59, No. 4. 464–472.

<sup>158</sup> Ly CL, Kataru RO, Mehrara B. Inflammatory Manifestations of Lymphedema. *Int J Mol Scie*. 2017. Jan; 18(1): 171.

<sup>159</sup> Grada AA, Phillips TJ. Lymphedema, Pathophysiology and clinical manifestations. *J Am Academ Dermatol*. 2017;77: 1009–20.

<sup>160</sup> Bakar Y, Tugral A. Lower Extremity Lymphedema Management after Gynecologic Cancer Surgery: A Review of Current Management Strategies. *Ann of Vasc Surg*. 2017. Vol. 44; 442–450.

<sup>161</sup> Warren AG, Brorson H, Borud LJ, Slavin SA. Lymphedema A Comprehensive Review. *Annals of Plastic Surgery*. 2007. Vol 59, No. 4. 464–472.

<sup>162</sup> The Johns Hopkins Hospital <https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/treating-lymphedema>.

<sup>163</sup> <https://www.cancerresearchuk.org/about-cancer/coping/physically/lymphoedema-and-cancer/infection-lymphoedema#:~:text=Infection%20in%20people%20with%20lymphoedema,and%20will%20need%20antibiotic%20treatment>.

of lymphedema in the arm and leg.<sup>164</sup> They have also shown to be effective in maintaining limb circumference.

Gradient compression garments designed for daytime use, while an individual is awake, are different than those for nighttime use, when an individual is asleep. Gradient compression garments meant for daytime (waking) provide a higher level of compression, and use of them while sleeping could cause new or additional damage to the affected tissue.<sup>165</sup> Additionally, gradient compression garments appropriate for daytime use can inadvertently become repositioned at night while the individual is sleeping and cause a tourniquet effect, essentially cutting off circulation to the limb and resulting in further swelling.<sup>165</sup> In contrast, gradient compression garments made for nighttime use or times of low activity offer milder compression and are less snug against the skin.<sup>166</sup> Wearing gradient compression garments designed for nighttime use may also help with skin abnormalities resulting from lymphedema and can help prevent a phenomenon called “creeping refill,” where swelling reoccurs during sleep.<sup>167</sup> Generally, more serious cases require gradient compression garments for both daytime and nighttime use. Various types of nighttime garments have been designed as alternatives to the day time compression system garments. Nighttime garments apply gentle gradient pressure to the limb through a garment with a foam liner and a series of adjustable straps. The garments are non-elastic and provide low resting pressure on the limb, making them safe to wear while sleeping at night.<sup>168</sup> Many of these garments are custom-made, but there are ready-to-wear options available as well. The elastic fibers of daytime compression garments will break down with wear. Because nighttime garments

are made of inelastic components, compared to the day-time garments, they do not commonly break down with wear and last longer. While proper care will increase the lifespan of garments, they will need to be replaced sometime within 1 to 3 years if used daily. Studies showed if the garments are used with aftercare regimen, that is, they are in minimum contact with moisturizer during use, they could last longer.<sup>169</sup> In meetings with CMS, some clinicians and lymphologists indicated that they believe that the nighttime garments are quite durable and can last for 2 to 3 years because the materials are more durable than the materials used with the daytime garments. They also indicated that previous versions used strapping in addition to more durable foam materials and could last for up to 5 years. In comparison, daytime garments are elastic garments that are typically made of breathable elastic fabrics such as nylon, cotton, spandex or natural rubber to provide compression and therefore have a much shorter lifespan of approximately 6 months.<sup>170</sup>

Gradient compression garments are either standard fit or custom-fit. Standard compression garments are also referred to as ready-made or ready-to-wear and are widely available pre-made, off-the-shelf and in a range of standard sizes. Individuals with mild or moderate lymphedema can often use standard fit garments. Standard gradient compression garments are easier to measure and are readily available at retailers without requiring a prescription, but they do not conform as well to limbs or provide homogenous compression. Standard fit compression wear for all gradient compression garments come in different compression classification ranges specified in mmHg. While there are no national standards for gradient compression hosiery,<sup>171</sup> the most common compression classification ranges for hosiery in the U.S. include: 8–15 mmHg (mild), 15–20 mmHg (medium or over the counter), 20–30 mmHg (firm or medical class 1), 30–40 mmHg (extra firm or medical class 2), and 40–50 mmHg (medical

class 3).<sup>172</sup> For all compression ranges, the highest compression is at the ankle or wrist, and compression slowly decreases as it moves up the extremity. Some manufacturers' compression class pressure ranges for hosiery may be different from the compression class ranges used for upper limb gradient compression garment.<sup>173</sup>

Alternatively, custom-fit gradient compression garments are garments that are uniquely sized, shaped, and custom-made to fit the exact dimensions of the affected extremity (circumferential measurements are every one and a half to two inches) and provide more accurate and consistent gradient compression to manage the individual's symptoms.<sup>174</sup> The type of gradient compression garment prescribed is influenced by the site and extent of the swelling, together with the individual's comfort, lifestyle, preferences, and ability to apply and remove garments. Poorly fitting gradient compression garments may not contain or resolve the lymphedema, can cause tissue damage, may be uncomfortable, and can dissuade a patient from long-term usage.<sup>175</sup>

Custom-fit gradient compression garments are typically required when an individual has severe shape distortion and/or short, long, or bulky limbs.<sup>176</sup> In addition, individuals with complex lower limb and torso lymphedema often require custom-fit gradient compression garments, as do those who need special adaptations or when there is need for varying levels of pressure within the same garment.<sup>177</sup> Some studies indicate that approximately 50 percent of lymphedema patients require custom-fit gradient compression garments versus standard fit gradient compression

<sup>164</sup> Yasuhara H, Shigematsu H, Muto T. A study of the advantages of elastic stockings for leg lymphedema. *Int Angiol.* 1996 Sep;15(3):272–7. PMID: 8971591. <https://pubmed.ncbi.nlm.nih.gov/8971591/>.

<sup>165</sup> Lymphedema Products, LLC. (2019, September 11). *Day Compression vs Night Compression.* [Lymphedemaproducts.com. https://www.lymphedemaproducts.com/blog/day-vs-night-compression-wear/](https://www.lymphedemaproducts.com/blog/day-vs-night-compression-wear/).

<sup>166</sup> Caring Touch Medical, Inc. *Can You Sleep in a Lymphedema Sleeve?* [Caringtouchmed.com. https://www.caringtouchmed.com/can-you-sleep-in-a-lymphedema-sleeve/](https://www.caringtouchmed.com/can-you-sleep-in-a-lymphedema-sleeve/).

<sup>167</sup> Mastectomy Shop. *Can You Sleep in a Lymphedema Sleeve?* [Mastectomyshop.com. https://www.mastectomyshop.com/blogs/can-you-sleep-in-a-lymphedema-sleeve/](https://www.mastectomyshop.com/blogs/can-you-sleep-in-a-lymphedema-sleeve/).

<sup>168</sup> McNeely, M. L. et al. Nighttime compression supports improved self-management of breast cancer related lymphedema: A multicenter randomized controlled trial. *Cancer* 128, 587–596 (2021).

<sup>169</sup> Macintyre, Lisa Ph.D.; Gilmartin, Sian BSc; Rae, Michelle BSc; *Journal of Burn Care & Research*: September/October 2007—Volume 28—Issue 5—pp 725–733.

<sup>170</sup> Mukhopadhyay, A., & Shaw, V. P. (2022). Reliability analysis of stretchable workwear fabric under abrasive damage: Influence of stretch yarn composition. *Journal of Natural Fibers*, 20(1).

<sup>171</sup> Lymphedema Framework. Best Practice for the Management of Lymphoedema. International Consensus. London. MEP Ltd, 2006. [https://www.woundsme.com/uploads/resources/content\\_11160.pdf](https://www.woundsme.com/uploads/resources/content_11160.pdf).

<sup>172</sup> Lymphedema Products, LLC. *Determining Compression Levels.* [Lymphedemaproducts.com. https://www.lymphedemaproducts.com/blog/how-to-determine-compression-levels-for-your-garments/](https://www.lymphedemaproducts.com/blog/how-to-determine-compression-levels-for-your-garments/).

<sup>173</sup> Lymphoedema Framework. Best Practice for the Management of Lymphoedema. International Consensus. London. MEP Ltd, 2006. [https://www.woundsme.com/uploads/resources/content\\_11160.pdf](https://www.woundsme.com/uploads/resources/content_11160.pdf).

<sup>174</sup> [https://www.forwardhealth.wi.gov/kw/html/3485\\_Compression\\_Garments.html](https://www.forwardhealth.wi.gov/kw/html/3485_Compression_Garments.html).

<sup>175</sup> Doherty DC, Morgan PA, & Moffatt CJ (2009). *Hosiery in Lower Limb Lymphedema. J Lymphoedema*, 4(1), 30–37. [https://www.woundsme.com/uploads/resources/content\\_11160.pdf](https://www.woundsme.com/uploads/resources/content_11160.pdf).

<sup>176</sup> Chang M–H, Chang DW, & Patel KM (2022). “Lymphedema Risk Reduction and Management” in *Principles and Practice of Lymphedema Surgery*, 2nd Ed., 78–90. <https://www.sciencedirect.com/topics/medicine-and-dentistry/compression-garment>.

<sup>177</sup> Doherty DC, Morgan PA, & Moffatt CJ (2009). *Hosiery in Lower Limb Lymphedema. J Lymphoedema*, 4(1), 30–37. [https://www.woundsme.com/uploads/resources/content\\_11160.pdf](https://www.woundsme.com/uploads/resources/content_11160.pdf).

garments for effective treatment, although estimates vary.<sup>178 179</sup> Patients requiring custom-fit gradient compression garments must be properly evaluated and fitted by a qualified practitioner with appropriate training and specialized skills in the evaluation of gradient compression, such as a physical or occupational therapist, or a physician.

### 3. Current Issues: Scope of the Benefit for Lymphedema Compression Treatment Items

This proposed rule would implement a new benefit category established at section 1861(s)(2)(JJ) of the Act for “lymphedema compression treatment items” defined at section 1861(mmm) of the Act as standard and custom fitted gradient compression garments and other items determined by the Secretary that are—

- Furnished on or after January 1, 2024, to an individual with a diagnosis of lymphedema for the treatment of such condition;
- Primarily and customarily used to serve a medical purpose and for the treatment of lymphedema, as determined by the Secretary; and
- Prescribed by a physician (or a physician assistant, nurse practitioner, or a clinical nurse specialist (as these terms are defined in section 1861(aa)(5)) to the extent authorized under State law).

We are proposing that any other items covered under this new benefit category in addition to gradient compression garments must also use compression in treating lymphedema since the specific category of medical items to be covered under section 1861(s)(2) of the Act are “lymphedema compression treatment items.” Similarly, we are proposing that this benefit category is limited to compression treatment items and does not include professional lymphedema treatment services or other services not directly related to the furnishing of the lymphedema compression treatment items. Payment for any covered professional service related to these items would be made under the Medicare Physician Fee Schedule. The statute limits the benefit to items used for the treatment of lymphedema as

determined by the Secretary, and we are proposing that this includes items used to treat all types or diagnoses of lymphedema, but does not include the same items when used to treat injuries or illnesses other than lymphedema. In other words, if a gradient compression garment or other lymphedema compression treatment item is furnished to treat an injury or illness other than lymphedema, those items would not be classified under the Medicare benefit category for lymphedema compression treatment items.

We are proposing that other compression items used to treat lymphedema that would be covered under this benefit category in addition to gradient compression garments would include ready-to-wear, non-elastic, gradient compression wraps with adjustable straps such as the items described by HCPCS code A6545. In addition, we are proposing that compression bandaging systems applied in a clinical setting as part of phase one decongestive therapy would also be items covered under the new benefit category for lymphedema compression treatment items if this rule is finalized. However, as discussed in section VII.B.6. of this rule, section 1834(j) of the Act, as amended by section 4133(b)(2) of the CAA, 2023, requires the therapists that furnish these items to become enrolled and accredited DMEPOS suppliers in order to bill for these items as lymphedema compression treatment items per section 1834(j)(5) of the Act or payment for the items applied during phase one of decongestive therapy would not be allowed. We also note that while these items may be covered under the new Part B benefit for lymphedema compression treatment items, the professional services of applying these items would not and would need to be covered under a different Medicare benefit category in order for Medicare payments to be made for these services. We are specifically soliciting comments on the topic of coverage of compression bandaging items under the new benefit for lymphedema compression treatment items. We are also soliciting comments on whether the professional services of applying these bandages could be covered under another Medicare benefit category, such as outpatient physical therapy services under section 1861(p) of the Act or physician services under section 1861(s) of the Act.

With regard to custom garments, we understand that therapists often take measurements of affected body areas and perform other fitting services related to the furnishing of these items. Since these measurements are necessary

for the furnishing of the custom garments and are part of what makes the garments custom garments rather than standard garments, these measurements are an integral part of furnishing the custom garments and the suppliers of the garments are responsible for fitting the garments they furnish. Typically, DMEPOS suppliers are responsible for all aspects of furnishing the item. Following that approach, a supplier receiving payment for furnishing a lymphedema compression treatment item to a beneficiary has responsibility for ensuring that any necessary fitting, training (how to appropriately don/doff and maintain), and adjustment services are provided as part of furnishing the item. Payment for all services necessary for furnishing a gradient compression garment are included in the rates paid by the Medicaid State agencies and we are proposing to use the average Medicaid payment rate plus twenty percent as the payment basis for Medicare (when such Medicaid rates are available). Therefore, the Medicare payments would likewise include payment for all services necessary for furnishing the gradient compression garment; this is consistent with how Medicare payment is made for DMEPOS. We understand that in many cases a therapist may take measurements and provide other fitting services necessary for furnishing a gradient compression garment that is then furnished by a separate supplier. Under this scenario, the supplier receiving payment for the garment would be responsible for paying the therapist for the fitting component that is an integral part of furnishing the item. An alternative option, which we are not proposing but are seeking comment on, would be to pay separately for the fitting component furnished by the therapist and then back this payment out of the payment for the garment. If a separate Medicare payment amount was made to an entity other than the supplier of the garment for fitting services necessary for furnishing the garment, this amount would have to be subtracted from the payment to the supplier of the garment in order to avoid paying twice for these services. For example, if code Axxx1 describes a “Gradient compression arm sleeve and glove combination, custom, each,” with a payment amount of \$350 established for each garment, a supplier furnishing two of these garments to a beneficiary for daytime use would receive \$700 if the garments are furnished on an assignment basis, and part of this payment would cover the cost of the fitting of the garment that is furnished by the supplier or a separate

<sup>178</sup> Lymphedema Advocacy Group (2021 Apr). “Cost and Utilization of Lymphedema Compression Garments.” <https://lymphedematreatmentact.org/wp-content/uploads/2021/04/Cost-and-Utilization-of-Lymphedema-Compression-Garments.pdf>.

<sup>179</sup> Boyages J, Xu Y, Kalfa S, Koelmeyer L, Parkinson B, Mackie H, Viveros H, Gollan P, & Taksa L (2017). Financial cost of lymphedema borne by women with breast cancer. *Psychooncology*, 26(6), 849–855. doi: 10.1002/pon.4239. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484300/>.

therapist that is then paid by the supplier for the cost of taking the fitting measurements. Alternatively, a separate allowance and code could be established for the fitting component, such as \$80 for Axxx2 for “Fitting of gradient compression arm sleeve and glove combination, custom, per two garments.” Under this scenario, it would be necessary to back out the payment for the cost of the separate fitting component from the payment for the two garments (\$700 – \$80 = \$620), since the payment for the garments already includes payment for all services necessary for furnishing the garment. As a result, the supplier furnishing the garments would be paid \$310 for each garment rather than \$350 since they did not conduct the fitting component that is paid for separately. We are not proposing this alternative because of many complexities. For example, the therapist providing the fitting component would be required to become an enrolled DMEPOS supplier, accredited for furnishing the garment fitting component, and responsible for meeting all of the requirements for being a DMEPOS supplier, such as meeting the DMEPOS supplier standards and quality standards, obtaining a surety bond, and submitting claims to the appropriate DME MAC. As part of the DMEPOS supplier standards, a supplier must accept return of substandard items. In cases where a mistake is made in measuring and fitting the beneficiary for two custom gradient compression garments, resulting in the furnishing and payment for custom gradient compression garments that do not properly fit the patient, the risk would be assumed by the fitter and not the supplier to accept return of the garments and cover the cost of two replacement

garments. Again, we are not proposing to make separate payment for the fitting services under this benefit when furnished by a supplier other than the supplier of the garments; however, we are specifically soliciting comments on the topic and comments on options to resolve the issues we outlined previously. We recognize that there is not necessarily a standard industry practice for the fitting and training components for furnishing lymphedema compression garments and seek comment on whether there are best practices in this space that CMS should consider further in the future. We also welcome comment on whether any HCPCS level I (Current Procedural Terminology or CPT®) codes may describe the services of the therapist in these scenarios.

Finally, there are accessories such as zippers in garments, liners worn under garments or wraps with adjustable straps, and padding or fillers that are not compression garments but may be necessary for the effective use of a gradient compression garment or wraps with adjustable straps. There are also accessories like donning and doffing aids for different body parts such as lower limb butlers or foot slippers that allow the patients to put on the compression stockings with minimum effort and are not used with compression bandaging systems or supplies. We are proposing that accessories necessary for the effective use of gradient compression garments and gradient compression wraps with adjustable straps would also fall under this new benefit for lymphedema compression treatment items. For example, a liner that is used with a garment because it is needed to prevent skin breakdown could be covered under

the new benefit because it is necessary for the effective use of the garment. We are specifically soliciting comments on the topic of coverage of accessories necessary for the effective use of gradient compression garment or wraps with adjustable straps, including what HCPCS codes should be established to describe these items, as well as comments on whether there are additional items other than the gradient compression garments, gradient compression wraps with adjustable straps, and compression bandaging supplies that could potentially fall under the new benefit category for lymphedema compression treatment items.

#### 4. Healthcare Common Procedure Coding System (HCPCS) Codes for Lymphedema Compression Treatment Items

HCPCS codes are divided into two principal subsystems, referred to as Level I and Level II of the HCPCS. Level I of the HCPCS is comprised of Current Procedural Terminology (CPT), a numeric coding system maintained by the American Medical Association (AMA). HCPCS Level II is a standardized coding system that is used primarily to identify drugs, biologicals and non-drug and non-biological items, supplies, and services not included in the CPT codes, such as ambulance services and DMEPOS when used outside a physician’s office. As shown in Table FF–A 1, there are currently Level II HCPCS codes for compression garments (stockings, sleeves, gloves, and gauntlets) and compression wraps with adjustable straps that may be used in the treatment of lymphedema and other conditions.

**TABLE FF-A 1: EXISTING HCPCS CODES FOR COMPRESSION TREATMENT ITEMS**

| <b>Code</b> | <b>Description</b>  |
|-------------|---|
| A6530       | Gradient compression stocking, below knee, 18-30 mmhg, each             |
| A6531       | Gradient compression stocking, below knee, 30-40 mmhg, each             |
| A6532       | Gradient compression stocking, below knee, 40-50 mmhg, each             |
| A6533       | Gradient compression stocking, thigh length, 18-30 mmhg, each           |
| A6534       | Gradient compression stocking, thigh length, 30-40 mmhg, each           |
| A6535       | Gradient compression stocking, thigh length, 40-50 mmhg, each           |
| A6536       | Gradient compression stocking, full length/chap style, 18-30 mmhg, each |
| A6537       | Gradient compression stocking, full length/chap style, 30-40 mmhg, each |
| A6538       | Gradient compression stocking, full length/chap style, 40-50 mmhg, each |
| A6539       | Gradient compression stocking, waist length, 18-30 mmhg, each           |
| A6540       | Gradient compression stocking, waist length, 30-40 mmhg, each           |
| A6541       | Gradient compression stocking, waist length, 40-50 mmhg, each           |
| A6545       | Gradient compression wrap, non-elastic, below knee, 30-50 mmhg, each    |
| A6549       | Gradient compression stocking/sleeve, not otherwise specified           |
|             |   |
| S8420       | Gradient pressure aid (sleeve and glove combination), custom made       |
| S8421       | Gradient pressure aid (sleeve and glove combination), ready made        |
| S8422       | Gradient pressure aid (sleeve), custom made, medium weight              |

| <b>Code</b> | <b>Description</b>  |
|-------------|---|
| S8423       | Gradient pressure aid (sleeve), custom made, heavy weight |
| S8424       | Gradient pressure aid (sleeve), ready made                |
| S8425       | Gradient pressure aid (glove), custom made, medium weight |
| S8426       | Gradient pressure aid (glove), custom made, heavy weight  |
| S8427       | Gradient pressure aid (glove), ready made                 |
| S8428       | Gradient pressure aid (gauntlet), ready made              |
| S8429       | Gradient pressure exterior wrap                           |
| S8430       | Padding for compression bandage, roll                     |
| S8431       | Compression bandage, roll                                 |

The items described by HCPCS codes A6531, A6532, and A6545 are covered by Medicare under the Part B benefit for surgical dressings at section 1861(s)(5) of the Act, when used in the treatment of an open venous stasis ulcer. Total allowed charges for these three codes in 2022 was approximately \$2.5 million, with around \$1.9 million for the non-elastic, below knee, gradient compression wrap with adjustable straps described by code A6545, \$500,000 for the below knee, gradient compression stocking code A6531, and \$100,000 for the below knee, gradient compression stocking code A6532. We are not proposing to change this policy with this rule, but we must address the

codes for items when they are covered under Medicare Part B as surgical dressing versus when they are covered under Medicare Part B as lymphedema compression treatment for billing and claims processing purposes. We are therefore proposing to add three new HCPCS codes for use when billing for A6531, A6532, and A6545 items used as surgical dressings. The proposed codes are as follows:

- A—Gradient compression stocking, below knee, 30–40 mmhg, used as surgical dressing in treatment of open venous stasis ulcer, each
- A—Gradient compression stocking, below knee, 40–50 mmhg, used as

surgical dressing in treatment of open venous stasis ulcer, each

- A—Gradient compression wrap with adjustable straps, non-elastic, below knee, 30–50 mmhg, used as surgical dressing in treatment of open venous stasis ulcer, each

The surgical dressing fee schedule amounts for codes A6531, A6532, and A6545 would be applied to the three new codes. The remaining discussion in this section addresses the coding for the lymphedema compression treatment items.

For gradient compression stockings, we are proposing to use existing codes A6530 through A6541, and code A6549 from Table FFA–1. For codes A6530

through A6541, we are soliciting comments on whether we should maintain the three pressure level differentiations in the codes and whether these differentiations should be something other than 18–30, 30–40, and 40–50 mmHg. We are also soliciting comments on whether there is a better way to describe the body areas these garments cover rather than “below knee,” “thigh-length,” “full-length/chap style,” and “waist-length.” For each code, we propose to add a matching code for the custom version of the garment. For example, if we continue to use codes A6530 through A6532 for below knee stockings with the current descriptions, we would add corresponding codes for the custom versions of these garments, such as the following:

- A—Gradient compression stocking, below knee, 18–30 mmhg, custom, each
- A—Gradient compression stocking, below knee, 30–40 mmhg, custom, each
- A—Gradient compression stocking, below knee, 40–50 mmhg, custom, each

For gradient compression garments for the upper extremities and areas of the body, we propose to use existing codes A6549 and S8420 through S8428. We propose renumbering codes S8420 through S8428 as “A” codes rather than S codes. We also propose removing the words “ready-made” and revising “custom made” to “custom” for the codes for the upper extremity gradient compression garments and replacing the word “pressure” with “compression,” in order to be consistent with the wording for the codes for the lower extremity garments. We propose to add the word “arm” in front of the word “sleeve” for the upper extremity garments. We also propose to add a code for a custom gauntlet. Finally, we propose to add the word “each” to the description for each code. If no other changes are made, the new codes would be as follows:

- —Gradient compression arm sleeve and glove combination, each
- A—Gradient compression arm sleeve and glove combination, custom, each
- A—Gradient compression arm sleeve, each
- A—Gradient compression arm sleeve, custom, medium weight, each
- A—Gradient compression arm sleeve, custom, heavy weight, each
- A—Gradient compression glove, each
- A—Gradient compression glove, custom, medium weight, each
- A—Gradient compression glove, custom, heavy weight, each

- A—Gradient compression gauntlet, each
- A—Gradient compression gauntlet, custom, each

We are soliciting comment on whether separate codes are needed for mastectomy sleeves or whether these items can be grouped together under the same codes used for other arm sleeves (S8422 thru S8424). We are soliciting comments on whether there is a need to retain codes S8420 through S8428, in addition to the renumbered A code versions, for use by other payers other than Medicare. If these codes are retained, they would be invalid for Medicare use, but could be used by other payers in lieu of the new A codes.

We are also proposing to add the following new codes for other upper body areas:

- A—Gradient compression garment, neck/head, each
- A—Gradient compression garment, neck/head, custom, each
- A—Gradient compression garment, torso and shoulder, each
- A—Gradient compression garment, torso/shoulder, custom, each
- A—Gradient compression garment, genital region, each
- A—Gradient compression garment, genital region, custom, each

For all of the codes for the upper extremities and upper body areas, we are soliciting comments on whether we should establish codes for pressure level differentiations similar to the pressure level differentiations in codes A6530 through A6541, possibly replacing the words medium and heavy weight, as well as whether codes are needed for additional upper body areas.

We are proposing the following new codes for nighttime garments:

- A—Gradient compression garment, glove, padded, for nighttime use, each
- A—Gradient compression garment, arm, padded, for nighttime use, each
- A—Gradient compression garment, lower leg and foot, padded, for nighttime use, each
- A—Gradient compression garment, full leg and foot, padded, for nighttime use, each

For gradient compression wraps with adjustable straps, we are proposing to use code A6545 in Table FF–A 1 for below knee wraps and solicit comments on whether additional codes or coding revisions are needed for the purpose of submitting claims for gradient compression wraps with adjustable straps. Regarding HCPCS codes for compression bandaging systems, we believe more codes are needed than existing codes S8430 (Padding for compression bandage, roll) and S8431

(Padding for compression bandage, roll), for example, to describe the supplies used in a compression bandaging system consisting of more than two layers. We also believe that specific base sizes should be added to the code, for example “10cm by 2.9m” rather than the vague unit of “roll” and are soliciting comments on HCPCS coding changes needed to adequately describe the various compression bandaging systems used for the treatment of lymphedema. Finally, as noted in section VII.B.3. of this rule, we are soliciting comments on HCPCS codes needed to describe accessories necessary for the effective use of gradient compression garments or wraps with adjustable straps.

#### 5. Procedures for Making Benefit Category Determinations and Payment Determinations for New Lymphedema Compression Treatment Items

We are proposing to implement the new Part B benefit for lymphedema compression treatment items and the initial set of HCPCS codes to identify these items for claims processing purposes, effective January 1, 2024. In the future, as new products come on the market and refinements are made to existing technology, there will be a need to determine whether these newer technology items are lymphedema compression treatment items covered under this new benefit and what changes to the HCPCS are needed to identify these items for claims processing purposes. There will also be a need to establish payment amounts for the newer items in accordance with the payment rules established as part of this rulemaking.

Currently, CMS uses the procedures at 42 CFR 414.114 to make benefit category determinations and payment determinations for new splints and casts, parenteral and enteral nutrition (PEN) items and services covered under the prosthetic device benefit, and intraocular lenses (IOLs) inserted in a physician’s office covered under the prosthetic device benefit. CMS uses the same procedures at 42 CFR 414.240 to make benefit category determinations and payment determinations for new DME items and services, prosthetics and orthotics, surgical dressings, therapeutic shoes and inserts, and other prosthetic devices other than PEN items and services and IOLs inserted in a physician’s office. These procedures involve the use of the HCPCS public meetings where consultation from the public is obtained on preliminary HCPCS coding determinations for new items and services. Public consultation is also obtained at these meetings on



preliminary benefit category determinations and preliminary payment determinations for the new items and services. To ensure appropriate and timely consideration of future items that may qualify as lymphedema compression treatment items, we are proposing to use these same procedures to make benefit category determinations and payment determinations for new lymphedema compression treatment items. Future changes to the HCPCS codes established in section 2 of this rule for lymphedema compression treatment items would also be made using this public meeting process.

We are proposing to use the same process described in § 414.240 to obtain public consultation on preliminary coding, benefit category, and payment determinations for new lymphedema compression treatment items. That is, when a request is received for a new HCPCS code or change to an existing HCPCS code(s) for a lymphedema compression treatment item, CMS would perform an analysis to determine if a new code or other coding change is warranted and if the item meets the definition of lymphedema compression treatment item at section 1861(mmm) of the Act. A preliminary payment determination would also be developed for items determined to be lymphedema compression treatment items and are implemented in April or October of each year. The preliminary determinations would be posted on *CMS.gov* approximately 2 weeks prior to a public meeting. As part of this coding and payment determination process, it may be necessary to combine or divide existing codes; in this situation, we are proposing to follow the same process as outlined in 42 CFR 414.236. After consideration of public input on the preliminary determinations, CMS would post final HCPCS coding decisions, benefit category determinations, and payment determinations on *CMS.gov*, and then issue program instructions to implement the changes.

In addition to these proposals for initial payment determinations for lymphedema treatment items and the proposed process for addressing new lymphedema treatment items, as required by the Act, we also propose to revise the DMEPOS regulations to include lymphedema treatment items in the competitive bidding process. We are proposing changes to 42 CFR 414.402 to add lymphedema treatment items to the definition of “items” for competitive bidding, § 414.408 to include lymphedema treatment items in the list of items for which payment would be made on a lump sum purchase basis

under the competitive bidding program in accordance with any frequency limitations established under proposed subpart Q in accordance with section 1834(z)(2) of the Act, and § 414.412 to add reference to the proposed subpart Q to the bid rules.

#### 6. Enrollment, Quality Standards, and Accreditation Requirements for Suppliers of Lymphedema Compression Treatment Items and Medicare Claims Processing Contractors for These Items

Section 1834(a)(20) of the Act requires the establishment of quality standards for suppliers of DMEPOS that are applied by independent accreditation organizations. Section 4133(b)(1) of the CAA, 2023 amends section 1834(a)(20)(D) of the Act to apply these requirements to lymphedema compression treatment items as medical equipment and supplies.

Section 1834(j) of the Act requires that suppliers of medical equipment and supplies obtain and continue to periodically renew a supplier number in order to be allowed to submit claims and receive payment for furnishing DMEPOS items and services. The suppliers must meet certain supplier standards in order to possess a supplier number and are also subject to other requirements specified in section 1834(j) of the Act. Section 4133(b)(2) of the CAA, 2023 amends section 1834(j)(5) of the Act to include lymphedema compression treatment items as medical equipment and supplies subject to the requirements of section 1834(j) of the Act.

Suppliers of DMEPOS meeting the requirements of sections 1834(a)(20) and 1834(j) of the Act, and related implementing regulations at 42 CFR 424.57 must enroll in Medicare or change their enrollment using the paper application Medicare Enrollment Application for DMEPOS Suppliers (CMS-855S) or through the Medicare Provider Enrollment, Chain, and Ownership System (PECOS). For more information on supplier enrollment, go to: <https://www.cms.gov/medicare/provider-enrollment-and-certification/become-a-medicare-provider-or-supplier>.

Regulations at 42 CFR 421.210 establish regional contractors to process Medicare claims for DMEPOS items and services. These contractors are known as Durable Medical Equipment Medicare Administrative Contractors (DME MACs). We are proposing to include lymphedema compression treatment items as DMEPOS items that fall within the general text of section 421.210(b)(7) for other items or services which are designated by CMS. Thus, claims for

these items would be processed by the DME MACs.

#### 7. Payment Basis and Frequency Limitations for Lymphedema Compression Treatment Items

Section 1834(z)(1) of the Act mandates an appropriate payment basis for lymphedema compression treatment items defined in section 1861(mmm) of the Act and specifically identifies payment rates from other government and private sector payers that may be taken into account in establishing the payment basis for these items. These sources include payment rates used by Medicaid state plans, the Veterans Health Administration (VHA), group health plans, and health insurance coverage (as defined in section 2791 of the Public Health Service Act). Section 1834(z)(1) of the Act also indicates that other information determined to be appropriate may be taken into account in establishing the payment basis for lymphedema compression treatment items.

Based on our research, Medicaid state plans generally classify and provide lymphedema compression treatment items in the same manner as other durable medical equipment and supplies for home health. While State Medicaid Director Letter #18-001 focuses on how states may demonstrate compliance with the restriction on claiming federal financial participation for “excess” durable medical equipment spending, it describes how Medicaid state plan payment for the broader category of such items (outside of a managed care contract) is usually made either through established fee schedules, a competitive bidding process of the state’s design, or through a manual pricing methodology based on the invoice submitted with each claim.<sup>180</sup> For the purpose of this proposed rule, we took into account the average Medicaid fee schedule payment amounts across all states that have published fee schedule amounts for these items in developing, in part, an appropriate payment basis for lymphedema compression treatment items under Medicare.

The VHA does not have established fee schedules for lymphedema compression treatment items, but rather follows a policy of paying for these items based on the reasonableness of vendor pricing. Based on our conversations with the VHA, we understand that for these items, vendor prices at or below acquisition cost plus 50 percent is typically considered

<sup>180</sup> Available at <https://www.medicare.gov/federal-policy-guidance/downloads/smd18001.pdf>

reasonable, while Medicaid state plans typically pay for DMEPOS items that do not have fee schedule amounts at acquisition cost plus 20 to 30 percent. Given this difference in the allowed supplier margin, the amounts determined to be reasonable payment rates for these items by the VHA may be approximated by increasing the average Medicaid payment rate by 20 to 30 percent. While the VHA may not have fee schedule amounts for these items, the Department of Defense's TRICARE system maintains fee schedule amounts for lower-extremity lymphedema compression garments. These amounts are approximately equal to the average Medicaid fee schedule amount plus 20 percent. We therefore believe that the average Medicaid fee schedule amount plus 20 percent represents what other government payers such as the VHA and TRICARE consider an appropriate payment basis for these items and a slightly higher payment basis than the average payment rates established by Medicaid state plans that have fee schedule amounts for these items; we are specifically soliciting comments on this. We also conducted a search of internet prices for lymphedema compression treatment items and found these prices to be in line with the TRICARE fee schedule amounts and

average Medicaid fee schedule amounts plus 20 percent. We believe that appropriate payment amounts for Medicare for lymphedema compression treatment items would be payment amounts that approximate the payment rates determined to be reasonable by other government payers such as TRICARE, State Medicaid agencies, and, as previously explained, estimates of the payment rates determined to be reasonable by the VHA based on 120 percent of the average Medicaid state plan rates. Because these rates are in line with internet retail prices, we have not closely examined non-government payers.

Having taken into account the payment amounts from the various sources, as previously described, as required by Act, we propose to set payment amounts for lymphedema compression treatment items using the following methodology. Where Medicaid state plan payment amounts are available for a lymphedema compression treatment item, we propose to set payment amounts at 120 percent of the average of the Medicaid payment amounts for the lymphedema compression treatment item. Where Medicaid payment amounts are not available for an item, we propose to set payment amounts at 100 percent of the

average of internet retail prices and payment amounts for that item from TRICARE. Where payment amounts are not available from Medicaid state plans or TRICARE for a given lymphedema compression treatment item, we propose to base payment amounts based on 100 percent of average internet retail prices for that item. We seek comment on these payment methodologies and whether further adjustments are appropriate.

As previously noted, payment rates for the supply of these items includes payment for fitting services and any other services necessary for furnishing the item. As noted earlier, taking measurements of affected body areas and other fitting services necessary for furnishing lymphedema compression treatment items are an integral part of furnishing the items and the suppliers receiving payment for furnishing lymphedema compression treatment items are responsible for ensuring that any necessary fitting services are provided as part of furnishing the items.

The following table presents a preliminary example of what payment amounts may be, based on the proposed methodology described, as previously detailed, and certain HCPCS codes that we are proposing to be classified under the Medicare Part B benefit category for lymphedema treatment items.

**TABLE FF-A 2: EXAMPLE PAYMENT AMOUNTS FOR LYMPHEDEMA COMPRESSION TREATMENT ITEMS**

| <b>Code</b> | <b>Description</b>  | <b>Example Payment Amount</b> |
|-------------|---|-------------------------------|
| A6530       | Gradient compression stocking, below knee, 18-30 mmhg, each             | \$37.95                       |
| A6531       | Gradient compression stocking, below knee, 30-40 mmhg, each             | \$54.92                       |
| A6532       | Gradient compression stocking, below knee, 40-50 mmhg, each             | \$73.49                       |
| A6533       | Gradient compression stocking, thigh length, 18-30 mmhg, each           | \$50.24                       |
| A6534       | Gradient compression stocking, thigh length, 30-40 mmhg, each           | \$60.32                       |
| A6535       | Gradient compression stocking, thigh length, 40-50 mmhg, each           | \$68.45                       |
| A6536       | Gradient compression stocking, full length/chap style, 18-30 mmhg, each | \$70.12                       |
| A6537       | Gradient compression stocking, full length/chap style, 30-40 mmhg, each | \$83.26                       |
| A6538       | Gradient compression stocking, full length/chap style, 40-50 mmhg, each | \$97.81                       |
| A6539       | Gradient compression stocking, waist length, 18-30 mmhg, each           | \$92.01                       |
| A6540       | Gradient compression stocking, waist length, 30-40 mmhg, each           | \$110.04                      |
| A6541       | Gradient compression stocking, waist length, 40-50 mmhg, each           | \$128.85                      |
| A6545       | Gradient compression wrap, non-elastic, below knee, 30-50 mmhg, each    | \$110.95                      |
| Axxxx       | Gradient compression arm sleeve and glove combination, custom, each     | \$369.90                      |
| Axxxx       | Gradient compression arm sleeve and glove combination, each             | \$94.55                       |

| Code  | Description  | Example Payment Amount |
|-------|--|------------------------|
| Axxxx | Gradient compression arm sleeve, custom, medium weight, each | \$172.29               |
| Axxxx | Gradient compression arm sleeve, custom, heavy weight, each  | \$177.98               |
| Axxxx | Gradient compression arm sleeve, each                        | \$58.10                |
| Axxxx | Gradient compression glove, custom, medium weight, each      | \$283.50               |
| Axxxx | Gradient compression glove, custom, heavy weight, each       | \$349.33               |
| Axxxx | Gradient compression glove, each                             | \$92.24                |
| Axxxx | Gradient compression gauntlet, each                          | \$42.85                |

Where new items are added to this benefit category, following the process outlined in section 3 of this section of this rule, the data sources (Medicaid, TRICARE, VHA, or internet prices) may not initially be available for establishing an appropriate payment amount. We are proposing that in this situation, until the data necessary for establishing the payment amount becomes available, the DME MACs would consider what an appropriate payment amount would be for each item on an individual, claim-by-claim basis and may consider using pricing for similar items that already have established payment amounts.

Section 1834(z)(2) of the Act authorizes the establishment of frequency limitations for lymphedema compression treatment items and specifies that no payment may be made for lymphedema compression treatment items furnished other than at a frequency established in accordance with this provision of the Act. Gradient compression garments are designed differently depending on whether for daytime or nighttime use. Those meant for daytime provide a higher level of compression while those for nighttime offer milder compression and are less snug against the skin. We are seeking comment on our proposal to cover and make payment for two garments or wraps with adjustable straps for daytime use (one to wear while another is being washed), per affected extremity, or part of the body, to be replaced every 6 months or when the items is lost, stolen, or irreparably damaged, or if needed based on a change in the beneficiary's medical or physical condition such as an amputation, complicating injury or illness, or a significant change in body weight. In order to maintain mobility, patients may require separate garments or wraps above and below the joint of the affected extremity or part of the body. As discussed in section B of this section of this rule, nighttime garments are inelastic and more durable than the elastic daytime garments and we believe it would be appropriate to replace these garments once per year. We are proposing to cover one nighttime garment per affected extremity or part of

the body to be replaced once a year or when the garment is lost, stolen, or irreparably damaged, or if needed based on a change in the beneficiary's medical or physical condition such as an amputation, complicating injury or illness, or a significant change in body weight. Lymphedema is a chronic condition that can be stabilized if properly treated. It may also worsen as the result of infection, radiation and chemotherapy, or progression of comorbid conditions such as obesity. At this point, patients may require changes in their garment prescription. Such changes due to medical necessity will not be subject to the frequency limitations, as previously described. In addition, as with other DMEPOS items, payment could be made for replacement of garments and other items when they are lost, stolen, or irreparably damaged. Examples of lost items include items left behind after evacuating due to a disaster like a hurricane or tornado. Examples of irreparably damaged items include items that burn in a fire, are exposed to toxic chemicals, or are damaged by some other event and does not include items that wear out over time.

With regard to replacement frequencies for compression bandaging systems and supplies, the weekly frequency and overall length of phase one (active) treatment is dependent on the severity of lymphedema. Some patients may require treatment 4 to 5 days per week in phase one while others may only need treatment 2 to 3 days per week. Bandages are used following some form of hands-on decompression to maintain the reduction. Therefore, we are not proposing specific replacement frequencies for the compression bandaging systems and supplies. We are proposing that the DME MACs would make determinations regarding whether the quantities of compression bandaging supplies furnished and billed during phase one of treatment of the beneficiary's lymphedema are reasonable and necessary.

As previously discussed, section 4133(a)(3) of the CAA, 2023 adds subparagraph D to section 1847(a)(2) of the Act to add lymphedema

compression treatment items to the DMEPOS competitive bidding program. Section 1834(z)(3)(A) of the Act specifies that the payment basis under section 1847(a) of the Act becomes the payment basis for lymphedema compression treatment items furnished under the competitive bidding program. Section 1834(z)(3)(B) of the Act provides authority to use information on the payment determined for these items under the competitive bidding program to adjust the payment amounts otherwise determined under section 1834(z) for an area that is not a competitive bidding area under section 1847 of the Act, and in the case of such adjustment, section 1842(b)(8) and (9) of the Act shall not be applied.

#### 8. Proposed Changes

We are proposing to amend 42 CFR 410.36 to add paragraph (a)(4) for lymphedema compression treatment items as a new category of medical supplies, appliances, and devices covered and payable under Medicare Part B, including: standard and custom fitted gradient compression garments; gradient compression wraps with adjustable straps; compression bandaging systems; other items determined to be lymphedema compression treatment items under the process established under § 414.1670; and accessories such as zippers in garments, liners worn under garments or wraps with adjustable straps, and padding or fillers that are necessary for the effective use of a gradient compression garment or wrap with adjustable straps. In order to maintain mobility, patients may require separate garments or wraps above and below the joint of the affected extremity or part of the body, and we are proposing that payment may be made in these circumstances. We are proposing that payment may be made for multiple garments used on different parts of the body when the multiple garments are determined to be reasonable and necessary for the treatment of lymphedema. For example, if it is determined that a beneficiary needs three daytime garments to cover one

affected area for the treatment of lymphedema, Medicare would pay for two sets of those three garments for that specific affected area, as well as any other areas of the body affected by lymphedema. For the purpose of establishing the scope of the benefit for these items, we are seeking comment on the following definitions we are proposing to add to 42 CFR 410.2 as they apply to lymphedema compression treatment items:

*Gradient compression* means the ability to apply a higher level of compression or pressure to the distal (farther) end of the limb or body part affected by lymphedema with lower, decreasing compression or pressure at the proximal (closer) end of the limb or body part affected by lymphedema.

*Custom fitted gradient compression garment* means a garment that is uniquely sized and shaped to fit the exact dimensions of the affected extremity or part of the body of an individual to provide accurate gradient compression to treat lymphedema.

The proposed definition of “gradient compression” would apply to all lymphedema compression treatment items (garments, wraps, etc.) that utilize gradient compression in treating lymphedema. The proposed definition of “custom fitted gradient compression garment” would apply to custom fitted gradient compression garments covered under the new benefit category for lymphedema compression treatment items. We believe these definitions are necessary for establishing the scope of this new benefit.

*Lymphedema compression treatment item* means standard and custom fitted gradient compression garments and other items specified under § 410.36(a)(4) that are—

- Furnished on or after January 1, 2024, to an individual with a diagnosis of lymphedema for treatment of such condition;
- Primarily and customarily used to serve a medical purpose and for the treatment of lymphedema; and
- Prescribed by a physician (or a physician assistant, nurse practitioner, or a clinical nurse specialist (as those terms are defined in section 1861(aa)(5) of the Social Security Act) to the extent authorized under State law.

We are proposing to modify and add to the existing HCPCS codes for surgical dressings and lymphedema compression treatment items as explained in section VII.B.4. of this rule. We are proposing that future changes to the HCPCS codes for these items based on external requests for changes to the HCPCS or internal CMS changes would be made through the HCPCS public meeting

process described at: <https://www.cms.gov/medicare/coding/medhpcsgeninfo/hcpcspublicmeetings>.

We are proposing to add § 414.1670 under new subpart Q and use the same process described in § 414.240 to obtain public consultation on preliminary benefit category determinations and payment determinations for new lymphedema compression treatment items. The preliminary determinations would be posted on CMS.gov in advance of a public meeting. After consideration of public input on the preliminary determinations, CMS would post final HCPCS coding decisions, benefit category determinations, and payment determinations on CMS.gov, and then issue program instructions to implement the changes.

We are proposing to add a new subpart Q under the regulations at 42 CFR part 414 titled, “Payment for Lymphedema Compression Treatment Items” to implement the provisions of section 1834(z) of the Act. We are proposing to add § 414.1600 to our regulations explaining the purpose and definitions under the new subpart Q. We are proposing to add § 414.1650 and paragraph (a) to establish the payment basis equal to 80 percent of the lesser of the actual charge for the item or the payment amounts established for the item under paragraph (b). We are proposing under § 414.1650(b) to establish the payment amounts for lymphedema compression treatment items based on the average of state Medicaid fee schedule amounts plus 20 percent. Where Medicaid rates are not available, we are proposing to use the average of average internet retail prices and payment amounts established by TRICARE (or, where there is no TRICARE fee schedule rate, the average of internet retail prices alone). We propose under § 414.1650(c) that, beginning January 1, 2025, and on January 1 of each subsequent year, the Medicare payment rates established for these items in accordance with section 1834(z)(1) of the Act and § 414.1650(b) would be increased by the percentage change in the Consumer Price Index for All Urban Consumers (CPI-U) for the 12-month period ending June of the preceding year. For example, effective beginning January 1, 2025, the payment rates that were in effect on January 1, 2024 would be increased by the percentage change in the CPI-U from June 2023 to June 2024.

We are also proposing to add § 414.1660 to address continuity of pricing when HCPCS codes for lymphedema compression treatment items are divided or combined. Similar to current regulations at 42 CFR 414.110

and 414.236, we propose that when there is a single HCPCS code that describes two or more distinct complete items (for example, two different but related or similar items), and separate codes are subsequently established for each item, the payment amounts that applied to the single code continue to apply to each of the items described by the new codes. We propose that when the HCPCS codes for several different items are combined into a single code, the payment amounts for the new code are established using the average (arithmetic mean), weighted by allowed services, of the payment amounts for the formerly separate codes.

We are proposing to add § 414.1680 and the following frequency limitations for lymphedema compression treatment items established in accordance with section 1834(z)(2) of the Act under new subpart Q:

- Two daytime garments or wraps with adjustable straps for each affected limb or area of the body, replaced every 6 months.
- One nighttime garment for each affected limb or area of the body, replaced once a year.

We are soliciting comments on whether two nighttime garments should be allowed, with both garments being replaced once every 2 years, to allow for more than 1 day for washing and drying of the garment(s). We are also proposing to cover replacements of garments or wraps that are lost, stolen, irreparably damaged, or when needed due to a change in the patient’s medical or physical condition. We are not proposing specific replacement frequencies for compression bandaging systems or supplies. We are proposing that determinations regarding the quantity of compression bandaging supplies covered for each beneficiary during phase one of decongestive therapy would be made by the DME MAC that processes the claims for the supplies.

We are proposing to revise the regulations for competitive bidding under subpart F at 42 CFR 414 to include lymphedema compression treatment items under the competitive bidding program as mandated by section 1847(a)(2)(D) of the Act. We propose to modify the list of items that may be included in competitive bidding described in § 414.402 to include lymphedema treatment items and revise § 414.408 to include lymphedema treatment items in the list of items for which payment would be made on a lump sum purchase basis under the competitive bidding program in accordance with any frequency limitations established under proposed

subpart Q in accordance with section 1834(z)(2) of the Act. Finally, we propose to add reference the proposed subpart Q to the bid rules described at § 414.412.

The methodologies for adjusting DMEPOS payment amounts for items included in the DMEPOS Competitive Bidding Program (CBP) that are furnished in non-CBAs based on the payments determined under the DMEPOS CBP are set forth at § 414.210(g). Section 4133(a)(3) of the CAA, 2023 amended section 1847(a)(2) of the Act to include lymphedema compression treatment items under the DMEPOS CBP, and section 4133(a)(2) of the CAA, 2023 amended section 1834 of the Act to provide authority to adjust the payment amounts established for lymphedema compression treatment items in accordance with new subsection z based on the payments determined for these items under the DMEPOS CBP. We believe the methodologies for adjusting DMEPOS payment amounts at § 414.210(g) should also be used to adjust the payment amounts for lymphedema compression treatment items included in the DMEPOS CBP that are furnished in non-CBAs. We see no reason why different methodologies for adjusting payment amounts based on payments determined under the DMEPOS CBP would need to be established for lymphedema compression treatment items. We are therefore proposing to add § 414.1690 indicating that the payment amounts established under § 414.1650(b) for lymphedema compression treatment items may be adjusted using information on the payment determined for lymphedema compression treatment items as part of implementation of the DMEPOS CBP under subpart F using the methodologies set forth at § 414.210(g).

### C. Definition of Brace

#### 1. Background

The Social Security Act of 1965 (the Act) defines the scope of benefits available to eligible Medicare beneficiaries under Medicare Part B, the voluntary supplementary medical insurance program defined by section 1832 of the Act. Section 1832(a)(1) of the Act establishes the Medicare Part B benefit for “medical and other health services.” Section 1861(s) of the Act further defines “medical and other health services” to include under paragraph (9) leg, arm, back, and neck braces, and artificial legs, arms, and eyes. Artificial legs, arms, and eyes are artificial replacements for missing legs, arms, and eyes and this rule does not address the scope of the Medicare

benefit for these items. Section 1834(h)(4)(C) of the Act details the payment rules for particular items and services including specifying that “the term ‘orthotics and prosthetics’ has the meaning given to such term in section 1861(s)(9).” Regulations at 42 CFR 410.36(a)(3) include leg, arm, back, and neck braces under the list of medical supplies, appliances, and devices in the scope of items paid for under Part B of Medicare. However, the term “brace” is not defined in the Act or in regulation. Specifically, the term brace is not defined in 42 CFR 410.2 Definitions for supplementary medical insurance benefits for Medicare.

The Medicare program instruction that defines the term brace is located at CMS Pub. 100–02, Chapter 15, § 130 of the Medicare Benefit Policy Manual for Part B coverage of “Leg, Arm, Back, and Neck Braces, Trusses, and Artificial Legs, Arms, and Eyes.” Within this instruction, braces are defined as “rigid and semi-rigid devices which are used for the purpose of supporting a weak or deformed body member or restricting or eliminating motion in a diseased or injured part of the body.” The Medicare definition of brace in program instructions dates back to the 1970s and was previously located in the Medicare Carriers Manual, HCFA Pub. 14, Part III, Chapter 2, § 2133. This longstanding definition of brace in our program instructions is used for the purpose of making benefit category determinations in accordance with the procedures located at 42 CFR 414.240 (86 FR 73911) regarding when a device constitutes or does not constitute a leg, arm, back, or neck brace for Medicare program purposes.

#### 2. Current Issues

We believe that adding the definition of brace to the regulations at 42 CFR 410.2 is necessary for describing the scope of the Medicare Part B benefit for leg, arm, back, and neck braces. We believe that codifying the definition that is currently located in Medicare program instructions would continue the efficiency of the administration of the Medicare program by providing clarity and transparency regarding the scope of the benefit, for example, whether a specific device is a leg, arm, back, or neck brace as defined in section 1861(s)(9) of the Act, and consequently, payment determinations for such items. We also believe that adding the definition of brace to the regulations would support our benefit category determination process described in 42 CFR 414.240 (86 FR 73911).

The orthopedic industry has long established the attributes of a “brace.”

We believe the definition of a brace in CMS Pub 100–02, Chapter 15, § 130 adequately captures the attributes of a brace. The words “rigid” and “semi-rigid” are used to describe the stiffness of a material. Rigid materials are used to eliminate motion but also to support underload. Components of a brace can use semi-rigid materials, which intentionally allow some amount of motion as compared to materials that completely immobilize a part of the body. Braces are typically prescribed to patients during the process of recovery and rehabilitation in order to stop limbs, joints, or specific body segments from moving for a pre-determined period. Braces may also be prescribed for ongoing medical problems that require restriction or limitation of joint movement; removal of weight or pressure from healing or injured joints, muscles, or body parts; or reduction of misalignment and function to reduce pain and facilitate improved mobility.<sup>181 182</sup>

In order for a brace to properly function, it must utilize a three-point pressure system to provide angular control over anatomical joints.<sup>183 184 185</sup> A three-point pressure system places a single force at the area of the deformity, while two counter forces act in the opposing direction. This pressure system requires that a brace be rigid or semi-rigid in structure to apply sufficient relevant force to support, restrict, or eliminate motion of the joint or specific body part. The rigidity level of a brace is dependent on the body part and purpose for which the brace is used. For example, a fully rigid brace is used to eliminate motion and support underload. We believe the definition of brace in CMS Pub 100–02, Chapter 15, § 130, and our proposed definition of

<sup>181</sup> Webster, J., Murphy, D., 2019, *Atlas of Orthoses and Assistive Devices*, 5th Edition, Elsevier, Philadelphia, PA. (Chapter 1) <https://www.sciencedirect.com/book/9780323483230/atlas-of-orthoses-and-assistive-devices>

<sup>182</sup> CHAMPVA OPERATIONAL POLICY MANUAL: CHAPTER: 2, SECTION: 17.4. [https://www.va.gov/va.gov/system/templates/selfservice/va\\_ssnew/help/customer/locale/en-US/portal/55440000001036/content/554400000008979/021704-ORTHOTICS](https://www.va.gov/va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/55440000001036/content/554400000008979/021704-ORTHOTICS)

<sup>183</sup> Webster, J., Murphy, D., 2019, *Atlas of Orthoses and Assistive Devices*, 5th Edition, Elsevier, Philadelphia, PA. (Chapter 18). <https://www.sciencedirect.com/book/9780323483230/atlas-of-orthoses-and-assistive-devices>

<sup>184</sup> Chalmers, D. D., & Hamer, G. P. (1985). Three-point dynamic orthosis. *Prosthetics and Orthotics International*, 9(2), 115–116. <https://journals.sagepub.com/doi/pdf/10.3109/03093648509164718>. <https://doi/pdf/10.3109/03093648509164718>. <https://journals.sagepub.com/doi/pdf/10.3109/03093648509164718>. <https://doi/pdf/10.3109/03093648509164718>.

<sup>185</sup> Article—Spinal Orthoses: TLSO and LSO—Policy Article (A52500) (*cms.gov*).

brace, adequately captures the various attributes of a brace.

It is important to note that a rigid or semi-rigid device may look like a brace in that it has metal struts, joints, and cuffs that go over a limb, but may be used for purposes other than bracing the limb. We believe that devices used for purposes other than supporting a weak or deformed body member or restricting or eliminating motion of a diseased or injured part of the body do not fall within the definition of a brace in accordance with Pub 100–02, Chapter 15, § 130 Medicare Benefit Policy Manual, and would not fall within our proposed definition of brace. However, items that are not braces may meet the Medicare Part B definition for durable medical equipment (DME) at 42 CFR 414.202. For example, continuous passive motion devices are covered as DME in accordance with CMS Pub 100–03, Chapter 1, Part 4, § 280.1 of the Medicare National Coverage Determinations Manual to rehabilitate the knee to increase range of motion following surgery. During continuous passive motion therapy, the joint area is secured to the device, which then moves the affected joint through a prescribed range of motion for an extended period of time. Continuous passive motion devices have metal struts, joints, and cuffs that go over a limb but are not used for the purpose of restricting or eliminating motion in a diseased or injured part of the body or to support a weak or deformed body member. While these devices do not meet the definition of a brace in accordance with Pub 100–02, Chapter 15, § 130 of the Medicare Benefit Policy Manual, they are covered by Medicare as DME. Similarly, dynamic adjustable extension/flexion devices and static progressive stretch devices are used to stretch an arm or leg or other part of the body to treat contractures and increase range of motion. While these devices may look similar to a brace, they are used for the purpose of treating contractures and are not used for the purpose of supporting a weak or deformed body member or restricting or eliminating motion in a diseased or injured part of the body. As a result, dynamic adjustable extension/flexion devices and static progressive stretch devices do not fall under the definition of brace in accordance with CMS Pub 100–02, Chapter 15, § 130, but are covered by Medicare as DME.

It is also important to note that although braces in the past have typically not included powered devices or devices with power features, technology has evolved to include newer technology devices with power

features designed to assist with traditional bracing functions. For example, effective January 1, 2020, code L2006 was added to the HCPCS for a knee ankle foot device, any material, single or double upright, swing and stance phase microprocessor control with adjustability, includes all components (for example, sensors, batteries, charger), any type activation, with or without ankle joint(s), custom fabricated). CMS classified this device as a brace because it supports a weak or deformed knee by preventing it from buckling under the patient. This brace includes a microprocessor controlled hydraulic swing and stance control knee joint that restricts/affects knee joint kinematics during the swing and stance phases of the gait cycle. There are also powered brace exoskeleton devices that support a patient's weak arms or legs and have been classified as DME in the past. We determined that these devices should be classified as braces due to their use in stabilizing, positioning, supporting and restoring the function of a patient's weak limbs. In addition, upper extremity powered exoskeleton devices used by patients with chronic arm weakness such as from complications of stroke or other neurological/neuromuscular injury and illness to support and assist movement of weak arms were recently introduced to the market. HCPCS codes L8701 (Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated) and L8702 (Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated)) were added to the HCPCS effective January 1, 2019 to describe two categories of these items. These devices support the arm of the patient and allows them to use volitional, intact electromyographic signals in weak muscles to control the device through a normal range of motion. A lower extremity powered exoskeleton device that supports the weak legs of a patient with spinal cord injury (SCI) at levels T7 to L5 to enable the patient to perform ambulatory functions was also recently introduced to the market. Code K1007 (Bilateral hip, knee, ankle, foot device, powered, includes pelvic component, single or double upright(s), knee joints any type, with or without ankle joints any type, includes all components and accessories, motors, microprocessors, sensors)) was added to the HCPCS

effective January 1, 2020 to describe this category of items. The device uses motion sensors with an exoskeleton frame and onboard computer system. Patients using all of the devices, as previously described, are better able to elongate and flex their limbs using the respective device, sometimes in a braced manner and sometimes in a controlled manner of motion, thus improving the functioning of the malformed body member and supporting the weak limbs. Additional information on the items, as previously discussed, can be found at: [www.cms.gov/files/document/2022-hcpcs-application-summary-biannual-1-2022-non-drug-and-non-biological-items-and-services.pdf](http://www.cms.gov/files/document/2022-hcpcs-application-summary-biannual-1-2022-non-drug-and-non-biological-items-and-services.pdf).

One additional issue related to leg braces with shoes that are an integral part of the brace. Section 1862(a)(8) of the Act generally excludes orthopedic shoes or other supportive devices for the feet from coverage under the Medicare program. However, longstanding policy at CMS Pub 100–02, Chapter 15, § 290 of the Medicare Benefit Policy Manual indicates that this exclusion does not apply to such a shoe if it is an integral part of a leg brace, and if that shoe or other supportive device for the feet is an integral part of a leg brace, then the cost of that shoe or device is included as part of the cost of the brace. We are proposing to include this exception in the proposed definition of a brace at § 410.2.

### 3. Proposed Regulation Changes

We are proposing to amend the regulations at 42 CFR 410.2 to add the definition of brace to improve clarity and transparency regarding coverage and payment for the term brace as defined in section 1861(s)(9) of the Act. Also, we believe adding the definition in regulations will improve the efficiency of the administration of the Medicare program when considering whether a new device is a leg, arm, back, or neck brace for benefit category and payment determinations under our review procedures at § 414.240. In addition, we believe that adding the definition of a brace in regulation would expedite coverage and payment for newer technology and powered devices, potentially providing faster access to these new healthcare technologies for Medicare beneficiaries.

We are proposing that the definition of brace at 42 CFR 410.2 would be consistent with CMS's longstanding brace policy and information at section 130 of chapter 15 of the Medicare Benefit Policy Manual (CMS Pub 100–02). Thus, we are proposing to specify in the definition that a brace is rigid or

semi-rigid and that the stiffness of the material used in making the device is essential to the definition of a brace for purposes of the scope of this Medicare benefit. Rigid refers to material used to eliminate motion but also to support underload. Components of a brace will use semi-rigid materials, which intentionally allow some amount of motion as compared to materials that completely immobilize. Also, we are proposing at 42 CFR 410.2 to specify in the definition that a brace is used for the purpose of supporting a weak or deformed body member or restricting or eliminating motion in a diseased or injured part of the body. In addition, we are proposing to specify at § 410.36(a)(3)(i)(A) that a brace may include a shoe if it is an integral part of a leg brace and its expense is included as part of the cost of the brace.

We note three HCPCS codes were established to permit billing of the powered upper extremity devices and powered lower extremity exoskeleton devices. Two HCPCS codes were established effective October 1, 2019 which are: L8701 (Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated) and L8702 (Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated). One HCPCS was established effective October 1, 2020 which is K1007 (Bilateral hip, knee, ankle, foot device, powered, includes pelvic component, single or double upright(s), knee joints any type, with or without ankle joints any type, includes all components and accessories, motors, microprocessors, sensors). However, corresponding Medicare benefit category and Medicare payment determinations were not finalized for these HCPCS codes to permit more time for evaluation. As a result of the proposal to amend the regulations at 42 CFR 410.2 to add the definition of brace, if finalized, these codes would be classified under the definition of brace. Using the processes outlined in regulations at 42 CFR 414.240, we intend to obtain public consultation on the payment determinations for these codes at an upcoming HCPCS Level II public meeting. Additional information on these HCPCS codes can be found in the HCPCS Level II Final Coding, Benefit Category and Payment Determinations First Biannual (B1), 2022 HCPCS Coding Cycle at [www.cms.gov/files/document/](http://www.cms.gov/files/document/)

*2022-hcpcs-application-summary-biannual-1-2022-non-drug-and-non-biological-items-and-services.pdf*. The agenda and dates for a public meeting will be available on the CMS HCPCS website: <https://www.cms.gov/Medicare/Coding/MedHCPCSGenInfo/HCPCSPublicMeetings>.

#### *D. Documentation Requirements for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies Products Supplied as Refills to the Original Order*

##### 1. Background

Durable medical equipment (DME) is covered as a benefit category under Part B under medical or other health services as described in section 1861(s)(6) of the Act and defined under section 1861(n) of the Act. We further defined DME in regulations at § 414.202 as equipment that can withstand repeated use, is primarily and customarily used to serve a medical purpose, is not generally useful to a person in the absence of an illness or injury, is appropriate for use in the home, and effective with respect to items classified as DME after January 1, 2012, has an expected life of at least 3 years. Certain items of DME require supplies for effective use. Supplies include, but are not limited to, drugs and biologicals that must be put directly into the equipment to achieve the therapeutic benefit or to assure the proper functioning of the equipment. Examples include oxygen, tumor chemotherapy agents transfused via an infusion pump, or diabetic test strips used with a home glucose monitor.

Prosthetics and orthotics are defined under section 1861(s)(9) of the Act and include leg, arm, back, and neck braces and artificial legs, arms, and eyes—including replacements if required because of a change in the patient's physical condition. These items are referred to collectively as Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS).

DMEPOS items and supplies may be furnished on a recurring basis to beneficiaries with chronic or longer-term conditions. For such items, the practitioner may be able to forecast and prescribe, at the time of the beneficiary's initial need or during later clinical interaction, the ongoing medical need for DMEPOS items and/or supplies. In other words, the practitioner may be able to determine the beneficiary's expected, ongoing medical need both at the time of the interaction and as anticipated need for later dates of service. In such cases, the practitioner may write an order for immediate use and refills for later dates of service.

Section 1893(a) of the Act authorized the Secretary to promote the program integrity of the Medicare program by entering into contracts with eligible entities to carry out activities specified in subsection (b) of such section. Section 1893(b)(1) of the Act, authorizes “[r]eview of activities of providers of services or other individuals and entities furnishing items and services for which payment may be made under this title . . . including medical and utilization review [emphasis added] . . .”. In response to concerns related to auto-shipments and delivery of DMEPOS supplies that may no longer be needed or not needed at the same level of frequency/volume (for example, stockpiling), CMS instituted policies to require suppliers to contact the beneficiary prior to dispensing DMEPOS refills. In CY 2004, we updated our Medicare Program Integrity Manual to include timeframes related to refillable DMEPOS items.<sup>186</sup> This was done to ensure that the refilled item was necessary and to confirm any changes/modifications to the order. At that time, CMS stated that contact with the beneficiary or designee regarding refills should take place no sooner than 7 days prior to the delivery/shipping date. CMS further stated that subsequent deliveries of refills of DMEPOS products should occur no sooner than 5 days prior to the end of the usage for the current product. This change intended to allow for shipping of refills on “approximately” the 25th day of the month in the case of a month's supply, as later clarified and emphasized in preamble discussion in the CY 2005 Physician Fee Schedule final rule (69 FR 66235).

In 2011, due to stakeholder concerns related to burden, we amended the Medicare Program Integrity Manual to state that contact with the beneficiary or designee regarding refills must take place no sooner than 14 calendar days prior to the delivery/shipping date, and that delivery of the DMEPOS product occur no sooner than 10 calendar days prior to the end of usage for the current product.<sup>187</sup> This is the current policy on DMEPOS refills as described in the Medicare Program Integrity Manual.<sup>188</sup>

<sup>186</sup> internet Only Manual 100–08, Program Integrity Manual (2004), available at: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R61PI.pdf>.

<sup>187</sup> internet Only Manual 100–08, Program Integrity Manual (2011), available at: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R378PI.pdf>.

<sup>188</sup> internet Only Manual 100–08, Program Integrity Manual, Chapter 5, Section 5.2.6—Refills of DMEPOS Items Provided on a Recurring Basis (2022), available at: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/pim83c05.pdf>.

We note that while the timeframes are applicable to all refillable items, they are most pertinent to the mail/delivery model because those beneficiaries could potentially be most at risk for receiving unnecessary or unsolicited items and supplies. For beneficiaries calling, texting, or otherwise contacting their pharmacy or retail store and picking up their refills, we note the decreased potential for providing supplies that may not be medically necessary or for which the beneficiary has sufficient supply. For items that the beneficiary obtains in-person at a retail store, the signed delivery slip or a copy of the itemized sales receipt is sufficient documentation of a request for refill.

Both delivery models are intended to allow for uninterrupted supply of the necessary item(s), and allow for the processing of claims for refills delivered/shipped prior to the beneficiary's complete exhaustion of their supply. We note that prior guidance related to this policy referred to this sort of permissible overlap as refills for items "pending exhaustion".

Despite the long-standing programmatic safeguards, compliance with refill procedures continues to cause concerns. As recently as 2019, the HHS Office of Inspector General (HHS OIG) did a national study demonstrating that suppliers did not maintain sufficient refill documentation.<sup>189</sup> In fact, one national DMEPOS supplier was recently revoked from the Medicare program due to billing for refills for beneficiaries that were deceased.<sup>190</sup>

Due to ongoing compliance concerns, and in efforts to promote transparency, we propose to codify our refill documentation requirements. At the same time, we are continuing our efforts to reduce administrative burden. We have worked to identify many obsolete and burdensome regulations that could be eliminated or reformed to improve effectiveness. We have also examined our longstanding policies and practices that are not codified in regulations but could be changed or streamlined to achieve better outcomes and reduce provider and supplier burden. Additionally, we are requesting comment on whether there are ways to reduce burden for certain beneficiary populations for future rulemaking.

<sup>189</sup> Medicare Improperly Paid Suppliers an Estimated \$92.5 Million for Inhalation Drugs, (October 2019), <https://oig.hhs.gov/oas/reports/region9/91803018.pdf>.

<sup>190</sup> Press Release: Mail-Order Diabetic Testing Supplier and Parent Company Agree to Pay \$160 Million to Resolve Alleged False Claims to Medicare (August 2, 2021), available at: <https://www.justice.gov/opa/pr/mail-order-diabetic-testing-supplier-and-parent-company-agree-pay-160-million-resolve-alleged>.

Our refill policy has primarily been maintained in the Medicare Program Integrity Manual, Local Coverage Determinations, and related articles. We propose to codify and update our refill policy, in this proposed rule, to maintain program integrity controls while being mindful of supplier burden.

## 2. Provisions of the Proposed Regulations

### a. Overview

At this time, we believe it is appropriate to codify policies related to refills of DMEPOS items; taking into consideration the need to balance program integrity concerns (for example, stockpiling) against supplier burden concerns. While we continue to believe it appropriate to confirm the medical need for the refill prior to disbursement, we have found that minor deviations in timing are not always reflective of medical need. Therefore, we are proposing to strengthen our program integrity requirements to not only require beneficiary contact, but to specify that such contact must result in affirmative response from the beneficiary or designee. We propose to eliminate the 14-day timeframe, for beneficiary contact, and to rather rely upon a single 30-day timeframe for contact and confirmation of the need for refill. That is, beneficiary contact and confirmation of need for the refill must occur within the 30-day period prior to the end of the current supply. We propose to remove the term "pending exhaustion", which may be subject to interpretation, and instead use the phrase "the expected end of the current supply."

We note that documentation of the need for refill, as obtained from the Medicare beneficiary or designee, is not expected to require specific quantities remaining—but rather to simply confirm their need for the next refillable item. Suppliers contacting the beneficiaries to confirm their need for the refill, shall confirm both that the beneficiary is using the item and requires the refill, as evidenced by the supplier documentation of an affirmative need for the refill. We believe this type of generalized affirmation, in conjunction with our claims processing controls, will provide sufficient program integrity controls.

We believe the refill policy ensures that beneficiaries are participating in their health care to confirm they get the DMEPOS item(s) ordered and needed, which prevents individuals from receiving unnecessary supplies. It also protects the Trust Fund from the unnecessary provision of DMEPOS. We

elongated the timeframe to 30-days and clarified that the beneficiary need not provide specific remaining quantities to comply. We believe this helps mitigate potential burden. However, we are seeking comment on if, due to beneficiary burdens, there are certain diagnosis/device combinations that a beneficiary should not need to confirm the need for a refill or confirm the need for refill with the same frequency. In other words, are there beneficiary populations for which we would not expect any fluctuations in the type or quantity of device, due to a permanent disability or health condition, for which the supplier verification of need would prove burdensome? Are there ways that Medicare could better balance the beneficiary burden of responding to supplier outreach (for example, text messaging, phone call to affirm need for recurring supply) when contrasted with the burden of receiving potentially unnecessary items (e.g., co-insurance payments)? We would take these comments into consideration for potential future policy changes to our DMEPOS refill policies.

We propose to codify our longstanding requirement that delivery of DMEPOS items (that is, date of service) be no sooner than 10 calendar days before the expected end of the current supply. We note that the shipping timeframes have been relied upon for approximately 20 years—to help both suppliers and Medicare Fee-for-Service contractors prevent overlapping billings and unnecessary refills. For example, contractors may use this timeframe to set up claims processing edits and alert suppliers when an item is being rendered/billed that was previously rendered and is not yet eligible for refill. We propose that date of service may be defined as either the date of delivery of the DMEPOS item, or for items rendered via delivery or shipping service, the supplier may use the shipping date as the date of delivery. We propose the shipping date may be defined as either the date the delivery/shipping service label is created or the date the item is retrieved for shipment by the mail carrier/delivering party; however, such dates should not demonstrate significant variation.

### b. Documentation To Support Refill

We propose to revise § 410.38, paragraph (d), by adding paragraph (d)(4) which outlines the documentation needed to support refill requirements. In paragraph (d)(4)(i), we define refills, date of service, and shipping date for purposes of this section. In paragraph (d)(4)(ii), we propose that



documentation must include the following:

- Evidence of the beneficiary or their representative's affirmative response of the need for supplies, which should be obtained as close to the expected end of the current supply as possible; Contact and affirmative response shall be within 30 calendar days from the expected end of the current supply.
- For shipped items, the beneficiary name, date of contact, the item requested, and an affirmative response from the beneficiary, indicative of the need for refill, prior to dispensing the product.
- For items obtained in-person from a retail store, the delivery slip signed by the beneficiary or their representative or a copy of the itemized sales receipt is sufficient documentation of a request for refill.

In paragraph (d)(4)(iii), we propose the date of service for DMEPOS items provided on a recurring basis be no sooner than 10 calendar days prior to the expected end of the current supply.

## VIII. Proposed Changes to the Provider and Supplier Enrollment Requirements

### A. Background

#### 1. Overview of Medicare Provider Enrollment

Section 1866(j)(1)(A) of the Act requires the Secretary to establish a process for the enrollment of providers and suppliers into the Medicare program. The overarching purpose of the enrollment process is to help confirm that providers and suppliers seeking to bill Medicare for services and items furnished to Medicare beneficiaries meet all applicable federal and state requirements to do so. The process is, to an extent, a “gatekeeper” that prevents unqualified and potentially fraudulent individuals and entities from entering and inappropriately billing Medicare. Since 2006, we have undertaken rulemaking efforts to outline our enrollment procedures. These regulations are generally codified in 42 CFR part 424, subpart P (currently §§ 424.500 through 424.575 and hereafter occasionally referenced as subpart P). They address, among other things, requirements that providers and suppliers must meet to obtain and maintain Medicare billing privileges.

As outlined in § 424.510, one such requirement is that the provider or supplier must complete, sign, and submit to its assigned Medicare Administrative Contractor (MAC) the appropriate enrollment form, typically the Form CMS–855 (OMB Control No. 0938–0685). The Form CMS–855, which

can be submitted via paper or electronically through the internet-based Provider Enrollment, Chain, and Ownership System (PECOS) process (SORN: 09–70–0532, PECOS), collects important information about the provider or supplier. Such data includes, but is not limited to, general identifying information (for example, legal business name), licensure and/or certification data, and practice locations. The application is used for a variety of provider enrollment transactions, including the following:

- Initial enrollment—The provider or supplier is—(1) enrolling in Medicare for the first time; (2) enrolling in another Medicare contractor's jurisdiction; or (3) seeking to enroll in Medicare after having previously been enrolled.

- Change of ownership—The provider or supplier is reporting a change in its ownership.

- Revalidation—The provider or supplier is revalidating its Medicare enrollment information in accordance with § 424.515. (Suppliers of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) must revalidate their enrollment every 3 years); all other providers and suppliers must do so every 5 years.)

- Reactivation—The provider or supplier is seeking to reactivate its Medicare billing privileges after it was deactivated in accordance with § 424.540.

- Change of information—The provider or supplier is reporting a change in its existing enrollment information in accordance with § 424.516.

After receiving the provider's or supplier's initial enrollment application, CMS or the MAC reviews and confirms the information thereon and determines whether the provider or supplier meets all applicable Medicare requirements. We believe this screening process has greatly assisted CMS in executing its responsibility to prevent Medicare fraud, waste, and abuse.

As previously discussed, over the years we have issued various final rules pertaining to provider enrollment. These rules were intended not only to clarify or strengthen certain components of the enrollment process but also to enable us to take action against providers and suppliers: (1) engaging (or potentially engaging) in fraudulent or abusive behavior; (2) presenting a risk of harm to Medicare beneficiaries or the Medicare Trust Funds; or (3) that are otherwise unqualified to furnish Medicare services or items. Consistent with this, and as we discuss in section VIII.B. of this proposed rule, we propose

several changes to our existing Medicare provider enrollment regulations.

#### 2. Legal Authorities

There are two principal categories of legal authorities for our proposed Medicare provider enrollment provisions:

- Section 1866(j) of the Act furnishes specific authority regarding the enrollment process for providers and suppliers.

- Sections 1102 and 1871 of the Act provide general authority for the Secretary to prescribe regulations for the efficient administration of the Medicare program.

### B. Proposed Provisions

#### 1. Provisional Period of Enhanced Oversight

Section 1866(j)(3)(A) of the Act states that the Secretary shall establish procedures to provide for a provisional period of between 30 days and 1 year during which new providers and suppliers—as the Secretary determines appropriate, including categories of providers or suppliers—would be subject to enhanced oversight. (Per section 1866(j)(3)(A) of the Act, such oversight can include, but is not limited to, prepayment review and payment caps). As authorized by section 1866(j)(3)(B) of the Act, CMS previously implemented such procedures through sub-regulatory guidance with respect to newly enrolling HHAs' requests for anticipated payments (RAP). RAPs were upfront payments that HHAs received from Medicare before the beginning of a 30-day period of home health services. “New” HHAs were subject to a suppression of RAPs for a period between 30 days to 1 year (as determined by CMS) during the timeframe they were in the provisional period of enhanced oversight (PPEO). Each new HHA received notice of the length of time for which it was to be in the PPEO with RAP suppression. (CMS eliminated the use of RAPs for HHAs; beginning January 1, 2022, CMS replaced RAP submissions with a Notice of Admission.)

During this prior PPEO, CMS received inquiries regarding the scope of the term “new HHA” as well as when the provisional period commenced. Although section 1866(j)(3)(B) of the Act states that we may implement procedures by program instruction, we believe in this particular instance (and based partly on our experience with the aforementioned HHA PPEO) that rulemaking is appropriate, though not statutorily required. This would help clarify: (1) what constitutes a “new”

provider or supplier for purposes of section 1866(j)(3) of the Act; and (2) when the PPEO begins. Such elucidation is important because we may, in the future, elect to apply our PPEO statutory authority to other categories of providers or suppliers per section 1866(j)(3)(A) of the Act. Accordingly, we propose the following provisions, both of which, we emphasize, would apply to PPEOs irrespective of the provider or supplier type involved.

First, we propose in new § 424.527(a) to define a “new” provider or supplier (exclusively for purposes of our PPEO authority under section 1866(j)(3) of the Act) as any of the following:

++ A newly enrolling Medicare provider or supplier. (This includes providers that must enroll as a new provider in accordance with the change in majority ownership provisions in § 424.550(b).)

++ A certified provider or certified supplier undergoing a change of ownership consistent with the principles of 42 CFR 489.18. (This includes providers that qualify under § 424.550(b)(2) for an exception from the change in majority ownership requirements in § 424.550(b)(1) but which are undergoing a change of ownership under 42 CFR 489.18).

++ A provider or supplier (including an HHA or hospice) undergoing a 100 percent change of ownership via a change of information request under § 424.516.

We are including these transactions within our proposed definition because they have historically and generally involved the effective establishment of a new provider or supplier for purposes of Medicare enrollment. (To illustrate, CMS typically treats suppliers such as ambulance companies that are undergoing 100 percent ownership changes as new suppliers because of our uncertainty about the new owner’s compliance with enrollment regulations, its billing behavior, etc.) Including such situations within proposed § 424.527(a) is therefore necessary for CMS to exercise enhanced oversight, when warranted, of such entities. CMS would rely on the codified version of this policy once it becomes effective.

Second, we propose in § 424.527(b) that the effective date of the PPEO’s commencement is the date on which the new provider or supplier submits its first claim (rather than, for example, the date the first service was performed or the effective date of the ownership change). There are two reasons for this proposal. One is that § 424.527(b) would align with our current practice as

outlined in sub-regulatory guidance. Also, we found during the previously-referenced HHA PPEO that certain affected HHAs refrained from billing after their placement in the PPEO to circumvent the enhanced oversight mechanism; then, once their PPEO lapsed, the HHA engaged in improper billing without the intended oversight. We believe § 424.527(b) would help stem this practice via the PPEO’s commencement upon the provider’s or supplier’s first claim submission. The provider or supplier would be unable to avoid the PPEO by delaying billing until the PPEO’s expiration, as was the case with the HHA PPEO.

Although we have elected to address the issues in proposed § 424.527 via rulemaking, we note that we retain the authority under section 1866(j)(3)(B) of the Act to establish and implement PPEO procedures via sub-regulatory guidance.

## 2. Retroactive Provider Agreement Terminations

Under section 1866(a)(1) of the Act, all Medicare providers (as that term is defined in section 1866(e) of the Act) must enter into a provider agreement with the Secretary. Subparts A, B, and E of 42 CFR part 489 contain regulations concerning provider agreements. In accordance with § 489.52, a provider may voluntarily terminate its provider agreement and thus depart the Medicare program. In doing so, and under existing sub-regulatory policy, the provider may request a retroactive termination effective date (for example, retroactive to the date the provider’s facility closed). To incorporate this practice into regulation, we propose in new § 489.52(b)(4) that a provider may request a retroactive termination date, but only if no Medicare beneficiary received services from the facility on or after the requested termination date. This latter caveat would financially protect beneficiaries by helping to ensure that Medicare may still cover the services furnished to them near the end of the provider’s operations.

## 3. Hospice-Specific Provisions

### a. Categorical Risk Screening

#### (1) Background

Under the authority granted to us by section 6401(a) of the Affordable Care Act (which amended section 1866(j) to the Act), § 424.518 outlines levels of screening by which CMS and its MACs review initial applications, revalidation applications, applications to add a practice location, and applications to report any new owner. These screening categories and requirements are based

on a CMS assessment of the level of risk of fraud, waste, and abuse posed by a particular type of provider or supplier. In general, the higher the level of risk a certain provider or supplier type poses, the greater the level of scrutiny with which CMS will screen and review providers or suppliers within that category.

There are three levels of screening in § 424.518: high, moderate, and limited. Irrespective of which level a provider or supplier type falls within, the MAC performs the following screening functions upon receipt of an initial enrollment application, a revalidation application, an application to add a new location, or an application to report a new owner:

- Verifies that the provider or supplier meets all applicable federal regulations and state requirements for their provider or supplier type.
- Conducts state license verifications.
- Conducts database checks on a pre- and post-enrollment basis to ensure that providers and suppliers continue to meet the enrollment criteria for their provider or supplier type.

Providers and suppliers at the moderate and high categorical risk levels must also undergo a site visit. Furthermore, for those at the high screening level, the MAC performs two additional functions under § 424.518(c)(2). First, the MAC requires the submission of a set of fingerprints for a national background check from all individuals who have a 5 percent or greater direct or indirect ownership interest in the provider or supplier. Second, it conducts a fingerprint-based criminal history record check of the Federal Bureau of Investigation’s Integrated Automated Fingerprint Identification System on these 5 percent or greater owners. These additional verification activities are meant to correspond to the heightened risk involved.

There currently are only five provider and supplier types that fall within the high categorical risk level under § 424.518(c)(1): newly/initially enrolling OTPs that have not been fully and continuously certified by SAMHSA since October 23, 2018 (hereafter collectively referenced as simply “OTPs” unless specified otherwise); newly/initially enrolling HHAs; newly/initially enrolling DMEPOS suppliers; newly/initially enrolling Medicare diabetes prevention program (MDPP) suppliers; and newly/initially enrolling skilled nursing facilities (SNFs). These five provider and supplier types are also subject to high-risk level screening if, as previously indicated, they are submitting a change of ownership

application under 42 CFR 489.18 or reporting any new owner (regardless of ownership percentage) in accordance with a change of information or other enrollment transaction under Title 42. They are subject to moderate level screening (rather than high) if they are revalidating their enrollment under § 424.518.

#### (2) Categorical Risk Designation—Hospices

Hospices are currently in the moderate-risk screening category under § 424.518. However, CMS in recent years has become increasingly concerned about program integrity issues within the hospice community, particularly (though not exclusively) potential and actual criminal behavior, fraud schemes, and improper billing. There have been a number of criminal and False Claims Act cases involving hospice owners and overseers that have arisen since our initial designation of hospices as moderate risk in 2011. These include, but are by no means limited to, the following:

- In May 2014, a Pennsylvania hospice owner was sentenced to 176 months in prison for organizing a scheme to defraud Medicare via his home hospice business. He had been found guilty of conspiracy to commit health care fraud, 21 counts of health care fraud, 11 counts of money laundering, and two counts of mail fraud. The owner's hospice had submitted to Medicare approximately \$16.2 million in false claims for patients who were ineligible for hospice services and/or never received the level of hospice services for which the hospice billed. Other activities included the owner and co-owner: (1) directing staff to alter patient files and rewrite nursing documentation to make patients appear sicker than they actually were; and (2) paying doctors and other health care professionals for referring patients to the hospice even when the patients were neither eligible nor appropriate for hospice care.<sup>191</sup>

- In 2020, the owner and the chief executive officer (CEO) of a Texas-based group of hospices and HHAs were sentenced to 20 and 15 years in prison, respectively. Both had falsely told thousands of patients with long-term incurable illnesses that they had under 6 months left to live so as to enroll them in hospice programs for which they did not qualify.<sup>192</sup> The OIG Dallas Region's

<sup>191</sup> <https://www.justice.gov/usao-edpa/pr/hospice-owner-sentenced-more-14-years-health-care-fraud-scheme>.

<sup>192</sup> <https://www.justice.gov/opa/pr/ceo-sentenced-150-million-health-care-fraud-and-money-laundering-scheme>; <https://www.justice.gov/opa/>

special agent in charge stated that the owner's scheme, which involved over \$150 million in false and fraudulent claims, included "paying kickbacks to physicians and fraudulently enrolling vulnerable beneficiaries in hospice care that prevented them from accessing curative care—all done to steal millions of dollars from Medicare to fund lavish personal spending."<sup>193</sup>

- A California hospice administrator in February 2021 was sentenced to 30 months in prison for his part in a multimillion-dollar Medicare fraud scheme. The administrator and others paid illegal kickbacks to patient recruiters for referring beneficiaries to the hospice. When hospice staff informed the administrator that these referred individuals did not qualify for hospice care, the administrator overruled them and caused the beneficiaries to receive hospice services.<sup>194</sup>

- In 2015, an Oklahoma hospice owner was convicted of Medicare fraud for submitting millions of dollars in fraudulent claims to Medicare. This included directing that certain medical documents be changed or written in a manner to: (1) give the appearance that nurses had visited patients or conducted assessments when they had not; and (2) make it appear that patients were sicker than they actually were.<sup>195</sup>

- A Georgia hospice owner in December 2021 pled guilty to one felony count of Medicaid fraud. State investigators found that the owner "frequently took flights out of the country on dates that the defendant claimed she had personally provided hospice care here in Georgia."<sup>196</sup>

- In August 2020, a New York hospice agreed to pay the United States \$4,850,000 to resolve civil allegations that it billed Medicare and Medicaid for services furnished to hospice beneficiaries at heightened levels of care for which the patients did not qualify.<sup>197</sup>

- A Florida hospice in July 2020 agreed to pay the United States \$3.2

*pr/owner-texas-chain-hospice-companies-sentenced-150-million-health-care-fraud-and-money.*

<sup>193</sup> <https://www.justice.gov/opa/pr/owner-texas-chain-hospice-companies-sentenced-150-million-health-care-fraud-and-money>.

<sup>194</sup> <https://www.justice.gov/opa/pr/hospice-administrator-sentenced-role-hospice-fraud-scheme>.

<sup>195</sup> <https://www.fbi.gov/news/stories/hospice-owner-falsified-numerous-claims>.

<sup>196</sup> <https://law.georgia.gov/press-releases/2021-12-22/carr-medicare-fraud-control-unit-secures-guilty-plea-dekalb-county>.

<sup>197</sup> <https://www.justice.gov/usao-edny/pr/new-york-hospice-provider-settles-civil-healthcare-fraud-allegations>.

million to resolve allegations that it knowingly submitted false claims to Medicare, Medicaid, and TRICARE for hospice care furnished to patients who did not qualify for it. According to the Department of Justice, the hospice "billed Medicare for four or more years of hospice care for certain patients who were not terminally ill for at least a portion of their greater than four-year hospice stay."<sup>198</sup>

- A multi-state hospice provider in December 2021 agreed to pay \$5.5 million to the federal government to resolve allegations that it knowingly violated the False Claims Act by submitting claims to Medicare for hospice services furnished to beneficiaries who were not terminally ill.<sup>199</sup>

- In December 2018, a Pennsylvania hospice agreed to pay over \$5.8 million to the federal government to resolve allegations that it violated the False Claims Act by submitting Medicare claims for hospice services that were medically unnecessary or lacked documentation.<sup>200</sup>

- Another Pennsylvania hospice and its owner and CEO agreed in February 2018 to pay the United States \$1.24 million to resolve allegations that the hospice: (1) fraudulently billed Medicare and Medicaid for hospice services furnished to beneficiaries who were not eligible for them; and (2) falsified records to support the false claims.<sup>201</sup>

- The founders of a Texas hospice and related HHA in January 2021 paid over \$1.8 million following an investigation into improper payments to physicians for referrals.<sup>202</sup>

- A Florida-headquartered hospice in December 2021 agreed to pay the federal government over \$5 million to resolve allegations that it knowingly billed Medicare and Medicaid for medically unnecessary and undocumented hospice services, including for at least 63 patients who had lengths of stays of more than 3 years. According to the government, for the 63 patients in question, the hospice either knowingly or recklessly did not document a

<sup>198</sup> <https://www.justice.gov/usao-mdfl/pr/hospice-agrees-pay-32-million-settle-false-claims-act-liability>.

<sup>199</sup> <https://www.justice.gov/usao-wdtn/pr/crossroads-hospice-agrees-pay-55-million-settle-false-claims-act-liability>.

<sup>200</sup> <https://www.justice.gov/usao-edpa/pr/hospice-care-provider-pays-nearly-6-million-resolve-false-claims-act-allegations>.

<sup>201</sup> <https://www.justice.gov/usao-wdpa/pr/hospice-company-and-owner-agree-pay-124-million-settle-two-false-claims-act>.

<sup>202</sup> <https://www.justice.gov/usao-sdtx/pr/hospice-home-health-agency-and-owners-pay-over-18m-resolve-claims-concerning-physician>.

legitimate reason for the initial commencement of hospice care and/or subsequent hospice coverage. The government added that “(m)any patients failed to demonstrate objective indications of decline throughout their time in the company’s care, despite some being in hospice for nearly six years. Some patients had their hospice diagnoses changed after several years when they did not show decline under their original ‘terminal’ diagnosis.”<sup>203</sup>

- A Minnesota-based hospice in July 2016 agreed to pay \$18 million to resolve False Claims Act allegations that it billed Medicare for services for non-terminally ill patients. The federal government alleged that the hospice aimed to maximize the number of its Medicare patients “without regard to whether the patients were eligible for and needed hospice. These business practices allegedly included discouraging doctors from recommending that ineligible patients be discharged from hospice.”<sup>204</sup>

- In February 2015, a multi-state hospice company agreed to pay \$4 million to resolve allegations that it knowingly submitted or caused to be submitted false claims for hospice beneficiaries who were not terminally ill. The federal government contended that the company “engaged in certain business practices that contributed to claims being submitted for patients who did not have a terminal prognosis of six months or less by . . . paying bonuses to staff, including hospice marketers, admission nurses and executive directors, based on the number of patients enrolled.”<sup>205</sup> The government also alleged that the hospice “hired medical directors based on their ability to refer patients, focusing particularly on medical directors with ties to nursing homes, which were seen as an easy source of patient referrals.”<sup>206</sup>

- A Mississippi-based hospice chain in September 2015 agreed to pay the United States over \$5.8 million to resolve False Claims Act allegations that it submitted false claims for continuous home care hospice services to beneficiaries who were not eligible to receive them.<sup>207</sup>

One recent and especially disturbing case involved the sentencing in January 2022 of the CEO of a Texas hospice agency to over 13 years in prison after pleading guilty to conspiracy to commit Medicare and Medicaid fraud. The CEO admitted that he: (1) billed Medicare and Medicaid for hospice services that were not provided, not directed by a medical professional, or provided to patients who were ineligible for hospice care; and (2) used blank, pre-signed controlled substance prescriptions to prescribe potent drugs even though the CEO was not a medical professional.<sup>208</sup> The CEO’s scheme involved other individuals, thirteen of whom (including physicians) also pled guilty to crimes such as conspiracy to commit health care fraud.<sup>209</sup> The acting United States Attorney for the case stated that the CEO “scammed federal healthcare programs out of millions of dollars, and worse yet, denied vulnerable patients the medical oversight they deserved, writing pain prescriptions without physician input and allowing terminally ill patients to go unexamined.”<sup>210</sup> The Federal Bureau of Investigation special agent in charge added: “In addition to causing fraudulent billing for tens of millions of dollars, [the CEO] preyed upon patients and families that did not have a true understanding of [the company] and hospice services. The core of the company was rooted in deception, and the lack of physician oversight allowed [the defendant] to make medical decisions for his own financial benefit.”<sup>211</sup>

The OIG, too, has noted the prevalence of hospice fraud schemes, issuing a July 2018 study titled “Vulnerabilities in the Medicare Hospice Program Affect Quality Care and Program Integrity” (OEI–02–16–00570). According to this report, Medicare in 2016 spent about \$16.7 billion for hospice care for 1.4 million beneficiaries, an increase from \$9.2 billion for less than 1 million beneficiaries in 2006; with this growth, the OIG stated that “significant vulnerabilities” have arisen, one of which involves improper activity.<sup>212</sup> The report noted that some such schemes involved: (1) paying recruiters to target beneficiaries who were

ineligible for hospice services; and (2) physicians falsely certifying beneficiaries as terminally ill when they were not. The OIG cited several of the cases discussed in this section VIII.B.3.a.(2) of this proposed rule as examples of this behavior.<sup>213</sup>

Given all of the foregoing, we believe that certain provider enrollment measures are necessary to help address these issues. One of these measures involves closer screening of the owners of hospices. We previously cited criminal convictions of hospice owners and overseers. Although not every case of hospice fraud involves or can be attributable to the hospice’s owner, we believe the owner can set the tone for the hospice’s operations as a whole. If, accordingly, an owner has a criminal background involving fraud or patient abuse, this could lead to similar activity within the hospice. We believe that the increasing number of fraud cases warrants a revisiting of our original assignment of hospices to the moderate risk category. With our obligation to protect the Trust Funds and vulnerable Medicare beneficiaries, we believe more thorough scrutiny of hospice owners is required.

To this end, we propose to revise § 424.518 to move initially enrolling hospices and those submitting applications to report any new owner (as described in § 424.518’s opening paragraph) into the “high” level of categorical screening; revalidating hospices would be subject to moderate risk-level screening. Requiring all hospice owners with 5 percent or greater direct or indirect ownership to submit fingerprints for a criminal background check would help us detect parties potentially posing a risk of fraud, waste, or abuse before it begins. Indeed, we have found our fingerprint-based criminal background checks to be of great assistance in detecting felonious behavior by the owners of high-risk providers and suppliers.

We note that there is precedent for performing criminal background reviews on hospice personnel. Under the hospice conditions of participation at 42 CFR 418.114(d): (1) the hospice must obtain a criminal background check on all hospice employees who have direct patient contact or access to patient records; and (2) hospice contracts must require that all contracted entities obtain criminal background checks on contracted employees who have direct patient contact or access to patient records. Considering that hospice owners generally have oversight authority or

<sup>203</sup> <https://www.justice.gov/usao-mdfl/pr/united-states-settles-false-claims-allegations-against-haven-hospice-more-5-million>.

<sup>204</sup> <https://www.justice.gov/opa/pr/minnesota-based-hospice-provider-pay-18-million-alleged-false-claims-medicare-patients-who>.

<sup>205</sup> <https://www.justice.gov/opa/pr/united-states-settles-false-claims-act-suit-against-good-shepherd-hospice-inc-and-related>.

<sup>206</sup> *Ibid.*

<sup>207</sup> <https://www.justice.gov/usao-sdms/pr/hospice-facility-and-its-manager-majority-owner-pay-approximately-586-million-resolve>.

<sup>208</sup> <https://www.justice.gov/usao-ndtx/pr/novus-hospice-ceo-sentenced-13-years-healthcare-fraud>.

<sup>209</sup> <https://www.justice.gov/usao-ndtx/pr/13-novus-healthcare-fraud-defendants-sentenced-combined-84-years-prison#:~:text=Bradley%20Harris%2C%20Novus%20CEO%2C%20pleaded,Dr.>

<sup>210</sup> <https://www.justice.gov/usao-ndtx/pr/novus-hospice-ceo-pleads-guilty-healthcare-fraud>.

<sup>211</sup> *Ibid.*

<sup>212</sup> <https://oig.hhs.gov/oei/reports/oei-02-16-00570.pdf>, p. 1.

<sup>213</sup> *Ibid.*

responsibility for all the hospice's operations, we believe it is important that the owner be subject to similar scrutiny.

Initially enrolling hospices would be incorporated within revised paragraph (c)(1)(vi). The current language in paragraph (c)(1)(vi) would be included within new proposed paragraph (c)(1)(vii), to which would be added hospices disclosing a new owner.

#### b. 36-Month Rule

The general purpose of a state survey or accreditation review for any Medicare provider or supplier type subject thereto is to determine whether the provider or supplier is in compliance with its regulatorily prescribed conditions of participation or conditions of coverage (hereafter collectively referenced as CoPs). CoPs are federal requirements that a provider or supplier must meet to participate in the Medicare program, and they generally focus on health and safety protections. Although they can vary by provider and supplier type, they address matters such as, but not limited to, the following:

- Personnel qualifications
- Infection prevention and control
- Emergency preparedness
- Staffing ratios
- Patient safety
- Patients' bill of rights
- Licensure
- Fire prevention
- Adherence to federal, state, and local requirements

CoPs are critical to ensuring that providers and suppliers are legitimate, bona fide entities capable of furnishing quality care and following safety requirements.

Though it is a provider enrollment provision, § 424.550(b)(1) recognizes the importance of the HHA survey and accreditation processes (hereafter sometimes collectively referenced as the "survey process"), which help confirm the HHA's compliance with the CoPs and the quality and safety requirements they entail. Section 424.550(b)(1) states if an HHA undergoes a change in majority ownership (occasionally referenced as a "CIMO") by sale within 36 months after the effective date of the HHA's initial enrollment in Medicare or within 36 months after the HHA's most recent CIMO, the provider agreement and Medicare billing privileges do not convey to the HHA's new owner. The prospective provider/owner of the HHA must instead: (1) enroll in Medicare as a new (initial) HHA; and (2) obtain a state survey or an accreditation from an approved accreditation organization. As defined in 42 CFR 424.502, a "change in

majority ownership" occurs when an individual or organization acquires more than a 50 percent direct ownership interest in an HHA during the 36 months following the HHA's initial enrollment or most recent CIMO; this includes an acquisition of majority ownership through the cumulative effect of asset sales, stock transfers, consolidations, or mergers. Under § 424.550(b)(1), a 42 CFR 489.18-level change of ownership and/or 100 percent ownership transfer is not necessary to trigger this "36-month rule." Only crossing the 50 percent ownership threshold is required.

Section 424.550(b)(1) was promulgated in 2009 and modified in 2010. There were two principal objectives behind its establishment.

First, there was a trend in the HHA community whereby an HHA applied for Medicare certification, underwent a survey, and became enrolled in Medicare, but then immediately sold the HHA without having seen a Medicare beneficiary or hired an employee. These brokers, in other words, enrolled in Medicare exclusively to sell the HHA rather than to provide services to beneficiaries. This practice enabled a purchaser of an HHA from the broker to enter Medicare with no survey, which, in turn, sometimes led that owner to soon sell the business to another party. The "flipping" or "turn-key" mechanism, in short, was used to circumvent the survey process.

Second, we were more broadly concerned about the lack of scrutiny of new owners as a whole, not merely in cases of flipping. We made clear in the CY 2010 HH PPS final rule (74 FR 58078), in which we promulgated § 424.550(b)(1), that the intent of § 424.550(b)(1) goes beyond the issue of "turn-key" operations.<sup>214</sup> We explained that if an HHA undergoes a change of ownership, CMS—at the current time—generally does not perform a survey pursuant thereto. Consequently, CMS has no sure way of knowing whether the HHA, under its new ownership and management, is in compliance with the HHA CoPs. Unless CMS can make this determination, there is a risk that the newly-purchased HHA, without having been appropriately vetted, will bill for services when it is out of compliance with the CoPs.<sup>215</sup> We added that in light of a GAO report we cited in the CY 2010 HH PPS proposed rule that outlined problematic activities involving HHAs, we believed it was imperative that we ensure that a newly-purchased HHA be

subjected to an appropriate level of review.<sup>216</sup>

We previously outlined in this section VIII.B.3.a.(2). of this proposed rule our growing concerns about improper behavior within the hospice community. Yet, we are equally concerned about the quality of care furnished in some of these facilities. Indeed, we have seen an increase in the number of hospice changes of ownership (including the types of CIMOs described in 42 CFR 424.550(b)(1)) in recent years, and a number of these ownership changes have occurred within the applicable 36-month timeframe. In fact, some such changes have taken place within only a few months after enrollment or the previous CIMO, akin to what we saw with the "flipping" practice outlined in the CY 2010 HH PPS proposed and final rules; specifically, we have received reports that hospices are being sold quickly after enrollment or purchase so that the new owner can avoid any survey. This is because, as had been our concern with HHAs, hospice ownership changes generally do not result in a state survey or accreditation review.

Aside from the July 2018 OIG report referenced earlier, which, as noted by its title, stated that vulnerabilities in the Medicare hospice program impact quality care, the Government Accountability Office (GAO) in October 2019 issued a report titled, "Medicare Hospice Care: Opportunities Exist to Strengthen CMS Oversight of Hospice Providers" (GAO-20-10).<sup>217</sup> The GAO observed therein that the number of: (1) Medicare hospice beneficiaries had almost tripled from 2000 to nearly 1.5 million by 2017; and (2) Medicare hospice providers had doubled.<sup>218</sup> The GAO stated that in light of this growth: "It is imperative that CMS's oversight of the quality of Medicare hospice care keeps pace with changes so that the agency can ensure the health and safety of these terminally ill beneficiaries."<sup>219</sup>

In sum, hundreds of hospice ownership changes have occurred since 2018 for which CMS may not know whether the facility under its new ownership and leadership is compliant with the hospice CoPs. This is a significant vulnerability. Many millions of dollars could be improperly paid to newly purchased hospices that are not adhering to Medicare requirements. More crucially, it is unknown whether

<sup>216</sup> 74 FR 58118–58119; "Improvements Needed to Address Improper Payments in Home Health" (GAO-09-185).

<sup>217</sup> <https://www.gao.gov/assets/gao-20-10.pdf>.

<sup>218</sup> *Ibid.*, p. 25.

<sup>219</sup> *Ibid.*

<sup>214</sup> 74 FR 58118.

<sup>215</sup> *Ibid.*

newly purchased hospices are furnishing quality care to the facility's beneficiaries, which, if they are not, can put patients' lives in danger; we previously saw in this section VIII.B.3.a.(2). of this proposed rule the great risks associated with uncommitted ownership. We believe that a comprehensive survey would be the most effective means of confirming that newly purchased hospices are meeting the CoPs and are positioned to provide quality care and protect beneficiaries.

Consequently, we are proposing to expand the scope of § 424.550(b)(1) to include hospice CIMOs within its purview. (The aforementioned definition of "change in majority ownership" in § 424.502 would also be expanded to incorporate hospices therein.) We believe that our previously detailed concerns about hospices, such as fraud schemes, patient abuse, and improper billing, require the level of scrutiny that a survey can furnish. Although surveys cannot by themselves entirely halt all of these issues, we are confident that a survey's thoroughness can greatly assist the vetting of the new owner to help ensure the latter's commitment to quality care.

We note that § 424.550(b)(2) contains several exceptions to the 36-month rule. Specifically, even if an HHA undergoes a CIMO, the requirement in § 424.550(b)(1) that the HHA enroll as a new HHA and undergo a survey or accreditation does not apply if any of the following four exceptions are implicated:

- The HHA submitted 2 consecutive years of full cost reports since initial enrollment or the last CIMO, whichever is later.
- An HHA's parent company is undergoing an internal corporate restructuring, such as a merger or consolidation.
- The owners of an existing HHA are changing the HHA's existing business structure (for example, from a corporation to a partnership (general or limited)), and the owners remain the same.
- An individual owner of an HHA dies.

These exceptions were added to § 424.550(b) in a final rule published in the **Federal Register** on November 17, 2010 titled, "Medicare Program; Home Health Prospective Payment System Rate Update for Calendar Year 2011; Changes in Certification Requirements for Home Health Agencies and Hospices" (75 FR 70372). We promulgated them because the HHA community had expressed concerns that the 36-month rule could inhibit bona fide HHA ownership transactions; for

example, prospective new owners may not wish to have to enroll as a new HHA and will therefore decline to purchase the entity. We believed that our exceptions struck a solid balance between the need for more scrutiny of new owners via the survey process while not inadvertently obstructing legitimate transactions involving legitimate parties. As an illustration, a CIMO resulting from an internal restructuring can frequently pose less of a risk of "flipping" than an HHA that—2 months after initial enrollment—is sold to another party strictly to circumvent the survey process. These exceptions, in our view, still soundly balance the two aforementioned considerations, and we therefore are not proposing to exempt hospices from them.

#### c. Additional Hospice Ownership Matters

CMS is taking additional provider enrollment steps to address (either wholly or in part) hospice ownership and program integrity. To illustrate, we proposed in a December 15, 2022 Paperwork Reduction Act submission (87 FR 76626) to revise the Form CMS–855A Medicare provider enrollment application (Medicare Enrollment Application—Institutional Providers; OMB Control No. 0938–0685) to collect from providers/suppliers (including hospices) that complete this form important data such as, but not limited to:

- Requiring the provider/supplier/hospice to specifically identify via a checkbox whether a reported organizational owner is itself owned by another organization or individual.
- Requiring the provider/supplier/hospice to explicitly identify whether a listed organizational owner/manager does or does not fall within the categories of entities listed on the application (for example, holding company, investment firm, etc.), with "private-equity company" and "real estate investment trust" being added to this list of organization types.

This information will assist CMS in better understanding the provider/supplier/hospice's indirect ownership relationships and the types of entities that own it.

In addition, in a proposed rule published in the **Federal Register** on April 4, 2023 titled "Medicare Program; FY 2024 Hospice Wage Index and Payment Rate Update, Hospice Conditions of Participation Updates, Hospice Quality Reporting Program Requirements, and Hospice Certifying Physician Provider Enrollment Requirements" (88 FR 20022), we

proposed to require physicians who order or certify hospice services for Medicare beneficiaries to be enrolled in or validly opted-out of Medicare as a prerequisite for the payment of the hospice service in question. We stated therein our belief that the careful screening the enrollment process entails would help us determine whether the physician meets all federal and state requirements (such as licensure) or presents any program integrity risks (for example, final adverse actions).

Our aforementioned hospice high-risk screening and 36-month rule proposals represent further steps towards addressing hospice ownership and payment safeguard issues, and we are considering additional measures regarding these topics.

#### 4. Deactivation for 12-Months of Non-Billing

Regulatory policies regarding the provider enrollment concept of deactivation are addressed in § 424.540. Deactivation means that the provider's or supplier's billing privileges are stopped but can be restored (or "reactivated") upon the submission of information required under § 424.540. A deactivated provider or supplier is not revoked from Medicare and remains enrolled. Also, per § 424.540(c), deactivation does not impact the provider's or supplier's existing provider or supplier agreement; the deactivated provider or supplier may also file a rebuttal to the action in accordance with § 424.546. Nonetheless, the provider's or supplier's ability to bill Medicare is halted pending its compliance with § 424.540's requirements for reactivation.

To reactivate its billing privileges, the affected provider or supplier per § 424.540(b) must recertify that its current enrollment information on file with Medicare is correct, furnish any missing information as appropriate, and be in compliance with all applicable enrollment requirements in Title 42. CMS reserves the right, though, to require the submission of a complete Form CMS–855 application prior to any reactivation. The reactivation process is designed to confirm that the deactivated provider or supplier is adherent to all applicable Title 42 provider enrollment provisions.

There are currently eight reasons under § 424.540(a) for which CMS can deactivate a provider or supplier, one of which is that the provider or supplier has not submitted any Medicare claims for 12 consecutive months. (The 12-month period begins the first day of the first month without a claims submission through the last day of the 12th month

without a submitted claim.) This particular deactivation ground was established via a final rule published in the **Federal Register** on April 21, 2006 titled “Medicare Program; Requirements for Providers and Suppliers to Establish and Maintain Medicare Enrollment” (71 FR 20754). In the April 25, 2003 proposed rule associated with this final rule, we proposed to have the authority to deactivate a provider or supplier after 6 months of Medicare non-billing.<sup>220</sup> Although, at the time per subregulatory guidance, our policy was to permit deactivation after 12 months, we proposed 6 months due to several program integrity issues related to inactive billing numbers. We outlined in that proposed rule our desire to prevent, for instance: (1) questionable businesses from deliberately obtaining multiple numbers so they could keep one ‘in reserve’ [for future use] if their active billing number is subject to a payment suspension; and (2) fraudulent entities from obtaining information about discontinued providers or suppliers and then, for example, using the Medicare billing number of a deceased physician.<sup>221</sup>

Based on feedback from commenters, we did not finalize our proposed reduction to 6 months in the April 21, 2006 final rule. Yet we remained concerned about situations where a provider or supplier does not bill for 6 months, as this could indicate, for instance, that the provider or supplier is no longer operational and that its billing number thus could be accessed by another party intent on improper billing. More importantly, we have recently detected fraud schemes involving extended periods of non-billing. A common situation involves a provider that: (1) establishes multiple enrollments with multiple billing numbers; (2) abusively or inappropriately bills under one billing number; (3) receives an overpayment demand letter or becomes the subject of investigation; (4) voluntarily terminates the billing number in question; and then (5) begins to bill via another of its billing numbers that is dormant (for example, 6 consecutive months without billing) but nonetheless active, repeating the same improper conduct as before. The problem in this case is that we cannot deactivate the dormant billing number (hence rendering it unusable and inaccessible pending a reactivation) under § 424.540(a)(1) because the

applicable 12-month period has not yet expired.

This type of “whack-a-mole” activity is similar to that which we cited previously in the April 25, 2003 proposed rule as justification for the proposed 6-month deactivation threshold therein. The difference, though, is that these fraud schemes have become increasingly prevalent in recent years such that we must revisit the current 12-month timeframe in § 424.540(a)(1). We do not believe we can or should wait for a year to elapse before taking deactivation action against these providers and suppliers. To protect the Trust Funds against improper payments, we must be able to move more promptly to deactivate these “spare” billing numbers so the latter cannot be inappropriately used or accessed.

However, we emphasize that our concerns are not limited to the aforementioned scenarios regarding fraudulent activity. A lack of billing for an extended period can, as previously discussed, indicate that the provider or supplier has ceased operations without notifying CMS. Deactivating the number enables CMS to not only prevent it from being accessed by other parties but also confirm via the deactivation process whether the provider or supplier is in fact operational—specifically, whether the provider or supplier responds with a reactivation application. In other words, action under § 424.540(a)(1) helps protect the Medicare program by deactivating the number while verifying whether the provider or supplier remains in existence; if it does, and it subsequently submits a reactivation application, CMS can validate the data thereon to ensure the provider’s or supplier’s continued credentials and compliance with Medicare requirements. This protective process, we believe, should be available to us upon the expiration of a 6-month non-billing period, for our earlier-referenced concerns exist whenever any extensive timeframe of non-billing occurs. The sooner we can address these non-billing cases, the better we can protect the Trust Funds. For these reasons, we propose to revise § 424.540(a)(1) to change the 12-month time therein to 6 months.

We certainly recognize that there are lengthy periods of non-billing that do not involve any improper activity. To illustrate, we know that some providers are required to be enrolled in Medicare in order to enroll in another health care program; as the provider does not intend to bill Medicare but only the other program, an extended period of Medicare non-billing can result. While

CMS retains the discretion, as it always has, to deactivate a provider or supplier if the contingency in § 424.540(a)(1) is triggered, providers and suppliers that are not typically deactivated for 12 months of non-billing should not assume they would be more likely to be so deactivated under our proposed change to 6 months.

#### 5. Definition of “Managing Employee”

Consistent with sections 1124 and 1124A of the Act, providers and suppliers are required to report their managing employees via the applicable Medicare enrollment application in order to enroll in Medicare. We currently define a “managing employee” in § 424.502 as a “general manager, business manager, administrator, director, or other individual that exercises operational or managerial control over, or who directly or indirectly conducts, the day-to-day operation of the provider or supplier (either under contract or through some other arrangement), whether or not the individual is a W–2 employee of the provider or supplier.” In a proposed rule published in the **Federal Register** on February 15, 2023 titled “Medicare and Medicaid Programs; Disclosures of Ownership and Additional Disclosable Parties Information for Skilled Nursing Facilities and Nursing Facilities” (88 FR 9820), we proposed to revise this definition under our proposed implementation via that rule of section 1124(c) of the Act. We specifically proposed that, for purposes of 42 CFR 424.516(g) and with respect to a SNF, a managing employee also includes a general manager, business manager, administrator, director, or consultant, who directly or indirectly manages, advises, or supervises any element of the practices, finances, or operations of the facility. As proposed, this SNF-exclusive definition would be in a new paragraph (2) of the managing employee definition in § 424.502; the existing version of the definition would be included within new paragraph (1).

We are proposing to further revise this definition in the present proposed rule. We have received questions from the hospice and SNF communities regarding whether hospice and SNF facility administrators and medical directors must be disclosed as managing employees on the enrollment application. It has been our experience in overseeing the Medicare provider enrollment process that such individuals indeed exercise managing control over the hospice or SNF, and we have long required that they be reported as managing employees.

<sup>220</sup> Medicare Program; Requirements for Establishing and Maintaining Medicare Billing Privileges (68 FR 22064).

<sup>221</sup> *Ibid.* (68 FR 22072).

Accordingly, we propose to further revise the managing employee definition in § 424.502 by adding the following language immediately after (and in the same paragraph as) the current definition: For purposes of this definition, this includes, but is not limited to, a hospice or skilled nursing facility administrator and a hospice or skilled nursing facility medical director. This change would be reflected in the first paragraph of the revised definition of this term as proposed in the February 15, 2023 proposed rule. That is, the revision described in this section VIII.(B)(5) would be added to the end of new paragraph (1) as the latter was proposed in the February 15, 2023 proposed rule.

We stress that this clarification regarding hospice and SNF facility administrators and medical directors should in no manner be construed as CMS' establishment of a minimum threshold for reporting managing employees of hospices, SNFs, or any other provider or supplier type. Put otherwise, simply because an individual has less managing control within a particular organization than a facility administrator or medical director does not mean that the person need not be disclosed. Any individual who meets the definition of managing employee in § 424.502 must be reported irrespective of the precise amount of managing control the person has. The exclusive purpose of our proposed elucidation is to address specific questions raised by hospices and SNFs concerning whether the individuals at issue must be reported. It is not meant to change existing reporting requirements regarding managing employees and who must be disclosed as such.

#### 6. Previously Waived Fingerprinting of High-Risk Providers and Suppliers

During the recent COVID-19 public health emergency (PHE), CMS temporarily waived the requirement for fingerprint-based criminal background checks (FBCBCs) for 5 percent or greater owners of newly enrolling providers and suppliers falling within the high-risk screening category in § 424.518(c). The principal purpose was to facilitate beneficiary access to services by potentially increasing the number of health care providers and suppliers. Given the scope of the emergency, we believed this had to take priority. To reduce the program integrity risks of this waiver, we continuously monitored criminal alerts produced via our internal screening mechanism. Nevertheless, we remained concerned during the waiver period about the lack of FBCBCs being performed. Although

the criminal alerts were useful, we have found FBCBCs to be the best and surest means of detecting felonious behavior by the owners of high-risk providers and suppliers.

With this in mind, we wish to perform FBCBCs for high-risk providers and suppliers that initially enrolled during the PHE upon their revalidation once the PHE ends. Yet this is not possible under our existing regulations because the revalidation applications would only be screened at the moderate-risk level. To remedy this, we propose to add new § 424.518(c)(1)(viii) that would incorporate within the high-screening category revalidating DMEPOS suppliers, HHAs, OTPs, MDPPs, and SNFs for which CMS waived the FBCBC requirement when they initially enrolled in Medicare. However, given the potential for future emergencies for which CMS might waive FBCBCs under applicable legal authority (such as that for the PHE), we more specifically propose in new § 424.518(c)(1)(viii) that this high-risk category (which would include hospices with respect to future waivers) would apply to situations where CMS waived FBCBCs, in accordance with applicable legal authority, due to a national, state, or local emergency declared under existing law. We emphasize that our proposal does not obligate CMS to waive the FBCBC requirement in any such emergency. Any decision to do so rests with CMS, and such waivers would, if they occur at all in the future, be reserved for the most exceptional of circumstances.

Along with adding new § 424.518(c)(1)(viii), we propose to delete current § 424.518(b)(1)(iv), (ix), (x), (xi), (xiii), and (xiv), which individually identify the six previously discussed provider and supplier types (including hospices) as moderate-risk if they are revalidating their enrollment. We would redesignate existing paragraphs (b)(1)(v) through (b)(1)(viii) as revised paragraphs (b)(1)(iv) through (b)(1)(vii). We would also redesignate existing paragraph (b)(1)(xii) as revised (b)(1)(viii), with the former paragraph being deleted. Revised paragraph (b)(1)(viii) would include both prospective and revalidating OTPs that have been fully and continuously certified by SAMHSA since October 23, 2018. Furthermore, we would establish a revised paragraph (b)(1)(ix) that would include within the moderate-risk category revalidating DMEPOS suppliers, HHAs, OTPs, MDPPs, and SNFs, and hospices that underwent FBCBCs: (1) when they initially enrolled in Medicare; or (2) upon revalidation after CMS waived the FBCBC requirement

(under the circumstances described in paragraph (c)(1)(viii)) when the provider or supplier initially enrolled in Medicare. This second provision is to clarify that the providers and suppliers referenced in paragraph (c)(1)(viii) do not remain in the high-screening category in perpetuity solely because they were not fingerprinted upon initial enrollment. Once the provider or supplier is fingerprinted upon revalidation, it would move to the moderate-risk category unless another basis exists under paragraph (c) for retaining it within the high-risk category.

As indicated previously, DMEPOS suppliers are required to revalidate their Medicare enrollment every 3 years; HHAs, OTPs, MDPPs, SNFs, and hospices must do so every 5 years. We note, though, that CMS under § 424.515(d) can perform off-cycle revalidations; that is, we can revalidate a provider or supplier at any time and need not wait until the arrival of their 5-year (or, for DMEPOS suppliers, 3-year) revalidation cycle. Should this proposed rule be finalized, CMS would accordingly reserve the right to conduct off-cycle revalidations of the previously discussed FBCBC-waived high-risk providers and suppliers.

#### 7. Expansion of Reapplication Bar

Section 424.530(f) permits CMS to prohibit a prospective provider or supplier from enrolling in Medicare for up to 3 years if its enrollment application is denied because the provider or supplier submitted false or misleading information on or with (or omitted information from) its application in order to enroll. The purpose of § 424.530(f) is to prevent dishonest providers and suppliers from submitting false information on their initial application and, after being denied enrollment on this ground under § 424.530(a)(4), simply submitting a new application with correct data.

The existing maximum length of a reapplication bar under § 424.530(f) is 3 years. We propose to expand this to 10 years to account for provider or supplier conduct of particular severity. We must be able to prevent such problematic parties from repeatedly submitting applications over many years with the goal of somehow getting into the program. We note that there is precedent for this 10-year period. Section 424.530(a)(3)(ii) states that a denial based on a felony conviction is for a period not less than 10 years from the date of conviction if the individual has been convicted on one previous occasion of one or more offenses. Too, reenrollment bars under



§ 424.535(c)(1)(i) are for a maximum 10-year timeframe. Although reenrollment bars are different from reapplication bars in terms of how and when they are applied, the aim of both is to protect Medicare and its beneficiaries. We believe it is largely immaterial from a program integrity standpoint whether a denial or revocation and subsequent bar stemming from the submission of false or misleading data involved a prospective or an enrolled provider, for the underlying conduct in either case is the same.

#### 8. Ordering, Referring, Certifying, and Prescribing Restrictions

We discussed previously: (1) the need to increase the maximum reapplication bar to keep dishonest providers and suppliers out of Medicare for longer than 3 years; and (2) our concerns about felonious provider and supplier activity. We believe such provider and supplier behavior should result in restrictions regarding the ordering, referring, certifying, or prescribing of Medicare services, items, and drugs, too. Indeed, such ordering, referring, certifying, or prescribing can involve improper conduct that is as harmful to Medicare beneficiaries as the actual furnishing of services; this includes, for example, the over-prescribing of opioids and the unnecessary ordering of potentially dangerous tests. Consequently, and using our general rulemaking authority under sections 1102 and 1871 of the Act, we propose the following two provisions.

First, we propose to add a new paragraph (3) to § 424.530(f) stating that a provider or supplier that is currently subject to a reapplication bar under paragraph (f) may not order, refer, certify, or prescribe Medicare-covered services, items, or drugs. To enforce this policy, we would further state in proposed § 424.530(f)(3) that Medicare does not pay for any otherwise covered service, item, or drug that is ordered, referred, certified, or prescribed by a provider or supplier that is currently under a reapplication bar.

Second, we propose in paragraph (a) of new § 424.542 that a physician or other eligible professional (regardless of whether he or she is or was enrolled in Medicare) who has had a felony conviction within the previous 10 years that CMS determines is detrimental to the best interests of the Medicare program and its beneficiaries may not order, refer, certify, or prescribe Medicare-covered services, items, or drugs. Akin to proposed § 424.530(f)(3), we would state in § 424.542(b) that Medicare does not pay for any otherwise covered service, item, or drug that is

ordered, referred, certified, or prescribed by a physician or other eligible professional (as that term is defined in section 1848(k)(3)(B) of the Act) who has had a felony conviction within the previous 10 years that CMS determines is detrimental to the best interests of the Medicare program and its beneficiaries.

These provisions would apply regardless of whether the provider or supplier has opted-out of Medicare. This is because the conduct associated with a reapplication bar and a felony conviction presents a risk irrespective of the provider's or supplier's opt-out status.

### IX. Collection of Information Requirements

#### A. Statutory Requirement for Solicitation of Comments

Under the Paperwork Reduction Act of 1995, we are required to provide a 60-day notice in the **Federal Register** and solicit public comment before a collection of information requirement is submitted to the Office of Management and Budget (OMB) for review and approval. In order to fairly evaluate whether an information collection should be approved by OMB, section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires that we solicit comment on the following issues:

- The need for the information collection and its usefulness in carrying out the proper functions of our agency.
- The accuracy of our estimate of the information collection burden.
- The quality, utility, and clarity of the information to be collected.
- Recommendations to minimize the information collection burden on the affected public, including automated collection techniques.

#### B. Information Collection Requirements (ICRs)

In the CY 2023 HH PPS rule, we solicited public comment on each of these issues for the following sections of this document that contain information collection requirements (ICRs).

##### 1. ICRs for HH QRP

As discussed in section III. of this proposed rule, we propose that HHAs would collect data on one new quality measure, the Discharge Function Score (DC Function) measure, beginning with assessments completed on January 1, 2024. However, the DC Function measure utilizes data items that HHAs already report to CMS for quality reporting purposes, and therefore, the burden is accounted for in the PRA package approved under OMB control

number 0938–1279 (expiration November 30, 2025).

As discussed in section III.C.2. of this proposed rule, we propose to remove a measure from the HH QRP, the Application of Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (Application of Functional Assessment/Care Plan) measure, beginning with admission assessments completed on January 1, 2025. We have also proposed to remove OASIS items for Self-Care Discharge Goals (that is, GG0130, Column 2) and Mobility Discharge Goals (that is, GG0170, Column 2) at the start of care and resumption of care timepoints with the next release of the OASIS in 2025. This amounts to a net reduction in 2 data elements. We assume that each data element requires 0.3 minutes of clinician time to complete. Therefore, we estimate that there would be a reduction in clinician burden per OASIS assessment of 0.3 minutes at start of care and 0.3 minutes at resumption of care.

As stated in section III.C.3. of this proposed rule, we propose to adopt the COVID–19 Vaccine: Percent of Patients/Residents Who Are Up to Date (Patient/Resident COVID–19 Vaccine) measure beginning with the CY 2025 HH QRP. This proposed assessment-based quality measure would be collected using the OASIS. The OASIS–E is currently approved under OMB control number 0938–1279 (CMS–10387). One data element would need to be added to the OASIS at the transfer of care, death at home, and discharge time points in order to allow for the collection of the Patient/Resident COVID–19 Vaccine measure. We assume this would result in an increase 0.3 minutes of clinician staff time at the transfer of care, death at home, and discharge time points starting with the CY 2025 HH QRP.

As stated in section III.E.3. of this proposed rule, we propose to remove the M0110—Episode Timing and M2220- Therapy Needs OASIS items, effective January 1, 2025. These items are no longer used by the HH QRP, nor are they intended for use by CMS payment, survey or the expanded HHVBP model. The removal of these two items would result in the removal of two data elements at start of care, two at resumption of care, and one data element at follow-up for a total reduction of five data elements.

The net effect of the proposals outlined in this proposed rule is a reduction in four data elements collected across all time points for the OASIS implemented on January 1, 2025.

Table G1 outlines the net change in data elements.

**TABLE G1 –NUMBER OF DATA ELEMENTS TO BE ADDED OR REMOVED IN JANUARY 2025**

| OASIS-E Item                           | Data Elements at Each Time Point |                    |           |                                   |               |  |
|--|----------------------------------|--------------------|-----------|-----------------------------------|---------------|--|
|  | Start of Care                    | Resumption of Care | Follow-up | Transfer to an Inpatient Facility | Death at Home | Discharge – not to an Inpatient Facility |
| Self-care/Mobility Goals GG0130/GG0170 | -1                               | -1                 |           |                                   |               |  |
| COVID-19 Patient Vaccination           |                                  |                    |           | +1                                | +1            | +1                                       |
| M0110 Episode Timing                   | -1                               | -1                 | -1        |                                   |               |  |
| M2200 Therapy Need                     | -1                               | -1                 |           |                                   |               |  |
| <b>Net Change (-4)</b>                 | <b>-3</b>                        | <b>-3</b>          | <b>-1</b> | <b>+1</b>                         | <b>+1</b>     | <b>+1</b>                                |

The OASIS is completed by RNs or PTs, or very occasionally by occupational therapists (OT) or speech language pathologists (SLP/ST). Data from 2021 show that the SOC/ROC OASIS is completed by RNs (approximately 77.14 percent of the time), PTs (approximately 22.16 percent of the time), and other therapists, including OTs and SLP/STs

(approximately 0.7 percent of the time). Based on this analysis, we estimated a weighted clinician average hourly wage of \$87.52, inclusive of fringe benefits, using the hourly wage data in Table G1. Individual providers determine the staffing resources necessary.

For purposes of calculating the costs associated with the information collection requirements, we obtained

mean hourly wages for these from the U.S. Bureau of Labor Statistics' May 2022 National Occupational Employment and Wage Estimates ([https://www.bls.gov/oes/current/oes\\_nat.htm](https://www.bls.gov/oes/current/oes_nat.htm)). To account for other indirect costs such as overhead and fringe benefits (100 percent), we have doubled the hourly wage. These amounts are detailed in Table G2.

**TABLE G2: U.S. BUREAU OF LABOR STATISTICS' MAY 2022 NATIONAL OCCUPATIONAL EMPLOYMENT AND WAGE ESTIMATES**

| Occupation Title                                   | Occupation Code | Mean Hourly Wage (\$/hr) | Fringe Benefit (100%) (\$/hr) | Adjusted Hourly Wage (\$/hr) |
|--|-----------------|--------------------------|-------------------------------|------------------------------|
| Registered Nurse (RN)                              | 29-1141         | \$42.80                  | \$42.80                       | \$85.6                       |
| Physical therapists (PT)                           | 29-1123         | \$47.10                  | \$47.10                       | \$94.2                       |
| Speech-Language Pathologists (SLP)                 | 29-1127         | \$43.01                  | \$43.01                       | \$86.02                      |
| Occupational Therapists (OT)                       | 29-1122         | \$44.61                  | \$44.61                       | \$89.22                      |
| Miscellaneous Health Technologists and Technicians | 29-2090         | \$25.39                  | \$25.39                       | \$50.78                      |

For purposes of estimating burden, we utilize item-level burden estimates for OASIS-E that will be released on January 1, 2025 compared to the

OASIS-E as currently implemented as of January 1, 2023. Table G3 shows the total number of OASIS assessments that HHAs actually completed in CY 2021,

as well as how those numbers would have decreased if non-Medicare and non-Medicaid OASIS assessments had been required at that time.

**TABLE G3. CY 2021 OASIS SUBMISSIONS BY TIME POINT**

| Time Point            | CY 2021 Assessments Completed |
|-----------------------|-------------------------------|
| Start of Care         | 6,561,902                     |
| Resumption of Care    | 919,325                       |
| Follow-up             | 3,666,923                     |
| Transfer of Care      | 1,848,699                     |
| Death at Home         | 49,516                        |
| Discharge from agency | 5,348,484                     |
| <b>TOTAL</b>          | <b>18,394,849</b>             |

Table G4 summarizes the estimated clinician hourly burden for the current

OASIS and the OASIS in 2025 with the net removal of four data elements for

each OASIS assessment type using CY 2021 assessment totals. We estimate a

net reduction of 58,540.1 hours of clinician burden across all HHAs or 5

hours for each of the 11,700 active HHAs.

**TABLE G4. SUMMARY OF ESTIMATED CLINICIAN HOURLY BURDEN**

| OASIS Assessment Type | Clinician Estimated Hourly Burden – OASIS 2023 | Clinician Estimated Hourly Burden – OASIS 2025 | Net Total        |
|-----------------------|--|--|------------------|
| Start of Care         | 6,266,616.41                                   | 6,200,997.39                                   | 65,619.02        |
| Resumption of Care    | 735,460  | 726,266.75                                     | 9,193.25         |
| Follow-up             | 806,723.06                                     | 788,388.44                                     | 18,334.62        |
| Transfer of Care      | 204,983.59                                     | 212,600.38                                     | -7,616.79        |
| Death at Home         | 2,228.22                                       | 2,475.80                                       | -247.58          |
| Discharge from agency | 3,583,484.28                                   | 3,610,226.7                                    | -26,742.42       |
| <b>TOTAL</b>          | <b>11,599,495.56</b>                           | <b>11,540,955.46</b>                           | <b>58,540.10</b> |

Table G5 summarizes the estimated clinician costs for the current OASIS and the OASIS in 2025 with the net removal of four data elements for each OASIS assessment type using CY 2021

assessment totals. We estimate a reduction in costs of \$5,123,429.55 related to the implementation of the proposals outlined in this proposed rule across all HHAs or a \$437 reduction for

each of the 11,700 active HHAs. This reduction in burden would begin with January 1, 2025 HHA discharges.

**TABLE G5. SUMMARY OF ESTIMATED CLINICIAN COSTS**

| OASIS Assessment Type | Clinician Estimated Cost – OASIS 2023 | Clinician Estimated Cost – OASIS 2025 |
|-----------------------|---------------------------------------|---------------------------------------|
| Start of Care         | \$548,454,268.20                      | \$542,711,291.57                      |
| Resumption of Care    | \$64,367,459.2                        | \$63,562,865.96                       |
| Follow-up             | \$70,604,402.21                       | \$68,999,756.27                       |
| Transfer of Care      | \$17,940,163.80                       | \$18,606,785.26                       |
| Death at Home         | \$195,013.81                          | \$216,682.02                          |
| Discharge from agency | \$313,626,544.19                      | \$315,967,040.78                      |
| <b>TOTAL</b>          | <b>\$1,015,187,851.41</b>             | <b>\$1,010,064,421.86</b>             |

2. ICRs for HHVBP

The proposals for the expanded HHVBP Model included in this proposed rule do not result in an increase in costs to HHAs. Section 1115A(d)(3) of the Act exempts Innovation Center model tests and expansions, which include the expanded HHVBP Model, from the provisions of the PRA. Specifically, this section provides that the provisions of the PRA do not apply to the testing and evaluation of Innovation Center models or to the expansion of such models.

3. ICRs for Hospice Information Dispute Resolution (IDR) and Hospice Special Focus Program (SFP)

In accordance with 5 CFR 1320.4(a)(2) and (c), the following information collection activities are exempt from the requirements of the Paperwork Reduction Act since they are associated with administrative actions: (1) proposed § 488.1130 Hospice IDR; and (2) proposed § 488.1135 Hospice SFP.

4. ICRs for DMEPOS Refills

In section VII.E. of this proposed rule, we are proposing to codify our refill policy, with some changes. The policy originally arose in response to concerns related to auto-shipments and delivery of DMEPOS products that may no longer be needed or not needed at the same level of frequency/volume. The policy has been historically maintained in the Medicare Program Integrity Manual, sporadically mentioned in certain Local Coverage Determinations (LCDs), and detailed in articles. We propose to require documentation indicating that the beneficiary confirmed the need for the refill within the 30-day period prior to the end of the current supply. We propose to codify our requirement that delivery of DMEPOS items (that is, date of service) must be no sooner than 10 calendar days before the expected end of the current supply.

5. ICRs for Provider Enrollment Provisions

Except as explained in this section IX. of this proposed rule, we do not anticipate that any of our proposed provider enrollment provisions would implicate an ICR burden.

a. High-Risk Screening and Fingerprinting

We are proposing to revise § 424.518 to: (1) move initially enrolling hospices (and those undergoing an ownership change as described in § 424.518) into the high-risk screening category; and (2) include within the high-risk screening category revalidating DMEPOS suppliers, HHAs, OTPs, MDPPs, and SNFs for whom CMS legally waived the fingerprint-based criminal background check requirement in § 424.518 when they initially enrolled in Medicare. These changes would result in an increase in the annual number of providers and suppliers that must submit the fingerprints for a national

criminal background check (via FBI Applicant Fingerprint Card FD-258) of all individuals with a 5 percent or greater direct or indirect ownership interest in the provider or supplier. The burden is currently approved by OMB under control number 1110-0046. We are not scoring the burden under this ICR section since the fingerprint card is not owned by CMS. However, an analysis of the impact of this requirement can be found in the RIA section of this proposed rule.

**b. Hospice 36-Month Rule**

We are proposing to expand § 424.550(b) to apply the 36-month rule provisions therein to hospices. This would require a hospice undergoing a change in majority ownership (as defined in § 424.502 and assuming no exceptions apply) to: (1) enroll in Medicare as a new hospice; and (2)

undergo a state survey or accreditation. The principal ICR burden of this requirement would involve the completion of an initial Form CMS-855A application rather than a Form CMS-855A change of ownership (CHOW) application or a Form CMS-855A change of information application. Consistent with the general time estimates for these three categories of applications, it typically takes a provider approximately 4 hours to complete an initial Form CMS-855A, 4 hours for a CHOW application, and 1 hour for a change of information application. The key ICR burden difference, therefore, would be between submitting an initial application and submitting a change of information (since there is no burden difference between an initial application and a CHOW application).

Based on internal CMS data, we estimate that each year approximately 50 hospices would be required to initially enroll in Medicare due to a change in majority ownership as opposed to simply reporting the sale via a change of information. This would result in an additional Form CMS-855A hour burden of 150 hours (50 × 3 hours), with the 3-hour figure reflecting the difference between initial applications and changes of information. In terms of cost, it has been our experience that Form CMS-855A applications are completed by the provider's office staff. Consequently, we will use the following wage category and hourly rate from the U.S. Bureau of Labor Statistics' (BLS) May 2022 National Occupational Employment and Wage Estimates for all salary estimates ([http://www.bls.gov/oes/current/oes\\_nat.htm](http://www.bls.gov/oes/current/oes_nat.htm)):

**TABLE G6: NATIONAL OCCUPATIONAL EMPLOYMENT AND WAGE ESTIMATES**

| Occupation Title                                     | Occupation Code | Mean Hourly Wage (\$/hr) | Fringe Benefits and Overhead (\$/hr) | Adjusted Hourly Wage (\$/hr) |
|--|-----------------|--------------------------|--------------------------------------|------------------------------|
| Office and Administrative Support Workers, All Other | 43-9199         | 20.75                    | 20.75                                | 41.50                        |

This results in an additional Form CMS-855A annual cost burden of \$6,225 (150 hours × \$41.50).

We anticipate the following additional costs associated with our 36-month rule expansion:

- *Fingerprinting:* As we proposed that hospices would be subject to high-risk level screening under § 424.518, hospices that must initially enroll under § 424.550(b) would have to submit a set of fingerprints for a national criminal background check (via FBI Applicant Fingerprint Card FD-258) from each individual with a 5 percent or greater

direct or indirect ownership interest in the hospice. An analysis of the impact of this requirement can be found in section X.C.8. of this proposed rule.

- *Application Fee:* Under § 424.514, an institutional provider (as that term is defined in § 424.502) that is initially enrolling in Medicare must pay the required application fee. Hospices that are initially enrolling in accordance with the 36-month rule would accordingly have to pay this fee. The application fee does not meet the definition of a "collection of information" and, as such, is not subject

to the requirements of the PRA. However, the cost is scored under section X.C.8. of this proposed rule.

- *Provider Agreement:* A hospice that is initially enrolling in Medicare (which would include those doing so in accordance with § 424.550(b)) must also sign a provider agreement per 42 CFR part 489 (Health Insurance Benefits Agreement—CMS Form 1561 (OMB control number 0938-0832)). The applicable May 2022 BLS categories and hourly wage rates for completing this form are as follows:

**TABLE G7: NATIONAL OCCUPATIONAL EMPLOYMENT AND WAGE ESTIMATES**

| Occupation Title                                  | Occupation Code | Mean Hourly Wage (\$/hr) | Fringe Benefits and Overhead (\$/hr) | Adjusted Hourly Wage (\$/hr) |
|---|-----------------|--------------------------|--------------------------------------|------------------------------|
| Chief Executive                                   | 11-1011         | \$118.48                 | \$118.48                             | \$236.96                     |
| Medical Secretaries and Administrative Assistants | 43-6013         | \$19.84                  | \$19.84                              | \$39.68                      |

We anticipate that 100 hospices per year would have to sign this provider

agreement due to our revision to § 424.550(b): the 50 previously

referenced hospices that would otherwise have reported the ownership

change via a Form CMS–855A change of information and another 50 that would have done so via a Form CMS–855A CHOW application. We anticipate that it would take the hospice 5 minutes at \$236.96/hr for a chief executive to review and sign the Form CMS–1561 and an additional 5 minutes at \$39.68/hr for a medical secretary to file the document when fully executed. This results in an annual hour burden of 17 hours ( $100 \times 0.166$  hours) and a cost of \$2,305 (or  $(\$236.96 \times 0.0833) + (\$39.68 \times 0.0833) \times 100$ ).

Combining these initial enrollment application and provider agreement ICR costs associated with a hospice's change in majority ownership results in an annual burden of 167 hours ( $150 + 17$ ) and a cost of \$8,530 ( $\$6,225 + \$2,305$ ).

We solicit comment from stakeholders, including hospices, regarding any other ICR costs that may be associated with our proposed expansion of the 36-month rule to incorporate hospices. This could include ICR costs incurred during the survey, accreditation, or certification processes.

#### c. Remaining Provider Enrollment Provisions

With one exception, we do not believe our other provider enrollment proposals would result in an information collection burden. Concerning the proposal in revised § 424.540(a)(1) to reduce the timeframe in which CMS can deactivate a provider or supplier for non-billing from 12 months to 6 months, an increase in the number of deactivations on this basis could result. However, we are unable to establish an estimate of this number or any associated burden for two reasons. First, fraud schemes change and fluctuate, meaning that CMS cannot predict the number of instances in which it would apply § 424.540(a)(1) to address such situations. Second, a deactivation is a purely discretionary action by CMS; that is, CMS can, but is not required to, impose a deactivation if a basis for doing so exists. Accordingly, we are unable to quantify the increase, if any, of cases where we would invoke revised § 424.540(a)(1).

#### C. Submission of PRA-Related Comments

We have submitted a copy of this final rule to OMB for its review of the rule's information collection requirements. The requirements are not effective until they have been approved by OMB.

To obtain copies of the supporting statement and any related forms for the proposed collections, as previously discussed, please visit the CMS website

at <https://www.cms.hhs.gov/PaperworkReductionActof1995>, or call the Reports Clearance Office at 410–786–1326.

We invite public comments on these potential information collection requirements.

## X. Regulatory Impact Analysis

### A. Statement of Need

#### 1. HH PPS

Section 1895(b)(1) of the Act requires the Secretary to establish a HH PPS for all costs of home health services paid under Medicare. In addition, section 1895(b) of the Act requires: (1) the computation of a standard prospective payment amount include all costs for home health services covered and paid for on a reasonable cost basis and that such amounts be initially based on the most recent audited cost report data available to the Secretary; (2) the prospective payment amount under the HH PPS to be an appropriate unit of service based on the number, type, and duration of visits provided within that unit; and (3) the standardized prospective payment amount be adjusted to account for the effects of case-mix and wage levels among HHAs. Section 1895(b)(3)(B) of the Act addresses the annual update to the standard prospective payment amounts by the home health applicable percentage increase. Section 1895(b)(4) of the Act governs the payment computation. Sections 1895(b)(4)(A)(i) and (b)(4)(A)(ii) of the Act requires the standard prospective payment amount be adjusted for case-mix and geographic differences in wage levels. Section 1895(b)(4)(B) of the Act requires the establishment of appropriate case-mix adjustment factors for significant variation in costs among different units of services. Lastly, section 1895(b)(4)(C) of the Act requires the establishment of wage adjustment factors that reflect the relative level of wages, and wage-related costs applicable to home health services furnished in a geographic area compared to the applicable national average level.

Section 1895(b)(3)(B)(iv) of the Act provides the Secretary with the authority to implement adjustments to the standard prospective payment amount (or amounts) for subsequent years to eliminate the effect of changes in aggregate payments during a previous year or years that were the result of changes in the coding or classification of different units of services that do not reflect real changes in case-mix. Section 1895(b)(5) of the Act provides the Secretary with the option to make changes to the payment amount

otherwise paid in the case of outliers because of unusual variations in the type or amount of medically necessary care. Section 1895(b)(3)(B)(v) of the Act requires HHAs to submit data for purposes of measuring health care quality, and links the quality data submission to the annual applicable percentage increase.

Sections 1895(b)(2) and 1895(b)(3)(A) of the Act, as amended by section 51001(a)(1) and 51001(a)(2) of the BBA of 2018 respectively, required the Secretary to implement a 30-day unit of service, for 30-day periods beginning on and after January 1, 2020. Section 1895(b)(3)(D)(i) of the Act, as added by section 51001(a)(2)(B) of the BBA of 2018, requires the Secretary to annually determine the impact of differences between assumed behavior changes, as described in section 1895(b)(3)(A)(iv) of the Act, and actual behavior changes on estimated aggregate expenditures under the HH PPS with respect to years beginning with 2020 and ending with 2026. Section 1895(b)(3)(D)(ii) of the Act requires the Secretary, at a time and in a manner determined appropriate, through notice and comment rulemaking, to provide for one or more permanent increases or decreases to the standard prospective payment amount (or amounts) for applicable years, on a prospective basis, to offset for such increases or decreases in estimated aggregate expenditures, as determined under section 1895(b)(3)(D)(i) of the Act. Additionally, 1895(b)(3)(D)(iii) of the Act requires the Secretary, at a time and in a manner determined appropriate, through notice and comment rulemaking, to provide for one or more temporary increases or decreases to the payment amount for a unit of home health services for applicable years, on a prospective basis, to offset for such increases or decreases in estimated aggregate expenditures, as determined under section 1895(b)(3)(D)(i) of the Act. The HH PPS wage index utilizes the wage adjustment factors used by the Secretary for purposes of sections 1895(b)(4)(A)(ii) and (b)(4)(C) of the Act for hospital wage adjustments.

#### 2. HH QRP

Section 1895(b)(3)(B)(v) of the Act authorizes the HH QRP, which requires HHAs to submit data in accordance with the requirements specified by CMS. Failure to submit data required under section 1895(b)(3)(B)(v) of the Act with respect to a program year will result in the reduction of the annual home health market basket percentage increase otherwise applicable to an HHA for the corresponding calendar year by 2 percentage points.

### 3. Expanded HHVBP Model

In the CY 2022 HH PPS final rule (86 FR 62292 through 62336) and codified at 42 CFR part 484 subpart F, we finalized our policy to expand the HHVBP Model to all Medicare certified HHAs in the 50 States, territories, and District of Columbia beginning January 1, 2022. CY 2022 was a pre-implementation year. CY 2023 is the first performance year in which HHAs individual performance on the applicable measures will affect their Medicare payments in CY 2025. In this proposed rule, we are proposing to remove five quality measures from the current applicable measure set and add three quality measures to the applicable measure set. Along with the proposed revisions to the current measure set, we propose to revise the weights of the individual measures within the OASIS-based measure category and within the claims-based measure category starting in the CY 2025 performance year. In addition, we are proposing to update the Model baseline year from CY 2022 to CY 2023 starting in the CY 2025 performance year to enable CMS to measure competing HHAs performance on benchmarks and achievement thresholds that are more current for the proposed applicable measure set. Additionally, we are amending the appeals process such that reconsideration decisions may be reviewed by the Administrator. We are including an update to the RFI, Future Approaches to Health Equity in the Expanded HHVBP Model, that was published in the CY 2023 HH PPS rule. We will also include an update that reminds interested parties that we will begin public reporting of HHVBP performance data on or after December 1, 2024.

### 4. Home IVIG Items and Services

Division FF, section 4134 of the CAA, 2023 (CAA, 2023) (Pub. L. 117–328) mandated that CMS establish a permanent, bundled payment for items and services related to administration of IVIG in a patient's home. The permanent, bundled home IVIG items and services payment is effective for home IVIG infusions furnished on or after January 1, 2024. Payment for these items and services is required to be a separate bundled payment made to a supplier for all items and services furnished in the home during a calendar day. This payment amount may be based on the amount established under the Demonstration. The standard Part B coinsurance and the Part B deductible apply. The separate bundled payment does not apply for individuals receiving

services under the Medicare home health benefit. The CAA, 2023 provision clarifies that a supplier who furnishes these services meet the requirements of a supplier of medical equipment and supplies.

### 5. Informal Dispute Resolution (IDR) and Hospice Special Focus Program (SFP)

The proposed hospice IDR would be an administrative process offered to hospice programs that is conducted by CMS, the SAs, or the accrediting organizations (AOs) as applicable, as part of their survey activities to provide an informal opportunity to address survey findings. The proposed Hospice SFP would be implementing a part of the hospice provisions required under the CAA 2021 directing the Secretary to create an SFP for poor-performing hospice programs.

### 6. DMEPOS CAA, 2023-Related Requirements

#### a. Conforming Changes to Regulations To Codify Change Mandated by Section 4139 of the Consolidated Appropriations Act, 2023

The purpose of the provision related to adjusted fees is to extend the 75/25 blend in non-rural, non-CBAs as described in 42 CFR 414.210(g)(9)(v). The statutory language for this provision is found in section 4139 of the CAA, 2023.

#### b. Scope of the Benefit and Payment for Lymphedema Compression Treatment Items

The purpose of the provision related to lymphedema compression treatment items is to define in regulation section 4133 of the CAA, 2023 that adds section 1861(s)(2)(JJ) to the Act establishing a Medicare Part B benefit for lymphedema compression treatment item. This provision would address the scope of the new benefit by defining what constitutes a standard or custom fitted gradient compression garment and determining what other compression items may exist that are used for the treatment of lymphedema and would fall under the new benefit. This rule would also implement section 1834(z) of the Act in establishing payment amounts for items covered under the new benefit and frequency limitations for lymphedema compression treatment items.

#### c. Definition of Brace

The purpose of the provision related to the definition of a brace is to codify in regulations the longstanding definition of brace that exists in Medicare program instructions.

### 7. Requirements for Refillable DMEPOS

This provision is needed to require documentation indicating that the beneficiary confirmed the need for the refill within the 30-day period prior to the end of the current supply and to codify our requirement that the delivery of DMEPOS items (that is, date of service) must be no sooner than 10 calendar days before the expected end of the current supply.

### 8. Provider Enrollment Provisions

This proposed rule is needed to make regulatory enhancements to our provider enrollment policies. These provisions focus on, but are not limited to: (1) subjecting a greater number of providers and suppliers, such as hospices, to the highest level of screening, which includes fingerprinting all 5 percent or greater owners of these providers and suppliers; and (2) applying the change in majority ownership (CIMO) provisions in 42 CFR 424.550(b) to hospices. These changes are necessary to help ensure that payments are made only to qualified providers and suppliers and that owners of these entities are carefully screened. As explained in section VIII. of this proposed rule, we believe that fulfilling both of these objectives would assist in protecting the Trust Funds and Medicare beneficiaries.

#### B. Overall Impact

We have examined the impacts of this rule as required by Executive Order 12866 on Regulatory Planning and Review (September 30, 1993), Executive Order 13563 on Improving Regulation and Regulatory Review (January 18, 2011), Executive Order 14094 on Modernizing Regulatory Review (April 6, 2023), the Regulatory Flexibility Act (RFA) (September 19, 1980, Pub. L. 96 354), section 1102(b) of the Act, section 202 of the Unfunded Mandates Reform Act of 1995 (March 22, 1995; Pub. L. 104–4), Executive Order 13132 on Federalism (August 4, 1999), and the Congressional Review Act (5 U.S.C. 804(2)).

Executive Orders 12866 and 13563 direct agencies to assess all costs and benefits of available regulatory alternatives and, if regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). Executive Order 14094 amends section 3(f) of Executive Order 12866 to define a “significant regulatory action” as an action that is likely to result in a rule: (1) having an annual effect on the

economy of \$200 million or more in any 1 year, or adversely affect in a material way the economy, productivity, competition, jobs, the environment, public health or safety, or State, local or tribal governments or communities; (2) creating a serious inconsistency or otherwise interfering with an action taken or planned by another agency; (3) materially altering the budgetary impacts of entitlement grants, user fees, or loan programs or the rights and obligations of recipients thereof; or (4) raising legal or policy issues for which centralized review would meaningfully further the President's priorities or the principles set forth in this Executive Order.

A regulatory impact analysis (RIA) must be prepared for major rules with significant regulatory action/s and/or with significant effects as per section 3(f)(1) of \$200 million or more in any 1 year. Based on our estimates, OMB'S Office of Information and Regulatory Affairs has determined this rulemaking is significant per section 3(f)(1) as measured by the \$200 million or more in any 1 year. According we have prepared a regulatory impact analysis that to the best of our ability presents the costs and benefits of the rulemaking. Therefore, OMB has reviewed this proposed rule, and the Departments have provided the following assessment of their impact. We solicit comments on the regulatory impact analysis provided.

### C. Detailed Economic Analysis

#### 1. Effects of the Proposed Changes for the CY 2024 HH PPS

This rule proposes to update Medicare payments under the HH PPS for CY 2024. The net transfer impact related to the changes in payments under the HH PPS for CY 2024 is estimated to be  $-\$375$  million ( $-2.2$  percent). The  $\$375$  million decrease in estimated payments for CY 2024 reflects the effects of the proposed CY 2024 home health payment update percentage of 2.7 percent ( $\$460$  million increase),

an estimated 5.1 percent decrease that reflects the effects of the permanent behavior adjustment ( $\$870$  million decrease) and an estimated 0.2 percent increase that reflects the effects of an updated FDL ( $\$35$  million increase).

We use the latest data and analysis available. However, we do not adjust for future changes in such variables as number of visits or case-mix. This analysis incorporates the latest estimates of growth in service use and payments under the Medicare home health benefit, based primarily on Medicare claims data for periods that ended on or before December 31, 2022. We note that certain events may combine to limit the scope or accuracy of our impact analysis, because such an analysis is future-oriented and, thus, susceptible to errors resulting from other changes in the impact time period assessed. Some examples of such possible events are newly-legislated general Medicare program funding changes made by the Congress or changes specifically related to HHAs. In addition, changes to the Medicare program may continue to be made as a result of new statutory provisions. Although these changes may not be specific to the HH PPS, the nature of the Medicare program is such that the changes may interact, and the complexity of the interaction of these changes could make it difficult to predict accurately the full scope of the impact upon HHAs.

Table GG 1 represents how HHA revenues are likely to be affected by the finalized policy changes for CY 2024. For this analysis, we used an analytic file with linked CY 2022 OASIS assessments and home health claims data for dates of service that ended on or before December 31, 2022. The first column of Table GG 1 classifies HHAs according to a number of characteristics including provider type, geographic region, and urban and rural locations. The second column shows the number of facilities in the impact analysis. The third column shows the payment effects

of the permanent behavior assumption adjustment on all payments. The aggregate impact of the permanent BA adjustment reflected in the third column does not equal the proposed  $-5.653$  percent permanent BA adjustment because the adjustment only applies to the national, standardized 30-day period payments and does not impact payments for 30-day periods which are LUPAs. The fourth column shows the payment effects of the recalibration of the case-mix weights offset by the case-mix weights budget neutrality factor. The fifth column shows the payment effects of updating the CY 2024 wage index with a 5-percent cap on wage index decreases. The sixth column shows the effect of the proposed CY 2024 labor-related share. The aggregate impact of the changes in the fifth and sixth columns is zero percent, due to the wage index budget neutrality factor and the labor-related share budget neutrality factor. The seventh column shows the payment effects of the proposed CY 2024 home health payment update percentage. The eighth column shows the payment effects of the revised FDL, and the last column shows the combined effects of all the proposed provisions.

Overall, it is projected that aggregate payments in CY 2024 would decrease by 2.2 percent which reflects the 5.1 percent decrease from the permanent behavior adjustment, the 2.7 payment update percentage increase, and the 0.2 percent increase from decreasing the FDL. As illustrated in Table GG 1, the combined effects of all of the changes vary by specific types of providers and by location. We note that some individual HHAs within the same group may experience different impacts on payments than others due to the distributional impact of the CY 2024 wage index, the percentage of total HH PPS payments that were subject to the LUPA or paid as outlier payments, and the degree of Medicare utilization.

**BILLING CODE 4120-01-P**

**TABLE GG 1: ESTIMATED HHA IMPACTS BY FACILITY TYPE AND AREA OF THE COUNTRY, CY 2024**

|   | Number of Agencies | Permanent Behavior Assumption Adjustment | CY 2024 Case-Mix Weights Recalibration | CY 2024 Wage Index | CY 2024 Proposed Labor-Related Share | CY 2024 Proposed HH Payment Update Percentage | Fixed-Dollar Loss (FDL) | Total        |
|---|--------------------|--|--|--------------------|--------------------------------------|---|-------------------------|--------------|
| <b>All Agencies</b>   | <b>9,559</b>       | <b>-5.1%</b>                             | <b>0.0%</b>                            | <b>0.0%</b>        | <b>0.0%</b>                          | <b>2.7%</b>                                   | <b>0.2%</b>             | <b>-2.2%</b> |
| <b>Facility Type and Control</b>                                |                    |  |  |                    |                                      |   |                         |              |
| Free-Standing/Other Vol/NP                                      | 908                | -5.0%                                    | -0.1%                                  | -0.1%              | 0.0%                                 | 2.7%  | 0.2%                    | -2.3%        |
| Free-Standing/Other Proprietary                                 | 7,375              | -5.2%                                    | 0.0%                                   | 0.0%               | 0.0%                                 | 2.7%  | 0.2%                    | -2.3%        |
| Free-Standing/Other Government                                  | 157                | -5.1%                                    | 0.3%                                   | -0.6%              | 0.1%                                 | 2.7%  | 0.2%                    | -2.4%        |
| Facility-Based Vol/NP   | 448                | -4.9%                                    | -0.1%                                  | 0.2%               | 0.0%                                 | 2.7%  | 0.3%                    | -1.8%        |
| Facility-Based Proprietary                                      | 48                 | -5.0%                                    | 0.0%                                   | 0.0%               | 0.1%                                 | 2.7%  | 0.2%                    | -2.0%        |
| Facility-Based Government                                       | 139                | -5.0%                                    | 0.1%                                   | -0.7%              | 0.1%                                 | 2.7%  | 0.2%                    | -2.6%        |
| Subtotal: Freestanding  | 8,440              | -5.2%                                    | 0.0%                                   | 0.0%               | 0.0%                                 | 2.7%  | 0.2%                    | -2.3%        |
| Subtotal: Facility-based  | 635                | -4.9%                                    | -0.1%                                  | 0.1%               | 0.0%                                 | 2.7%  | 0.3%                    | -1.9%        |
| Subtotal: Vol/NP  | 1,356              | -4.9%                                    | -0.1%                                  | 0.0%               | 0.0%                                 | 2.7%  | 0.3%                    | -2.0%        |
| Subtotal: Proprietary   | 7,423              | -5.2%                                    | 0.0%                                   | 0.0%               | 0.0%                                 | 2.7%  | 0.2%                    | -2.3%        |
| Subtotal: Government  | 296                | -5.0%                                    | 0.2%                                   | -0.7%              | 0.1%                                 | 2.7%  | 0.2%                    | -2.5%        |
| <b>Facility Type and Control: Rural</b>                         |                    |  |  |                    |                                      |   |                         |              |
| Free-Standing/Other Vol/NP                                      | 217                | -5.0%                                    | 0.0%                                   | -0.7%              | 0.2%                                 | 2.7%  | 0.2%                    | -2.6%        |
| Free-Standing/Other Proprietary                                 | 757                | -5.3%                                    | 0.0%                                   | -0.5%              | 0.3%                                 | 2.7%  | 0.1%                    | -2.7%        |
| Free-Standing/Other Government                                  | 105                | -5.0%                                    | 0.1%                                   | -0.7%              | 0.2%                                 | 2.7%  | 0.3%                    | -2.4%        |
| Facility-Based Vol/NP   | 195                | -4.8%                                    | 0.2%                                   | -0.7%              | 0.2%                                 | 2.7%  | 0.3%                    | -2.1%        |
| Facility-Based Proprietary                                      | 16                 | -5.0%                                    | 0.2%                                   | -0.5%              | 0.2%                                 | 2.7%  | 0.3%                    | -2.1%        |
| Facility-Based Government                                       | 102                | -4.9%                                    | 0.3%                                   | -1.1%              | 0.2%                                 | 2.7%  | 0.3%                    | -2.5%        |
| <b>Facility Type and Control: Urban</b>                         |                    |  |  |                    |                                      |   |                         |              |
| Free-Standing/Other Vol/NP                                      | 691                | -5.0%                                    | -0.2%                                  | 0.0%               | -0.1%                                | 2.7%  | 0.3%                    | -2.3%        |
| Free-Standing/Other Proprietary                                 | 6,610              | -5.2%                                    | 0.0%                                   | 0.1%               | 0.0%                                 | 2.7%  | 0.2%                    | -2.2%        |
| Free-Standing/Other Government                                  | 52                 | -5.1%                                    | 0.4%                                   | -0.6%              | 0.0%                                 | 2.7%  | 0.2%                    | -2.4%        |
| Facility-Based Vol/NP   | 253                | -4.9%                                    | -0.2%                                  | 0.4%               | -0.1%                                | 2.7%  | 0.3%                    | -1.8%        |
| Facility-Based Proprietary                                      | 32                 | -5.1%                                    | -0.1%                                  | 0.2%               | 0.1%                                 | 2.7%  | 0.2%                    | -2.0%        |
| Facility-Based Government                                       | 37                 | -5.1%                                    | 0.0%                                   | -0.5%              | 0.0%                                 | 2.7%  | 0.2%                    | -2.7%        |
| <b>Facility Location: Urban or Rural</b>                        |                    |  |  |                    |                                      |   |                         |              |
| Rural   | 1,392              | -5.2%                                    | 0.0%                                   | -0.6%              | 0.3%                                 | 2.7%  | 0.2%                    | -2.6%        |
| Urban   | 7,675              | -5.1%                                    | 0.0%                                   | 0.1%               | 0.0%                                 | 2.7%  | 0.2%                    | -2.1%        |
| <b>Facility Location: Region of the Country (Census Region)</b> |                    |  |  |                    |                                      |   |                         |              |
| New England   | 314                | -5.0%                                    | -0.1%                                  | -0.8%              | -0.1%                                | 2.7%  | 0.3%                    | -3.0%        |
| Mid Atlantic  | 398                | -5.0%                                    | -0.2%                                  | 1.0%               | -0.1%                                | 2.7%  | 0.2%                    | -1.4%        |
| East North Central  | 1,481              | -5.1%                                    | 0.0%                                   | -0.4%              | 0.1%                                 | 2.7%  | 0.2%                    | -2.5%        |
| West North Central  | 586                | -5.0%                                    | 0.0%                                   | -0.7%              | 0.1%                                 | 2.7%  | 0.3%                    | -2.6%        |
| South Atlantic  | 1,568              | -5.2%                                    | -0.2%                                  | 0.1%               | 0.1%                                 | 2.7%  | 0.2%                    | -2.3%        |
| East South Central  | 360                | -5.3%                                    | -0.2%                                  | -0.4%              | 0.3%                                 | 2.7%  | 0.1%                    | -2.8%        |
| West South Central  | 2,049              | -5.2%                                    | 0.2%                                   | 0.1%               | 0.2%                                 | 2.7%  | 0.2%                    | -1.8%        |
| Mountain  | 705                | -5.1%                                    | 0.2%                                   | -0.9%              | 0.0%                                 | 2.7%  | 0.2%                    | -2.9%        |
| Pacific   | 2,055              | -5.1%                                    | 0.3%                                   | 0.2%               | -0.4%                                | 2.7%  | 0.2%                    | -2.1%        |
| Outlying  | 43                 | -5.2%                                    | 0.2%                                   | -1.2%              | 0.9%                                 | 2.7%  | 0.2%                    | -2.4%        |
| <b>Facility Size (Number of 30-day Periods)</b>                 |                    |  |  |                    |                                      |   |                         |              |
| < 100 periods   | 2,207              | -5.1%                                    | 0.6%                                   | 0.0%               | 0.0%                                 | 2.7%  | 0.2%                    | -1.6%        |
| 100 to 249  | 1,482              | -5.1%                                    | 0.5%                                   | -0.1%              | 0.0%                                 | 2.7%  | 0.2%                    | -1.8%        |
| 250 to 499  | 1,650              | -5.1%                                    | 0.4%                                   | 0.0%               | 0.0%                                 | 2.7%  | 0.2%                    | -1.8%        |
| 500 to 999  | 1,906              | -5.2%                                    | 0.3%                                   | -0.1%              | 0.0%                                 | 2.7%  | 0.2%                    | -2.1%        |
| 1,000 or More   | 2,314              | -5.1%                                    | -0.1%                                  | 0.0%               | 0.0%                                 | 2.7%  | 0.2%                    | -2.3%        |



**Source:** CY 2022 Medicare claims data for periods with matched OASIS records ending in CY 2022 (as of March 17, 2022).

**Notes:**

1. The permanent BA adjustment reflected in the third column does not equal the proposed -5.653 percent permanent BA adjustment. The -5.1 percent reflected in column 3 includes all payments while the proposed -5.653 percent BA adjustment only applies to the national, standardized 30-Day period payments and does not impact payments for 30-day periods which are LUPAs.
2. The CY 2024 home health payment update percentage reflects the proposed home health productivity-adjusted market basket percentage update of 2.7 percent as described in section I.L.C.4.f. of this proposed rule.
3. The "Fixed Dollar Loss (FDL) Update" column reflects a change in the FDL from 0.35 to 0.31.
4. Due to missing Provider of Services file information (from which home health agency characteristics are obtained), some subcategories in the impact tables have fewer agencies represented than the overall total (of 9,559): totals involving facility type or control only add up to 9,075 and totals involving urban/rural locations only add up to 9,067.

**REGION KEY:**

**New England**=Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont

**Middle Atlantic**=Pennsylvania, New Jersey, New York

**South Atlantic**=Delaware, District of Columbia, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia

**East North Central**=Illinois, Indiana, Michigan, Ohio, Wisconsin

**East South Central**=Alabama, Kentucky, Mississippi, Tennessee

**West North Central**=Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South Dakota

**West South Central**=Arkansas, Louisiana, Oklahoma, Texas

**Mountain**=Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming

**Pacific**=Alaska, California, Hawaii, Oregon, Washington

**Other**=Guam, Puerto Rico, Virgin Islands

**BILLING CODE 4120-01-C**

2. Effects of the Proposed Changes for the HH QRP for CY 2024

Failure to submit HH QRP data required under section 1895(b)(3)(B)(v) of the Act with respect to a program year will result in the reduction of the annual home health market basket percentage increase otherwise applicable to an HHA for the corresponding calendar year by 2 percentage points. For the CY 2023 program year, 820 of the 11,549 active Medicare-certified HHAs, or approximately 7.1 percent, did not receive the full annual percentage increase because they did not meet assessment submission requirements. The 820 HHAs that did not satisfy the reporting requirements of the HH QRP for the CY 2023 program year represent \$149 million in home health claims payment dollars during the reporting period out of a total \$16.4 billion for all HHAs.

This proposed rule proposes the adoption of the "COVID-19 Vaccine: Percent of Patients/Residents Who Are Up to Date" (Patient/Resident COVID-19 Vaccine) measure to the HH QRP beginning with the CY 2025 HH QRP. CMS also proposes to adopt the "Functional Discharge Score" (DC Function) measure to the HH QRP beginning with the CY 2025 HH QRP. With the addition of the Discharge Function measure, we propose to remove the "Application of Percent of Long-Term Care Hospital (LTCH) Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function" (Application of Functional Assessment/Care Plan) measure from the HH QRP

beginning with the CY 2025 HH QRP. CMS additionally propose the removal of two OASIS items no longer necessary for collection, the M0110—"Episode Timing" and M2220—"Therapy Needs" items. The net effect of these proposals is a reduction of four data elements across all OASIS data collection time points and a net reduction in burden.

Section IX.B.1. of this proposed rule provides a detailed description of the net decrease in burdens associated with the proposed changes. We proposed that additions and removal of data elements associated with the HH QRP proposals would begin with January 1, 2025 discharges. The cost impact of this proposed changes was estimated to be a net decrease of \$5,123,429 in annualized cost to HHAs, discounted at 7 percent relative to year 2021, over a perpetual time horizon beginning in CY 2025. We described the estimated burden and cost reductions for these measures in section IX of this proposed rule. In summary, the implementation of proposals outlined in this proposed rule for the HH QRP is estimated to decrease the burden on HHAs by \$437 per HHA annually, or \$5,123,429 for all HHAs annually.

3. Effects of the Proposed Changes for the Expanded HHVBP Model

In the CY 2023 HH PPS final rule (87 FR 66883), we estimated that the expanded HHVBP Model would generate a total projected 5-year gross FFS savings for CYs 2023 through 2027 of \$3,376,000,000. The proposed changes to the applicable measure set and the Model baseline year in this proposed rule will not change those estimates because they do not change

the number of HHAs in the Model or the payment methodology.

Based on proposed policies discussed in this proposed rule, Tables GG2A and GG2B display the distribution of possible payment adjustments using CY 2021 data as the performance year and CY 2019 for the baseline year. Note that due to limited data availability, this impact analysis does not account for improvement points for the PPH measure because this measure is not available based on CY 2022 data at the time of the release of this proposed rule.

Table GG2A and GG2B shows the value-based incentive payment adjustments for the estimated 6,750 HHAs that would qualify to compete in the expanded Model based on CY 2021 performance data stratified by volume-based cohort, as defined in section III.F. of the CY 2022 HH PPS final rule (86 FR 62312). This impact analysis used CY 2019 to determine HHA size instead of the calendar year prior to the performance year (that is, CY 2020) to avoid using data impacted by the Public Health Emergency (PHE). Using CY 2021 performance year data and the finalized payment adjustment of 5 percent, based on the 10 proposed quality measures, the 6,504 HHAs in the larger-volume cohort would have an average payment adjustment of positive 0.164 percent (+0.164 percent). Furthermore, 246 HHAs have fewer than 60 unique beneficiaries in CY 2019 and are, therefore, included in the smaller-volume cohort. Overall, smaller-volume HHAs would have an average payment adjustment of negative 0.114 percent (-0.114 percent). Twenty-four states/territories do not have any HHAs in the smaller-volume cohort, including

Alabama, District of Columbia, and Georgia. The remaining states/territories have HHAs in both volume-based cohorts. Florida, for example, has 622 HHAs in the larger-volume cohort with an average payment adjustment of positive 1.154 percent (+1.154 percent) and 17 HHAs in the smaller-volume cohort with an average payment adjustment of positive 0.102 percent (+0.102 percent). The next columns provide the distribution of payment adjustment by percentile. Specifically, 10 percent of HHAs in the larger-volume cohort would receive downward payment adjustments of more than negative 3.851 percent (−3.851 percent). Among smaller-volume HHAs, 10 percent of HHAs would receive downward payment adjustments of more than negative 4.120 percent (−4.120 percent). For larger-volume HHAs in Florida, the payment adjustments range from negative 3.161 percent (−3.161 percent) at the 10th percentile to positive 5.000 percent

(+5.000 percent) at the 90th percentile, while the median (50th percentile) payment adjustment is positive 1.160 percent (+1.160 percent).

Table GG3 provides the payment adjustment distribution based on the proportion of dual-eligible beneficiaries, average case mix using Hierarchical Condition Category (HCC) scores, proportion of beneficiaries that reside in rural areas, and HHA organizational status. To define cutoffs for the “percentage of dual eligible beneficiaries,” low through high percentage dual-eligible are based on the 20th, 40th, 60th, and 80th percentiles of percent dual eligible beneficiaries, respectively, across HHAs in CY 2021. To define case mix cutoffs, low, medium, or high acuity are based on less than the 25th percentile, between the 25th and 75th percentiles, and greater than the 75th percentile of average HCC scores, respectively, across HHAs in CY 2021. To define cutoffs for percentage of rural beneficiaries, all

non-rural, up to 50 percent rural, and over 50 percent rural are based on the home health beneficiaries’ core-based statistical area (CBSA) urban versus rural designation. Based on CY 2021 data, HHAs with the highest proportion of dual-eligible beneficiaries served have a positive average payment adjustment (+0.035 percent). In addition, a higher proportion of rural beneficiaries served is associated with better performance. Specifically, HHAs serving over 50 percent rural beneficiaries have an average payment adjustment of positive 0.728 percent (+0.728 percent), compared to HHAs serving only rural beneficiaries or HHAs serving up to 50 percent rural beneficiaries. Among organizational type, proprietary HHAs have a slightly negative average payment adjustment of 0.092, whereas HHAs in other organizational type categories have a positive average payment adjustment.

**BILLING CODE 4120-01-P**

**TABLE GG2A: PAYMENT ADJUSTMENT DISTRIBUTION BY VOLUME-BASED COHORT: LARGE-VOLUME COHORT**

| Larger-volume Cohort |                |                                |         |         |         |         |         |         |         |         |         |
|----------------------|----------------|--------------------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| State                | Number of HHAs | Average Payment Adjustment (%) | 10%     | 20%     | 30%     | 40%     | 50%     | 60%     | 70%     | 80%     | 90%     |
| AK                   | 11             | (1.059)                        | (3.247) | (2.196) | (1.961) | (1.313) | (0.425) | (0.412) | 0.103   | 0.159   | 0.381   |
| AL                   | 112            | 1.078                          | (1.926) | (0.938) | (0.051) | 0.278   | 1.004   | 1.579   | 2.428   | 3.218   | 4.888   |
| AR                   | 90             | 0.567                          | (2.550) | (1.630) | (0.661) | (0.150) | 0.885   | 1.235   | 1.872   | 2.321   | 3.702   |
| AZ                   | 104            | (0.215)                        | (3.943) | (3.307) | (2.171) | (1.241) | (0.249) | 0.671   | 1.436   | 2.362   | 3.603   |
| CA                   | 924            | 0.066                          | (4.450) | (3.378) | (2.261) | (1.401) | (0.293) | 0.821   | 2.388   | 4.333   | 5.000   |
| CO                   | 102            | 0.405                          | (3.134) | (2.313) | (1.513) | (0.910) | 0.189   | 0.930   | 1.960   | 3.996   | 5.000   |
| CT                   | 64             | (1.171)                        | (4.176) | (3.695) | (2.811) | (2.380) | (1.973) | (1.376) | (0.518) | 1.021   | 3.985   |
| DC                   | 6              | 1.525                          | (2.334) | (0.057) | (0.057) | 1.519   | 2.113   | 2.707   | 3.528   | 3.528   | 3.787   |
| DE                   | 12             | 0.783                          | (2.652) | (0.709) | (0.071) | 0.106   | 0.575   | 1.147   | 1.913   | 2.116   | 5.000   |
| FL                   | 622            | 1.154                          | (3.161) | (1.977) | (0.942) | 0.037   | 1.160   | 2.386   | 3.774   | 5.000   | 5.000   |
| GA                   | 98             | 0.065                          | (3.169) | (2.312) | (1.574) | (1.058) | (0.270) | 0.186   | 1.266   | 3.035   | 4.362   |
| GU                   | 2              | (4.087)                        | (4.301) | (4.301) | (4.301) | (4.301) | (4.087) | (3.874) | (3.874) | (3.874) | (3.874) |
| HI                   | 13             | 0.888                          | (2.573) | (1.652) | (1.636) | 1.298   | 1.493   | 1.892   | 2.780   | 2.897   | 4.267   |
| IA                   | 88             | 1.648                          | (2.620) | (0.756) | (0.100) | 0.923   | 2.066   | 3.128   | 3.916   | 4.732   | 5.000   |
| ID                   | 43             | 0.972                          | (3.269) | (2.017) | (1.566) | 0.114   | 1.568   | 2.635   | 3.579   | 4.032   | 5.000   |
| IL                   | 356            | (0.103)                        | (4.434) | (3.242) | (2.270) | (1.220) | (0.404) | 0.699   | 2.008   | 3.139   | 4.955   |
| IN                   | 126            | (0.383)                        | (4.318) | (2.731) | (1.975) | (1.248) | (0.437) | 0.247   | 0.973   | 2.031   | 3.476   |
| KS                   | 80             | 0.531                          | (3.881) | (2.400) | (1.234) | (0.242) | 0.850   | 1.393   | 2.244   | 3.810   | 5.000   |
| KY                   | 87             | 0.878                          | (2.134) | (1.004) | (0.243) | 0.292   | 0.897   | 1.354   | 1.767   | 3.128   | 4.036   |
| LA                   | 165            | 0.484                          | (3.009) | (2.249) | (1.528) | (0.541) | 0.536   | 1.208   | 2.215   | 3.375   | 4.468   |
| MA                   | 101            | (0.090)                        | (3.418) | (2.291) | (1.342) | (1.061) | (0.476) | (0.036) | 1.113   | 1.929   | 4.649   |
| MD                   | 48             | 1.343                          | (1.697) | (1.470) | (0.328) | 0.299   | 1.113   | 1.761   | 2.691   | 4.484   | 5.000   |
| ME                   | 19             | 1.084                          | (2.414) | (1.110) | (0.549) | 0.627   | 1.017   | 2.000   | 2.598   | 2.912   | 5.000   |
| MI                   | 282            | 1.150                          | (3.159) | (1.766) | (0.904) | 0.099   | 1.340   | 2.262   | 3.355   | 5.000   | 5.000   |
| MN                   | 89             | 0.470                          | (2.178) | (1.724) | (0.594) | (0.019) | 0.411   | 0.984   | 1.581   | 2.678   | 3.932   |
| MO                   | 116            | 0.874                          | (3.578) | (2.593) | (1.273) | (0.067) | 1.152   | 2.175   | 3.438   | 4.615   | 5.000   |
| MS                   | 43             | 1.104                          | (0.394) | (0.160) | 0.209   | 0.592   | 0.825   | 1.609   | 1.970   | 2.386   | 3.513   |
| MT                   | 20             | 0.185                          | (2.906) | (1.573) | (1.188) | (0.814) | (0.103) | 0.566   | 1.473   | 2.503   | 2.981   |
| NC                   | 152            | 0.541                          | (2.925) | (1.801) | (1.023) | (0.414) | 0.089   | 1.062   | 2.315   | 3.120   | 4.720   |
| ND                   | 13             | 1.342                          | (1.963) | (0.817) | (0.751) | 0.374   | 0.696   | 2.716   | 2.848   | 5.000   | 5.000   |
| NE                   | 44             | 1.172                          | (3.509) | (2.051) | (0.108) | 1.075   | 1.542   | 2.408   | 3.038   | 4.257   | 5.000   |
| NH                   | 20             | 0.493                          | (2.620) | (1.468) | (0.300) | 0.273   | 0.493   | 0.945   | 1.324   | 2.573   | 3.405   |
| NJ                   | 41             | 0.446                          | (2.132) | (1.482) | (0.928) | (0.352) | (0.105) | 0.424   | 1.202   | 2.302   | 4.127   |
| NM                   | 56             | (0.601)                        | (4.428) | (3.181) | (2.494) | (1.795) | (0.995) | (0.310) | 1.434   | 2.155   | 3.513   |
| NV                   | 95             | (1.722)                        | (4.897) | (4.479) | (3.918) | (2.915) | (1.933) | (1.264) | (0.555) | 0.277   | 2.540   |

| Larger-volume Cohort |                |                                |  |                |                |                |                |              |              |              |              |  |
|----------------------|----------------|--------------------------------|--|----------------|----------------|----------------|----------------|--------------|--------------|--------------|--------------|--|
| State                | Number of HHAs | Average Payment Adjustment (%) | Payment Adjustment Percentile Distribution (%) |                |                |                |                |              |              |              |              |  |
|                      |                |                                | 10%  | 20%            | 30%            | 40%            | 50%            | 60%          | 70%          | 80%          | 90%          |  |
| NY                   | 98             | 0.637                          | (2.517)  | (1.731)        | (0.836)        | (0.109)        | 0.300          | 0.806        | 1.950        | 3.375        | 4.604        |  |
| OH                   | 248            | (0.065)                        | (4.290)  | (2.925)        | (2.158)        | (1.563)        | (0.476)        | 0.681        | 1.966        | 3.123        | 5.000        |  |
| OK                   | 174            | (1.016)                        | (4.142)  | (3.485)        | (2.695)        | (2.166)        | (1.578)        | (0.633)      | 0.058        | 1.373        | 2.847        |  |
| OR                   | 42             | (0.223)                        | (3.417)  | (2.686)        | (2.079)        | (1.310)        | (0.568)        | 0.407        | 1.611        | 2.453        | 3.013        |  |
| PA                   | 198            | 0.858                          | (3.014)  | (1.804)        | (0.987)        | (0.139)        | 0.623          | 1.826        | 2.847        | 4.181        | 5.000        |  |
| PR                   | 32             | (1.760)                        | (3.603)  | (3.454)        | (2.960)        | (2.530)        | (2.398)        | (1.416)      | (0.833)      | 0.074        | 0.631        |  |
| RI                   | 19             | 1.069                          | (3.533)  | (1.920)        | (1.347)        | (0.267)        | 0.986          | 2.164        | 3.078        | 5.000        | 5.000        |  |
| SC                   | 65             | 0.654                          | (2.618)  | (1.604)        | (0.779)        | (0.103)        | 0.452          | 1.601        | 2.025        | 2.653        | 3.889        |  |
| SD                   | 17             | 2.122                          | (3.764)  | 0.075          | 1.752          | 1.792          | 2.543          | 3.698        | 4.187        | 5.000        | 5.000        |  |
| TN                   | 109            | 0.289                          | (2.659)  | (1.776)        | (1.073)        | (0.640)        | (0.014)        | 0.655        | 1.353        | 2.422        | 3.824        |  |
| TX                   | 824            | (1.233)                        | (4.536)  | (3.700)        | (2.943)        | (2.152)        | (1.534)        | (0.801)      | (0.026)      | 1.104        | 2.370        |  |
| UT                   | 62             | 1.291                          | (2.113)  | (1.758)        | (0.892)        | 0.112          | 0.881          | 2.928        | 3.746        | 4.758        | 5.000        |  |
| VA                   | 171            | 0.144                          | (3.732)  | (2.615)        | (1.853)        | (0.887)        | (0.222)        | 1.062        | 2.099        | 2.616        | 5.000        |  |
| VI                   | 2              | 2.815                          | 0.631  | 0.631          | 0.631          | 0.631          | 2.815          | 5.000        | 5.000        | 5.000        | 5.000        |  |
| VT                   | 10             | (2.293)                        | (4.134)  | (4.105)        | (3.751)        | (2.960)        | (2.229)        | (1.849)      | (1.095)      | (0.365)      | (0.255)      |  |
| WA                   | 54             | 0.430                          | (2.423)  | (1.958)        | (0.908)        | (0.524)        | (0.089)        | 1.087        | 1.892        | 2.911        | 3.644        |  |
| WI                   | 69             | 0.733                          | (3.547)  | (1.980)        | (1.218)        | (0.311)        | 1.019          | 1.548        | 2.951        | 3.603        | 5.000        |  |
| WV                   | 47             | 0.828                          | (1.905)  | (1.303)        | (0.825)        | (0.159)        | 0.440          | 1.530        | 2.014        | 3.365        | 4.681        |  |
| WY                   | 19             | (0.389)                        | (4.210)  | (2.721)        | (2.083)        | (1.582)        | (0.297)        | 0.003        | 0.911        | 2.412        | 3.607        |  |
| <b>ALL</b>           | <b>6,504</b>   | <b>0.164</b>                   | <b>(3.851)</b>                                 | <b>(2.658)</b> | <b>(1.789)</b> | <b>(0.931)</b> | <b>(0.079)</b> | <b>0.876</b> | <b>1.938</b> | <b>3.251</b> | <b>5.000</b> |  |

**TABLE GG2B: PAYMENT ADJUSTMENT DISTRIBUTION BY VOLUME-BASED COHORT: SMALL-VOLUME COHORT**

| State | Number of HHAs | Average Payment Adjustment (%) | Smaller-volume Cohort                          |         |         |         |         |         |         |         |         |         |         |         |
|-------|----------------|--------------------------------|--|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
|       |                |                                | Payment Adjustment Percentile Distribution (%) |         |         |         |         |         |         |         |         |         |         |         |
|       |                |                                | 10%  | 20%     | 30%     | 40%     | 50%     | 60%     | 70%     | 80%     | 90%     |         |         |         |
| AK    | 1              | (1.697)                        | (1.697)  | (1.697) | (1.697) | (1.697) | (1.697) | (1.697) | (1.697) | (1.697) | (1.697) | (1.697) | (1.697) | (1.697) |
| AL    | 0              | -                              | -  | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       |
| AR    | 1              | (0.995)                        | (0.995)  | (0.995) | (0.995) | (0.995) | (0.995) | (0.995) | (0.995) | (0.995) | (0.995) | (0.995) | (0.995) | (0.995) |
| AZ    | 3              | 0.779                          | (0.578)  | (0.578) | (0.578) | 0.418   | 0.418   | 0.418   | 0.418   | 0.418   | 0.418   | 2.496   | 2.496   | 2.496   |
| CA    | 63             | 1.032                          | (3.748)  | (2.655) | (1.570) | (0.175) | 2.283   | 3.005   | 3.592   | 4.888   | 5.000   | (1.931) | (1.931) | (1.931) |
| CO    | 1              | (1.931)                        | (1.931)  | (1.931) | (1.931) | (1.931) | (1.931) | (1.931) | (1.931) | (1.931) | (1.931) | (1.931) | (1.931) | (1.931) |
| CT    | 2              | (0.745)                        | (2.244)  | (2.244) | (2.244) | (2.244) | (2.244) | (2.244) | (2.244) | (2.244) | (2.244) | (2.244) | (2.244) | (2.244) |
| DC    | 0              | -                              | -  | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       |
| DE    | 0              | -                              | -  | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       |
| FL    | 17             | 0.102                          | (3.200)  | (2.957) | (2.678) | (2.604) | (1.370) | 0.442   | 1.995   | 4.974   | 5.000   | -       | -       | -       |
| GA    | 0              | -                              | -  | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       |
| GU    | 0              | -                              | -  | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       |
| HI    | 0              | -                              | -  | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       |
| IA    | 5              | 1.278                          | (0.889)  | (0.435) | 0.018   | 0.194   | 0.370   | 1.512   | 2.654   | 3.446   | 4.238   | -       | -       | -       |
| ID    | 0              | -                              | -  | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       |
| IL    | 33             | 0.066                          | (4.435)  | (2.972) | (2.331) | (1.212) | 0.377   | 0.871   | 2.735   | 3.387   | 4.242   | (1.507) | (1.507) | (1.507) |
| IN    | 4              | (2.732)                        | (4.509)  | (4.509) | (2.976) | (2.976) | (2.457) | (1.937) | 1.075   | 1.075   | 1.075   | 1.075   | 1.075   | 1.075   |
| KS    | 2              | (0.517)                        | (2.109)  | (2.109) | (2.109) | (2.109) | (2.109) | (2.109) | (2.109) | (2.109) | (2.109) | (2.109) | (2.109) | (2.109) |
| KY    | 0              | -                              | -  | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       |
| LA    | 0              | -                              | -  | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       |
| MA    | 5              | (1.726)                        | (5.000)  | (3.151) | (1.302) | (1.185) | (1.068) | (0.992) | (0.915) | (0.630) | (0.345) | -       | -       | -       |
| MD    | 0              | -                              | -  | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       |
| ME    | 0              | -                              | -  | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       |
| MI    | 21             | 1.110                          | (2.837)  | (2.223) | (1.397) | (1.291) | 2.307   | 3.044   | 4.086   | 4.365   | 5.000   | -       | -       | -       |
| MN    | 5              | 1.750                          | (1.605)  | (1.401) | (1.196) | 0.511   | 2.219   | 3.276   | 4.333   | 4.666   | 5.000   | -       | -       | -       |
| MO    | 4              | 1.116                          | (0.627)  | (0.627) | 0.205   | 0.205   | 1.247   | 2.289   | 2.289   | 2.598   | 2.598   | -       | -       | -       |
| MS    | 0              | -                              | -  | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       | -       |
| MT    | 2              | (0.419)                        | (3.359)  | (3.359) | (3.359) | (3.359) | (0.419) | 2.520   | 2.520   | 2.520   | 2.520   | 2.520   | 2.520   | 2.520   |
| NC    | 1              | 2.597                          | 2.597  | 2.597   | 2.597   | 2.597   | 2.597   | 2.597   | 2.597   | 2.597   | 2.597   | 2.597   | 2.597   | 2.597   |
| ND    | 1              | 2.817                          | 2.817  | 2.817   | 2.817   | 2.817   | 2.817   | 2.817   | 2.817   | 2.817   | 2.817   | 2.817   | 2.817   | 2.817   |
| NE    | 6              | 0.167                          | (4.555)  | (1.213) | (1.213) | (0.954) | (0.569) | (0.184) | 2.908   | 2.908   | 2.908   | 2.908   | 2.908   | 2.908   |

| Smaller-volume Cohort |                |                                |  |                |                |                |                |              |              |              |              |              |              |              |
|-----------------------|----------------|--------------------------------|--|----------------|----------------|----------------|----------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| State                 | Number of HHAs | Average Payment Adjustment (%) | Payment Adjustment Percentile Distribution (%) |                |                |                |                |              |              |              |              |              |              |              |
|                       |                |                                | 10%  | 20%            | 30%            | 40%            | 50%            | 60%          | 70%          | 80%          | 90%          |              |              |              |
| NH                    | 0              | -                              | -  | -              | -              | -              | -              | -            | -            | -            | -            | -            | -            | -            |
| NJ                    | 0              | -                              | -  | -              | -              | -              | -              | -            | -            | -            | -            | -            | -            | -            |
| NM                    | 0              | -                              | -  | -              | -              | -              | -              | -            | -            | -            | -            | -            | -            | -            |
| NV                    | 4              | (3.419)                        | (5.000)  | (4.261)        | (4.261)        | (3.881)        | (3.502)        | (3.502)      | (0.915)      | (0.915)      |              |              |              |              |
| NY                    | 0              | -                              | -  | -              | -              | -              | -              | -            | -            | -            | -            | -            | -            | -            |
| OH                    | 2              | 3.690                          | 2.381  | 2.381          | 2.381          | 3.690          | 5.000          | 5.000        | 5.000        | 5.000        | 5.000        | 5.000        | 5.000        | 5.000        |
| OK                    | 7              | (2.967)                        | (5.000)  | (4.600)        | (4.083)        | (4.083)        | (3.335)        | (2.264)      | (2.264)      | (0.965)      | (0.965)      |              |              |              |
| OR                    | 1              | (1.623)                        | (1.623)  | (1.623)        | (1.623)        | (1.623)        | (1.623)        | (1.623)      | (1.623)      | (1.623)      | (1.623)      | (1.623)      | (1.623)      | (1.623)      |
| PA                    | 6              | 1.596                          | (2.246)  | (1.211)        | (1.211)        | 2.032          | 2.147          | 2.263        | 3.736        | 3.736        | 3.736        | 3.736        | 3.736        | 5.000        |
| PR                    | 0              | -                              | -  | -              | -              | -              | -              | -            | -            | -            | -            | -            | -            | -            |
| RI                    | 0              | -                              | -  | -              | -              | -              | -              | -            | -            | -            | -            | -            | -            | -            |
| SC                    | 0              | -                              | -  | -              | -              | -              | -              | -            | -            | -            | -            | -            | -            | -            |
| SD                    | 2              | 3.553                          | 2.106  | 2.106          | 2.106          | 3.553          | 5.000          | 5.000        | 5.000        | 5.000        | 5.000        | 5.000        | 5.000        | 5.000        |
| TN                    | 1              | (1.067)                        | (1.067)  | (1.067)        | (1.067)        | (1.067)        | (1.067)        | (1.067)      | (1.067)      | (1.067)      | (1.067)      | (1.067)      | (1.067)      | (1.067)      |
| TX                    | 35             | (2.851)                        | (4.798)  | (4.494)        | (3.973)        | (3.848)        | (3.276)        | (2.926)      | (1.646)      | (0.939)      | (0.471)      |              |              |              |
| UT                    | 6              | (0.020)                        | (3.317)  | (1.115)        | (1.097)        | (0.500)        | 0.096          | 0.096        | 1.419        | 1.419        | 1.419        | 1.419        | 3.894        | 3.894        |
| VA                    | 3              | (1.854)                        | (4.103)  | (4.103)        | (3.651)        | (3.651)        | (3.651)        | (3.651)      | 2.192        | 2.192        | 2.192        | 2.192        | 2.192        | 2.192        |
| VI                    | 0              | -                              | -  | -              | -              | -              | -              | -            | -            | -            | -            | -            | -            | -            |
| VT                    | 0              | -                              | -  | -              | -              | -              | -              | -            | -            | -            | -            | -            | -            | -            |
| WA                    | 0              | -                              | -  | -              | -              | -              | -              | -            | -            | -            | -            | -            | -            | -            |
| WI                    | 2              | (1.218)                        | (4.023)  | (4.023)        | (4.023)        | (1.218)        | 1.587          | 1.587        | 1.587        | 1.587        | 1.587        | 1.587        | 1.587        | 1.587        |
| WV                    | 0              | -                              | -  | -              | -              | -              | -              | -            | -            | -            | -            | -            | -            | -            |
| WY                    | 0              | -                              | -  | -              | -              | -              | -              | -            | -            | -            | -            | -            | -            | -            |
| <b>ALL</b>            | <b>246</b>     | <b>(0.114)</b>                 | <b>(4.120)</b>                                 | <b>(3.266)</b> | <b>(2.298)</b> | <b>(1.507)</b> | <b>(0.904)</b> | <b>0.377</b> | <b>2.307</b> | <b>3.475</b> | <b>5.000</b> | <b>5.000</b> | <b>5.000</b> | <b>5.000</b> |

**TABLE GG3: PAYMENT ADJUSTMENT DISTRIBUTION BY HHA CHARACTERISTICS**

| HHA Characteristics             | # of HHAs | Average Payment Adjustment (%) | Payment Adjustment Percentile Distribution (%) |         |         |         |         |         |       |       |       |
|---------------------------------|-----------|--------------------------------|--|---------|---------|---------|---------|---------|-------|-------|-------|
|                                 |           |                                | 10%  | 20%     | 30%     | 40%     | 50%     | 60%     | 70%   | 80%   | 90%   |
| <b>Percentage Dual-eligible</b> |           |                                |  |         |         |         |         |         |       |       |       |
| 1st Quintile: % Dual-eligible   | 1,344     | 0.781                          | (3.242)  | (2.080) | (1.160) | (0.216) | 0.730   | 1.662   | 2.592 | 4.241 | 5.000 |
| 2nd Quintile: % Dual-eligible   | 1,343     | 0.377                          | (3.128)  | (2.100) | (1.344) | (0.610) | 0.173   | 1.081   | 1.966 | 3.025 | 4.678 |
| 3rd Quintile: % Dual-eligible   | 1,344     | 0.176                          | (3.418)  | (2.365) | (1.563) | (0.836) | (0.045) | 0.746   | 1.709 | 2.908 | 4.408 |
| 4th Quintile: % Dual-eligible   | 1,343     | (0.565)                        | (4.232)  | (3.276) | (2.370) | (1.754) | (0.882) | (0.071) | 0.859 | 2.096 | 3.887 |
| 5th Quintile: % Dual-eligible   | 1,343     | 0.035                          | (4.588)  | (3.667) | (2.655) | (1.554) | (0.392) | 0.953   | 2.668 | 4.672 | 5.000 |
| <b>Acuity (HCC)</b>             |           |                                |  |         |         |         |         |         |       |       |       |
| 1-Lowest Acuity                 | 1,678     | 0.599                          | (4.046)  | (2.775) | (1.586) | (0.591) | 0.495   | 1.764   | 3.075 | 4.846 | 5.000 |
| 2-Medium Acuity                 | 3,354     | 0.095                          | (3.743)  | (2.646) | (1.823) | (0.995) | (0.145) | 0.782   | 1.717 | 2.988 | 4.884 |
| 3-Highest Acuity                | 1,677     | (0.145)                        | (3.843)  | (2.650) | (1.878) | (1.178) | (0.406) | 0.419   | 1.361 | 2.494 | 4.224 |
| <b>% Rural Beneficiaries</b>    |           |                                |  |         |         |         |         |         |       |       |       |
| 1-All non-rural                 | 3,448     | 0.114                          | (4.164)  | (2.938) | (2.004) | (1.095) | (0.195) | 0.863   | 2.114 | 3.591 | 5.000 |
| 2-Up to 50% rural               | 1,998     | (0.118)                        | (3.675)  | (2.651) | (1.896) | (1.180) | (0.405) | 0.425   | 1.361 | 2.549 | 4.220 |
| 3-Over 50% rural                | 1,266     | 0.728                          | (3.078)  | (1.916) | (0.976) | (0.086) | 0.664   | 1.523   | 2.461 | 3.595 | 5.000 |
| <b>Organizational Type</b>      |           |                                |  |         |         |         |         |         |       |       |       |
| 1-Vol Non-Profit-Religious      | 273       | 1.309                          | (2.449)  | (0.989) | (0.327) | 0.509   | 1.444   | 2.096   | 3.058 | 3.918 | 5.000 |
| 2-Vol Non-Profit-Private        | 548       | 0.878                          | (3.078)  | (1.944) | (1.051) | (0.068) | 0.822   | 1.675   | 2.908 | 4.206 | 5.000 |
| 3-Vol Non-Profit-Other          | 447       | 0.909                          | (2.811)  | (1.684) | (0.680) | 0.106   | 0.846   | 1.738   | 2.709 | 3.785 | 5.000 |
| 4-Proprietary                   | 5,233     | (0.092)                        | (4.086)  | (2.943) | (2.060) | (1.273) | (0.436) | 0.485   | 1.609 | 2.956 | 5.000 |
| 5-Govt-State/County             | 149       | 1.043                          | (2.682)  | (1.719) | (0.654) | 0.255   | 1.142   | 2.074   | 3.080 | 3.918 | 4.796 |
| 6-Govt-Govt & Voluntary         | 10        | 2.227                          | (0.890)  | 0.488   | 1.133   | 1.762   | 2.424   | 2.853   | 3.491 | 4.498 | 4.977 |
| 7-Govt-Local                    | 90        | 1.096                          | (2.591)  | (1.275) | (0.699) | 0.320   | 1.059   | 1.810   | 2.872 | 4.096 | 5.000 |

**Notes:**

- Dual: Based on 20<sup>th</sup>, 40<sup>th</sup>, 60<sup>th</sup>, and 80<sup>th</sup> percentiles of the percent of beneficiaries with any dual indicated across all HHAs in 2021.
- HCC Score Acuity: low, medium, high are based on 25<sup>th</sup> and 75<sup>th</sup> percentiles of the average HCC of beneficiaries across all HHAs in 2021.
- Percentage rural beneficiaries: based on CBSA of beneficiaries' ZIP code aggregated to the HHA level in 2021.
- The total number of HHAs differ by category due to missing HHAs in some data sources.

4. Impacts of Home IVIG Items and Services

The following analysis applies to the home IVIG items and services payment rate as set forth in section V.D.1. of this rule as added by section 4134 of the CAA, 2023 and accordingly, describes the impact for CY 2024 only. Table GG 5 represents the estimated costs of home IVIG users for CY 2024. We used CY 2022 data to identify beneficiaries

actively enrolled in the IVIG demonstration (that is, beneficiaries with Part B claims that contain the Q2052 HCPCS code) to estimate the number of potential CY 2024 active enrollees in the new benefit, which are shown in column 2. In column 3, CY 2022 claims for IVIG visits under the Demonstration were again used to estimate potential utilization under the new benefit in CY 2024. Column 4 shows the proposed CY 2024 home IVIG

items and services rate. The fifth column estimates the cost to Medicare for CY 2024 (\$8,779,095). The estimated cost for CY 2023 under the Demonstration is \$8,543,520 (not shown in chart) resulting in an increase of \$235,575 in payments to providers under the permanent benefit. Table GG 6 represents the estimated impacts of the home IVIG items and services payment for CY 2024 by census region.

**TABLE GG5: ESTIMATED COSTS OF COVERED IVIG ITEMS AND SERVICES, CY 2024**

| Year    | Number of Active Enrollees <sup>1</sup> | Number of IVIG Visits <sup>1</sup> | Nationwide Rate | Estimated Cost |
|---------|---|------------------------------------|-----------------|----------------|
| CY 2024 | 1,846                                   | 20,940                             | \$419.25        | \$8,779,095    |

<sup>1</sup>The number of active enrollees and IVIG visits in CY 2022 was used to estimate utilization in CY 2023 and CY 2024. Claims data were extracted on January 30, 2023.

**TABLE GG6—ESTIMATED IMPACTS OF THE HOME IVIG ITEMS AND SERVICES PAYMENT BY REGION, CY 2024**

| Census Region      | States                             | Number of Active Enrollees <sup>1</sup> | Number of IVIG Visits <sup>1</sup> | Estimated CY 2024 Cost |
|--------------------|------------------------------------|---|------------------------------------|------------------------|
| New England        | CT, ME, MA, NH, RI, VT             | 170                                     | 1,969                              | \$ 825,503             |
| Middle Atlantic    | NJ, NY, PA                         | 204                                     | 2,409                              | \$ 1,009,973           |
| South Atlantic     | DE, DC, FL, GA, MD, NC, SC, VA, WV | 470                                     | 5,145                              | \$ 2,157,041           |
| East North Central | IL, IN, MI, OH, WI                 | 163                                     | 1,748                              | \$ 732,849             |
| East South Central | AL, KY, MS, TN                     | 182                                     | 1,984                              | \$ 831,792             |
| West North Central | IA, KS, MN, MO, NE, ND, SD         | 125                                     | 1,532                              | \$ 642,291             |
| West South Central | AR, LA, OK, TX                     | 175                                     | 1,973                              | \$ 827,180             |
| Mountain           | AZ, CO, ID, MT, NV, NM, UT, WY     | 148                                     | 1,622                              | \$ 680,024             |
| Pacific            | AK, CA, HI, OR, WA                 | 209                                     | 2,558                              | \$ 1,072,442           |
| Other              | GU, PR, VI                         | 0                                       | 0                                  | \$ -                   |

<sup>1</sup>The number of active enrollees and IVIG visits in CY 2022 was used to estimate utilization in CY 2024. Claims data were extracted on January 30, 2023.

5. Effects of the Proposed Changes for Hospice IDR and SFP

The proposed hospice IDR is an administrative process to be conducted by CMS, SAs, or AOs as part of their survey activities, and is separate from the SFP. SAs and AOs may already have existing IDR processes in place for the HHA IDR requirements. The hospice IDR requirements will align with HHA. The Congress has already allocated \$10 million annually to CMS to implement the CAA 2021 hospice survey and enforcement provisions, which includes the SFP. Additionally, CMS obligates monies to the SAs to carry out survey and certification responsibilities under their agreement with the Secretary under section 1864 of the Act. Therefore, no additional burden will be incurred by CMS, SAs, or AOs.

6. Effects of the Proposed Changes for DMEPOS CAA, 2023-Related Provisions

a. Conforming Changes to Regulations To Codify Change Mandated by Section 4139 of the Consolidated Appropriations Act, 2023

One benefit of this provision is that it provides additional revenue to DMEPOS suppliers. One cost of this provision is that it increases the copayments of the Medicare beneficiaries. The transfer from the Medicare program to the DMEPOS suppliers of \$100 million for CY 2023 paid in CY 2023 and CY 2024. The amount of copayments from Medicare beneficiaries over the same period is expected to be \$30 million. The Federal share of Medicaid for the copayments for dual eligibles is expected to be \$5 million and the State share of the Medicare payments for this

populations is expected to be \$4 million.

b. Scope of the Benefit and Payment for Lymphedema Compression Treatment Items

The benefits of this provision are that Medicare enrollees suffering from lymphedema will have Medicare pay 80 percent off the cost of the lymphedema compression treatment items. This Medicare payment should enable more Medicare enrollees suffering from lymphedema to access treatment items in the home, reducing both the financial burden of lymphedema and, by encouraging earlier treatment, the frequency of institutional care for infections or other complications of lymphedema. The transfer from the Medicare program to the lymphedema compression treatment suppliers is estimated to be \$230 million from CY



2024 to CY 2028. The amount of copayments from Medicare beneficiaries over the same period is expected to be \$50 million. The Federal share of Medicaid expenditures for the copayments of dual eligibles is expected to be \$9 million and the State share for this population is expected to be \$6 million.

#### c. Definition of Brace

The benefit of this provision is to add the definition of brace in regulation to more clearly identify what is included in the definition of a brace. This is purely an administrative effort with no impact on Medicare coverage or expenditure, and, for this reason, has no cost or transfer associated with it.

#### 7. Effects of the Proposed Changes to the Requirements for Refillable DMEPOS

This rule proposes to codify and clarify our requirements for refillable DMEPOS items. The fiscal impact of these requirements cannot be estimated as claims often deny for multiple reasons, which may include non-compliance with our refill requirements; creating an inability for us to accurately demonstrate a causal relationship. In addition, to demonstrate impacts we would have to be able to predict behaviors and anticipated non-compliance in future claim submissions, which are unknown variables to us.

#### 8. Effects of the Proposed Changes Regarding for Provider Enrollment Requirements

There are four principal impacts of our provider enrollment proposals outlined in section VIII. of this proposed rule.

The first was addressed in section IX. and involves the ICR burden associated with a hospice's completion of an initial Form CMS-855A application and Form CMS-1561 provider agreement in accordance with a § 424.550(b) change in majority ownership for which an exception does not apply. The combined annual burden was estimated to be 167 hours at a cost of \$8,530.

The second involves moving hospices from the moderate-risk screening category to the high-risk screening level.

The third involves incorporating within the high-risk screening category revalidating DMEPOS suppliers, HHAs, OTPs, MDPPI suppliers, and SNFs for which CMS waived the fingerprint-based criminal background check

requirement when they initially enrolled in Medicare.

The fourth involves the fingerprinting and application fee requirements (referenced in section IX. of this proposed rule) associated with a § 424.550(b) change in majority ownership.

We address the second, third, and fourth impacts as follows:

#### a. Moving Hospices to High-Risk

With this change to § 424.518, hospices that are initially enrolling in Medicare or reporting any new owner would have to submit the fingerprints of their 5 percent or greater direct or indirect owners for a Federal Bureau of Investigation criminal background check. Based on enrollment statistics and our experience, we project that 1,782 hospices per year (425 initially enrolling + 1,357 reporting a new 5 percent or greater owner) would be required to submit these fingerprints. (This figure does not include hospices initially enrolling pursuant to § 424.550(b); this matter is addressed in section X.C.8.d. of this proposed rule). Using an estimate of one owner per hospice (which aligns with previous fingerprinting projections we have made), 1,782 sets of fingerprints per year would be submitted.

Consistent with prior burden estimates, we project that it would take each owner approximately 2 hours to be fingerprinted. According to the most recent BLS wage data for May 2022, the mean hourly wage for the general category of "Top Executives" (the most appropriate BLS category for owners) is \$62.04. With fringe benefits and overhead, the figure is \$124.08. This would result in an estimated annual burden of this proposed change of 3,564 hours (1,782 × 2) at a cost of \$442,221 (3,564 × \$124.08).

#### b. Providers and Suppliers Previously Waived From Fingerprinting

Approximately 6,388 high-risk level providers and suppliers were waived from fingerprinting when they initially enrolled in Medicare during the PHE. We are proposing that these providers and suppliers, upon their revalidation, be subject to high-risk category screening and, consequently, fingerprinting. Using our estimates from section X.C.8.a. of this proposed rule, we project the total burden of this proposal to be 12,776 hours (6,388 × 2 hr) and \$1,585,246 (12,776 × \$124.08).

Calculated as annual figures over a 3-year period, this results in a burden of 4,259 hours and \$528,415.

#### c. Hospice Changes in Majority Ownership

Hospices that are initially enrolling in Medicare due to a change in majority ownership under § 424.550(b) would be subject to fingerprinting and must pay an application fee in accordance with § 424.514. Using the fingerprinting estimates already referenced in section X.C.8. of this proposed rule, we estimate an annual fingerprinting burden to hospices per § 424.550(b) of 200 hours (100 × 2 hr) at a cost of \$24,816 (200 hr × \$124.08).

The application fees for each of the past 3 calendar years were or are \$599 (CY 2021), \$631 (CY 2022), and \$688 (CY 2023). Consistent with § 424.514, the differing fee amounts were predicated on changes/increases in the CPI for all urban consumers (all items; United States city average, CPI-U) for the 12-month period ending on June 30 of the previous year. While we cannot predict future changes to the CPI, the fee amounts between 2021 and 2023 increased by an average of \$45 per year. We believe this is a reasonable barometer with which to establish estimates (strictly for purposes of this proposed rule) of the fee amounts in the first 3 calendar years of the proposed provision (that is, 2024, 2025, and 2026). Thus, we project a fee amount of \$733 in 2024, \$778 for 2025, and \$823 for 2026.

Applying these prospective fee amounts to the annual number of projected hospices impacted by our change in majority ownership proposal, this results in a cost of \$73,300 (or 100 × \$733) in the first year, \$77,800 in the second year, and \$82,300 in the third year.

Applying these prospective fee amounts to the annual number of projected hospices impacted by our change in majority ownership proposal, this results in a cost of \$73,300 (or 100 × \$733) in the first year, \$77,800 in the second year, and \$82,300 in the third year.

#### d. Totals

The following table outlines the total annual costs associated with the proposals addressed in section X.C.8. of this proposed rule for each of the first 3 years.

**TABLE GG7—ESTIMATED COSTS OF HIGH-RISK SCREENING AND CHANGE IN MAJORITY OWNERSHIP PROPOSALS**

| Requirement   | Year 1    | Year 2    | Year 3    |
|---|-----------|-----------|-----------|
| Hospice Completion of Initial Form CMS-855A and Provider Agreement Per § 424.550(b) | 8,530     | 8,530     | 8,530     |
| Hospice High-Risk Screening (Fingerprinting)  | 442,221   | 442,221   | 442,221   |
| Providers and Suppliers Previously Waived from Fingerprinting                       | 528,415   | 528,415   | 528,415   |
| Hospice Fingerprinting for Change in Majority Ownership                             | 24,816    | 24,816    | 24,816    |
| Hospice Application Fee for Change in Majority Ownership                            | 73,300    | 77,800    | 82,300    |
| Total   | 1,077,282 | 1,081,782 | 1,086,282 |

We solicit comment from stakeholders, including hospices, regarding any other RIA costs that may be associated with our proposed expansion of the 36-month rule to incorporate hospices. This could include costs incurred during the survey, accreditation, and/or certification processes.

#### D. Regulatory Review Cost Estimation

If regulations impose administrative costs on private entities, such as the time needed to read and interpret this proposed or final rule, we should estimate the cost associated with regulatory review. Due to the uncertainty involved with accurately quantifying the number of entities that will review the rule, we assume that the total number of unique commenters on last year's proposed rule will be the number of reviewers of this proposed rule. We acknowledge that this assumption may understate or overstate the costs of reviewing this rule. It is possible that not all commenters reviewed last year's rule in detail, and it is also possible that some reviewers chose not to comment on the proposed rule. For these reasons we thought that the number of past commenters would be a fair estimate of the number of reviewers of this rule. We seek comments on the approach used in estimating the number of entities reviewing this proposed rule. We also recognize that different types of entities are in many cases affected by mutually exclusive sections of this proposed rule, and therefore for the purposes of our estimate we assume that each reviewer reads approximately 50 percent of the rule. We seek comments on this assumption.

Using the wage information from the BLS for medical and health service managers (Code 11-9111), we estimate that the cost of reviewing this rule is \$115.22 per hour, including overhead and fringe benefits [https://www.bls.gov/oes/current/oes\\_nat.htm](https://www.bls.gov/oes/current/oes_nat.htm). Assuming an average reading speed, we estimate that it would take approximately 1.98 hours for the staff to review half of this

proposed rule. For each entity that reviews the rule, the estimated cost is \$228.14 (1.98 hours × \$115.22). Therefore, we estimate that the total cost of reviewing this regulation is \$205,554.14 (\$228.14 × 901) [901 is the number of estimated reviewers, which is based on the total number of unique commenters from last year's proposed rule].

#### E. Alternatives Considered

##### 1. HH PPS

For the CY 2024 HH PPS proposed rule, we considered alternatives to the provisions articulated in section II.C. of this proposed rule. As described in section II.C.1.g. of this rule, to help prevent future over or underpayments, we calculated a permanent prospective adjustment by determining what the 30-day base payment amount should have been in CYs 2020, 2021, and 2022 in order to achieve the same estimated aggregate expenditures as obtained from the simulated 60-day episodes. One alternative to the proposed – 5.653 percent permanent payment adjustment included halving the proposed adjustment similar to how we finalized the permanent adjustment for CY 2023. Another alternative would be a phase-in approach, where we could reduce the permanent adjustment, by spreading out the CY 2024 permanent adjustment over a specified period of years, rather than halving the adjustment in CY 2024 and adjusting the CY 2025 rate by the rest of that amount. Another alternative would be to delay the permanent adjustment to a future year. However, we believe that a reduction, a phase-in approach, or delay in the permanent adjustment would not be appropriate, as reducing, phasing in, or delaying the permanent adjustment would further impact budget neutrality and likely lead to a compounding effect creating the need for a larger reduction to the payment rate in future years.

We also considered proposing to implement the one-time temporary adjustment to reconcile retrospective overpayments in CYs 2020, 2021, and

2022. However, as stated previously in this rule, we believe that implementing both the permanent and temporary adjustments to the CY 2024 payment rate may adversely affect HHAs given the magnitude of the adjustment to the payment rate in a single year. Likewise, section 1895(b)(3)(D)(iii) of the Act gives CMS the authority to make any temporary adjustment in a time and manner appropriate though notice and comment rulemaking. Therefore, we believe it is best to propose only the implementation of the permanent decrease of 5.653 percent to the CY 2024 base payment rate.

##### 2. HH QRP

We considered alternative measures to the Discharge Function measure and determined this measure was the strongest. No appropriate alternative was available for the COVID-19 Patient Vaccination measure.

##### 3. Expanded HHVBP Model

We discuss the alternatives we considered to the proposed weights of the individual measures within the OASIS-based measure category and within the claims-based measure category starting in the CY 2025 performance year for the expanded HHVBP Model in section IV.B.2. of this proposed rule.

##### 4. Home IVIG Items and Services

For the CY 2024 HH PPS proposed rule, we did not consider alternatives to implementing the home IVIG items and services payment for CY 2024 because section 1842(o)(8) of the Act requires the Secretary to establish a separate bundled payment to the supplier for all items and services related to the administration of intravenous immune globulin to an individual in the patient's home during a calendar day effective January 1, 2024. We did consider alternatives to annually updating this payment rate, as articulated in section II.V.D. of this proposed rule. We considered updating the annual rate using the LUPA rate for skilled nursing in accordance with the demonstration

program update. However, as the IVIG services payment is not geographically wage adjusted, and the LUPA rate incorporates a wage index budget neutrality factor, we believe it is more appropriate to annually adjust the IVIG items and services payment rate only by the home health payment update percentage. We also considered annually updating the rate by the CPI-U percentage increase in accordance with the annual update to the home infusion therapy services payment rate. However, the Demonstration has never used the CPI-U percentage increase to update the payment rate, and we believe it is more beneficial to keep the permanent payment as closely aligned with the Demonstration rate as possible.

5. IDR and Hospice SFP

We did not consider any alternatives in this proposed rule for either proposal. An initial alternative proposal was published in CY 22 Home Health PPS proposed rule (86 FR 35874) but was not finalized due to public comments and requests that CMS establish a Technical Expert Panel (TEP) to inform the development of the SFP. We believe the new proposed methodology, based on feedback provided by the TEP, is the best way to identify and remedy the issue of poor-performing hospices.

6. DMEPOS CAA, 2023-Related Provisions

a. Scope of the Benefit and Payment for Lymphedema Compression Treatment Items

As this provision is statutorily mandated, CMS needed to consider no alternatives for implementation. Similarly, the statutory language provided a definition for the lymphedema compression treatment items to be covered by this benefit, so CMS did not consider any alternative to coverage of a list of items meeting the statutory requirements. Regarding the payment methodology, CMS considered numerous sources for prices as suggested in statute. Different combinations of internet and insurer prices were alternatives considered. Ultimately, CMS decided on a payment methodology that CMS considered reasonable given the market for these items.

b. Conforming Changes to Regulations To Codify Change Mandated by Section 4139 of the Consolidated Appropriations Act, 2023

This is a conforming change to a statutory mandate and therefore required no alternatives be considered.

c. Definition of Brace

This is a codification of an existing definition and therefore required no alternatives be considered.

7. Refillable DMEPOS

At this time, we did not consider alternatives as this is existing policy that is being codified with additional leniencies based on prior experiences. We welcome the submission of comments.

8. Provider Enrollment Provisions

We considered several alternatives for addressing our provider enrollment-related concerns regarding hospice program integrity and quality of care. We concluded that moving hospices to the high-risk screening category and expanding § 424.550(b) to include hospices were the most appropriate provider enrollment regulatory means of addressing these issues.

F. Accounting Statements and Tables

1. HH PPS

As required by OMB Circular A-4 (available at [https://www.whitehouse.gov/wp-content/uploads/legacy\\_drupal\\_files/omb/circulars/A4/a-4.pdf](https://www.whitehouse.gov/wp-content/uploads/legacy_drupal_files/omb/circulars/A4/a-4.pdf)), in Table GG 8, we have prepared an accounting statement showing the classification of the transfers and benefits associated with the CY 2024 HH PPS provisions of this rule.

**TABLE GG 8: ACCOUNTING STATEMENT: HH PPS CLASSIFICATION OF ESTIMATED TRANSFERS AND BENEFITS, FROM CY 2023 TO 2024**

| Category                       | Transfers                  |
|--------------------------------|----------------------------|
| Annualized Monetized Transfers | -\$375 million             |
| From Whom to Whom?             | Federal Government to HHAs |

2. HH QRP

As required by OMB Circular A-4 (available at <https://www.whitehouse.gov/sites/>

[whitehouse.gov/sites/whitehouse.gov/files/omb/circulars/A4/a-4.pdf](https://www.whitehouse.gov/sites/whitehouse.gov/files/omb/circulars/A4/a-4.pdf)), in Table GG 9, we have prepared an accounting statement showing the classification of the expenditures associated with this final

rule as they relate to HHAs. Table GG 9 provides our best estimate of the increase in burden for OASIS submission.

**TABLE GG 9: ACCOUNTING STATEMENT: CLASSIFICATION OF ESTIMATED COSTS OF OASIS ITEM COLLECTION, FROM CY 2026 TO CY 2027**

| Category   | Costs       |
|--|-------------|
| The net impact of the COVID-19 QM, Removal of the Application of Functional Assessment/Care Plan QM, and removal of the M0110 – Episode Timing and M2220-Therapy Needs items | \$4,786,239 |

## 3. Expanded HHVBP Model

As required by OMB Circular A-4 (available at <https://>

[www.whitehouse.gov/sites/whitehouse.gov/files/omb/circulars/A4/a-4.pdf](http://www.whitehouse.gov/sites/whitehouse.gov/files/omb/circulars/A4/a-4.pdf)), in Table GG 10 we have prepared an accounting statement. Table

GG 10 provides our best estimate of the decrease in Medicare payments under the expanded HHVBP Model.

**TABLE GG10: ACCOUNTING STATEMENT: EXPANDED HHVBP MODEL CLASSIFICATION OF ESTIMATED TRANSFERS FOR CYs 2023 – 2027**

| Category                       | Transfers                                | Discount Rate | Period Covered |
|--------------------------------|--|---------------|----------------|
| Annualized Monetized Transfers | -\$662.4 Million                         | 7%            | CYs 2023-2027  |
| Annualized Monetized Transfers | -\$669.7 Million                         | 3%            | CYs 2023-2027  |
| From Whom to Whom?             | Federal Government to Hospitals and SNFs |               |                |

## 4. Home IVIG Items and Services

As required by OMB Circular A-4 (available at <https://>

[www.whitehouse.gov/wp-content/uploads/legacy\\_drupal\\_files/omb/circulars/A4/a-4.pdf](http://www.whitehouse.gov/wp-content/uploads/legacy_drupal_files/omb/circulars/A4/a-4.pdf)), in Table GG 11, we have prepared an accounting

statement showing the classification of the transfers and benefits associated with the CY 2024 IVIG provisions of this rule.

**TABLE GG 11: ACCOUNTING STATEMENT: IVIG CLASSIFICATION OF ESTIMATED TRANSFERS AND BENEFITS, FROM CY 2023 TO 2024**

| Category                       | Transfers                              |
|--------------------------------|--|
| Annualized Monetized Transfers | \$8.8 million                          |
| From Whom to Whom?             | Federal Government to DMEPOS suppliers |

## 5. DMEPOS

a. Conforming Changes to Regulations To Codify Change Mandated by Section 4139 of the Consolidated Appropriations Act, 2023

As required by OMB Circular A-4 (available at <https://>

[www.whitehouse.gov/sites/whitehouse.gov/files/omb/circulars/A4/a-4.pdf](http://www.whitehouse.gov/sites/whitehouse.gov/files/omb/circulars/A4/a-4.pdf)), in Table GG 12, we have prepared an accounting statement showing the classification of the expenditures associated with this

provision. Table GG 12 provides our best estimate of the transfers.

**TABLE GG 12: ACCOUNTING STATEMENT:**

| Category                 | Transfers  | Units       |               |                   |
|--------------------------|--|-------------|---------------|-------------------|
|                          |  | Year Dollar | Discount Rate | Period Covered    |
| <b>Transfers</b>         |  |             |               |                   |
| Annualized Monetized     | \$53 million   | 2023        | 7%            | CY 2023 – CY 2024 |
|                          | \$53 million   | 2023        | 3%            | CY 2023 – CY 2024 |
| <b>From Whom to Whom</b> | <b>Transfers from Federal Government to DME Suppliers</b>          |             |               |                   |
| Annualized Monetized     | \$15 million   | 2023        | 7%            | CY 2023 – CY 2024 |
|                          | \$15 million   | 2023        | 3%            | CY 2023 – CY 2024 |
| <b>From Whom to Whom</b> | <b>Transfers from Federal Government to Medicare Beneficiaries</b> |             |               |                   |
| Annualized Monetized     | \$2 million  | 2023        | 7%            | CY 2023- CY 2024  |
|                          | \$2 million  | 2023        | 3%            | CY 2023 – CY 2024 |

b. Scope of the Benefit and Payment for Lymphedema Compression Treatment Items

As required by OMB Circular A-4 (available at <https://>

[www.whitehouse.gov/sites/whitehouse.gov/files/omb/circulars/A4/a-4.pdf](http://www.whitehouse.gov/sites/whitehouse.gov/files/omb/circulars/A4/a-4.pdf)), in Table GG 13, we have prepared an accounting statement showing the classification of the

expenditures associated with this provision. Table GG 13 provides our best estimate of the transfers.

**TABLE GG 13: ACCOUNTING STATEMENT: RELATED TO LYMPHEDEMA COMPRESSION TREATMENT ITEM PROVISION**

| Category             | Transfers   | Units       |               |                   |
|----------------------|---|-------------|---------------|-------------------|
|                      |   | Year Dollar | Discount Rate | Period Covered    |
| Transfers            |   |             |               |                   |
| Annualized Monetized | \$61 million  | 2023        | 7%            | CY 2024 – CY 2028 |
|                      | \$62 million  | 2023        | 3%            | CY 2024 – CY 2028 |
| From Whom to Whom    | Transfers from Federal Government to DME Suppliers          |             |               |                   |
| Annualized Monetized | \$14 million  | 2023        | 7%            | CY 2024 – CY 2028 |
|                      | \$14 million  | 2023        | 3%            | CY 2024 – CY 2028 |
| From Whom to Whom    | Transfers from Federal Government to Medicare Beneficiaries |             |               |                   |
| Annualized Monetized | \$2 million   | 2023        | 7%            | CY 2024- CY 2028  |
|                      | \$2 million   | 2023        | 3%            | CY 2024 – CY 2028 |
| From Whom to Whom    | Transfers from State Government to Beneficiaries            |             |               |                   |

*G. Regulatory Flexibility Act (RFA)*

The RFA requires agencies to analyze options for regulatory relief of small entities, if a rule has a significant impact on a substantial number of small entities. For purposes of the RFA, small entities include small businesses, nonprofit organizations, and small governmental jurisdictions. In addition,

HHAs are small entities, as that is the term used in the RFA. Individuals and States are not included in the definition of a small entity.

The NAICS was adopted in 1997 and is the current standard used by the Federal statistical agencies related to the U.S. business economy. We utilized the NAICS U.S. industry title “Home Health

Care Services” and corresponding NAICS code 621610 in determining impacts for small entities. The NAICS code 621610 has a size standard of \$19 million<sup>222</sup> and approximately 96 percent of HHAs are considered small entities. Table GG 14 shows the number of firms, revenue, and estimated impact per home health care service category.

**TABLE GG 14: NUMBER OF FIRMS, REVENUE, AND ESTIMATED IMPACT OF HOME HEALTH CARE SERVICES BY NAICS CODE 621610**

| NAICS Code | NAICS Description         | Enterprise Size | Number of Firms | Receipts (\$1,000) | Estimated Impact (\$1,000) per Enterprise Size |
|------------|---------------------------|-----------------|-----------------|--------------------|--|
| 621610     | Home Health Care Services | <100            | 5,861           | 210,697            | \$35.95  |
| 621610     | Home Health Care Services | 100-499         | 5,687           | 1,504,668          | \$264.58                                       |
| 621610     | Home Health Care Services | 500-999         | 3,342           | 2,430,807          | \$727.35                                       |
| 621610     | Home Health Care Services | 1,000-2,499     | 4,434           | 7,040,174          | \$1,587.77                                     |
| 621610     | Home Health Care Services | 2,500-4,999     | 1,951           | 6,657,387          | \$3,412.29                                     |
| 621610     | Home Health Care Services | 5,000-7,499     | 672             | 3,912,082          | \$5,821.55                                     |
| 621610     | Home Health Care Services | 7,500-9,999     | 356             | 2,910,943          | \$8,176.81                                     |
| 621610     | Home Health Care Services | 10,000-14,999   | 346             | 3,767,710          | \$10,889.34                                    |
| 621610     | Home Health Care Services | 15,000-19,999   | 191             | 2,750,180          | \$14,398.85                                    |
| 621610     | Home Health Care Services | ≥20,000         | 961             | 51,776,636         | \$53,877.87                                    |
| 621610     | Home Health Care Services | Total           | 23,801          | 82,961,284         | \$3,485.62                                     |

**Source:** Data obtained from United States Census Bureau table “us\_6digitnaics\_rcpts\_size\_2017” (SOURCE: 2017 County Business Patterns and Economic Census) Release Date: 5/28/2021: <https://www2.census.gov/programs-surveys/susb/tables/2017/>

**Notes:** Estimated impact is calculated as Receipts (\$1,000)/Number of firms.

The economic impact assessment is based on estimated Medicare payments (revenues) and HHS’s practice in interpreting the RFA is to consider effects economically “significant” only if greater than 5 percent of providers reach a threshold of 3 to 5 percent or more of total revenue or total costs. The majority of HHAs’ visits are Medicare

paid visits and therefore the majority of HHAs’ revenue consists of Medicare payments. Based on our analysis, we conclude that the policies finalized in this rule would result in an estimated total impact of 3 to 5 percent or more on Medicare revenue for greater than 5 percent of HHAs. Therefore, the Secretary has determined that this HH

PPS final rule will have significant economic impact on a substantial number of small entities. We estimate that the net impact of the policies in this rule is approximately \$375 million in decreased payments to HHAs in CY 2024. The \$375 million in decreased payments are reflected in the last column of the first row in Table GG 14

<sup>222</sup> <https://www.sba.gov/sites/sbagov/files/2023-03/Table%20of%20Size%20Standards%20Effective%20March%202017%202023.xlsx>.

as a 2.2 percent decrease in expenditures when comparing CY 2024 payments to estimated CY 2023 payments. The 2.2 percent decrease is mostly driven by the impact of the permanent behavior assumption adjustment reflected in the third column of Table GG 1. Further detail is presented in Table GG 1, by HHA type and location.

With regards to options for regulatory relief, we note that section 1895(b)(3)(D)(i) of the Act requires CMS to annually determine the impact of differences between the assumed behavior changes finalized in the CY 2019 HH PPS final rule with comment period (83 FR 56455) and actual behavior changes on estimated aggregate expenditures under the HH PPS with respect to years beginning with 2020 and ending with 2026. Additionally, section 1895(b)(3)(D)(ii) and (iii) of the Act requires us to make permanent and temporary adjustments to the payment rate to offset for such increases or decreases in estimated aggregate expenditures through notice and comment rulemaking. While we find that the – 5.653 percent permanent payment adjustment, described in section II.C.1.g. of this proposed rule, is necessary to offset the increase in estimated aggregate expenditures for CYs 2020 through 2022 based on the impact of the differences between assumed behavior changes and actual behavior changes, we will also continue to reprice claims, per the finalized methodology, and make any additional adjustments at a time and manner deemed appropriate in future rulemaking. As discussed previously, we also explored alternatives to the proposed – 5.653 percent permanent payment adjustment including a phase-in approach, where we could reduce the permanent adjustment, by spreading out the CY 2024 permanent adjustment over a period of years. Another alternative would be to delay the permanent adjustment to a future year. However, we believe that a reduction to the permanent adjustment, a phase-in approach, or delay in the permanent adjustment would not be appropriate, as reducing, phasing in, or delaying the permanent adjustment would further impact budget neutrality and likely lead to a compounding effect creating the need for a larger reduction to the payment rate in future years. We also considered proposing to implement the one-time temporary adjustment to reconcile retrospective overpayments in CYs 2020, 2021, and 2022. However, as stated previously in this rule, we recognize that applying the full

permanent and temporary adjustments to the CY 2024 payment rate may adversely affect HHAs, including small entities. We are soliciting comments on the overall HH PPS RFA analysis.

Guidance issued by HHS interpreting the Regulatory Flexibility Act considers the effects economically ‘significant’ only if greater than 5 percent of providers reach a threshold of 3 to 5 percent or more of total revenue or total costs. Among the over 7,500 HHAs that are estimated to qualify to compete in the expanded HHVBP Model, we estimate that the percent payment adjustment resulting from this rule would be larger than 3 percent, in magnitude, for about 28 percent of competing HHAs (estimated by applying the proposed 5-percent maximum payment adjustment under the expanded Model to CY 2019 data). As a result, more than the RFA threshold of 5-percent of HHA providers nationally would be significantly impacted. We refer readers to Tables 43 and 44 in the CY 2022 HH PPS final rule (86 FR 62407 through 62410) for our analysis of payment adjustment distributions by State, HHA characteristics, HHA size, and percentiles.

Thus, the Secretary has certified that this final rule would have a significant economic impact on a substantial number of small entities. Though the RFA requires consideration of alternatives to avoid economic impacts on small entities, the intent of the rule, itself, is to encourage quality improvement by HHAs through the use of economic incentives. As a result, alternatives to mitigate the payment reductions would be contrary to the intent of the rule, which is to test the effect on quality and costs of care of applying payment adjustments based on HHAs’ performance on quality measures.

In addition, section 1102(b) of the Act requires us to prepare an RIA if a rule may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 603 of RFA. For purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside of a metropolitan statistical area and has fewer than 100 beds. This rule is not applicable to hospitals. Therefore, the Secretary has certified that this proposed rule would not have a significant economic impact on the operations of small rural hospitals.

#### *H. Unfunded Mandates Reform Act (UMRA)*

Section 202 of UMRA of 1995 UMRA also requires that agencies assess

anticipated costs and benefits before issuing any rule whose mandates require spending in any 1 year of \$100 million in 1995 dollars, updated annually for inflation. In 2023, that threshold is approximately \$177 million. This proposed rule would not impose a mandate that will result in the expenditure by State, local, and Tribal Governments, in the aggregate, or by the private sector, of more than \$177 million in any one year.

#### *I. Federalism*

Executive Order 13132 establishes certain requirements that an agency must meet when it promulgates a proposed rule (and subsequent final rule) that imposes substantial direct requirement costs on State and local governments, preempts State law, or otherwise has Federalism implications. We have reviewed this final rule under these criteria of Executive Order 13132 and have determined that it would not impose substantial direct costs on State or local governments.

#### *J. Conclusion*

In conclusion, we estimate that the provisions in this proposed rule will result in an estimated net decrease in home health payments of 2.2 percent for CY 2024 (– \$375 million). The \$375 million decrease in estimated payments for CY 2024 reflects the effects of the CY 2024 home health payment update percentage increase of 2.7 percent (\$460 million increase), a 0.2 percent increase in payments due to the new lower FDL ratio, which will increase outlier payments in order to target to pay no more than 2.5 percent of total payments as outlier payments (\$35 million increase) and an estimated 5.1 percent decrease in payments that reflects the effects of the permanent behavior adjustment (\$870 million decrease).

Chiquita Brooks-LaSure, Administrator of the Centers for Medicare & Medicaid Services, approved this document on June 26, 2023.

#### **List of Subjects**

##### *42 CFR Part 409*

Health facilities, Medicare.

##### *42 CFR Part 410*

Diseases, Health facilities, Health professions, Laboratories, Medicare, Reporting and recordkeeping requirements, Rural areas, X-rays.

##### *42 CFR Part 414*

Administrative practice and procedure, Health facilities, Health professions, Kidney diseases, Medicare,

Reporting and recordkeeping requirements.

42 CFR Part 424

Emergency medical services, Health facilities, Health professions, Medicare, Reporting and recordkeeping requirements.

42 CFR Part 484

Administrative practice and procedure, Grant programs-health, Health facilities, Health professions, Home health care, Medicare, Reporting and recordkeeping requirements.

42 CFR Part 488

Administrative practice and procedure, Health facilities, Health professions, Medicare, Reporting and recordkeeping requirements.

42 CFR Part 489

Health facilities, Medicare, Reporting and recordkeeping requirements.

For the reasons stated in the preamble, the Centers for Medicare & Medicaid Services proposes to amend 42 CFR Chapter IV as follows:

PART 409—HOSPITAL INSURANCE BENEFITS

■ 1. The authority citation for part 409 continues to read as follows:

Authority: 42 U.S.C. 1302 and 1395hh.

§ 409.50 [Amended]

■ 2. In § 409.50 amend paragraph (b) by removing the phrase “for furnishing the Negative Pressure Wound Therapy (NPWT) using a disposable device” and adding in its place the phrase “for the disposable Negative Pressure Wound Therapy (NPWT) device”.

PART 410—SUPPLEMENTARY MEDICAL INSURANCE (SMI) BENEFITS

■ 3. The authority citation for part 410 continues to read as follows:

Authority: 42 U.S.C. 1302, 1395m, 1395hh, 1395rr, and 1395ddd.

■ 4. Amend § 410.2 by adding the definitions of “Brace”, “Custom fitted gradient compression garment”, “gradient compression”, and “lymphedema compression treatment item” in alphabetical order to read as follows:

§ 410.2 Definitions

Brace means a rigid or semi-rigid device used for the purpose of supporting a weak or deformed body member or restricting or eliminating

motion in a diseased or injured part of the body.

\* \* \* \* \*

Custom fitted gradient compression garment means a garment that is uniquely sized and shaped to fit the exact dimensions of the affected extremity or part of the body, of an individual to provide accurate gradient compression to treat lymphedema.

\* \* \* \* \*

Gradient compression means the ability to apply a higher level of compression or pressure to the distal (farther) end of the limb or body part affected by lymphedema with lower, decreasing compression or pressure at the proximal (closer) end of the limb or body part affected by lymphedema.

Lymphedema compression treatment item means standard and custom fitted gradient compression garments and other items specified under § 410.36(a)(4) that are—

(1) Furnished on or after January 1, 2024, to an individual with a diagnosis of lymphedema for treatment of such condition;

(2) Primarily and customarily used to serve a medical purpose and for the treatment of lymphedema; and

(3) Prescribed by a physician (or a physician assistant, nurse practitioner, or a clinical nurse specialist (as those terms are defined in section 1861(aa)(5) of the Act) to the extent authorized under State law.

\* \* \* \* \*

§ 410.10 [Amended]

■ 5. In § 410.10 amend paragraph (y) by removing the phrase “globulin administered” and adding in its place the phrase “globulin, including items and services, administered”.

■ 6. Amend § 410.36 by revising paragraph (a)(3) and adding paragraph (a)(4) to read as follows:

§ 410.36 Medical supplies, appliances, and devices: Scope.

\* \* \* \* \*

(a) \* \* \*

(3)(i) Leg, arm, back, and neck braces.

(A) A leg brace may include a shoe if it is an integral part of the brace (necessary for the leg brace to function properly) and its expense is included as part of the cost of the brace.

(ii) Artificial legs, arms, and eyes; and

(iii) Replacements for the devices specified in paragraphs (a)(3)(i) and (ii) if required because of a change in the individual’s physical condition.

(4) Lymphedema compression treatment items, including the following:

(i) Standard and custom fitted gradient compression garments.

(ii) Gradient compression wraps with adjustable straps.

(iii) Compression bandaging systems.

(iv) Other items determined to be lymphedema compression treatment items under the process established under § 414.1670.

(v) For the purposes of paragraphs (i) and (ii) of this paragraph, the scope of the benefit for lymphedema compression treatment items includes accessories such as zippers in garments, liners worn under garments or wraps with adjustable straps, and padding or fillers that are necessary for the effective use of a gradient compression garment or wrap with adjustable straps.

\* \* \* \* \*

■ 7. Section 410.38 is amended by adding paragraph (d)(4) to read as follows:

§ 410.38 Durable medical equipment, prosthetics, orthotics and supplies (DMEPOS): Scope and conditions.

\* \* \* \* \*

(d) \* \* \*

(4) Refills—(i) Definitions. As used in this paragraph (d):

Date of service (for refilled items) means either—

(1) The date of delivery for the DMEPOS item; or

(2) For items rendered via delivery or shipping service, the shipping date.

Refills mean DMEPOS products that are provided on a recurring basis secondary to a medically necessary DMEPOS order.

Shipping date means—

(1) The date the delivery/shipping service label is created; or

(2) The date that the item is retrieved for delivery. These dates must not demonstrate significant variation.

(ii) Documentation. The DMEPOS supplier must document contact with the beneficiary or their representative to verify the refill is needed. This documentation must include both of the following:

(A) Evidence of the beneficiary or their representative’s affirmative response of the need for supplies, which should be obtained as close to the expected end of the current supply as possible. Contact and affirmative response must be within 30 calendar days from the expected end of the current supply.

(B)(1) For shipped items, the beneficiary name, date of contact, the item requested, and an affirmative response from the beneficiary, indicative of the need for refill, prior to dispensing the product; or

(2) For items obtained in-person from a retail store, the delivery slip signed by the beneficiary or their representative or

a copy of the itemized sales receipt is sufficient documentation of a request for refill.

(iii) *Delivery of DMEPOS items provided on a recurring basis.* The date of service for DMEPOS items provided on a recurring basis must be no earlier than 10 calendar days before the expected end of the current supply.

\* \* \* \* \*

**PART 414—PAYMENT FOR PART B MEDICAL AND OTHER HEALTH SERVICES**

■ 8. The authority citation for part 414 continues to read as follows:

**Authority:** 42 U.S.C. 1302, 1395hh, and 1395r(b)(l).

■ 9. Section 414.210 is amended by—

■ a. In paragraph (g)(2)(ii) introductory text, removing the phrase “(42 U.S.C. 1320b–5(g)(1)(B)), whichever is later” and adding in its place the phrase “(42 U.S.C. 1320b–5(g)(1)(B)), or December 31, 2023, whichever is later”;

■ b. In paragraph (g)(2)(iii) introductory text, removing the phrase “(42 U.S.C. 1320b–5(g)(1)(B)), whichever is later” and adding in its place the phrase “(42 U.S.C. 1320b–5(g)(1)(B)), or December 31, 2023, whichever is later”;

■ c. In paragraph (g)(9)(iii) removing the phrase “from June 1, 2018 through December 31, 2020 or through the duration” and adding in its place the phrase “from June 1, 2018 through the duration of the emergency period described in section 1135(g)(1)(B) of the Act (42 U.S.C. 1320b–5(g)(1)(B)) or December 31, 2023”;

■ d. Revising paragraph (g)(9)(v); and

■ e. In paragraph (g)(9)(vi), removing the date “February 28, 2022” and adding in its place the date “January 1, 2024”.

The revision reads as follows:

**§ 414.210 General payment rules.**

\* \* \* \* \*

(g) \* \* \*

(9) \* \* \*

(v) For items and services furnished in areas other than rural or noncontiguous areas with dates of service from March 6, 2020, through the remainder of the duration of the emergency period described in section 1135(g)(1)(B) of the Act (42 U.S.C. 1320b–5(g)(1)(B)) or December 31, 2023, whichever is later, based on the fee schedule amount for the area is equal to 75 percent of the adjusted payment amount established under this section and 25 percent of the unadjusted fee schedule amount.

\* \* \* \* \*

■ 10. Amend § 414.402 by revising the definition of “Item” to read as follows:

**§ 414.402 Definitions.**

\* \* \* \* \*

*Item* means a product included in a competitive bidding program that is identified by a HCPCS code, which may be specified for competitive bidding (for example, a product when it is furnished through mail order), or a combination of codes with or without modifiers, and includes the services directly related to the furnishing of that product to the beneficiary. Items that may be included in a competitive bidding program are as follows:

(1) DME other than class III devices under the Federal Food, Drug and Cosmetic Act, as defined in § 414.402, group 3 complex rehabilitative power wheelchairs, complex rehabilitative manual wheelchairs, manual wheelchairs described by HCPCS codes E1235, E1236, E1237, E1238, and K0008, and related accessories when furnished in connection with such wheelchairs, and further classified into the following categories:

(i) Inexpensive or routinely purchased items, as specified in § 414.220(a).

(ii) Items requiring frequent and substantial servicing, as specified in § 414.222(a).

(iii) Oxygen and oxygen equipment, as specified in § 414.226(c)(1).

(iv) Other DME (capped rental items), as specified in § 414.229.

(2) Supplies necessary for the effective use of DME other than inhalation and infusion drugs.

(3) Enteral nutrients, equipment, and supplies.

(4) Off-the-shelf orthotics, which are orthotics described in section 1861(s)(9) of the Act that require minimal self-adjustment for appropriate use and do not require expertise in trimming, bending, molding, assembling or customizing to fit a beneficiary.

(5) Lymphedema compression treatment items.

\* \* \* \* \*

■ 11. Amend § 414.408 by adding paragraph (g)(5) to read as follows:

**§ 414.408 Payment rules.**

\* \* \* \* \*

(g) \* \* \*

(5) Lymphedema compression treatment items.

\* \* \* \* \*

■ 12. Amend § 414.412 by revising paragraph (b)(2) to read as follows:

**§ 414.412 Submission of bids under a competitive bidding program.**

\* \* \* \* \*

(b) \* \* \*

(2) The bid submitted for each lead item and product category cannot exceed the payment amount that would

otherwise apply to the lead item under—

(i) Subpart C of this part, without the application of § 414.210(g);

(ii) Subpart D of this part, without the application of § 414.105; or

(iii) Subpart Q of this part, without the application of § 414.1690.

\* \* \* \* \*

■ 13. Add subpart Q, consisting of §§ 414.1600 through 414.1690, to read as follows:

**Subpart Q—Payment for Lymphedema Compression Treatment Items**

Sec.

414.1600 Purpose and definitions.

414.1650 Payment basis for lymphedema compression treatment items.

414.1660 Continuity of pricing when HCPCS codes are divided or combined.

414.1670 Procedures for making benefit category determinations and payment determinations for new lymphedema compression treatment items.

414.1680 Frequency limitations.

414.1690 Application of competitive bidding information.

**Subpart Q—Payment for Lymphedema Compression Treatment Items**

**§ 414.1600 Purpose and definitions.**

(a) *Purpose.* This subpart implements section 1834(z) of the Act and establishes procedures for making benefit category determinations and payment determinations for lymphedema compression treatment items.

(b) *Definitions.* For purposes of this subpart the following definitions apply:

*Benefit category determination* means a national determination regarding whether an item or service meets the Medicare definition of lymphedema compression treatment item at section 1861(mmm) of the Act and the rules of this subpart and is not otherwise excluded from coverage by statute.

*Lymphedema compression treatment item* means an item as described in § 410.2.

**§ 414.1650 Payment basis for lymphedema compression treatment items.**

(a) *General payment rule.* For items furnished on or after January 1, 2024, Medicare pays for lymphedema compression treatment items on the basis of 80 percent of the lesser of –

(1) The actual charge for the item; or

(2) The payment amount for the item, as determined in accordance with paragraph (b) of this section.

(b) *Payment amounts.* The payment amounts for covered lymphedema compression treatment items paid for under this subpart are established based on one of the following:

(1) If payment amounts are available from Medicaid state plans, then 120



percent of the average of the Medicaid payment amounts.

(2) If payment amounts are not available from Medicaid state plans, then 100 percent of the average of average internet retail prices and payment amounts from TRICARE (Department of Defense).

(3) If payment amounts are not available from Medicaid state plans or TRICARE, then 100 percent of average internet retail prices.

(c) *Updates to payment amounts.* The payment amounts for covered lymphedema compression treatment items established in accordance with paragraph (b) of this section are increased on an annual basis beginning on January 1 of the year subsequent to the year in which the payment amounts are initially established based on the percent change in the Consumer Price Index for all Urban Consumers (CPI-U) for the 12-month period ending with June of the previous year.

**§ 414.1660 Continuity of pricing when HCPCS codes are divided or combined.**

(a) *General rule.* If HCPCS codes for lymphedema compression treatment items are divided or combined, the payment amounts for the old codes are mapped to the new codes to ensure continuity of pricing.

(b) *Mapping of payment amounts.* (1) If there is a single code that describes two or more distinct complete items (for example, two different but related or similar items), and separate codes are subsequently established for each item, then the payment amounts that applied to the single code continue to apply to each of the items described by the new codes.

(2) If the codes for several different items are combined into a single code, then the payment amounts for the new code are established using the average (arithmetic mean), weighted by allowed services, of the payment amounts for the formerly separate codes.

**§ 414.1670 Procedures for making benefit category determinations and payment determinations for new lymphedema compression treatment items.**

The procedures for determining whether new items and services addressed in a request for a HCPCS Level II code(s) or by other means meet the definition of items and services paid for in accordance with this subpart are as follows:

(a) At the start of a HCPCS coding cycle, CMS performs an analysis to determine if the item is statutorily excluded from coverage under Medicare under section 1862 of the Act.

(1) If not excluded by statute, then CMS determines whether the item is a

lymphedema compression treatment item as defined under section 1861(mmm) of the Act.

(2) If excluded by statute, the analysis is concluded.

(b) If a preliminary determination is made that the item is a lymphedema compression treatment item, CMS makes a preliminary payment determination for the item or service.

(c) CMS posts preliminary benefit category determinations and payment determinations on *CMS.gov* approximately 2 weeks prior to a public meeting.

(d) After consideration of public consultation provided at a public meeting on preliminary benefit category determinations and payment determinations for items, CMS establishes the benefit category determinations and payment determinations for items through program instructions.

**§ 414.1680 Frequency limitations.**

(a) *General rule.* With the exception of replacements of items that are lost, stolen, or irreparably damaged, or if needed due to a change in the patient's medical or physical condition, no payment may be made for gradient compression garments or wraps with adjustable straps furnished other than at the frequencies established in paragraphs (b) and (c) of this section.

(b) *Initial furnishing of lymphedema compression treatment items.* The following frequency limitations apply to items initially furnished to the beneficiary if determined to be reasonable and necessary for the treatment of lymphedema:

(1) Two units of daytime gradient compression garments or wraps with adjustable straps per affected extremity or part of the body.

(2) One garment for nighttime use per affected extremity or part of the body.

(c) *Replacements of lymphedema compression treatment items.* The following frequency limitations apply to replacements of lymphedema compression treatment items if determined to be reasonable and necessary for the treatment of lymphedema:

(1) Payment for the replacement of gradient compression garments or wraps with adjustable straps per each affected extremity or part of the body can be made once every 6 months.

(2) Payment for the replacement of nighttime garments per each affected extremity or part of the body can be made once a year.

(d) *Replacements of lymphedema compression bandaging systems or supplies.* Specific frequency limitations

are not established for these items. Determinations regarding the quantity of compression bandaging supplies needed by each beneficiary during phase one of decongestive therapy are made by the DME MAC that processes the claims for the supplies.

**§ 414.1690 Application of competitive bidding information.**

The payment amounts for lymphedema compression treatment items under § 414.1650(b) may be adjusted using information on the payment determined as part of implementation of the programs under subpart F using the methodologies set forth at § 414.210(g).

■ 14. Add subpart R, consisting of § 141.1700, to read as follows:

**Subpart R—Home Intravenous Immunoglobulin (IVIG) Items and Services Payment**

**§ 414.1700 Basis of payment.**

(a) *General rule.* For home intravenous immunoglobulin (IVIG) items or services furnished on or after January 1, 2024, Medicare payment is made on the basis of 80 percent of the lesser of the following:

(1) The actual charge for the item or service.

(2) The fee schedule amount for the items and services, as determined in accordance with the provisions of this section.

(b) *Per visit amount.* A single payment amount is made for items and services furnished by a DME supplier per visit.

(c) *Initial establishment of the payment amount.* In establishing the initial per visit IVIG items and services payment amount for CY 2024, CMS used the CY 2023 bundled payment rate under the IVIG Demonstration updated by the home health payment percentage update for CY 2024.

(d) *Annual payment adjustment.* The per visit payment amount represents payment in full for all costs associated with the furnishing of home IVIG items and services and is subject to the following adjustment:

(1) Beginning in 2025, an annual increase in the per-visit payment amount from the prior year by the home health update percentage increase for the current calendar year.

(2) [Reserved]

**PART 424—CONDITIONS FOR MEDICARE PAYMENT**

■ 15. The authority for part 424 continues to read as follows:

**Authority:** 42 U.S.C. 1302 and 1395hh.

### Subpart P—Requirements for Establishing and Maintaining Medicare Billing Privileges

■ 16. Further amend § 424.502 (as proposed to be amended at 88 FR 9829, February 15, 2023) by—

- a. In the definition of “Change in majority ownership” removing the term “HHA” and in its place the phrase “HHA or hospice” wherever it appears.
- b. Revising paragraph (1) of the proposed definition of “Managing employee”.

The revision reads as follows:

#### § 424.502 Definitions.

\* \* \* \* \*

*Managing employee means*—(1) A general manager, business manager, administrator, director, or other individual that exercises operational or managerial control over, or who directly or indirectly conducts, the day-to-day operation of the provider or supplier, either under contract or through some other arrangement, whether or not the individual is a W–2 employee of the provider or supplier. For purposes of this definition, this includes a hospice or skilled nursing facility administrator and a hospice or skilled nursing facility medical director.

\* \* \* \* \*

■ 17. Amend § 424.518 by—

- a. Removing paragraph (b)(1)(iv);
- b. Redesignating paragraphs (b)(1)(v) through (b)(1)(viii) as paragraphs (b)(1)(iv) through (b)(1)(vii);
- c. Redesignating paragraph (b)(1)(xii) as paragraph (b)(1)(viii);
- d. Revising newly redesignated paragraph (b)(1)(viii) and paragraph (b)(1)(ix);
- e. Removing paragraphs (b)(1)(x) through (b)(1)(xiv);
- f. Revising (c)(1)(vi); and
- g. Adding paragraphs (c)(1)(vii) and (viii).

The revisions and additions read as follows:

#### § 424.518 Screening levels for Medicare providers and suppliers.

\* \* \* \* \*

(b) \* \* \*

(1) \* \* \*

(viii) Prospective (newly enrolling) and revalidating opioid treatment programs that have been fully and continuously certified by the Substance Abuse and Mental Health Services Administration (SAMHSA) since October 23, 2018.

(ix) Revalidating opioid treatment programs that have not been fully and continuously certified by SAMHSA since October 23, 2018, revalidating DMEPOS suppliers, revalidating MDPP

suppliers, revalidating HHAs, revalidating SNFs, and revalidating hospices to which CMS applied the fingerprinting requirements outlined in paragraph (c)(2)(ii) of this section upon the provider’s or supplier’s—

(A) New/initial enrollment; or

(B) Revalidation after CMS waived the fingerprinting requirements, under the circumstances described in paragraph (c)(1)(viii) of this section, when the provider or supplier initially enrolled in Medicare.

\* \* \* \* \*

(c) \* \* \*

(1) \* \* \*

(vi) Prospective (newly enrolling) hospices.

(vii) Enrolled opioid treatment programs that have not been fully and continuously certified by SAMHSA since October 23, 2018, DMEPOS suppliers, MDPP suppliers, HHAs, SNFs, and hospices that are submitting a change of ownership application under 42 CFR 489.18 or reporting any new owner (regardless of ownership percentage) in accordance with a change of information or other enrollment transaction under title 42.

(viii) Except as stated in paragraph (b)(1)(ix) of this section, revalidating opioid treatment programs that have not been fully and continuously certified by SAMHSA since October 23, 2018, revalidating DMEPOS suppliers, revalidating MDPP suppliers, revalidating HHAs, revalidating SNFs, and revalidating hospices for which, upon their new/initial enrollment, CMS waived the fingerprinting requirements outlined in paragraph (c)(2)(ii) of this section in accordance with applicable legal authority due to a national, state, or local emergency declared under existing law.

\* \* \* \* \*

■ 18. Add § 424.527 to read as follows:

#### § 424.527 Provisional period of oversight.

(a) *New provider or supplier.* Exclusively for purposes of both section 1866(j)(3) of the Act and this § 424.527, the term “new provider or supplier” is defined as any of the following:

(1) A newly enrolling Medicare provider or supplier. (This includes providers that are required to enroll as a new provider in accordance with the change in majority ownership provisions in § 424.550(b).)

(2) A certified provider or certified supplier undergoing a change of ownership consistent with the principles of 42 CFR 489.18. (This includes providers that qualify under § 424.550(b)(2) for an exception from the change in majority ownership

requirements in § 424.550(b)(1) but which are undergoing a change of ownership under 42 CFR 489.18).

(3) A provider or supplier (including an HHA or hospice) undergoing a 100 percent change of ownership via a change of information request under § 424.516.

(b) *Effective date.* The effective date of a provisional period of enhanced oversight that is commenced under section 1866(j)(3) of the Act is the date on which the new provider or supplier submits its first claim.

■ 19. Amend § 424.530 by—

- a. In paragraph (f) introductory text removing the phrase “3 years” and adding in its place “10 years”.
- b. Adding paragraph (f)(3).

The revision and additions read as follows:

#### § 424.530 Denial of enrollment in the Medicare program.

\* \* \* \* \*

(f) \* \* \*

(3)(i) A provider or supplier that is currently subject to a reapplication bar under paragraph (f) of this section may not order, refer, certify, or prescribe Medicare-covered services, items, or drugs.

(ii) Medicare does not pay for any otherwise covered service, item, or drug that is ordered, referred, certified, or prescribed by a provider or supplier that is currently under a reapplication bar.

■ 20. Section 424.540(a)(1) is amended by removing the number “12” and adding in its place the number “6” wherever it appears.

■ 21 Add § 424.542 to read as follows:

#### § 424.542 Prohibition on ordering, certifying, referring, or prescribing based on felony conviction.

(a) *General prohibition.* A physician or other eligible professional (regardless of whether he or she is or was enrolled in Medicare) who has had a felony conviction within the previous 10 years that CMS determines is detrimental to the best interests of the Medicare program and its beneficiaries may not order, refer, certify, or prescribe Medicare-covered services, items, or drugs.

(b) *Payment.* Medicare does not pay for any otherwise covered service, item, or drug that is ordered, referred, certified, or prescribed by a physician or other eligible professional (as that term is defined in section 1848(k)(3)(B) of the Act) who has had a felony conviction within the previous 10 years that CMS determines is detrimental to the best interests of the Medicare program and its beneficiaries.

■ 22. Amend § 424.550 by—

- a. Revising paragraph (b)(1) introductory text;
- b. In paragraph (b)(1)(i) removing the term “HHA” and adding in its place the phrase “HHA or hospice”;
- c. In paragraph (b)(2)(i) removing the phrase “The HHA submitted two consecutive years” and adding in its place the phrase “The HHA or hospice submitted 2 consecutive years”;
- d. In paragraph (b)(2)(ii), removing the term “HHA’s” and adding in its place the phrase “HHA’s or hospice’s”;
- e. In paragraph (b)(2)(iii), removing the phrase “The owners of an existing HHA are changing the HHA’s” and adding in its place the phrase “The owners of an existing HHA or hospice are changing the HHA’s or hospice’s”;
- f. In paragraph (b)(2)(iv) removing the term “HHA” and adding in its place the phrase “HHA or hospice”.

The revision reads as follows:

**§ 424.550 Prohibitions on the sale or transfer of billing privileges.**

\* \* \* \* \*

(b) \* \* \*

(1) Unless an exception in paragraph (b)(2) of this section applies, if there is a change in majority ownership of a home health agency (HHA) or hospice by sale (including asset sales, stock transfers, mergers, and consolidations) within 36 months after the effective date of the HHA’s or hospice’s initial enrollment in Medicare or within 36 months after the HHA’s or hospice’s most recent change in majority ownership, the provider agreement and Medicare billing privileges do not convey to the new owner. The prospective provider/owner of the HHA or hospice must instead do both of the following:

\* \* \* \* \*

**PART 484—HOME HEALTH SERVICES**

■ 23. The authority citation for part 484 continues to read as follows:

Authority: 42 U.S.C. 1302 and 1395hh.

■ 24. Section 484.202 is amended by revising the definition of “Furnishing Negative Pressure Wound Therapy (NPWT) using a disposable device” to read as follows:

**§ 484.202 Definitions.**

\* \* \* \* \*

*Furnishing Negative Pressure Wound Therapy (NPWT) using a disposable device* means the device is paid separately (specified by the assigned CPT® code) and does not include payment for the professional services. The nursing and therapy services are to be included as part of the payment

under the home health prospective payment system.

\* \* \* \* \*

■ 25. Section 484.245 is amended by redesignating paragraph (b)(2) as paragraph (b)(2)(i) and adding paragraph (b)(2)(ii) to read as follows:

**§ 484.245 Data submission requirements under the home health quality reporting program.**

\* \* \* \* \*

(b) \* \* \*

(2) \* \* \*

(ii) *Data completion thresholds.* (A) A home health agency must meet or exceed the data submission threshold set at 90 percent of all required OASIS or successor instrument records within 30-days of the beneficiary’s admission or discharge and submitted through the CMS designated data submission systems.

(B) A home health agency must meet or exceed the data submission compliance threshold described in paragraph (b)(2)(ii)(A) of this section to avoid receiving a 2-percentage point reduction to its annual payment update for a given fiscal year described under § 484.225(b).

\* \* \* \* \*

■ 26. Add § 484.358 to read as follows:

**§ 484.358 HHVBP Measure removal factors.**

CMS may remove a quality measure from the expanded HHVBP Model based on one or more of the following factors:

(a) Measure performance among HHAs is so high and unvarying that meaningful distinctions in improvements in performance can no longer be made (that is, topped out).

(b) Performance or improvement on a measure does not result in better patient outcomes.

(c) A measure does not align with current clinical guidelines or practice.

(d) A more broadly applicable measure (across settings, populations, or conditions) for the particular topic is available.

(e) A measure that is more proximal in time to desired patient outcomes for the particular topic is available.

(f) A measure that is more strongly associated with desired patient outcomes for the particular topic is available.

(g) Collection or public reporting of a measure leads to negative unintended consequences other than patient harm.

(h) The costs associated with a measure outweigh the benefit of its continued use in the program.

■ 27. Amend § 484.375 by revising paragraph (b)(5) to read as follows:

**§ 484.375 Appeals process for the Expanded Home Health Value-Based Purchasing (HHVBP) Model.**

\* \* \* \* \*

(b) \* \* \*

(5) *Reconsideration decision.* (i) CMS reconsideration officials issue a written decision that is final and binding upon issuance unless the CMS Administrator—

(A) Renders a final determination reversing or modifying the reconsideration decision; or

(B) Does not review the reconsideration decision within 14 days of the request.

(ii) An HHA may request that the CMS Administrator review the reconsideration decision within 7 calendar days of the decision.

(iii) If the CMS Administrator receives a request to review, the CMS Administrator must do one of the following:

(A) Render a final determination based on his or her review of the reconsideration decision.

(B) Decline to review a reconsideration decision made by CMS. Choose to take no action.

(iv) If the CMS Administrator does not review an HHA’s request within 14 days (as described in paragraph (b)(5)(iii)(B) or (C) of this section), the reconsideration official’s written reconsideration decision is final.

**PART 488—SURVEY, CERTIFICATION, AND ENFORCEMENT PROCEDURES**

■ 28. The authority citation for part 488 continues to read as follows:

Authority: 42 U.S.C. 1302 and 1395hh.

**Subpart M—Survey and Certification of Hospice Programs**

■ 29. Amend § 488.1105 by adding the definitions of “Hospice Special Focus Program”, “IDR”, “SFP status”, and “SFP survey” in alphabetical order to read as follows:

**§ 488.1105 Definitions.**

\* \* \* \* \*

*Hospice Special Focus Program (SFP)* means a program conducted by CMS to identify hospices as poor performers, based on defined quality indicators, in which CMS selects hospices for increased oversight to ensure that they meet Medicare requirements. Selected hospices either successfully complete the SFP program or are terminated from the Medicare program.

*IDR* stands for informal dispute resolution.

\* \* \* \* \*

*SFP status* means the status of a hospice provider in the SFP with

respect to the provider's progress in the SFP, which is indicated by one of the following status levels:

- (1) Level 1—in progress.
- (2) Level 2—completed successfully.
- (3) Level 3—terminated from the Medicare program.

*SFP survey* means a standard survey as defined in this section that is applied after a hospice is selected for the SFP. The survey is conducted every 6 months, up to 3 occurrences.

\* \* \* \* \*

■ 30. Add § 488.1130 to read as follows:

**§ 488.1130 Informal dispute resolution (IDR).**

(a) *Opportunity to refute survey findings.* Upon the provider's receipt of an official statement of deficiencies, hospice programs can request an informal opportunity to dispute condition-level survey findings.

(b) *Failure to conduct IDR timely.* Failure of CMS, the State, or the AO, as appropriate, to complete IDR must not delay the effective date of any enforcement action.

(c) *Revised statement of deficiencies as a result of IDR.* If any findings are revised or removed by CMS, the State, or the AO based on IDR, the official statement of deficiencies is revised accordingly and any enforcement actions imposed solely as a result of those cited deficiencies are adjusted accordingly.

(d) *Notification.* (1) If the survey findings indicate a condition-level deficiency, the hospice program is notified in writing of its opportunity for participating in an IDR process at the time the official statement of deficiencies is issued.

(2) The request for IDR must—

- (i) Be submitted in writing;
- (ii) Include the specific deficiencies that are disputed; and

(iii) Be made within the same 10 calendar day period that the hospice program has for submitting an acceptable plan of correction.

■ 31. Add § 488.1135 to read as follows:

**§ 488.1135 Hospice Special Focus Program (SFP).**

(a) *Applicability.* (1) The provisions of this section are effective on or after [the effective date of the final rule]; and

(2) SFP selection begins in CY 2024.

(b) *Selection criteria.* (1) Selection of hospices for the SFP is made based on the highest aggregate scores based on the algorithm used by CMS.

(2) Hospice programs with accrediting organization deemed status placed in the SFP—

(i) Do not retain deemed status; and

(ii) Are placed under CMS or State survey agency jurisdiction until completion of the SFP or termination.

(c) *Survey and enforcement criteria.* A hospice in the SFP—

(1) Is surveyed not less than once every 6 months by CMS or the State agency; and

(2) With condition level deficiencies on any survey is subject to standard enforcement actions and may be subject to progressive enforcement remedies at the discretion of CMS.

(d) *Completion criteria.* A hospice in the SFP that has two SFP surveys within 18 months with no condition-level deficiencies, and that has no pending complaint survey triaged at an immediate jeopardy or condition level, or that has returned to substantial compliance with all requirements may complete the SFP.

(e) *Termination criteria.* (1) A hospice in the SFP that does not meet the SFP completion requirements in paragraph (d) of this section is considered for termination from the Medicare program in accordance with 42 CFR 489.53.

(2) CMS may consider termination from the Medicare program in accordance with § 488.1225 if any survey results in an immediate jeopardy citation while the hospice is in the SFP.

(f) *Public reporting.* CMS posts all of the following at least annually on a CMS public-facing website:

(1) A subset of 10 percent of hospice programs based on the highest aggregate scores as determined by the algorithm used by CMS.

(2) Hospice SFP selection from the list in paragraph (f)(1) of this section as determined by CMS.

(3) SFP status as defined in § 488.1105.

**PART 489—PROVIDER AGREEMENTS AND SUPPLIER APPROVAL**

■ 32. The authority citation for part 489 continues to read as follows:

**Authority:** 42 U.S.C. 1302, 1395i–3, 1395x, 1395aa(m), 1395cc, 1395ff, and 1395(hh).

■ 33. Section 489.52 is amended by adding paragraph (b)(4) to read as follows:

**§ 489.52 Termination by the provider.**

\* \* \* \* \*

(b) \* \* \*

(4) A provider may request a retroactive termination date if no Medicare beneficiary received services from the facility on or after the requested termination date.

\* \* \* \* \*

Dated: June 28, 2023.

**Xavier Becerra,**

*Secretary, Department of Health and Human Services.*

[FR Doc. 2023–14044 Filed 6–30–23; 4:15 pm]

**BILLING CODE 4120–01–P**